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Abstract 
 
The first part of present doctoral thesis is dedicated to sesterterpenoid natural products, which 
constitute a relatively small subclass of the family of terpenoid compounds. In particular, a 
small number of biosynthetically closely related iso-propyl-substituted trans-hydrindane-
based congeners were chosen as targets for a synthetic program that envisioned their chemical 
construction via a unified approach. In this context, the first total synthesis of the complex 
tetracarbocyclic sesterterpenoid (−)-nitidasin was disclosed. To this end, a highly convergent 
installation of its western cyclopentane moiety was demonstrated by use of an unprecedented 
Li-alkenyl addition to a versatile trans-hydrindanone building block. An efficient closure of 
the central 8-membered carbocycle was achieved by means of ring-closing metathesis that 
benefitted from finely tuned conformational parameters of the employed substrate. In 
summary, the developed protocol provides a scalable and continuously high yielding route for 
the assembly of the rare carbon skeleton of (−)-nitidasin. Furthermore, advanced synthetic 
studies toward the pentacyclic natural products retigeranic acid B and astellatol are described. 
Notably, the latter involved a biomimetic retrosynthetic proposal for the elaboration of its 
unique fused ring system. Two different strategies were followed in order to access viable 
precursors for the suggested cationic cascade, of which the latter allowed for the investigation 
of the mentioned key step experimentally and via computational methods.  
In the second section of this manuscript, the design and synthesis of the first known 
photochromic antagonist for L-type voltage-gated calcium channels is presented. The ultimate 
goal of this project lies in the establishment of a photopharmacological tool that supports the 
further elucidation of Ca2+-dependent cellular events, especially in neurons. The central 
pharmacophore of the prepared compounds was derived from the benzothiazepine drug 
cis-(+)-diltiazem. This parent substance also served as the starting point for the developed 
short and convergent semisynthetic strategy. Thirteen analogues were synthesized in total and 
a preliminary lead structure was identified using electrophysiolocigal methods. Based on 
these findings, two compounds of increased solubility and desirable photochemical properties 
were prepared. A possible explanation for their photodependent mode of action was proposed, 
which is currently subject of our ongoing investigations. 
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1. Introduction 
 
1.1 Terpenoids: Definition, Subclasses and Biosynthesis 
 
Terpenoids are an ubiquitous class of natural products and represent the largest and most 
diverse collection of secondary metabolites, with over 55.000 members isolated to date.[1] For 
mankind, these functional molecules truly hold a special place in both world and chemical 
history, as their deliberate use can be traced back as far as ancient Egypt. Since then, 
scientists and non-scientists have found numerous applications for terpenoids, ranging from 
flavours, fragrances, hormones and therapeutical agents to even functional materials like 
rubber.[2]  
Originally, the term ‘terpenes’ had been coined by Kekulé to refer to the hydrocarbon content 
of the tree gum turpentine (lat. Balsamum terebinthinae).[3] This definition has been extended 
since then and today all natural compounds built up by isoperene units are typically included. 
Although the terms ‘terpenes’ and ‘terpenoids’ are often used synonymously for this type of 
molecule, official nomenclature according to IUPAC[4] states that the former comprises only
  
 
Scheme 1.1:  Classification of terpenoids according to the number of included C5 isoprene units. Phytoene (3) 
was drawn in the unnatural 15-trans configuration for simplicity. 
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4 
pure hydrocarbons of biological origin, whereas the latter refers to oxygenated and further 
functionalized congeners.i  
The search for the biosynthetic origin of terpenoid natural products in general and in 
particular has motivated innumerable scientific studies ever since the dawn of organic 
chemistry. In the beginning, the ground breaking studies by Wallach[5] and later by Ruzicka[6] 
led to the formulation of the already indicated ‘isoprene rule’, which states that all members 
of this family of compounds are built up from a varying number of a fundamental monomer, 
namely isoprene (1). Therefore, terpenoids are also sometimes denoted as ‘isoprenoids’, even 
though mentioned monomer itself is not involved in their biosynthesis. In nature, they occur 
predominately as functionalized or elaborately cyclized versions of their basic parent 
hydrocarbons, which are depicted in scheme 1.1. According to the number of C5 building 
blocks, these natural products are subdivided in the classes of hemi-, mono-, sesqui-, di-, 
sester-, tri-, tetra- and polyterpenoids. As it can be seen in the exemplified tri-(2) and 
tetraterpenoid (3) chains, biosynthesis not only arranges tail-to-head connectivity but also 
tail-to-tail linkage is possible. This further structural diversification was first recognized by 
Ruzicka in 1953 in his extended ‘biogenetic isoprene rule’.[7] 
Identification of the actual biosynthetic precursors of natural occurring terpenoids was 
reported in the seminal investigations of Bloch[8] and Lynen.[9] In their studies, both authors 
disclosed that the two activated C5 building blocks isopentenyl pyrophosphate (IPP, 10) and 
dimethylallyl pyrophosphate (DMAPP, 11) are nature’s equivalents for isoprene (1). After
  
 
Scheme 1.2:  The mevalonate pathway as the first elucidated biosynthetic origin of IPP (10) and DMAPP (11). 
Involved enzymes are indicated grey. 
                                                
iFor the sake of consistency, present doctoral thesis will only use the term ‘terpenoid(s)’. 
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the fundamental discovery that both compounds can be traced back to acetyl-CoA (12), 
subsequent investigations led to the formulation and refinement of the so-called mevalonate 
pathway (scheme 1.2) and marked the first detailed mechanistic insights into terpenoid 
biogenesis.[10] To this end, it was proven that initially an equivalent of acetyl-CoA (12) reacts 
with an enzyme-bound acetyl function to furnish diketone 13, in a manner resembling a 
Claisen condensation. The resulting natural analogue of acetoacetate then undergoes 
diastereo-selective aldol addition of another thioester bound acetyl group (14). Ensuing 
hydrolysis accounts for the formation of β-hydroxy-β-methylglutaryl-CoA (15), which in turn 
is reduced by dihydronicotinamide adenine dinucleotide (NADPH/H+) to mevaldic acid (16). 
A second NADPH/H+-mediated reduction step then gives rise to (R)-mevalonic acid (MVA, 
17), the key intermediate that serves as eponym for this pathway. In the following, two 
sequential phosphorylation steps, which are mediated by one equivalent of adenosine 
triphosphate (ATP) each, form the pyrophosphate 18. In a final ATP-assisted enzymatic 
transformation, substance 18 is decarboxylated and dehydrated to IPP (10). This first 
important building block can in turn be converted to the second – DMAPP (11) – by the thiol-
based IPP isomerase.[2] Interestingly, this formal [1,3]-hydride shift has been proposed to 
proceed via a two-base mechanism and starts with the stereospecific enzymatic removal of the 
pro-R proton in IPP (10).[11] 
For several decades, these milestone achievements completely eclipsed the existence of a 
second metabolic route for the biosynthesis of IPP (10) and DMAPP (11), mainly occurring
  
 
Scheme 1.3:  The non-mevalonate pathway as the major source of IPP (10) and DMAPP (11) in plants. 
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6 
in plants, protozoa, bacteria and algae.[12] The methylerythriol phosphate (MEP) pathway, 
which has also come to be known as the non-mevalonate pathway, was pioneered by the 
groups of Rohmer[13] and Arigoni.[14] In detail, the sequence starts with pyruvic acid (20), 
which upon reaction with thiamine pyrophosphate (TPP) forms thiazole 21 under extrusion of 
carbon dioxide.[15] After this umpolung step, the enamine in substance 21 can nucleophilically 
attack glyceraldehyde 3-phosphate (22), giving rise to 1-desoxy-D-xylulose-5-phosphate 
(DOXP, 23). Notably, this intermediate is also the branching point for the biogenesis of 
pyridoxal (vitamin B6, not shown) and thiamine (vitamin B1, not shown). Along the terpenoid 
avenue, an enzyme-promoted skeletal rearrangement that is accompanied by a NADPH/H+-
dependent reduction leads to the generation of MEP (24). Subsequently, an ester interchange 
between MEP (24) and the nucleotide cytidine triphosphate (CTP) forms the mixed 
diphosphate 25 (ME-CDP), driven by the expulsion of a molecule of pyrophosphate. An 
additional kinase promoted phosphorylation of the tertiary alcohol function (26, MEP-CDP) 
is then followed by intramolecular cyclization, proceeding again via transesterification and 
the release of cytidine monophosphate (CMP). Reductive ring opening toward phosphorylated 
alcohol 27 is achieved by a ferredoxin containing enzyme complex and delivers the last 
precursor for the formation of IPP (10) and DMAPP (11). This final step comes along with 
the oxidation of one equivalent of NADPH/H+ and the release of water, eventually yielding 
IPP (10) and DMAPP (11) in a ratio of 5:1 to 4:1. However, the mechanism for this 
transformation has not been fully clarified to date.  
  
 
Scheme 1.4:  Selected hemiterpenes as imminent biosynthetic descendants of IPP (10) or DMAPP (11). 
The smallest subclass of terpenoids, the hemiterpenes, only consists of about 50 known 
congeners, which are directly synthesized from either one of the presented C5 precursors.[2] In 
nature they rarely occur in an unbound state, but rather are found as their respective glycoside 
or phosphate derivatives. Isoprene (1) itself is formed in plants from DMAPP (11) – assisted 
by the isoprene synthase – and represents the only true hemiterpene that is isolable from 
natural sources. Other important members of this subclass are prenol (29), tiglic acid (30), 
angelic acid (31), isovaleric acid (32) and senecioic acid (33), of which the latter four often 
appear as their respective esters in alkaloid natural products (scheme 1.4). 
The biosynthetic diversion to more complex terpenoid structures starts with the formation of 
geranyl pyrophosphate (GPP, 34) by a prenyl transferase-promoted nucleophilic attack of 
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IPP (10) at an allylic cation generated from DMAPP (11). This initial head-to-tail connection 
is followed by the stereospecific elimination of the pro-R proton from cation 35 and leads to 
the fundamental all-carbon precursor of all monoterpenoids (scheme 1.5a).[10d] Approximately 
1500 naturally occurring monoterpenes have been documented to date.[2] Besides the basic 
open-chain members of this subtype, which comprise the fragrances (+)-citronellol (36), 
geraniol (37) and perillene (38), also more interlaced carbocyclic architectures are found. 
Upon elimination of pyrophosphate from GPP (34), the generated allylic cation (39) can 
undergo a variety of cyclization reactions. These ring formations often represent only the first 
part of more substantial skeletal rearrangements that are concomitant to cationic cascades. 
Scheme 1.5b lists the basic mono- and bicyclic architectures observed  
in nature and showcases some prominent oxygenated derivatives, like for instance 
(−)-menthol (40), (+)-camphor (41) and (+)-α-pinene (42). Furthermore, the so-called iridoids 
constitute an important subclass of monoterpenoids, whose biogenesis has been traced back to 
geraniol (37).[10d] Important congeners are the constituents of devil’s claw, harpagide (43) and 
procumbide (44), which have been demonstrated to inhibit thromboxane biosynthesis 
similarly to aspirin (not shown).[16] A somewhat special category of C10 terpenoids are the
  
 
Scheme 1.5:  Biosynthesis of GPP (34), basic carbon skeletons of monoterpenoids and selected examples. 
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irregular monoterpenoids like chrysanthemic acid (45), which have been found exclusively in 
the Compositae/Asteraceae plant family. Although IPP (10) and DMAPP (11) have been 
proven to be part of their biosynthesis, GPP (34) or related head-to-tail connected 
intermediates appear not to be involved. 
Analogously to the assembly of GPP (34), its carbon chain can be elongated even further by 
another C5 unit, which consequently leads to the formation of farnesyl pyrophosphate (54). 
This activated allylic compound is then biosynthetically processed in a fashion, which is 
comparable to the one that has been detailed for the generation of monoterpenoids previously 
(scheme 1.6). Because of the increased chain length and the additional carbon–carbon double 
bond, the number of possible cyclization modes is vastly increased, which is why already over 
10000 sesquiterpenoids have been isolated so far.[2] While (+)-nerolidol (55) constitutes a 
simple acyclic sequiterpenoid and is commonly used in perfumery, the mono- and 
bicarbocyclic elephantopin (56), artemisinin (57) and picrotoxinin (58) represent highly 
functionalized and potent bioactive derivatives. A fascinating aromatic sesquiterpenoid that 
can be isolated from the gorgonian Euplexaura erecta is guaiazulene (59). This compound 
features a deep blue colour, which is due to the charge separation that is inherent to the 
azulene core and establishes a stable chromophore. 
  
 
Scheme 1.6:  Chain elongation of GPP (34) to farnesyl pyrophosphate (54) and selected sesquiterpenoids.  
It is not surprising that both the C20 diterpenoids and C25 sesterterpenoids are biosynthesized 
from their respective isoprene-elongated versions of farnesyl pyrophosphate (54). Whilst the 
subclass of sesterterpenoids will be discussed in more detail later (cf. chapter 1.3), scheme 
1.7a provides a short selection of exemplary diterpenoids, which have been synthesized in the 
Trauner research group recently.[17] Although the number of realizable polycyclic 
architectures increases even further for the diterpenoids, only approximately 5000 natural 
descendants of geranylgeranyl pyrophosphate (61) are known to date.[18] To provide a 
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single but significant example for the complexity of the observed carbon frameworks, 
taxadiene (62) shall be named. This skeleton is the central motif of a prominent class of 
anticancer drugs and is enzymatically formed by the taxadiene cyclase. A special feature that 
was first discovered at this terpene cyclase is its ability to utilize an intermediary released 
proton for reprotonation of another, distant double bond to effectively relocate the cationic 
center during the biosynthetic cascade (1.7b).[19]  
  
 
Scheme 1.7:  a) Geranylgeranyl pyrophosphate (61) and selected sesquiterpenoids recently accessed by total 
synthesis in the Trauner group. b) Biosynthetic formation of the taxadiene scaffold (62). 
Interestingly, the natural precursors for tri- and tetraterpenoids are not assembled by the 
outlined IPP (10) homologation, but rather by a complex dimerization process of two 
molecules of farnesyl- (54) or geranylgeranyl pyrophosphate (61), respectively. In the case of 
triterpenoids, the mechanism of squalene (72) biosynthesis has been established in the 1970s 
after the isolation of presqualene diphosphate (73), an intermediate in the reaction sequence 
(scheme 1.8).[20] This pathway commences with a nucleophilic attack of the C-2 situated 
double bond onto a previously formed farnesyl cation (74) upon which intermediate 75 is 
generated. A subsequent enzymatically catalyzed proton loss is accompanied with the 
formation of a cyclopropane moiety and leads directly to presqualene diphosphate (73). The 
ensuing expulsion of the pyrophosphate substituent comes along with a Wagner-Meerwein-
type [1,2]-alkyl shift and gives rise to cyclopropane compound 76. This species ultimately 
undergoes a ring-opening reaction and NADPH/H+-dependent reduction to yield squalene 
(72). Further transformations, like site-selective epoxidation to (3S)-2,3-oxido-squalene (77), 
set the stage for a series of thoroughly investigated epoxide-opening cascades.[21] Triggered 
cationic cyclizations and rearrangements are the basic principles for the biogenesis of tetra- 
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and pentacarbocylic triterpenoids like lanosterol (78) or similar steroid precursors. A thorough 
discussion of the natural product class of steroids that are, strictly speaking, classified as 
nor-terpenoidsii would be beyond the scope of this thesis. At this point, only two examples 
shall be given: namely the complex octacyclic nor-terpenoid micrandilactone A (79, scheme 
1.17)[22] and cholesterol (80), which is one of many steroid congeners possessing a trans-
hydrindane substructure (cf. chapter 1.4).  
  
 
Scheme 1.8:  Biogenesis of the triterpenoid precursor squalene (72) and further epoxidation/cyclization to 
lanosterol (78) and steroids like cholerstol (80). The trans-hydrindane portion of the latter was 
highlighted bold. 
The last category of naturally occurring classical oligoterpenoids are the C40 tetraterpenoids, 
of which approximately 500 natural abundant congeners are known to date.[2] Their common 
biosynthetic precursor is the C2V symmetric substance (Z)-phytoene (83, scheme 1.9), which 
is processed from two molecules of geranylgeranyl pyrophosphate (61) in similar manner as 
already described earlier for squalene (72, vide supra). As this subclass is only represented 
by one group of compounds, they are also often referred to as ‘carotenoids’. Although 
(Z)-phytoene (83) itself is colourless, the extended π-electron system of most derived 
tetraterpenoids confers colour to them. Lycopene (84), for example, is the characteristic 
pigment in ripe tomato fruits and β-carotene (85) accounts for the orange colour of carrots. 
Apart from their function as natural dyes, carotenoids also exhibit favourable anti-oxidant
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Scheme 1.9:  Biosynthetic origin of (Z)-phytoene (83) and molecular structures of selected carotenoides, 
apocarotenoids and megastigmanes. 
properties and play an important role in photosynthesis and the vision process.[10d] Natural de-
gradation products of the tetraterpenoids are the apocarotenoids, diapocarotenoids and 
megastigmanes. The first two substance groups are formed via oxygenative double bond 
cleavage of one or two terminal sections in, for example, β-carotene (85). They include retinol 
(86) that is also known as vitamin A1. The megastigmanes involve even further biosynthetic 
degradation and are the most important fragrant components of flowers of various plant types, 
as it is the case for α-ionone (87). 
It shall be mentioned that besides the described more ‘classical’ terpenoid subtypes, also 
meroterpenoids and higher – most often polymeric – terpenoids exist in nature. Especially the 
meroterpenoids constitute a widespread class of natural products.[23] In addition to the 
terpenoid portion, their carbon skeletons usually include structural elements that are derived 
from other metabolic sources, e.g. from the acetate and the shikimate pathway, or even from 
amino acid biosynthesis. For instance, an interesting structural mixture is present in stachyflin 
(88, scheme 1.10) and related compounds, which also exhibit interesting antiviral properties 
due to their interference with low-pH conformational change of hemaglutinin.[24] 
Furthermore, several terpenoids with halogenated and polyhalogenated carbon frameworks,
     
 
Scheme 1.10:  Selected examples for meroterpenoids and halogenated terpenoids. 
(Z)-phytoene (83)
lycopene (84)
β-carotene (85) retinol (86)
OH
O
α-ionone (87)
PPO
61
phytoene
synthase
O
Cl
HO
OH
MeH
merochlorin B (90)
O
HN
O
Me
Me
HHO
OH
stachyflin (88)
Cl
HO
Br
elatol (89)
1.1 Terpenoids: Definition, Subclasses and Biosynthesis 
 
12 
like elatol (89), have been isolated from marine organisms such as sponges, algae and 
cnidarians.[25] An example of meroterpenoids with additional halogen substituents are the 
merochlorins,[26] for which Trauner and co-workers most recently disclosed the first total 
synthesis of merochlorin B (90).[27] 
 
1.2 Terpenoids: Pharmaceutical Relevance and Synthetic Aspects 
 
The biological role of terpenoid natural products is manifold and varies amongst the different 
organisms they are found in. Plants produce them, in part as defense agents against 
microorganisms and insects but also for the fulfillment of other important functions, as for 
instance carotenoids for photosynthesis or volatile molecules for their pollinator-attractive 
properties. In mammals, terpenoids contribute to stabilizing cell membranes, participate in 
metabolic pathways, and act as regulators in some enzymatic reactions.[28] In general, the 
large structural diversity inherent to this class of secondary metabolites ensures a broad range 
of biological properties, which has ultimately led to their use in treatment of human diseases. 
This is exemplified by their current clinical application in treatment of malaria and certain 
types of cancer.[29] This chapter will provide a selection of pharmaceutically relevant 
terpenoids and illustrate how their laboratory preparation has propelled the development of 
new synthetic strategies and methodologies in organic synthesis. 
Already some of the small monoterpenoids, which are best known as constituents in essential 
oils, have been shown to possess anti-tumor activity. Primarily limonene (91) and perillyl 
alcohol (92) have long been established as chemopreventive and therapeutic agents against 
many tumor cell lines (scheme 1.11) and their clinical trials have progressed to phase 1 and 
phase 2,[30,31] respectively.[29] Their mechanism of action involves the induction of apoptosis 
and interference of the prenylation of key regulatory proteins.[32] Furthermore, the pyrethrins 
(93 and 94), which are members of a small group of related monoterpenoid esters, exhibit 
valuable insecticidal properties and are used for the treatment of skin parasites such as head 
lice.[33] Due to their ability to block sodium channel repolarization in arthropod neurons,  
their application leads to paralysis and death of target vermin.[34] Today, several synthetic
  
 
Scheme 1.11:  Molecular structures of selected pharmaceutically relevant monoterpenoids.  
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Scheme 1.12:  Molecular structures of selected bioactive sesquiterpenoids and artemisinic acid (97). 
analogues with increased toxicity and resistance against biodegradation have been developed 
and become widely used household and agricultural insecticides.[10d] 
The sesquiterpenoid lactone parthenolide (95, scheme 1.12) is the major active component of 
one of the oldest traditional remedies that comes from the plant Tanacetum parthenium. This 
plant is commonly called feverfew and is today widely used for the relief of arthritis, 
migraine, asthma and psoriasis.[29] However, parthenolide (95) may occasionally cause some 
allergic side effects, due to its capability to alkylate proteogenic thiol groups.[10d] 
(−)-Gossypol (96), an interesting dimerized sesquiterpenoid, is one of the major components 
in cottonseed and has been found to act as a male contraceptive. Extensive clinical trials in 
China established that the antifertility effect is usually reversible after stopping the treatment, 
provided that the consumption has not been too prolonged.[35] Besides its desired function in 
altering sperm maturation, spermatozoid motility and inactivation of sperm enzymes 
necessary for fertilization, severe side effects were observed including high rates of 
hypokalemia among test subjects.[36] Another drawback for its clinical use is the toxicity of 
the concomitant atropisomer (+)-gossypol (not shown), which cannot be separated fully upon 
isolation. Hence, research on this compound was widely abandoned in the late 1990’s.[37]  
In contrast, the sesquiterpenoid artemisinin (57) is an approved drug for the treatment of 
malaria. It is isolated in 0.1–0.4 wt-% from the widespread herb species Artemisia annua. 
Early records reveal that this plant was already used by Chinese herbalists more than two 
thousand years ago.[10d] Although the discovery of artemisinin (57) and the first investigations 
on its mode of action were part of a secret Chinese military project, it is today accepted that 
Y. Tu was the original principal investigator back in 1969.[38] In 2012, it was reported that 
artemisinin-based therapies were the most effective clinical treatment of malaria at that 
time.[39] The actual mode of artemisinin’s (57) anti-malarial action is still a topic of 
considerable debate. One mechanism that is discussed refers to the effect of the endoperoxide 
group on free Fe3+, which is released during digestion of hemoglobin. It is suggested that 
the iron directly reduces the peroxide bond in artemisinin (57), generating high-valent 
iron-oxo species. This supposedly results in a cascade of reactions that produce reactive 
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oxygen radicals, which ultimately damage the parasite and lead to its death.[40] Today, 
artemisinin (57) is largely accessed via isolation and semisynthesis, starting from the naturally 
more abundant relative artemisinic acid (97). Industrial semisynthesis was first conducted by 
the company Amyris and was accomplished according to the ground breaking work of Acton, 
Roth[41] and Brown.[42] Very recently, the company Sanofi published their improved 
semisynthetic protocol, which is detailed in scheme 1.13.[43] It features a highly 
diastereoselective hydrogenation of the exocyclic double bond of artemisinic acid (97) using a 
Ru(II)- and (R)-DTMB-SEGPHOS-based (not shown) catalyst system. After transformation 
of substance 98 to activated mixed anhydride 99, an initial Schenck ene reaction[44] with 
singlet oxygen leads to peroxide 100, which undergoes sequential protonation and Hock 
cleavage[45] to intermediate 111. Final oxygenation and cyclization then yield the desired drug 
(57) in 55% over three steps. Notably, Sanofi uses a modification of Keasling’s biosynthetic 
pathway for the in vivo preparation of artemisinic acid (97) in yeast.[46] Although a plethora of 
total syntheses of artemisinin (57) has been disclosed in the past, none of those can compete 
with the semisynthetic approach in terms of cost.[47]  
  
 
Scheme 1.13:  Sanofi’s semisynthesis of artemisinin (57) from biochemically prepared precursor 97. The 
Ligand L equals to (R)-DTMB-SEGPHOS. 
Regarding diterpenoid natural products, the ginkgolides represent a structurally intriguing 
bioactive subclass and can be isolated from Ginkgo biloba.[48] The standardized extracts of the 
plant leaves are marketed for treatment of cerebral vascular disease and senile dementia, for 
which virtually all clinical studies have reported positive results. After the discovery that 
especially ginkgolide B (116, scheme 1.14) is an antagonist of the platelet-activating factor 
(PAF) receptor, extensive clinical studies on their potential use against respiratory infections 
were initiated.[48] Although these studies could show that the compound is well tolerated with
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Scheme 1.14:  Structures of selected bioactive diterpenoids and of natural occurring Taxol® precursor 118. 
very few side effects, it was never registered as a drug due to a lack of efficacy. The probably 
best-investigated and pharmaceutically most valuable class of diterpenoids are the taxanes. 
Over 100 different species have been characterized to date, one of which is paclitaxel (117, 
Taxol®) that is clinically used for the treatment of ovarian and breast cancer.[10d] First isolated 
from the bark of the pacific yew tree Taxus brevifolia in 1967, the natural product underwent 
thorough investigation until it was eventually approved as a drug by the FDA in 1992.[49] 
Several increasingly soluble and potent synthetic analogues have been subjected to clinical 
trials, aiming at countering multiple drug resistance.[50] Like several other anticancer drugs, 
paclitaxel (117) interacts with tubulin (more accurately the β-tubulin subunit) and effectively 
inhibits cell proliferation. Several in-depth studies have established that the drug retards 
microtubule depolymerization by formation of unusually stable microtubules.[51] This leads to 
a disruption of the dynamic reorganization of the microtubule network, thus causing cellular 
arrest in the G2/M phase of the mitotic cycle. By 1992, about 30 research teams were working 
on a total synthesis of paclitaxel (117),[52] which culminated in a ‘photo finish’ between the 
groups of Nicolaou[53] and Holton,[54] who both have to be credited for the first independent 
successfully disclosed syntheses. Besides numerous studies, which have made substantial 
contributions to the development of synthetic methodology, to date seven total syntheses and 
two formal syntheses of paclitaxel (117) are known.[55] However, today plant cell fermen-
   
 
Scheme 1.15:  Baran’s synthesis of taxadienone (119). Compounds 120 and 121 are prepared in one step each. 
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tation from specific Taxus cell lines has relieved the former less economic semisynthetic 
process.[56] The latter starts from 10-deacetylbaccatin III (118), a more abundant taxane 
derivative, which is isolated predominately from European yew.[57] Although still not being 
competitive in terms of cost, Baran and co-workers recently published a high yielding short 
sequence toward taxadienone (119, scheme 1.15)[53] that exemplifies the ongoing advances in 
organic synthesis. After combining two very easily prepared building blocks (120 and 121) 
via Lewis acid assisted organocopper 1,6-addition, they demonstrated an elegant use of 
Alexakis’ enantioselective conjugate addition methodology[58] to access enantioenriched TMS 
ether 122. Ensuing Mukaiyama[59] aldol addition under Kobayashi’s conditions[60] and one-pot 
treatment with Jones’ reagent[61] forged precursor 123 for the substrate-controlled key Diels-
Alder reaction. Although the aldol addition step suffers from low diastereoselectivity, the high 
overall yield (18–20%) of this scalable route poses an impressive synthetic achievement.  
Omitting the large family of steroid-based pharmaceuticals, the diterpenoid ingenol 
mebutate (127) shall be mentioned as a last, synthetically relevant example of a successfully 
approved drug. The parent natural product ingenol (128) was first isolated in 1968[62] from 
Euphorbia ingens and soon attracted chemists after the elucidation of its intriguing strained 
molecular structure.[63] Several ester derivatives of this diterpenoid have been reported to 
exhibit important in-vivo anti-HIV or anticancer activity due to their interaction with protein 
kinase C.[64] Ingenol mebutate (127) itself is currently sold by LEO Pharma under the name 
Picato® as a first-class treatment of actinic keratosis, a precancerous skin condition.[65] The
  
 
Scheme 1.16:  Baran’s synthesis of ingenol (128) and molecular structures of phorbol (133) and Picato® (127). 
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drug is produced by semisynthesis starting from ingenol (128), which can be obtained by a 
tedious isolation protocol in a low yield of approximately 250 mg/kg.[66] Consequently, 
chemists have invested several decades of effort to provide the compound more economically, 
which culminated in four total syntheses and numerous approaches toward its carbon 
skeleton.[65,67] Interestingly, the most recent approach, disclosed by Baran and co-workers and 
supported by LEO Pharma, has the potential to become one the few total syntheses that are 
applied for the industrial production of a therapeutic compound. In their ingenious 14-step 
synthesis (scheme 1.16), they demonstrate the construction of all-carbon precursor 129 in 
only six transformations starting from the readily available monoterpenoid (+)-carene (130). 
Prominent features are a one-pot methylation/aldol addition protocol and a rhodium-catalyzed 
allenic Pauson-Khand reaction.[68] Continuing in the sequence, a most intriguing and possibly 
biomimetic[65,69] vinylogous pinacol rearrangement is applied to convert the phorbol-type 
carbon skeleton (131) into the strained ingenol system (132). The announced further 
development to an industrial process would prove the viability of economic large-scale total 
syntheses of complex organic molecules. 
Terpenoids in general have attracted synthetic chemists ever since the dawn of modern 
organic chemistry. A major stimulus has come from the quest for the discovery of novel 
bioactivity and the potential development and large-scale production of therapeutic 
compounds. Additionally, the sheer challenge of constructing the complex molecular 
frameworks devised by nature has often been an inherent motivation. Since Komppa 
established the first process for the industrial preparation of camphor (41) in the early 
1900’s,[70] a plethora of synthetic methodologies was devised and substantial mechanistic 
insights in organic transformations were gained in the course of terpenoid total syntheses. 
Prominent examples for elucidated novel modes of reactivity are, for instance, the Wagner-
Meerwein rearrangement,[71] or biomimetic epoxide opening[72] and cationic cyclization 
cascades.[73] Further important contributions to the evolution of synthesis stem from the long-
lasting extensive explorations in steroid chemistry, which involved Woodward’s pioneering 
use of Diels-Alder reactions.[74] Organocatalysis and its important applications in modern 
asymmetric synthesis can also be traced back to the seminal work published on the 
construction of the Wieland-Miescher ketone[75] (not shown) and the Eder-Sauer-Wiechert-
Hajos-Parrish ketone (138, cf. chapter 2.3).[76] Furthermore, essential principles in chemistry 
such as retrosynthetic[77] and conformational analysis[78] were originally developed and 
adopted for terpenoid synthesis. Last but not least, total synthesis of natural products still 
remains an indispensable technique for structural elucidation, although the advent of modern 
1.2 Terpenoids: Pharmaceutical Relevance and Synthetic Aspects 
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analytical methods such as two-dimensional NMR spectroscopy and X-ray crystallography 
provides relief in many cases.[1a] In particular, the absolute stereochemical configuration of 
complex polycyclic skeletons can often only be established by means of preparative synthetic 
methods, which is exemplified by the nor-terpenoid micrandilactone A (79, scheme 1.17).[22] 
Selected examples of renowned, recently disclosed terpenoid syntheses comprise the intricate 
molecules resiniferatoxin (139, Wender, 1997),[79] phomactin A (140, 2002, Pattenden),[80] 
maoecrystal V (141, 2011, Reisman)[81] and taiwaniadduct B (142, 2014, Li).[82]  
   
 
Scheme 1.17:  Complex polycyclic terpenoids, of which compounds 139 to 142 were recently accessed by 
means of total synthesis. 
 
1.3 Sesterterpenoids: Chemical Synthesis, Subtypes and Background 
 
In this chapter, the subclass of sesterterpenoids will be introduced in detail, for one target of 
this doctoral thesis is the development of the first total syntheses of a certain type of 
biosynthetically closely related congeners (cf. chapter 1.5). At first, the most prominent parent 
architectures will be categorized and short biological profiles will be provided. 
The sesterterpenoids represent, with about 1000 currently characterized compounds, a 
relatively small subgroup of terpenoid natural products. This is surprising with regard to their 
comparatively large size, structural complexity and molecular diversity.[83] Scientists have 
recovered them from widespread biological sources comprising distinct organisms like 
terrestrial fungi, lichens, higher plants, insects and various marine species,[84] particularly 
sponges.[85] They contain two and a half (lat. sester) ‘terpene units’, which is related to a 
historic nomenclature and based on the outdated assumption that terpenoids are assembled 
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Scheme 1.18:  Common carbon frameworks found in sesterterpenoid natural products and ophiobolin A (151). 
from pieces made of ten carbons.[2b] Accordingly, sesterterpenoids are constituted of C25 (or 
slightly fewer) architectures and essentially originate from their previously discussed 
biogenesis (cf. chapter 1.1) that branches off at the shared precursor geranylfarnesyl pyro-
phosphate (143, cf. scheme 2.3). In this context, terpene cyclase-mediated cationic cascade 
reactions, enzymatic oxygenations and partial skeletal degradations provide a multitude of 
intricate polycyclic frameworks. These pose highly attractive targets for total synthesis and 
allow for the validation of new chemical methodology at complex molecular settings.[83] Over 
the course of the last decades, an increasing number of review articles has been dedicated to 
this family of compounds, which is partially attributed to intensified studies on their 
biological properties.[86] Commonly, sesterterpenoids are classified with respect to their basic 
carbon skeletons that include linear, mono-, di-, tri-, tetra- and even pentacarbocyclic 
congeners. Furthermore, six major subtypes of ring systems have been observed to occur 
more frequently in nature (scheme 1.18), namely the cericeranes (144), prenyldolabellanes 
(145), diprenyldrimanes (146), cheilanthanes (147), ophiobolanes (148) and scalaranes 
(149).[2b] A very recent addition to this list is denoted by the leucosceptroids (150), of which 
already 23 family members have been isolated to date.[87] The first characterization of a 
natural occurring sesterterpenoid was reported in 1958 by Nakamura.[88] The compound was 
named ophiobolin A (151), according to its host organism Ophiobolus miyabeanus, and was 
early on described as an antibiotic. After the elucidation of its molecular structure via X-ray 
crystallographic analysis,[89] more than 20 related compounds were found that share the 
central fused 5-8-5-membered ring system. They have been evidenced as potent agents 
against certain strains of bacteria and fungi, as well as anticancer cycotoxins.[90] The largest
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Scheme 1.19:  Kocienski’s asymmetric syntheses of (+)-manoalide (152) and (3R,4R)-luffariolide E (158). 
family of sesterterpenoids are the cheilanthanes, with over 50 currently known members. 
Several total synthesis have been published on this subtype in the past, of which the majority 
focused on semisynthetic approaches and have been reviewed elsewhere.[86g] The total 
number of syntheses of – or synthetic studies toward – sesterterpenoid natural products still 
remains in the two-digit regime. A comprehensive summary dedicated to this topic has been 
published by Hog et al. in 2012 and served as model for the following second part of  
this chapter.[83] Progressing from mono- to pentacarbocyclic architectures, a selection of 
distinguished strategies toward some of the most prominent congeners of this substance class 
will be presented.iii In addition, the advances published in this field over the last two years 
will be added. To this end, the focus will lie on transformations dealing with the construction 
of the central carbon ring systems and showcase the key intermediates utilized therein.  
The discussion starts with the relatively simple monocarbocyclic sesterterpenoid 
(+)-manoalide (152) that was isolated in 1980 by Silva and Scheuer from Luffariella 
variabilis, a marine sponge.[91] Although it bears only one stereocenter, seven racemic and 
two enantioselective total syntheses have already been reported by the groups of 
Katsamura,[92] Garst,[93] Sandano,[94] Hoffmann,[95] and Kocienski.[96] This can be attributed to 
the significant pro-inflammatory properties of this natural product, which are due to a potent 
irreversible inhibition of phospholipase A2.[97] The latest asymmetric approach that was 
disclosed by Kocienski and co-workers in 2003 starts from furyl aldehyde 153 and sets the 
                                                
iiiThe entirety of known total syntheses of iso-propyl trans-hydrindane sesterterpenoids will be discussed in 
chapter 1.4.2. 
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single stereogenic center via Sharpless’ kinetic resolution[98] at an early stage (scheme 1.19). 
After Mo(0)-catalyzed cycloisomerization and in situ stannylation (154), the further strategy 
hinged on a copper-mediated 1,2-metalate rearrangement. Mechanistically, this key step 
proceeds via an initial metal exchange with sec-BuLi and subsequent addition of a mixed 
cuprate (155) to trigger the desired alkyl shift. The sequence is terminated by quenching 
species 156 with iodine, which forms another functional handle for following coupling 
reactions in a very elegant way. The use of β-ionone (157) as precursor for fragment 155 
showcases another feature common to synthetic strategies toward complex terpenoids, namely 
the processing of small inexpensive monoterpenoid building blocks. This is most often 
combined with the convenient introduction of chiral centers. Notably, Kozcienski and co-
workers also synthesized (3R,4R)-luffariolide E (158) by an analogous 1,2-metalate 
rearrangement protocol, but this time directly carboxylating the generated intermediary 
cuprate species.[99] 
Another classical target in sesterterpenoid synthesis is the bicarbocyclic fungal metabolite 
terpestacin (161), which was first isolated in 1993 by the group of Oki.[100] It was already
  
 
Scheme 1.20:  a) Tius’ 15-step synthesis of racemic terpestacin (161) and b) Myers’ enantioselective 18-step 
synthesis of (−)-terpestacin (161). 
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characterized early on as a promising candidate for the treatment of HIV, as it inhibits the 
formation of syncytia, i.e. multinuclear cell bodies that are an indirect but major cause of 
infection-induced death of T4 cells.[100] The intriguing molecular structure, which comprises 
four stereogenic centers and a fused 15-membered ring system with three internal 
trisubstituted olefins, renders this natural product an archetype for the strategic application of 
modern synthetic carbon–carbon bond forming methodologies. Hence, it is not surprising that 
seven total syntheses have been devised to date, four of which are enantioselective. Four of 
those successful strategies involved macrocyclization via means of a Horner-Wadsworth-
Emmons (HWE) reaction and were reported by the groups of Tatsuta (1998),[101] Tius 
(2007)[102] and Qui (2012).[103] Tius’ exemplary work allows access to the racemic natural 
product in only 15 consecutive reactions in a highly convergent manner and excellent 6.4% 
overall yield (scheme 1.20a). Starting from γ-butyrolactone (162), the authors set the initial 
stereocenter via allenyl ether Nazarov cyclization[104] (163). Next, they used the 
stereochemical bias of the resulting cyclopentene system (164) to direct an alkylation with 
allylic bromide 165. Ensuing deprotection, oxidation and HWE olefination under modified 
Masamune-Roush conditions[105] gave rise to the bicyclic core structure (166). A final 6-step 
sequence was required to arrive at (±)-terpestacin (161). 
Myers’ enantioselective synthesis from 2002[106] introduces chirality via ψ-ephedrine derived 
building block 167 that can be accessed using the method for asymmetric, auxiliary-assisted 
alkylation reactions developed in the same group (scheme 1.20b).[107] To begin, a 4-step 
protocol sets the stage for the key fragment combination of lactone 168 with allylic bromide 
169, which proceeded via substrate-controlled enolate alkylation and forms substance 170. 
Later in the synthesis, the authors describe another intramolecular enolate allylation to 
construct the desired fused 12-memberd carbocycle (171) diastereoselectively. The natural 
product was then obtained after seven further transformations. 
   
 
Scheme 1.21:  Key intermediates 176 and 175 in a) Jamison’s and b) Trost’s syntheses of terpestacin (161). 
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Two more enantioselective syntheses of (−)-terpestacin (161) have been disclosed by Jamison 
(2003)[108] and by Trost (2007),[109] respectively. The first of these resorted again to an 
intramolecular allylation protocol that bears similarities to Myers’ approach (scheme 1.21a). 
In contrast, the second case describes the use of a RCM reaction to achieve the key ring 
closure (scheme 1.21b), which is facilitated by the allylic alcohol function (cf. chapter 3.5) in 
pentaene precursor 175. 
 
Scheme 1.22:  Magauer’s synthesis of (+)-norleucosceptroid A (180), (−)-norleucosceptroid B (181) and 
leucosceptroid K (184). 
A novel synthetic challenge is presented by the relatively young class of leucosceptroid 
sesterterpenoids, of which the first member was isolated from Leucosceptrum canum only 
10 years ago.[110] Attracted by the plant’s high resistance to herbivores and pathogens,  
it was soon established that this natural product class in general displays potent  
antifeedant activity. Consequently, these compounds have been considered as an alternative  
to conventional synthetic pesticides.[87,111] Structurally, all members share a highly 
functionalized 5,6,5-membered polycyclic framework that differs in the oxidation state at 
C-11 and the substitution of the C-14 ethyl linkage (cf. scheme 1.18). Following the 
pioneering work of Horne and co-workers,[112] who reported a first approach to the core of the 
leucosceptroids, the group of Liu published the first total synthesis of leucosceptroid B (not 
shown) in 2013.[113] Very recently, Magauer and co-worker reported a general entry to this 
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Hauser-Kraus-type annulation[114] (178) that in turn furnished tricycle 179 in a 3:1 mixture of 
diastereomers on multi-gram scale. Although they encountered an unexpected retro-Claisen 
condensation en route, they were able to circumvent this reactivity and accessed building 
block 180 in eight further steps. When this material was submitted to regioselective 
hydroxylation and subsequent IBX-mediated intramolecular acetal formation, 
(+)-norleucosceptroid A (181) and (−)-norleucosceptroid B (182) were isolated as the 
major and minor products, respectively. A final HWE-type olefination with phosphonate 183 
gave rise to leucosceptroid K (184) in 18 steps longest linear sequence. 
   
 
Scheme 1.23:  Uenishi’s biomimetic synthesis of (−)-ircinianin (187) and (+)-wistarin (188). 
Two complex bicarbocyclic furanosesterterpenoids, namely (−)-ircinianin (187)[115] and 
(+)-wistarin (188),[116] were isolated from marine sponges of the genus Ircinia in 1977 and 
1982, respectively. Inspired by the published biosynthetic proposal, Yoshii and Takeda 
achieved the first racemic synthesis of ircinianin (187) in 1986.[117] Several years later, 
Uenishi and co-workers refined this strategy and devised a successful enantioselective route 
to both related natural products 187 and 188 (scheme 1.23).[118] Their approach hinged on a 
key fragment coupling by means of a Nozaki-Hiyama-Kishi reaction[119] between (R)-Roche 
ester (189) derived aldehyde 190 and alkenyl iodide 191, which was accessed in 12 steps from 
3-furyl aldehyde (192). Interestingly, only the main diastereomer that was produced in this 
reaction immediately underwent the biomimetic intramolecular Diels-Alder cyclization to 
yield trans-hydrindane system 193. However, the authors showed that Lewis acid catalysis by 
the present CrCl2 was crucial for this reaction to proceed at room temperature. Three further 
transformations led to (−)-ircinianin (187), which in turn was converted to (+)-wistarin (188) 
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via a two-step iodolactonization/radical dehalogenation protocol. Notably, the compound was 
the first example of a sesterterpenoid that occurs naturally in both enantiomeric forms.[120] 
Regarding the family of tricarbocyclic sesterterpenoids, the previously mentioned ophiobolins 
have been the target of a considerable amount of synthetic studies since their inital discovery 
56 years ago (vide infra).[83] From a structural point of view, the artificial construction of their 
highly functionalized fused 5-8-5-carbocyclic framework poses an intricate challenge even  
to modern chemistry. Especially the closure of 8-membered ring systems still requires  
careful retrosynthetic planning and was of high significance for the reported studies on 
ophiobolin natural products,[121] as well as for the experimental work of the present doctoral 
thesis. To this end, the only two completed total syntheses of (+)-ophiobolin C (195, 1989, 
Kishi)[61] and (+)-ophiobolin A (151, 2011, Nakada)[122,123] shall showcase late-stage 
cyclization strategies. 
   
 
Scheme 1.24:  Kishi’s enantioselective synthesis of (+)-ophiobolin C (195), using an intramolecular Nozaki-
Hiyama-Kishi reaction to construct the central cyclooctene ring system. 
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adjustment of the substitution pattern required another 9 transformations to complete 
(+)-ophiobolin C (195). 
The more recent synthesis of (+)-ophiobolin A (151), which was published by Nakada and 
co-workers, made elegant use of the considerable advancement of modern Ru-catalyzed olefin 
metathesis chemistry (scheme 1.25).[125] However, the preparation of a suitable diene 
precursor had to comply with the overall complexity of the molecule and required 40 steps 
from acid 203 that in turn was accessed by an enzymatic desymmetrization protocol. Notably, 
a highly diastereoselective Reformatsky-type reaction[126] between aldehyde 204 and bromide 
205 was applied in order to install the western cyclopentane moiety in a more convergent 
manner. The following sequence was mainly shaped by protecting group manipulations, as 
the RCM reaction turned out to be highly sensitive toward steric congestion at the reaction 
sites. The actual RCM reaction was conducted with Hoveyda-Grubbs II catalyst (206, cf. 
scheme 3.19) under the addition of 1,4-benzoquinone (not shown), which was required to 
prevent undesired double bond isomerization. As demonstrated in Trost’s terpestacin (161) 
synthesis, an allylic alcohol was used to facilitate the key step (vide infra). An ensuing 6-step 
sequence furnished the natural product in an overall remarkable synthetic effort. 
   
 
Scheme 1.25:  Nakada’s enantioselective strategy toward (+)-ophiobolin A (151), closing the 8-membered ring 
via a highly optimized RCM reaction. 
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functionalized, ophiobolane-type carbon skeletons.[127] The central challenge in their 
construction is again the octanoid ring system that is embedded in a 5-8-5-tricarbocyclic 
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(+)-ceroplastol II (211) and albolic acid (212),[128] both isolated previously from the wax 
secretion of the scale insect Ceroplastes albolineatus.[129] Their approach resorted to a Ti(II)-
mediated reductive carbonyl-carbonyl coupling strategy (scheme 1.26) and served as an 
important example of the feasibility of the later described first-generation retrosynthetic 
analysis of astellatol (213, cf. chapter 4.2). Despite its overall length, with 42 synthetic steps, 
Kato’s synthesis features interesting transformations such as the initial diol formation toward 
substance 214 that once more employs in situ generated TiCl2 reagent.[130] In the following, an 
optical resolution of the corresponding (−)-menthyl esters (not shown) was conducted and 
both enantiomers were processed to building blocks 215 and 216 in 8 and 14 steps, 
respectively. A CrCl2-promoted reductive coupling of both compounds gave rise to 
intermediate 217, which was converted to bisaldehyde 218 in 15 further steps. Interestingly 
the key ring closure to tricycle 219 was not accompanied by any vinylogous side reactions (cf. 
chapter 4.4) and provided a remarkable 96% yield. In nine final transformations, ester 220 
was accessed and either reduced to (+)-ceroplastol II (211) or saponified to albolic acid (212). 
   
 
Scheme 1.26:  Kato’s enantioselective route toward (+)-ceroplastol II (211) and (+)-albolic acid (212), featuring 
an intramolecular reductive diol formation to construct the 8-membered carbocycle. 
In close progression, Boeckman (1989, racemic)[131] and Paquette (1993, enantioselective)[132] 
published their syntheses of (+)-ceroplastol I (222), which opted for ring opening and ring 
expansion strategies, respectively, to elaborate the cyclooctane framework. Scheme 1.27 
illustrates the key intermediates that were involved in both strategies. Boeckman and 
co-workers used a base-induced Grob fragmentation[133] to convert tricycle 223 to cyclo-
octene 224. In contrast, Paquette and co-workers devised a sequential Tebbe olefination[134] 
and Claisen rearrangement[135] protocol to construct cyclooctenone 225. In summary, both 
   
O
O
221
prepared in
1 step
Zn
TiCl4 OH
OH
Me
COOMe
214
8 steps
12 steps
via (− )-menthol
ester resolution
CHO
215
216
Cl
HMe OBn
OHMe
OBn
Me
HCrCl2
217
15 steps
Me
H H
Me OPivO O
H
218
Zn
TiCl4
Me
H H
Me OPiv
H
219
9 steps
OHHO
Me
H H
Me
H
220
for 211
LiAlH4
for 212
NaOH
EtOOC
Me
H H
Me
H
R
(+)-ceroplastol II (211) 
(+)-albolic acid (212)
R = CH2OH
COOH
stereochemistry
not elucidated
1.3 Sesterterpenoids: Chemical Synthesis, Subtypes and Background 
 
28 
 
Scheme 1.27:  Total syntheses of ceroplastol I (222) published by the groups of Boeckman and Paquette. 
approaches are of similar length and reach completion of the natural product after 23 and 27 
steps, respectively. 
For tetracarbocyclic sesterterpenoids, largely semisyntheses of scalarane-type natural 
products[136] and one successful approach toward cerorubenic acid III (not shown)[137] are 
known. Instead, Liu’s very recently published first total synthesis of the structurally complex 
pentacarbocyclic molecule bolivianine (227),[138] which was isolated in 2007 from 
Hedyosmum angustifolium,[139] will be presented as a closing example for this chapter. 
Although no biological properties of the compound are known to date, an interesting 
biosynthetic proposal was put forward. It was hypothesized that the known sesquiterpenoid 
onoseriolide (228) might undergo condensation with an equivalent of geranyl pyrophosphate 
(34) and – after further processing – react in an intramolecular hetero-Diels-Alder cyclization 
to yield bolivianine (227).[138] In their enantioselective synthesis, Liu and co-workers started 
from the naturally abundant monoterpenoid (+)-verbenone (229) and accessed hydrazone 230 
in an initial 5-step sequence (scheme 1.28). From this substance, the western 3- and  
5-membered rings in trans-hydrindane system 231 were constructed via palladium-catalyzed 
cyclopropanation. After another six transformations they obtained onoseriolide (228). This 
material was oxidized with IBX and the resulting aldehyde was submitted to a sealed tube 
thermal Diels-Alder/hetero-Diels-Alder cascade reaction using the monoterpenoid 
β-(E)-ocimene (232) as the initial diene. In total, only 14 steps were needed to construct the 
natural product’s highly convoluted heptacyclic framework and to provide experimental proof 
of the proposed modified biogenetic pathway. 
The synthetic strategies outlined in this chapter exemplify that – like ever so often in 
terpenoid chemistry – the artificial construction of sesterterpenoids is greatly shaped by the 
challenges that lie in the formation of fused- and macrocyclic ring systems, as well as in the
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Scheme 1.28:  Liu’s biomimetic synthesis of bolivianine (227), featuring a Diels-Alder/hetero-Diels-Alder 
cascade. 
construction of their concomitant non-heteroatom-substituted stereogenic centers. The 
presented natural product syntheses have spurred the development of a variety of chemical 
methodologies, like the different protocols that were devised to construct the 8-membered 
ring system of the ophiobolane framework (vide infra). Besides supplying material for 
biological studies, also theseindirect proof of proposed biosynthetic pathways could be given. 
The next chapter will focus more on the last members of the sesterterpenoid family that have 
not yet been discussed, namely the iso-propyl-substituted trans-hydrindane sesterterpenoids. 
 
1.4  iso-Propyl-Substituted trans-Hydrindane Sesterterpenoids 
 
1.4.1 Comprehensive Overview of the Subclass 
 
Amongst the sesterterpenoid natural products isolated so far,[84–86] 20 compounds have been 
documented to share a common structural feature, namely a trans-fused hydrindane system, 
which is additionally substituted by an angular methyl group at the ring junction and an 
iso-propyl-type function at the C-3 position.iv In almost all cases, the remaining carbon atoms 
of the biosynthetic precursor geranylfarnesyl pyrophosphate (143, cf. chapter 1.1) are 
incorporated in intricate fused ring systems and no chain-like substructures are formed. A 
further plausible classification, according to the connectivity of mentioned trans-hydrindane 
moiety to the respective other carbocycles, was suggested by Hog[140] and was adopted for the 
discussions presented in this doctoral thesis (scheme 1.29). Correspondingly, congeners of 
this sesterterpenoid subclass are distinguished as type A (234) and type B (235), where ring 
fusion occurs either at the C-5 to C-6 edge or the neighboring C-4 to C-5 edge of the 
                                                
ivThe nomenclature for hydrindane-type carbocyclic systems was adopted from the IUPAC.[4] 
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hydrindane hexacycle, respectively. Interestingly, both epimers of the C-3 stereocenter have 
been described for molecules of type A, whilst only the trans-orientation of the angular 
methyl group and the iso-propyl substituent is known for type B. Amongst the latter family, a 
concomitant unsaturation to an iso-propenyl functionality is encountered frequently. For the 
sake of a simplified structural comparison, some compounds were drawn as their unnatural 
enantiomers in the following section.v  
   
 
Scheme 1.29:  Classification of known iso-propyl-substituted trans-hydrindane sesterterpenoids into type A 
(234) and type B (235), according to Hog. 
In 1965, the first iso-propyl-substituted trans-hydrindane sesterterpenoid was isolated from a 
Himalayan lichen species and named retigeranic acid A (236, scheme 1.30).[141–143] Besides 
the in detail discussed hydrindane motif, ongoing investigations revealed an at that time 
unprecedented angular triquinane portion.[144–146] Further details on its structural elucidation, 
proposed biosynthesis, and the discovery of its C-3 epimer retigeranic acid B (237) are 
provided in chapter 2.1, where experimental results of our synthetic studies toward these 
natural products will be presented. Notably, retigeranic acid A (236) was the only member of 
this family that had been successfully addressed by total synthesis prior to 2014. Attracted by 
its daunting structure, the groups of Corey,[147,148] Paquette,[149,150] Hudlicky[151,152] and 
Wender[153] published their synthetic studies in the late 1980’s, which have since then become 
classics in terpenoid synthesis and are detailed in the next chapter. Two related type A natural 
products are nitidasin (238)[154] and astellatol (213),[155] found in Gentaniella nitida and 
Aspergillus variecolor, respectively. For both compounds, a very similar cationic cascade is 
part of their biogenesis and was of central importance for the retrosynthetic approaches 
developed over the course of this doctoral thesis (cf. chapters 3 and 4). At this point, the 
completed synthesis of nitidasin (238)[156] and previous synthetic investigations towards the 
construction of astellatol (213) that were conducted in our group shall be referenced.[157] 
Historically, the tetracarbocyclic sesterterpenoid aleurodiscal (239) was the first known 
congener of the discussed family that possesses the characteristic 5-8-6-5-membered ring
   
                                                
vIf no sign of the optical rotation is provided (dexrotatory or levrotatroy), the absolute configuration of the 
natural product has not been assigned yet, to the best of our knowledge. 
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Scheme 1.30:  Molecular structures of all seven known type A iso-propyl-substituted trans-hydrindane 
sesterterpenoids. Compounds 236, 237 and 239 were drawn as their unnatural enantiomers. 
system of nitidasin (238) and was isolated in 1989 from the fungus Aleurodiscus 
mirabilis.[157] Concomitant with the isolation, its structure was verified via X-ray 
crystallography and the absolute configuration was elucidated by means of hydrolytic 
cleavage of the glycoside linkage to D-(+)-xylose (not shown). Although the natural product 
showed promising antifungal activity by inhibiting the incorporation of N-acetyl-D-
glucosamine (not shown) into chitin and chitosan, no further studies on its bioactivity have 
been published so far. Aleurodiscal (239) and retigeranic acid A (236) are unique amongst the 
type A subclass, as they feature a trans-relationship between the iso-propyl residue and the 
angular methyl group at the hydrindane system. From a synthetic point of view, the double 
unsaturation of the central cyclooctadiene framework in aleurodiscal (239) poses a 
considerable challenge in terms of chemoselectivity and could not yet be found in any other 
natural occurring substances. One last type A sesterterpenoid that comprises the 5-8-6-5 
carbocyclic backbone has been isolated by Wang et. al from the fungal strain Codinaea 
simplex in 1998 and was entitled YW 3699 (240).[158] The molecular structure and relative 
configuration of its stereocenters was elucidated by means of 2D NMR spectroscopical 
investigations. Although the relative stereochemistry of the heptanoate side chain could not be 
assigned, several studies on the bioactivity of this compound have been described so far. 
Therein, it was disclosed that both YW 3699 and the related lactone YW 3548 (241)[159] 
exhibit potent and selective inhibition of the GPI-anchoring biosynthesis in mammalian 
cells.[160] In combination with their extended SAR studies, Wang and co-workers proposed 
that the YW compounds exert their toxicity by preventing the incorporation of [3H]myo-
inositol (not shown) into proteins, which in turn frustrates the transport of GPI-anchored 
proteins to the Golgi apparatus.[159,160] 
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Continuing to the subclass of type B iso-propyl-substituted trans-hydrindane sesterterpenoids, 
the five known variecolins represent the majority of the known congeners (scheme 1.31). In 
1991, Hensens and co-workers described the isolation of variecolin (242) from Aspergillus 
variecolor – the same biological source reported previously for astellatol (213).[161] Together 
with the structural elucidation of variecolin (242) by means of 2D NMR spectroscopy, they 
put forth a biosynthetic proposal that links the variecolins closely together with opbiobolin- 
and ceriferene-type[162] natural products (vide infra). Furthermore, they evaluated the 
compound as an angiotensin II receptor binding inhibitor. Later on, the related compounds 
variecolol (243),[163] variecolactone (244),[163] variecoacetal A (245)[164] and variecoacetal B 
(246)[164] were found and characterized as immunomodulatory agents. In 2004, four additional 
variecolin-type sesterterpenoids were isolated by the Butler research group from the extract of 
the fungus Emericella aurantiobrunnea.[165] Despite their inherent structural similarity to the 
variecolins, the authors named those compounds emericolins A–D (247–250). Interestingly, 
they obtained variecolin (242) from the same organism and confirmed its structure 
unambiguously via X-ray crystallographic analysis. In 2013, She et al. discovered the latest 
member of the type B subgroup, asperterpenoid A (251), in a fungal strain of the genus 
Aspergillus.[166] Its complex pentacarbocyclic molecular structure was first investigated by 
means of NMR spectroscopy and eventually established via X-ray crystallographic analysis. 
The proposed biosynthetic pathway accounts for a close kinship with the variecolins. The 
latter branch off at the common cationic cyclization cascade by generating the iso-propenyl 
substituent via elimination, rather than undergoing the [1,5]-hydride migration that is 
suggested for the formation of asperterpenoid A (251). The resulting [7.1.0]cyclooctane motif 
   
 
Scheme 1.31:  Listing of all known type B iso-propyl-substituted trans-hydrindane sesterterpenoids. 
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surely represents a daunting target for synthetic chemists, which is emphasized by the natural 
product’s potent inhibitory properties against Mycobacterium tuberculosis protein tyrosine 
phosphatase B.[167]  This enzyme is secreted by the parent microbe and manipulates the host’s 
signal transduction in order to facilitate the infection process. Thus, inhibitors like 
asperterpenoid A (251) are currently considered to be promising targets for curing pulmonary 
tuberculosis.[168] 
   
 
 
Scheme 1.32:  Molecular structures of the three non-canonical iso-propyl trans-hydrindane type sester-
terpenoids alborosin (252), nitiol (254) and variculanol (253). The carbon atom numbering refers 
to the nomenclature given in scheme 1.29. 
Besides the shown canonical type A and type B iso-propyl trans-hydrindane sesterterpenoids, 
three further natural occurring molecules shall be included in the parent classification. The 
first of those is the tricarbocyclic triketone alborosin (252), which was named according to its 
biological source Gentaniella alborosea by Kawahara and co-workers in 2000 (scheme 
1.4.4).[169] Comparison to nitidasin (238, vide supra) suggests that this substance is 
biosynthetically formed via oxidative carbon–carbon bond cleavage of a 1,2-diol function, 
that would be generated previously upon E1cB-type eliminative epoxide opening. Although 
the original investigators could not establish four of the stereocenters contained in this 
degradation product, it is reasonable to assume that they match the configurations 
encountered in nitidasin (238). In chapter 3.7, our experimental efforts to achieve this diol 
cleavage with chemical tools will be discussed briefly. In contrast, variculanol (253)[170] and 
nitiol (254)[171] possess a central 10-membered ring system, which is fused to two pentacyclic 
moieties. Their isolation sources were the already mentioned organisms Aspergillus 
variecolor and Gentaniella nitida, which indicates a possible biosynthetic relationship to the 
variecolins and nitidasin (238), respectively. Indeed, when drawing their structures in an 
appropriate fashion, it becomes apparent that the C-5 to C-6 linkage of the imaginary 
hydrindane system is missing. This finding might be explained either by a differing 
cyclization mode upon biogenesis from geranylfarnesyl pyrophosphate (143), or via a 
late-stage enzymatic ring opening, similar to the alborosin (252) case. However, the observed 
oxygenation pattern rather supports the first proposal. Whilst no data on the bioactivity of 
variculanol (253) has been published so far, the biological properties of nitiol (254) will be 
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detailed in chapter 3.1 in the course of the introduction of nitidasin (238). Although their 
hydrindane portions remain unfinished, both substance 253 and 254 were adopted into the 
discussed family of compounds with regard to the presumable common biosynthetic origin 
and the obvious similarities in substitution patterns.  
 
1.4.2 Literature-known Synthetic Approaches 
 
Although the iso-propyl-substituted trans-hydrindane sesterterpenoids display some of the 
most intriguing polycyclic frameworks found in terpenoid chemistry, only a very limited 
number of synthetic studies has been dedicated to those commonly potent bioactive 
compounds so far. The major reason for this might lie in the concomitant occurrence of highly 
substituted and strained trans-hydrindane motifs, together with the frequently observed fused 
cyclooctane ring systems, which were identified early on as a major challenge in the 
construction of ophiobolin-type natural products (vide infra). In the following section, an 
outline of the known synthetic strategies for the construction of retigeranic acid A (236), the 
variecolin family, nitiol (254), aleurodiscal (239) and YW 3699 (240) shall be provided. In 
this context, the transformations that led to the construction of the crucial ring junctions and 
thereby generated selectivities will take center stage, as they constitute the most direct 
showcases for the experimental work of this doctoral thesis. 
To begin, the efforts of Dake and co-workers toward an enantioselective total synthesis of 
nitiol (254) shall be mentioned, even though this target omits the difficulty of the installment 
of a trans-hydrindane system.[172] Their approach was published in 2001 and hinged  
on a convergent combination of two cyclopentane building blocks, of which the first was 
accessed in a 12-step sequence from geraniol derived alcohol 255 (scheme 1.33). The ring
  
 
Scheme 1.33:  Dake’s enantioselective synthetic approach toward the tricyclic sesterterpenoid nitiol (254). 
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closure was achieved with a diastereoselectivity of 6:1 (256) by means of a Pauson-Khand 
reaction[68] and subsequent vinylogous reduction with L-Selectride®. This was followed by 
the elegant use of a photoinduced Norrish-type 1 fragmentation[173] to effect the desired 
substitution pattern at the western ring system of nitiol (254). Five further transformations 
then gave rise to alkenyl stannane 257. An ensuing Pd(PPh3)4-catalyzed Stille cross-
coupling[174] to triflate 258 provided the first connectivity of the macrocycle, at which the 
second fragment was prepared in 5 steps from a readily accessible, literature-known 
compound. Over the course of the investigation of several macrocylization strategies, the 
obtained intermediate was further processed to iodide 259 in seven steps and then 
successfully reacted to tricycle 260 under Nozaki-Hyama-Kishi-type conditions.[119] However, 
the required final deoxygenation that would yield nitiol (254) remained unfeasible in their 
hands. 
 
Scheme 1.34:  A RCM-based strategy toward YW-3699 (240), published by Tori and co-workers in 2009. 
Tori’s synthetic studies on the natural product YW 3699 (240), which were published in 2009, 
describe the racemic construction of its 5-8-6-membered ring system and neglect the 
trans-hydrindane substructure (scheme 1.34).[175] In the beginning of the developed sequence, 
rac-enone 263 was transformed to aldehyde 264 in five steps, using amongst others a 
substrate-controlled 1,4-cuprate addition. Intermediate 264 was then combined with racemic 
alkenyl lithium species 265 that in turn can be prepared by a Shapiro reaction[176] from the 
corresponding trisylhydrazone and t-BuLi. After two further steps, diene 266 was obtained as 
a mixture of four diastereomers, with respect to the configurations of the epoxide moiety and 
the allyl substituent. Surprisingly, only the illustrated species (266) underwent RCM reaction 
when 30 mol-% of Grubbs II (267, cf. scheme 3.19) catalyst were employed in refluxing 
CH2Cl2. The identity of substance 268 was verified unambiguously via X-ray crystallographic 
analysis. Although no further explanation on the observed reactivity was provided by the 
authors, this case points out the strong dependency on conformational preorganization that 
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RCM reactions toward cyclooctene systems have repeatedly demonstrated in the past.[177] It 
is noteworthy to mention, that Tori and co-workers were also able to install the required 
exo-methylene function in diene 269 using Tebbe’s reagent.[134] 
 
Scheme 1.35:  Paquette’s asymmetric approach toward aleurodiscal (239), using an anionic oxy-Cope 
rearrangement to construct the central cyclooctene ring system. 
The first completion of a 5-8-6-5 carbocyclic backbone was described by Paquette and 
co-worker in 1998 in the course of their attempts to synthesize the β-D-xyloside 
sesterterpenoid aleurodiscal (239).[178] Their enantioselective route started from  
hydrindenone 271, which they prepared initially in a racemic fashion from commercially 
available melonal (272, vide infra), according to Corey[147] and Snider.[179,180] Using the 
lithium salt of Johnson’s (+)-(S)-sulfoximine (273),[181] a separation of the resulting 
diastereomers could be achieved and the ketone function was then regenerated via thermal 
induction of a retro-hetero-ene reaction. In order to introduce the trans-ring junction, they 
refered to a facially controlled hydrogenation protocol that was originally devised by 
Engler[148] and delivered alcohol 274 as a single diastereomer. This material was then 
regioselectively dehydrated with Burgess reagent[182] and subsequently reacted via [2+2] 
cycloaddition with dichloroketene in the presence of Zn–Cu couple. Gratifyingly, the 
exclusive formation of the desired regio- and stereoisomer (275) was observed. Seven further 
transformations gave rise to tricyclic ketone 276, which was then coupled with cyclopentenyl 
lithium reagent 277, triggering an accompanying anionic oxy-Cope rearrangement.[183] 
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scavenged with a selenium electrophile to furnish tetracycle 279. However, at this stage the 
authors encountered severe problems when they tried to introduce the aldehyde function or at 
inverting the wrong set stereocenters at carbon C-5 (hydrindane numbering) and the western 
cyclopentane ring. The most advanced intermediate (280) was reached when enolate 278 was 
quenched by protonation and then submitted to a 3-step sequence that ultimately installed the 
glycosidic linkage of the natural product. 
Progress toward the synthesis of the variecolin family has been reported by the research 
groups of Piers (1997)[184] and Molander (2001).[185] In 2002, Piers’ work was complemented 
by the doctoral thesis of Walker, one of his co-workers (scheme 1.36).[186] Their linear 
approach commences with the racemic 3-step preparation of bicyclic ketone 285 from 
3-methyl cyclohexenone (286). This initial sequence comprised an optimized 1,4-cuprate 
addition/aldol condensation annulation protocol, followed by another highly diastereo-
selective vinylogous nucleophilic attack of iso-propenyl cuprate. Biased by the newly set 
stereocenter, an ensuing base-promoted epimerization furnished the desired trans-ring 
junction in compound 287 in excellent selectivity (cis/trans = 11:1). Using kinetic 
deprotonation conditions, two consecutive alkylations and an iododestannylation reaction 
gave rise to intermediate 288. This material was then submitted to iodine/lithium exchange 
with n-BuLi, which led to intramolecular 1,2-addition according to their previously 
established methodology.[187] In order to correct the stereochemistry at carbon atom C-4, a 
combination of a Dauben oxidation[188] and a Birch-type reduction was conducted and allowed 
access to ketone 289 in moderate selectivity (dr = 2.2:1). Afterwards, 15 transformations were 
required to relocate the carbonyl function, expand the 7-membered ring system and install the 
western cyclopentane moiety. Performing a hydroxyl group directed late-stage C–H activation 
  
 
Scheme 1.36:  Piers’ racemic route toward variecolin-type sesterterpenoids, featuring a ring annulation via 
intramolecular Li-alkenyl addition. 
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with Pb(OAc)4, 5-desoxyvariecolol (290) was obtained and further oxidized to 5-desoxy-
variecolactone (291) with Collins’ reagent[189]. Unfortunately, a shortage of material pre-
vented the authors from reaching the stage of a completed variecolin-type natural product. 
In contrast, Molander’s approach toward variecolin (242) was based on photochemical 
intramolecular radical addition of a primary chloride function, which was promoted by the 
addition of SmI2 and catalytic amounts of NiI2 (scheme 1.37).[185] The viability of this 
transformation was proven on a model system (294) before they started to elaborate the 
building blocks for their envisaged key intermediate. The hydrindane-based portion was 
originally derived from enantiopure ketone (+)-138 (cf. chapter 2.3) that was converted to 
enone 295 in a 3-step sequence. Their solution to install the critical trans-ring-fusion involved 
a nickel borate-mediated diastereoselective reduction. The obtained unstable intermediate was 
then immediately subjected to a one-pot hydrogenation/acetalization protocol to form tricyclic 
compound 296. In eleven consequential reactions it was possible to access chloride 297, 
which was meant to be coupled to cyclopentane system 298 according to the devised 
retrosynthetic plan. However, the synthesis of the latter fragment was not finished and the 
authors have published no further progress on this project so far. 
  
 
Scheme 1.37:  Synthetic studies toward variecolin (242) and evaluation of the envisaged key step on model 
compound 294, published by Molander and co-workers. 
The first successful total synthesis of an iso-propyl-substituted trans-hydrindane sester-
terpenoid was described in 1985 by Corey and co-workers in their racemic strategy toward 
retigeranic acid A (236).[147,148] Although the authors were mainly attracted by the angular 
triquinane ring system of the natural product, they also developed a new method to construct 
the required hydrindane portion that was later used by Paquette in his studies toward 
aleurodiscal (239, vide supra). To this end, they submitted melonal (272) to a Robinson-type 
annulation[190] with methyl vinyl ketone (300) und subsequently obtained bicyclic enone 271 
via a Lewis acid-catalyzed Prins reaction[191] (scheme 1.38). The following 4-step protocol
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Scheme 1.38: Corey’s racemic synthesis of retigeranic acid A (236), featuring a diastereoselective Diels-
Alder reaction, a [2+2] ketene cycloaddition and an intramolecular aldol condensation. 
that installed the trans-ring junction has been previously discussed (cf. scheme 1.35). Alcohol 
274 was then sequentially oxidized with Jones’ reagent[192], reacted with vinyl Grignard and 
dehydrated with KHSO4 to result in diene 301. A thermally-induced Diels-Alder reaction with 
excess of dienophile 302 furnished the tricyclic system 303 as the major isomer in 61% yield. 
Six further transformations gave rise to acid 304, which was reacted in a highly 
diastereoselective intramolecular [2+2] cycloaddition via the corresponding ketene generated 
in situ. The cyclobutane ring was then expanded in four steps by a CuOTf-mediated 
thio-pinakol rearrangement of intermediate 305 under concomitant installation of the western 
most methyl substituent. Fulfilling their synthetic plan, diketone compound 306 was reached 
in 7 additional reactions. This compound also represents an envisaged intermediate of the 
retrosynthetic plan that was pursued during the experimental work of present doctoral thesis 
(cf. chapter 2.2). Intramolecular aldol condensation and ensuing Pinnick oxidation[193] 
eventually provided retigeranic acid A (236). 
Two years later, Paquette and co-workers disclosed a more convergent route toward 
retigeranic acid A (236).[149,150] Their synthetic plan envisaged the coupling of a triquinane 
building block (309) and a cyclopentane system (310) to implement the trans-fused 
6-membered ring of the hydrindane system at a late stage (scheme 1.39). The construction of 
the first fragment started from the inexpensive monoterpenoid (+)-pulegone (176) and 
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similar to the one utilized in present work (cf. chapter 2.4). Performing an alkylation and later 
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formations. This material was then submitted to a diastereoselective 1,4-addition of a cuprate 
side chain (313), followed by a one-pot deprotection and aldol addition to yield tricycle 314. 
Chugaev elimination,[195] Wolff-Kishner reduction and allylic oxidation eventually gave rise 
to triquinane 309. The second key intermediate was elaborated in 16 steps from (−)-limonene 
(91), which involved amongst others a Wittig-Still rearrangement[196] to install the 
cis-relationship between the angular methyl group and the iso-propyl moiety in compound 
315. Unfortunately, the nature of retigeranic acid B (237) had not been elucidated at that 
moment and the further synthetic sequence inverted the stereocenter of the larger substituent. 
Fragment combination was achieved via the respective Grignard reagent of bromide 310 and 
proceeded exclusively as the 1,4-addition. Unfortunately, the ensuing ozonolysis provided 
aldehyde 316 only as the minor diastereoisomer (dr = 1:3), thus indicating that the 
1,4-addition had delivered the wrong selectivity. Furthermore, closure of the six-membered 
ring by aldol condensation required quite harsh conditions, namely piperidine and HOAc in 
toluene at 100 °C for 48 hours. As a consequence, epimerization was observed at C-15 
(retigeranic acid numbering) and the trans-ring junction in pentacycle 317 was only obtained 
as the minor result (dr = 1:4) after HPLC purification. A final five-step sequence furnished 
the natural product for the first time in an enantiopure manner. 
Building on the work of Corey and Paquette, an asymmetric total synthesis of retigeranic acid
    
 
Scheme 1.39: Paquette’s convergent total synthesis of (−)-retigeranic acid A (236), constructing three of five 
ring systems via aldol addition chemistry. 
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A (236) was published in 1988 by Hudlicky and co-workers.[151,152] This work opted for the 
combination of trans-hydrindane compound 319 and bicycle 312 (vide supra), while 
postponing the construction of the central ring C (cf. scheme 2.1) to a later point of the 
sequence (scheme 1.40). Additionally, they devised a new strategy for the enantioselective 
preparation of the first intermediate that started from (+)-menthene (320). Referring to 
established chemistry, they produced triene 321 in six consecutive transformations. A 
thermally-induced intramolecular inverse electron-demand Diels-Alder cyclization gave rise 
to ester 322 as an inconsequential mixture of double bond isomers with complete selectivity 
for the trans-ring junction. Acid-catalyzed enol ether hydrolysis and subsequent Krapcho 
decarboxylation[197] provided the known ketone 323 in 9 steps overall. Further elaboration of 
this material led to α-bromoester 319, which was annulated to Paquette’s diquinane 312 via 
dienolate-mediated 1,4-addition. A concomitant nucleophilic substitution of the bromide by 
the intermediary formed enolate yielded cyclopropane system 324 as a 1:1 mixture of 
stereoisomers. Flash vacuum pyrolysis (585 °C, 10−6 mm Hg) triggered the desired skeletal 
rearrangement and formed pentacarbocyclic compound 325 in high yield, but with moderate 
diastereoselectivity (4:1 to 2:1, varying with the isomer of 324). From this intermediate, five 
terminal reactions were needed to obtain the natural product in the shortest linear sequence of 
all successful approaches known to date (19 steps). 
    
 
Scheme 1.40: Hudlicky’s asymmetric approach toward (−)-retigeranic acid A (236), constructing the 
trans-hydrindane system via a diastereoselective Diels-Alder cyclization. 
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photochemical arene-alkene cycloadditions,[198] they were able to isolate tetracycle 328 as the 
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minor constituent in a 1:2 mixture with the respective linear fused triquinane compound (not 
shown). However, the good overall yield of these reactions allowed access to the desired 
isomer in multi-gram quantities and thus rendered the reaction useful for preparative 
purposes. Subsequent ring opening of the cyclopropane moiety in compound 328 was 
accomplished by reaction with a photochemically generated acyl radical that led to 
fragmentation of the resulting intermediary cyclopropylcarbinyl radical. N-methylation, 
allylic oxidation, base-mediated condensation to acid 329 and decarboxylative dehydration 
gave rise to triene 330, the envisaged precursor for a Diels-Alder cyclization to close the 
trans-hydrindane portion. Thus, the desired pentacycle (331) was obtained upon heating to 
250 °C as the major isomer in a moderate overall yield of 64%. In the following, a 7-step 
sequence was required to relocated the carbon–carbon double bond into conjugation and 
finish the natural product, suffering from poor selectivity at the hydrogenative construction of 
the final stereocenter.  
      
 
Scheme 1.41: Wender’s synthetic strategy toward retigeranic acid A (236), making use of a photochemical 
arene-alkene cycloaddition and an intramolecular Diels-Alder reaction. 
The last mentioned strategy illustrates again the complexity of the fused ring system inherent 
to the retigeranic acids and points out how troublesome the construction of the stereocenters 
at the respective junctions has been in the past. Additionally, no finished total synthesis of any 
cyclooctane containing iso-propyl-substituted trans-hydrindane sesterterpenoid had been 
published at the outset of this doctoral thesis.  
 
1.4.3 Evolution of a Unified Synthetic Approach 
 
Several years ago, the Trauner laboratories set out to develop a general synthetic approach 
toward iso-propyl trans-hydrindane sesterterpenoids. Pioneering work on this project was 
conducted by Dr. D. T. Hog and partially published in 2012 (scheme 1.42).[140] The key sub-
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Scheme 1.42: The previously developed unified approach toward iso-propyl-substituted trans-hydrindane 
sesterterpenoids and branching points for their enantiopure preparation from ketone (+)-138. 
structure that was identified as a suitable framework for outmost common intermediates was a 
trans-hydrindane system (333) with an oxygenation at its C-5 atom (cf. chapter 1.4.1) that 
would serve as a functional handle for the installation of further ring systems. To this end, 
three major building blocks (323, 334 and 335) were accessed via a reliable and highly 
scalable route, which features several branching points for the variation of the substitution 
pattern of the cyclopentane moiety. The choice of Hajos-Parrish-Sauer-Eder-Wiechert 
ketone[76] (138) as a starting point enables an easy transfer of all reactions to the 
complementary enantiomeric series. Furthermore, a catalyst-based diversification of the 
stereochemistry of the iso-propyl substituent was found when alkene 333 was subjected to 
either Pd/C- or Adams’ catalyst[199]-promoted hydrogenation. Thus, except for the variecolin-
type natural products, all iso-propyl trans-hydrindane sesterterpenoids could in principle be 
traced back to alkene 333. Further elaboration of both saturated epimers 336 and 337 gave 
rise to the oxygenation patterns of carbon atoms C-1 and C-2 so far observed in the target 
compound family. Experimental and theoretical details of the established synthetic protocols 
are discussed in chapters 2.3 and 3.3, as substances 334 and 335 played an essential role in the 
finished and attempted total syntheses described in present manuscript. Previously 
investigated synthetic approaches toward the natural products astellatol (213), nitiol (254) and 
YW 3548 (241), which were based on the above-described unified approach, are outlined in 
the doctoral thesis of Dr. D. T. Hog.[156] Renewed synthetic investigations on the construction 
of YW 3548 (241) are currently in progress in the Trauner research group and are being 
carried out by B.Sc. M. Maier. 
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Building on the previously established chemistry of the above-described unified synthetic 
approach toward iso-propyl trans-hydrindane sesterterpenoids, the major goal of the present 
project was the elaboration of novel synthetic strategies to access, in particular, type A 
congeners of this class of natural products. As those structurally highly tangled compounds 
have proven to be formidable challenges even to modern synthetic chemistry 
(cf. chapter 1.4.2), a primary challenge lies in the successful incorporation of the developed 
trans-hydrindanone building blocks. To this end, further adjustments on their substitution 
pattern were not excluded in retrosynthetic planning. 
   
 
Scheme 1.43: Initial challenges that are encountered for potential total syntheses of retigeranic acid B (237), 
nitidasin (238) and astellatol (213) commencing via the developed unified approach. 
More precisely, we were inspired by the intriguing variation of ring size and cyclization 
pattern that is evident in the retigeranic acids (236 and 237), nitidasin (238) and astellatol 
(213), while frequently maintaining a similar configuration at their stereogenic centers. 
Consequently, a common target in our synthetic design was the stereoselective installation of 
a functional handle or beneficially an advanced side chain construct that would enable the 
required intramolecular closure of the unfinished carbocycles of these natural products. Two 
possible modifications were identified as an initial challenge, which would either exploit the 
nucleophilicity of the C-6 position in a preformed enolate species or refer to manipulation of 
the electrophilic carbonyl function at C-5 (scheme 1.43). Further requisitions to such a 
transformation were high scalability, selectivity and simple preparative purification, as the 
ensuing sequence toward the natural products would possibly involve several consecutive 
synthetic steps. 
Motivated by the previously discovered convenient catalyst-promoted epimerization of the 
iso-propyl substituent (cf. chapter 1.4.3), it was our idea to utilize the rarely achieved 
trans-relationship to the angular methyl group for a potential first total synthesis of retigeranic 
acid B (237, scheme 1.44). Although the isomer retigeranic acid A (236) had been finalized
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Scheme 1.44: Molecular structures of the sesterterpenoids retigeranic acid A (237) and B (236), and their 
proposed total syntheses from the known trans-hydrindane building blocks 323 and 334. 
several times before, all disclosed strategies either suffered from unfavourable selectivities or 
ample use of lengthy synthetic sequences. Thus, the project aimed at developing a convergent 
combination of trans-hydrindanones 323 or 334 with an appropriate building block that 
would enable a rapid substrate-controlled construction of the triquinane moiety, ideally via a 
one-pot reaction cascade. This more robust route was intended to be applied to both 
iso-propyl epimers and to give rise to substantial amounts of the natural products to elucidate 
their still unknown mode of bioactivity. 
Furthermore, we recognized the close resemblance of the cationic intermediates proposed for 
the biogenesis[200] of astellatol (213) to its close relative nitidasin (238) and were poised to 
investigate a simultaneous construction of both compounds from shared 5-8-6-5 carbocyclic 
precursors (scheme 1.45). We were especially fascinated by a supposedly biomimetic 
formation of the unique convoluted pentacarbocyclic framework of astellatol (213) by a 
homoallyl-cyclopropylcarbinyl-cyclobutyl rearrangement.[201] This would not only allow to 
provide experimental proof of mentioned biosynthetic hypothesis, but also resemble the first 
application of this cascade reaction to preparative organic chemistry. Hence, the prominent 
task of this subproject was the preliminary assembly of the cyclooctanoid carbon skeleton 
(340), which had been precedented only by a single case prior to present doctoral thesis 
(cf. chapter 1.4.2). Once this ring system is completed, either adjustment of the oxygenation
     
 
Scheme 1.45: Molecular structures of the sesterterpenoids nitidasin (238) and astellatol (213), potentially 
accessible by total synthesis from a shared tetracarbocyclic intermediate (340). 
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pattern or conversion to a stable entry point for the bioinspired rearrangement would have to 
be addressed in order to yield nitidasin (238) or astellatol (213), respectively. Again, 
manufacturing those molecules via total synthesis should allow further investigation of their 
biological activity, for which, in both cases, no relevant data has been published to date.  
Last but not least, all chosen synthetic targets represent outstanding examples for the 
application and development of state-of-the-art organo chemical methodology on complex 
polycarbocyclic architectures. Specifically the establishment of cascade reactions has 
emerged as a figurehead of the synthetic programs launched in the Trauner research 
group[27,202] and became a prevailing theme for the studies toward the total syntheses of 
type A iso-propyl-substituted trans-hydrindane sesterterpenoids that will be presented in the 
following chapters. 
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2. Synthetic Studies Toward Retigeranic Acid B 
 
2.1 A Comprehensive Introduction to Retigeranic Acid A and B 
 
The compounds which have come to be known as retigeranic acid A (236) and B (237) 
(scheme 2.1) were first isolated by Seshedari and co-workers[141–143] in 1961 from a lichen 
species called Lobaria retigera, which was collected in different parts of the western 
Himalayas. It must be clarified, that at this point the retigeranic acids were obtained as a 
mixture but considered to be one single compound, simply named ‘retigeranic acid’. Later, in 
1972, Shibata and co-workers isolated the same mixture from the related species Lobaria 
isidiosa and Lobaria subretigera, which they collected in eastern Bhutan.[144,145] They found 
the retigeranic acids in the chloroform-soluble fractions of the ethereal extracts of those plants 
and were able to record first NMR spectra. By the additional use of mass spectroscopy, they 
identified the compounds as sesterterpenoids. Knowing of the presence of an α,β-unsaturated
  
 
Scheme 2.1:  Molecular structures of retigeranic acid A (236) and B (237) and crystal structure of the latter. 
Carbon and ring numbering was adopted from Shibata and co-workers.[2.5] 
acid from reaction with tetranitromethane and according to Liebermann-Burchard,[203] they 
were able to obtain the corresponding p-bromoanilide of retigeranic acid A (236) and 
crystallized it from acetone to elucidate its structure. However, several years later Corey and 
co-workers managed to synthesize racemic ‘retigeranic acid’ for the first time.[147] Modifying 
the natural product by means of esterification, they proved via HPLC separation that the 
isolated compound is a mixture of the minor, just synthesized retigeranic acid A (236) and the 
major, isomeric retigeranic acid B (237). Their suggestion that the two isomers vary at the 
stereocenter on C-7 (retigeranic acid numbering) was refuted by Shibata and co-workers in 
1991.[146] The authors were able to grow crystals of both isomers from different fractions 
obtained via HPLC methods. They could show that both compounds are diastereomeric in 
regard of the configuration of the iso-propyl substituent at C-18. Interestingly, they also 
managed to co-crystallize retigeranic acid A (236) and B (237) as a 1:1 mixture. 
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Scheme 2.2:  Molecular structures of hirsutene (342), isocomene (343) and modhephene (344) as examples for 
linear, angular and propellane-type triquinane natural products.  
The retigeranic acids possess some intriguing structural features, as foremost to mention their 
angular triquinane motif (rings A, B, C), which is based on the [6.3.0.01,5]undecane carbon 
skeleton (341, scheme 2.2). Notably, they were also the first structurally elucidated natural 
occurring compounds to have this substructure. In the years following their discovery, several 
other triquinane natural products like e.g. hirsutene (342),[204] isocomene (343)[205] and 
modhephene (344)[206] were found. This led to a sheer race in total synthesis in the 1980’s and 
1990’s, producing more than 130 different syntheses, of which the four previously mentioned 
retigeranic acid A (236) syntheses were amongst (cf. chapter 1.4.2). Furthermore, the 
retigeranic acids are constituted of 8 stereogenic centers, three of which are quaternary. They 
exhibit an extraordinarily low degree of functionalization, having only an α,β-unsaturated acid 
moiety. Last but not least, the retigeranic acids hold a sterically encumbered iso-propyl-
substituted trans-hydrindane portion, characteristic for this subclass of natural products. 
   
 
Scheme 2.3:  Proposed biosynthesis for the formation of the retigeranic acids.[2.4] Only one isomer is shown 
for clarity. The single oxidation event was highlighted in red. 
Despite their unique and synthetically challenging pentacarbocyclic structure that nature must 
have devised for a certain purpose, no data on the biological activity of both acids has been 
published, to the best of our knowledge. Solely the respective ozonide derivatives have been 
proven to act as anti-inflammatory agents.[207] Concomitantly to their first structural 
investigations, Shibata and co-workers proposed a biosynthetic pathway[144] (scheme 2.3),  
which involves the following sequential steps and starts from geranylfarnesyl pyrophosphate 
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(143): pyrophosphate elimination, 15-endo-trig and then 5-exo-trig cyclization (345), [1,5]-
hydride shift, 6-exo-trig and subsequent 5-exo-trig cyclization, elimination (346), re-
protonation and 5-exo-trig cyclization, [1,2]-hydride shift, elimination (347) and finally 
oxidation to yield the natural products. Nevertheless, no further chemical or theoretical proof 
of this hypothesis has been published yet. 
As the major diastereomer retigeranic acid B (237) comprises the sterically more challenging 
substitution pattern at the trans-hydrindane moiety and due to the fact that it has not been 
accessed by total synthesis yet, we planned to synthesize this natural product. Our efforts to 
incorporate this project into the developed unified approach toward iso-propyl-substituted 
trans-hydrindane sesterterpenoids[140] will be described in the following chapters. 
 
2.2 Retrosynthetic Analysis 
 
The pursued retrosynthetic strategy toward retigeranic acid B (237) commenced with the 
disconnection of pentacycle B (scheme 2.4). In the forward sense, this ring would be closed 
by a sequential aldol condensation and Pinnick oxidation[193] that is based on Corey’s racemic 
synthesis of retigeranic acid A (236)[147] and requires a preceding ester reduction and re-
oxidation to the corresponding aldehyde. All in all, this traces back to ketoester 348. Closure 
of ring A should be addressed via a 5-exo-trig type vinylogous radical cyclization, at which 
the initial trisubstituted radical at C-3 should be generated possibly via the corresponding 
xantogenate of tertiary alcohol 349. The formation of the desired stereochemistry at C-10 is
  
 
Scheme 2.4:  Retrosynthetic analysis for the construction of retigeranic acid B (237) from trans-hydrindanone 
building block 334, featuring an aldol addition and a radical cyclization key step. 
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well precedented for similar systems[208] and would arise from the kinetic preference for the 
significantly less strained cis-diquinane system. Furthermore, it can be reasoned that the 
stereochemical outcome at C-3 would be favourably guided by the steric bulk of the 
neighboring trans-hydrindane substituent. It was speculated that by generating the initial C-3 
centered radical via SmI2-mediated conditions, the later on occurring α-keto radical 
intermediate could potentially combine with a C-12 located ketyl radical to additionally form 
ring C in the same step. This termination of the radical cascade bears similarities to samarium 
Barbier reactions, which have been investigated extensively in the past.[209] Tertiary alcohol 
349 itself should be synthesized via aldol-condensation between trans-hydrindanone 334 and 
ketone 350. Such a fragment combination would probably involve the use of boron-based 
enolate conditions, which are known to stabilize the aldol product from retro-aldol 
reaction.[210] trans-Hydrindanone 334 was intended to be prepared from Hajos-Parrish-Eder-
Sauer-Wiechert ketone (138)[211] by a 15-step sequence that had been published by the 
Trauner group previously.[140] The cyclopentane building block 350 was planned to be 
accessed from ketoester 351 by performing a conjugate addition to methyl vinyl ketone (300). 
In the forward sense, subsequent decarboxylation and a final regioselective Horner-
Wadsworth-Emmons olefination would install the desired α,β-unsaturated ester. Ketoester 
351 itself can be readily obtained by a 3-step protocol, which proceeds via a Favorskii 
rearrangement[194] and starts from the inexpensive chiral building block (R)-pulegone 
(176).[212] 
 
2.3 Synthesis of a Model System for the trans-Hydrindanone Moiety 
 
To reduce our retrosynthetic plan into practice, we started with the synthesis of a chiral 
building block for the envisaged trans-hydrindanone 334. A common and well established 
precursor for the trans-hydrindane motif, which is also often found in steroid-type 
compounds, is the Hajos-Parrish-Eder-Sauer-Wiechert ketone (138).[76] Following a detailed 
literature-known procedure,[211] we reacted 100 g of diketone 352 with methyl vinyl ketone 
(300) using catalytic amounts of acetic acid to promote the occurring Michael-addition 
(scheme 2.5). Crude triketone 353 was then immediately subjected to (R)-proline (354) 
catalyzed aldol condensation, forming bicycle 355. After acid-mediated elimination and 
thorough purification, 97 g of enone (−)-138 were obtained from a single reaction batch in 
67% yield (calculated from diketone 352). The enantiomeric excess was determined to be an
   
Synthetic Studies Toward Retigeranic Acid B 
 
51 
 
Scheme 2.5:  (R)-proline (354) catalyzed formation of chiral enone (−)-138, according to Hajos and Parrish.[76] 
Transition states 357 and 356 have been proposed by the mentioned authors or by Houk and 
co-workers respectively.[213] 
excellent 99.6% via optical rotation, which in this case has been accepted as the method of 
choice by the community.[211] The transition state that accounts for the enantioselectivity of 
the reaction has been subject of considerable debate. Based on calculations, Houk proposed 
an enamine-type mechanistic model (356) in 2001.[213] However, this has surprisingly been 
rejected by Hajos, who still held on to his originally proposed carbinolamine (357) 
mechanism.[76,214] 
In order to construct the desired trans-junction, several literature-known procedures were 
considered. As we knew from earlier experiments conducted in our group, the usage of bulky 
CuH species as described by Daniewski and co-workers,[215,216] suffers from low 
reproducibility in terms of its yield, chemo-, and diastereoselectivity, as well as from 
insufficient scalability.[156] Thus, we were curious to apply conditions that were established 
more recently by Buchwald and co-workers for an enantioselective 1,4-reduction of cyclic 
enone systems (scheme 2.6).[217] At this, we speculated that, in a matched case, the utilized 
(S)-TolBINAP ligand (not shown) would enhance the diastereoselectivity of the 
CuH-mediated reduction. Unfortunately, we only observed 1,2-reduction of both ketone 
functionalities of compound (−)-138. Consequently, we had to refer to an industrial, scalable 
5-step route,[218] which has already been implemented in several total syntheses in the 
past.[219] To this end, we first reduced the cyclopentanone moiety to alcohol 358 in 
quantitative yield and complete chemo- and stereoselectivity, using stoichiometric amounts of 
NaBH4. Although TBS ethers have proven to be a viable protecting group for the generated 
alcohol in very similar synthetic sequences,[220] we decided for the installment of a tert- 
butyl ether, which is a commonly used and less acid labile alternative. Furthermore, we had 
    
AcOH (cat.)
(−)-138
352
O
O
Me
353
O
O
MeO
O
355
N
H
COOH
OMe
O OH
H2SO4
 95 °C
(67%, three
 steps)
OMe
O
300
354
ee = 99.6%
NO
O
OH
O
Me
‡
356
O
HO
Me
N
O
O
O H
H
357
‡
+
2.3 Synthesis of a Model System for the trans-Hydrindanone Moiety 
52 
 
Scheme 2.6:  Attempts toward the scalable and selective installment of the trans-junction in compound 361. 
in mind that a more stable ether function would facilitate the use of substance 359 as a model 
system for screening purposes toward envisaged aldol addition step (vide supra). It must be 
mentioned that the original authors have described the presence of a sterically demanding 
residue as being crucial for the diastereoselectivity of the later on following hydrogenation 
step.[218] Using iso-butylene (360) under H3PO4- and BF3⋅OEt2-mediated acid catalysis, we 
obtained ether 359 in excellent yield and could verify its structure via X-ray crystallography 
(scheme 2.7). Interestingly, reaction of ether 359 under Buchwald’s conditions[217] formed the 
desired hydrindane 361 with perfect trans-selectivity. However, 1,2-reduction was observed 
to be the major pathway again and was presumably caused by the inherent steric bulk of the 
chiral ligand. Hence, the 22% yield of substance 361 could not be improved by variation of 
the reaction parameters. Nevertheless, from this transformation we obtained material pure 
enough to grow crystals that were suitable for X-ray crystallographic analysis. 
  
 
Scheme 2.7:  Pursued industrial route for the preparation of trans-hydrindanone 361.[2.23] Indicated diastereo-
meric ratio refers to the crude reaction mixture. 
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According to the mentioned industrial route, ether 359 was α-carboxylated by employing 
Stiles reagent (scheme 2.7).[221] Due to a momentarily lack in commercial availability of this 
reagent and its extremely laborious preparation, an aged batch was used, which led to 
somewhat lower conversion of ether 359 than previously reported.[140] The concomitantly 
formed regioisomeric β-ketoacid (not shown) readily decarboxylated during acidic work up, 
which allowed for the convenient recovery of ether 359. The solid-state structure obtained 
from the isolated material of compound 362 is shown in scheme 2.7. Although no obvious 
change in the overall shape of the molecule is noticeable when being compared to enone 359 
or diketone (−)-138, hydrogenation of β-ketoacid 362 now preferentially led to the trans-
fused system, whilst enone 359 would yield the corresponding cis-hydrindane as the major 
product.[218] The reasons for these findings have not been clarified to date. It might be 
suspected that a possible interaction of the newly introduced carboxylic group with the 
surface of the employed heterogeneous Pd/BaSO4 catalyst system alters the preferred face for 
the delivery of surface-bound hydrogen. Accordingly, when 3.4 atmospheres of hydrogen gas 
were applied, saturated β-ketoacid 363 could be obtained as a rather labile compound. 
Consequently, it was submitted to immediate decarboxylation at elevated temperature under 
reduced pressure. 1H NMR analysis of the crude reaction mixture revealed a cis/trans-ratio of 
compound 361 of roughly 4:1. Thorough separation by column chromatography yielded pure 
trans-hydrindane 361 in good yield (62%, two steps) on multi-gram scale.  
Due to the excellent disposability and inherent similarity of this compound in comparison to 
the envisioned final trans-hydrindanone building block 334, it was used as a model system for 
the investigations toward a fragment combination with ketone 350 (vide infra). Therefore, 
attention was turned toward constructing this very ketone (350) at this point. Scheme 2.8
  
 
Scheme 2.8: Transformations required for the completion of trans-hydrindanone 334. This synthetic sequence 
has been developed in the Trauner group previously and was published by Hog et al.[140] 
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summarizes the transformations that are necessary for the completion of building block 334 
and have been developed in the Trauner group previously.[140] The majority of the steps will 
be outlined in detail in chapter 3.3 for the respective enantiomeric series. Final saturation of 
alkene 364 has been described by means of diimide reduction,[222] as hydrogenation using 
Pd/C or PtO2 would lead to epimerization of the neighboring iso-propyl-substituted 
stereocenter.[140] 
 
2.4 Synthesis of the Cyclopentane Moiety 
 
The synthesis of the B ring containing cyclopentane 350 started from (R)-pulegone (176), a 
common and inexpensive chiral building block. Already in 1918, Wallach described the 
formation of cis- and trans-pulegonic acid (368) when (R)-pulegone dibromide (369), which 
is readily available via bromination of (R)-pulegone (176), was treated with aqueous sodium 
hydroxide solution.[223] Later, Wolinski and co-worker suggested that mechanistically a 
Favorskii rearrangement has to account for this transformation (scheme 2.9).[224] Since then, 
several groups have used and refined this procedure to access chiral cyclopentane building 
blocks. Prominent examples were given by the groups of Hudlicky and Paquette during the 
construction of the triquinane portion of retigeranic acid A (236)[2.32] or the synthesis of  
(−)-silphiperfol-6-ene (370),[150] as well as by Cossy and co-workers during their synthesis of 
(+)-conocephalenol (371).[225] 
    
 
Scheme 2.9: Transformation of (R)-pulegone (176) to a mixture of pulegonic acids (368) via Favorskii 
rearrangement. Illustrated mechanism was adopted from Loftfield.[226] The pulegone-derived 
parts of the natural products 370 and 371 have been highlighted in bold. 
Accordingly, we started with the bromination of 25 g of (R)-pulegone (176) using 
stoichiometric amounts of bromine in NaHCO3-buffered diethyl ether. Dibromide 369 was 
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obtained quantitatively as deep purple oil and directly used for the following rearrangement 
step. Therefore, dibromide 369 was refluxed in a freshly prepared methanolic sodium 
methoxide solution and the resulting crude product was purified via distillation to yield 
methyl ester 376 in very good yield as a 3:1 mixture of trans/cis-isomers (scheme 2.10).[227] 
Next, the alkene functionality was cleaved via ozonolysis with successive application of 
reductive work-up conditions. Hence, β-ketoester 311 was isolated in 72% yield in a cis/trans 
ratio of 1:2. This isomeric mixture was inconsequential for the following step and could be 
enhanced by base-catalyzed equilibration. Repeated column chromatography allowed for the 
separation and characterization of trans-β-ketoester 311. Thereafter, the 1,4-addition of 
deprotonated β-ketoester 311 to methyl vinyl ketone (300) was investigated, at which the 
stereogenic methyl group would direct the attack to the desired face. Referring to conditions 
described by Santelli and co-workers,[228] Cs2CO3 was employed as an enolizing base and 
diketone 377 could be isolated in 75% yield, along with trace amounts of the undesired 
diastereomer. It was found that the actual 1,4-additon step starts proceeding at approximately 
−35 °C and becomes sufficiently fast at −25 °C. Warmer reaction temperatures led to the 
formation of significant amounts of polymeric side products. 
  
 
Scheme 2.10: Conducted transformations toward diketone 377, comprising a Favorskii rearrangement, an 
ozonolysis with reductive work-up and a base-promoted addition to methyl vinyl ketone (300). 
From the seminal work of Paquette et. al. on the construction of angular triquinane systems, it 
is known that compounds similar to diketone 377 tend to react via intramolecular aldol 
addition at elevated temperatures,[150] which are usually required for the envisaged Krapcho 
decarboxylation.[197] To circumvent this undesired reactivity, it was planned to selectively 
protect the acyclic, less sterically hindered ketone functionality to the respective  
1,3-dioxolane (scheme 2.11). Transformations like this are possible by using a protocol 
developed by Noyori,[229] at which TMS+ serves as a proton-like catalyst.[230] Due to the low 
reaction temperatures involved, site-selectivity of the acetal formation could be demonstrated 
in several cases.[231] When diketone 377 was subjected to these conditions, dioxolane 378 was 
obtained in almost quantitative yield on multi-gram scale. Subsequent Krapcho 
decarboxylation with lithium iodide in DMF at 150 °C[152a] went smoothly and provided 
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substance 379 in an excellent yield (85%). The initially observed cis/trans ratio of 1:3.4 could 
be improved conveniently to 1:6.7 by conducting the chromatographic step with 
triethylamine-deactivated silica.  
   
 
Scheme 2.11: Synthesis of α,β-unsaturated ester 381 via selective dioxolane formation, Krapcho decarboxyl-
ation and Horner-Wadsworth-Emmons olefination. 
When the construction of the α,β-unsaturated ester functionality was investigated, conditions 
reported by Nangia et al. in their (−)-mitsugashiwalactone (not shown) synthesis for the 
olefination of a very similar cyclopentanone were first evaluated.[232] These authors describe 
the application of classical Horner-Wadsworth-Emmons conditions as being superior to a 
wide variety of methods, but only when using super-stoichiometrical amounts of triethyl 
phosphonoacetate (380) and sodium hydride in THF. The same finding held true for 
cyclopentenone 379 and the oxygen-sensitive α,β-unsaturated ester 381 was obtained in 67% 
yield. Further screened reaction conditions (bases: KH, n-BuLi, KOt-Bu, NaOt-Bu; DBU, 
LiCl, MeCN; MeOC(O)CHPPh3, toluene, 110 °C) unfortunately failed to improve the yield of 
this transformation. Repeated attempts to apply a Peterson olefination protocol that was 
known from different cyclopentanone syntheses[233] remained futile. This is probably due to 
the steric hindrance exerted by the α-substituent at the electrophilic carbonyl functionality. 
Interestingly, deprotonated ethyl acetate could be added to compound 379 and gave rise to 
tertiary alcohol 382 in moderate yield as a single diastereomer. Although literature suggests 
that elimination of such an alcohol using Martin’s sulfurane[234] would preferentially yield the 
E-alkene,[233b] we only observed a 1:1 ratio of isomers in 1H NMR spectra recorded from the 
crude reaction mixture. Since this reflects an unselective E1 mechanism, and because of 
competing decomposition reactions, we dismissed this two-step sequence.   
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Scheme 2.12: Final deprotection step yielding desired diketone 385. Both compounds 381 and 385 degrade to 
their respective γ-hydroxy esters 386 and 387 when exposed to air. 
Final dioxolane cleavage was achieved with para-toluenesulfonic acid (p-TsOH) in a mixture 
of water and THF and provided 385 in 82% yield (scheme 2.12). Due to the long reaction 
duration of 7 days, the formation of two oxygenated byproducts 386 and 387 was observed, 
which were isolated in low quantities using HPLC methods. The structures of compounds 386 
and 387 were assigned via NMR spectroscopy and the corresponding mass were found by 
EI-HRMS measurements. Both γ-hydroxy esters occurred as 1:1 diastereomeric mixtures, 
which suggests that they are formed via radical attack of oxygen at the stabilized γ-position 
and by subsequent reductive breakdown of an intermediary generated peroxy species. 
 
2.5 Model Studies on the Fragment Combination 
 
With completed fragment 385 and model system 361 in our hands, we started to investigate 
aldol addition-type coupling conditions. Although ketone-ketone aldol additions are supposed 
to be slightly endothermic processes as such,[210] retro-aldol reactions can be circumvented. 
Modern aldol chemistry provides a variety of protocols, such as Mukaiyama aldol[59] or boron 
and titanium Lewis acid-catalyzed reactions, which stabilize the aldol product either as the 
respective silyl ether or as its respective metal complex. 
Table 2.1 summarizes the conditions evaluated for envisaged combination of model  
ketone 361 with either cyclopentane 385 or the in principle equivalent, but commercially 
available 4-phenylbutan-2-one (388, scheme 2.13). Simple enolization of ketone 361 or 
ZnCl2-mediated reactions did not result in any of the desired products 389 and 390, 
respectively (entries 1,2). Even when the sterically less demanding acetone was used as 
electrophilic coupling partner, no conversion could be induced. It has to be noted that acetone 
is well precedented in such ketone-ketone coupling reactions.[235] Boron-based reagents 
proved to be ineffective as well (entries 3,4). In 2012, Nakajima and co-workers published a 
protocol specifically dedicated to enantioselective ketone-ketone aldol additions.[236] 
Referring to the concept developed by Denmark,[237] they describe the use of SiCl3OTf as
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Table 2.5.1: Model studies on the envisaged fragment combination via aldol addition. 
 
entry ketonea solvent reagents T [°C] t [h] observation 
       
1 388 THF KHMDS −78 to rt 2 h n.r. 
2 385, 388 THF LDA, ZnCl2 −78 to rt 5 h n.r. 
3 388 Et2O (n-Bu)2BOTfb, DIPEA −50 to rt 4 h n.r. 
4 388 Et2O (Ipc)2BCl, Et3N −20 to rt 4 h n.r. 
5 385, 388 i-PrCN Cl3SiOTf
b, DIPEA, 
BINAPO 
−60 to rt 6 h n.r. 
a) The ketone entry denotes the respective reaction partner of trans-hydrindanone 361. b) The reagent was prepared 
according to ref. 238. 
   
the Lewis acid and BINAPO (not shown) as the Lewis base activator. In summary, their 
methodology produces yields up to 88% and ee-values that reach 83%. Performing an initial 
control experiment with ketone 388 and cyclohexanone, the viability of this methodology 
could be confirmed, although aldol condensation was observed as a significant side reaction. 
However, when these conditions were applied to substances 361 and 388, no reaction was 
triggered at all (entry 5). 
  
 
Scheme 2.13: Synthesis of TMS ether 391 as substrate for Mukaiyama-type aldol additions. 
Meanwhile, we also investigated Mukaiyama-type aldol reactions.[59] Therefore, we prepared 
TMS ether 391 by deprotonating ketone 361 with LiHMDS and trapping of resulting enolate 
species with TMSCl in excellent yield (scheme 13). It was observed that the usage of less 
bulky bases like LDA would result in the formation of considerable amounts of the respective 
regioisomeric TMS ether. Table 2.2 lists the screened literature-known Mukaiyama aldol 
protocols. We hoped, that the method developed by Yamamoto and co-workers[239] would 
prevent retro-aldol reaction by the in situ formation of the respective TMS ethers of the 
desired aldol products 389 or 390. Unfortunately, none of the applied conditions worked as 
intended. 
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Table 2.5.1: Evaluated literature-known Mukaiyama aldol conditions. 
entry solvent reagents T [°C] t [h] observation 
       
1 CH2Cl2 TiCl4a −78 to rt 2 h decomp. 
2 CH2Cl2 TMSOTf −78 to rt 5 h loss of TMS 
3 CH2Cl2 SnCl4 −50 to rt 4 h loss of TMS 
4 CH2Cl2 
Sn(OTf)2,  
N-ethyl piperidine 0 to rt 4 h loss of TMS 
5 Et2O HNTf2 −60 to rt 6 h n.r. 
a) Commercial and self-prepared solutions of TiCl4 were tried. 
 
At this point we reasoned that the nucleophilicity of the enolate of trans-hydrindane 361 
might be too low, or its steric bulk too high, to react with non-activated ketones. To prove this 
hypothesis, we tried to react substrate 361 with increasingly electrophilic carbonyl 
compounds like ethyl pyruvate (392) under the already investigated ZnCl2-mediated 
conditions (scheme 2.14). As suspected, this transformation proceeded smoothly and 
furnished α-hydroxyester 393 in good yield as a 5:4 mixture of diastereomers. Although the 
stereochemistry at carbon atom C-2 (retigeranic acid numbering) was elucidated by NOESY 
NMR measurements to be of the desired R-configuration, the obtained diastereomers could 
not be assigned to the respective configurations of the tertiary alcohol function. The addition 
of Mander’s reagent[240] (394) was reproduced in the course of present doctoral thesis and 
proceeded with somewhat higher yield of methyl ester 395 than reported previously.[156] 
  
 
Scheme 2.14: Addition of enolized hydrindanone 361 to ethyl pyruvate (392) and Mander’s reagent (394). 
In light of the outcome of the conducted experiments, it was decided to abandon the ketone-
ketone aldol addition approach. In order to functionalize the C-2 position of substrate 361, 
future approaches will have to consider more electrophilic or less sterically demanding 
reagents. 
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2.5 Conclusion and Future Aspects 
 
In summary, the synthesis of the B-ring containing cyclopentane building block 385 was 
accomplished in 8 steps with 20% overall yield and started from commercially available 
(R)-pulegone (176) (cf. chapter 2.3). To this end, a literature-known three-step sequence was 
used to access ketoester 311 on a multi-gram scale. Selective 1,3-dioxolane formation via 
Noyori’s conditions and subsequent Krapcho decarboxylation formed cyclopentenone 379, 
which was successfully olefinated by optimized Horner-Wadsworth-Emmons conditions. 
Concomitant to the final deprotection step the two decomposition products 386 and 387, 
which were formed upon exposure to air, were isolated and characterized. Furthermore, 
enantiopure trans-hydrindanone 361 was synthesized on a multi-gram scale and used as a 
model system when screening aldol addition conditions (cf. chapter 2.2). However, studies 
toward a more direct installation of the required trans-junction in compound 361 were 
hampered by unprofitably low yields. 
Unfortunately, all conducted attempts toward the desired fragment combination via ketone-
ketone aldol addition were met with failure (cf. chapter 2.4). Although regioselective enolate 
formation could be demonstrated via the synthesis of TMS ether 391, bisalkyl-substituted 
carbonyl electrophiles did not react with any of the preformed enolate species. Performing an 
addition to ethyl pyruvate (392) and Mander’s reagent (394), it was shown that more 
electrophilic carbonyl species would undergo the desired coupling reaction. Furthermore, the 
formation of the desired stereochemistry at carbon atom C-2 was proven via NOESY 
correlation in diastereomeric α-hydroxyesters 393. 
  
 
Scheme 2.15: Possible second-generation approach toward radical cyclization precursor 349. 
Future approaches toward the desired radical cyclization precursor (349) might, for example, 
start from β-ketoester 396 (scheme 2.15). Transformation to the respective Weinreb amide[241] 
and protection of C-12 centered carbonyl as 1,3-dioxolane (397) would allow for the addition 
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of vinyl magnesium bromide.[242] Subsequent 1,2-addition of methyl lithium[242], olefin cross-
metathesis of alkene 398 with, for instance, building block 399, hydrogenation and dioxolane 
cleavage could ultimately yield the desired precursor (349). Due to steric hindrance, the 
metathesis step would most likely require the use of special catalysts systems developed by 
Stewart and Grubbs.[244] 
  
 
Scheme 2.16: A potential convergent synthesis of envisaged radical cyclization precursor 349. 
Another, more convergent strategy might aim for the construction of a more electrophilic 
handle for the cyclopentane coupling partner (scheme 2.16). One could envision an enolate 
addition to acid chloride 400, which would require an ensuing discrimination of the ketone 
functionalities in structure 401 in order to selectively install the desired tertiary alcohol at 
C-3. A possible way to achieve this selectivity was demonstrated by Shibasaki and 
co-workers via O-allylation at a similar 1,3-diketone system for their racemic synthesis of 
Garsubellin A[245] (not shown). At this point, selective 1,2-addition to the C-3 centered ketone 
could prove challenging, but should be achievable by Lewis acid-promoted activation of the 
ketone functionality. Removal of the allyl moiety in compound 402 would then forge the 
aspired precursor (349).  
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3. The Total Synthesis of (−)-Nitidasin 
 
3.1 A Comprehensive Introduction to (−)-Nitidasin 
 
The sesterterpenoid nitidasin (238) was first isolated in 1997 by the Kawahara group from the 
biennal plant Gentaniella nitida, which can be found in the Andes region.[154] This gentian 
species and its close relative Gentaniella alborosea together compose the Peruvian traditional 
folk medicine ‘Hercampuri’, which is used as an aqueous whole plant extract for the 
treatment of hepatitis, diabetes, hypertension and obesity.[246] Nitidasin (238) was found in the 
CH2Cl2-soluble fractions of the methanolic extract of G. nitida, along with various xanthones
   
 
Scheme 3.1: The three sesterterpenoids nitidasin (238, flat structure, three-dimensional drawing and crystal 
structure), alborosin (252) and nitiol (254), all isolated from the same plant mixture. 
and phenolic compounds, and then purified via silica gel column chromatography, followed 
by reversed-phase low-pressure liquid chromatography. Its molecular structure was first 
proposed by Kawahara and co-worker on the basis of extensive use of 2D NMR methods and 
later confirmed by X-ray crystallographic analysis (scheme 3.1).[154]  
After aleurodiscal (239), nitidasin (238) was only the second natural product to be isolated 
that possesses the extremely rare 5-8-6-5-membered pentacarbocyclic ring system. In total, 
nitidasin (238) contains 10 stereogenic centers, one of which is quaternary. Furthermore, it 
incorporates the sterically encumbered iso-propyl-substituted trans-hydrindane portion, which 
is a common feature of the parent subclass of sesterterpenoids (cf. chapter 1.4.1). From a 
synthetic point of view, nitidasin’s (238) highly substituted, boat-chair-configured 
cyclooctane ring poses a considerable challenge. Heteroatom substituents exist only in form 
of a ketone and a tetrasubstituted epoxide with an adjacent tertiary alcohol. Thus, the 
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construction of this complex carbon skeleton requires a carefully elaborated retrosynthetic 
analysis. 
To the best of our knowledge, a detailed biosynthetic pathway for the construction of nitidasin 
(238) has not been proposed so far. Due to its inherent structural similarity to astellatol (213) 
and retigeranic acids B (237), we reason that the mechanism shown in scheme 3.2 is most 
likely accountable for nitidasin’s (238) formation in nature. In this context, the biosynthetic 
steps starting from geranylfarnesyl pyrophosphate (143) to homoallyl cation 403 are the same 
as published for the biosynthesis of astellatol (213) by Simpson et al. (cf. chapter 4.1).[200] An 
ensuing [1,2]-hydride shift would generate the stabilized allyl cation 404, which then could be 
trapped by a molecule of water to yield 405. Epoxidation and final oxidation of carbon C-17 
to the ketone functionality will furnish nitidasin (238). However, no investigations of the 
biosynthetic clusters of this and familiar sesterterpenoids have been published up to date. 
   
 
Scheme 3.2: Proposed biosynthesis of nitidasin (238) and alborosin (252). Similarities to the biogenesis of 
retigeranic acid B (237) are indicated via mimetic drawing (cf. scheme 2.3). The oxygen 
introducing events were highlighted in red. 
Regarding nitidasin’s (238) biosynthesis, two directly related natural products have to be 
mentioned. Again, both compounds were found in ‘Hercampuri’, as reported by Kawahara 
and co-workers in 1999. The first was nitiol (254),[171] which was isolated from G. nitida 
itself. The second was named alborosin (252)[169] and was purified from the chloroform 
extract of G. alborosea. Although the relative stereochemistry of alborosin’s (252) C-3, C-6 
and C-7 (nitidasin numbering) located stereocenters was not elucidated, its biosynthetic origin 
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is hardly speculative. Epoxide opening via E1cB-type elimination at atom C-8 and subsequent 
diol-cleavage by an intradiol enzyme would directly yield alborosin (252) from nitidasin 
(238). It has to be noted that despite the solved X-ray structure of nitidasin (238), the absolute 
configurations of the three mentioned sesterterpenoids 238, 252 and 254 had not been 
determined prior to present doctoral thesis. 
For nitidasin (238) itself, no studies on its bioactivity have been published to date. However, 
it has been shown that the same extracts that contain the identified sesterterpenoids act 
antifungally against Candida albicans, Trichophyton mentagrophytes and Microsporum 
gypseum.[247] Interestingly, nitiol (254) has been found to enhance gene expression of 
interleukin-2 (IL-2) raising its mRNA levels in Jurkat cells by a factor of three.[171] IL-2 is a 
polypeptide, responsible for the growth and proliferation of T cells, thus being relevant for the 
immunotherapy of renal cell cancer and malignant melanoma.[248] To the surprise of the 
authors, nitidasin (238) did not show any effect in these studies, which levels the question to 
what purpose this molecule might serve in nature. It was our intention that a total synthesis of 
nitidasin (238), which will be described in the following sections, would provide enough 
material to continue the investigations into nitidasin’s (238) biological activity. Synthetic 
work presented in these chapters was conducted over large parts in cooperation with Dr. D. T. 
Hog, to whom the author would like to address a special acknowledgement.  
 
3.2 Retrosynthetic Analysis 
 
The retrosynthetic analysis of nitidasin (238), which had evolved from more obvious but 
unsuccessful approaches, envisioned a late-stage substrate-controlled epoxidation and a 
deprotection/oxidation sequence of a C-17 (nitidasin numbering) located alcohol moiety 
(scheme 3.3). A first disconnection of the ring system was planned at the C4–C5 bond. In the 
forward sense, the central ring A was meant to be closed by means of RCM reaction of the 
corresponding diene containing precursor 409. Although it was known that approaches toward 
cyclooctane carbon frameworks generally suffer from predominant side reactions,[177] it was 
reasoned that in the presented case the low degree of rotational freedom of structure 409 
could possibly result in a favourable conformational preorganization of the system. Triene 
409 in turn should be accessed by a highly convergent Li-alkenyl addition of metallated vinyl 
cyclo-pentane 410 to the ketone functionality of trans-hydrindanone 411. Although this 
reaction type was unprecedented for tetrasubstituted alkenes, previous experiments conducted
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Scheme 3.3:  Retrosynthetic analysis for the construction of nitidasin (238) from trans-hydrindanone 411 and 
vinyl cyclopentane 410 and possible access to astellatol (213) from a common intermediate. 
in the Trauner research group had shown that addition to similar trans-hydrindane based 
ketones proceeds smoothly with the desired stereochemical outcome.[140] A key feature of this 
retrosynthetic approach is the possibility to access astellatol (213) from triene 409 as well, 
which will be discussed in detail later on (cf. chapter 4).  
For the preparation of vinyl cyclopentane building block 410, which comprises a cis-cis-cis 
relationship of its ring and double bond substituents that had not been accessed prior to this 
work, an iodide source-quenched metalla-enyne cyclization was envisaged. In the forward 
sense, this should be followed by an elimination/hydroboration sequence to correct the 
stereochemistry at C-6. Thereafter, oxidation to the aldehyde and subsequent Wittig 
olefination would construct the desired monosubstituted alkene. Enyne 412 was planned to be 
obtained from commercially available (−)-citronellene (413) via a literature-known diol 
cleavage protocol,[249] followed by a methyl iodide-quenched Corey-Fuchs homologation. 
Ketone building block 411 would in principle arise via diastereoselective crotylation of 
alcohol protected trans-hydrindanone 335. Initially, we planned to address this challenging 
transformation by an O-alkylation/Claisen rearrangement procedure or by regioselective 
intramolecular allylation, which had been reported for similar systems by Nicolaou and 
co-workers in their colombiasin A synthesis (not shown).[250] However, we eventually had to 
use a more lengthy, but scalable 9-step route. This protocol was originally investigated by Dr. 
D. T. Hog[156] and was modified to the more robust SEM protecting group for C-17 centered 
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alcohol (cf. chapter 3.4). The synthesis of required alcohol 335 has been published previously 
by the Trauner laboratories and would be achieved in eight transformations on the respective 
enantiomeric series of already the described trans-hydrindane 361 (cf. chapter 2.3).[140] 
 
3.3 Synthesis of the Vinyl Cyclopentane Moiety 
 
Presented studies toward the synthesis of vinyl cyclopentane 410 commenced from 
commercially available (−)-citronellene (413), which was at that time available as a technical 
grade, enantioenriched mixture. This mixture results from its industrial origin, where it is 
prepared via pyrolysis from (−)-cis- (414) and (+)-trans-pinane (415), which in turn often 
stem from synthesis via catalytic hydrogenation of pinene composites.[251,252] Detailed 
mechanistic studies on this thermal transformation have been published, revealing that a 
biradical mechanism (416 and 417) has to be accounted for and that the formation of (−)-
citronellene (414) itself would be highly enantioselective (scheme 3.4).[253] Thus, the exact 
enantiomeric ratio of the employed starting material was unknown initially and would depend 
on the purity of its pinane precursor. Nevertheless, it was reasoned that it should be sufficient 
for initial synthetic studies. Enantiopure diene 413 can be accessed via a bromination/elimi-
nation sequence from commercial, but somewhat expensive, (−)-citronellol (36).[254] 
   
 
Scheme 3.4:  Industrial synthesis of (−)-citronellene (413) and its side product 418, together with a possible 
literature-known route toward enantiopure (−)-citronellene (413).[253,254] 
Using the scalemic mixture of diene 413, the trisubstituted and more electron-rich double 
bond was first epoxidized chemoselectively with m-CPBA in CH2Cl2. The isolated 
inconsequential mixture of diastereomers (419) was then submitted to periodic acid-mediated 
diol cleavage conditions in diethyl ether, all according to a published protocol 
(scheme 3.5).[249] Yields and analytical data toward aldehyde 420 were comparable to the 
literature and are not further specified in the experimental section of present manuscript. 
Subsequent transformation of aldehyde 420 to dibromoalkene 421 proceeded smoothly in 
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good yield via modified Ramirez reaction conditions,[255] employing zinc to lower the 
required amount of PPh3 and resulting OPPh3 to one equivalent. When standard Corey-Fuchs 
homologation conditions were applied to dibromoalkene 421,[256] quenching the via Fritsch-
Buttenberg-Wiechell rearrangement[257] intermediary formed alkinyl lithium species with 
methyl iodide, complete and clean conversion was observed. However, enyne 412 proved to 
be highly volatile, which significantly decreased the obtained yield to 42%, even when being 
concentrated carefully from n-pentane by distillation using a Vigreux column. 
   
 
Scheme 3.5:  Synthesis of diiodide 431, starting from commercially available scalemic (−)-citronellene (413). 
Only the major diastereomer of diiodide 431 is shown for clarity. 
Next, the focus was turned toward the planned enyne cyclization step, for which a variety of 
different methods has been developed over the years.[258] Scheme 3.6 provides a general 
version of the catalytic cycle present in those transformations. As a metal source, different 
possible options exist, ranging from Pd, Pt, Ru, Ni, Au, Fe, Co, In to Ti and Zr. Even 
combinations of these with other organometallic reagents have been reported. In the begin-
   
 
Scheme 3.6:  General catalytic cycle for metal-mediated enyne cyclization reactions. 
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ning, the metal species (422) coordinates to an enyne substrate (423) and forms a chelated 
π-complex (424). An oxidative coupling then generates a metallacycle (425). However, most 
of the described choices for the metal would preferentially undergo ß-elimination at this 
intermediate (425). This would yield an alkene substituent (cf. structures 426 and 427) at 
carbon C-6 (nitidasin numbering) with an undesired trans-configuration in respect to 
the C-7 centered methyl group.[258] Several synthetic steps would be required to correct 
mentioned stereocenter and thereafter to restore the alkene functionality. Although 
Pd-catalyzed protocols have been published, e.g. by Lu and co-workers, that target the 
construction of a cis-relationship at C-6 and C-7, those methods suffer from inversion of the 
stereochemistry of the halogen substituent.[259] Metallacycles derived from group 4 metals 
(Ti, Zr) possess no vacant site of coordination and are inert toward ß-elimination. 
Consequently, they are able to react selectively with one or two equivalents of an electrophile 
(cf. structure 428).[258] In this context, especially a method developed in 1992 by Negishi and 
co-workers seemed attractive, where the authors describe the stoichiometric use of a  
14-electron Cp2Zr species that can be generated from two equivalents n-BuLi and 
Cp2ZrCl2.[261] By reacting the intermediary formed zirconacycle with two equivalents of I2, it 
was possible to access the respective alkenyl-alkyl-diiodides, having the desired 
stereochemistry at the iodoalkene moiety. When this methodology was adopted for substrate 
413, the best results were obtained when quenching the initially formed complex 430 with 
NIS.[262] Cp2TiCl2 showed the same reactivity, but did not result in improved yields.[263]  
     
 
Scheme 3.7:  Elimination/hydroboration sequence to synthesize alcohol 433 and Mosher ester analysis 
thereof (435, only major isomer shown). The magnified 1H NMR spectra exemplifies the 
obtained ratio of diastereomers, arising from scalemic (−)-citronellene (413). 
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Purification via column chromatography allowed for the isolation of diiodide 431 as an 
inconsequential diastereomeric mixture of 5:1 in an acceptable 46% yield. 
As diiodide 431 was not indefinitely stable and still somewhat volatile, we were delighted 
when it was found that yields would significantly rise, when diiodide 431 was only shortly 
filtered over silica and used as such for further transformations (scheme 3.7). Elimination of 
the alkyl iodide substituent with DBU furnished diene 432, which exhibited partial 
isomerization at the cis-iodo position to the trans-compound on an hour time scale upon 
purification. The driving force of this isomerization is most likely the inherent high 1,3-allylic 
strain of the molecule. Thus, the following hydroboration step was conducted with crude 
diene 432 immediately after its extraction. For this transformation, 9-BBN was found to be 
the best choice as the bulkiness of this hydroboration reagent enhances the facial bias of the 
stereogenic methyl group of the substrate. Counting from enyne 412, the desired alcohol 433 
could be obtained on gram scale in three steps in excellent 63% yield along with 10% of the 
undesired isomer (434). 
   
 
Scheme 3.8:  Synthesis of diene 410 and TES protected alcohol 437 as substrates for envisaged Li-alkenyl 
addition step (cf. chapter 3.2). 
Having set the desired stereochemistry, preferably neutral pH conditions were screened for 
the oxidation of alcohol 433 to aldehyde 436 as am olefination precursor (scheme 3.8). Initial 
experiments referred to classical Swern conditions, using oxalyl chloride, DMSO and then 
DIPEA, or Dess-Martin periodinane-mediated oxidation, failed and led to decomposition of 
alcohol 433. Ley oxidation, which is supposed to be one of the mildest methods,[264] did result 
in the formation of aldehyde 436, but only in moderate yield. Interestingly, when we revisited 
Swern-type conditions, this time using triethylamine as a base- and phosphate-buffered work-
up, aldehyde 436 was furnished cleanly as a single diastereomer. This indicated that no 
epimerization at C-6 had taken place. Otherwise, a thermodynamic mixture of isomers would 
be expected to be visible in 1H NMR spectra of the crude reaction mixture. It is assumed that 
considerable 1,3-allylic strain renders enolization energetically unfavourable in this system, 
despite the potentially resulting conjugated system. Subsequent Wittig olefination with in situ 
generated Ph3PCH2 proceeded smoothly and yielded stable diene 410 in excellent 83% over 
two steps. Whilst investigating the oxidation/olefination protocol, the TES protected alcohol 
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437 was already synthesized as an alternative coupling partner for the envisaged fragment 
combination step (cf. chapter 3.2). On the one hand, this would require a less convergent 
construction of the C-7 alkene handle after coupling, but on the other hand provide a possibly 
more stable lithium alkenyl species (pKA ≈ 42), due to the lack of a comparably acidic 
bisallylic proton at carbon C-6 (pKA ≈ 35).[265] 
 
3.4 Synthesis of the trans-Hydrindanone Moiety 
 
The following chapter will describe the syntheses of coupling fragment 411 and of the more 
conveniently accessible model system 438 (cf. scheme 3.16), which start from Hajos-Parrish-
Eder-Sauer-Wiechert ketone (138).[76] As the first steps toward ketone 439 have already been 
described in detail in chapter 2.3 at the respective enantiomeric series, they will not be shown 
again. The synthetic protocol for the preparation of alcohol 335 has been published by the 
Trauner research group previously.[140,156] The detailed evolution of these methods is outlined 
in corresponding references.vi Present manuscript will only provide information about the 
successfully adopted transformations. 
   
 
Scheme 3.9:  Synthesis of enone 444 from 439 and the involved intermediary formed Pd-allyl species 445 and 
446 of the Saegusa-Ito oxidation step. 
The sequence commenced with the deprotection of ether 439 with aqueous HCl (6 M) in 
ethanol under refluxing conditions (scheme 3.9). Although these conditions are quite harsh, 
no elimination or rearrangement-caused side products were observed and alcohol 440 was 
furnished quantitatively. Protection of compound 440 with ethylene glycol was carried out 
                                                
viEmployed synthetic protocols have been developed by Dr. D. T. Hog. 
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under standard acid-catalyzed (p-TsOH) conditions, removing the formed water via azeo-
tropic distillation from toluene using a Dean-Stark apparatus.[266] Thus, 1,3-dioxolane 441 was 
isolated in excellent yield on multi-gram scale. The following transformation to ketone 442 
was achieved via NaOAc-buffered PCC oxidation. When conducted on large scale, it proved 
to be crucial to thoroughly elutriate and wash the resulting slimy precipitate of reduced 
chromium species to achieve consistency of the yields. In such a way, ketone 442 was 
obtained as a highly crystalline solid and could be purified from remaining trace amounts of 
respective cis-hydrindane derivative (not shown), via recrystallization from n-hexane at 4 °C. 
Notably, the determined yield exceeded the previously described one by 12%.[140] With this 
material in hand, the unsaturation of the cyclopentanone moiety was center stage. Previous 
experiments had shown that classical Saegusa-Ito conditions[267] would perform best in this 
transformation.[156] Conversion of ketone 442 to TMS ether 443 proceeded smoothly by 
deprotonating with LDA and intercepting the formed enolate with TMSCl in the presence of 
triethylamine. Silyl ether 443 was used crude after simple basic work up, extraction and 
thorough drying in vacuo. Oxidation with stoichiometric amounts of Pd(OAc)2 in a mixture of 
CH2Cl2 and MeCN at 40 °C yielded enone 444, along with small quantities of recovered 
ketone 442. This is due to TMS ether cleavage by acetic acid that takes place over the course 
of the reaction. Resubmitting this material to the same two-step protocol led to an overall 
yield of enone 444 of 76%. At the Saegusa-Ito oxidation the mechanistically relevant 
η1-allyl (445) and η3-allyl (446) PdII species undergo β-hydride elimination and subsequent 
reductive formation of acetic acid under concomitant precipitation of Pd0.[268] Due to the high 
costs of stoichiometric use of Pd reagents, either recovery of formed Pd0 via filtration 
(conducted during present thesis) and laborious re-conversion to Pd(OAc)2,[269] or the 
utilization of catalytic variants of the Saegusa-Ito oxidation are worth considering Various 
methods for the in situ re-oxidation of Pd0 to PdII have been described, such as the use of 
benzoquinone,[270] oxygen atmosphere using DMSO as a solvent or in combination with 
enamine co-catalysis,[271] Pd(OH)2 with t-BuOOH,[272] and the oxidation of allyl enol 
carbonates by catalytic amounts of Pd(OAc)2 and diphenylphosphinoethane.[273] 
Unfortunately, those methods suffer from lower and sometimes not consistently reproducible 
yields. However, Lebel and co-workers recently published a method that employs inexpensive 
Oxone® as co-oxidant and could demonstrate that this allows obtaining yields largely 
comparable with the uncatalytic parent protocol.[274] As the focus of present doctoral studies 
lay on the principal development of a synthetic route toward nitidasin (238), we have not 
revisited this synthetic step by evaluating Lebel’s conditions, yet.  
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Scheme 3.10: Stereoselective cuprate addition and stereochemical diversification by hydrogenation with 
different heterogeneous metal catalysts. 
For the installation of the iso-propyl substituent at C-18 the use of Normant-cuprate-based 
nucleophiles was intended. This was largely encouraged by procedures published by 
Molander and Bull, at which they surprisingly observed the addition of methyl or 
iso-propenyl cuprates from the more sterically hindered pro-S face of their trans-hydrindane 
system.[275] In our hands, iso-propyl-based cuprate addition had only given unsatisfying 
results,[156] presumably due to lower reactivity compared to alkenyl cuprates and the 
inherent tendency toward β-hydride elimination.[276] Addition of superstoichiometric amounts 
of iso-propenyl-based Normant-cuprate, generated from two equivalents iso-pro- 
penyl magnesium bromide (368) and CuCN at −78 °C, yielded desired saturated 
trans-hydrindanone 333 in 85% on 1.8 g scale (scheme 3.10). Reaction on higher scale was 
avoided due to a decrease in yield, which is probably attributed to a less efficient heat transfer 
that leads to undesired side reactions. The structure of addition product 333 was confirmed 
via NOE correlation of the angular methyl group to the iso-propenyl substituent and later on 
unambiguously via X-ray crystallographic analysis.[156] In collaboration with the research 
group of Houk we set out to investigate the observed selectivity theoretically and the 
identified determinants will be published in due course. Reduction of the introduced alkene 
via hetereogenous catalytic hydrogenation had previously yielded an unexpected 
diversification that became the central motif of our unified approach toward iso-propyl-
substituted trans-hydrindane sesterterpenoids (cf. chapter 1.4.3).[140] When Pd/C (2 mol-%) 
was employed in methanol as solvent system, hydrogenation (1 atm H2) resulted in a 
concomitant inversion of the stereogenic iso-propyl substituent and primarily ketone 336 was 
yielded.[256] This is attributed to the inherent ability of transition metal-based catalysts to 
achieve the involved initial hydropalladation step (447) in equilibrium, thus rendering  
double bond migration into neighboring positions possible.[277] In the presented case, this led
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Scheme 3.11:  Stereocontrolled installation of the C-17 centered alcohol functionality and preparation of 
(−)-Ipc borane (451) for the hydroboration step. 
to isomerization of stereocenter C-18. At this, hydrogenation of alkene 448 would again occur 
syn to the angular methyl substituent (scheme 3.10). Gratifyingly, when Adams’ catalyst 
(PtO2, 5 mol-%) was used instead and the solvent system altered to ethanol, desired 
hydrindanone 337 was obtained exclusively. The latter finding was also reported by Reddy et 
al. on a similar trans-hydrindane-based substrate.[278] 
Next, the construction of the C-17 centered alcohol was conducted, which had to be achieved 
stereoselectively for a potential synthesis of astellatol (213) and the YW compounds (240 
and 241) from common intermediates. In order to access alcohol 335, an alkene functionality 
was introduced first via a two-step Pd-catalyzed reductive hydride coupling (scheme 3.11). To 
this end, ketone 337 was converted to its respective enol triflate (449), using KHMDS and 
then PhNTf2. After extraction and removal of the solvents in vacuo, the crude triflate was 
heated with n-Bu3N, formic acid and Pd(PPh3)2Cl2 in DMF. Under these conditions, that were 
originally developed by Cacchi and co-workers,[279] a Pd–H source is generated from formic 
acid by expelling CO2. This Pd–H species then undergoes reductive coupling to the alkenyl-
ligand generated from the oxidative insertion of Pd0 into the carbon-oxygen bond of triflate 
449. The whole two-step protocol proved to be highly scalable and yielded alkene 450 in 
excellent 95% on 4.7 gram scale. 
Hydroboration of alkene  450 was best achieved using chiral (−)-Ipc borane (451) in a 
matched case. It has been shown that different borane-based reagents would result in lower 
diastereo- and regioselectivity of the transformation.[156] Due to a lack of commercial 
availability, (−)-Ipc borane (451) had to be prepared freshly from (S)-Alpine-BoramineTM 
(452) by addition of two equivalents of BF3·OEt2.[280] After separation from precipitated 
TMEDA adduct 453, (−)-Ipc borane (451) was obtained as a solution in THF and 
immediately used for hydroboration of alkene  450 in THF at 0 °C. Ensuing treatment with 
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H2O2 and aqueous NaOH furnished alcohol 454 in perfect facial selectivity in an 8:3 mixture 
with its regioisomer 455. Thorough separation by flash column chromatography allowed 
enriching of alcohol 454 to a ratio of 8:1 in 67% yield.!
 
Scheme 3.12:  Dioxolane cleavage and SEM ether formation toward trans-hydrindanone 456. 
Having synthesized gram quantities of dioxolane 454, the ketone protecting group was 
removed using PPTS in an acetone/water mixture,[281] in order to activate position C-2 for 
further functionalization (scheme 3.12). Here it was possible to remove remaining contents of 
the regioisomeric alcohol conveniently via flash column chromatography. In the following, it 
was intended to protect the alcohol functionality in substance 335. Earlier experiments had 
shown that a TBS ether would not allow for an orthogonal cleavage of a secondary TES ether 
(vide infra) in the later stages of the synthesis.[156] Besides, we were hesitant to employ 
hydrogenation labile hydroxyl protecting groups like benzyl ethers,[266] as for a potential total 
synthesis of astellatol (213), its exo-methylene group would pose a venturous selectivity 
challenge. Hence, the 2-(trimethylsilyl)ethoxymethyl (SEM) protecting group was chosen, 
which would on the one hand provide considerable stability against a variety of chemical 
transformations and on the other hand should be cleavable via basic fluoride conditions.[266] 
Using SEMCl in DIPEA, SEM ether 456 was isolated in excellent yield on gram scale. 
A further challenge in our retrosynthetic plan was the installation of the stereocenters located 
at C-2 and C-3.vii As it was already demonstrated that the stereo selectivity of enolate-based 
functionalizations at C-2 (cf. chapter 2.5) proceeds in favour of the desired configuration, it 
was tried to adopt these findings for a stereocontrolled crotylation of ketone 456. Tsuji 
crotylations via a mixed carbonate were ruled out due to the difficulties associated with 
diastereoselectivity and mixtures of branched and linear products.[250,282] Furthermore, early 
experiments in our group revealed that O-alkylation of enolates, generated from similar trans-
hydrindanones, would not proceed or rather yield attack via the non-stabilized carbon 
centered anion.[156] Accordingly, a Claisen rearrangement approach that would form both 
stereocenters via a chair-like 6-membered transition state, could not be evaluated to date.  
 
                                                
viiThe further synthetic sequence until alkene 475 was first evaluated on test system 439 by Dr. D. T. Hog[156] and 
experimental work toward the preparation of alkene 477 was conducted in cooperation. 
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Scheme 3.13:  Pd-catalyzed allylation of SEM ether 456. Outer and inner sphere mechanisms are still subject of 
scientific debate. 
Fortunately, studies published by Covey and co-workers on the construction of rearranged 
steroid systems had shown that trans-hydrindanone 439 can be regioselectively allylated with 
allylic electrophiles.[283]  Using potassium enoxyborates in the presence of catalytic amounts 
of Pd(PPh3)4, they were able to achieve allylation at carbon C-2 with the required 
diastereoselectivity. Employed methodology was originally developed by Negishi and 
co-workers in the early 1980’s and can be applied to a broad variety of ketones.[284] When  
this protocol was adopted, Covey’s results on ketone 439 were reproduced first 
(cf. chapter 4.2) and it was recognized that this procedure is highly sensitive toward oxygen, 
presumably due to the use of alkylboron species. Gratifyingly, the established SEM ether 456 
underwent the envisioned allylation as well (scheme 3.13). Regioselective generation of the 
potassium enolate (457) with KHMDS at room temperature was followed by transmetallation 
to boron using a self-prepared and thoroughly degassed solution of triethylborane at −78 °C. 
Subsequent addition of distilled allylbromide and Pd(PPh3)4 (7.5 mol-%) resulted in 74% 
yield of alkene 458 as a single diastereomer. The relative configuration at the newly formed 
stereocenter was again proven by 2D NOESY correlation between the angular methyl group 
and the C-2 located methine proton. The mechanisms of Tsuji-Trost allylations are currently 
459
460
[Pd0]Ln
[PdII]Ln-2
Br−
oxidative addition
463
Me
H
OSEM
OEt3B
−
K+
457
Me
H
OSEM
KO
KHMDS
456
Me
H
OSEM
O
BEt3
K(Et3BBr)
462
Me
H
OSEM
OLn-3[Pd
II]
461
Me
H
OSEM
OLn-3[Pd
II]
Me
H
458
OSEM
O
H
460
Me
H
OSEM
O
BEt3
−
K+
459
[PdII]Ln-2
Br−
464
[PdII]Ln-2
Br−
+
+
+
reductive 3,3'-elemination
inner sphere
 mechanism
outer sphere
 mechanism
transmetallation
(74%)
KHMDS
→ BEt3
→ Pd(PPh3)4
allylbromide
Me
H
458
OSEM
O
H
single diastereomer
NOE
allylbromide
3.4 Synthesis of the trans-Hydrindanone Moiety 
76 
still under investigation by the chemical community.[282d] It is undisputed that the catalytic 
cycle begins with the oxidative addition of Pd0 to allyl bromide to form PdII π-allyl species 
459. For a so-called inner sphere mechanism, transmetallation of enoxyboronate 460 would 
yield a PdII π-allyl species, which could be formulated either as a η1,η3- (461) or as the 
respective η1,η1-complex (462). A reductive 3,3’-elimination process then furnishes the 
desired allylated compound 458 and regenerates the initial Pd0 species (463). Evidence for the 
inner sphere mechanism has been given by Stoltz and Goodard by their calculations on 
enantioselective decarboxylative Tsuji allylations.[285] However, calculated differences in 
transition state energies for inner- and outer sphere mechanisms sometimes resided only in the 
region of 1.6 kcal/mol.[285b] Notably, the described 7-membered transition states, which are 
comparable to structure 462, seem to be 41 kcal/mol lower in energy than the respective 
‘conventional’ 3-center reductive elimination. The inner sphere mechanism provides a 
convenient explanation for the regioselectivity often observed for branched substrates.[286] 
The outer sphere mechanism can be formulated as an SN2'-type attack of enoxyboronate 460 
at η1-PdII π-allyl species 464. Proof for the occurrence of such a reaction pathway has been 
found by Helmchen and co-workers for Pd-catalyzed allylations of stabilized enolates.[287] 
  
 
Scheme 3.14:  Synthesis of tricyclic lactone 468 and illustration of the so-called ‘open book effect’ on a three-
dimensional drawing of this compound. 
In order to construct the C-3 located stereocenter, it was planned to perform a substrate-
controlled diastereoselective methylation. In particular, it was intended to tie back the allyl 
substituent to the cyclic carbon skeleton, preferably as a lactone to facilitate C–H activation. 
In literature this is often described using a reduction/ozonolysis sequence with subsequent 
oxidation of formed cyclic lactole.[288] Accordingly, we reduced ketone 458 with the sterically 
demanding hydride source K-Selectride® (465) in THF, which selectively furnished alcohol 
466 in excellent yield (scheme 3.14).[288b,289] This proceeds via an equatorial nucleophilic 
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attack that is directed by the steric clash between the angular methyl group and the hydride 
source 465. The configuration of formed stereogenic alcohol was elucidated via 2D NOESY 
experiments. In the following, a Lemieux-Johnson oxidation protocol[290] proved to be best for 
the conversion of substrate 466 to cyclic lactol 467. This procedure includes dihydroxylation, 
diol cleavage and intramolecular lactone formation in one-pot. Using catalytic amounts of 
OsO4, accompanied by NaIO4 and 2,6-lutidine in 1,4-dioxane/water at room temperature, 
lactol 467 was obtained as an inconsequential mixture of diastereomers, which was 
immediately subjected to PCC-mediated oxidation. Thus, γ-lactone 468 could be isolated in 
94% yield over two steps. Scheme 3.14 illustrates the so-called ‘open book effect’ inherent to 
bicyclic systems with cis-junction. Any kind of reagent will approach from the convex rather 
than from the considerably more shielded concave face. The desired methylation then 
proceeded smoothly in excellent 91% yield and produced lactone 469 as a single diastereomer 
by deprotonating with LiHMDS in THF (scheme 3.15). A similar methylation of a 
cis-hexahydrobenzofuranone system has been described e.g. by Wipf et al. in their synthesis 
of (−)-tuberostemonine (not shown).[291] Although the stereochemical outcome of these 
methylations is well precedented in literature,[292] it was additionally verified via X-ray 
crystallography on model system 470 in a prior report.[156,293]  
  
 
Scheme 3.15:  Diastereoselective methylation of lactone 468 and further transformation to aldehyde 474 via 
reduction with LiAlH4, double TES protection and deprotective Swern oxidation. The crystal 
structure of lactone 470 was reproduced from ref. 156. 
In order to restore the alkene handle required for the envisaged RCM step, lactone 469 was 
reduced with LiAlH4 in THF, which furnished diol 471 cleanly. In principle, diol 471 was 
already pure enough for the following TES protection after simple extraction and 
concentration. Thus, bis-silyl ether 472 was accessed via reaction with TESCl and imidazole 
using catalytic amounts of DMAP in 89% yield over two steps. The use of more expensive 
TESOTf in combination with the base 2,6-lutidine was also possible and led to equally good 
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yields for test system 473 (cf. chapter 4.3). For the selective deprotection and oxidation of the 
primary alcohol function in compound 472, a deprotective Swern oxidation protocol was 
applied, which is known to be able to discriminate between primary and secondary TES 
protected alcohols.[294] Using the standard reagents DMSO and oxalyl chloride, substrate 472 
had to be reacted at −60 °C for 8 hours or longer before addition of NEt3 could follow. If in 
this first part of the procedure the temperature exceeded −60 °C, isolable yields would 
significantly diminish due to double deprotection and oxidation. However, performing 
thorough temperature control, aldehyde 474 could be obtained in 94% yield as a single 
diastereomer without any observable epimerization (judged by NMR analysis). Following 
this, aWittig olefination was conducted with excess of in situ generated Ph3PCH2 in THF at  
0 °C (scheme 3.16). After one hour, full conversion was achieved and alkene 475 was isolated 
in 96% yield, again as single diastereomer. Altogether, 1.1 g of this advanced intermediate 
was prepared and kept at this stage for the time being, in order to allow for the investigation 
of alternative synthetic strategies. 
  
 
Scheme 3.16:  Final steps toward envisioned building block 477. Model system 438 was constructed employing 
the same synthetic procedures starting from hydrindanone 439. 
Moving forward to the required orthogonal deprotection of the secondary TES ether, 
substoichiometric amounts of (R)-campher sulfonic acid (CSA) were used in a solvent 
mixture of CH2Cl2 and methanol. Gratifyingly, we observed outright selectivity and alcohol 
476 was cleanly formed without loss of its SEM ether. Thus obtained crude material was 
immediately subjected to Dess-Martin periodinane-mediated oxidation, being buffered with 
NaHCO3. Counting from TES ether 475, the finished trans-hydrindanone building block 477 
was isolated in almost quantitative yield (95%). 
Summarizing, we synthesized coupling fragment 477 from known alcohol 335 in outstanding 
41% by a scalable 12-step protocol that allowed the construction of chiral centers C-2 and C-3 
in a highly diastereoselective manner. To conserve this valuable and highly advanced 
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intermediate, a model compound (438) was elaborated in 11 steps starting from ether 439 
in again excellent yield (42%). This largely similar trans-hydrindanone compound (438) 
was employed for all initial studies toward fragment combination and construction of the 
5-8-6-5-membered carbon skeleton that are described in the following section (vide infra). 
 
3.5 Model Studies Toward the Construction of the Central Cyclooctane Motif 
 
With substantial amounts of alkenyl iodides 410 and 437 and of model hydrindanone 438viii in 
hand, the planned fragment coupling via lithium alkenyl addition was investigated. Since we 
were worried that the alkenyl lithium species of diene 410 might be prone to undergo 
1,3-metallotropic rearrangement similar to arylalkynes,[295] or suffer from intramolecular 
proton shift, silyl ether 437 was employed initially (scheme 3.17). The required Li-alkenyl 
species was prepared in THF in situ via addition of two equivalents of t-BuLi at −78 °C.[296] 
When ketone 438 was added slowly to this solution, we were delighted to see a facile reaction 
course, furnishing tertiary alcohol 478 in 48% yield. It was possible to separate the undesired 
diastereomer (not shown) resulting from scalemic alkenyl iodide 437 by flash column 
chromatography. Furthermore, it was recognized that one has to employ slightly 
substoichiometric amounts of lithiation reagent, because any surplus amount of t-BuLi would 
add itself into the carbonyl functionality of substrate 438 and consequentially lower the 
obtained yield. The reactivity shown in this transformation is particularly worth noting 
since tetrasubstituted alkenyl lithium species are rarely used in organic synthesis. Especially
  
 
Scheme 3.17:  First synthetic investigations toward the construction of triene 479 via Li-alkenyl addition.ix 
                                                
viiiApproximately one gram of model system 438 was provided by Dr. D. T. Hog. 
ixDepicted experiments were carried out together with Dr. D. T. Hog. 
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addition to ketones, particularly to sterically encumbered ones such as ketone 438, are 
unprecedented to the best of our knowledge.[297] In order to elaborate envisaged metathesis 
precursor 479, the TES ether was cleaved next using PPTS under conditions similar to those 
described before (cf. chapter 3.4). Fortunately, the allylic alcohol moiety did not react via 
elimination and diol 480 was obtained almost quantitatively. Swern oxidation of the primary 
alcohol functionality was accompanied with spontaneous intramolecular cyclization to lactol 
481, which was isolated as a single isomer.[298] Although the stereochemistry at the newly 
formed lactol center could not be elucidated by means of 2D NMR methods, compound 481 
provided indirect proof that the double bond geometry of employed alkenyl iodide 437 had 
been retained upon lithiation. Next it was tried to react lactol 481 directly under Wittig 
olefination conditions using in situ generated Ph3PCH2, which has been precedented for 
similar lactol systems frequently.[299] Unfortunately, lactol 481 was not converted in the 
desired fashion, even when the temperature was risen to refluxing conditions. 
   
 
Scheme 3.18:  Fragment coupling toward triene 479, accompanied by kinetic resolution of scalemic 410. 
Encouraged by these results, it was tried to transfer the developed lithiation and addition 
conditions to diene 410 (scheme 3.18). To our delight the procedure furnished triene 479 
smoothly, but as an inseparable mixture of diastereomers, due to the low ee-value (60%) of 
diene 410. Interestingly, when 1.3 equivalents of the scalemic lithium alkenyl species were 
employed, triene 479 was obtained in a diastereomeric ratio of 10:1. This reflects a kinetic 
resolution of iodide 410 under the reaction conditions, which gratifyingly leads to preferential 
addition of the desired enantiomer. Furthermore, it was recognized that the addition speed of 
ketone 438 is a crucial parameter for this reaction. Supposedly, generated alcoholate of 
triene 479 started to enolize substrate 438 in situ, when extended exposure due to 
inhomogeneous distribution occurred. When addition times were prolonged to 30 min, yields 
would reach to excellent 84%. X-ray crystallographic analysis allowed for the verification of 
the relative configuration of all stereogenic centers and the alkene geometry. Careful 
inspection of the solid-state structure of triene 479 also revealed a close proximity between 
both terminal alkene functionalities. Solely, a 120° rotation around the C2–C3 axis would be 
required to result in an ideal conformational preorganization for envisaged RCM step. 
Me
HO
HMe Ot-Bu
410,  t-BuLi
−78 °C
(84%)
Me I
Me
Me
H
H
Me
Ot-Bu
HO
479
dr = 10:1
≡
438 479
The Total Synthesis of (−)-Nitidasin 
81 
With this knowledge in mind, we were poised to explore the key closure of nitidasin’s (238) 
central octacycle by means of ring-closing metathesis. As literature precedence is comparably 
marginal anyway, there is no catalyst system reported to be superior for the construction of 
8-membered ring systems.[177] However, Nakada and co-workers had successfully employed 
ruthenium-based Grubbs catalysts in their recent synthesis of ophiobolin A on a similar 
system (209, cf. chapter 1.3).[122,123] Table 3.1 summarizes the conditions screened for the 
transformation of triene 479. Interestingly, when using Grubbs first-generation catalyst (482, 
vide infra) in CH2Cl2 at 40 °C (entry 1), traces of a cyclized product were observed by  
1H NMR and EI mass spectroscopy, which was tentatively assigned as tetracycle 483. Similar 
results were obtained employing Grubbs second-generation catalyst (267) in both CH2Cl2 at 
40 °C and DCE at 82 °C (entries 2,3). Exchange of the chlorinated solvents for benzene led to 
quick consumption of triene 484 and a new product was formed selectively. Surprisingly, 
NMR spectroscopic analysis revealed that the tetrasubstituted double bond had participated in 
the metathesis reaction and that ring B (nitidasin notation) had been expelled accordingly. 
Careful chromatographic purification using triethylamine (1 vol.-%) in the eluent mixture was 
required to obtain highly acid sensitive tricycle 484 in 60% yield. Otherwise allylic 
transposition of the tertiary alcohol functionality was effected and led to a 1:1 mixture of 
diastereomeric products. 
  
Table 3.1: Model studies on the formation of nitidasin’s (238) 8-membered carbocycle via RCM. 
 
entrya catalystb solventc T [°C] t [h] observation 
       
1 Grubbs I (482) CH2Cl2 40 16 h 483 (traces) 
2 Grubbs II (267) CH2Cl2 40 16 h 483 (traces) 
3 Grubbs II (267) DCE 82 16 h 483 (traces) 
4 Grubbs II (267) C6H6 85 2 h 484 (60%)d, 483 (traces) 
a) All reactions were carried out on 4 mg scale in 0.8 mM dilution. b) Catalyst loadings were 10 mol-%. For catalyst 
structures see scheme 3.19. c) Solvents were degassed prior to addition of the catalyst (Ar bubbling). d) Catalyst loading was 
15 mol-%. 
 
It was reasoned that this finding is most likely attributed to the presence of the tertiary allylic 
alcohol next to the tetrasubstituted double bond. Regarding the general catalytic cycle for 
olefin metathesis, which was first proposed by Chauvin[300] in 1971 and later on elucidated in 
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more detail by Grubbs,[301] one recognizes that the site of catalyst initiation at substrate 479 is 
the key determinant of its cyclization mode. The catalytic cycle that is generally accepted for 
Ru-based catalyst systems[362] starts with the formation of Ru-alkylidene 485 by the so-called 
catalyst initiation (scheme 3.19). This happens via a series of transformations analogue to the 
one that is described to lead from alkylidene 485 to complex 486, involving: ligand 
dissociation to an active 16-electron species, alkene (487) coordination to π-complex 488, 
cyclization to metallacyclobutane 489 and subsequent ring opening via the productive retro-
reaction. Repetition of this sequence with another alkene molecule (490) ultimately yields 
desired metathesis product 491, at which the carbon–carbon bond geometry may be tuned by 
the choice of catalyst. General driving force of this equilibrium process is the expulsion of 
ethane or similar low molecular-weight congeners. It is known from several studies that free 
tertiary allylic alcohols enhance the rate of metathesis of alkene substrates significantly.[303] 
The reason for this is not undisputed. Hoye et al. propose in their systematic studies that a 
rapid and reversible ligand exchange with the alkoxy functionality promotes reaction via pre-
association.[304] However, Grubbs and co-workers suggest that rather the electron donating 
properties of oxygen account for faster and more efficient alkylidene formation. The latter 
mentioned authors state that chelation in the allylic position of the metal alkylidene to the 
metal center should be disfavoured, forming a strained, four-membered ring.[305]  
   
 
Scheme 3.19:  Dissociative mechanism of olefin metathesis after Chauvin and Grubbs, Grubbs-Hoveyda 
catalyst (206) and catalyst systems used in the course of present work.[300,301] 
In the presented case, catalyst initiation at the lower terminal double bond of triene 479 is 
unlikely, because this would involve the formation of a thermodynamically disfavoured, 
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strained cyclopropene (scheme 3.20). We reason that initiation takes places at the C-4 
centered double bond (494), upon which the tertiary alcohol reversibly binds to the catalyst 
center. This renders the sterically highly encumbered tetrasubstituted double bond more 
accessible to the now close Ru-alkylidene (495). Due to the electronically activating effect of 
the allylic hydroxyl substituent, this double bond now reacts rapidly in metallacycle 
formation, not allowing the catalyst to reach for the remaining terminal double bond. For the 
minor diastereomer 496, it may be suggested that the altered position of the C-6 substituent 
exerts increased steric hindrance on the allylic tertiary alcohol (497), effectively blocking it 
from the Ru-catalyst. Thus, structure 498 transforms smoothly to cyclooctadiene 483, whereas 
desired substrate 479 preferably undergoes described side reaction. It was also tried to protect 
the tertiary alcohol of triene 479 as bulky as possible (499), in order to prevent speculated 
reversible catalyst coordination. Unfortunately, all attempts to functionalize this oxygen atom 
remained unfruitful, which is attributed to the overall steric encumbrance at C-12 (table 3.2).  
  
 
Scheme 3.20:  Possible mechanistic explanation for the formation of cyclooctadiene 483 and cyclopentene 484. 
Illustrated 3-dimensional drawings were derived in style of the solid-state structure of triene 479.  
Eventually this strategy was abandoned and a relay ring-closing metathesis-based (RRCM) 
approach was devised. This aimed at a shift of catalyst initiation from the C-4 centered double 
bond to the second terminal double bond of triene 479. The concept of RRCM was originally 
developed by Hoye et al. and allows directing metal movement throughout olefin metathesis 
via installation of least substituted, more accessible carbon–carbon double bonds.[306] 
Exploiting the privileged formation of pentacyclic systems in RCM reactions, the additional 
relay handle would be expelled, thus forming the respective Ru-alkenylidene required for 
target ring formation.  
To reduce this plan into practice, the vinyl cyclopentane building block was modified 
as shown in scheme 3.21. The needed Wittig salt 500 was synthesized from commercially
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Table 3.2: Conditions screened for protection of the tertiary alcohol functionality of triene 479. 
 
entrya reagentsb solvent T [°C]c t [h] observation 
       
1 TESCl, im, DMAP DMF 0 to 50 6 h n.r. 
2 TESOTf, 2,6-lutidine CH2Cl2 0 to 40 6 h n.r. 
3 NaH; TMSCl THF 0 to 40 5 h n.r. 
4 n-BuLi; TMSOTf THF −78 to rt 2 h n.r. 
5 NaH; MeI DMF 0 to 50 6 h n.r. 
6 NaH; Me2SO4 DMF 0 to 50 12 h tracesd 
7 NaH; MeSO3F DMF 0 to 50 12 h n.r. 
a) Reactions were carried out on 2 or 4 mg scale. b) Reagents were used in large excess to triene 479. c) The temperature was 
raised gradually, monitoring the reaction course via TLC analysis. d) Observed via TLC and MS, but not isolated. 
 
available alcohol 501 as described by Hiersemann and co-worker.[307] Using their two-step 
protocol, which proceeds via Appel reaction[308] and subsequent SN2-type substitution of 
the furnished iodide (502) with triphenylphosphine, reagent 500 was isolated in 79% over two 
steps. Compound 500 was then reacted with known aldehyde 436 under the previously 
employed Wittig conditions (cf. chapter 3.3), at which triene 503 was obtained as a single 
double bond isomer in very good yield. Lithiation of 503 and subsequent addition to model 
system 438 furnished the desired RRCM precursor (504) in excellent 86% yield. Again, 
a kinetic resolution of scalemic alkenyl iodide 503 took place, although in somewhat lesser 
    
 
Scheme 3.21:  Synthesis of RRCM precursor 504, using a modified vinyl cyclopentane building block (503). 
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extent than reported for the previous explorations. Despite the flexible alkene handle of 
tetraene 504, single crystals suitable for X-ray crystallographic analysis could be grown, 
revealing a similar conformational arrangement as discussed for triene 479 (vide supra). 
Next, RRCM reaction conditions were screened as outlined in table 3.3. Unfortunately, when 
using the Grubbs first- (482) or second-generation (267) catalyst in benzene, again tricycle 
484 was formed accompanied with varying amounts of homodimer 505 and known 
diastereomer 483 (entries 1,2). Upon changing the solvent system to DCE, only dimer 505 
could be observed (entry 3). In order to enhance the catalyst’s preference to initiate at the 
least substituted double bond, catalyst 506 was employed, which was developed by Stewart 
and Grubbs.[244] Unfortunately this only led to formation of significantly increased amounts  
of homodimer 505 (entries 4,5). Ultimately, we examined the activity of Schrock’s catalyst  
(507),[309] which interestingly did not result in any reaction (entry 6). 
  
Table 3.3: Conditions screened for RRCM reaction of tetraene 504 and observed products (cf. table 3.1). 
 
entrya catalystb solventc T [°C] t [h] observation 
       
1 Grubbs I (482) C6H6 85 3 h 483 (traces), 505 (traces) 
2 Grubbs II (267) C6H6 85 3 h 484 (11%) 
3 Grubbs II (267) DCE 82 8 h 505 (traces) 
4 catalyst 506 C6H6 85 5 h 505 (31%) 
5 catalyst 506 DCE 82 5 h 505 (traces) 
6 Schrock’s catalyst (507) C6H6 40; 85 3 h n.r. 
a) All reactions were carried out on 3 mg scale in 0.6 mM dilution. b) Catalyst loadings were in all cases 10 mol-%. For 
catalyst structures see scheme 3.19. c) Solvents were degassed prior to addition of the catalyst (Ar bubbling). 
 
Since all attempts to circumvent participation of the tetrasubstituted double bond in RCM had 
failed so far, it was decided to mask this reaction site. Changing the order of events, it was 
considered bringing forward the envisaged late-stage epoxidation (cf. chapter 3.2). 
Gratifyingly, exposure of triene 479 to m-CPBA led to clean, chemoselective and 
diastereoselective reaction (scheme 3.22). Virtually no epoxidation of the terminal double 
bonds was observed under applied reaction conditions, even when a large excess of 
reagent was used. Purification via flash column chromatography allowed for the separation of
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Scheme 3.22:  Selective formation of epoxide 508 and key-step RCM, forming cyclooctene 509. The magnified 
characteristic 1H NMR signals belong to the alkene function of tetracycle 509. 
undesired isomers that resulted from employed 10:1 diastereomeric mixture of triene 479. 
This provided pure epoxide 508 in 72% yield. Due to the lack of meaningful NOE signals, the 
identity of the newly formed stereogenic centers had to be elucidated by X-ray 
crystallographic analysis. The obtained structure again shows close proximity of the terminal 
double bonds and confirms that desired epoxide was formed. Since unique reactivity of 
triene 479 was observed when using Grubbs second-generation catalyst (267) in benzene, 
diene 508 was submitted to the very same reaction conditions. To our delight, this time ring-
closing metathesis occurred uneventfully and delivered the desired tetracycle 509 in almost 
quantitative yield. Scheme 3.22 illustrates the characteristic alkene signals of recorded 
1H NMR spectra, which constitute the anticipated doublet of doublet splitting pattern. 
Although no single crystals could be grown from this material, 2D NMR analysis confirmed 
the closure of the central 8-membered ring unambiguously. 
To complete the synthesis of nitidasin’s (238) carbon framework at rings A, B and C, 
alkene 509 was hydrogenated in the presence of Pd/C (20 mol-%) in methanol (scheme 3.23). 
Although prolonged exposure to these conditions resulted in increased fractions of 
unaccounted side-reaction, desired saturated tetracycle 510 was obtained in 82% after three 
hours reaction duration. In order to compare model compound 510 with the data recorded 
from isolated nitidasin (238), we dissolved it in CDCl3 as NMR solvent. Interestingly, rapid 
conversion of epoxide 510 was triggered to the corresponding exo-methylene compound 511. 
This is attributed to trace amounts of DCl, causing proton-catalyzed epoxide opening 
that is followed by E1-type elimination. Notably, the newly formed allylic alcohol motif of
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Scheme 3.23:  Completion of the chosen model system for nitidasin’s (238) tetracyclic carbon skeleton and acid 
catalyzed epoxide opening to exo-methylene compound 511. 
tetracycle 511 resembles YW 3699 (240) and YW 3548 (241) at respective carbon centers 
(cf. chapter 1.4.1). Consequently, this finding might be of synthetic usefulness for an aspired 
total synthesis of those natural products. Although NMR spectroscopic comparison of 
compound 511 to nitidasin (238) remained impractical, we were confident that we had 
completed the natural product, except for the substitution pattern on ring D. Thus, we moved 
on to apply developed transformations to trans-hydrindanone 477. 
 
3.6 The Stage is Set – Completion of (−)-Nitidasin 
 
Encouraged by the presented model studies, we now exposed the further elaborated trans-
hydrindanone 477 to lithiated vinyl cyclopentane 410 (scheme 3.24). For this substrate, 
increasing the equivalents of lithium organyl to 2.2 equivalents provided optimized results. In 
agreement with the previous results, the addition to the carbonyl functionality was found to be 
completely diastereoselective regarding the newly formed stereogenic center at carbon C-12 
(nitidasin numbering). The diastereomers originating from scalemic iodide 410 were readily 
separable via flash column chromatography and 7% of the minor adduct (512) were isolated. 
Interestingly, the desired major isomer 513 turned out to be unstable upon concentration in 
vacuo. At this, the reconstitution of ketone 477 and the formation of a not ascertained low 
molecular weight fragment was observed. Consequently, triene 513 was directly employed for 
following epoxidation step, although being not thoroughly dried from n-pentane. Exposure to 
three equivalents of m-CPBA under the established reaction conditions yielded desired 
diene 514, again with chemo- and diastereoselectivity. Accordingly, the desired RCM 
precursor (514) was obtained in very good 71%, counting over two steps. Although the yield 
of triene 513 could not be determined, the value calculated for the consecutive transformation 
allows to conclude that for the Li-alkenyl addition the previously described kinetic resolution 
had afforded a diastereomeric mixture equal to or higher than 10:1 (cf. chapter 3.5). The 
ensuing RCM proceeded smoothly, using Grubbs second-generation catalyst (267) in benzene  
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Scheme 3.24:  Synthesis of tetracycle 515, using the established 3-step sequence. The solid-state structure of  
515 verified the correct relative configuration for all stereocenters found in the natural product. 
as established on model system 508. However, in present case, better yields were obtained 
when fresh catalyst 267 was added in three batches each hour, employing 5 mol-% loading at 
a time. Doing so, envisioned cyclooctene 515 was isolated in 94% yield and it became 
possible to grow crystals suitable for X-ray crystallographic analysis. This solid-state 
structure for the first time verified the relative configuration of all eleven stereogenic centers 
embedded in the carbon framework.  
Furthermore, it was noticed that obtained tetracycle 515 was only poorly soluble in protic 
solvents, due to its inherent lipophilic nature caused by the flat, steroid-like shape. Hence, it 
was aspired to postpone hydrogenation of its alkene moiety after deprotection of the SEM 
ether, as this was established on model system 509 using methanol as a solvent system. The 
sensitivity of tetracycle 515, combined with little amounts of material available for testing 
purposes prompted us to investigate the deprotection at a less advanced intermediate, namely 
ketone 456. Table 3.4 outlines the screened conditions. Although being promising due the 
reported mildness, a protocol published by Hoffmann and co-worker[310] that suggests the use 
of anhydrous MgBr2 in a mixture of MeNO2 and diethyl ether did not result in any reaction 
with model compound 456 (entry 1). Procedures based on basic fluoride sources did not yield 
conversion either at room temperature (entries 2–4). At this, elevated temperatures led to 
decomposition of the starting material. The use of strong Brønsted acids like TFA in CH2Cl2 
or HCl in methanol (entries 5,6) gave rise to alcohol 335, but was accompanied with 
unaccounted side reaction, observed by TLC analysis. To our delight, switching to less acidic 
HF/py in four volumes of THF led to clean formation of alcohol 335 in 92% yield (entry 7). 
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Table 3.4: Investigated conditions for the deprotection of SEM ether 456. 
 
entrya reagent solvent T [°C] t [h] observation 
       
1 MgBr2  Et2O, MeNO2 rt to 30 12 h n.r. 
2 TASF HMPA 50 12 h decomp. 
3 TBAF, 4 Å MS DMPU rt to 50 5 h n.r. then decomp. 
4 TBAF·3H2O, 4 Å MS THF rt to 40 2 h n.r. then decomp. 
5 TFA CH2Cl2 0 5 h 335 (66%) 
6 HCl (0.05 M)b MeOH rt 6 h 335 (75%) 
7 HF/py THF rt 36 h 335 (92%) 
a) All reactions were carried out on 10 mg scale under strict anhydrous conditions. b) The reagent was prepared freshly via 
addition of AcCl to MeOH. 
Keeping in mind that the epoxide functionality of tetracycle 515 suffers from pronounced 
lability toward acidic conditions, it was decided to remove the SEM group in advance of 
established fragment combination. Generated free alcohol would then require the use of an 
additional, sacrificial equivalent of the lithiated species of 410. Therefore, it was intended to 
free the secondary alcohol in trans-hydrindanone 477 (scheme 3.25). When this building 
block was submitted to HF/py in THF as described above, initially only 72% of alcohol 516 
were obtained, together with recovered starting material and epimerized alcohol 517. The 
latter two fractions were resubmitted to the original reaction conditions, which led to an 
overall yield of 90% of desired deprotected ketone 516. 
    
 
Scheme 3.25: Deprotection of the SEM ether in trans-hydrindanone 477. Grey hued yields refer to the first 
reaction cycle. 
Gratifyingly, addition of 3.1 equivalents of the Li-alkenyl of 410 resulted in similar reactivity 
as observed before (scheme 3.26). The diastereomeric mixture originating from scalemic 
iodide 410 was again separated via flash column chromatography and 3% of the undesired 
adduct (518) were isolated. On the basis of the discussed results for compound 513 we 
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directly employed the major isomer 519 for following transformation as a not completely 
solvent free mixture. Substrate-controlled chemoselective epoxidation of triene 519 with 
2.3 equivalents of m-CPBA then provided diene 520 in excellent 74% yield over two steps. 
Comparison of yields determined for isomer 518 and diene 520 suggests that for the 
Li-alkenyl addition the known kinetic resolution had afforded a diastereomeric mixture equal 
to or higher than 25:1. Following the obvious trend in this series, it becomes clear that 
increasing the amount of Li-alkenyl leads to a favoured formation of the respective desired 
tertiary alcohol adducts. However, this requires incremental wasteful use of synthetically 
precious vinyl cyclopentane building block 410. Subsequent RCM reaction of diene 520 gave 
best results when fresh catalyst 267 was added in three batches each hour, as described 
previously (vide supra). Employing a total of 15 mol-% catalyst loading, desired unprotected 
tetracycle 521 was isolated in almost quantitative yield. Interestingly, the dilution of diene 
520 had to be increased slightly to 0.6 mM to prevent formation of minor amounts of 
homodimeric side products.  
    
 
Scheme 3.26: Three-step synthesis of unprotected tetracycle 521 and an alternative route, using modified SEM 
deprotection conditions. 
Having established a reliable route toward alkene 521, the SEM ether removal was revisited 
on leftover material of substrate 515. Using TBAF in DMPU, solely slow decomposition was 
induced. The application of TBAF·3H2O and 4 Å MS in THF simply triggered the loss of the 
TMS moiety without concomitant ether cleavage. Switching the fluoride source to TASF and 
the solvent to HMPA at elevated temperature did not provide any transformation at first. 
However, addition of thoroughly activated 4 Å MS led to the formation of freed alcohol 521 
in 72% along with recovered starting material. Hence, an alternative route to substance 521 
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Table 3.5: Evaluated hydrogenation conditions toward unsaturation of the cyclooctene moiety. 
 
entrya R catalyst loading solvent p(H2)  t [h] observationd 
        
1 SEM Pd/Cb 0.2 eq. MeOH 1 bar 24 522 (20%) 
2 H Pd/Cb 0.2 eq. MeOH 1 bar 4 30% consumption 
3 SEM Pd/Cb 0.2 eq. EtOAc 8 bar 6 40% consumption 
4 H, SEM Pd/Cb 0.2 eq. EtOAc 20 bar 12 60% consumption 
5 H Pd/Cb 0.2 eq. MeOH 30 bar 10 full consumption 
6 H PtO2 0.1 eq. EtOH 1 bar 10 slow decomp. 
7 SEM catalyst 524 0.1 eq. CH2Cl2 1 bar 1 rapid decomp. 
8 SEM Rh/Al2O3c 0.2 eq. EtOH 1 bar 25 80% consumption 
9 H Pd/Cb 3 eq. MeOH 1 bar 1.25 523 (90%) 
10 SEM Pd/Cb 3 eq. MeOH 1 bar 1.25 522 (85%) 
a) Reactions were carried out on 0.5 or 1.0 mg scale, except for entries 1,9 and 10. b) 10 wt-% Pd. c). 5 wt-% Rh. d) For 
entries 2–5 and 8, converted material was a mixture of 522 or 523 and decomposition products. 
was established via a previously unknown modification of SEM ether deprotection 
conditions.[266] 
In order to complete nitidasin (238), we meanwhile had moved on to hydrogenate alkene 515 
under the conditions employed for model system 509 (cf. chapter 3.5). This resulted in 
comparably slow conversion and only 20% of desired saturated substrate 522 were isolated, 
due to prevailing decomposition. It was suspected that mentioned low solubility of  
tetracycle 515 in methanol might be responsible. Thus, different solvent systems and catalysts 
were screened and the effect of increasing the applied hydrogen pressure (table 3.5) was 
evaluated. The variation of pressure and solvent system did not speed up the reaction 
sufficiently to compete with decomposition side reactions, when using catalytic amounts of 
Pd/C (entries 1–5). Furthermore, the use of Adams’ catalyst[199] in ethanol did not result in 
any product formation at all (entry 6). Crabtree’s catalyst (524),[311] which is known to 
coordinate to nearby alcohol functionalities, thus rendering even hindered alkenes accessible 
for hydrogenation, led to rapid decomposition. This is presumably due to its Lewis acidic 
nature (entry 7). Catalytic amounts of Rh/Al2O3, which is supposed to exhibit hydrogenation 
rates superior to Pd/C, also failed to effect improved results (entry 8).[312] To our delight, 
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simply increasing the catalyst loading of Pd/C to three equivalents yielded desired 
cyclooctanes 522 and 523 at reduced reaction durations and in very good yield (entries 9,10). 
A reasonable explanation for this finding involves the predominant coordination of substrates 
515 and 521 to the catalytic sites of employed heterogeneous systems, thereby effectively 
blocking hydrogen transfer to the alkene moieties. As application of superstoichiometrical 
amounts of catalyst obviously provides the needed active catalytic sites, the speculated 
coordinative deactivation must be caused either by the epoxide, the tertiary alcohol or by the 
protected and unprotected secondary alcohol functions in compounds 515 and 521. 
    
 
Scheme 3.27: Completion of (−)-nitidasin (238) via Ley oxidation of nitidasol (523). Depicted solid-state 
structure was produced from data recorded from synthetically obtained material. 
Final transformation of ‘nitidasol’ (523), which might be the direct biosynthetic precursor of 
nitidasin (238), had to resort to non-acidic, mild methodologies. Already the use of NaHCO3-
buffered DMP oxidation conditions led to complete decomposition of alcohol 523. To our 
delight, Ley oxidation with TPAP/NMO[264] furnished the natural product in very good 89% 
yield (scheme 3.27). Unambiguous confirmation of the molecular structure of our synthetic 
material was achieved via X-ray crystallographic analysis. Obtained solid-state structure was 
identical to the one published by Kawahara and co-workers.[154] In order to compare NMR 
spectroscopic data of the synthesized compound to the isolated material, thoroughly 
acid-freed CDCl3 had to be prepared.[313] A complete lineup of recorded 1H and 13C NMR 
data and published values can be found in section V of the appendix. The optical rotation of 
the artificial sample was levorotatory as reported for the natural sample. The developed total 
synthesis enabled the preparation of all in all 16.3 mg of (−)-nitidasin (238) over the course of 
present doctoral thesis. 
 
3.7 A Brief Synthetic Digression Toward Alborosin 
 
The assumed biosynthetic origin of alborosin (252) is nitidasin (238), as already outlined 
earlier (cf. chapter 3.1). Having access to the latter substance via the established total 
synthesis and to model system 510, we were curious to examine weather their epoxide 
functionality could be opened regioselectively to form a 1,2-diol (525) with adjacent tertiary 
Me
Me
HO
H
H
Me
O Me
OH
523
H
Me
Me
HO
H
H
Me
O Me
O
(−)-nitidasin (238)
H
TPAP
 NMO  
 (89%)
≡
238
The Total Synthesis of (−)-Nitidasin 
93 
alcohol (scheme 3.28). It was recognized that for this transformation a concomitant 
elimination would have to be triggered rather into the C-9 than into the C-6 position (nitidasin 
numbering), in order to form the required double bond. A glycol cleavage of intermediate 525 
would then directly furnish alborosin (252), assuming drawn stereochemistry matches the 
isolated compound. 
   
 
Scheme 3.28: Retrosynthetic analysis for a semisynthesis of alborosin (252) starting from nitidasin (238). 
It was known from previous experiments that proton-catalyzed epoxide opening would 
furnish respective 1,3-diol motif (vide supra), rather than envisioned 1,2-diol 526 
(scheme 3.29). Therefore, based-promoted epoxide opening via E1cB mechanism was 
investigated next. However, the use of LDA in diethyl ether on model system 510 led to clean 
formation of exo-methylene compound 511 with complete regioselectivity. This finding is 
explained by the increased steric encumbrance of methylene carbon C-9, compared to methyl 
carbon C-20. Furthermore, the solid-state structure of nitidasin (238) reveals that both 
hydrogen atoms at C-9 cannot not easily be aligned in a proper antiperiplanar fashion, which 
is ideally required for an E1cB-type epoxide opening. Consequently, we turned our attention 
to Lewis acid-promoted epoxide openings. It was reasoned that regioselective opening would 
be favoured, if precoordination of the Lewis acid with the tertiary alcohol function and the 
epoxide could be achieved. Table 3.6 summarizes the conducted efforts, which were limited 
by the quantity of available epoxide 510. Most promising seemed the methodology published 
by Kita and co-workers, using hypervalent iodine(III) reagents to open 2,3-epoxy alcohols 
and achieve glycol cleavage in one step.[314] Unfortunately, treatment of model system 510 
with PIFA did not result in any reaction at all (entry 1). The effect of Ti(Oi-Pr)4 was 
also examined at varying reaction temperatures, as this reagent was shown to affect desired
    
 
Scheme 3.29: Selective base-promoted epoxide opening to exo-methylene compound 511. 
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transformation for less hindered 2,3-epoxy alcohol systems (entries 3,4).[315] Again, this did 
not provide any reaction until slow decomposition of substrate 510 was initiated at 110 °C. 
Furthermore, the use of Pb(OAc)4 did not promote desired reactivity either (entry 4). 
Interestingly, when compound 510 was treated with HIO4 in diethyl ether, the slow formation 
of a new product was observed, of which it was not possible to elucidate the structure via 
NMR spectroscopic analysis. However, using mass spectroscopy we saw, that characteristic 
desired product signals were absent in this sample. We stopped our investigations on the 
semisynthesis of alborosin (252) at this point, due to a lack of material for screening purposes.  
  
Table 3.6: Investigated conditions for the regioselective epoxide opening (cf. scheme 3.29) 
entrya reagent solvent T [°C] t [h] observation 
       
1 PIFA  CH3CN, H2O 0 to rt 6 h n.r. 
2 Ti(Oi-Pr)4b CH2Cl2 0 to rt 6 h n.r. 
3 Ti(Oi-Pr)4b toluene rt to 110 6 h n.r. then decomp. 
4 Pb(OAc)4 CH2Cl2 rt  24 h n.r. then decomp. 
5 HIO4 Et2O 0 to rt 12 h u.p.c 
a) All reactions were carried out on 0.5 mg scale. b) Reagent was freshly distilled. c) The identity of the product of this 
reaction could not be elucidated.  
 
3.8 Conclusion and Future Aspects 
 
In conclusion, we have successfully established the first total synthesis of the complex 
sesterterpenoid (−)-nitidasin (238). The presented convergent synthetic route features several 
highly diastereoselective transformations, which enabled the construction of nine of 
nitidasin’s (238) ten stereogenic centers from scratch. The natural product was prepared from 
inexpensive, commercially available starting materials in 34 steps (longest linear sequence) in 
1.8% overall yield (scheme 3.30). In addition, obtained synthetic material allowed to assign 
the relative stereochemistry of the natural product by comparing measured optical rotations. 
Initiated by previous work conducted in the Trauner laboratories,[140,156] we developed 
trans-hydrindane building block 475. This versatile compound served not only as an 
advanced intermediate in the nitidasin (238) synthesis, but also takes a central role in 
currently ongoing synthetic investigations toward total syntheses of astellatol (213), alborosin 
(252), YW 3699 (240) and YW 3548 (241). The outlined synthetic sequence is especially
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Scheme 3.30: The total synthesis of (−)-nitidasin (238), starting from commercial scalemic citronellene (413) 
and known trans-hydrindanone 477. 
marked by its reliable, scalable and high yielding transformations, e.g. affording trans-hydrin-
dane 477 in 41% over 12 steps starting from known alcohol 335 (cf. chapter 3.4). 
Furthermore, it was possible to construct vinyl cyclopentane 410 in gram quantity via 
zirconium-mediated enyne cyclization. This was followed by correction of the configuration 
of C-6 located stereocenter (nitidasin numbering), using an elimination/hydroboration 
sequence (cf. chapter 3.3). This building block possesses a literature unprecedented cis-cis-cis 
relationship in respect to its vinyl iodide and adjacent ring substituents. Subsequently, a 
fragment combination was achieved under kinetic resolution via a completely 
diastereoselective addition of a tetrasubstituted alkenyl lithium species – generated from 
scalemic compound 410 – to trans-hydrindanone 477. Later on, a remarkably efficient 
RCM-based formation of the central, highly substituted 8-membered ring of nitidasin (238) 
was demonstrated. At this, several solid-state structures were obtained and provided insights 
in the conformational preorganization of prepared substrates and the presumable course of 
their RCM reactions (cf. chapter 3.5 and 3.6). 
Prepared synthetic (−)-nitidasin (238) is currently subject of investigation, regarding its 
bioactivity. However, first evaluation on the effect of the natural product on proliferation and 
induction of cell-death on MDA-MB-231 breast cancer cells did not show any effect so far.x 
Once nitidasin’s (238) biological purpose and mode of activity has been revealed, future work 
might aim at a modification of the established synthetic route in order to prepare analogues 
with possibly increased potency. Scheme 3.31 highlights the positions of the natural product 
at which differing substitution patterns would be accessible most easily. Although our efforts
   
                                                
xThese experiments were conducted in co-work with the group of Prof. Dr. A. Vollmar. 
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Scheme 3.31: An alternative route for the semisynthesis of alborosin (252), starting from nitidasin (238). Grey 
arrows indicate sites, at which variation of the substitution pattern can be easily achieved. 
toward a semisynthesis of alborosin (252) have remained unfruitful so far (cf. chapter 3.7), a 
different synthetic approach would be conceivable. If one would de-epoxidize nitidasin (238) 
using Sharpless’ protocol,[316] an allylic transposition of the tertiary alcohol could yield 
structure 527. Disconnection of the carbon-carbon double bond via ozonolysis and a final 
regioselective elimination step would provide alborosin (252) in a slightly longer sequence 
than previously aspired. 
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4. Synthetic Studies Toward Astellatol 
 
4.1 A Comprehensive Introduction to Astellatol 
 
In 1989 Simpson and Sadler isolated the sesterterpenoid astellatol (213) from the fungus 
Aspergillus variecolor (syn. A. stellatus) within their studies on a series of xanthone 
pigments.[155] The authors were able to grow crystals of both, the natural product and its 
oxidatively derived ketone (not shown), which however were not suitable for X-ray 
crystallographic analysis. Hence, astellatol’s (213) molecular structure was established by 
application of a variety of one- and two-dimensional NMR techniques (scheme 4.1).[317] Its
   
 
Scheme 4.1: The sesterterpenoid astellatol (213): flat generic structure, three-dimensional drawing and force 
field refined structure (MMFF94). 
unique pentacyclic carbon backbone comprises a four-, two five-, a six- and a seven-
membered ring, that are fused over edges and at the atoms C-1 and C-13 (astellatol 
numbering) via two spiro centers. Astellatol (213) features in total ten stereogenic centers, 
three of which are quaternary all-carbon-substituted. In similarity to nitidasin (238), present 
natural product also incorporates an iso-propyl-substituted trans-hydrindane motif. Its 
exo-methylene-substituted cyclobutane ring system and the single secondary alcohol pose the 
only two functional handles of the molecule, which renders the construction of its carbocyclic 
skeleton an intricate synthetic challenge. 
Together with mentioned NMR studies, Simpson conducted labeling experiments at which 
[1,2-13C2]acetate was fed to cultures of the parent fungus.[200] The observed 13C-coupling 
pattern was consistent with the biosynthetic pathway shown in scheme 4.2. Accordingly, it 
was proposed that geranylfarnesyl pyrophosphate (143) undergoes initial folding and 
cyclization, corresponding to the proposed biosynthesis of retigeranic acid A (236) and 
B (237), to give the bicyclic intermediate 406 (cf. chapter 3.1). An ensuing [1,5]-hydride shift, 
which has been observed in the biosynthesis of a number of different sesterterpenoids,[318] and 
a subsequent 6-exo-trig cyclization complete the trans-hydrindane system and lead to tricyclic 
tertiary carbocation 407. This species now undergoes a series of stereospecific [1,2]-hydride 
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shifts, which are accompanied by a 5-endo-trig cyclization to yield in tetracyclic cation 408. 
This intermediate also represents the branching point for the formation of nitidasin (238) as 
proposed earlier (cf. chapter 3.1). In the case of the formation of astellatol (213), homoallyl 
cation 403 is the entry to a so-called homoallyl-cyclopropylcarbinyl-cyclobutyl 
rearrangement, which has been found to be an equilibrium process.[319] This intriguing 
cationic rearrangement proceeds via an initial 3-exo-trig cyclization (528), which is followed 
by a [1,2]-migration that forms the bond between C-1 and C-17 in a stereoselective manner 
(529). Final elimination to exo-methylene compound 530 delivers the thermodynamic driving 
force and terminates the cationic cascade. Stereoselective enzymatic oxidation of C-5 then 
completes the natural product. To date, there is no published data on astellatol’s (213) 
biological activity. Notably, its D and E ring systems are identical to those found in the potent 
GPI-anchor inhibitors YW 3699 (240) and YW 3548 (241).[160] 
    
 
Scheme 4.2: Proposed biosynthesis of astellatol (213). The single oxidation step is highlighted red. 
Shown biosynthetic pathway puts forth an compelling retrosynthetic disconnection for the 
artificial construction of astellatols (213) central 5-4-7-6-membered ring system. If one could 
address carbocation 403 or any later ionic intermediate by means of total synthesis, this would 
allow for the biomimetic formation of the desired carbon skeleton in an otherwise unfeasible 
efficient way. To the best of our knowledge, this would also be the first synthetic application 
of mentioned cationic rearrangement. Thus, a total synthesis of astellatol (213) would not 
only provide the chance to thoroughly investigate its bioactivity, but it would additionally 
establish its absolute configuration, confirm its structure unambiguously and prove the 
synthetic usefulness of the homoallyl-cyclopropylcarbinyl-cyclobutyl rearrangement. 
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4.2 Retrosynthetic Analysis 
 
In the forefront of discussing novel synthetic approaches toward astellatol (213), a short 
overview of unsuccessful retrosyntheses, which had been investigated in the Trauner labora-
tories previously will be presented (scheme 4.3). Research conducted in this field was carried 
out by Dr. D. T. Hog and is outlined in his doctoral thesis.[156] In short, two distinct ideas to 
construct astellatol (213) were at hand. The first strategy envisaged the use of the natural 
product’s biosynthetic cationic cascade (cf. scheme 4.2), which was meant to be entered at a 
stage similar to cation 407 via ionization of allylic alcohol 531. Attempts to close the required 
11-membered ring by means of RCM (532), B-alkyl Suzuki coupling (533) or intramolecular 
allylation (534) failed. This was either due to predominant side reactions during the ring 
closure or because the desired precursor could not be accessed. In a second attempt, it was 
tried to access the central polycyclic ring motif via ketene-alkene cycloaddition (535).[320,321] 
At this, no reliable route toward a viable ketene precursor could be found, yet.  
  
 
Scheme 4.3: Synthetic approaches toward astellatol (213) previously investigated in the Trauner research 
group. Depicted late-stage intermediates 532, 533, 534 and 536 are the most advanced 
compounds reliably accessed at respective routes. 
In light of these previous endeavors, it was sought to establish a more convergent strategy for 
a potential biomimetic total synthesis of astellatol (213). In particular, we opted for a route 
involving a 5-8-6-5-membered ring system that would have the correct relative configuration 
at carbon C-14 (astellatol numbering) already in place and thus reduce the number of events 
in the key cascade. As outlined in scheme 4.4, diene 537 was envisioned as key precursor for 
a biomimetic synthesis of astellatol (213). Upon treatment with acid, protonation was 
supposed to trigger the homoallyl-cyclopropylcarbinyl-cyclobutyl rearrangement. Closure of
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Scheme 4.4: Retrosynthetic analysis of astellatol (213), relying on the construction of cyclooctadiene 537 via 
means of reductive carbonyl-carbonyl coupling. Not specified stereocenters are inconsequential. 
the central 8-membered carbocycle should be achieved by reductive carbonyl-carbonyl 
coupling, e.g. under McMurry conditions.[322–324] The required diketone (538) was planned to 
arise from known SEM protected trans-hydrindane 475 (cf. chapter 3.4) and triflate 539, 
using B-alkyl Suzuki coupling conditions. The latter fragment was meant to be prepared from 
3-pentynol (540) in an enantioselective manner. At this, the required 1,3-diketone precursor 
(not shown) would be constructed via hydrogenative ring opening of isoxazoline 541 and 
subsequent oxidation of resulting β-keto alcohol function. Mentioned heterocycle could be 
obtained by means of 1,3-diploar cycloaddition (Huisgen reaction)[325] of an in situ generated 
nitrile oxide species. In addition, an auxiliary-controlled enantioselective alkylation could 
provide an entry for required open-chain building block and would refer to a suitable 
electrophilic derivative of commercially available alkyne 540.[326] A key feature of this 
retrosynthetic approach is the close structural similarity of envisioned intermediates 537 and 
538 to the natural products nitidasin (238) and alborosin (252), respectively (cf. chapter 3). 
Thus, the outlined route would potentially allow to access three sesterterpenoids from 
common building blocks 539 and 475 in a highly convergent way. 
 
4.3 Enantioselective Synthesis of the Cyclopentenol Triflate Fragment 
 
First attempts conducted in order to address an enantioselective entry by means of auxiliary-
assisted nucleophilic substitution reaction, involved the use of propionylated oxazolidinone 
542 in an Evans-type alkylation (scheme 4.5).[327] This compound was prepared in three 
steps from (S)-phenylalanine (543) in 70% yield, according to well established literature 
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Scheme 4.5: Preparation of compound 542 and iodide 548 and unsuccessful coupling via Evans alkylation.  
known procedures. In short, the performed transformations were: reduction with LiAlH4 to 
aminoalcohol 544,[328] oxazolidinone formation with diethylcarbonate (545)[329] and 
subsequent acylation of substance 546 using propionyl chloride (547).[330] As electrophilic 
reaction partner, the known iodide 548 was prepared initially by a 2-step procedure. After 
almost quantitative tosylation of alkyne 540 with TsCl and triethylamine in CH2Cl2, the 
sulfonate substituent in 549 was exchanged against iodine under classical Finkelstein 
conditions, employing NaI in acetone at 60 °C. Purified by repeated distillation under inert 
gas atmosphere, electrophile 548 was obtained dry in 82% yield and was indefinitely stable as 
a solid upon storage at −20 °C under exclusion of light. Unfortunately, when iodide 548 was 
added to the in situ generated Li- or Na-enolates of compound 542, only trace amounts of the 
desired alkylation product were observed. It was reasoned that iodide 548 is not electrophilic 
enough to react with stabilized enolates, like those that are derived from oxazolidinones. 
Literature states that the respective triflates are more reactive and the reagents of choice in 
such cases.[331] Accordingly, the very sensitive triflate 550 was prepared via addition of triflic 
anhydride to a mixture of alcohol 540 and pyridine in CH2Cl2 in excellent yield (scheme 4.6). 
As intended, this reagent underwent alkylation reaction with Li-enolate 551 to yield desired
    
 
Scheme 4.6: Evans alkylation of enolate 551 with triflate 550 and explanation of its stereochemical outcome. 
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alkyne 552 as a single diastereomer in 69% yield. Observed selectivity can be explained by a 
conformational fixation of generated (Z)-enolate (551) via chelation of lithium to the 
1,3-situated carbonyl functions.[327] Consequently, the benzyl substituent shields the  
si-face of enolate 551 and directs electrophile 550 to the re-face. However, selective semi-
hydrogenation of alkyne 552 to its respective alkene (553) remained unsuccessful.  
When Lindlar hydrogenation conditions (Pd/CaCO3, poisend with 5 wt-% Pb)[332] were  
applied – with or without the addition of quinoline – overreduction of the alkyne function and 
decomposition of the oxazolidinone moiety was observed.  
As Birch reduction conditions are obviously too harsh for substrate 552 and semi-reduction 
via diimide-mediated hydrogen transfer would be a capricious venture, it was tried to switch 
the chiral auxiliary and chosen to explore Myers’ alkylation methodology with 
(1S,2S)-pseudoephedrine (554, scheme 4.7).[107] Again, the auxiliary (554) was first acylated 
with propionic anhydride (555) as described in Myers’ publication and amide 556 was 
obtained in excellent 98% yield. Beneficially, this detailed alkylation protocol allowed the use 
of less sensitive iodide 548. When two equivalents of enolate species 557 were reacted, the 
desired product (558) was isolated in 75% yield with no observable formation of the 
respective diastereomer. Regarding the reaction mechanism, a complex three-dimensional 
model of formed (Z)-enolate 557 was proposed by the original authors, at which the si-face is 
sterically blocked due to oxygen centered solvated lithium ions.[107] It shall be noted, that this 
rational has not been confirmed unambiguously up to date, as it does not account for 
the actual transition state.[107,333] To our delight, we were able to obtain single crystals from 
amide 558, which were suitable for X-ray crystallographic analysis and confirmed  
desired stereochemical outcome. Ensuing hydrogenation of alkyne 558 in the presence  
of Pd/BaSO4 in pyridine selectively yielded corresponding cis-alkene 559.[334] Attempts, at
  
 
Scheme 4.7: Myers alkylation of enolate 557 with iodide 548, explanation of its stereochemical outcome, 
semi-hydrogenation to alkene 559 and subsequent LAB reduction to alcohol 560. 
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which classical Lindlar hydrogenation conditions[332] were employed, resulted again in 
immediate overreduction to the respective alkane (not shown). Subsequent cleavage of the 
auxiliary with in situ generated lithium amidotrihydroborate (LAB) in THF led to clean 
formation of volatile alcohol 560.[335] At this stage, chiral intermediate 560 was converted to 
its respective Mosher ester (561, scheme 4.8) under the previously described conditions in 
87% yield (cf. chapter 3.3). Evaluation of recorded 19F NMR spectra of ester 561 revealed an 
enantiomeric ratio of alcohol 560 of 99:1, which is consistent with the published data for 
comparable substrates.[107] In order to synthesize envisaged isoxazoline 541, it was first 
intended to transform alcohol 560 into its aldoxime congener (562). This functional group 
represents a well literature precedented precursor for the in situ generation of nitrile oxide 
species and has been used for intramolecular Huisgen reactionsxi before.[336] Encouraged by 
previous positive results with Swern oxidations on α-chiral alcohols (cf. chapter 3),  
aldehyde 563 was synthesized under the same conditions. Due to its high volatility, 
intermediate 563 was not thoroughly freed from solvents, but directly employed for 
subsequent oxime formation. Upon reaction with NaOAc-buffered hydroxylamine 
hydrochloride in methanolic solution, the less volatile aldoxime 562 was obtained in 77% 
over two steps in an inconsequential 5:2 mixture of E- and Z-isomers. The focus was then 
directed toward the nitrile oxide (564) formation, which was first tried with aqueous sodium 
hypochloride in CH2Cl2. This transformation proved to be straightforward and yielded the 
product of the aspired intramolecular 1,3-dipolar cycloaddition in excellent 98% yield. In 
perfect agreement with studies on the diastereoselectivity of such Huisgen-type bicycle 
formations (cf. structures 565 and 566) that were published by Houk[337] and Kozikowski,[338] 
a mixture of syn- and anti-541 of 2:3 was observed. Using NOESY correlation, it was 
  
 
Scheme 4.8: Synthesis of isoxazoline 541 via Huisgen reaction and Mosher ester formation with alcohol 560. 
                                                
xiThis type of reaction has come to be known as intramolecular nitrile oxide cycloadditon (INOC). 
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Scheme 4.9: Ring opening transformations of isoxazolines and examples for their application in synthesis. 
possible to assign the major diastereomer to the anti-configuration. The isoxazoline 
hetereocycle (567) has found numerous applications in total synthesis, as it can be 
transformed to a variety of functional group motifs (scheme 4.9), due its weak N–O bond 
(157 kJ/mol).[339,340] Base-mediated ring opening with e.g. LDA may yield un- 
saturated α,β-oximes (568),[341] whilst nucleophilic addition of Grignard reagents to the  
carbon–nitrogen double bond leads to respective isoxazolidinones (not shown).[342] Lin et al. 
reported in their synthesis of (–)-cocaine (569) a decarboxylative fragmentation of an 
isoxazoline ring (570) under thermal conditions, yielding nitrile 571.[343] Furthermore, 
isoxazoline reduction by hydride sources or hydrogenation can provide the respective 
β-amino alcohols (572), which found its very first application in Confalone’s racemic 
synthesis of biotin (573).[344] For our synthetic route, the most relevant cleavage method is 
represented by the selective catalytic hydrogenation of the N–O bond. At this, the resulting 
iminium function first remains intact and is then hydrolyzed in situ to yield β-hydroxy 
carbonyls (574). The most commonly used protocol for this transformation was published by 
Curran in 1982 and employs borate or boronic acid buffered Raney® Nickel in wet methanolic
  
 
Scheme 4.10: Chemoselective hydrogenation of bicycle 541 and subsequent Swern oxidation toward enol 583. 
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solution under an atmosphere of hydrogen.[340,345] When the mixture of syn- and anti-541 was 
submitted to these conditions, the expected hydroxy ketone 582 was isolated in 73% yield as a 
mixture of all four possible diastereomers (scheme 4.10) While oxidation with DMP and 
according to Ley[264] led to complete decomposition of substrate 541, Swern oxidation 
conditions furnished the desired product, which exists predominately in its enol form 583, 
according to NMR spectroscopy. Although TLC analysis indicated a clean transformation, 
only a moderate 67% yield was realized and attributed to the volatility of product 583.  
  
 
Scheme 4.11: Triflate formation on model system 584 and on advanced intermediate 583. 
The final triflate formation was first investigated on commercially available diketone 584 
(scheme 4.11). The use of sodium hydride as base and subsequent addition of triflic anhydride 
resulted in surprisingly low yields, which is why the use of the milder triflation reagent 
PhNTf2 was evaluated. Under these conditions triflate 585 was obtained in excellent yield. 
Due to its convenient fast preparation, we used this material as a model system for 
investigating the planned fragment coupling (vide infra). Unfortunately, when the established 
conditions were applied to advanced intermediate 583, only 6% of the desired triflate (539) 
could be isolated. Further attempts toward an improvement of the reaction yield remained 
unsuccessful so far. 
 
4.4 Model Studies on the Fragment Combination and Cyclooctadiene Formation 
 
In order to conserve trans-hydrindanone 475, a model system was synthesized for 
investigating the envisaged fragment combination and the following transformations toward 
aspired rearrangement precursor 537. As several grams of surplus ether 361 were available 
from our synthetic studies toward retigeranic acid B (237, cf. chapter 2.3), we applied the 
transformations already outlined in chapter 3.5 to access alkene 586. It has to be noted that the 
use of non-chiral triflate 585 renders the absolute configuration of substance 586 irrelevant 
for screening purposes. 
Hence, ether 361 was submitted to Tsuji allylation conditions[283] and desired alkene 587 was 
obtained in an optimized reaction yield of 84% (scheme 4.12). Subsequent diastereoselective 
reduction with K-Selectride® (465) proceeded smoothly and alcohol 588 was isolated quanti-
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Scheme 4.12: Gram scale synthesis of model system 586 via the developed 9-step sequence (cf. chapter 3.4). 
tatively. One-pot dihydroxylation and glycol cleavage under Lemieux-Johnson conditions[290] 
was directly followed by PCC-mediated oxidation and gave rise to tricyclic lactone 589 in 
very good yield (92%). Next, the C-10 (astellatol numbering) centered stereogenic methyl 
group was installed via the established substrate-controlled alkylation procedure. Substance 
590 was then reduced with LiAlH4, which allowed for the isolation of diol 591 in quantitative 
yield. The following double protection to silyl ether 473 was straightforward and was 
conducted with TESOTf and 2,6-lutidine in CH2Cl2. When this material was reacted under 
deprotective Swern conditions, varying yields of aldehyde 592 were achieved (70–82%). 
Notably, the use of newly opened reagent batches did effect a less complete conversion of 
silyl ether 473, which was presumably due to a reduced amount of available HCl traces.[294] 
Final Wittig olefination of aldehyde 592 furnished alkene 586 without any observable side 
reaction. All in all, it was possible to synthesize 3.37 g of model compound 586 in an 
outstanding yield of 58% over 9 steps. 
At this time it became possible to investigate the envisaged key intermolecular B-alkyl  
Suzuki coupling.[346] Table 4.1 summarizes the conditions that were tested to achieve the 
fusion of alkene 586 and triflate 585. For the initial hydroboration of substrate 586, 9-BBN 
was employed in THF at 40 °C. At this, it was crucial to use two equivalents of the boron 
reagent to effect full conversion of the alkene functionality. Subsequently, an aqueous 
solution of either K3PO4 or Cs2CO3 was added to quench excess 9-BBN and to generate 
boronate 593 (scheme 4.13). This intermediate was then combined with triflate 585 in the 
presence of the respective Pd-based catalyst and solvent system. AsPh3 was used optionally as 
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an additional ligand. The conditions originally published by Suzuki and co-workers for the 
coupling of aryl- and alkenyl triflates were evaluated first (entry 1).[347] The low isolated yield 
prompted us to try the addition of frequently used AsPh3 (entry 2), which has been proven to 
provide cleaner coupling reactions at higher turnover rates.[348] Switching the catalyst to 
Pd(dppf)Cl2 (entry 3) and using Cs2CO3 as a base (entry 5), we literally optimized the reaction 
process to quantitative yield. Interestingly, conditions published by Carreira and Weiss for 
their (+)-daphmanidin E (not shown) synthesis,[349] at which they describe Pd2(dba)3 as 
being superior to phosphine ligand-based Pd0 sources, produced enone 594 only in trace 
amounts (entry 4). 
  
Table 4.1: Investigated conditions for B-alkyl Suzuki-type coupling of fragments 585 and 586.  
 
entrya catalyst additived solvent T [°C] t [h] Yield 
       
1 Pd(PPh3)4 K3PO4 1,4-dioxane 85 14 h 8% (72% brsm) 
2 Pd(PPh3)4 Cs2CO3, AsPh3 1,4-dioxane 85  14 h 68% 
3 Pd(dppf)Cl2b K3PO4, AsPh3  DMF rt 18 h 82%  
4 Pd2(dba)3c K3PO4, AsPh3 DMF 45  14 h traces 
5 Pd(dppf)Cl2b Cs2CO3, AsPh3 DMF rt 18 h quant. 
a) All reactions were carried out using 20 mg of alkene 586 and 2.0 eq. of triflate 585 at catalyst loadings of 5 mol-%. 
Solutions were thoroughly degassed via Ar bubbling. b) The more stable CH2Cl2 mono-adduct was used. c) The more stable 
CH3Cl mono-adduct was used. d) Cs2CO3 and K3PO3 were used as 3 M aqueous solution. 
The mechanism of the B-alkyl Suzuki reaction is well understood and is illustrated in 
scheme 4.13 for Pd-based coupling.[346] In most cases, the catalytically active Pd0 
species (595) are generated in the beginning via reduction that is induced e.g. by the 
phosphine ligand. Following oxidative addition of the alkenyl triflate (585) may be assisted 
by the use of KBr. The triggered ligand exchange (596) has been shown to suppress 
degradation of formed PdII species (597) by reductive elimination of phosphonium 
salts (598).[347] Transmetallation of previously generated boronate 593 delivers intermediate 
599 and byproduct 600. Pd-complex 599 can either undergo reductive elimination to  
form desired coupling product 594, thus closing the catalytic cycle, or react in  
β-hydride elimination of the alkyl ligand. This side reaction will lead to the backformation of
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Scheme 4.13: Mechanism of the Pd-catalyzed B-alkyl Suzuki coupling reaction of preformed boronate 593 and 
triflate 585. The optional ligand exchange step was not necessary in the presented case. 
the initially employed alkene 586. Concomitantly generated Pd–H species (601) would in turn 
instantly regenerate active Pd0 species 595 and yield the protodetriflated alkene 602. It has 
been demonstrated that bidentate ligands with large bite angles, or monodentate ligands with 
bigger Tolman angles, effectively omit β-hydride elimination by acceleration of the reductive 
elimination in intermediate 599.[350] Hence, it is not surprising that dppf-ligand-based catalyst 
systems provided the best results in the presented investigations. 
Ensuing TES deprotection was first evaluated using TBAF and 4 Å molecular sieves in THF. 
This led to significant amounts of decomposition, presumably due to the highly basic 
environment generated by this protocol. Gratifyingly, when the conditions were switched to 
acidic 3HF·NEt3 in acetonitrile, clean cleavage of the ether function was observed and desired 
alcohol 603 was isolated in almost quantitative yield (scheme 4.14). Oxidation of this 
substrate, employing NaHCO3-buffered Dess-Martin periodinane in CH2Cl2, was straight-
forward and gave rise to diketone 604. 
  
 
Scheme 4.14: Deprotection and oxidation sequence, yielding diketone 604. 
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Scheme 4.15: Reaction of diketone 604 under McMurry or SmI2-mediated conditions. The relative 
configurations of the newly formed stereocenters of substances 605 and 606 could not be 
verified unambiguously. 
Having found a convenient route to model diketone 604, we went on to investigate the 
envisaged reductive intramolecular carbonyl-carbonyl coupling. To this end, McMurry 
coupling protocols were tried first. Accordingly, substrate 604 was slowly added to a 
suspension of low-valent titanium, which was generated in situ from commercially available 
TiCl3(THF)3 and freshly prepared Zn–Cu couple, in DME (scheme 4.15). Amongst various 
possible known reduction systems,[323,324] these conditions are stated to be most reliable and 
reproducible.[351] Interestingly, this reagent combination did not furnish the desired 
8-membered ring, but resulted in the diastereoselective formation of pentacyclic product 605. 
However, the configuration of the newly formed stereocenters could not be determined 
unambiguously, despite the use of extensive NMR spectroscopic studies. To the best of our 
knowledge, this type of cyclization cascade is unprecedented in literature and the resulting 
ring system has not been accessed by other means to date. 
Since reductive carbonyl-carbonyl coupling can also be achieved via diol formation, we next 
turned our attention towards SmI2-mediated reactions.[352,353] In agreement with the previous 
results from McMurry-type conditions, the envisioned 8-membered ring containing product 
was not observed. Instead, seemingly the same cyclization mode occurred and yielded 
pentacyclic hemiacetal 606 as a single diastereomer. Scheme 4.16 shows the isomer of the
  
 
Scheme 4.16: Possible 11-membered ring transition state, explaining the formation of the proposed cis-decalin 
junction at the SmI2-mediated cyclization of diketone 604. 
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isolated substance 606 that represents the most probable relative configuration, according to 
observed NOESY signals. The proposed cis-decalin junction is in agreement with results 
published by Matsuda et al. In the course of their vinigrol (not shown) synthesis, these 
authors describe a comparable carbonyl-alkene coupling of a cyclohexanone moiety to a 
α,β-unsaturated ester function.[354] In a study on asymmetric reductive cyclizations that was 
published by Little and co-worker, an 11-membered ring transition state is proposed. Transfer 
of this model to system 607 supports the stereochemistry that was deduced for the newly 
formed quaternary center (scheme 4.16).[355] However, in the following drawings the 
configuration of those centers will be left undefined, in order to refrain from speculations. 
  
 
Scheme 4.17: A plausible mechanism for observed reductive intramolecular cyclization cascade. 
Mechanistically, we propose a general reaction pathway that is illustrated in scheme 4.17 for 
both the McMurry-type and the SmI2-mediated transformations. Upon formation of a ketyl 
radical at the more electrophilic carbonyl moiety of diketone 604, intermediate 608 undergoes 
a Michael addition in a 6-exo-trig fashion.[354,355] A subsequent one-electron reduction of the 
resulting oxygen centered radical is followed by protonation. Keto-enol tautomerization then 
generates the carbonyl functionality in alcoholate 609 that immediately cyclizes to form a 
hemiacetal 610. The latter step and the following loss of oxygen is probably assisted by Lewis 
acidic titanium species. The resulting oxonium ion (611) would then be reduced in another 
two-electron step to corresponding ether 605. The combination of milder reaction conditions 
with the less pronounced Lewis acidic properties of SmI2 presumably account for the fact that 
in this case no final deoxygenation was observed. 
A further screening of reaction conditions toward a reductive carbonyl-carbonyl coupling 
proved less fruitful. In light of these findings and the fact that the low yielding 
triflate formation remained a bottleneck in the synthetic roadmap for building block 539, the
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Scheme 4.18: B-alkyl Suzuki coupling of triflate 539 and trans-hydrindanone 475. 
presented strategy was abandoned at this point. It is worth to mention that the optimized 
B-alkyl Suzuki conditions also succeeded to couple both advanced fragments – triflate 539 
and trans-hydrindane 475 – and delivered enone 612 in good yield (scheme 4.18). 
Concomitantly, a second diastereomer (613) was observed in this coupling, indicating that a 
partial epimerization of the selectively installed stereogenic center at carbon C-14 may have 
taken place in the course of pursued route (cf. chapter 4.3). A quantification of the ratio of 
those compounds was not feasible by means of HPLC, GCMS or LMCS methods. Calculating 
from the partially overlaying isomeric signals in recorded 1H NMR spectra, the dr-value lies 
between 5:1 and 10:1 and is in favour of desired product 612. 
 
4.5 Second-generation Approach: Branching Off at the (−)-Nitidasin Synthesis 
 
In chapter 3.2 it was already hinted that a different approach toward the construction of 
astellatol’s (213) carbocyclic skeleton would be possible from common intermediate 513. As 
outlined in the retrosynthetic analysis in scheme 4.19, it was envisioned to enter the proposed 
biomimetic rearrangement from allylic alcohol 614. After an initial ionization, this would 
require an additional [1,2]-hydride shift to form the desired homoallyl cation. Although this 
hydride shift would clearly be endothermic for itself, the final formation of the stable  
natural product (213) was supposed to deliver the driving force for the equilibrium 
cationic cascade. A further disconnection of allylic alcohol 614 traces back to triene 513. In
  
 
Scheme 4.19: Second-generation retrosynthetic analysis of astellatol 213, starting from known triene 513. 
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the forward sense, this triene (513) was originally planned to undergo RCM-mediated 
cyclization to yield the 5-8-6-5-membered ring system. However, it was not possible to access 
an cyclooctadiene system directly from triene 513 or from similar compounds by means of 
olefin metathesis-based approaches (cf. chapter 3.5). The unexpected participation of the 
tetrasubstituted double bond could only be avoided when this function was first epoxidized to 
diene 514. Ensuing RCM reaction and hydrogenation, employing the previously established 
conditions, gave rise to saturated tetracycle 522 (scheme 4.20), of which crystals were 
obtained that were suitable for X-ray crystallographic analysis. With these results in mind, the 
synthetic strategy was changed and a protocol that was developed by Sharpless and 
co-workers was considered.[316,356] This method allows for the transformation of epoxides to 
their respective alkenes, by using low valent tungsten species that are generated in situ from 
WCl6 and two equivalents of n-BuLi. The mechanism of this reaction is still not clarified to 
date, but the original authors proposed that intermediary formed tungsten(IV) leads to a 
concerted deoxygenation and installment of the carbon–carbon double bond. Application of 
those conditions to model compound 510 resulted in clean conversion to desired allylic 
alcohol 615 in very good yield. Accordingly, transfer to advanced intermediate 522 finally 
provided the precursor (616) for the planned cationic cascade in excellent 94% yield. Since 
signal broadening thwarted the structure analysis by 13C NMR spectroscopy for both allylic 
alcohols 615 and 616, the identity of the latter compound had to be proven by means of X-ray
  
 
Scheme 4.20: Preparation of allylic alcohols 615 and 616, using a tungsten(IV)-mediated deoxygenation. 
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crystallography. In summary, an epoxide function was effectively used as a protective group 
in order to achieve RCM-mediated closure of the 8-membered ring system. 
At long last, we were now in the position to examine the proposed cationic cascade for the 
synthesis of astellatol (213) experimentally for the first time. In order to achieve the initial 
ionization step to species 617, the use of Brønsted acids in a variety of solvent systems of
    
Table 4.2: Investigated conditions for the cationic cascade toward the construction of astellatol (213). Only 
the reaction pathway for allylic alcohol 616 is shown for clarity. SEM deprotection is optional. 
 
entrya substrate reagent solvent T [°C] observation 
       
1 615 p-TsOH toluene 60 to 120 elimination, deprotection 
2 615, 616 CSA CH3CN rt elimination, 621c (1–2%) 
3 615 Re2O7 DCM rt elimination, deprotection 
4 615 Re2O7, p-TsOH DCE 60 elimination, deprotection 
5 615 TFA-d1 CDCl3 rt elimination, decomp. 
6 616 CSA THF/H2O rt to 65 elimination, deprotection 
7 616 HF/py THF rt elimination, 621c (5–7%), 
deprotection 
8 616 CSA acetone rt to 60 elimination 
9 616 CSA 1,4-dioxane rt to 65 elimination, 621c (3–4%), 
deprotection 
10 616 CSA CH3NO2 rt to 45 elimination, deprotection 
11 616 HClO4 CH3NO2 rt decomp. 
12 616 HClb MeOH rt elimination, deprotection 
13 616 p-TsOH TFE rt elimination, deprotection 
14 616 CSA DMF rt to 60 elimination 
15 616 CSA DMSO/H2O rt to 60 elimination 
a) All reactions were carried out on 1.0 or 0.5 mg scale. b) Used in 1 M concentration and freshly prepared via addition of 
AcCl to dry MeOH. c) The identity of 621 could not be elucidated. 1H NMR analysis suggests that 621 contains an exo-
methylene function. 
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different polarities was investigated first (table 4.2). When no reaction could be observed, the 
temperature was raised gradually until conversion took place. Unfortunately, the prevailing 
reaction pathway led to the formation of several kinds of elimination products. This was 
accompanied by SEM or t-Bu group removal in certain cases. The addition of perrhenate 
species like Re2O7, which are known to catalyze transposition of allylic alcohols,[357] could not 
avoid the undesired elimination reactions either (entries 3,4). The characteristic signals of the 
exo-methylene group (δ = 4.80 and 4.63 ppm) of astellatol (213) were observed at none of the 
presented cases when 1H NMR spectra were recorded from the crude reaction mixtures.[155] 
Under certain conditions a different exo-methylene containing compound (621, entries 2,7,9) 
was found, which showed clearly distinct chemical shifts for the relevant two protons 
(δ = 4.97 and 4.84 ppm). However, the separation of this compound from the accompanying 
elimination products was impossible, due to the inherent low polarity of the mixture. Thus, 
the identity of this side product could not be elucidated further.  
The same finding held true when Lewis acids (e.g. BF3⋅OEt2, Ti(OiPr)4, TiCl4, Cp2ZrCl2, 
AlCl3) were employed instead. In those cases, either elimination, no reaction or complete 
decomposition took place. According to those results, it is supposed that the required initial 
[1,2]-hydride shift toward homoallyl cation 618 exhibits an energetic barrier that is too high 
to compete with elimination side reactions into all possible four positions.  
 
4.6 Theoretical Investigations on the Envisaged Cationic Cascade 
 
In order to investigate the viability of the proposed cationic cascade and to provide further 
mechanistical insights into the presumably biomimetic homoallyl-cyclopropylcarbinyl-
cyclobutyl rearrangement, we set out to conduct supporting theoretical studies. To this end, 
calculations on the relative energies of involved cationic intermediates and on the enthalpic 
outcome of the overall reaction were performed in cooperation with B.Sc. M. Maier. In order 
to reduce computational time and effort, we cut out the C-5 situated alkoxy substituent 
(astellatol numbering) of astellatol (213), as this function showed no obvious effect on the 
conformation of the direct reaction environment. 
For the initial conformational search of allylic alcohol 622 (vide infra), we applied molecular 
mechanics on the MMFF94 force-field level.[358] The number of found species of reasonable 
low energy was limited as it was expected according to the overall rigidity of the system. 
Only the B ring, the carbon atom chain from C-9 to C-13 and the iso-propyl group were able 
to adopt rotameric orientations. Hence, twelve relevant conformers were identified and 
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equivalent arrangements served as starting points for refinement of the geometries of 
determined reaction intermediates and transition states.xii The computational investigations on 
the cationic cascade involved a two-level DFT approach. For structure optimization, the well-
established B3LYP functional[359] was used in combination with the def2-SVP basis set.[360] 
For the approximation of solvation energies, the COSMO model[361] was employed and THF 
was chosen as an appropriate polar environment[201] with regard to the experimentally 
observed solubility properties of allylic alcohol 616. Furthermore, the RIJCOSX and RI 
approximations,[362] as well as the D3 and gCP corrections[360] were applied to improve 
calculation speed and accuracy, respectively. Notably, the latter mentioned terms have 
   
 
Scheme 4.21: Calculated energy profile for the proposed cationic rearrangement toward desoxy-astellatol (627). 
                                                
xiiReported results refer to the lowest energy conformers of respective species in THF. Gas-phase energies and 
further details on employed programs and methods are listed in sections I and V of the appendix. 
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been shown to provide results being superior to the commonly employed B3LYP/6-31G* 
approach.[363] The found relative energies of all cationic intermediates and transition states are 
illustrated in scheme 4.21 in terms of a reaction profile. As a point of reference, allylic 
cation 623 was chosen. Most importantly, it was shown that the transition state 624 for the 
non-biomimetic [1,2]-hydride shift has an unexpected high energy of +80.1 kJ/mol. The 
calculated structure suggests that this is presumably a result of the high conformational 
change of the central 8-membered ring, which is required to effect the syn-periplanar 
orientation of the C-13 bound hydrogen and C-17 centered sp2-atom orbital. Starting from the 
favourable boat-chair configuration, the cyclooctene ring system gets distorted to the 
approximate shape of a hyperbolic paraboloid. In combination with the concomitant loss of 
the stabilizing conjugation effect, this accounts for the experimentally observed preference for 
reaction via elimination pathways. It was concluded that once the homoallyl cation 
corresponding to 625 can be addressed synthetically, the following steps of the cationic 
cascade would proceed without any difficulty, as the highest encountered barrier in energy is 
only of +20.6 kJ/mol. In summary, the actual biomimetic rearrangement is exothermic by 
−35.5 kJ/mol, when arriving at the final cyclobutyl cation 626. Hence, ensuing elimination 
toward desoxy-astellatol (627) should effectively remove the cationic species from the 
equilibrium cascade. Nevertheless, future computational work will have to address the 
additionally conceivable elimination side reactions, which emanate from intermediary 
cationic species 625 and 628. 
  
 
Scheme 4.22 Calculated energies and structures of possible elimination products of alcohol 622. All values 
describe the respective generic dehydratization reactions and refer to conformer 622 (vide infra). 
It has to be mentioned, that both the starting allylic alcohol 622 and the ultimately resulting 
desoxy-astellatol 627 are not incorporated quantitatively, as initial ionization and final 
elimination steps are largely reagent-dependent processes. Interestingly, the overall reaction 
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enthalpy for a generic dehydration that yields water and pentacycle 627 shows a slightly 
positive value (+4.6 kJ/mol). However, this does not account for the favourable entropic 
contribution that arises from the formation the additional molecule of water, but states the 
high stability of allylic alcohol 622. In line with this, the respective reaction enthalpies for the 
formation of all possible four elimination products of allylic cation 623 were calculated 
(scheme 4.22). Especially both the octadienes 631 and 632 seem to be energetically favoured. 
This suggests that the retrosynthetic approach presented in chapter 4.2, which envisages the 
very generation of the latter diene, would most likely suffer from the same problems as the 
second-generation approach. However, a more detailed theoretical investigation of involved 
transition states would be necessary to rigorously disprove this synthetic strategy. 
Furthermore, the conducted conformational search of allylic alcohol 622 provided reasonable 
explanation for the experimentally observed signal broadening in recorded 13C spectra. 
Although the solvent system differed for the calculations (THF), it can be seen that two 
energetically similar conformations prevail (scheme 4.23). These species exhibit significant 
spatial relocation of carbons C-10 to C-16, including the stereogenic methyl group C-24. The
   
 
Scheme 4.23 Calculated structures 622 and 635 and relative energies for spectroscopically observed rotamers, 
 as well as comparison of 13C NMR spectra of substance 616 (cf. scheme 4.19) recorded at 22 
(blue) and 50 °C (red), respectively. 
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transformation that is needed to interchange those rotamers requires the inward and outward 
flipping of methylene group C-11 and connected carbons C-10 and C-24, respectively. To 
prove the existence of a rotameric mixture of 622 and 635 in solution experimentally, high 
temperature 13C NMR measurements were conducted at 50 °C. As expected, the so far 
missing carbon signals emerged and the already visible, but broadened peaks exhibited 
significantly narrowed line shapes. It has to be mentioned that two signals at δ = 34.6 and 
34.8 ppm could not be resolved completely and remained as a major and a shoulder peak, 
respectively. In order to preserve the valuable material that had to be employed in entirety, it 
was not tried to record spectra at even more elevated temperatures, as the required 
measurement times already exceeded 15 hours. 
 
4.7 Conclusion and Future Aspects 
 
In summary, two different synthetic approaches toward the sesterterpenoid astellatol (213) 
were presented, both of which planned to exploit the natural products biosynthetic cationic 
cascade for the assembly of its central ring motif in a final synthetic transformation. 
  
 
Scheme 4.24: Enantioselective 11-step synthesis of triflate 539 and B-alkyl-Suzuki coupling to substrate 475. 
The first approach relied on the construction of a fused cyclooctadien motif (537,  
scheme 4.4), which would allow entering the biomimetic rearrangement toward astellatol 
(213) upon initial protonation. Therefore, the envisaged cyclopentene triflate 539 was 
prepared by a enantioselective 11-step route, which was based on an early-stage introduction 
of the stereogenic center via Myers alkylation (scheme 4.24). Using the so-called INOC 
strategy, a highly efficient cyclization to a bicyclic isoxazoline ring system (541) could be 
demonstrated, which allowed for the reductive installation of required oxygenation pattern in 
an additional step. Unfortunately, the final triflate (539) formation remained a bottleneck in  
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Scheme 4.25: Preparation of model system 586 and thereof synthesized pentacyclic compounds 605 and 606. 
this synthetic sequence, which leaves room for future optimization. At this, the effect of bases 
different from NaH or other transfer reagents like the increasingly reactive Comin’s 
reagent[364] might be explored. In addition, a highly efficient B-alkyl Suzuki coupling was 
presented on model system 586 and toward the authentic coupling product (612, cf. 
chapter 4.4). The application of reductive carbonyl-carbonyl coupling methods resulted in a 
literature unprecedented cyclization cascade (605 and 606, scheme 4.25). A plausible 
mechanism for this cyclization mode and a suggestion for the not unambiguously clarified 
stereochemical outcome were given. Although the formed pentacyclic skeleton is not included 
in any reported natural product or synthetic target, the discovered cyclization reactions 
provide an intriguingly fast construction of three fused ring systems and four adjacent 
stereogenic centers, two of which are quaternary.  
  
 
Scheme 4.26: A possible synthetic route for the preparation of alborosin 252 from enone 612. R = SEM. 
Furthermore, this synthetic route might lead to a future total synthesis of the related 
sesterterpenoid alborosin (252, scheme 4.26), as the inherent structural similarity to the 
already accessed enone 612 suggests. Although the C-13 (astellatol numbering) located 
sp2-center is highly substituted, introduction of required stereochemistry could possibly be 
achieved using substrate- or reagent-controlled CuH-based 1,4-reduction methods.[217,365,366] A 
thus generated enolate could be trapped as silyl ether and directly employed in a Rubottom 
oxidation.[367] The selective formation of alcohol 636 could be biased by the adjacent ring 
substituents or by using an asymmetric modification.[368] Subsequent conversion to an 
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Scheme 4.27: Synthesis of alcohol 616 as precursor for proposed cationic cascade toward astellatol (213). 
appropriate leaving group and elimination via an E1cB mechanism would then provide the 
desired unsaturation pattern. Final deprotection and oxidation to the natural product should be 
straightforward. 
The second investigated approach toward astellatol (213) originally opted for the use of triene 
513 as a precursor being common to the nitidasin (238) synthesis (cf. chapter 3.5). To this 
end, a tungsten(IV)-based deoxygenation protocol was applied to 522 in order to access the 
envisaged allylic alcohol 616 (scheme 4.27). However, experimental investigations on the 
proposed cationic cascade did not provide the carbon skeleton of the natural product under a 
variety of conditions. In parallel conducted theoretical investigations were in agreement with 
the experimental results and suggested that aspired initial [1,2]-hydride shift exhibits an 
energetic barrier (+80.1 kJ/mol), which is to high to compete with elimination reactions. 
According to those calculations, the actual homoallyl-cyclopropylcarbinyl-cyclobutyl 
rearrangement would proceed smoothly, once the homoallyl cation corresponding to species 
625 can be addressed by synthesis (cf. chapter 4.6). From this point onward, the most 
endothermic transition state between involved cationic species was determined to have a 
relative energy of only +20.6 kJ/mol. 
In the light of these results, it is reasoned that homoallyl alcohol 637 (scheme 4.27) represents 
the appropriate precursor for the biomimetic formation of astellatol (213). However, at this 
point reasonable retrosynthetic proposal for its construction is lacking, as this would probably 
require a complete redesign of the established 8-membered ring formation sequence. 
  
 
Scheme 4.28: Homoallylic alcohol 637 as a potential target for future synthetic approaches toward a total 
synthesis of astellatol (213) 
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5. Experimental Section 
 
5.1 General Notes 
 
All reactions were magnetically stirred and carried out under a positive pressure of inert gas 
(N2 or argon) utilizing standard Schlenk-techniques. Glassware was dried in an oven at 
120 °C and repeatedly at 650 °C in vacuo prior to use. Liquid reagents and solvents were 
added by syringes or oven-dried stainless steel cannulas through rubber septa. Solids were 
added under inert gas counter flow or were dissolved in appropriate solvents. Low-
temperature reactions were carried out in a Dewar vessel filled with a cooling agent: 
acetone/dry ice (−78 °C), acetonitrile/liquid N2 (−40 °C), NaCl/ice (−20 °C) or H2O/ice 
(0 °C). Reaction temperatures above room temperature were conducted in a heated oil bath. 
High-pressure reactions were carried out in a miniclave steel apparatus from BÜCHI AG. If 
literature-known procedures were followed, the respective references were given in the 
discussion part. Yields refer to isolated homogenous and spectroscopically pure materials, if 
not indicated otherwise. 
 
Solvents and Reagents 
 
Tetrahydrofuran (THF) and diethyl ether (Et2O) were distilled under N2 atmosphere from 
Na/benzophenone as drying reagent prior to use. Triethylamine (Et3N), diisopropylamine 
(DIPA) and Hünig’s base (DIPEA) were distilled under N2 atmosphere from CaH2 as  
drying agent prior to use. Further dry solvents such as dichloromethane (CH2Cl2), 
N,N-dimethylformamide (DMF), acetonitrile (MeCN), HMPA, acetone, methanol (MeOH), 
benzene and toluene were purchased from commercial suppliers and used as received. 
(S)-Alpine-BoramineTM (452) was purchased from Sigma-Aldrich and stored in a UNIlab 
glove-box from MBRAUN. Methyl vinyl ketone (300) and allyl bromide were distilled prior to 
use and stored under an argon gas atmosphere. Solvents for extraction, crystallization and  
flash column chromatography were purchased in technical grade and distilled under  
reduced pressure prior to use. (+)-Eder-Sauer-Wiechert-Hajos-Parrish ketone (138),[211]  
aldehyde 420,[249] DMP,[369] Zn–Cu couple,[351a] oxazolidinone 542,[328–330] and amide 556,[107] 
were prepared as described previously. Solutions of BEt3 were freshly prepared from neat 
BEt3 and thoroughly degassed THF (3 × freeze-pump-thaw). All other reagents and solvents 
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were purchased from chemical suppliers (Sigma-Aldrich, Acros Organics, Alfa Aesar, Strem 
Chemicals, ABCR, TCI Europe) and were used as received. 
 
Chromatography 
 
Reactions and chromatography fractions were monitored by qualitative thin-layer 
chromatography (TLC) on silica gel F254 TLC plates from Merck KGaA. Analytes on the glass 
plates were visualized by irradiation with UV-light and/or by immersion of the TLC plate in 
an appropriate staining solution followed by heating with a hot-air gun (350 °C). The 
following staining solutions were applied: 
• p-anisaldehyde staining solution (3.7 mL p-anisaldehyde (671), 5.0 mL concentrated 
aqueous H2SO4, 1.5 mL glacial AcOH, 135 mL EtOH). 
• Hanessian’s staining solution (CAM, 5.0 g, Ce(SO4)2, 25 g (NH4)6Mo7O24⋅4H2O, 
50 mL concentrated aqueous H2SO4, 450 mL H2O). 
• KMnO4 staining solution, (3.0 g KMnO4, 20 g K2CO3, 5.0 mL aqueous 5% NaOH, 
300 mL H2O). 
Flash column chromatography was performed on Geduran® Si60 (40−63 µm) silica gel from 
Merck KGaA. All fractions containing a desired substrate were combined and solvents were 
removed under reduced pressure followed by drying in high vacuo (10−2 mbar). 
 
NMR spectroscopy 
 
NMR spectra were measured on a Bruker Avance III HD 400 MHz spectrometer equipped 
with a CryoProbeTM operating at 400 MHz for proton nuclei (100 MHz for carbon nuclei) or 
by the analytic section of the Department of Chemistry of the Ludwig-Maximilians-
Universität München using Bruker AXR300, Varian VXR400 S and Bruker AMX600 
spectrometers operating at 300 MHz, 400 MHz and 600 MHz for proton nuclei (75 MHz, 
100 MHz, 150 MHz for carbon nuclei, 382 MHz for fluoride nuclei), respectively. CDCl3 and 
C6D6 were purchased from Sigma-Aldrich and Euriso-top. The 1H NMR shifts are reported in 
ppm related to the residual shift of TMS. 1H NMR shifts were calibrated to residual solvent 
resonances: CDCl3 (7.26 ppm), C6D6 (7.16 ppm). 13C NMR shifts were calibrated to the 
center of the multiplet signal of the residual solvent resonance: CDCl3 (77.16 ppm), 
C6D6 (128.06 ppm). 1H NMR spectroscopic data are reported as follows: Chemical shift in 
ppm (multiplicity, coupling constants J, integration intensity). The multiplicities are 
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abbreviated with s (singlet), br (broad signal), d (doublet), t (triplet), q (quartet), m (multiplet) 
and mC (centrosymmetric multiplet). In case of combined multiplicities, the multiplicity with 
the larger coupling constant is stated first. Except for multiplets, the chemical shift of all 
signals, as well for centrosymmetric multiplets, is reported as the center of the resonance 
range. Additionally to 1H, 19F and 13C NMR measurements, 2D NMR techniques as 
homonuclear correlation spectroscopy (COSY), heteronuclear single quantum coherence 
(HSQC) and heteronuclear multiple bond coherence (HMBC) were used to assign signals. For 
further elucidation of 3D structures of the analytes, nuclear Overhauser enhancement 
spectroscopy (NOESY) was conducted. Coupling constants J are reported in Hz. All NMR 
spectra were analyzed using the program MestRe NOVA 8.1 from Mestrelab Research S. L. 
 
Mass spectrometry 
 
All mass spectra were measured by the analytic section of the Department of Chemistry of the 
Ludwig-Maximilians-Universität München. Mass spectra were recorded on the following 
spectrometers (ionization mode in brackets): MAT 95 (EI) and MAT 90 (ESI) from Thermo 
Finnigan GmbH or JMS-700 (FAB) from Jeol Ltd. Mass spectra were recorded in high-
resolution and the only characteristic molecule fragments or molecule ion peaks are indicated 
for each analyte. The used method is reported at the relevant section of the experimental part. 
 
IR spectroscopy 
 
IR spectra were recorded on a PerkinElmer Spectrum BX II FT-IR system. If required, 
substances were dissolved in CH2Cl2 prior to direct application on the ATR unit. The 
measured wave numbers are reported in cm−1. 
 
Optical rotation 
 
Optical rotation values were recorded on a polarimeter P8000-T from A. Krüss Optronic 
GmbH or on a PerkinElmer 241 polarimeter. The specific rotation is calculated as follows: 
 
! !! =
! ∙ 100
! ∙ !  
 
Thereby, the wavelength λ is reported in nm and the measuring temperature ϑ in °C. 
α resembles the recorded optical rotation at the apparatus, c the concentration of the analyte in 
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10 mg/mL and d the length of the cuvette in dm. Thus, the specific rotation is given in 
10−1·deg·cm2·g−1. Usage of the sodium D line (λ = 589 nm) is indicated by D instead of the 
wavelength in nm. The respective concentration as well as the solvent is denoted in the 
analytical part of the experimental description.  
 
Melting points 
 
Melting points were measured on the apparatus BÜCHI Melting Point B-540 from BÜCHI 
Labortechnik AG or on an EZ-Melt apparatus form Stanford Research Systems and are 
uncorrected. 
 
5.2 Experimental Procedures for Chapter 2: ‘Synthetic Studies Toward Retigeranic 
Acid B’ 
 
Synthesis of Ester 311 
   
 
   
To a solution of (R)-pulegone (176, 25.0 g, 164 mmol, 1.0 eq.) in dry diethyl ether (190 mL) 
was added NaHCO3 (4.14 g, 49.0 mmol, 0.3 eq.) and the mixture was cooled to 0 °C. Then, 
bromine (9.25 mL, 181 mmol, 1.1 eq.) was added dropwise over a period of 15 min. The 
reaction mixture was stirred for 50 min at this temperature before it was quenched via the 
slow addition of saturated aqueous Na2S2O3 (80 mL). After diluting with saturated aqueous 
NaCl (200 mL) the layers were separated and the aqueous phase was extracted with diethyl 
ether (3 × 100 mL). The combined organic layers were dried over Na2SO4 and carefully 
concentrated in vacuo (min. 50 mbar, 30 °C) yielding dibromide 369 as a purple, viscous oil, 
which was used for the next synthetic step without further purification. 
176 376
C6H7F3O3S
M = 216.17 g/mol
Br2 (1.1 eq.)
NaHCO3 (0.3 eq.)
Et2O
0 °C, 1 h
O3 (1 atm);
Zn (5.6 eq.), AcOH
CH2Cl2
−78 to 0 °C, 3 h
(72%) 311
C18H21NO3
M = 299.37 g/mol
O
OMe
O
Me
O
Me OMe
O
Me
369
O
Me
Br
Br
NaOMe (1.0 eq.)
MeOH
70 °C, 12 h
(81%, two
 steps)
Experimental Section 
125 
Small chunks of sodium (11.3 g, 493 mmol, 3.0 eq.) were slowly added to dry methanol 
(160 mL) at 0 °C. After stirring for one hour at this temperature, the ice bath was removed 
and stirring was continued for another hour at room temperature. Subsequently, the mixture 
was heated to reflux for two hours until all sodium was consumed. Then, a solution of 
dibromide (assumed 164 mmol, 1.0 eq.) in dry methanol (25 mL) was added at room 
temperature and the resulting solution was heated to reflux for 12 hours. After treatment with 
aqueous HCl (200 mL, 5 wt-%), the mixture was extracted with diethyl ether (3 × 200 mL) 
and the combined organic layers were dried over Na2SO4. The crude mixture was carefully 
concentrated in vacuo (50 mbar, 30 °C) the product was purified via distillation (boiling  
point = 56 °C, 1 mbar) to yield ester 376 (24.1 g, 132 mmol, 81%) as a colorless liquid as a 
mixture of cis/trans isomers in a ratio of 1:3.  
 
Rf = 0.85 (i-Hex:EtOAc = 20:1). 
 
1H NMR (CDCl3, 200 MHz, characteristic signals): δ = 3.06 (s, br, 1H), 2.92 (s, br, 1H), 1.01 
(d, J = 6.8 Hz, 3H), 0.95 (d, J = 6.8 Hz, 3 H) ppm. 
 
EI-MS for C11H18O2+ [M+]: calcd. 182.1307 
 found 182.1299. 
 
IR (ATR): ῦ/cm−1 = 2951, 2926, 2870, 1728, 1684, 1454, 1433, 1373, 1348, 1287, 1257, 
1234, 1190, 1167, 1144, 1091, 1074, 1026, 1010, 954, 931, 909, 891, 840, 804, 779, 742 . 
 
 = +43.0 (c 1.00, CH2Cl2). 
 
Ester 376 (10 g, 54.9 mmol, 1.0 eq.) was dissolved in dichloromethane (180 mL) and cooled 
to −78 °C. Ozone was bubble thorough this solution at a constant flow for 50 min until the 
reaction mixture had acquired a deep blue color. Then, argon was bubble through the blue 
solution for 20 min until the color had disappeared completely. After the slow addition of 
glacial acetic acid (100 mL), zink powder (20.1 g, 307 mmol, 5.6 eq.) was added in one 
portion and the resulting suspension was stirred for one hour at 0 °C. Having filtrated the 
reaction mixture over a plug of Celite© (CH2Cl2 washings), saturated aqueous NaHCO3 was 
added until pH = 7 was reached. Then, the layers were separated, the aqueous phase was 
extracted with dichloromethane (3 × 100 mL) and the combined organic layers were dried 
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over Na2SO4. The solvents were evaporated under reduced pressure and the crude product 
was purified by flash column chromatography (silica, i-Hex:EtOAc = 97:3 to 9:1) to yield the 
title ester 311 (6.13 g, 39.3 mmol, 72%) as a colorless oil as an inseparable mixture of 
diastereomers (cis/trans = 1:2). For NMR analysis, a sample was enriched with the 
trans-isomer to a dr of 93:7 via repeated flash column chromatography. 
 
Rf = 0.35 (i-Hex:EtOAc = 20:1). 
 
1H NMR (CDCl3, 600 MHz, major isomer quoted): δ = 3.76–3.70 (s, 3H), 2.79–2.73 (d, 
J = 11.5 Hz 1H), 2.57 (mC, 1H), 2.43–2.36 (m, 1H), 2.33–2.26 (m, 1H), 2.19–2.14 (m, 1H), 
1.53–1.41 (m, 1H), 1.17–1.12 (m, 3H) ppm. 
 
13C NMR (CDCl3, 150 MHz, major isomer quoted): δ = 212.1, 169.7, 63.0, 52.5, 38.9, 36.4, 
29.4, 19.3 ppm. 
 
EI-MS for C8H12O3+ [M+]: calcd. 156.0786 
 found 156.0777. 
 
IR (ATR): ῦ/cm−1 = 3458, 2957, 2873, 1753, 1723, 1658, 1619, 1458, 1436, 1406, 1380, 
1364, 1334, 1286, 1258, 1229, 1202, 1179, 1154, 1125, 1076, 1046, 1004, 956, 930, 909, 887, 
844, 797, 775, 751, 663. 
 
 = +88.4 (c 1.00, CH2Cl2). 
 
Synthesis of Diketone 377 
   
 
   
Cs2CO3 (16.7 g, 51.0 mmol, 0.5 eq.) was added in one portion to a stirred solution of ester 311 
(16.0 g, 102 mmol, 1.0 eq.) in dry acetone (800 mL) at −78 °C. After having stirred the 
mixture for 10 min, freshly distilled methyl vinyl ketone (300, 16.7 g, 51.0 mmol, 0.5 eq.) 
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was added dropwise. The reaction was carefully and gradually warmed to −25 °C over a 
period of five hours. Subsequently, saturated aqueous NaHCO3 (200 mL) was added and the 
layers were separated. The aqueous phase was extracted with dichloromethane (3 × 200 mL), 
the combined organic layers were dried over Na2SO4, and the solvent was removed in vacuo 
(caution: residual methyl vinyl ketone will co-evaporate!). The crude product was combined 
with another reaction batch, at which 15.0 g of ester 311 were transformed. Purification by 
flash column chromatography (silica, i-Hex:EtOAc = 9:1 to 3:1) to yielded the title compound  
(377, 33.6 g, 148 mmol, 75%) as a colorless oil.  
On a smaller reaction scale 5.00 g of ester 311 were transformed, at which diketone 377 
(5.02 g, 22.1 mmol, 69%) and its diastereomer 377’ (106 mg, 4.68 mmol, 2%) were isolated. 
 
Analytical data for diketone 377: 
 
Rf = 0.50 (i-Hex:EtOAc = 3:2). 
 
1H NMR (CDCl3, 600 MHz): δ = 3.68 (s, 3H), 2.83 (ddd, J = 17.8, 10.3, 5.0 Hz, 1H),  
2.53–2.45 (m, 2H), 2.26 (ddd, J = 19.0, 11.1, 8.9 Hz, 1H), 2.19–2.03 (m, 3H), 2.12 (s, 3H), 
1.85 (ddd, J = 14.5, 10.3, 5.0 Hz, 1H), 1.73 (dtd, J = 12.6, 11.1, 8.5 Hz, 1H), 1.02 (d, 
J = 6.9 Hz, 3H) ppm. 
 
13C NMR (CDCl3, 150 MHz): δ = 216.5, 208.2, 170.9, 61.8, 52.0, 42.2, 38.7 (2C), 30.0, 28.3, 
26.6, 16.0 ppm. 
 
EI-MS for C12H18O4+ [M+]: calcd. 226.1205 
 found 226.1202. 
 
IR (ATR): ῦ/cm−1 = 3454, 2957, 1746, 1726, 1711, 1455, 1434, 1405, 1356, 1291, 1272, 
1235, 1190, 1160, 1125, 1058, 995, 953, 912, 888, 867, 812, 766, 711. 
 
 = +50.8 (c 1.00, CH2Cl2). 
 
Analytical data for diketone 377’: 
 
Rf = 0.49 (i-Hex:EtOAc = 3:2). 
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1H NMR (CDCl3, 600 MHz): δ = 3.70 (s, 3H), 2.71–2.63 (m, 2H), 2.57 (ddd, J = 18.7, 8.0, 
5.6 Hz, 1H), 2.42–2.27 (m, 2H), 2.12–2.03 (m, 1H), 2.09 (s, 3H), 1.99 (ddd, J = 13.9, 8.0, 
5.6 Hz, 1H), 1.86 (ddd, J = 14.6, 8.0, 6.6 Hz, 1H), 1.72 (mC, 1H), 1.04 (d, J = 7.0 Hz, 
3H) ppm. 
 
13C NMR (CDCl3, 150 MHz): δ = 215.5, 208.2, 172.6, 62.3, 52.4, 41.3, 38.3, 37.7, 30.1, 27.6, 
20.2, 14.1 ppm. 
 
EI-MS for C12H18O4+ [M+]: calcd. 226.1205 
 found 226.1203. 
 
IR (ATR): ῦ/cm−1 = 3448, 2958, 1742, 1712, 1460, 1434, 1406, 1367, 1353, 1289, 1250, 
1206, 1164, 1129, 1105, 1053, 1022, 989, 889, 868, 795, 781, 738, 712. 
 
 = +26.0 (c 0.50, CH2Cl2). 
 
Synthesis of Dioxolane 378 
   
 
   
Diketone 377 (5.00 g, 22.1 mmol, 1.0 eq.), which was freed of water traces via azeotropic 
removal together with benzene, was dissolved in dry CH2Cl2 (100 mL) and cooled to −78 °C. 
To this, 1,2-bis(trimethylsiloxy)ethane (384, 5.96 mL, 24.3 mmol, 1.1 eq.) and TMSOTf 
(1.00 mL, 5.52 mmol, 0.25 eq.) were added sequentially. The mixture was stirred for 48 hours 
at this temperature before being quenched via the addition of dry pyridine (1 mL). Then, 
saturated aqueous NaHCO3 (50 mL) was added and the layers were separated after being 
warmed to room temperature. The aqueous phase was extracted with CH2Cl2 (3 × 100 mL) 
and the combined organic layers were dried over Na2SO4. After removal of the solvent in 
vacuo, the crude product was purified by flash column chromatography (silica, i-Hex:EtOAc 
= 9:1 to 4:1) to yield the title dioxolane 378 (5.65 g, 20.8 mmol, 95%) as a colorless oil.  
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Note: Dioxolane 378 and diketone 377 behaved co-polar on common silica TLC plates. The 
given Rf-value refers to basic alumina TLC plates. 
 
Rf = 0.54 (n-pentane:Et2O = 4:3). 
 
1H NMR (CDCl3, 600 MHz): δ = 3.92–3.87 (m, 4H), 3.64 (s, 3H), 2.52–2.47 (m, 1H),  
2.23–2.10 (m, 2H), 2.02 (mC, 1H), 1.94– 1.90 (m, 1H), 1.82–1.70 (m, 3H), 1.50–1.44 (m, 
1H), 1.29 (s, 3H), 1.01 (d, J = 6.9 Hz, 3H) ppm. 
 
13C NMR (CDCl3, 150 MHz): δ = 216.3, 171.1, 109.8, 64.7 (2C), 62.4, 51.8, 40.2, 38.8, 33.3, 
28.3, 26.4, 23.8, 16.0 ppm. 
 
EI-MS for C14H22O5+ [M+]: calcd. 270.1467 
 found 270.1466. 
 
IR (ATR): ῦ/cm−1 = 3449, 2958, 2880, 1746, 1727, 1452, 1433, 1404, 1378, 1345, 1331, 
1290, 1227, 1190, 1163, 1117, 1055, 996, 947, 917, 877, 849, 812, 793, 765, 697. 
 
 = +64.0 (c 1.00, CH2Cl2). 
 
Synthesis of Cyclopentanone 379 
    
 
    
To a solution of dioxolane 378 (1.13 g, 4.18 mmol, 1.0 eq.) in dry DMF (12 mL) was added 
lithium iodide (2.80 g, 20.9 mmol, 5.0 eq.). The resulting suspension was vigorously stirred 
and heated to 150 °C for a period of 2.5 hours. After cooling to room temperature, CH2Cl2 
(100 mL) was added and the mixture was washed with saturated aqueous NaCl (100 mL). The 
aqueous phase was extracted with CH2Cl2 (3 × 50 mL) and the combined organic layers were 
dried over Na2SO4. After removal of the solvent in vacuo, the crude product was purified by 
flash column chromatography (silica, deactivated with 1 wt-% NEt3, i-Hex:EtOAc = 9:1 to 
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17:3) to yield the title cyclopentanone 379 (0.76 g, 3.56 mmol, 85%) as a colorless oil in a 
trans/cis isomeric ratio of 6.7:1. Analytical data were recorded from this mixture. 
Note: Without using thoroughly deactivated silica for flash column chromatography, 
cyclopentanone 379 was obtained in a trans/cis isomeric ratio of 3.4:1. 
 
Rf = 0.48 (n-pentane:Et2O = 3:2). 
 
1H NMR (CDCl3, 600 MHz, major isomer quoted): δ =3.95–3.89 (m, 4H), 2.34–2.29 (m, 1H), 
2.10–2.03 (m, 2H), 1.99–1.77 (m, 2H), 1.68–1.59 (m, 4H), 1.41–1.36 (m, 1H), 1.31 (s, 3H), 
1.14 (d, J = 6.5 Hz, 3H) ppm. 
 
13C NMR (CDCl3, 150 MHz, major isomer quoted): δ = 220.9, 110.0, 64.7 (2C), 56.2, 38.2, 
37.1, 36.1, 29.7, 23.8, 22.3, 19.8 ppm. 
 
EI-MS for C12H20O3+ [M+]: calcd. 212.1412 
 found 212.1421. 
 
IR (ATR): ῦ/cm−1 = 3357, 2954, 2872, 1734, 1454, 1407, 1376, 1286, 1218, 1156, 1044, 947, 
865, 829, 789. 
 
 = +40.0 (c 1.00, CH2Cl2). 
 
Synthesis of Ester 381 
   
 
   
To a suspension of sodium hydride (188 mg, 60% wt-% in mineral oil, 4.70 mmol, 5.0 eq.) in 
dry THF (3 mL) was added phosphonate 380 (0.97 mL, 4.90 mmol, 5.2 eq.) dropwise at 0 °C. 
The resulting mixture was stirred for one hour at room temperature before a solution of 
cyclopentanone 379 (200 mg, 0.94 mmol, 1.0 eq.) in dry THF (1 mL) was added slowly. 
After stirring for 41 hours, water (2 mL) and then CH2Cl2 (30 mL) were added. The layers 
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were separated and the aqueous phase was extracted with CH2Cl2 (3 × 50 mL). Having dried 
the combined organic layers over Na2SO4, the solvents were removed in vacuo. The crude 
product was purified by flash column chromatography (silica, i-Hex:EtOAc = 47:3) to yield 
ester 381 (207 mg, 0.73 mmol, 67%) as a colorless oil.  
Note: Ester 381 was not air-stable in our hands. Therefore, analytical data were  
recorded from material that was freshly purified via reversed-phase HPLC (Rt = 54 min, 
CH3CN:H2O = 1:1). 
 
Rf = 0.40 (n-pentane:Et2O = 3:2). 
 
1H NMR (C6D6, 600 MHz): δ = 6.10 (q, J = 2.5 Hz, 1H), 4.23–4.14 (m, 2H), 3.65–3.60 (m, 
4H), 3.35 (mC, 1H), 2.85 (mC, 1H), 1.97–1.94 (m, 1H), 1.81–1.70 (m, 5H), 1.57 (mC, 1H), 
1.37 (s, 3H), 1.12 (t, J = 7.1 Hz, 4H), 0.91 (d, J = 6.6 Hz, 3H) ppm. 
 
13C NMR (C6D6, 150 MHz): δ = 171.1, 166.7, 112.4, 110.1, 64.7 (2C), 59.4, 53.6, 37.8, 35.9, 
32.9, 32.2, 25.1, 24.1, 19.0, 14.5 ppm. 
 
EI-MS for C16H26O4+ [M+]: calcd. 282.1831 
 found 282.1820. 
 
IR (ATR): ῦ/cm−1 = 3371, 2952, 2873, 1709, 1648, 1453, 1417, 1370, 1344, 1255, 1192, 
1136, 1095, 1038, 947, 864, 790. 
 
 = +10.4 (c 1.00, CH2Cl2). 
 
Synthesis of Alcohol 382 
   
 
   
To a solution of diisopropylamine (0.17 mL, 1.18 mmol, 5.0 eq.) in dry THF (1.4 mL) at 
−78 °C was added n-BuLi (0.49 mL, 2.4 M solution in hexanes, 1.18 mmol, 5.0 eq.) dropwise. 
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After stirring for 15 min, dry ethylacetate (0.12 mL, 1.18 mmol, 5.0 eq.) was added slowly 
and the reaction mixture was then stirred for another 30 min. Subsequently, a solution of 
ketone 379 (0.05 g, 0.24 mmol, 1.0 eq.) in dry THF (0.5 mL) was added dropwise and stirring 
was continued for 3 hours. After the addition of saturated aqueous NH4Cl (10 mL),  
the mixture was warmed to room temperature and extracted with CH2Cl2  
(3 × 25 mL). The combined organic layers were dried over Na2SO4 and the solvents were 
removed in vacuo. Thus alcohol 382 (34 mg, 0.11 mmol, 48%) was obtained as colorless oil. 
Note: Alcohol 382 decomposes on silica and by time in CDCl3. 
 
Rf = 0.20 (n-pentane:Et2O = 1:1). 
 
1H NMR (CDCl3, 200 MHz): δ = 4.17 (q, J = 7.1 Hz, 2H), 3.95–3.90 (m, 4H), 2.71 (d,  
J = 15.5 Hz, 1H), 2.35 (d, J = 15.5 Hz, 1H), 2.04 –1.83 (m, 2H), 1.83–1.61 (m, 5H),  
1.59–1.36 (m, 2H), 1.32 (s, 3H), 1.27 (t, J = 7.1 Hz, 3H), 1.20–1.06 (m, 1H), 1.01 (d, 
J = 6.5 Hz, 3H) ppm. 
 
EI-MS for C15H25O5+ [(M−CH3)+]: calcd. 285.1697 
 found 285.1658. 
 
IR (ATR): ῦ/cm−1 = 3451, 2970, 2901, 1730, 1460, 1452, 1401, 1352, 1308, 1258, 1208, 
1180, 1117, 1109, 1046, 1011, 888, 832, 815, 732, 709. 
 
 = +26.3 (c 0.33, CH2Cl2). 
 
Synthesis of Ketoester 385 
   
 
    
Ester 381 (168 mg, 0.59 mmol, 1.0 eq.) was dissolved in a thoroughly degassed mixture of 
THF (5.3 mL) and water (0.9 mL). After the addition of p-toluenesulfonic acid (17.0 mg, 
0.09 mmol, 0.15 eq.), the resulting mixture was stirred for one week at room temperature. 
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Subsequently water (20 mL) and CH2Cl2 (50 mL) were added and the layers were separated. 
The aqueous phase was extracted with CH2Cl2 (3 × 50 mL) and the combined organic layers 
were dried over Na2SO4. The crude product was purified via flash column chromatography 
(silica, i-Hex:EtOAc = 23:2) to yield ketoester 385 (116 mg, 0.49 mmol, 82%) as a colorless 
oil.  
Note: Ketoester 381 was not air-stable in our hands. Therefore, analytical data were 
recorded from material that was freshly purified via reversed-phase HPLC (Rt = 41 min, 
CH3CN:H2O = 1:1). 
 
Rf = 0.32 (n-pentane:Et2O = 3:2). 
 
1H NMR (C6D6, 600 MHz): δ = 5.82 (q, J = 2.4 Hz, 1H), 4.09 (qd, J = 7.1, 0.9 Hz, 2H), 3.22 
(dddd, J = 19.7, 8.4, 3.6, 2.3 Hz, 1H), 2.73–2.64 (m, 1H), 2.69 (mC, 2H), 1.95–1.85 (m, 2 H), 
1.76–1.73 (m, 1H), 1.70–1.62 (m, 3H), 1.59 (s, 3H), 1.30 (mC, J = 8.3, 6.3, 1H), 1.04 (t, 
J = 7.1 Hz, 3H), 0.97 (dq, J = 12.4, 8.7 Hz, 1H), 0.76 (d, J = 6.6 Hz, 3H) ppm. 
 
13C NMR (C6D6, 150 MHz): δ = 205.8, 170.7, 166.6, 112.6, 59.5, 53.0, 39.6, 37.9, 32.7, 32.1, 
29.4, 24.6, 19.0, 14.5 ppm. 
 
EI-MS for C14H22O3+ [M+]: calcd. 238.1569 
 found 238.1527. 
 
IR (ATR): ῦ/cm−1 = 3451, 2978, 2910, 2852, 1726, 1479, 1456, 1392, 1368, 1355, 1345, 
1321, 1311, 1258, 1207, 1186, 1163, 1115, 1102, 1048, 1019, 967, 890, 850, 836, 814, 784, 
774, 733, 709.  
 
 = +8.0 (c 1.00, CH2Cl2). 
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Synthesis of Hajos-Parrish-Sauer-Eder-Wiechert-ketone (138) 
   
 
   
To a suspension of 2-methyl-1,3-cyclopentadione (352, 100 g, 892 mmol, 1.0 eq.) in water 
(205 mL) was added freshly distilled methyl vinyl ketone (300, 129 mL, 1.53 mol, 1.7 eq.) 
and then glacial acetic acid (2.68 mL, 47.0 mmol, 5.3 mol-%). The reaction mixture was 
heated to 75 °C under exclusion of light for 4 hours. After cooling to room temperature 
CH2Cl2 (500 mL) was added and the layers were separated. The aqueous phase was extracted 
with CH2Cl2 (2 × 100 mL) and the combined organic layers were washed with saturated 
aqueous NaCl (2 × 250 mL). After re-extraction with CH2Cl2 (2 × 100 mL) the combined 
organic layers were dried over Na2SO4. Having removed the solvent in vacuo, triketone 353 
(154 g, 845 mmol, 95%) was obtained as slightly yellow oil, which used for further syntheses.  
A degassed (3 × freeze-pump-thaw) suspension of (R)-proline (354, 2.92 g, 25.4 mmol, 
3 mol-%) in dry DMF (666 mL) was stirred at 16 °C under the exclusion of light for one hour. 
Subsequently, a degassed solution of triketone 353 (154 g, 845 mmol, 1.0 eq.) in dry DMF 
(220 mL) was added and the resulting mixture was stirred for 3 days at 14 to 18 °C, upon 
which TLC analysis suggested complete consumption of the starting material.  
Then, a solution of H2SO4 in DMF – being prepared via dropwise addition of concentrated 
H2SO4 (6.66 mL) to dry DMF (121 mL) – was added at −20 °C. This mixture was then heated 
to 95 °C for a period of 3.5 hours, before being cooled to room temperature again. After 
removal of the solvent in vacuo, the remaining dark brown oil was re-dissolved in CH2Cl2 
(1.20 L), washed with NaCl-saturated aqueous H2SO4 (1 M, 500 mL), NaCl-saturated aqueous 
NaHCO3 (2 × 200 mL), as well as saturated aqueous NaCl (500 mL) and then each aqueous 
layer was re-extracted with the same fraction of CH2Cl2 (2 × 200 mL). The combined organic 
layers were dried over Na2SO4, concentrated in vacuo and the crude product was taken up in 
EtOAc (200 mL). After filtration over a plug of dry silica (EtOAc washings) the obtained 
brown solid was subjected to bulb-to-bulb distillation (185 °C, 0.2 mbar). The resulting pale 
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yellow solid was recrystallized (Et2O/n-hexane) to yield the title diketone (−)-138 (96.6 g, 
588 mmol, 67%) as colorless crystals.  
 
Rf = 0.30 (i-Hex:EtOAc = 1:1). 
 
Melting point = 63.5–64.3 °C (Et2O/n-hexane) 
 
1H NMR (CDCl3, 600 MHz): δ = 5.96 (d, J = 2.4 Hz, 1H), 2.94 (dddd, J = 17.1, 11.0, 9.9, 
2.4 Hz, 1H), 2.81– 2.71 (m, 2H), 2.58 – 2.36 (m, 3H), 2.09 (ddd, J = 13.6, 5.3, 2.2 Hz, 1H), 
1.84 (dddd, J = 14.2, 13.5, 5.2, 0.7 Hz, 1H), 1.31 (s, 3H) ppm. 
 
13C NMR (CDCl3, 150 MHz): δ = 216.6, 198.2, 169.8, 124.0, 48.8, 36.0, 33.0, 29.3, 27.0, 
20.7 ppm 
 
EI-MS for C10H12O2+ [M+]: calcd. 164.0837 
 found 164.0833. 
 
IR (ATR): ῦ/cm−1 = 2954, 1740, 1696, 1656, 1453, 1418, 1404, 1375, 1317, 1293, 1255, 
1228, 1218, 1202, 1194, 1146, 1061, 996, 975, 962, 939, 891, 869, 846, 813, 767, 713, 670.  
 
 = −384.6 (c 1.00, toluene). 
 
Synthesis of Alcohol 358 
   
 
   
A stirred solution of diketone (−)-138 (25.0 g, 152 mmol, 1.0 eq.) in absolute ethanol  
(370 mL) was cooled to −20 °C and subsequently NaBH4 (1.59 g, 41.9 mmol, 0.3 eq.) that 
was dissolved in absolute ethanol (250 mL) was added dropwise over a period of 4 hours. 
After being stirred for another hour, the reaction was slowly quenched via the addition of 
aqueous HCl (10 wt-%) until pH = 5 was reached. The ethanol was then removed in vacuo 
and the residual aqueous phase was extracted with EtOAc (4 × 250 mL). The combined 
[ ]20Dα
NaBH4 (0.3 eq.)
EtOH
 −20 °C, 5 h
(quant.)
358
C10H14O2
M = 166.22 g/mol
(−)-138
OHMe
O
OMe
O
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organic layers were dried over Na2SO4 and the solvent was removed under reduced pressure. 
The crude product was purified via flash column chromatography (silica, CH2Cl2:MeOH = 
93:7) to yield alcohol 358 (25.2 g, 152 mmol, quant.) as a slightly yellow solid.  
 
Rf = 0.30 (CH2Cl2:MeOH = 20:1). 
 
Melting point = 22.0–23.3 °C (CH2Cl2/MeOH) 
 
1H NMR (CDCl3, 600 MHz): δ = 5.76 (s, 1H), 3.83 (dd, J = 10.4, 7.6 Hz, 1H), 2.69 (ddtd, 
J = 19.8, 11.6, 2.3, 0.7 Hz, 1H), 2.50 (ddd, J = 17.8, 14.4, 5.4 Hz, 1H), 2.46–2.34 (m, 3H), 
2.15–2.08 (m, 2H), 1.85–1.73 (m, 2H), 1.13 (s, 3H) ppm. 
 
13C NMR (CDCl3, 150 MHz): δ = 199.5, 175.5, 123.5, 80.7, 45.3, 34.2, 33.4, 29.2, 26.6,  
15.2 ppm. 
 
EI-MS for C10H14O2+ [M+]: calcd. 166.0994 
 found 166.0989. 
 
IR (ATR): ῦ/cm−1 = 3357, 2962, 2931, 2910, 2867, 1693, 1632, 1469, 1446, 1416, 1371, 
1349, 1333, 1324, 1307, 1288, 1269, 1258, 1220, 1205, 1136, 1074, 1037, 1016, 1006, 973, 
954, 932, 901, 870, 847, 802, 768, 720.  
 
 = −82.6 (c 1.00, CH2Cl2). 
  
Synthesis of Ether 359 
   
 
    
Alcohol 358 (28.7 g, 173 mmol, 1.0 eq.) was dissolved in dry CH2Cl2 (290 mL) and cooled to 
−20 °C. To the stirred solution was added H3PO4 (3.2 mL, prepared from 2.0 g P2O5 and 
6.5 mL conc. H3PO4, 0.3 eq.), isobutene (360, approximately 140 mL, 1.47 mmol, 8.5 eq.) 
[ ]20Dα
(360, 8.5 eq.)
BF3⋅OEt2 (0.3 eq.)
H3PO4 (0.3 eq.)
CH2Cl2
 −78 °C to rt, 22 h
(94%)
359
C14H22O2
M = 222.33 g/mol
358
Ot-BuMe
O
OHMe
O
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and subsequently boron trifluoride etherate (7.37 mL, 58.7 mmol, 0.3 eq.). The reaction was 
stirred for 30 min at this temperature and then gradually warmed to room temperature over 
the course of 6 hours. Meanwhile, isobutene was re-condensed into the reaction via the use of 
a dry ice reflux condenser. Thereafter stirring was continued for another 16 hours, upon which 
aqueous ammonia (2 M, 280 mL) was added. The layers were separated and the aqueous 
phase was extracted with CH2Cl2 (4 × 250 mL). The combined organic layers were dried over 
Na2SO4, concentrated in vacuo and the crude product was purified via flash column 
chromatography (silica, i-Hex:EtOAc = 3:1 to 2:1) to yield ether 359 (36.2 g, 173 mmol, 
94%) as a colorless solid.  
 
Crystals suitable for X-ray analysis were obtained by slow evaporation of a solution of  
ether 359 from n-Hex at −20 °C. 
 
Rf = 0.65 (i-Hex:EtOAc = 3:1). 
 
Melting point = 61.9–62.9 °C (CH2Cl2/MeOH) 
 
1H NMR (CDCl3, 600 MHz): δ = 5.75 (s, 1H), 3.56 (dd, J = 9.9, 7.6 Hz, 1H), 2.68 (ddt, 
J = 19.6, 11.7, 2.4 Hz, 1H), 2.50 (ddd, J = 17.8, 14.5, 5.4 Hz, 1H), 2.39–2.32 (m, 2H),  
2.04–1.95 (m, 2H), 1.78 (dddd, J = 13.1, 11.7, 9.9, 8.8 Hz, 1H), 1.71 (td, J = 13.8, 5.0 Hz, 
1H), 1.17 (s, 9H), 1.10 (s, 3H) ppm. 
 
13C NMR (CDCl3, 150 MHz): δ = 199.6, 175.6, 123.0, 79.8, 73.2, 45.0, 34.5, 33.6, 29.7,  
15.9 ppm. 
 
EI-MS for C14H23O2+ [M+]: calcd. 223.1693 
 found 223.1697. 
 
IR (ATR): ῦ/cm−1 = 3029, 2969, 2937, 2905, 2864, 1699, 1668, 1639, 1454, 1415, 1392, 
1369, 1361, 1343, 1333, 1321, 1303, 1261, 1249, 1224, 1214, 1198, 1190, 1130, 1088, 1045, 
1028, 1002, 977, 957, 932, 909, 891, 865, 806, 766, 757, 732, 683. 
 
 = −52.8 (c 1.00, CH2Cl2). 
 
[ ]20Dα
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Synthesis of Ketoacid 362 
    
 
    
Magnesium methyl carbonate (78.7 mL, 2 M in DMF, 15.7 mmol, 3.5 eq.) was added slowly 
to a solution of ether 359 (10.0 g, 45.0 mmol, 1.0 eq.) in dry DMF (98 mL). After degassing 
the mixture (Ar bubbling, 10 min), the reaction vessel was added to an oil bath (pre-heated to 
130 °C) and the reaction was stirred for 4 hours. After cooling to 0 °C, aqueous HCl (2 M) 
was added until the mixture solidified. Subsequently, diethyl ether (80 mL) was added, 
followed by conc. aqueous HCl until a pH of 2–3 was reached and two homogenous layers 
had formed. The layers were separated and the aqueous phase was extracted with diethyl ether 
(5 × 100 mL). The combined organic layers were dried over Na2SO4, concentrated in vacuo 
and the crude product was recrystallized from n-hexane at −78 °C to yield ketoacid 362 
(4.62 g, 17.3 mmol, 39%) as a colorless solid. The mother liquor was then concentrated and 
the resulting mixture was submitted to flash column chromatography (silica, 
i-Hex:EtOAc:HOAc = 9:1:0.05 to 4:1:0.08) to yield additional ketoacid 362 (520 mg, 
1.95 mmol, 2%) and ether 359 (4.97 g, 22.3 mmol, 49%) as a colorless wax. The recovered 
starting material was subjected to another reaction cycle. Overall ketoacid 362 (9.01 g, 
33.8 mmol) was obtained in 75% yield. 
 
Crystals suitable for X-ray analysis were obtained by slow evaporation of a solution of 
ketoacid 362 from n-Hex at −20 °C. 
 
Rf = 0.30 (i-Hex:EtOAc:HOAc = 4:1:0.05). 
 
Melting point = 31.7–43.3 °C (n-Hex) 
 
1H NMR (CDCl3, 600 MHz): δ = 13.10 (s, 1H), 3.66 (dd, J = 10.3, 7.2 Hz, 1H), 3.31–3.17 (m, 
2H), 2.78 (ddd, J = 18.7, 14.4, 5.8 Hz, 1H), 2.64 (ddd, J = 18.7, 5.4, 1.8 Hz, 1H), 2.13–2.02 
(m, 2H), 1.92–1.77 (m, 2H), 1.19 (s, 12H) ppm. 
 
DMF
130 °C, 4 h
(94%) 362
C15H22O4
M = 266.34 g/mol
359
Ot-BuMe
O
Ot-BuMe
O
(3.5 eq.)
O OH
MeOMg O OMe
O
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13C NMR (CDCl3, 150 MHz): δ = 203.0, 196.3, 164.4, 120.5, 79.0, 73.6, 48.5, 33.7, 32.1, 
31.6, 30.1, 28.8, 16.4 ppm. 
 
ESI-MS for C15H21O4− [(M−H)−]: calcd. 265.1445 
 found 265.1440. 
 
IR (ATR): ῦ/cm−1 = 2976, 2966, 2938, 2908, 2870, 2763, 1734, 1623, 1597, 1437, 1415, 
1388, 1359, 1351, 1338, 1320, 1309, 1283, 1274, 1263, 1221, 1208, 1190, 1142, 1098, 1029, 
1018, 992, 979, 940, 923, 890, 855, 818, 798, 771, 759, 709, 686. 
 
 = −29.2 (c 1.00, CH2Cl2). 
 
Synthesis of Hydrindanone 361 
   
 
    
A stirred suspension of ketoacid 362 (3.00 g, 11.3 mmol 1.0 eq.) and Pd/BaSO4 (600 mg, 
5 wt-% Pd, 0.28 mmol, 2.5 mol-%) in dry methanol (24 mL) was pressurized with H2 
(3.4 bar) for 4 hours. Thereafter, the pressure was released and the crude mixture was filtered 
over a pad of Celite® (MeOH washings). After removal of the solvent in vacuo, the crude 
saturated ketoacid 363 was obtained as pale yellow foam and directly employed for further 
reaction. 
Saturated ketoacid 363 was transferred to a flask with high inner surface area, which was then 
evacuated (1 mbar) and subsequently heated to 90 °C for a period of one hour. After cooling 
to room temperature the crude product was purified by flash column chromatography (silica, 
i-Hex:EtOAc = 1:0 to 19:1) to yield hydrindanone 361 (1.56 g, 6.95 mmol, 62%) as a 
colorless solid as a single diastereomer.  
 
Crystals suitable for X-ray analysis were obtained by slow evaporation of a solution of 
hydrindanone 361 from n-Hex at −20 °C. 
 
[ ]20Dα
H2 (3.4 bar)
Pd/BaSO4
(2.5 mol-%)
MeOH
rt, 3 h
363362
Ot-BuMe
O
Ot-BuMe
O
O OHOHO
neat
90 °C, 1 h
(62%, two
steps)
vacuo
361
C14H24O2
M = 224.34 g/mol
Ot-BuMe
OH H
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Rf = 0.70 (i-Hex:EtOAc = 16:1). 
 
Melting point = 40.2–40.9 °C (n-Hex) 
 
1H NMR (CDCl3, 400 MHz): δ = 3.46 (dd, J = 9.1, 7.6 Hz, 1H), 2.42 (ddd, J = 16.4, 13.0, 
6.9 Hz, 1H), 2.34–2.28 (m, 3H), 2.04–1.92 (m, 2H), 1.77–1.68 (m, 1H), 1.64–1.55 (m, 2H), 
1.47–1.36 (m, 2H), 1.14 (s, 9H), 0.97 (d, J = 0.7 Hz, 3H) ppm. 
 
13C NMR (CDCl3, 100 MHz): δ = 212.3, 79.5, 72.7, 44.8, 43.1, 42.2, 37.6, 35.4, 31.9, 28.8, 
25.9, 10.4 ppm. 
 
EI-MS for C14H24O2+ [M+]: calcd. 224.1776 
 found 224.1778. 
 
IR (ATR): ῦ/cm−1 =2971, 2874, 1708, 1463, 1412, 1390, 1361, 1336, 1317, 1289, 1252, 1224, 
1193, 1122, 1104, 1059, 1032, 998, 967, 934, 917, 901, 853, 754, 685. 
 
 = −84.8 (c 1.00, CH2Cl2). 
 
Synthesis of Enol Ether 391 
   
 
    
To a solution of hydrindanone 361 (20 mg, 0.9 mmol, 1.0 eq.) in dry THF (1 mL) at −78 °C 
was added LiHMDS (0.2 mL, 1 M solution in THF, 1.8 mmol, 2.0 eq.). After stirring for 
15 min freshly distilled TMSCl (20 µL, 1.6 mmol, 1.8 eq.) was added an the reaction mixture 
was warmed to −30 °C for 30 min. Subsequently, saturated aqueous NaHCO3 (5 mL) was 
added and the resulting solution was extracted with diethyl ether (3 × 10 mL). The combined 
organic layers were dried over Na2SO4 and concentrated in vacuo to yield enol ether 391 
(25 mg, 0.9 mmol, 96%) as colorless oil, which required no further purification. 
 
Rf = 0.95 (i-Hex:EtOAc = 20:1). 
[ ]20Dα
LiHMDS (2.0 eq.)
→ TMSCl (1.8 eq.)
THF
−78 to −30 °C, 1 h
(96%) 391C17H32O2Si
M = 296.57 g/mol
361
Ot-BuMe
TMSO
Ot-BuMe
O HH
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1H NMR (C6D6, 600 MHz): δ = 4.94 (dtd, J = 5.8, 2.0, 0.7 Hz, 1H), 3.30 (t, J = 8.4 Hz, 1H), 
2.13 (ddd, J = 16.6, 5.3, 2.3 Hz, 1H), 2.02 (ddd, J = 15.9, 5.8, 2.0 Hz, 1H), 1.99–1.94 (m, 
1H), 1.87–1.83 (m, 1H), 1.82–1.76 (m, 1H), 1.59 (dddd, J = 13.3, 11.7, 8.0, 3.7 Hz, 1H), 
1.55–1.44 (m, 2H), 1.29–1.22 (m, 1H), 1.09 (s, 9H), 0.97 (s, 3H), 0.21 (s, 9H) ppm. 
 
13C NMR (C6D6, 150 MHz): δ = 150.6, 128.3, 103.4, 80.5, 72.2, 41.6, 36.8, 33.8, 32.1, 28.9, 
26.1, 11.0, 0.5 ppm. 
 
EI-MS for C17H32O2Si + [M+]: calcd. 296.22 
 found 296.22. 
 
IR (ATR): ῦ/cm−1 = 2971, 1714, 1655, 1462, 1389, 1362, 1251, 1190, 1142, 1115, 1069, 
1059, 1021, 901, 886, 844, 755. 
 
 = −89.6 (c 0.25, CH2Cl2). 
 
Synthesis of Hydroxy Ester 393 
   
 
   
To a solution of ketone 361 (0.03 g, 0.13 mmol, 1.0 eq.) in dry THF (1 mL) at −78 °C was 
added LDA (0.13 mL, 2 M solution in THF, 0.27 mmol, 2.0 eq.) dropwise. The resulting 
solution was stirred 10 min at this temperature and additional 30 min at room temperature. 
After being re-cooled to −78 °C, a premixed solution of ethyl pyruvate (392, 0.03 mL, 
0.27 mmol, 2.0 eq.) and ZnCl2 (0.27 mL, 1 M solution in THF, 0.27 mmol, 2.0 eq.) in dry 
THF (1 mL) was added slowly. The reaction was stirred for one hour upon which half-
saturated aqueous NH4Cl (10 mL) was added. After warming to room temperature, the 
mixture was extracted with CH2Cl2 (3 × 25 mL). The combined organic layers were dried 
over Na2SO4 and the solvents were removed in vacuo. The crude product was purified via 
flash column chromatography (silica, i-Hex:EtOAc = 40:1 to 20:1) to yield hydroxy ester 393 
(30.6 mg, 0.09 mmol, 67%) as colorless oil and as a 5:4 mixture of diastereomers. 
[ ]20Dα
                          
                 ZnCl (2.0 eq.)
 392 (2.0.eq.)
Me
O
Ot-Bu
H
HHO
EtO
O
COOEt
O
THF
−78 °C, 1 h
(67%)
dr = 5:4
Me
O
Ot-Bu
H
361
LDA (2.0 eq.)
393
C19H32O5
M = 340.46 g/mol
→
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Note: 1H and 13C NMR signals were attributed to the major and minor isomer according to 
2D NMR spectroscopy. 
 
Rf = 0.30 (i-Hex:EtOAc = 10:1). 
 
1H NMR (C6D6, 600 MHz, major isomer): δ = 4.28–4.14 (m, 2H), 3.52 (dd, J = 9.0, 7.5 Hz, 
1H), 3.32 (s, br, 1H), 3.03 (dd, J = 12.9, 6.5 Hz, 1H), 2.33–2.29 (m, 2H), 2.09 (dd, J = 12.5, 
6.4 Hz, 1H), 2.04–1.92 (m, 2H), 1.63–1.57 (m, 3H), 1.54 (t, J = 12.6 Hz, 1H), 1.29–1.25 (m, 
3H), 1.27 (s, 3H), 1.16 (s, 9H), 1.02 (s, 3H) ppm. 
 
1H NMR (C6D6, 600 MHz, minor isomer): δ = 4.28–4.14 (m, 2H), 3.45 (dd, J = 8.8, 7.7 Hz, 
1H), 3.34 (s, br, 1H), 2.99 (dd, J = 12.6, 0.9 Hz, 1H), 2.33–2.29 (m, 1H), 2.33–2.28 (m, 1H), 
2.03–1.96 (m, 1H), 1.95–1.88 (m, 2H), 1.73–1.64 (m, 2H), 1.63–1.55 (m, 1H), 1.49–1.37 (m, 
1H), 1.34 (s, 3H), 1.29–1.25 (m, 3H), 1.13 (s, 9H), 1.07–1.03 (m, 3H) ppm. 
 
13C NMR (CDCl3, 150 MHz, major isomer): δ = 211.9, 177.3, 79.6, 73.9, 72.8, 61.8, 53.1, 
44.6, 42.9, 42.3, 35.6, 32.0, 28.9, 25.9, 25.8, 14.2, 11.5 ppm. 
 
13C NMR (CDCl3, 150 MHz, minor isomer): δ = 213.1, 177.3, 78.9, 74.5, 72.8, 61.7, 58.5, 
46.0, 43.7, 37.8, 35.4, 32.1, 28.8, 27.0, 23.9, 14.2, 11.8 ppm. 
 
EI-MS for C19H32O5+ [M+]: calcd. 340.2250 
 found 340.2246. 
 
IR (ATR): ῦ/cm−1 = 3507, 2973, 2940, 2905, 2874, 1732, 1706, 1559, 1540, 1465, 1447, 
1423, 1389, 1362, 1340, 1292, 1241, 1192, 1175, 1121, 1108, 1063, 1028, 974, 963, 941, 902, 
865, 848, 804, 761, 712. 
 
Since the product was isolated as a mixture of diastereomers, the optical rotation of the 
product mixture was not determined. 
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5.3 Experimental Procedures for Chapter 3: ‘The Total Synthesis of (−)-Nitidasin’ 
 
Synthesis of Alcohol 440 
   
 
   
Hydrindanone 439 (6.80 g, 30.3 mmol) was dissolved in ethanol (70 mL) and aqueous HCl 
(6 M, 10 mL) was added. The resulting solution was heated to reflux (90 °C oil bath) for 
5 hours and then cooled to 0 °C. The pH of the mixture was adjusted to 7 via addition of neat 
Na2CO3, upon which the solvent was removed in vacuo. The residue was re-dissolved in 
CH2Cl2 (100 mL) and water (50 mL) was added. The layers were separated and the aqueous 
phase was extracted with CH2Cl2 (3 × 100 mL). Subsequently, the combined organic layers 
were dried over Na2SO4, concentrated in vacuo and the crude product was purified by flash 
column chromatography (silica, i-Hex:EtOAc = 3:2 to 1:1) to yield alcohol 440 (5.09 g, 
30.3 mmol, quant.) as colorless wax. 
 
Rf  = 0.20 (i-Hex:EtOAc = 1:1). 
 
1H NMR (CDCl3, 400 MHz): δ = 3.74 (t, J = 8.6 Hz, 1H), 2.45–2.22 (m, 4H), 2.21–2.11 (m, 
1H), 2.00 (ddd, J = 12.9, 6.8, 2.1 Hz, 1H), 1.91 (s, br, 1H), 1.75 (mC, 1H), 1.66–1.54 (m, 2H), 
1.50–1.39 (m, 2H), 0.98 (s, 3H) ppm. 
 
13C NMR (CDCl3, 100 MHz): δ = 211.8, 80.4, 44.8, 43.0, 42.5, 37.3, 34.8, 31.2, 25.3,  
9.8 ppm.  
 
EI-MS for C10H16O2+ [M+]: calcd. 168.1150 
 found 168.1145. 
 
IR (ATR): ῦ/cm−1 = 3404, 2950, 2870, 1697, 1464, 1453, 1443, 1415, 1383, 1368, 1353, 
1315, 1289, 1239, 1223, 1199, 1155, 1122, 1101, 1041, 1024, 996, 962, 914, 852, 826, 794, 
729, 686. 
 
HCl (6 M)
EtOH
90 °C, 5 h
(quant.)
OHMe
H
440
C10H16O2
M = 168.24 g/mol
O
Ot-BuMe
H
439
O
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 = +76.1 (c 1.00, CH2Cl2). 
 
Synthesis of Dioxolane 441 
   
 
    
Alcohol 440 (5.04 g, 30.2 mmol, 1.0 eq.) was dissolved in dry benzene (110 mL) and ethylene 
glycol (14.3 mL, 257 mmol, 8.5 eq.) and p-toluenesulfonic acid (0.63 g, 3.33 mmol, 
11 mol-%) were added. The resulting mixture was stirred vigorously and heated to reflux 
(100 °C oil bath) for two hours, at which the newly formed water was removed via a 
Dean-Stark apparatus. After cooling to room temperature, saturated aqueous NaHCO3 
(100 mL) was slowly added and the layers were separated. The aqueous phase was extracted 
with EtOAc (3 × 100 mL), and the combined organic layers were then dried over Na2SO4 and 
concentrated in vacuo. The crude product was purified by flash column chromatography 
(silica, i-Hex:EtOAc = 3:2) to yield dioxolane 441 (6.09 g, 28.7 mmol, 97%) as colorless 
solid. 
 
Rf  = 0.48 (i-Hex:EtOAc = 1:1). 
 
1H NMR (CDCl3, 400 MHz): δ = 3.94–3.89 (m, 4H), 3.70 (t, J = 7.8 Hz, 1H), 2.10 (mC, 1H), 
1.76– 1.43 (m, 9H), 1.36–1.27 (m, 2H), 0.80 (s, 3H) ppm. 
 
13C NMR (CDCl3, 100 MHz): δ = 110.1, 81.1, 64.4, 64.3, 42.6, 42.5, 35.8, 33.7, 31.2, 31.1, 
25.1, 9.7 ppm.  
 
EI-MS for C12H20O3+ [M+]: calcd. 212.1412 
 found 212.1400. 
 
IR (ATR): ῦ/cm−1 = 3476, 2953, 2938, 2873, 2855, 1469, 1449, 1444, 1430, 1407, 1375, 
1347, 1334, 1325, 1305, 1290, 1261, 1253, 1226, 1233, 1189, 1136, 1112, 1071, 1043, 986, 
972, 949, 943, 938, 897, 886, 856, 830, 800, 763, 734, 701, 677. 
[ ]20Dα
p-TsOH⋅H2O
(11 mol-%)
(HOCH2)2 (8.5 eq.)
C6H6
100 °C, 2 h
(97%)
OHMe
H
441
C12H20O3
M = 212.29 g/mol
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H
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O
O
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 = +18.8 (c 1.00, CH2Cl2). 
 
Synthesis of Ketone 442 
   
 
   
Dioxolane 441 (6.10 g, 28.7 mmol, 1.0 eq.) was dissolved in dry CH2Cl2 (34 mL). This 
solution was then added dropwise to an ice-cold suspension of PCC (15.5 g, 71.8 mmol, 
2.5 eq.) and NaOAc (11.8 g, 144 mmol, 5.0 eq.) in dry CH2Cl2 (160 mL). After warming to 
room temperature, the mixture was stirred for 4 hours, before being directly applied to flash 
column chromatography (silica, i-Hex:EtOAc = 2:1). Thus obtained crude ketone 442 (5.90 g, 
28.1 mmol, 98%) was further purified via recrystallization from n-Hex at 4 °C to yield the 
title compound 442 (5.03 g, 23.9 mmol, 83%) as a colorless solid. 
 
Rf  = 0.65 (i-Hex:EtOAc = 1:1). 
 
Melting point = 75.3–76.9 °C (n-Hex). 
 
1H NMR (CDCl3, 400 MHz): δ = 3.62–3.51 (m, 4H), 2.15–1.98 (m, 2H), 1.87–1.62 (m, 7H), 
1.38 (dddd, J = 12.3, 8.9, 5.9, 1.3 Hz, 1H), 1.18 (mC, 1H), 0.66 (s, 3H) ppm. 
 
13C NMR (CDCl3, 150 MHz): δ = 219.8, 109.6, 64.7, 64.4, 47.2, 42.8, 36.2, 35.6, 30.9, 28.7, 
23.7, 12.3 ppm.  
 
EI-MS for C12H18O3+ [M+]: calcd. 210.1256 
 found 210.1270. 
 
IR (ATR): ῦ/cm−1 = 2956, 2939, 2881, 2859, 1728, 1688, 1485, 1464, 1451, 1434, 1408, 
1380, 1350, 1338, 1325, 1305, 1286, 1266, 1233, 1203, 1185, 1140, 1117, 1092, 1081, 1065, 
1035, 1014, 1001, 986, 970, 947, 937, 925, 898, 856, 823, 806, 768, 678. 
 
[ ]20Dα
PCC (2.5 eq.)
NaOAc (5.0 eq.)
CH2Cl2
0 °C to rt, 4 h
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 = +84.8 (c 1.00, CH2Cl2). 
 
Synthesis of Enone 444 
   
 
   
A solution of diisoproylamine (12.0 mL, 85.6 mmol, 3.0 eq.) in dry THF (120 mL) at −78 °C 
was slowly treated with n-BuLi (34.2 mL, 2.51 M solution in hexanes, 85.6 mmol, 3.0 eq.) 
and the resulting mixture was stirred for 10 min at this temperature and for 15 min at 0 °C, 
before being cooled to −78 °C again. Then, ketone 442 (6.00 g, 28.5 mmol, 1.0 eq.) that was 
dissolved in dry THF (25 mL) was added over the course of 20 min. Stirring was continued 
for 45 min, at which point NEt3 (17.9 mL, 128 mmol, 4.5 eq.) and freshly distilled TMSCl 
(14.4 mL, 114 mmol, 4.0 eq.) were added sequentially. The reaction was stirred for another 
30 min and then allowed to warm to 0 °C. After the addition of half-saturated NaHCO3 
(100 mL), the mixture was diluted with n-pentane (200 mL) and the layers were separated. 
The aqueous phase was extracted with n-pentane (3 × 150 mL) and the combined organic 
layers were dried over Na2SO4. Careful evaporation of the solvents (30 °C, min. 100 mbar) 
yielded silyl enol ether 443, being pure enough for the use in further transformations. 
Thus obtained silyl enol ether 443 was re-dissolved in dry CH2Cl2 (100 mL) and dry 
acetonitrile (34 mL). Pd(OAc)2 (7.42 g, 31.3 mmol, 1.1 eq.) was added to this solution in one 
portion. This mixture was then added to an oil bath (pre-heated to 37 °C) and vigorously 
stirred for 4 hours. The resulting black suspension was directly applied to brief flash column 
chromatography (silica, i-Hex:EtOAc = 1:1). After removal of the solvents, further 
purification via flash column chromatography (silica, i-Hex:EtOAc = 8:1 to 6:1 to 4:1) 
yielded enone 444 (3.61g, 17.3 mmol, 61%) as colorless crystals, along with recovered 
ketone 442 (1.45 g, 6.90 mmol, 24%). Performing a second cycle of the above-described 
reaction conditions led to an overall yield of enone 444 (4.51g, 21.7 mmol) of 76%. 
 
Rf  = 0.45 (i-Hex:EtOAc = 1:1). 
 
Melting point = 125.3–126.9 °C (CH2Cl2).  
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1H NMR (CDCl3, 600 MHz): δ = 7.38 (dd, J = 6.0, 0.8 Hz, 1H), 6.03 (dd, J = 5.9, 3.2 Hz, 
1H), 3.99–3.94 (m, 4H), 3.05 (mC, 1H), 1.95–1.89 (m, 3H), 1.78 (mC, 2H), 1.70 (td, J = 13.2, 
4.9 Hz, 1H), 1.14 (s, 3H) ppm. 
 
13C NMR (CDCl3, 150 MHz): δ = 211.8, 160.6, 132.0, 109.7, 64.8, 64.3, 50.7, 48.1, 33.6, 
31.7, 26.9, 19.4 ppm.  
 
EI-MS for C12H16O3+ [M+]: calcd. 208.1100 
 found 208.1087. 
 
IR (ATR): ῦ/cm−1 = 2963, 2931, 2862, 2878, 1695, 1660, 1560, 1484, 1466, 1454, 1444, 
1436, 1377, 1370, 1351, 1344, 1314, 1274, 1251, 1229, 1206, 1179, 1133, 1086, 1066, 1035, 
1002, 990, 971, 956, 938, 934, 894, 879, 827, 807, 767, 744, 711, 683, 669. 
 
 = −66.4 (c 1.00, CH2Cl2). 
 
Synthesis of Alkene 333 
    
 
    
Powdered CuCN (1.77 g, 19.8 mmol, 2.3 eq.) was suspended in dry diethyl ether (58 mL) and 
cooled to 0 °C. Then, iso-propylmagensium bromide (368, 79.0 mL, 0.5 M solution in THF, 
19.8 mmol, 4.5 eq.) was added slowly and the resulting mixture was stirred for 30 min before 
being cooled to −78 °C. After the dropwise addition of a solution of enone 444 (1.83 g, 
8.79 mmol, 1.0 eq.) in dry THF (18 mL), the reaction was stirred for additional two hours. 
Saturated aqueous NH4Cl (50 mL) was then added and the reaction was warmed to room 
temperature, filtered over a plug of Celite® (Et2O washings) and the resulting layers were 
separated. The aqueous phase was extracted with diethyl ether (3 × 75 mL) and the combined 
organic layers were dried over Na2SO4 and concentrated in vacuo. The crude products of 
several reaction batches of similar size were then combined and purification via flash column 
chromatography (silica, i-Hex:EtOAc = 8:1 to 5:1) to yield alkene 333 as colorless solid. 
[ ]20Dα
CuCN (2.3 eq.)
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 −78 °C, 2h
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H
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Overall enone 444 (7.83 g, 37.6 mmol) was converted to alkene 333 (7.52 g, 30.2 mmol) in 
80% yield. 
 
Rf  = 0.50 (i-Hex:EtOAc = 3:1). 
 
Melting point = 69.0–70.1 °C (CH2Cl2).  
 
1H NMR (CDCl3, 400 MHz): δ = 4.96 (s, 1H), 4.83 (s, 1H), 3.99–3.92 (m, 4H), 2.86 (t, 
J = 8.3 Hz, 1H), 2.77 (dd, J = 19.7, 1.8 Hz, 1H), 2.48 (dd, J = 19.7, 9.1 Hz, 1H), 2.38 (dt, 
J = 9.9, 7.5 Hz, 1H), 1.96–1.93 (m, 2H), 1.80 (s, 3H), 1.79–1.60 (m, 3H), 1.42 (td, J = 13.2, 
4.8 Hz, 1H), 1.03 (s, 3H) ppm. 
 
13C NMR (CDCl3, 150 MHz): δ = 220.6, 146.1, 112.3, 109.8, 64.7, 64.4, 47.1, 45.7, 42.2, 
41.9, 35.7, 30.9, 30.9, 24.9, 15.3 ppm.  
 
EI-MS for C15H22O3+ [M+]: calcd. 250.1569 
 found 250.1561. 
 
IR (ATR): ῦ/cm−1 = 2952, 2886, 1734, 1644, 1432, 1378, 1345, 1295, 1234, 1188, 1153, 
1136, 1093, 1052, 1032, 1012, 997, 967, 948, 940, 930, 923, 904, 862, 815, 770, 747, 678. 
 
 = +31.0 (c 1.00, CH2Cl2). 
 
Synthesis of Ketone 337 
   
 
    
Alkene 333 (10.0 g, 40.0 mmol, 1.0 eq.) was dissolved in absolute ethanol (750 mL) and PtO2 
(554 mg, 2.00 mmol, 5 mol-%) was added in one batch. The resulting suspension was 
vigorously stirred, saturated with hydrogen (3 × evacuate and backfill) and then stirred under 
a hydrogen gas atmosphere (1 atm) for one hour. Thereafter, the mixture was filtered over  
[ ]20Dα
H2 (1 atm)
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a plug of Celite® (Et2O washings) and the solvents were removed in vacuo. The crude  
product was purified via flash column chromatography (silica, i-Hex:EtOAc = 5:1) to yield 
ketone 337 as colorless solid. 
 
Rf  = 0.55 (i-Hex:EtOAc = 3:1). 
 
Melting point = 62.6–64.0 °C (CH2Cl2).  
 
1H NMR (CDCl3, 400 MHz): δ = 3.98–3.90 (m, 4H), 2.49 (dd, J = 19.7, 2.4 Hz, 1H), 2.37 
(dd, J = 19.8, 8.6 Hz, 1H), 2.28 (ddd, J = 13.6, 7.0, 3.3 Hz, 1H), 2.00 (t, J = 13.1 Hz, 1H), 
1.93–1.61 (m, 6H), 1.44 (td, J = 13.0, 5.2 Hz, 1H), 1.04 (s, 3H), 0.96 (d, J = 6.0 Hz, 3H), 0.88 
(d, J = 6.2 Hz, 3H) ppm. 
 
13C NMR (CDCl3, 100 MHz): δ = 220.7, 109.9, 64.6, 64.4, 46.5, 45.5, 43.5, 41.9, 35.8, 30.7, 
30.6, 29.9, 23.7, 23.2, 15.9 ppm.  
 
EI-MS for C15H24O3+ [M+]: calcd. 252.1725 
 found 252.1728. 
 
IR (ATR): ῦ/cm−1 = 2953, 2927, 2879, 1734, 1470, 1430, 1405, 1382, 1347, 1327, 1305, 
1290, 1262, 1230, 1209, 1171, 1138, 1112, 1102, 1084, 1067, 1043, 1010, 989, 969, 948, 941, 
919, 884, 860, 814, 768, 721, 680, 667. 
 
 = +55.0 (c 1.00, CH2Cl2). 
 
Synthesis of Alkene 450 
   
 
    
To a solution of ketone 337 (5.23 g, 20.7 mmol, 1.0 eq.) in dry THF (205 mL) was added 
KHMDS (58.0 mL, 0.5 M solution in toluene, 29.0 mmol, 1.4 eq.) dropwise at −78 °C and the 
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resulting yellow mixture was stirred for 15 min. Then, PhNTf2 (11.1 g, 31.1 mmol, 1.5 eq.) 
was added in five portions and stirring was continued for 5 min. The reaction was allowed to 
warm to 0 °C and stirred for 30 min. Half-saturated aqueous NH4Cl (80 mL) and diethyl ether 
(200 mL) were added. The layers were separated and the aqueous phase was extracted with 
diethyl ether (3 × 50 mL). The combined organic layers were dried over Na2SO4 and then 
carefully concentrated in vacuo (30 °C, min. 100 mbar). Thus obtained crude enol triflate 449 
was immediately used for the next transformation without further purification. 
Enol triflate 449 was re-dissolved in dry DMF (52 mL) and n-Bu3N (14.7 mL, 62.2 mmol, 
3.0 eq.), formic acid (1.95 mL, 51.8 mmol, 2.5 eq.) and Pd(PPh3)2Cl2 (726 mg, 1.04 mmol,  
5 mol-%) were added sequentially. The yellow suspension was added to an oil bath (pre-
heated to 75 °C) and vigorously stirred for one hour. The formed black suspension was cooled 
to room temperature and quenched via the addition of water (50 mL). After filtration over a 
plug of Celite® (Et2O washings), the aqueous layer was separated and extracted with diethyl 
ether (3 × 50 mL). The combined organic layers were dried over Na2SO4 and then carefully 
concentrated in vacuo (30 °C, min. 500 mbar). The crude product was purified by flash 
column chromatography (silica, n-pentane:Et2O = 50:1 to 30:1) to yield alkene 450 (4.65 g, 
19.7 mmol, 95%) as colorless oil. 
 
Rf  = 0.40 (i-Hex:EtOAc = 10:1).  
 
1H NMR (CDCl3, 400 MHz): δ = 5.85 (d, J = 6.0 Hz, 1H), 5.80 (dd, J = 5.9, 2.8 Hz, 1H), 
3.97–3.94 (m, 4H), 2.17 (ddd, J = 11.3, 7.5, 5.4 Hz, 1H), 2.08 (mC, 1H), 1.92–1.86 (m, 2H), 
1.81 (dd, J = 13.8, 5.3 Hz, 1H), 1.76–1.64 (m, 2H), 1.60–1.45 (m, 2H), 1.01 (s, 3H), 0.90 (d, 
J = 6.4 Hz, 3H), 0.84 (d, J = 6.7 Hz, 3H) ppm. 
 
13C NMR (CDCl3, 100 MHz): δ = 141.6, 134.1, 110.6, 64.5, 64.3, 54.2, 48.3, 45.8, 35.1, 35.0, 
32.1, 29.8, 23.7, 22.5, 21.3 ppm.  
 
EI-MS for C15H24O2+ [M+]: calcd. 236.1776 
 found 236.1762. 
 
IR (ATR): ῦ/cm−1 = 3047, 2953, 2931, 2870, 1465, 1432, 1383, 1364, 1349, 1291, 1249, 
1185, 1120, 1108, 1084, 1052, 1014, 986, 972, 942, 879, 782, 740, 718, 671. 
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 = −73.6 (c 1.00, CH2Cl2). 
 
Synthesis of Alcohol 454 
    
 
    
A solution of (+)-IpcBH2 (451, ca. 1 M in THF) was freshly prepared as followed: A solution 
of (S)-Alpine-BoramineTM (452, 3.15 g, 7.57 mmol, 1.0 eq.) in dry THF (12 mL) was treated 
with BF3⋅Et2O (1.87 mL, 1.51 mmol, 2.0 eq.) at room temperature and the resulting mixture 
was stirred for two hours. The formed colorless precipitate was filtered off via syringe filter 
and the remaining solution was used for the generation of alcohol 454. 
To a solution of alkene 451 (1.38 g, 5.82 mmol, 1.0 eq.) in dry THF (150 mL) at 0 °C was 
dropwise added the prepared solution of (+)-IpcBH2 (451, 8.73 mL, ca. 1 M in THF,  
8.73 mmol, 1.5 eq.) and the resulting mixture was allowed to warm to room temperature. 
After stirring for one hour the reaction was cooled to 0 °C and methanol (2 mL), aqueous 
NaOH (3 M, 25 mL) and aqueous H2O2 (30 wt-%, 25 mL) were added sequentially. The 
biphasic mixture was heated to 55 °C for one hour and was then diluted with half-saturated 
aqueous NH4Cl (100 mL) and diethyl ether (50 mL) at room temperature. The layers were 
separated and the aqueous phase was extracted with diethyl ether (3 × 75 mL). The combined 
organic layers were dried over Na2SO4 and concentrated in vacuo. The crude product was 
submitted to brief flash column chromatography (silica, i-Hex:EtOAc = 2:1), yielding alcohol 
454 (1.43 g, 5.63 mmol, 97%) as a 8:3 mixture with isomeric alcohol 455. Subsequent two 
cycles of flash column chromatography (silica, i-Hex:EtOAc = 4:1 to 3:1) yielded alcohol 454 
(1.12 g, 4.40 mmol, 75%) as colorless oil as an 8:1 mixture with its regioisomer 455. 
Note: An analytical sample of alcohol 454 (purity as judged from 1H NMR: 95 mol-%) was 
obtained by repeated flash column chromatography. 
 
Rf  = 0.35 (i-Hex:EtOAc = 2:1).  
 
1H NMR (CDCl3, 400 MHz): δ = 4.33 (ddd, J = 8.9, 7.1, 4.3 Hz, 1H), 3.97–3.92 (m, 4H), 
2.25 (ddd, J = 13.8, 10.3, 3.3 Hz, 1H), 2.01 (dd, J = 11.6, 7.1 Hz, 1H), 1.86 (ddd, J = 12.6, 
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3.2, 2.2 Hz, 1H), 1.76–1.38 (m, 8H), 1.29–1.15 (m, 1H), 1.00 (d, J = 6.6 Hz, 3H), 0.94 (d, 
J = 6.3 Hz, 3H), 0.87 (s, 3H) ppm. 
 
13C NMR (CDCl3, 100 MHz): δ = 110.4, 77.9, 64.5, 64.3, 57.2, 50.1, 46.9, 41.2, 36.9, 34.8, 
30.8, 29.9, 24.1, 22.0, 19.1 ppm.  
 
EI-MS for C15H26O3+ [M+]: calcd. 254.1882 
 found 254.1868. 
 
IR (ATR): ῦ/cm−1 = 3293, 2941, 2890, 1469, 1455, 1383, 1366, 1351, 1289, 1254, 1191, 
1168, 1158, 1139, 1107, 1093, 1082, 1064, 1038, 1002, 992, 945, 938, 928, 891, 874, 821, 
767, 716, 706, 651, 638, 609. 
 
 = −3.0 (c 1.00, CH2Cl2). 
 
Synthesis of Hydrindanone 335 
   
 
    
A solution of an 8:1 mixture of alcohols 454 and 455 (200 mg, 0.79 mmol, 1.0 eq.) in acetone 
(16 mL) and water (1.6 mL) was treated with PPTS (257 mg, 1.02 mmol, 1.3 eq.). The 
resulting mixture was heated to 60 °C for 3 hours. After cooling to room temperature, half-
saturated aqueous NaHCO3 (30 mL) and diethyl ether (50 mL) were added. The layers were 
separated and the aqueous phase was extracted with diethyl ether (3 × 25 mL). The combined 
organic layers were dried over Na2SO4 and then concentrated in vacuo. Purification via flash 
column chromatography (silica, i-Hex:EtOAc = 3:1 to 5:2) yielded pure alcohol 335 (142 mg, 
0.67 mmol, 86%) as colorless solid. 
 
Rf  = 0.20 (i-Hex:EtOAc = 2:1).  
 
Melting point = 54.0–55.3 °C (CH2Cl2). 
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1H NMR (CDCl3, 400 MHz): δ = 4.41 (ddd, J = 8.9, 7.0, 4.8 Hz, 1H), 2.57 (dt, J = 13.5, 
2.1 Hz, 1H), 2.44–2.29 (m, 4H), 2.09 (dd, J = 11.8, 7.0 Hz, 1H), 1.83 (ddd, J = 13.1, 6.9, 
2.2 Hz, 1H), 1.73–1.53 (m, 2H), 1.62–1.53 (m, 2H), 1.30 (dd, J = 11.8, 9.3 Hz, 1H), 1.03 (s, 
3H), 1.03 (d, J = 6.1 Hz, 1H), 0.93 (d, J = 6.3 Hz, 3H) ppm. 
 
13C NMR (CDCl3, 100 MHz): δ = 212.2, 77.6, 56.5, 49.3, 48.5, 41.6, 40.9, 37.7, 37.2, 29.2, 
24.2, 21.7, 19.0 ppm.  
 
EI-MS for C13H22O2+ [M+]: calcd. 210.1620 
 found 210.1621. 
 
IR (ATR): ῦ/cm−1 = 3270, 2938, 2860, 1702, 1461, 1423, 1385, 1368, 1320, 1287, 1273, 
1260, 1230, 1218, 1170, 1149, 1129, 1099, 1035, 1002, 954, 939, 926, 877, 811, 760, 693, 
667, 639, 621. 
 
 = +75.2 (c 0.50, CH2Cl2). 
 
Synthesis of Ketone 456 
   
 
    
To a solution of alcohol 335 (630 mg, 3.00 mmol, 1.0 eq.) in CH2Cl2 (30 mL) at 0 °C were 
consecutively added DIPEA (2.60 mL, 15.0 mmol, 5.0 eq.) and SEMCl (1.30 mL, 7.50 mmol, 
2.5 eq.). The mixture was allowed to warm to room temperature and stirred for 16 h. Then, 
EtOH (2.5 mL) was added and the mixture was stirred for an additional 15 min, before being 
diluted with saturated aqueous NaHCO3 (30 mL). The layers were separated and the aqueous 
phase was extracted with CH2Cl2 (3 × 50 mL). The combined organic layers were washed 
with saturated aqueous NaCl (40 mL) and dried over MgSO4. The solvents were evaporated 
under reduced pressure and the crude product was purified by flash column chromatography 
(silica, i-Hex:EtOAc = 20:1 to 7:1) to yield ketone 456 (934 mg, 2.74 mmol, 91%) as a 
colorless oil. 
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On a slightly larger scale, alcohol 335 (1.09 g, 5.19 mmol) was converted to ketone 456 
(1.56 g, 4.58 mmol) in 88% yield.  
 
Rf = 0.23 (i-Hex:EtOAc = 10:1). 
 
1H NMR (CDCl3, 400 MHz): δ = 4.68 (d, J = 7.0 Hz, 1H), 4.63 (d, J = 7.0 Hz, 1H), 4.29 (ddd, 
J = 8.7, 6.9, 4.0 Hz, 1H), 3.68−3.52 (m, 2H), 2.58 (ddd, J = 14.6, 3.9, 1.5 Hz, 1H), 2.46−2.35 
(m, 2H), 2.35−2.22 (m, 2H), 2.18 (dd, J = 11.8, 7.0 Hz, 1H), 1.84 (ddd, J = 13.0, 6.8, 2.2 Hz, 
1H), 1.75−1.66 (m, 2H), 1.57 (ddd, J = 12.9, 12.9, 6.1 Hz, 1H), 1.27 (dd, J = 11.6, 8.9 Hz, 
1H), 1.03 (s, 3H), 0.99 (d, J = 6.1 Hz, 3H), 0.96−0.89 (m, 5H), 0.01 (s, 9H) ppm. 
  
13C NMR (CDCl3, 100 MHz): δ = 212.1, 93.6, 82.2, 65.4, 53.9, 48.2, 47.0, 41.5, 40.8, 37.9, 
37.3, 28.9, 24.4, 21.5, 19.0, 18.2, −1.3 ppm.  
 
 
EI-MS for C17H32O3Si+ [(M−C2H4)+]: calcd. 312.2115 
 found 312.2119. 
 
IR (ATR): ῦ/cm−1 = 2954, 2927, 1710, 1463, 1420, 1388, 1248, 1107, 1058, 1029, 936, 860, 
835. 
 
 = +43.2 (c 1.00, CH2Cl2). 
 
Synthesis of Ketone 458 
   
 
   
To a solution of ketone 456 (876 mg, 2.58 mmol, 1.0 eq.) in degassed THF (40 mL) was 
added KHMDS (7.70 mL, 0.5 M solution in toluene, 3.75 mmol, 1.5 eq.) at room temperature 
and the resulting yellow solution was stirred for 30 min, before being cooled to −78 °C. Then, 
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Et3B (7.70 mL, 0.5 M freshly prepared solution in THF, 3.75 mmol, 1.5 eq.) was added 
dropwise and the mixture was stirred for 5 min. After slowly adding a solution of Pd(PPh3)4 
(223 mg, 194 µmol, 7.5 mol-%) and allyl bromide (334 µL, 3.85 mmol, 1.5 eq.) in degassed 
THF (5 mL), the cold bath was removed and the mixture was stirred for 2 hours at room 
temperature. The reaction was quenched by addition of saturated aqueous NH4Cl (30 mL) and 
diluted with Et2O (30 mL). The layers were separated and the aqueous phase was extracted 
with Et2O (3 × 50 mL). The combined organic layers were washed with saturated aqueous 
NaCl (50 mL) and dried over MgSO4. The solvents were evaporated under reduced 
pressure and the crude product was purified by flash column chromatography (silica, 
i-Hex:EtOAc = 34:1 to 24:1) to yield ketone 458 (725 mg, 1.90 mmol, 74%) as a colorless oil. 
On a slightly larger scale, ketone 456 (1.43 g, 4.21 mmol) was converted to its allylated 
congener 458 (1.09 g, 2.87 mmol) in 68% yield.  
 
Rf = 0.47 (i-Hex:EtOAc = 10:1) 
 
1H NMR (CDCl3, 600 MHz): δ = 5.74 (mC, 1H), 5.04−4.97 (m, 2H), 4.67 (d, J = 7.0 Hz, 1H), 
4.63 (d, J = 7.0 Hz, 1H), 4.30 (mC, 1H), 3.66−3.54 (m, 2H), 2.63−2.54 (m, 2H), 2.48−2.37 (m, 
2H), 2.23−2.15 (m, 2H), 2.02−1.94 (m, 2H), 1.74−1.66 (m, 2H), 1.27−1.22 (m, 2H), 1.08 (s, 
3H), 0.99 (d, J = 6.1 Hz, 3H), 0.95−0.89 (m, 5H), 0.01 (s, 9H) ppm. 
  
13C NMR (CDCl3, 150 MHz): δ =212.0, 136.6, 116.5, 93.6, 82.2, 65.4, 54.3, 49.4, 47.0, 45.2, 
44.9, 41.9, 41.6, 33.9, 29.1, 24.3, 21.6, 19.9, 18.2, −1.3 ppm.  
 
EI-MS for C22H40O3Si+ [M+]: calcd. 380.2741 
 found 380.2732. 
 
IR (ATR): ῦ/cm−1 = 3076, 2955, 2928, 1708, 1464, 1388, 1249, 1162, 1099, 1058, 1033, 917, 
860, 836. 
 
 = +27.4 (c 0.50, CH2Cl2). 
 
 
 
 
[ ]20Dα
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Synthesis of Alcohol 466 
   
 
   
To a solution of ketone 458 (1.08 g, 2.84 mmol, 1.0 eq.) in THF (30 mL) was added 
K-Selectride® (465, 4.26 mL, 1.0 M solution in THF, 4.26 mmol, 1.5 eq.) dropwise at  
−78 °C. The mixture was stirred for 10 min at this temperature, an additional 50 min at room 
temperature and then cooled to 0 °C. Then, MeOH (4.9 mL) was added followed by aqueous 
NaOH (3 M, 8.0 mL) and H2O2 (30 wt-%, 6.5 mL). The mixture was stirred at room 
temperature for 1.5 h and subsequently diluted with saturated aqueous NH4Cl (40 mL). The 
layers were separated and the aqueous phase was extracted with Et2O (3 × 50 mL). The 
combined organic layers were washed with saturated aqueous NaCl (40 mL) and dried over 
MgSO4. The solvents were evaporated under reduced pressure and the crude product was 
purified by flash column chromatography (silica, n-pentane:Et2O = 2:1) to yield alcohol 466 
(1.01 g, 2.64 mmol, 93%) as a colorless oil. 
 
Rf = 0.22 (i-Hex:EtOAc = 7:1) 
 
1H NMR (CDCl3, 400 MHz): δ = 5.81 (ddt, J = 17.2, 10.0, 7.0 Hz, 1H), 5.06 (mC, 1H), 5.01 
(mC, 1H), 4.68 (d, J = 7.1 Hz, 1H), 4.63 (d, J = 7.1 Hz, 1H), 4.21 (mC, 1H), 3.97 (mC, 1H), 
3.69−3.53 (m, 2H), 2.28 (mC, 1H), 2.20−2.12 (m, 1H), 2.06 (dd, J = 11.5, 7.1 Hz, 1H), 
2.03−1.91 (m, 2H), 1.72−1.58 (m, 4H), 1.43−1.36 (m, 2H), 1.32−1.20 (m, 2H), 0.98−0.91 (m, 
8H), 0.82 (s, 3H), 0.01 (s, 9H) ppm. 
 
13C NMR (CDCl3, 100 MHz): δ = 137.5, 116.0, 93.5, 81.7, 69.2, 65.3, 54.2, 48.0, 42.0, 41.9, 
41.4, 37.3, 36.7, 32.4, 29.6, 24.4, 21.9, 19.8, 18.3, −1.3 ppm. 
 
ESI-MS for C22H46O3SiN+ [(M+NH4)+]: calcd. 400.3241 
 found 400.3240. 
 
IR (ATR): ῦ/cm−1 = 3474, 3076, 2953, 2929, 1462, 1378, 1250, 1100, 1056, 1026, 911, 860, 
836. 
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 = +21.6 (c 0.50, CH2Cl2). 
 
Synthesis of Lactone 468 
   
 
    
To a solution of alkene 466 (640 mg, 1.68 mmol, 1.0 eq.) and 2,6-lutidine (390 µL, 
3.35 mmol, 2.0 eq.) in a mixture of 1,4-dioxane (24 mL) an H2O (8 mL) were sequentially 
added OsO4 (170 µL, 4 wt-% solution in H2O, 16.8 µmol, 1 mol-%) and NaIO4 (1.44 g, 
6.70 mmol, 4.0 eq.) at 0 °C. The mixture was allowed to warm to room temperature and was 
stirred for 16 h, forming a white suspension. The mixture was partitioned between H2O 
(30 mL) and CH2Cl2 (50 mL) and the layers were separated. The aqueous phase was extracted 
with CH2Cl2 (3 × 50 mL) and the combined organic layers were washed with saturated 
aqueous NaCl (40 mL). After drying over MgSO4, the solvents were evaporated under 
reduced pressure to yield crude lactol 467 (Rf = 0.19, i-Hex:EtOAc = 4:1) which was used in 
the next step without further purification. 
To a suspension of PCC (905 mg, 4.20 mmol, 2.5 eq.) and NaOAc (689 mg, 8.40 mmol, 
5.0 eq.) in CH2Cl2 (30 mL) was added a solution of crude lactol 467 (assumed 1.68 mmol, 
1.0 eq.) in CH2Cl2 (4 mL) at 0 °C. The mixture was allowed to warm to room temperature and 
stirred for 3 hours before being directly applied to flash column chromatography (silica, 
i-Hex:EtOAc = 4:1). The title compound (468, 611 mg, 1.59 mmol, 94% over two steps) was 
obtained as pale yellow oil. 
On a slightly larger scale, alkene 466 (995 mg, 2.60 mmol) was converted to lactone 468 
(910 mg, 2.38 mmol) in an overall yield of 91%. 
 
Rf = 0.27 (i-Hex:EtOAc = 4:1). 
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1H NMR (CDCl3, 400 MHz): δ = 4.68−4.59 (m, 3H), 4.17 (mC, 1H), 3.67−3.53 (m, 2H), 2.71 
(dd, J = 16.8, 7.0 Hz, 1H), 2.49 (mC, 1H), 2.35 (mC, 1H), 2.17 (d, J = 16.8 Hz, 1H), 2.13−2.04 
(m, 2H), 1.81−1.62 (m, 4H), 1.23−1.17 (m, 1H), 1.11 (mC, 1H), 0.99−0.89 (m, 8H), 0.82 (s, 
3H), 0.01 (s, 9H) ppm. 
 
13C NMR (CDCl3, 100 MHz): δ = 177.1, 93.6, 81.2, 80.0, 65.4, 53.2, 47.3, 42.3, 41.1, 40.4, 
38.3, 32.3, 29.2, 26.4, 24.5, 21.7, 19.1, 18.3, −1.3 ppm.  
 
ESI-MS for C21H42O4Si+ [(M+ΝH4)+]: calcd. 400.2878 
 found 400.2876. 
 
IR (ATR): ῦ/cm−1 = 2952, 1779, 1462, 1422, 1387, 1287, 1248, 1192, 1156, 1103, 1056, 
1031, 942, 906, 861, 835.  
 
 = −0.8 (c 0.50, CH2Cl2). 
 
Synthesis of Lactone 469 
   
 
   
To a solution of lactone 468 (910 mg, 2.38 mmol, 1.0 eq.) in THF (40 mL) was added 
LiHMDS (5.24 mL, 1.0 M solution in THF, 5.24 mmol, 2.2 eq.) dropwise at −78 °C and the 
resulting mixture was stirred for 30 min. Then, MeI (1.19 mL, 19.0 mmol, 8.0 eq.) was added 
and the mixture was allowed to warm to −40 °C. After stirring for an additional 30 min at this 
temperature, the reaction was quenched by addition of half-saturated aqueous NH4Cl (40 mL). 
The biphasic mixture was allowed to warm to room temperature and diluted with 
Et2O (50 mL). The layers were separated and the aqueous phase was extracted with Et2O 
(3 × 50 mL). The combined organic layers were consecutively washed with saturated aqueous 
Na2S2O3 (40 mL), saturated aqueous NaCl (30 mL) and dried over MgSO4. The solvents were 
evaporated under reduced pressure and the crude product was purified by flash column 
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chromatography (silica, i-Hex:EtOAc = 5:1) to yield lactone 469 (857 mg, 2.16 mmol, 91%) 
as a colorless oil.  
 
Rf = 0.47 (i-Hex:EtOAc = 4:1). 
 
1H NMR (CDCl3, 400 MHz): δ = 4.75 (mC, 1H), 4.67 (d, J = 7.1 Hz, 1H), 4.62 (d, J = 7.2 Hz, 
1H), 4.16 (mC, 1H), 3.66−3.53 (m, 2H), 2.39−2.27 (m, 2H), 2.15−2.02 (m, 3H), 1.80−1.61 (m, 
4H), 1.29 (d, J = 7.6 Hz, 3H), 1.19 (mC, 1H), 1.09 (mC, 1H), 0.99−0.89 (m, 8H), 0.80 (s, 3H), 
0.01 (s, 9H) ppm. 
  
13C NMR (CDCl3, 100 MHz): δ = 180.2, 93.6, 81.2, 77.8, 65.4, 53.2, 47.3, 44.8, 42.7, 41.2, 
40.4, 39.1, 29.2, 26.4, 24.5, 21.7, 19.0, 18.3, 14.9, −1.3 ppm.  
 
ESI-MS for C22H40O4NaSi+ [MNa+]: calcd. 419.2588 
 found 419.2589. 
 
IR (ATR): ῦ/cm−1 = 2952, 2900, 1772, 1460, 1385, 1248, 1190, 1098, 1057, 1031, 942, 860, 
836. 
 
 = −6.8 (c 0.50, CH2Cl2). 
 
Synthesis of Silyl Ether 472 
   
 
   
To a suspension of LiAlH4 (201 mg, 5.29 mmol, 2.5 eq.) in THF (26 mL) at 0 °C was added a 
solution of lactone 469 (840 mg, 2.12 mmol, 1.0 eq.) in THF (10 mL) dropwise and the 
mixture was stirred for 15 min. The reaction was quenched by careful addition of half-
saturated aqueous Rochelle salt (50 mL), diluted with Et2O (30 mL) and the biphasic mixture 
was stirred vigorously at room temperature for one hour. The layers were separated and the 
aqueous phase was extracted with Et2O (3 × 50 mL). The combined organic layers were 
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washed with saturated aqueous NaCl (30 mL) and dried over MgSO4. Having evaporated the 
solvents under reduced pressure, the crude product was purified by brief flash column 
chromatography (silica, CH2Cl2:MeOH = 40:1) to yield diol 471, which was immediately 
used in the next reaction. 
To a solution of diol 471 (assumed 2.12 mmol, 1.0 eq.) in CH2Cl2 (20 mL) were sequentially 
added imidazole (865 mg, 12.7 mmol, 6.0 eq.), DMAP (52.0 mg, 0.42 mmol, 20 mol-%) and 
Et3SiCl (1.44 mL, 8.50 mmol, 4.0 eq.) at 0 °C. The mixture was allowed to warm to room 
temperature and stirred for 16 hours. The reaction was filtered over a pad of Celite® (CH2Cl2 
washings) and the clear solution was washed with saturated aqueous NaHCO3 (30 mL). The 
aqueous phase was extracted with CH2Cl2 (3 × 50 mL) and the combined organic layers were 
washed with saturated aqueous NaCl (40 mL). After drying over MgSO4, the solvent was 
evaporated under reduced pressure and the crude product was purified by flash column 
chromatography (silica, i-Hex:EtOAc = 100:1 to 60:1) to yield the title compound 472 
(1.19 g, 1.89 mmol, 89% over two steps) as a colorless oil. 
 
Rf = 0.24 (i-Hex:EtOAc = 30:1). 
 
1H NMR (CDCl3, 400 MHz): δ = 4.70 (d, J = 7.1 Hz, 1H), 4.65 (d, J = 7.1 Hz, 1H), 4.22 (mC, 
1H), 4.07 (mC, 1H), 3.72−3.54 (m, 2H), 3.51−3.42 (m, 2H), 2.37 (mC, 1H), 2.05 (dd, J = 11.4, 
7.0 Hz, 1H), 1.84 (mC, 1H), 1.70−1.50 (m, 5H), 1.39−1.29 (m, 2H), 1.23 (mC, 1H), 0.99−0.91 
(m, 26H), 0.86 (d, J = 6.9 Hz, 3H), 0.80 (s, 3H), 0.63−0.54 (m, 12H), 0.01 (s, 9H) ppm. 
  
13C NMR (CDCl3, 100 MHz): δ = 93.5, 81.9, 70.6, 66.3, 65.3, 54.3, 48.3, 41.8, 41.6, 38.0 
(2C), 37.2, 33.3, 29.8, 24.4, 21.9, 20.0, 18.3, 15.0, 7.2, 7.0, 5.5, 4.6, −1.3 ppm.  
 
ESI-MS for C34H76O4NSi3+ [(M+NH4)+]: calcd. 646.5077 
 found 646.5085. 
 
IR (ATR): ῦ/cm−1 = 2952, 2910, 2875, 1459, 1414, 1388, 1249, 1097, 1056, 949, 859, 835, 
726.  
 
 = +24.4 (c 0.50, CH2Cl2). 
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Synthesis of Aldehyde 474 
   
 
   
To a solution of dry DMSO (670 µL, 9.52 mmol, 8.0 eq.) in dry CH2Cl2 (20 mL) at −78 °C 
was added dropwise oxalyl chloride (2.38 mL, 2.0 M solution in CH2Cl2, 4.78 mol, 4.0 eq.) 
and the mixture was stirred for 15 min at this temperature. Then, a solution of silyl ether 472 
(750 mg, 1.19 mmol, 1.0 eq.) in CH2Cl2 (4 mL) was added over 30 min. The mixture was 
allowed to warm to −60 °C and was stirred for 8 hours at −65 to −60 °C. The reaction was 
then cooled to −78 °C and Et3N (2.65 mL, 19.0 mmol, 16 eq.) was added dropwise. The cold 
bath was replaced by an ice/water bath and the mixture was stirred for 30 min at 0 °C, at 
which point the reaction was quenched by addition of H2O (40 mL) and diluted with CH2Cl2 
(40 mL). The layers were separated and the aqueous layer was extracted with CH2Cl2 
(3 × 40 mL). The combined organic layers were washed with saturated aqueous NaCl 
(50 mL) and dried over MgSO4. Having evaporated the solvents under reduced pressure, the 
crude product was purified by flash column chromatography (silica, i-Hex:EtOAc = 40:1 to 
20:1) to yield aldehyde 474 (577 mg, 1.12 mmol, 94%) as a pale yellow oil. 
On a larger scale, silyl ether 472 (1.18 g, 1.88 mmol) was converted to aldehyde 474 (657 mg, 
1.28 mmol) in 69% yield. In addition, unreacted starting material 472 (225 mg, 385 µmol, 
30%) was recovered. 
 
Rf = 0.22 (i-Hex:EtOAc = 15:1). 
 
1H NMR (CDCl3, 400 MHz): δ = 9.73 (d, J = 1.7 Hz, 1H), 4.70 (d, J = 7.1 Hz, 1H), 4.65 (d, 
J = 7.1 Hz, 1H), 4.22 (mC, 1H), 4.11 (mC, 1H), 3.70−3.55 (m, 2H), 2.42−2.32 (m, 2H), 2.08 
(dd, J = 11.4, 7.1 Hz, 1H), 1.93−1.83 (m, 2H), 1.69−1.53 (m, 4H), 1.38 (dd, J = 12.3, 3.7 Hz, 
1H), 1.25 (dd, J = 11.3, 8.5 Hz, 1H), 1.05 (d, J = 7.2 Hz, 3H), 0.98−0.91 (m, 17H), 0.84 (s, 
3H), 0.62−0.54 (m, 6H), 0.01 (s, 9H) ppm. 
  
13C NMR (CDCl3, 100 MHz): δ = 205.1, 93.5, 81.7, 68.8, 65.3, 54.2, 48.3, 48.1, 41.9, 41.5, 
39.7, 39.1, 32.5, 29.7, 24.4, 21.9, 19.8, 18.3, 12.1, 7.1, 5.3, −1.3 ppm.  
Me
H
H
474
C28H56O4Si2
M = 512.92 g/mol
DMSO (8.0 eq.)
(COCl)2 (4.0 eq.)
→  NEt3 (16 eq.)
CH2Cl2
−78 to −60 °C, 8h
−78 to 0 °C, 30  min
(94%)
OSEM
O
O
Me
Me
H
H
472
OSEM
TESO
TESO
Me
SiEt3
H
5.3 Experimental Procedures for Chapter 3: ‘The Total Synthesis of (−)-Nitidasin’ 
162 
ESI-MS for C28H57O4Si2+ [MH+]: calcd. 513.3790 
 found 513.3797. 
 
IR (ATR): ῦ/cm−1 = 2951, 2875, 1725, 1457, 1379, 1248, 1100, 1055, 946, 859, 835, 730.  
 
 = +48.0 (c 0.25, CH2Cl2). 
 
Synthesis of Alkene 475 
   
 
   
To a suspension of Ph3PMeBr (3.31 g, 9.28 mmol, 8.0 eq.) in THF (50 mL) was added 
n-BuLi (3.25 mL, 2.5 M solution in hexanes, 8.12 mmol, 7.0 eq.) dropwise at 0 °C and the 
mixture was allowed to warm to room temperature. The suspension was stirred for one hour 
and subsequently cooled to −78 °C. Then, a solution of aldehyde 474 (594 mg, 1.16 mmol, 
1.0 eq.) in THF (10 mL) was added slowly. The cold bath was removed and the mixture was 
stirred for 1.5 hours at room temperature. Then, the reaction was quenched by addition of 
half-saturated aqueous NH4Cl (30 mL) and the biphasic mixture was extracted with Et2O 
(3 × 50 mL). The combined organic layers were washed with saturated aqueous NaCl 
(30 mL) and were dried over MgSO4. Having evaporated the solvents under reduced pressure, 
the crude product was purified by flash column chromatography (silica, i-Hex:EtOAc = 100:1 
to 40:1) to yield alkene 475 as a colorless oil. 
Flash column chromatography was performed combined with the crude product of a smaller 
reaction batch. Overall, aldehyde 474 (645 mg, 1.26 mmol) was converted to alkene 475 
(617 mg, 1.21 mmol) in 96% yield. 
 
Rf = 0.38 (i-Hex:EtOAc = 15:1). 
 
1H NMR (CDCl3, 400 MHz): δ = 5.74 (ddd, J = 17.3, 10.2, 8.3 Hz, 1H), 4.97 (mC, 1H), 4.92 
(mC, 1H), 4.70 (d, J = 7.0 Hz, 1H), 4.65 (d, J = 7.1 Hz, 1H), 4.22 (mC, 1H), 4.07 (mC, 1H), 
3.70−3.54 (m, 2H), 2.37 (mC, 1H), 2.20 (mC, 1H), 2.05 (dd, J = 11.2, 7.1 Hz, 1H), 1.85 (mC, 
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1H), 1.68−1.47 (m, 3H), 1.40 (dd, J = 11.3, 2.6 Hz, 1H), 1.34−1.19 (m, 3H), 1.00−0.87 (m, 
20H), 0.79 (s, 3H), 0.63−0.55 (m, 6H), 0.01 (s, 9H) ppm. 
  
13C NMR (CDCl3, 100 MHz): δ = 144.8, 113.1, 93.5, 81.9, 69.5, 65.3, 54.2, 48.2, 42.9, 41.9, 
41.6, 38.9, 38.6, 33.1, 29.8, 24.4, 21.9, 20.1, 18.6, 18.3, 7.3, 5.6, −1.3 ppm.  
 
EI-MS for C27H53O3Si2+ [(M−C2H5)+]: calcd. 481.3528 
 found 481.3530. 
 
IR (ATR): ῦ/cm−1 = 3076, 2954, 2877, 1460, 1415, 1370, 1260, 1099, 1048, 946, 910, 859, 
835, 794, 727.  
 
 = +28.5 (c 0.33, CH2Cl2). 
 
Synthesis of Ketone 477 
   
 
   
To a solution of TES ether 475 (200 mg, 391 µmol, 1.0 eq.) in a mixture of CH2Cl2 (28 mL) 
and MeOH (4 mL) was added CSA (18.0 mg, 78.0 µmol, 20 mol-%) and the mixture was 
stirred for 6 hours. The reaction was quenched by the addition of saturated aqueous NaHCO3 
(40 mL) and was then diluted with CH2Cl2 (30 mL). The layers were separated and the 
aqueous phase was extracted with CH2Cl2 (3 × 50 mL). The combined organic layers were 
washed with saturated aqueous NaCl (20 mL) and dried over Na2SO4. The solvents were 
removed under reduced pressure to give crude alcohol 476 (Rf = 0.20, i-Hex:EtOAc = 7:1), 
which was directly used without further purification. 
To a solution of crude alcohol 476 (assumed 391 µmol, 1.0 eq.) in CH2Cl2 (20 mL) was 
consecutively added NaHCO3 (164 mg, 1.96 mmol, 5.0 eq.) and Dess-Martin periodinane 
(415 mg, 978 µmol, 2.5 eq.) and the suspension was stirred for one hour. The reaction was 
carefully quenched by the addition of saturated aqueous NaHCO3, saturated aqueous Na2S2O3 
and H2O (1:1:1, 20 mL). The resulting mixture was vigorously stirred until two distinct layers 
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were obtained. The phases were separated and the aqueous layer was extracted with CH2Cl2 
(3 × 50 mL). The combined organic layers were dried over Na2SO4 and the solvent was 
evaporated under reduced pressure. The crude product was purified by flash column 
chromatography (silica, i-Hex:EtOAc = 20:1) to yield ketone 477 (147 mg, 373 µmol, 95% 
over two steps) as a highly viscous, colorless oil. 
 
Rf = 0.50 (i-Hex:EtOAc = 7:1). 
 
1H NMR (CDCl3, 400 MHz): δ = 5.79 (mC, 1H), 5.03−4.95 (m, 2H), 4.68 (d, J = 7.1 Hz, 1H), 
4.63 (d, J = 7.1 Hz, 1H), 4.29 (mC, 1H), 3.68−3.54 (m, 2H), 2.89 (mC, 1H), 2.59 (dd, J = 14.7, 
4.0 Hz, 1H), 2.45−2.36 (m, 2H), 2.23−2.14 (m, 2H), 1.78 (dd, J = 12.8, 6.3 Hz, 1H), 
1.74−1.64 (m, 2H), 1.37 (dd, J = 13.0, 13.0 Hz, 1H), 1.27 (dd, J = 11.7, 8.7 Hz, 1H), 1.04 (s, 
3H), 0.99 (d, J = 6.1 Hz, 3H), 0.97−0.89 (m, 8H), 0.01 (s, 9H) ppm. 
 
13C NMR (CDCl3, 100 MHz): δ = 211.5, 142.6, 113.9, 93.6, 82.1, 65.4, 54.2, 49.7, 48.5, 47.3, 
42.0, 41.2, 39.4, 35.5, 29.0, 24.3, 21.6, 19.7, 18.2, 14.8, −1.3 ppm.  
 
EI-MS for C23H42O3Si+ [M+]: calcd. 394.2898 
 found 394.2914. 
 
IR (ATR): ῦ/cm−1 = 3075, 2955, 2932, 2876, 1705, 1462, 1382, 1372, 1249, 1160, 1103, 
1058, 1030, 936, 915, 860, 835. 
 
 = +29.8 (c 0.50, CH2Cl2). 
 
Synthesis of Dibromide 421 
   
 
   
To a suspension of Zn (10.5 g, 160 mmol, 4.0 eq.) in CH2Cl2 (300 mL) was added  
PPh3 (41.9 g, 160 mmol, 4.0 eq.) at 0 °C and the mixture was stirred for 5 min. Then, CBr4 
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(53.0 g, 160 mmol, 4.0 eq.) was added and the resulting green suspension was stirred for an 
additional 90 min. at 0 °C. At this point, a solution of aldehyde 420 (4.48 g, 40.0 mmol, 
1.0 eq.) in CH2Cl2 (20 mL) was added. The cold bath was removed and the mixture was 
stirred for 3 hours at room temperature, changing its color to dark brown. The suspension was 
diluted with n-pentane (300 mL) and the solvents were decanted. The resulting brown solid 
was suspended in CH2Cl2 (50 mL). n-Pentane (50 mL) was added before the solvents were 
decanted again. This wash was repeated two more times and the suspension was filtered over 
a plug of silica (n-pentane washings). The solvent of the product containing fractions was 
carefully removed under reduced pressure and the crude product was purified by flash column 
chromatography (silica, n-pentane) to yield dibromoalkene 421 (8.42 g, 31.4 mmol, 79%) as a 
light yellow liquid. 
 
Rf = 0.88 (n-pentane). 
 
1H NMR (CDCl3, 400 MHz): δ = 6.40 (t, J = 7.3 Hz, 1H), 5.69 (ddd, J = 17.3, 10.2, 7.7 Hz, 
1H), 5.05−4.95 (m, 2H), 2.22−2.02 (m, 3H), 1.48−1.40 (m, 2H), 1.03 (d, J = 6.9 Hz, 3H) 
ppm. 
  
13C NMR (CDCl3, 100 MHz): δ = 143.8, 138.8, 113.5, 88.7, 37.5, 34.6, 31.0, 20.3 ppm.  
 
EI-MS for C8H11Br2+ [(M−H)+]: calcd. 264.9222 
 found 264.9207. 
 
IR (ATR): ῦ/cm−1 = 3076, 2955, 2923, 2862, 1807, 1704, 1638, 1452, 1417, 1373, 1270, 
1233, 1144, 994, 912, 796, 749, 665. 
 
 = −1.2 (c 1.00, CH2Cl2). 
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Synthesis of Enyne 412 
   
 
   
To a solution of dibromoalkene 421 (7.70 g, 28.7 mmol, 1.0 eq.) in THF (56 mL) at −78 °C 
was added dropwise n-BuLi (28.7 mL, 2.5 M solution in hexanes, 72.8 mmol, 2.5 eq.) and the 
resulting mixture was stirred for 30 min. Then, HMPA (12.5 mL, 72.8 mmol, 2.5 eq.) was 
added and the mixture was stirred for an additional 5 min, at which point MeI (17.9 mL, 
287 mmol, 10 eq.) was added dropwise. The mixture was stirred for 30 min at −78 °C and for 
90 min at room temperature. Then, the reaction was quenched by the addition of half-
saturated NH4Cl (100 mL) and the mixture was diluted with n-pentane (100 mL). The phases 
were separated and the aqueous layer was extracted with n-pentane (3 × 80 mL). The 
combined organic layers were subsequently washed with H2O (3 × 100 mL), saturated 
aqueous Na2S2O3 (100 mL) and saturated aqueous NaCl (2 × 100 mL). After drying over 
MgSO4, the solvents were distilled off at atmospheric pressure (20 cm Vigreux) and the 
resulting residue was purified by flash column chromatography (silica, n-pentane) to yield the 
desired enyne 412 (1.83 g, 5:2 mixture with n-pentane, 12.1 mmol, 42%) as a light yellow, 
volatile liquid.  
Note: The solvent of the product containing fractions was distilled off at atmospheric 
pressure.  
 
Rf = 0.29 (n-pentane). 
 
1H NMR (CDCl3, 400 MHz): δ = 5.65 (mC, 1H), 4.98 (mC, 1H), 4.93 (mC, 1H), 2.25 (mC, 1H), 
2.18−2.03 (m, 2H), 1.77 (t, J = 2.6 Hz, 3H), 1.47 (m, 2H), 0.99 (d, J = 6.6 Hz, 3H) ppm. 
  
13C NMR (CDCl3, 100 MHz): δ = 143.9, 113.3, 79.3, 75.6, 37.0, 35.9, 20.0, 16.7, 3.6 ppm.  
 
 
EI-MS for C9H13+ [(M−H)+]: calcd. 121.1012 
 found 121.1020. 
n-BuLi (2.5 eq.)
→ HMPA (3.0 eq.)
MeI (10 eq.)
THF, hexanes
−78 °C, 30 min
−78 °C to rt, 90 min
(42%)
Me
412
C9H14
M = 122.21 g/mol
Me Br
Br
421
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IR (ATR): ῦ/cm−1 = 3078, 2958, 2919, 2861, 1829, 1639, 1454, 1433, 1419, 1373, 1346, 
1309, 1148, 1111, 1075, 995, 911, 771, 680. 
 
 = −22.4 (c 0.50, CH2Cl2). 
 
Synthesis of Alcohols 433 and 434 
   
 
   
To a solution of Cp2ZrCl2 (1.84 g, 6.29 mmol, 1.05 eq.) in THF (39 mL) was added 
n-BuLi (4.73 mL, 2.65 M solution in hexanes, 12.8 mmol, 2.1 eq.) dropwise at −78 °C and the 
resulting yellow solution was stirred at this temperature for one hour. Then, a solution of 
enyne 412 (730 mg, 5.99 mmol, 1.00 eq.) in THF (5 mL) was added within 20 min. The 
mixture was allowed to warm to room temperature over the course of two hours and stirred 
for an additional 14 hours, changing its color to light red. The resulting intermediate was 
added to a solution of NIS (3.37 g, 15.0 mmol, 2.5 eq.) in CH2Cl2 (40 mL) at −78 °C within 
90 min. The mixture was stirred for 15 min at −78 °C, for 30 min at −50 °C and an additional 
hour at room temperature. The reaction was quenched by the addition of saturated aqueous 
NH4Cl (30 mL) and diluted with n-pentane (40 mL). The resulting suspension was filtered 
over a pad of Celite® (n-pentane washings). The layers were separated and the aqueous layer 
was extracted with n-pentane (3 × 40 mL). The combined organic layers were consecutively 
washed with saturated aqueous Na2S2O3 (50 mL), saturated aqueous NaHCO3 (50 mL) and 
saturated aqueous NaCl (50 mL). After drying over Na2SO4, the solvents were evaporated 
under reduced pressure and the crude product was purified by flash column chromatography 
(silica, n-pentane) to yield crude diiodide 431 (2.05 g, 5.45 mmol, 85%) as a brownish liquid. 
Such material was obtained as an inconsequential 3:1 to 5:1 mixture of diastereomers and was 
[ ]20Dα
Cp2ZrCl2 (1.1 eq)
n-BuLi (2.5 eq.)
→  NIS (2.5 eq.)
THF, hexanes
−78 °C to rt, 14 h
CH2Cl2, −78 °C to rt
90 min
Me
431
C9H14I2
M = 376.02 g/mol
Me
412
I
I DBU
(10 eq.)
CH2Cl2
0 °C to rt, 10 h
Me
432
C9H13I
M = 248.11 g/mol
I
9-BBN (3.0 eq.)
→  NaOH, H2O2
THF, 0 °C to 45 °C, 2h
H2O, 0 °C to rt, 90 min
(63% 433, 10% 434, three
steps)
Me
433
C9H15IO
M = 266.12 g/mol
I
HO
+
Me
434
C9H15IO
M = 266.12 g/mol
I
HO
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employed in the next step without further purification. An analytical sample was obtained by 
repeated flash column chromatography. 
 
Rf = 0.57 (n-pentane). 
 
1H NMR (C6D6, 400 MHz, only major isomer quoted): δ = 3.37 (dd, J = 9.7, 3.1 Hz, 1H), 
2.90 (mC, 1H), 2.48 (mC, 1H), 2.16−2.06 (m, 4H), 2.04−1.93 (m, 1H), 1.93−1.82 (m, 1H), 
1.56 (mC, 1H), 1.10 (mC, 1H), 0.75 (d, J = 7.1 Hz, 3H) ppm. Characteristic signal for minor 
isomer: δ = 1.00 (d, J = 6.9 Hz, 3H) ppm. 
  
13C NMR (C6D6, 100 MHz, only major isomer quoted): δ = 149.4, 91.6, 60.5, 39.0, 32.2, 
30.8, 29.5, 20.1, 10.2 ppm.  
 
EI-MS for C9H14I2+ [M+]: calcd. 375.9180 
 found 375.9185. 
 
IR (ATR): ῦ/cm−1 = 2951, 2922, 2866, 2840, 1641, 1453, 1431, 1418, 1374, 1348, 1312, 
1286, 1263, 1243, 1211, 1199, 1173, 1159, 1145, 1102, 1058, 1016, 968, 948, 912, 879, 833, 
790, 763, 679, 655. 
 
Since this compound was obtained as a mixture of diastereomers, no optical rotation was 
measured. 
 
To a solution of diiodide 431 (2.05 g, 5.45 mmol, 1.0 eq.) in CH2Cl2 (110 mL) was slowly 
added DBU (7.93 mL, 54.5 mmol, 10 eq.) at 0 °C. The mixture was allowed to warm to room 
temperature and stirred for 10 hours. The reaction was quenched by the addition of H2O 
(50 mL) and the resulting mixture was diluted with n-pentane (100 mL). The layers were 
separated and the aqueous phase was extracted with n-pentane (3 × 100 mL). The combined 
organic layers were consecutively washed with saturated aqueous NH4Cl (100 mL), saturated 
aqueous NaCl (100 mL) and were dried over Na2SO4. The solvents were carefully  
removed under reduced pressure and the obtained crude diene 432 was immediately used in 
the next step. 
Note: Intermediate 432 is very prone to decomposition. A sample suitable for NMR analysis 
could be obtained by quick flash column chromatography (silica, n-pentane).  
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Rf = 0.64 (n-pentane). 
 
1H NMR (C6D6, 400 MHz): δ = 6.42 (d, J = 2.2 Hz, 1H), 4.90 (d, J = 1.6 Hz, 1H), 2.33 
(s, 3H), 2.37−2.26 (m, 1H), 2.17 (mC, 1H), 2.05−1.94 (m, 1H), 1.51 (mC, 1H), 0.95 (d, 
J = 6.8 Hz, 1H), 0.99−0.88 (m, 3H) ppm. 
 
13C NMR (C6D6, 100 MHz): δ = 154.1, 142.3, 109.1, 86.7, 41.4, 33.7, 32.2, 32.1, 18.6 ppm. 
 
To a solution of crude diene 432 (assumed 4.79 mmol, 1.0 eq.) in THF (90 mL) was slowly 
added 9-BBN (29 mL, 0.5 M solution in THF, 14.5 mmol, 3.0 eq.) at 0 °C. The reaction was 
allowed to warm to room temperature and stirred for one hour at 45 °C. The mixture was 
cooled to 0 °C and EtOH (9.0 mL) was added slowly. The mixture was stirred for 10 min and 
subsequently NaOH (32.0 mL, 3.0 M solution in H2O, 96.0 mmol, 20 eq.) and H2O2 (9.60 mL, 
30 wt-%, 96.0 mmol, 20 eq.) were added. After stirring for 90 min at room temperature, 
H2O (50 mL) was added and the biphasic mixture was extracted with Et2O (3 × 100 mL). The 
combined organic layers were washed with saturated aqueous NaCl (30 mL) and dried over 
Na2SO4. Having evaporated the solvents under reduced pressure, the crude product was 
purified by flash column chromatography (silica, n-pentane/Et2O = 6:1 to 5:1) to yield the 
desired alcohol 433 (1.01 g, 3.76 mmol, 63% over three steps) as a colorless low melting solid 
along with its diastereomer 434 (170 mg, 639 µmol, 10% over three steps) as a colorless oil. 
 
Analytical data for major isomer 433: 
 
Rf = 0.29 (n-pentane/Et2O = 20:1). 
 
Melting point = 28–31 °C (n-pentane). 
 
1H NMR (C6D6, 600 MHz): δ = 3.79−3.69 (m, 1H), 3.57−3.49 (m, 1H), 2.56 (mC, 1H), 2.17 
(q, J = 1.4 Hz, 3H), 2.14−2.04 (m, 1H), 1.99−1.84 (m, 2H), 1.73−1.63 (m, 1H), 1.57−1.49 (m, 
1H), 1.02 (d, J = 7.1 Hz, 3H), 0.73−0.61 (m, 1H) ppm. 
  
13C NMR (C6D6, 150 MHz): δ = 150.0, 88.6, 61.2, 56.9, 37.4, 34.2, 30.7, 30.5, 15.5 ppm.  
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EI-MS for C9H15IO+ [M]+: calcd. 266.0162 
 found 266.0147. 
 
IR (ATR): ῦ/cm−1 = 3366, 2951, 2869, 1646, 1472, 1454, 1429, 1373, 1321, 1294, 1260, 
1213, 1181, 1132, 1100, 1074, 1055, 1036, 1000, 982, 950, 933, 839, 802, 703, 673. 
 
 = −56.0 (c 0.10, C6D6). 
 
Analytical data for minor isomer 434: 
 
Rf = 0.26 (n-pentane/Et2O = 20:1). 
 
1H NMR (C6D6, 400 MHz): δ = 3.71–3.65 (m, 1H), 3.39 (mC, 1H), 2.42–2.34 (m, 1H),  
2.24–2.16 (m, 1H), 2.19 (mC, 3H), 2.16−2.07 (m, 1H), 1.98–1.88 (m, 1H), 1.76 (mC, 1H), 1.19 
(mC, 1H), 0.88 (br s, 1H), 0.85 (d, J = 7.0 Hz, 3H) ppm. 
  
13C NMR (C6D6, 100 MHz): δ = 148.4, 89.6, 63.1, 61.2, 35.7, 32.9, 31.0, 30.1, 20.5 ppm.  
 
EI-MS for C9H15IO+ [M]+: calcd. 266.0162 
 found 266.0157. 
 
IR (ATR): ῦ/cm−1 = 3259, 2952, 2867, 1640, 1455, 1428, 1379, 1312, 1260, 1238, 1209, 
1175, 1059, 1027, 1016, 983, 970, 899, 855, 798, 731, 685. 
 
 = +25.6 (c 0.25, C6D6). 
 
 
 
 
 
 
 
 
 
[ ]20Dα
[ ]20Dα
Experimental Section 
171 
Preparation of Mosher Ester 435  
   
 
   
To a solution of alcohol 433 (10 mg, 38 µmol, 1.0 eq.) in CH2Cl2 (1.0 mL) was added 
pyridine (15 µL, 0.2 mmol, 5.0 eq.) at 0 °C. Subsequently, (R)-Mosher’s acid chloride (638, 
18 µL, 94 µmol, 2.5 eq.) was added and the resulting mixture was stirred for 14 hours at room 
temperature. After the addition of half-saturated aqueous NaHCO3 solution (10 mL), the 
mixture was extracted with CH2Cl2 (3 × 10 mL). The combined organic layers were dried 
over Na2SO4 and concentrated under reduced pressure. 1H NMR analysis of the crude reaction 
mixture indicated a diastereomeric mixture of 435:639 = 4:1. The crude product was purified 
via flash column chromatography (silica, n-pentane/Et2O = 19:1) to yield the ester 435 
(17 mg, 35 µmol, 94%) as a colorless oil, which retained its content mixture of 435:639 = 4:1. 
 
Rf = 0.74 (i-Hex /EtOAc = 25:1). 
 
1H NMR (C6D6, 400 MHz, both isomers quoted): δ = 7.72–7.60 (m, 2H, 435, 639), 7.12–6.94 
(m, 3H, 435, 639), 4.60–4.55 (m, 1H, 435, 639), 4.24 (dd, J = 11.4, 2.0 Hz, 1H, 639), 4.12 
(dd, J = 11.4, 2.1 Hz, 1H, 435), 3.43–3.43 (m, 3H, 435), 3.39–3.37 (m, 3H, 639), 2.65 (t, 
J = 7.0 Hz, 1H, 435), 2.59 (t, J = 7.0 Hz, 1H, 639), 2.12 (mC, 3H, 639), 2.04–2.02 (m, 3H, 
435), 1.80–1.59 (m, 3H, 435, 639), 1.58–1.45 (m, 1H, 435, 639), 1.22 (m, 1H, 435, 639), 0.72 
(d, J = 7.0 Hz, 3H, 435), 0.71 (d, J = 7.0 Hz, 3H, 639) ppm. 
  
13C NMR (C6D6, 100 MHz, only major isomer quoted): δ = 166.4, 148.2, 133.4, 129.5, 128.5, 
127.6, 125.7, 89.8, 85.4–84.6 (m), 64.4, 55.6, 53.2, 36.9, 33.8, 30.4, 30.3, 15.1 ppm. 
 
EI-MS for C19H22F3IO3+ [M]+: calcd. 482.0560 
 found 482.0567. 
 
Me
435
C19H22F3IO3
M = 482.28 g/mol
I
Cl Ph
O CF3
OMe
638 (2.5 eq.)
pyridne (5.0 eq.)
CH2Cl2
0 °C to rt, 14 h
(94%)
Me
433
I
OH O
O F3C
OMe
+
Me
639
C19H22F3IO3
M = 482.28 g/mol
I
O
O F3C
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IR (ATR): ῦ/cm−1 = 2952, 2875, 2846, 1747, 1648, 1497, 1451, 1376, 1323, 1271, 1253, 
1165, 1120, 1104, 1079, 1058, 1040, 1028, 1012, 1000, 950, 916, 802, 764, 731, 717, 695, 
676. 
 
 = −12.4 (c 0.50, CH2Cl2). 
 
Synthesis of Diene 411 
   
 
   
To a solution of dry DMSO (850 µL, 12.0 mmol, 8.0 eq.) in CH2Cl2 (20 mL) was slowly 
added oxalyl chloride (5.36 mL, 2.0 M solution in CH2Cl2, 10.5 mmol, 7.0 eq.) at −78 °C and 
the mixture was stirred for 15 min. Then, a solution of alcohol 433 (400 mg, 1.50 mmol, 
1.0 eq.) in CH2Cl2 (6 mL) was added dropwise and the mixture was stirred for an additional 
two hours before adding Et3N (2.93 mL, 21.0 mmol, 14 eq.). The reaction mixture was 
allowed to warm to 0 °C over a period of 60 min and was then quenched by the addition of 
aqueous phosphate buffer (10 mL, 2 M, pH = 6.3). After separating the phases, the aqueous 
layer was extracted with n-pentane (3 × 50 mL). The combined organic layers were washed 
with aqueous phosphate buffer (10 mL, 2 M, pH = 6.3) and dried over Na2SO4. The solvents 
were carefully removed under reduced pressure and the crude product was purified by quick 
flash column chromatography (silica, n-pentane/Et2O = 9:1) to yield aldehyde 436 (392 mg, 
1.48 mmol, 99%), which was immediately used in the next step. 
 
Rf = 0.68 (i-Hex:EtOAc = 20:1). 
 
1H NMR (C6D6, 400 MHz): δ = 9.55 (dd, J = 3.3, 0.6 Hz, 1H), 3.31 (m, 1H), 2.17 –2.07 (m, 
1H), 2.10 (s, 3H), 1.79 (m, 2H), 1.63–1.49 (m, 1H), 1.41–1.25 (m, 1H), 0.82 (d, J = 7.0 Hz, 
3H) ppm. 
 
13C NMR (C6D6, 100 MHz): δ = 199.6, 146.3, 91.5, 67.0, 38.7, 34.5, 31.1, 30.3, 15.4 ppm.  
 
[ ]20Dα
I
HO
Me
DMSO (8.0 eq.)
 (COCl)2 (7.0 eq.)
→ Et3N (14.0 eq.)
CH2Cl2
 −78 to 0 °C, 1 h
433
I
O
Me
436
C9H13IO
M = 264.11 g/mol
n-BuLi (5.0 eq.)
PPh3MeBr (6.0 eq.)
THF
−78 to 0 °C, 2 h
(83%, two steps)
IMe
H
411
C10H15I
M = 262.13 g/mol
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EI-MS for C9H13IO+ [M+]: calcd. 264.0006. 
 found 263.9996. 
 
IR (ATR): ῦ/cm−1 = 2955, 2872, 2717, 1715, 1647, 1459, 1431, 1378, 1347, 1274, 1213, 
1175, 1133, 1119, 1097, 1058, 1009, 971, 945, 899, 789, 722, 676.  
 
 = −20.8 (c 0.50, n-pentane). 
 
To a suspension of Ph3PMeBr (3.21 g, 9.0 mmol, 6.0 eq.) in THF (50 mL) was slowly added 
n-BuLi (2.80 mL, 2.7 M solution in hexanes, 7.50 mmol, 5.0 eq.) at 0 °C. The resulting orange 
suspension was allowed to warm to room temperature and stirred for 60 min, before being 
cooled to −78 °C. A solution of aldehyde 436 (392 mg, 1.48 mmol, 1.0 eq.) in THF (8.5 mL) 
was then added slowly. The cold bath was replaced by an ice/water bath and the mixture was 
stirred for additional 60 min at 0 °C, prior to quenching the reaction by the addition of half-
saturated aqueous NH4Cl (30 mL). The layers were separated and the aqueous layer was 
extracted with n-pentane (3 × 50 mL). The combined organic layers were washed with 
saturated aqueous NaCl (50 mL) and dried over Na2SO4. Having carefully removed the 
solvents under reduced pressure, the crude product was purified by flash column 
chromatography (silica, n-pentane) to yield diene 411 (326 mg, 1.2 mmol, 83% over the two 
steps) as a colorless oil.  
 
Rf = 0.90 (i-Hex:EtOAc = 20:1). 
 
1H NMR (C6D6, 600 MHz): δ = 5.53–5.39 (m, 1H), 5.22–5.15 (m, 2H), 3.17 (t, J = 7.5 Hz, 
1H), 2.20 (q, J = 1.3 Hz, 3H), 2.13–2.08 (m, 1H), 2.00–1.93 (m, 1H), 1.86–1.78 (m, 1H), 
1.67–1.62 (m, 1H), 1.33–1.25 (m, 1H), 0.84 (d, J = 6.8 Hz, 3H) ppm. 
 
13C NMR (C6D6, 100 MHz): δ = 149.2, 133.6, 117.2, 89.2, 60.2, 38.2, 33.2, 30.3 (2C),  
15.7 ppm.  
 
EI-MS for C10H15I+ [M+]: calcd. 262.0213. 
 found 262.0213. 
 
[ ]20Dα
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IR (ATR): ῦ/cm−1 = 3077, 2953, 2869, 1649, 1633, 1455, 1430, 1415, 1404, 1375, 1349, 
1285, 1232, 1212, 1268, 1140, 1115, 1096, 1083, 1056, 988, 910, 865, 688, 660. 
 
 = −38.4 (c 0.25, CH2Cl2). 
 
Synthesis of Silyl Ether 437 
   
 
   
To a solution of alcohol 433 (200 mg, 751 µmol, 1.0 eq.) in DMF (16 mL) were consecutively 
added imidazole (307 mg, 4.51 mmol, 6.0 eq.), Et3SiCl (0.38 mL, 2.25 mmol, 3.0 eq.) and 
DMAP (18.3 mg, 0.15 mmol, 20 mol-%) at 0 °C. The mixture was allowed to warm to room 
temperature and stirred for one hour, before being quenched by the addition of H2O (50 mL). 
The layers were separated and the aqueous phase was extracted with n-pentane (3 × 50 mL). 
The combined organic layers were washed with half-saturated aqueous NaCl (30 mL) and 
dried over Na2SO4. Having evaporated the solvents under reduced pressure, the crude product 
was purified by flash column chromatography (silica, n-pentane) to yield silyl ether 437 
(273 mg, 718 µmol, 96%) as colorless oil. 
 
Rf = 0.51 (n-pentane). 
 
1H NMR (C6D6, 400 MHz): δ = 3.99 (dd, J = 10.2, 5.6 Hz, 1H), 3.70 (dd, J = 10.1, 2.5 Hz, 
1H), 2.60 (mC, 1H), 2.24 (mC, 3H), 2.30−2.17 (m, 1H), 2.09−1.94 (m, 2H), 1.79−1.70 (m, 
2H), 1.15 (d, J = 7.1 Hz, 3H), 1.02 (t, J = 7.9 Hz, 9H), 0.62 (q, J = 7.9 Hz, 6H) ppm. 
  
13C NMR (C6D6, 100 MHz): δ = 150.6, 88.0, 61.3, 56.6, 37.6, 34.6, 31.2, 30.5, 15.7, 7.2, 
4.9 ppm.  
 
EI-MS for C13H24OISi+ [(M−C2H5)+]: calcd. 351.0636 
 found 351.0619. 
 
[ ]20Dα
I
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DMAP (20 mol-%)
DMF
0 °C to rt, 1h
(96%)
433
I
TESO
Me
437
C15H29IOSi
M = 380.38 g/mol
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IR (ATR): ῦ/cm−1 = 2951, 2909, 2872, 1648, 1457, 1412, 1374, 1282, 1237, 1183, 1137, 
1085, 1064, 1009, 987, 962, 941, 895, 875, 817, 790, 741, 724, 667. 
 
 = −48.4 (c 0.50, C6D6). 
 
Synthesis of Allylic Alcohol 478 
   
 
   
To a solution of vinyl iodide 437 (57.1 mg, 0.15 mmol, 1.3 eq.) in Et2O (6.0 mL) at −78 °C 
was slowly added t-BuLi (0.17 mL, 1.7 M solution in n–pentane, 0.29 mmol, 2.6 eq.) and the 
mixture was stirred for one hour at this temperature. Then, a solution of ketone 438 (31.7 mg, 
0.11 mmol, 1.0 eq.) in Et2O (2.5 mL) was added dropwise. The resulting mixture was stirred 
for one hour at −78 °C, at which point the reaction was quenched by the addition of half-
saturated aqueous NH4Cl (6 mL). The mixture was allowed to warm to room temperature and 
the phases were separated. The aqueous layer was extracted with Et2O (3 × 10 mL) and the 
combined organic layers were washed with saturated aqueous NaCl (10 mL). After drying 
over MgSO4, the solvents were evaporated under reduced pressure and the crude product was 
purified by flash column chromatography (silica, n-pentane:Et2O = 80:1 to 30:1) to yield the 
title compound 478 (28.2 mg, 0.53 mmol, 48%) as a colorless oil. 
 
Rf = 0.27 (i-Hex:EtOAc = 30:1). 
 
1H NMR (C6D6, 400 MHz): δ = 6.01 (ddd, J = 17.3, 10.2, 7.2 Hz, 1H), 5.09 (mC, 1H), 4.98 
(mC, 1H), 4.06 (s, 1H), 3.87−3.73 (m, 2H), 3.52−3.38 (m, 2H), 2.63 (mC, 1H), 2.45−2.23 (m, 
2H), 2.20−2.06 (m, 2H), 1.96−1.84 (m, 2H), 1.77 (dd, J = 12.3, 3.8 Hz, 1H), 1.73−1.67 (m, 
4H), 1.66−1.52 (m, 5H), 1.43–1.32 (m, 1H), 1.40 (d, J = 7.1 Hz, 3H), 1.27−1.16 (m, 1H), 1.11 
(s, 9H), 1.04−0.97 (m, 12H), 0.91 (d, J = 7.1 Hz, 3H), 0.70−0.60 (m, 6H) ppm. 
  
[ ]20Dα
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H
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13C NMR (C6D6, 100 MHz): δ = 145.8, 139.0, 136.4, 111.6, 81.2, 80.4, 72.2, 61.8, 47.5, 42.5, 
41.0, 39.7, 39.1, 37.8, 36.9, 34.3, 31.6, 31.0, 29.6, 28.5, 25.9, 17.6, 17.3, 15.2, 11.0, 6.6, 
4.1 ppm.  
 
EI-MS for C33H60O3Si+ [M+]: calcd. 532.4306 
 found 532.4308 
 
IR (ATR): ῦ/cm−1 = 3446, 3072, 2955, 2875, 1460, 1361, 1238, 1195, 1130, 1061, 1004, 906, 
802, 743.  
 
 = −8.0 (c 0.20, CH2Cl2). 
 
Synthesis of Diol 480 
   
 
   
To a solution of silyl ether 478 (21 mg, 39 µmol, 1.0 eq.) in a mixture of CH2Cl2 (11 mL) and 
MeOH (1.5 mL), PPTS (5.0 mg, 20 µmol, 0.5 eq.) was added in one portion and the resulting 
mixture was stirred for 90 min at this temperature. The reaction was quenched by the addition 
of saturated aqueous NaHCO3 (10 mL). The layers were separated and the aqueous phase was 
extracted with CH2Cl2 (3 × 10 mL). The combined organic layers were washed with saturated 
aqueous NaCl (10 mL), and dried over MgSO4. After evaporation of the solvents under 
reduced pressure and subsequent co-evaporation with benzene (3 × 3 mL), diol 480 (16 mg, 
38 µmol, 97%) was obtained as colorless oil, which requird no further purification. 
 
Rf = 0.23 (i-Hex:EtOAc = 7:1). 
 
1H NMR (C6D6, 400 MHz): δ = 5.97 (ddd, J = 17.3, 10.3, 6.7 Hz, 1H), 5.08 (mC, 1H), 4.98 
(mC, 1H), 3.87 (mC, 1H), 3.51 (mC, 1H), 3.46 (dd, J = 9.9, 5.2 Hz, 1H), 2.97 (dd, J = 11.8, 
9.9 Hz, 1H), 2.59 (mC, 1H), 2.35−2.07 (m, 4H), 1.99−1.80 (m, 2H), 1.79−1.51 (m, 7H), 1.66 
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(s, 3H), 1.44−1.30 (m, 2H), 1.27 (d, J = 7.0 Hz, 3H), 1.14 (s, 9H), 1.03 (s, 3H), 0.80 (d, 
J = 7.0 Hz, 3H) ppm. 
  
13C NMR (C6D6, 100 MHz): δ = 146.1, 138.1, 136.4, 111.6, 81.2, 81.1, 72.2, 59.8, 46.8, 43.0, 
41.4, 39.6, 39.4, 38.0, 36.7, 33.9, 32.1, 32.0, 29.9, 29.0, 26.3, 17.9, 16.2, 15.2, 11.5 ppm.  
 
EI-MS for C27H46O3+ [M+]: calcd. 418.3441 
 found 418.3442. 
 
IR (ATR): ῦ/cm−1 = 3279 , 2955, 2874, 1461, 1361, 1195, 1129, 1061, 906.  
 
 = +18.0 (c 0.50, CH2Cl2). 
 
Synthesis of Lactol 481 
   
 
    
To a solution of dry DMSO (24.1 µL, 0.34 mmol, 12 eq.) in CH2Cl2 (4.0 mL) was slowly 
added oxalyl chloride (90.0 µL, 2.0 M solution in CH2Cl2, 0.18 mmol, 6.0 eq.) at −78 °C and 
the resulting mixture was stirred for 15 min. Then, a solution of diol 480 (12.0 mg, 28.7 µmol, 
1.0 eq.) in CH2Cl2 (1.0 mL) was added and the mixture was stirred for two hours. 
Subsequently, DIPEA (125 µL, 696 µmol, 24 eq.) was added and the mixture was allowed to 
warm to 0 °C and. After being stirred for 30 min, the reaction was quenched by the addition 
of H2O (5 mL) and was then diluted with CH2Cl2 (5 mL). The layers were separated and the 
aqueous phase was extracted with CH2Cl2 (3 × 7 mL). The combined organic layers were 
washed with saturated aqueous NaCl (10 mL) and dried over MgSO4. Having evaporated the 
solvent under reduced pressure, the crude product was purified by flash column 
chromatography (silica, i-Hex:EtOAc = 7:1) to yield lactol 481 (7.0 mg, 17 µmol, 58%) as a 
colorless oil and as single diastereomer. The relative stereochemistry at the lactol moiety was 
not elucidated. 
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Rf = 0.23 (i-Hex:EtOAc = 7:1). 
 
1H NMR (C6D6, 400 MHz): δ = 5.83 (mC, 1H), 4.97 (mC, 1H), 4.89 (mC, 1H), 4.81 (dd, 
J = 7.7 Hz, 1H), 3.51 (mC, 1H), 2.43 (mC, 1H), 2.32 (mC, 1H), 2.20−2.05 (m, 2H), 2.01−1.89 
(m, 3H), 1.76−1.43 (m, 11H), 1.38−1.25 (m, 2H), 1.19 (d, J = 6.9 Hz, 3H), 1.13 (s, 9H), 0.98 
(s, 3H), 0.77 (d, J = 7.1 Hz, 3H) ppm. 
  
13C NMR (C6D6, 100 MHz): δ = 145.4, 134.9, 130.4, 111.9, 94.5, 84.2, 81.2, 72.2, 50.4, 42.9, 
40.8, 39.4, 39.1, 36.7, 34.9, 34.1, 32.5, 32.0, 29.0, 27.6, 26.2, 15.7, 15.3, 14.3, 11.3 ppm.  
 
EI-MS for C27H44O3+ [M+]: calcd. 416.3285 
 found 416.3291. 
 
IR (ATR): ῦ/cm−1 = 3432, 3074, 2969, 2955, 2869, 1460, 1388, 1375, 1361, 1254, 1192, 
1132, 1061, 907.  
 
 = +12.8 (c 0.25, CH2Cl2). 
 
Synthesis of Triene 479 
    
 
    
To a solution of vinyl iodide 410 (48.0 mg, 18.4 µmol, 1.4 eq.) in Et2O (3.4 mL) was added 
t-BuLi (195 µL, 1.8 M solution in n-pentane, 34.2 µmol, 2.6 eq.) at −78 °C and the resulting 
mixture was stirred for 45 min. Then, a solution of ketone 438 (36.6 mg, 13.2 µmol, 1.0 eq.) 
in Et2O (1.6 mL) was added dropwise over a period of 20 min. The reaction was stirred for an 
additional 90 min and was then quenched by the addition of half-saturated aqueous NH4Cl 
(8 mL). The mixture was allowed to warm to room temperature and was extracted with 
diethyl ether (3 × 25 mL). The combined organic layers were washed with saturated aqueous 
NaCl (20 mL) and dried over Na2SO4. The solvents were evaporated under reduced 
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pressure and the crude product was purified by flash column chromatography (silica, 
n-pentane:Et2O = 98:1) to yield the title compound (479, 46.0 mg, 11.1 µmol, 84%) as a 
colorless solid and as an inseparable mixture 10:1 mixture of diastereomers, originating from 
the moderate enantiomeric excess of vinyl iodide 410.  
 
Crystals suitable for X-ray analysis were grown from slow evaporation of a solution of triene 
479 in MeOH/Et2O/n-pentane. 
 
Rf = 0.69 (i-Hex:EtOAc = 10:1). 
 
Melting point = 113.5−114.5 °C (MeOH/n-pentane/Et2O). 
 
1H NMR (C6D6, 400 MHz, only major isomer quoted): δ = 5.87 (mC, 1H), 5.77 (mC, 1H), 
5.09−4.98 (m, 3H), 4.93 (mC, 1H), 4.04 (mC, 1H), 3.46 (mC, 1H), 2.43−2.36 (m, 2H), 
2.25−2.19 (m, 2H), 2.15−2.07 (m, 2H), 1.98−1.80 (m, 2H), 1.71−1.48 (m, 10H), 1.37−1.29 
(m, 1H), 1.21−1.10 (m, 13H), 0.98 (s, 3H), 0.90 (d, J = 6.9 Hz, 3H) ppm. 
  
13C NMR (C6D6, 100 MHz, only major isomer quoted): δ = 145.5, 141.4, 139.6, 134.5, 115.7, 
112.0, 82.5, 81.2, 72.2, 51.5, 43.0, 41.2, 40.0, 39.0, 38.0, 36.9, 33.9, 33.2, 32.0, 30.1, 29.0, 
26.2, 17.7, 16.5, 16.2, 11.4 ppm.  
 
EI-MS for C28H46O2+ [M+]: calcd. 414.3492 
 found 414.3477. 
 
IR (ATR): ῦ/cm−1 = 3583, 3073, 2970, 2955, 2870, 1636, 1459, 1388, 1375, 1361, 1254, 
1197, 1127, 1063, 1001, 907.  
 
Since the product was isolated as a mixture of diastereomers, the optical rotation of the 
product mixture was not determined. 
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Synthesis of Tricycle 484 
   
 
   
To a solution of triene 479 (4.0 mg, 9.7 µmol, 1.0 eq.) in degassed benzene (12 mL) was 
added Grubbs second-generation catalyst (267, 1.2 mg, 1.5 µmol, 15 mol-%). The mixture 
was placed in an oil bath (pre-heated to 85 °C) and stirred at this temperature for one hour, 
before being allowed to cool to room temperature. The solvent was evaporated under reduced 
pressure and the obtained crude product was purified by flash column chromatography (silica, 
deactivated with NEt3, n-pentane:Et2O = 24:1 to 23:2) to yield the cyclized product 484 
(1.7 mg, 5.8 µmol, 60%) as a colorless oil. 
Note: This material decomposes in CDCl3 by time. Measurement in C6D6 is recommended. 
 
Rf = 0.39 (i-Hex:EtOAc = 50:3). 
 
1H NMR (C6D6, 400 MHz): δ = 5.24–5.23 (mC, 1H), 3.48 (dd, J = 8.9, 7.1 Hz, 1H), 2.31–2.15 
(m, 2H), 1.97–1.88 (m, 1H), 1.79 (dd, J = 11.0, 2.4 Hz, 1H), 1.70 (dd, J = 12.2, 3.5 Hz, 1H), 
1.67–1.60 (m, 1H), 1.63 (dd, J = 2.4, 1.7 Hz, 3H), 1.43–1.20 (m, 4H), 1.12 (s, 9H), 0.97–0.93 
(m, 6H), 0.47 (s, br, 1H) ppm. 
 
13C NMR (C6D6, 100 MHz): δ = 146.2, 135.4, 83.4, 80.3, 72.2, 54.2, 44.2, 39.8, 38.7, 34.0, 
33.7, 32.5, 29.0, 26.1, 17.2, 12.3, 12.0 ppm.  
 
EI-MS for C19H32O2+ [M+]: calcd. 292.2397 
 found 292.2393. 
 
IR (ATR): ῦ/cm−1 = 3472, 2953, 2923, 2868, 2851, 1740, 1444, 1387, 1373, 1361, 1260, 
1196, 1117, 1094, 1063, 1033, 998, 980, 946, 924, 915, 863, 849, 802, 729.  
 
 = +40.0 (c 0.10, CH2Cl2). 
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Synthesis of Wittig Salt 500 
   
 
   
To a solution of PPh3 (15.7 g, 59.9 mmol, 1.2 eq.) and imidazole (4.08 g, 59.9 mmol, 1.2 eq.) 
in CH2Cl2 (100 mL) was added I2 (15.2 g, 59.9 mmol, 1.2 eq.) in portions at 0 °C over 10 min 
and the resulting solution was stirred for an additional 15 min. Subsequently, 5-hexen-1-ol 
(501, 5.00 g, 49.9 mmol, 1.0 eq.) was added dropwise over a period of 5 min. The resulting 
mixture was warmed to room temperature and stirred for 2.5 hours. After filtration over a 
pad of Celite® (n-pentane washings) the solvents were removed under reduced pressure 
(min. 500 mbar). The crude product was purified by flash column chromatography (silica, 
n-pentane) and the product containing fractions were carefully concentrated under reduced 
pressure (min. 100 mbar) to yield iodide 502 (9.54 g, 4.54 mmol, 91%) as colorless oil. 
 
Rf = 0.92 (n-pentane:Et2O = 25:1). 
 
1H NMR (C6D6, 400 MHz): δ = 5.58 (ddt, J = 17.6, 9.7, 6.7 Hz, 1H), 4.97–4.84 (m, 2H), 2.68 
(t, J = 7.0 Hz, 2H), 1.75 (mC, 2H), 1.47–1.34 (m, 2H), 1.19–1.08 (m, 2H) ppm. 
 
13C NMR (C6D6, 100 MHz): δ = 138.3, 115.1, 33.1, 32.9, 29.8, 6.5 ppm.  
 
EI-MS for C6H11I+ [M+]: calcd. 209.9900 
 found 209.9904. 
 
IR (ATR): ῦ/cm−1 = 3075, 2997, 2975, 2930, 2854, 1930, 1640, 1453, 1426, 1349, 1281, 
1246, 1214, 1173, 1080, 988, 910, 854, 788, 735, 724. 
 
To a solution of PPh3 (3.56 g, 13.6 mmol, 0.95 eq.) in benzene (20 mL) was added iodide 502 
(3.00 g, 14.3 mmol, 1.0 eq.) and the mixture was heated in a pressure tube at 105 °C for  
11 hours. After cooling to room temperature, the precipitate was filtered of and washed with 
benzene. Recrystallization (CH2Cl2/benzene) afforded Wittig salt 500 (5.58 g, 11.8 mmol, 
87%) as colorless solid. 
HO
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Melting point = 167.3−169.2 °C (CH2Cl2/benzene). 
 
1H NMR (CDCl3, 400 MHz): δ = 7.85–7.73 (m, 9H), 7.74–7.63 (m, 6H), 5.65 (ddt, J = 16.9, 
10.2, 6.7 Hz, 1H), 4.97–4.81 (m, 2H), 3.63 (mC, 2H), 2.04 (q, J = 7.0 Hz, 2H), 1.80–1.69 (m, 
2H), 1.69–1.53 (m, 2H) ppm. 
  
13C NMR (CDCl3, 100 MHz): δ = 137.5, 135.2, 135.2, 133.7, 133.6, 130.7, 130.5, 118.4, 
117.6, 115.4, 32.9, 29.3, 29.1, 23.2, 22.7, 21.8, 21.7 ppm.  
 
ESI-MS for C24H26P+ [M+]: calcd. 345.17666 
 found 345.17619. 
 
IR (ATR): ῦ/cm−1 = 3040, 3010, 2989, 2889, 2863, 2798, 1640, 1585, 1485, 1438, 1413, 
1344, 1332, 1316, 1261, 1242, 1191, 1171, 1162, 1113, 1027, 995, 918, 888, 856, 810, 788, 
761, 744, 737, 722, 699, 688. 
 
Synthesis of Triene 503 
   
 
   
To a solution of dry DMSO (63.9 µL, 900 µmol, 8.0 eq.) in CH2Cl2 (1.5 mL) was slowly 
added oxalyl chloride (394 µL, 2.0 M solution in CH2Cl2, 788 µmol, 7.9 eq.) at −78 °C and 
the mixture was stirred for 15 min. Then, a solution of alcohol 433 (30.0 mg, 107 µmol, 
1.0 eq.) in CH2Cl2 (0.3 mL) was added dropwise and the reaction was stirred for an additional 
2 hours before adding Et3N (220 µL, 1.60 mmol, 14 eq.). The solution was allowed to warm 
to 0 °C over a period of 60 min and was then quenched by the addition of aqueous phosphate 
buffer (5.0 mL, 2 M, pH = 6.3). The layers were separated, the aqueous layer was extracted 
with n-pentane (3 × 50 mL) and the combined organic layers were washed with saturated 
aqueous phosphate buffer (10 mL, 2 M, pH = 6.3). After drying over Na2SO4, the solvents 
were carefully removed under reduced pressure and the crude product was purified by quick 
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flash column chromatography (silica, n-pentane:Et2O = 9:1) to yield aldehyde 436 as a yellow 
oil, which was immediately used in the next step.  
To a suspension of Wittig salt 500 (320 mg, 678 µmol, 6.0 eq.) in THF (4 mL) was slowly 
added n-BuLi (196 µL, 2.86 M solution in hexanes, 560 µmol, 5.0 eq.) at 0 °C. The resulting 
red solution was allowed to warm to room temperature and stirred for 60 min, before being 
cooled to −78 °C. Then, a solution of aldehyde 436 (assumed 110 µmol, 1.0 eq.) in THF 
(1 mL) was added slowly. The cold bath was replaced by an ice/water bath and the mixture 
was stirred for additional 60 min at 0 °C, prior to quenching the reaction by the addition of 
half-saturated aqueous NH4Cl (15 mL). The layers were separated and the aqueous phase was 
extracted with n-pentane (3 × 50 mL). The combined organic layers were washed with 
saturated aqueous NaCl (25 mL) and dried over Na2SO4. Having carefully removed the 
solvents under reduced pressure, the crude product was purified by flash column 
chromatography (silica, n-pentane) to yield triene 503 (29.9 mg, 90.4 µmol, 80% over two 
steps) as colorless oil and as inseparable mixture of double bond isomers (E:Z = 19:1).  
 
Rf = 0.95 (i-Hex:EtOAc = 20:1). 
 
1H NMR (C6D6, 400 MHz, only major isomer quoted): δ = 5.83 (ddt, J = 16.9, 10.1, 6.6 Hz, 
1H), 5.59–5.48 (m, 1H), 5.16–4.89 (m, 3H), 3.45 (dd, J = 10.9, 6.8 Hz, 1H), 2.42–2.27 (m, 
1H), 2.26–1.93 (m, 5H), 2.20 (mC, 3 H), 1.88 (mC, 1H), 1.75–1.39 (m, 3H), 1.41–1.21 (m, 
1H), 0.88 (d, J = 6.8 Hz, 3H) ppm. 
 
13C NMR (C6D6, 100 MHz, only major isomer quoted): δ = 150.8, 139.1, 131.5, 125.0, 114.8, 
87.9, 54.7, 38.8, 34.2, 33.5, 30.5, 30.4, 29.7, 28.3, 15.9 ppm.  
 
EI-MS for C15H23I+ [M+]: calcd. 330.0839. 
 found 330.0846. 
 
IR (ATR): ῦ/cm−1 = 3073, 3003, 2923, 2868, 1640, 1451, 1431, 1374, 1347, 1311, 1285, 
1247, 1176, 1130, 1096, 1055, 986, 964, 908, 869, 799, 728, 675. 
 
 = −35.6 (c 0.50, CH2Cl2). 
 
 
[ ]20Dα
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Synthesis of Tetraene 504 
   
 
    
To a solution of alkenyl iodide 503 (20.0 mg, 60.5 µmol, 1.4 eq.) in Et2O (1.4 mL) at −78 °C 
was added t-BuLi (68.0 µL, 1.65 M solution in n-pentane, 112 µmol, 2.6 eq.) and the resulting 
mixture was stirred for 45 min. Then, a solution of ketone 438 (12 mg, 43.2 µmol, 1.0 eq.) in 
Et2O (1.0 mL) was added dropwise. The mixture was stirred for an additional 45 min and the 
reaction was quenched by the addition of half-saturated aqueous NH4Cl (10 mL). The mixture 
was allowed to warm to room temperature and was extracted with Et2O (3 × 25 mL). The 
combined organic layers were washed with saturated aqueous NaCl (10 mL) and dried over 
Na2SO4. The solvents were evaporated under reduced pressure and the crude product was 
purified by flash column chromatography (silica, n-pentane:Et2O = 200:1 to 100:1) to yield 
the title compound (504, 17.9 mg, 37.1 µmol, 86%) as a colorless solid and as an inseparable 
87:13 mixture of diastereomers, originating from the moderate enantiomeric excess of vinyl 
iodide 503.  
 
Crystals suitable for X-ray analysis were grown by slow evaporation of a solution of tetraene 
504 in n-pentane/MeOH. 
 
Rf = 0.72 (i-Hex:EtOAc = 25:1). 
 
Melting point = 86.2–88.7 °C (n-pentane/MeOH). 
 
1H NMR (C6D6, 400 MHz, only major isomer quoted): δ = 5.89 (ddt, J = 17.2, 10.3, 6.9 Hz, 
1H), 5.74 (ddt, J = 16.9, 10.1, 6.7 Hz, 1H), 5.47–5.37 (m, 1H), 5.28–5.14 (m, 1H), 5.11–4.88 
(m, 4H), 4.35 (dd, J = 10.8, 6.6 Hz, 1H), 3.41 (dd, J = 8.9, 7.3 Hz, 1H), 2.51–2.38 (m, 2H), 
2.36–2.04 (m, 6H), 2.04–1.81 (m, 4H), 1.78–1.63 (m, 3H), 1.66–1.39 (m, 6H), 1.59 (s, 3H), 
1.40–1.13 (m, 2H), 1.18 (d, J = 6.9 Hz, 3H), 1.10 (s, 9H), 1.03–0.89 (m, 6H) ppm. 
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13C NMR (C6D6, 100 MHz, only major isomer quoted): δ = 145.6, 141.1, 138.8, 133.4, 131.1, 
130.6, 114.8, 112.0, 82.4, 81.1, 72.2, 45.7, 43.0, 41.1, 40.9, 38.9, 38.1, 36.9, 34.0 (2C), 33.3, 
32.0, 30.7, 29.5, 28.9, 27.8, 26.2, 17.9, 16.6, 16.2, 11.4 ppm.  
 
EI-MS for C33H54O2+ [M+]: calcd. 482.4118 
 found 482.4130. 
 
IR (ATR): ῦ/cm−1 = 3564, 3080, 2969, 2927, 2869, 1633, 1454, 1409, 1386, 1360, 1265, 
1252, 1195, 1144, 1124, 1095, 1063, 1039, 1011, 1000, 945, 921, 907, 874, 865, 806, 722, 
695.  
 
Since the product was isolated as a mixture of diastereomers, the optical rotation of the 
product mixture was not determined. 
 
Synthesis of Homodimer 505 
   
 
   
Tetraene 504 (2.0 mg, 4.14 µmol, 1.0 eq.) was dissolved in benzene (6.7 mL) and the 
resulting solution was degassed (3 × freeze-pump-thaw). Then, catalyst 506 (0.3 mg, 
0.41 µmol, 5 mol-%) was added and the mixture was heated to 85 °C for 3 hours. After 
addition of a second batch of catalyst 506 (0.3 mg, 0.41 µmol, 5 mol-%), heating was 
continued for another 2 hours, before the reaction mixture was cooled to room temperature 
and concentrated in vacuo. The crude product was purified by flash column chromatography 
(silica, n-pentane:Et2O = 500:1) to yield the title compound (505, 1.2 mg, 1.28 µmol, 31%) as 
a colorless wax and as a single diastereomer.  
 
Rf = 0.66 (i-Hex:EtOAc = 25:1). 
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1H NMR (C6D6, 400 MHz): δ = 5.89 (ddd, J = 17.1, 10.3, 6.8 Hz, 2H), 5.51–5.37 (m, 4H), 
5.29–5.17 (m, 2H), 5.11–4.93 (m, 4H), 4.39–4.33 (m, 2H), 3.50–3.38 (m, 2H), 2.47– 2.43 (m, 
2H), 2.37–2.22 (m, 8H), 2.16–2.07 (m, 4H), 2.04–1.87 (m, 8H), 1.76–1.65 (m, 6H), 1.64–1.50 
(m, 8H), 1.59 (s, 6H), 1.50–1.42 (m, 4H), 1.41–1.25 (m, 4H), 1.20 (d, J = 7.0 Hz, 6H),  
1.14–1.11 (m, 18H), 1.00 (s, 12H) ppm. 
 
13C NMR (C6D6, 100 MHz): δ = 145.6, 141.2, 133.3, 131.3, 130.6, 130.5, 112.0, 82.4, 81.1, 
72.2, 45.7, 43.0, 41.1, 41.0, 38.9, 38.7, 38.1, 36.8, 33.9, 33.3, 32.9, 32.0, 30.7, 30.2, 29.0, 
27.9, 26.2, 18.0, 16.6, 16.3, 11.4 ppm. 
 
ESI-MS for C64H104ClO4− [(M+Cl)−]: calcd. 971.7623 
 found 971.7619. 
 
IR (ATR): ῦ/cm−1 = 3567, 3075, 2955, 2870, 1457, 1388, 1373, 1361, 1318, 1261, 1231, 
1196, 1127, 1098, 1062, 1008, 970, 945, 905, 875, 856, 802, 734, 663. 
 
 = −101 (c 0.08, C6D6). 
 
Synthesis of Epoxide 508 
   
 
   
To a solution of triene 479 (29 mg, 70 µmol, 1.0 eq.) in CH2Cl2 (8.1 mL) at 0 °C was slowly 
added m-CPBA (524 µL, 0.2 M solution in CH2Cl2, 105 µmol, 1.5 eq.). The mixture was 
stirred for 45 min at this temperature and an additional 3 hours at room temperature. The 
reaction was quenched by the addition of saturated aqueous NaHCO3 (10 mL) and the layers 
were separated. The aqueous phase was extracted with CH2Cl2 (3 × 10 mL) and the combined 
organic layers were consecutively washed with saturated aqueous K2CO3 (10 mL), saturated 
aqueous NaCl (10 mL) and dried over Na2SO4. Having evaporated the solvents under reduced 
pressure, the crude product was purified by flash column chromatography (silica, 
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n-pentane:Et2O = 20:1 to 10:1) to yield epoxide 508 (22 mg, 50 µmol, 72%) as colorless solid 
and as single diastereomer. 
 
Crystals suitable for X-ray analysis were grown from slow evaporation of a solution of 
epoxide 508 in n-pentane/Et2O/MeOH. 
 
Rf = 0.31 (i-Hex:EtOAc = 10:1). 
 
Melting point = 132.2−135.3 °C (n-pentane/Et2O/MeOH).  
 
1H NMR (C6D6, 400 MHz): δ = 5.85 (mC, 1H), 5.41 (mC, 1H), 5.07−4.91 (m, 4H), 3.41 (mC, 
1H), 2.74 (dd, J = 10.2, 5.6 Hz, 1H), 2.49−2.36 (m, 2H), 2.10−2.01 (m, 1H), 1.98−1.73 (m, 
5H), 1.73−1.55 (m, 4H), 1.53−1.38 (m, 2H), 1.32 (mC, 1H), 1.24 (s, 3H), 1.12 (s, 9H), 1.08 (d, 
J = 6.9 Hz, 3H), 1.10−1.02 (m, 1H), 0.92 (s, 3H), 0.91 (d, J = 7.0 Hz, 3H) ppm. 
  
13C NMR (C6D6, 100 MHz): δ = 145.4, 134.8, 118.0, 111.8, 81.1, 79.7, 77.8, 72.2, 69.5, 
55.3, 42.9, 39.4, 38.7, 38.5, 35.6, 35.3, 34.0, 33.0, 31.9, 28.9, 28.3, 26.1, 19.9, 17.2, 16.3, 
11.3 ppm.  
 
EI-MS for C28H46O3+ [M+]: calcd. 430.3441 
 found 430.3434. 
 
IR (ATR): ῦ/cm−1 = 3562, 3478, 2073, 2969, 2870, 1636, 1462, 1374, 1361, 1197, 1130, 
1064, 992, 907.  
 
 = +36.4 (c 0.50, C6D6). 
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Synthesis of Tetracycle 509 
   
 
   
To a solution of diene 508 (17 mg, 40 µmol, 1.0 eq.) in degassed benzene (48 mL) was added 
Grubbs second-generation catalyst (267, 5.0 mg, 5.9 µmol, 15 mol-%). The mixture was 
placed in an oil bath (pre-heated to 85 °C) and stirred for 2 hours, before being allowed  
to cool to room temperature. The solvent was evaporated under reduced pressure  
and the obtained crude product was purified by flash column chromatography (silica, 
n-pentane:Et2O = 20:1) to yield the cyclized product (509, 15.6 mg, 39 µmol, 98%) as a 
colorless, fluffy solid. 
Note: This material decomposes in CDCl3 by time. Measurement in C6D6 is recommended. 
 
Rf = 0.48 (i-Hex:EtOAc = 10:1). 
 
Melting point = 54.0−55.5 °C (Et2O/n-pentane). 
 
1H NMR (CDCl3, 400 MHz): δ = 5.44 (dd, J = 10.9, 7.8 Hz, 1H), 5.34 (mC, 1H), 3.45 (mC, 
1H), 3.19 (mC, 1H), 2.89 (mC, 1H), 2.73 (s, 1H), 2.40−2.31 (m, 1H), 2.27 (mC, 1H), 1.99−1.83 
(m, 2H), 1.89 (dd, J = 13.0, 13.0 Hz, 1H), 1.80 (dd, J = 12.7, 5.1 Hz, 1H), 1.75−1.58 (m, 2H), 
1.56−1.40 (m, 4H), 1.40−1.22 (m, 2H), 1.26 (s, 3H), 1.14 (s, 9H), 1.03 (mC, 1H), 1.01 (d, 
J = 6.8 Hz, 3H), 0.94 (d, J = 6.9 Hz, 3H), 0.69 (s, 3H) ppm. 
  
13C NMR (CDCl3, 100 MHz): δ = 141.1, 128.0, 84.6, 81.1, 76.1, 72.5, 66.8, 46.4, 42.0, 40.5, 
39.8, 38.4, 37.7, 35.0, 33.0, 32.4, 31.2, 28.9, 27.5, 25.5, 20.9, 17.0, 16.4, 10.7 ppm.  
 
EI-MS for C26H42O3+ [M+]: calcd. 402.3128 
 found 402.3127. 
 
IR (ATR): ῦ/cm−1 = 3480, 3007, 2968, 2871, 1460, 1376, 1361, 1235, 1196, 1150, 1134, 
1092, 1072, 1007, 987.  
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 = +1.2 (c 0.33, CH2Cl2). 
 
Synthesis of Tetracycle 510 
   
 
    
To a solution of alkene 509 (3.3 mg, 8.2 µmol, 1.0 eq.) in MeOH (2.5 mL) was added Pd/C 
(10 wt-% Pd, 2.1 mg, 1.6 µmol, 20 mol-%) and the resulting suspension was stirred under an 
atmosphere of H2 for 3 hours. The mixture was filtered over a pad of Celite® (Et2O washings) 
and the solvent was evaporated under reduced pressure. The crude product was purified by 
flash column chromatography (silica, n-pentane:Et2O = 15:1) to yield tetracylce 510 (2.7 mg, 
6.7 µmol, 82%) as colorless oil. 
Note: Substrate 509 and product 510 behaved co-polar at TLC analysis. 
 
Rf = 0.48 (i-Hex:EtOAc = 10:1). 
 
1H NMR (C6D6, 400 MHz): δ = 3.36 (mC, 1H), 2.68−2.58 (m, 1H), 2.47−2.37 (m, 1H), 2.31 
(s, 1H), 2.03−1.69 (m, 7H), 1.67−1.57 (m, 1H), 1.55-1.37 (m, 4H), 1.37−1.17 (m, 5H), 1.19 
(s, 3H), 1.16–1.05 (m, 1H), 1.11 (s, 9H), 1.00 (d, J = 7.1 Hz, 3H), 0.99−0.89 (m, 1H), 0.92 (s, 
3H), 0.87 (d, J = 6.8 Hz, 3H) ppm. 
  
13C NMR (C6D6, 100 MHz): δ = 81.1, 78.6, 75.2, 72.2, 67.2, 43.0, 42.8, 42.6, 40.0, 38.0, 37.8, 
36.4, 35.5, 32.6, 32.5, 31.9, 28.9, 27.0, 25.9, 25.2, 23.5, 16.4, 15.2, 11.4 ppm.  
 
EI-MS for C26H44O3+ [M+]: calcd. 404.3285 
 found 404.3292. 
 
IR (ATR): ῦ/cm−1 = 3489, 2969, 2872, 1461, 1374, 1361, 1197, 1067.  
 
 = +28.0 (c 0.10, CH2Cl2). 
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Synthesis of Diol 511 
   
 
   
A sample of epoxide 510 was dissolved in CDCl3 and NMR spectra were recorded 
immediately. The NMR analysis showed complete conversion to tetracycle 511. This 
compound slowly reacted further in the NMR solvent to a mixture of unknown compounds. 
Thus, no further analytical data could be determined. 
 
1H NMR (CDCl3, 400 MHz): δ = 5.18 (s, 1H), 4.98 (s, 1H), 3.46 (mC, 1H), 2.82−2.64 (m, 
2H), 2.31 (mC, 1H), 2.09 (mC, 1H), 1.97−1.85 (m, 3H), 1.85−1.70 (m, 3H), 1.68-1.61 (m, 1H), 
1.59−1.39 (m 7H), 1.38−1.18 (m, 2H), 1.17−1.08 (m, 1H), 1.14 (s, 9H), 1.05−0.98 (m, 1H), 
0.96−0.85 (m, 1H), 0.93 (d, J = 6.7 Hz, 3H), 0.88 (d, J = 6.9 Hz, 3H), 0.78 (s, 3H) ppm. 
  
13C NMR (CDCl3, 100 MHz): δ = 160.6, 110.5, 87.9, 80.9, 79.4, 72.4, 51.7, 46.5, 45.2, 42.6, 
38.7, 38.5, 35.2, 34.5(2), 31.5, 30.7, 28.9, 27.4, 25.5, 24.8, 23.5, 15.7, 11.1 ppm.  
 
Synthesis of Epoxide 514 
   
 
   
To a solution of vinyl iodide 410 (56 mg, 0.21 mmol, 2.2 eq.) in Et2O (3.6 mL) was slowly 
added t-BuLi (0.25 mL, 1.7 M solution in n-pentane, 0.42 mmol, 4.4 eq.) at −78 °C and the 
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resulting mixture was stirred for 45 min at this temperature. Then, a solution of ketone 477 
(38 mg, 0.10 mmol, 1.0 eq.) in Et2O (1.4 mL) was added within 30 min and stirring was 
continued for an additional 45 min. The reaction was quenched by the addition of half-
saturated aqueous NH4Cl (10 mL) and was then allowed to warm to room temperature. The 
phases were separated and the aqueous layer was extracted with Et2O (3 × 75 mL). The 
combined organic layers were washed with saturated aqueous NaCl (10 mL) and dried over 
Na2SO4. The solvents were carefully removed under reduced pressure (min. 500 mbar) 
and the crude product was purified by flash column chromatography (silica, 
n-pentane:Et2O = 97:3). The solvents of the product containing fractions were carefully 
removed under reduced pressure (min. 300 mbar) and the obtained addition product 513 was 
immediately used in the next step. 
To a solution of triene 513 (41 mg, assumed 77 µmol, 1.0 eq.) in CH2Cl2 (8.9 mL) was added 
m-CPBA (0.80 mL, 0.2 M solution in CH2Cl2, 0.16 mmol, 2.0 eq.) and the mixture was stirred 
for 90 min at room temperature, at which point additional m-CPBA (0.40 mL, 0.2 M solution 
in CH2Cl2, 80 µmol, 1.0 eq.) was added. Stirring was continued for one hour and the reaction 
was then quenched by the addition of saturated aqueous NaHCO3 (10 mL). The phases were 
separated and the aqueous layer was extracted with CH2Cl2 (3 × 50 mL). The combined 
organic layers were consecutively washed with saturated aqueous K2CO3 (10 mL), saturated 
aqueous NaCl (10 mL) and dried over Na2SO4. The solvents were evaporated under reduced 
pressure and the crude product was purified by flash column chromatography (silica, 
n-pentane:Et2O = 23:2 to 9:1) to yield epoxide 514 (38 mg, 69 µmol, 71% over two steps) as 
colorless oil and as a single diastereomer. 
 
Rf = 0.33 (i-Hex:EtOAc = 10:1). 
 
1H NMR (C6D6, 400 MHz): δ = 5.82 (mC, 1H), 5.38 (mC, 1H), 5.04−4.93 (m, 4H), 4.78 (d, 
J = 7.0 Hz, 1H), 4.73 (d, J = 6.9 Hz, 1H), 4.37 (mC, 1H), 3.79 (mC, 1H), 3.71 (mC, 1H), 2.68 
(dd, J = 10.3, 5.8 Hz, 1H), 2.48 (mC, 1H), 2.45−2.33 (m, 2H), 2.15 (dd, J = 11.5, 7.0 Hz, 1H), 
2.09−1.97 (m, 2H), 1.97−1.80 (m, 3H), 1.74−1.57 (m, 3H), 1.53 (mC, 2H), 1.45 (mC, 1H), 
1.32 (dd, J = 12.3, 3.8 Hz, 1H), 1.24 (s, 3H), 1.10 (d, J = 6.8 Hz, 3H), 1.07−0.96 (m, 3H), 
1.02 (d, J = 6.3 Hz, 3H), 0.99 (d, J = 6.9 Hz, 3H), 0.92 (d, J = 6.9 Hz, 3H), 0.77 (s, 3H), 0.02 
(s, 9H) ppm. 
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13C NMR (C6D6, 100 MHz) δ = 145.4, 134.6, 118.0, 111.8, 93.7, 81.9, 79.7, 77.9, 69.5, 65.3, 
55.2, 55.0, 43.0, 41.7, 38.8, 38.4, 36.9, 35.6, 33.8, 33.1, 29.9, 28.3, 24.8, 22.7, 22.1, 19.9, 
19.8, 18.4, 17.0, 16.3, −1.3 ppm.  
 
ESI-MS for C33H62O4NSi+ [(M+NH4)+]: calcd. 546.4443 
 found 546.4445. 
 
IR (ATR): ῦ/cm−1 = 3575, 3248, 3079, 2967, 2871, 1697, 1634, 1460, 1412, 1387, 1370, 
1362, 1263, 1197, 1160, 1126, 1099, 1066, 1033, 1014, 1000, 992, 948, 924, 905, 874, 857, 
815, 755, 703, 678. 
 
 = −3.0 (c 1.00, C6D6). 
 
Synthesis of Tetracycle 515 
   
 
   
To a solution of diene 514 (40.4 mg, 73.9 µmol, 1.0 eq.) in degassed benzene (116 mL) was 
added a solution of Grubbs second-generation catalyst (267, 8.3 mg, 9.7 µmol, 15 mol-%) in 
degassed benzene (1.0 mL). The mixture was placed in an oil bath (pre-heated to 85 °C) and 
stirred at this temperature for 3 hours, before being allowed to cool to room temperature. The 
solvent was evaporated under reduced pressure and the obtained crude product was purified 
by flash column chromatography (silica, n-pentane:Et2O = 93:7) to yield the cyclized product 
515 (36.2 mg, 69.8 µmol, 94%) as colorless needles. 
Note: Substrate 514 and product 515 behaved almost co-polar at TLC analysis. However, the 
product appears less intense blue when staining the TLC plate with PAA. 
 
Crystals suitable for X-ray analysis were obtained by slow evaporation of a solution of alkene 
515 in n-pentane/MeOH. 
 
Rf = 0.33 (i-Hex:EtOAc = 10:1). 
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Melting point = 122.1–122.9 °C (n-pentane/MeOH). 
 
1H NMR (C6D6, 400 MHz): δ = 5.45−5.30 (m, 2H), 4.77 (d, J = 6.9 Hz, 1H), 4.73 (d, 
J = 7.0 Hz, 1H), 4.33 (mC, 1H), 3.82−3.67 (m, 2H), 3.43 (mC, 1H), 3.20 (mC, 1H), 2.88 (d, 
J = 1.4 Hz, 1H), 2.63 (mC, 1H), 2.33−2.21 (m, 1H), 2.19−2.01 (m, 3H), 1.95 (ddd, J = 10.3, 
10.3, 4.4 Hz, 1H), 1.87−1.72 (m, 3H), 1.70−1.52 (m, 3H), 1.51−1.36 (m, 3H), 1.20 (s, 3H), 
1.10 (d, J = 6.6 Hz, 3H), 1.06−1.00 (m, 2H), 0.96 (d, J = 6.3 Hz, 3H), 0.95−0.90 (m, 6H), 
0.71 (s, 3H), 0.02 (s, 9H) ppm. 
 
13C NMR (C6D6, 100 MHz) δ = 141.4, 128.1 (obscured by residual solvent), 93.8, 84.6, 81.9, 
76.4, 66.4, 65.3, 54.8, 48.7, 46.6, 43.5, 42.1, 41.3, 39.7, 37.1, 35.1, 33.3, 32.4, 30.0, 27.6, 
24.6, 22.3, 21.0, 19.9, 18.4, 17.1, 16.4, −1.3 ppm.  
 
EI-MS for C31H54O4Si+ [M+]: calcd. 518.3786 
 found 518.3770. 
 
IR (ATR): ῦ/cm−1 = 3480, 2951, 1459, 1377, 1248, 1101, 1057, 937, 860.  
 
 = +6.4 (c 0.25, C6D6). 
 
Synthesis of Tetracycle 522 
   
 
   
To a solution of alkene 515 (36.2 mg, 69.8 µmol, 1.0 eq.) in MeOH (80 mL) was added Pd/C 
(10 wt-% Pd, 268 mg, 209 µmol, 3.0 eq.) and the suspension was stirred under an atmosphere 
of H2 for 75 min. The mixture was filtered over a pad of Celite® (Et2O washings) and the 
solvent was evaporated under reduced pressure. The crude product was purified by flash 
column chromatography (silica, n-pentane:Et2O =93:7) to yield substance 522 (30.9 mg, 
59.3 µmol, 85%) as colorless solid. 
Note: Substrate 515 and product 522 behave co-polar at TLC analysis. 
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Crystals suitable for X-ray analysis were obtained by slow evaporation of a solution of 522 in 
n-pentane/MeOH. 
 
Rf = 0.81 (n-pentane:Et2O = 1:3). 
 
Melting point = 120.1−121.3 °C (n-pentane/MeOH). 
 
1H NMR (C6D6, 400 MHz): δ = 4.78 (d, J = 7.0 Hz, 1H), 4.73 (d, J = 7.0 Hz, 1H), 4.38–4.33 
(mC, 1H), 3.84–3.64 (m, 2H), 2.70–2.57 (m, 2H), 2.43–2.35 (mC, 1H), 2.22 (s, 1H), 2.13 (dd, 
J = 11.5, 6.9 Hz, 1H), 2.04–1.88 (m, 2H), 1.87–1.58 (m, 6H), 1.49–1.20 (m, 7H), 1.23 (s, 3H), 
1.12 (d, J = 6.6 Hz, 3H), 1.15–1.01 (m, 3H), 0.97 (d, J = 6.3 Hz, 3H), 0.94−0.83 (m, 7H), 0.75 
(s, 3H), 0.02 (s, 9H) ppm. 
 
13C NMR (C6D6, 100 MHz): δ = 93.7, 82.1, 78.6, 75.4, 67.2, 65.3, 54.8, 48.6, 42.9, 42.5, 42.3, 
42.1, 41.9, 36.4 (2C), 35.5, 32.6, 32.4, 30.2, 27.0, 25.1, 24.7, 23.4, 22.3, 20.1, 18.4, 16.5, 
15.2, −1.2 ppm. 
  
ESI-MS for C31H60NO4Si+ [(M+NH4) +]: calcd. 538.4286 
 found 538.4287. 
 
IR (ATR): ῦ/cm−1 = 3490, 2953, 2924, 1558, 1458, 1377, 1261, 1250, 1097, 1057, 1029, 940, 
860, 834, 880, 688, 669. 
 
 = +26.0 (c 0.20, C6D6). 
 
Synthesis of Alcohol 516 
   
 
   
To a solution of ketone 477 (100 mg, 253 µmol, 1.0 eq.) in THF (14 mL) was added 
HF/pyridine (4.0 mL) at 0 °C. The resulting mixture was stirred at room temperature for 
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12 hours, at which point additional HF/pyridine (0.4 mL) was added. After stirring for further 
44 hours, the reaction mixture was poured into saturated aqueous NaHCO3 solution (200 mL) 
and subsequently extracted with CH2Cl2 (3 × 150 mL). The combined organic layers were 
dried over Na2SO4, concentrated under reduced pressure and the crude product was purified 
via flash column chromatography (silica, n-pentane:Et2O = 3:1 to 7:3) to yield alcohol 516 
(49.7 mg, 0.19 mmol, 74%) as a colorless solid, as well as recovered ketone 477 (8.5 mg, 
0.02 mmol, 8.5%) and epimerized alcohol 517 (9.0 mg, 0.04 mmol, 13%). 
When epimerized alcohol 517 and the re-isolated ketone 477 were submitted to the same 
reaction conditions as described above, further alcohol 516 (12 mg, 46 µmol, 18%) could be 
obtained. 
 
Rf = 0.30 (i-Hex:EtOAc = 5:2). 
 
Melting point = 75.3–75.7 °C (Et2O). 
 
1H NMR (C6D6, 400 MHz): δ = 5.89–5.74 (m, 1H), 5.07–4.94 (m, 2H), 4.05 (mC, 1H), 3.02 
(mC, 1H), 2.45 (dd, J = 14.1, 3.7 Hz, 1H), 2.12 (mC, 1H), 1.99 (m, 1H), 1.91–1.71 (m, 2H), 
1.51 (dd, J = 12.6, 6.2 Hz, 1H), 1.43–1.22 (m, 2H), 1.21–1.09 (m, 2H), 1.05 (d, J = 6.9 Hz, 
3H), 1.03–0.98 (m, 1H), 0.91 (d, J = 6.3 Hz, 3H), 0.76 (d, J = 6.0 Hz, 3H), 0.61 (s, 3H) ppm. 
 
13C NMR (C6D6, 100 MHz) δ = 208.7, 143.0, 113.8, 77.3, 56.8, 50.0, 49.6, 48.8, 41.9, 41.1, 
39.5, 36.0, 29.4, 24.1, 21.7, 19.4, 15.1 ppm. 
 
EI-MS for C17H28O2 + [M+]: calcd. 264.2084 
 found 264.2098. 
 
IR (ATR): ῦ/cm−1 = 3249, 2958, 2932, 2868, 1695, 1638, 1462, 1387, 1369, 1354, 1262, 
1226, 1101, 1035, 992, 909, 871, 816, 754, 682. 
 
 = +11.4 (c 1.00, C6D6). 
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Synthesis of Epoxide 520 
   
 
   
To a solution of vinyl iodide 410 (76.9 mg, 0.29 mmol, 3.10 eq.) in Et2O (5.3 mL) was slowly 
added t-BuLi (0.34 mL, 1.7 M solution in n-pentane, 0.57 mmol, 6.05 eq.) at −78 °C and the 
resulting mixture was stirred for 45 min at this temperature. Then, a solution of ketone 516 
(25.0 mg, 9.46 µmol, 1.00 eq.) in Et2O (1.4 mL) was added within 30 min and the mixture 
was stirred for an additional 45 min. The reaction was quenched by the addition of half-
saturated aqueous NH4Cl (10 mL) and was then warmed to room temperature. The phases 
were separated and the aqueous layer was extracted with Et2O (3 × 100 mL). The combined 
organic layers were washed with saturated aqueous NaCl (20 mL) and dried over Na2SO4. 
The solvents were carefully removed under reduced pressure (min. 500 mbar) and the crude 
product was purified by flash column chromatography (silica, n-pentane:Et2O = 17:3). The 
solvent of the product containing fractions was carefully removed under reduced pressure 
(min. 300 mbar) and the obtained addition product 519 was immediately used for the next 
transformation. 
To a solution of triene 519 (assumed 9.46 µmol, 1.00 eq.) in CH2Cl2 (8.7 mL) was added 
m-CPBA (0.85 mL, 0.2 M solution in CH2Cl2, 0.17 mmol, 1.90 eq.) and the mixture was 
stirred for 90 min at room temperature. After the addition of further m-CPBA (0.20 mL, 0.2 M 
solution in CH2Cl2, 40.0 µmol, 0.40 eq.), stirring was continued for 30 min. The reaction was 
quenched by the addition of saturated aqueous NaHCO3 (10 mL) and the phases were 
separated. The aqueous layer was extracted with CH2Cl2 (3 × 100 mL). The combined organic 
layers were consecutively washed with saturated aqueous K2CO3 (10 mL), saturated  
aqueous NaCl (10 mL) and dried over Na2SO4. The solvents were evaporated under 
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reduced pressure and the crude product was purified by flash column chromatography (silica, 
n-pentane:Et2O = 19:6 to 16:9) to yield epoxide 520 (29.3 mg, 70.3 µmol, 74%) as colorless 
solid and as a single diastereomer. 
 
Rf = 0.42 (i-Hex:EtOAc = 3:1). 
 
Melting point = 166.7–167.3 °C (C6D6). 
 
1H NMR (C6D6, 600 MHz): δ = 5.85–5.79 (mC, 1H), 5.43–5.36 (mC, 1H), 5.09–4.93 (m, 4H), 
4.19–4.16 (mC, 1H), 2.76 (dd, J = 10.4, 5.7 Hz, 1H), 2.51–2.32 (m, 3H), 2.08–2.03 (mC, 1H), 
1.99 (dd, J = 13.6, 3.4 Hz, 1H), 1.93 (dd, J = 11.5, 7.1 Hz, 1H), 1.89–1.80 (m, 2H), 1.73–1.65 
(m, 1H), 1.65–1.48 (m, 4H), 1.34–1.26 (m, 3H), 1.23 (s, 3H), 1.10–1.02 (m, 1H), 1.02–0.98 
(m, 9H), 0.94 (d, J = 6.8 Hz, 3H), 0.73 (s, 3H) ppm. 
 
13C NMR (C6D6, 100 MHz) δ = 145.4, 134.6, 118.1, 111.8, 79.7, 78.0, 77.3, 69.6, 57.7, 55.1, 
51.2, 43.3, 41.8, 38.8, 38.5, 36.8, 35.6, 33.8, 33.1, 30.2, 28.3, 24.5, 22.1, 19.9, 19.8, 17.0, 
16.4 ppm.  
 
ESI-MS for C27H45O3+ [M+]: calcd. 417.3363 
 found 417.3378. 
 
IR (ATR): ῦ/cm−1 = 3422, 2966, 2954, 2927, 2888, 1635, 1464, 1410, 1389, 1369, 1302, 
1273, 1222, 1192, 1135, 1086, 1060, 1044, 1029, 1010, 991, 959, 944, 934, 901, 871, 860, 
804, 776, 754, 723, 693, 681, 667. 
 
 = −28.4 (c 0.50, C6D6). 
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Synthesis of Tetracycle 521 
   
 
   
To a solution of diene 520 (15 mg, 36 µmol, 1.0 eq.) in degassed benzene (30 mL) was added 
Grubbs second-generation catalyst (267, 1.5 mg, 1.8 µmol, 5 mol-%). The mixture was placed 
in an oil bath (pre-heated to 85 °C) and stirred at this temperature. After one and two hours, 
respectively, another two batches of Grubbs second-generation catalyst (267, 1.5 mg, 
1.8 µmol, 5 mol-%) were added and stirring was continued to a total reaction time of 3 hours. 
The reaction mixture was allowed to cool to room temperature. The solvent was evaporated 
under reduced pressure and the obtained crude product was purified by flash column 
chromatography (silica, n-pentane:Et2O = 3:1 to 7:3) to yield the cyclized product 521 
(11 mg, 21 µmol, 86%) as a colorless wax. 
 
Rf = 0.38 (i-Hex:EtOAc = 3:1). 
 
1H NMR (C6D6, 600 MHz): δ = 5.40 (dd, J = 10.7, 8.0 Hz, 1H), 5.34 (dd, J = 10.7, 8.1 Hz, 
1H), 4.12 (mC, 1H), 3.45 (t, J = 6.6 Hz, 1H), 3.25–3.15 (m, 1H), 2.94 (s, 1H), 2.54 (mC, 1H), 
2.35–2.22 (m, 1H), 2.12 (mC, 1H), 2.00 (t, J = 13.2 Hz, 1H), 1.88 (dd, J = 11.4, 7.0 Hz, 1H), 
1.84–1.72 (m, 2H), 1.62 (dd, J = 12.4, 4.9 Hz, 1H), 1.60–1.41 (m, 4H), 1.38–1.25 (m, 1H), 
1.36 (t, J = 12.4 Hz, 1H), 1.25–1.12 (m, 5H), 1.00 (d, J = 6.4 Hz, 3H), 0.98–0.89 (m, 9H), 
0.66 (s, 3H) ppm. 
 
13C NMR (C6D6, 100 MHz) δ = 141.4, 128.1 (obscured by residual solvent), 84.7, 77.3, 76.4, 
66.4, 57.5, 51.6, 46.7, 43.3, 42.4, 41.3, 39.6, 37.1, 35.2, 33.2, 32.4, 30.3, 27.6, 24.4, 22.2, 
21.0, 19.8, 17.1, 16.4 ppm. 
 
EI-MS for C25H40O3+ [M+]: calcd. 388.2972 
 found 388.2968. 
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IR (ATR): ῦ/cm−1 = 3495, 3266, 2950, 2930, 2873, 1457, 1378, 1329, 1260, 1233, 1170, 
1148, 1096, 1075, 1040, 1011, 986, 970, 942, 914, 883, 862, 841, 794, 778, 734, 711, 684, 
668, 663.  
 
 = −32.5 (c 0.85, C6D6). 
 
Synthesis of Tetracycle 521 
   
 
   
To a solution of compound 515 (5.0 mg, 9.5 µmol, 1.0 eq.) and TASF (50 mg, 1.9 mmol, 
20 eq.) in HMPA (4.5 mL) were added molecular sieves (4 Å, 50 mg). The vessel was 
transferred to an oil bath (pre-heated to 75 °C) and the reaction was stirred for 16 hours. After 
the addition of further TASF (50 mg, 1.9 mmol, 20 eq.) and molecular sieves (4 Å, 50 mg) in 
HMPA (1 mL), stirring was continued for another 8 hours at 75 °C. The reaction was allowed 
to cool to room temperature and the mixture was diluted with water (20 mL), and extracted 
with Et2O (4 × 50 mL). The combined organic layers were washed with half-saturated 
aqueous NaCl (2 × 10 mL), dried over Na2SO4 and the solvents were evaporated under 
reduced pressure. The crude product was purified by flash column chromatography (silica, 
n-pentane:Et2O = 3:1 to 7:3) to yield the alcohol 521 (2.6 mg, 7.0 µmol, 70%) as a colorless 
wax, along with recovered starting material 515 (1.1 mg, 2.1 µmol, 22%). 
Note: The measured analytical data was identical to the data of the material obtained from 
ring-closing metathesis of triene 520 (vide supra).  
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Synthesis of Tetracycle 523 
   
 
   
To a solution of alkene 521 (4.0 mg, 10 µmol, 1.0 eq.) in MeOH (8 mL) was added Pd/C 
(10 wt-% Pd, 40 mg, 31 µmol, 3.0 eq.). The argon atmosphere was exchanged with hydrogen 
(1 atm) and the suspension was stirred for 75 min. The mixture was filtered over a 
pad of Celite® (Et2O washings) and the solvents were evaporated under reduced pressure. 
Purification of the crude product by flash column chromatography (silica, 
n-pentane:Et2O = 1:1) yielded alcohol 523 (3.5 mg, 9.0 mmol, 90%) as colorless oil. 
On a slightly higher reaction scale, alkene 521 (13 mg, 33 µmol) was hydrogenated to alcohol 
523 (12 mg, 30 µmol) in 90% yield. 
Note: Product 523 and alkene 521 behaved co-polar at TLC analysis. 
 
Rf = 0.24 (i-Hex:EtOAc = 4:1). 
 
1H NMR (C6D6, 400 MHz): δ = 4.13, (mC, 1H), 2.69−2.50 (m, 2H), 2.47−2.34 (m, 1H), 2.27 
(s, 1H), 1.97−1.85 (m, 2H), 1.84−1.67 (m, 4H), 1.63 (dd, J = 11.9, 3.9 Hz, 1H), 1.59−1.49 (m, 
1H), 1.47−1.26 (m, 5H), 1.26−1.17 (m, 6H), 1.14−1.06 (m, 1H), 1.00 (d, J = 6.6 Hz, 3H), 
0.95−0.85 (m, 10H), 0.70 (s, 3H) ppm. 
 
13C NMR (C6D6, 100 MHz) δ = 78.6, 77.5, 75.4, 67.2, 57.5, 51.5, 42.6, 42.5, 42.4, 42.2, 41.9, 
36.5, 36.4, 35.5, 32.6, 32.4, 30.5, 27.0, 25.1, 24.4, 23.5, 22.2, 20.0, 16.5, 15.2 ppm.  
 
EI-MS for C25H42O3+ [M+]: calcd. 390.3129 
 found 390.3145. 
 
IR (ATR): ῦ/cm−1 = 3464, 2930, 2870, 1459, 1044.  
 
[ ]20Dα  = +6.2 (c 0.50, CH2Cl2). 
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Synthesis of (−)-Nitidasin (238) 
   
 
    
To a solution of alcohol 523 (11.0 mg, 28.2 µmol, 1.0 eq.) in CH2Cl2 (7.3 mL) were added 
molecular sieves (4 Å, 55.0 mg) and the suspension was cooled to 0 °C. Then, NMO 
(26.0 mg, 225 µmol, 5.0 eq.) and TPAP (1.98 mg, 5.64 µmol, 20 mol-%) were consecutively 
added and the mixture was stirred for one hour. The reaction was filtered over a pad of silica 
(Et2O washings) and the solvents were evaporated under reduced pressure. The crude product 
was purified by flash column chromatography (silica, n-pentane:Et2O = 9:1 to 17:3) to yield 
(−)-nitidasin (238, 9.8 mg, 25.2 µmol, 89%) as a colorless solid. 
 
Crystals sutibable for X-ray crystallography were obtained from slow evaporation of a 
solution of (−)-nitidasin (238) in MeOH at −20 °C. 
 
Rf = 0.67 (i-Hex:EtOAc = 4:1). 
 
Melting point = 145.7–146.3 °C (C6D6) , Lit.:[154] 145−147 °C (MeOH). 
 
1H NMR (C6D6, 400 MHz): δ = 2.63−2.48 (m, 2H), 2.41 (mC, 1H), 2.29 (s, 1H), 2.01 (t, 
J = 13.1 Hz, 1H), 1.98 (d, J = 17.0 Hz, 1H), 1.83−1.59 (m, 7H), 1.53 (dd, J = 12.3, 4.0 Hz, 
1H), 1.47−1.27 (m, 3H), 1.27−1.14 (m, 3H), 1.20 (s, 3H), 1.18 (d, J = 6.3 Hz, 3H), 1.12−1.06 
(m, 1H), 0.95−0.81 (m, 10H), 0.71 (s, 3H) ppm. 
 
13C NMR (C6D6, 100 MHz) δ = 217.5, 78.7, 75.1, 67.0, 55.7, 55.6, 42.7, 42.5, 42.0, 41.8, 
39.1, 36.4, 35.3, 34.7, 32.6, 32.3, 28.7, 27.0, 25.5, 25.1, 23.4, 21.6, 20.2, 16.4, 15.2 ppm.  
 
EI-MS for C25H40O3+ [M+]: calcd. 388.2972 
 found 388.2976. 
 
IR (ATR): ῦ/cm−1 = 3480, 2954, 2872, 1732, 1461, 1378; Lit.:[154] ῦ/cm−1 = 3423, 1738.  
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[ ]20Dα  = −102 (c 0.10, CHCl3), Lit.:
[154] [ ]20Dα  = −41.4 (c 0.28, CHCl3). 
 
Synthesis of Diol 640 – Transformation of (−)-Nitidasin (238) in Acidic CDCl3 
   
 
   
A sample of (−)-nitidasin (238, 1.3 mg, 2.8 µmol) was dissolved in CDCl3 (0.7 mL) that was 
taken from a fresh ampule and the NMR spectra were immediately recorded. NMR analysis 
showed complete conversion to diol 640 after five days. After removal of the solvent in vacuo 
diol 640 (1.1 mg, 2.4 µmol, 85%) was obtained as colorless oil. This compound reacted 
further in the NMR solvent at prolonged exposure to a mixture of unknown compounds.  
Note: The reaction time was dependent on the HCl content of the employed CDCl3 and cannot 
be estimated easily. Even different ampullas of the same 10-ampullas box led to unequal 
reaction times, ranging from 15 min to 5 days. 
 
1H NMR (CDCl3, 400 MHz): δ = 5.26 (s, 1H), 5.07 (s, 1H), 4.18 (br s, 1H), 2.84–2.69 (m, 
2H), 2.63 (ddd, J = 13.1, 8.9, 3.2 Hz, 1H), 2.38 (ddd, J = 13.5, 11.9, 6.9 Hz, 1H), 2.23 (t, 
J = 13.3 Hz, 1H), 2.18–2.00 (m, 3H), 1.99–1.80 (m, 4H), 1.74 (ddd, J = 12.6, 3.5, 2.2 Hz, 
2H), 1.70–1.61 (m, 1H), 1.54 (s, 2H), 1.37–1.22 (m, 3H), 1.20–1.11 (m, 1H), 1.04–0.98 (m, 
7H), 0.98–0.91 (m, 6H), 0.87 (d, J = 7.2 Hz, 3H) ppm. 
 
13C NMR (CDCl3, 100 MHz): δ = 160.3, 111.1, 88.2, 79.0, 56.1, 56.0, 51.6, 46.3, 42.6, 42.3, 
40.9, 39.5, 35.5, 34.5, 34.4, 30.6, 29.9, 28.6, 27.3, 25.7, 24.7, 23.5, 21.3, 20.4, 15.7.ppm.  
 
EI-MS for C25H40O3+ [M+]: calcd. 388.2972 
 found 388.2965. 
 
IR (ATR): ῦ/cm−1 = 3417, 2956, 2925, 2865, 1732, 1560, 1540, 1452, 1383, 2361, 1175, 
1096, 1025, 947, 898, 799. 
 
 = −51.8 (c 0.73, CHCl3). 
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5.4 Experimental Procedures for Chapter 2: ‘Synthetic Studies Toward Astellatol’ 
 
Synthesis of Tosylate 549 
   
 
   
To a solution of 3-pentynol (540, 5.0 g, 59.4 mmol, 1.0 eq.) and Et3N (9.1 mL, 65.4 mmol, 
1.1 eq.) in CH2Cl2 (60 mL) was added TsCl (12.5 g, 65.4 mmol, 1.1 eq.) at 0 °C in one 
portion and the resulting solution was stirred at room temperature for 12 hours. After diluting 
with H2O (100 mL), the layers were separated and the aqueous phase was extracted with 
CH2Cl2 (3 × 75 mL). The combined organic layers were dried over Na2SO4 and concentrated 
under reduced pressure. The crude product was purified by flash column chromatography 
(silica, i-Hex:EtOAc = 19:1 to 17:3) to yield tosylate 549 (13.4 g, 56.3 mmol, 95%) as a 
colorless solid. 
 
Rf = 0.93 (i-Hex:EtOAc = 3:2). 
 
Melting point = 40–41 °C (i-Hex/EtOAc). 
 
1H NMR (CDCl3, 300 MHz): δ = 7.69–7.63 (m, 2H), 7.25–7.18 (m, 2H), 3.91 (td, J = 7.1, 
0.6 Hz, 2H), 2.40–2.26 (m, 2H), 2.31 (mC, 3H), 1.57 (td, J = 2.6, 0.6 Hz, 3H) ppm. 
 
13C NMR (CDCl3, 75 MHz): δ = 144.9, 133.0, 129.9, 127.9, 78.2, 73.2, 68.3, 21.6, 19.7 (2C), 
3.4 ppm.  
 
EI-MS for C12H14O3S+ [M+]: calcd. 238.0664. 
 found 238.0667. 
 
IR (ATR): ῦ/cm−1 = 2960, 2893, 1590, 1357, 1195, 1186, 1172, 1091, 1067, 940 760, 691, 
660. 
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Synthesis of Iodide 548 
   
 
   
To a solution of tosylate 549 (10.8 g, 45.3 mmol, 1.0 eq.) in acetone (85 mL) was added NaI 
(13.6 g, 90.6 mmol, 2.0 eq.) in one portion. The resulting mixture was heated to 60 °C and 
stirred under exclusion of light for 4 hours. Subsequently, the mixture was diluted with Et2O 
(300 mL) and washed with H2O (100 mL). The aqueous phase was re-extracted with Et2O 
(3 × 40 mL). The combined organic layers were dried over Na2SO4 and concentrated under 
reduced pressure (200 mbar, 30 °C). The crude product was purified by distillation (boiling 
point = 65 °C, 14 mbar) under an argon atmosphere to yield iodide 548 (7.18 g, 37.0 mmol, 
82%) as a colorless oil, which was indefinitely stable as a solid upon storage at −20 °C under 
exclusion of light. 
 
Rf = 0.96 (i-Hex:EtOAc = 3:1). 
 
1H NMR (CDCl3, 400 MHz): δ = 3.20 (t, J = 7.4 Hz, 2H), 2.71 (tq, J = 7.4, 2.5 Hz, 2H), 1.77 
(t, J = 2.5 Hz, 3H) ppm. 
 
13C NMR (CDCl3, 100 MHz): δ = 78.1, 77.9, 24.3, 3.7, 2.7 ppm.  
 
EI-MS for C5H7I+ [M+]: calcd. 193.9587. 
 found 193.9587. 
 
IR (ATR): ῦ/cm−1 = 2963, 2916, 2851, 1434, 1421, 1377, 1333, 1248, 1170, 1151, 1029, 904, 
840, 774, 727. 
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Synthesis of Alkyne 542 
   
 
   
To a solution of 3-pentynol (540, 1.08 g, 12.9 mmol, 1.0 eq.) and pyridine (1.04 mL, 
12.9 mmol, 1.0 eq.) in CH2Cl2 (12 mL) was added freshly distilled Tf2O (2.39 mL,  
14.2 mmol, 1.1 eq.) dropwise at 0 °C and the resulting mixture was stirred for 30 min. The 
reaction was quenched by the addition of H2O (20 mL). The layers were separated and the 
aqueous phase was extracted with CH2Cl2 (3 × 10 mL). The combined organic layers were 
dried over Na2SO4 and then carefully concentrated under reduced pressure (400 mbar, 30 °C). 
The resulting crude product was filtered through a short Na2SO4 plug (CH2Cl2 washings) and 
was again concentrated to yield triflate 550 (2.58 g, 11.9 mmol, 93%), which was used 
immediately in the next reaction. 
Note: Triflate 550 could not be stored longer than two days at −20 °C before decomposition 
took place. 
 
Rf = 0.95 (i-Hex:EtOAc = 3:2). 
 
1H NMR (C6D6, 400 MHz): δ = 3.85 (mC, 2H), 1.98 (mC, 2H), 1.49 (td, J = 2.5, 0.5 Hz,  
3H) ppm. 
 
13C NMR (C6D6, 100 MHz): δ = 119.3 (q, J = 319 Hz), 79.2, 74.6, 72.4, 20.0, 3.0 ppm. 
 
19F NMR (C6D6, 376 MHz): δ = −75.4 ppm 
 
EI-MS for C6H6F3O3S+ [(M−H)+]: calcd. 214.9984. 
 found 214.9983. 
 
IR (ATR): ῦ/cm−1 = 2955, 2935, 2876, 1460, 1414, 1380, 1361, 1237, 1200, 1128, 1060, 
1000, 960, 947, 860, 792, 710. 
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To a solution of oxazolidinone 542 (100 mg, 0.43 mmol, 1.0 eq.) in THF (1.5 mL) was added 
LiHMDS (0.47 mL, 1 M solution in THF, 0.47 mmol, 1.1 eq.) dropwise at −78 °C. The 
resulting mixture was stirred for 30 min, upon which a solution of freshly prepared  
triflate 550 (0.28 g, 1.29 mmol, 3.0 eq.) in THF (0.5 mL) was added dropwise. After stirring 
for an additional 30 min, the reaction was allowed to warm to room temperature over 
10 hours. The resulting viscous mixture was diluted with CH2Cl2 (20 mL) and washed with 
saturated aqueous NaCl (20 mL). The aqueous phase was extracted with CH2Cl2 (3 × 20 mL) 
and the combined organic layers were dried over Na2SO4. The solvent was removed under 
reduced pressure and the crude product was purified by flash column chromatography (silica, 
i-Hex:EtOAc = 9:1 to 17:3) to yield alkyne 542 (89 mg, 0.30 mmol, 69%) as a colorless oil 
and a single diastereomer. 
 
Rf = 0.60 (i-Hex:EtOAc = 3:1). 
 
1H NMR (CDCl3, 600 MHz): δ = 7.35–7.30 (m, 2H), 7.29–7.25 (m, 1H), 7.24–7.18 (m, 2H), 
4.67 (ddt, J = 9.6, 7.7, 3.2 Hz, 1H), 4.20–4.10 (m, 2H), 3.88 (sept, J = 6.8 Hz, 1H), 3.29 (dd, 
J = 13.4, 3.4 Hz, 1H), 2.74 (dd, J = 13.4, 9.7 Hz, 1H), 2.22–2.19 (m, 2H), 2.01 (dq, J = 13.4, 
7.2 Hz, 1H), 1.77 (t, J = 2.6 Hz, 3H), 1.63 (mC, 1H), 1.19 (d, J = 6.9 Hz, 3H) ppm. 
 
13C NMR (CDCl3, 150 MHz): δ = 176.8, 153.1, 135.4, 129.5, 129.1, 127.4, 78.2, 76.5, 66.1, 
55.5, 38.1, 37.0, 32.9, 17.0, 16.7, 3.6 ppm. 
 
EI-MS for C18H21NO3+ [M+]: calcd. 299.1521. 
 found 299.1518. 
 
IR (ATR): ῦ/cm−1 = 2955, 2935, 2876, 1460, 1414, 1380, 1361, 1237, 1200, 1128, 1060, 
1000, 960, 947, 860, 792, 710. 
 
 = +26.8 (c 1.00, CH2Cl2). 
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Synthesis of Alkyne 558 
   
 
   
To a suspension of flame-dried LiCl (8.27 g, 0.19 mol, 12.8 eq.) in THF (90 mL) was added 
freshly distilled diisopropylamine (8.77 mL, 62.5 mmol, 4.15 eq.) and the resulting mixture 
was cooled to −78 °C. Then, n-BuLi (20.8 mL, 2.95 M solution in hexanes, 61.5 mmol, 
4.1 eq.) was added dropwise and the suspension was stirred for 15 min at −78 and 5 min at 
0 °C. After being cooled to −78 °C, a solution of amide 556 (7.00 g, 31.6 mmol, 2.1 eq.) in 
THF (41 mL) was added dropwise over a period of 15 min. The reaction was stirred at this 
temperature for one hour, at 0 °C for 15 min and at room temperature for another 5 min. 
Subsequently, iodide 548 (2.92 g, 15.0 mmol, 1.0 eq.) was added dropwise at 0 °C and the 
mixture was stirred for 5 hours before being warmed slowly to room temperature over night. 
The reaction was quenched by the addition of saturated aqueous NH4Cl (50 mL) and diluted 
with CH2Cl2 (50 mL). The layers were separated and the aqueous phase was extracted with 
CH2Cl2 (3 × 75 mL). The combined organic layers were dried over Na2SO4 and concentrated 
in vacuo. Purification by flash column chromatography (silica, i-Hex:EtOAc = 7:3 to 6:4 to 
0:1) yielded alkyne 558 (6.81 g, 23.7 mmol, 75%) as a colorless oil, which slowly solidified 
upon prolonged drying in vacuo. Furthermore, amide 556 (3.01 g, 13.6 mmol) could be re-
isolated. 
Note: The employed LiCl had to be flame-dried thoroughly and needed to be ground under 
argon gas atmosphere. Yields were significantly lower when the LiCl was not dried or ground 
properly. 
 
Rf = 0.68 (i-Hex:EtOAc = 1:3). 
 
Melting point = 94.3–95.9 °C (CH2Cl2). 
 
1H NMR (C6D6, 400 MHz, major rotamer): δ = 7.34–7.28 (m, 2H), 7.19–7.12 (m, 2H),  
7.11–7.06 (m, 1H), 4.92 (s, br 1H), 4.55 (d, J = 7.0 Hz, 1H), 4.26 (s, br, 1H), 2.66–2.56 (m, 
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1H), 2.39 (s, 3H), 2.12–2.00 (m, 2H), 1.99–1.88 (m, 1H), 1.52 (t, J = 2.5 Hz, 3H), 1.41 (m, 
1H), 0.99 (d, J = 6.9 Hz, 3H), 0.96 (d, J = 6.8 Hz, 3H) ppm. 
 
1H NMR (C6D6, 400 MHz, minor rotamer): δ = 7.34–7.28 (m, 2H), 7.19–7.12 (m, 2H),  
7.11–7.06 (m, 1H), 4.92 (s, br 1H), 4.25 (d, J = 10.0 Hz, 1H), 4.04 (mC, 1H), 3.10 (mC, 1H), 
2.80 (s, 3H), 2.32–2.27 (m, 2H), 1.60 (t, J = 2.4 Hz, 3H), 1.04 (d, J = 6.8 Hz, 3H), 0.66 (d, 
J = 6.7 Hz, 3H) ppm. 
 
13C NMR (C6D6, 100 MHz, major rotamer): δ = 177.7, 143.8, 128.4, 127.4, 126.8, 79.1, 76.4, 
75.9, 59.5, 35.5, 33.5, 33.3 (br), 17.3, 17.0, 14.4, 3.3 ppm. 
 
13C NMR (C6D6, 100 MHz, minor rotamer): δ = 176.6, 142.8, 128.7, 127.5, 126.8, 79.9, 76.2, 
75.5, 58.1, 35.0, 33.7, 27.0, 18.1, 17.3, 15.4, 3.7 ppm. 
 
ESI-MS for C18H26NO2+ [MH+]: calcd. 288.1958. 
 found 288.1958. 
 
IR (ATR): ῦ/cm−1 = 3374, 3030, 2968, 2933, 2874, 1613, 1451, 1409, 1374, 1302, 1257, 
1199, 1108, 1080, 1049, 1028, 918, 838, 761, 700. 
 
 = +26.4 (c 1.00, CH2Cl2). 
 
Synthesis of Alkene 559 
   
 
   
A suspension of Pd/BaSO4 (740 mg, 5 wt-% Pd, 350 µmol, 5 mol-%) in dry pyridine (60 mL) 
was saturated with hydrogen via bubbling for 10 min. A solution of alkyne 558 (2.00 g, 
6.96 mmol, 1.0 eq.) was then added and the reaction was stirred at room temperature under 
hydrogen atmosphere (1 atm) for 30 min. After filtration over Celite© (EtOAc washings), the 
reaction mixture was concentrated under reduced pressure. The crude product was purified by 
[ ]20Dα
558 559
C18H27NO2
M = 289.42 g/mol
OH
Me
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O
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H2 (1 atm)
Pd/BaSO4 (6 mol-%)
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flash column chromatography (silica, i-Hex:EtOAc = 1:1) to yield alkene 559 (2.00 g, 
6.96 mmol, quant.) as a colorless oil. 
 
Rf = 0.62 (i-Hex:EtOAc = 2:3). 
 
1H NMR (C6D6, 400 MHz, major rotamer): δ = 7.36–7.34 (m, 2H), 7.25–7.14 (m, 2H),  
7.12–7.05 (m, 1H), 5.49–5.41 (m, 1H), 5.38–5.28 (m, 1H), 4.98 (s, br, 1H), 4.55 (t,  
J = 6.9 Hz, 1H), 4.38 (s, br, 1H), 2.31 (s, 3H), 2.33–2.27 (m, 1H), 2.03–1.82 (m, 3H), 1.50 (d, 
J = 6.5 Hz, 3H), 1.34–1.24 (m, 1H), 0.98 (d, J = 6.7 Hz, 3H) 0.97 (d, J = 5.9 Hz, 3H) ppm. 
 
1H NMR (C6D6, 400 MHz, minor rotamer): δ = 7.36–7.34 (m, 2H), 7.25–7.14 (m, 2H),  
7.12–7.05 (m, 1H), 5.66–5.50 (m, 2H), 4.24 (d, J = 8.2 Hz, 1H), 3.93 (quin, J = 6.9 Hz, 1H), 
3.12 (m, 1H), 2.86–2.80 (m, 1H), 2.83 (s, 3H), 2.26–2.12 (m, 3H), 1.64 (d, J = 6.5 Hz, 3H), 
1.60–1.53 (m, 1H), 1.07 (d, J = 6.9 Hz, 3H), 0.68 (d, J = 6.7 Hz, 3H) ppm. 
 
13C NMR (C6D6, 100 MHz, major rotamer): δ = 178.0, 143.8, 130.6, 128.4, 127.4, 126.9, 
124.5, 76.4, 58.9 (br), 36.0, 34.0, 32.7 (br), 25.0, 17.7, 14.4, 12.9 ppm. 
 
13C NMR (C6D6, 100 MHz, minor rotamer): δ = 176.9, 142.9, 131.3, 128.6, 127.4, 126.9, 
124.2, 75.5, 58.1, 35.7, 34.3, 27.2, 25.4, 18.3, 15.4, 13.1 ppm. 
 
ESI-MS for C18H28NO2+ [MH+]: calcd. 290.21146. 
 found 290.21149. 
 
IR (ATR): ῦ/cm−1 = 3376, 3061, 3008, 2967, 2932, 2871, 1613, 1478, 1450, 1405, 1371, 
1316, 1299, 1257, 1197, 1107, 1082, 1048, 1027, 986, 915, 837, 753, 698, 608. 
 
 = +67.0 (c 1.00, CDCl3). 
 
 
 
 
 
 
[ ]20Dα
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Synthesis of Alcohol 560 
   
 
   
To a solution of diisopropylamine (4.07 mL, 29.0 mmol, 4.2 eq.) in THF (29 mL) at −78 °C 
was added n-BuLi (8.70 mL, 3.10 M solution in hexanes, 27.0 mmol, 3.9 eq.) dropwise. The 
resulting mixture was stirred for 15 min at −78 and another 15 min at 0 °C. Then, borane-
ammonia complex (0.85 g, 27.7 mmol, 4.0 eq.) was added in one portion. The resulting 
mixture was stirred for 15 min at 0 °C and for 15 min at room temperature, before being 
cooled to 0 °C again. Subsequently, a solution of alkene 559 (2.0 g, 6.96 mmol, 1.0 eq.) in 
THF (17 mL) was added dropwise over a period of 10 min and the resulting solution was 
stirred at room temperature for two hours. After cooling to 0 °C, aqueous HCl (3 M, 60 mL) 
was added slowly and the mixture was stirred for 10 min at room temperature. The layers 
were separated and the aqueous phase was extracted with Et2O (4 × 10 mL). The combined 
organic layers were dried over Na2SO4 and carefully concentrated under reduced pressure 
(400 mbar, 30 °C). The crude product was purified by flash column chromatography (silica, 
n-pentane:Et2O = 17:3 to 7:3) to yield alcohol 560 (747 mg, 5.82 mmol, 84%) as a colorless 
liquid. 
 
Rf = 0.84 (i-Hex:EtOAc = 3:2). 
 
1H NMR (CDCl3, 400 MHz): δ = 5.41 (mC, 2H), 3.54–3.49 (m, 1H), 3.46–3.41 (m, 1H),  
2.18–1.96 (m, 2H), 1.69–1.57 (m, 4H), 1.47 (dddd, J = 13.3, 9.3, 6.7, 5.3 Hz, 1H), 1.35 (s, br, 
1H), 1.18 (dddd, J = 13.3, 9.3, 8.2, 6.0 Hz, 1H), 0.94 (d, J = 6.7 Hz, 3H) ppm. 
 
13C NMR (CDCl3, 100 MHz): δ = 130.7, 124.1, 68.4, 35.5, 33.0, 24.4, 16.6, 12.9 ppm. 
 
EI-MS for C8H16O+ [M+]: calcd. 128.1196. 
 found 128.1185. 
 
559 560
C8H16O2
M = 128.22 g/mol
n-BuLi (3.9 eq.)
DIPA (4.2 eq.)
→ BH3⋅NH3 (4.0 eq.)
THF
−78 °C to 0 °C, 30 min
 0 °C to rt, 2.5 h
(84%)
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N
O
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IR (ATR): ῦ/cm−1 = 3332, 3012, 2953, 2915, 2872, 1656, 1454, 1403, 1376, 1251, 1225, 
1190. 1099, 1034, 995, 905, 763, 698, 628, 619, 605. 
 
 = +8.0 (c 0.50, CDCl3). 
 
Preparation of Mosher Ester 561  
   
 
   
To a solution of alcohol 560 (3.0 mg, 23.4 µmol, 1.0 eq.) in CH2Cl2 (1.0 mL) were 
consecutively added pyridine (13 µL, 0.16 mmol, 7.0 eq.) and (R)-Mosher’s acid chloride 
(638, 15 µL, 81.9 µmol, 3.5 eq.) at 0 °C. The resulting mixture was stirred for 12 hours at 
room temperature. The reaction was quenched by the addition of half-saturated aqueous 
NaHCO3 (10 mL) and was then extracted with CH2Cl2 (3 × 10 mL). The combined organic 
layers were dried over Na2SO4 and concentrated under reduced pressure. 1H NMR analysis of 
the crude reaction mixture did not indicated the existence of any second diastereomer. The 
crude product was purified via flash column chromatography (silica, n-pentane/Et2O = 199:1) 
to yield ester 561 (7 mg, 20.3 µmol, 87%) as a colourless wax.  
Note: 19F NMR spectra recorded of the purified product revealed a diastereomeric mixture of 
Mosher ester 561 of 99:1. 
 
Rf = 0.50 (i-Hex:EtOAc = 25:1). 
 
1H NMR (CDCl3, 400 MHz): δ = 7.54–7.49 (m, 2H), 7.42–7.38 (m, 3H), 5.48–5.39 (m, 1H), 
5.34–5.27 (m, 1H), 4.21–4.13 (m, 2H), 3.55 (mC, 3H), 2.10–1.97 (m, 2H), 1.92–1.84 (m, 1H), 
1.59 (d, J = 6.7 Hz, 3H), 1.45–1.38 (m, 1H), 1.31–1.17 (m, 1H), 0.94 (d, J = 6.8 Hz, 3H) ppm. 
 
13C NMR (CDCl3, 100 MHz): δ = 166.8, 132.5, 130.0, 129.7, 128.5, 127.5, 124.4, 84.8 (q, 
J = 27.5 Hz), 71.2, 55.6, 32.9, 32.2, 29.9, 24.1, 16.8, 12.9 ppm. 
 
[ ]20Dα
OH
Me
Cl Ph
O CF3
OMe
638 (3.5 eq.)
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CH2Cl2
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19F NMR (CDCl3, 382 MHz): δ = −71.4 (minor), −71.6 (major) ppm 
 
ESI-MS for C18H23ClF3O3− [(M+Cl)−]: calcd. 379.12878. 
 found 379.12886. 
 
IR (ATR): ῦ/cm−1 = 3067, 3012, 2958, 2856, 1746, 1658, 1606, 1497, 1463, 1451, 1404, 
1388, 1378, 1259, 1167, 1121, 1106, 1081, 1019, 1001, 966, 917, 802, 764, 718, 695. 
 
 = +28.0 (c 0.1, CDCl3). 
 
Synthesis of Oxime 562 
   
 
   
To a solution of dry DMSO (1.04 mL, 14.6 mmol, 2.5 eq.) in CH2Cl2 (50 mL) was added 
oxalyl chloride (5.85 mL, 2 M solution in CH2Cl2, 11.7 mmol, 2.0 eq.) dropwise at −78 °C. 
The resulting mixture was stirred for 15 min, before a solution of alcohol 560 (750 mg,  
5.85 mmol, 1.0 eq.) in CH2Cl2 (4 mL) was added over a period of 10 min. Stirring was 
continued for two hours, at which Et3N (3.24 mL, 23.4 mmol, 4.0 eq.) was added slowly. This 
mixture was stirred for an additional two hours at −78 °C, before being gradually warmed to 
−20 °C over one hour. The reaction was quenched by addition of aqueous phosphate buffer 
(10 mL, 2 M, pH = 6.5) and the layers were separated. The aqueous phase was extracted with 
Et2O (4 × 10 mL). The combined organic layers were subsequently dried over Na2SO4 and 
carefully concentrated under reduced pressure (400 mbar, 30 °C). The crude product was 
purified by flash column chromatography (silica, n-pentane:Et2O = 19:1) to yield  
aldehyde 563 (628 mg, 4.97 mmol, 85%) as a 2:15 mixture with n-pentane as a colorless 
liquid, which was immediately used in the next step. 
 
Rf = 0.95 (i-Hex:EtOAc = 10:1). 
 
[ ]20Dα
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C8H14O
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To a mixture of hydroxylamine hydrochloride (1.45 g, 20.9 mmol, 5.0 eq.) and NaOAc 
(3.43 g, 41.8 mmol, 10 eq.) in MeOH (26 mL), a solution of aldehyde 563 (528 mg, 12 mol-% 
solution in n-pentane, 4.19 mmol, 1.0 eq.) in MeOH (2 mL) was added. The reaction was 
stirred for 24 hours at room temperature before being quenched by the addition of half-
saturated aqueous NaHCO3 (20 mL). After extraction with Et2O (4 × 25 mL) the combined 
organic layers were dried over Na2SO4 and concentrated under reduced pressure (300 mbar, 
30 °C). The crude product was purified by flash column chromatography (silica, 
n-pentane:Et2O = 9:1 to 4:1) to yield oxime 562 (639 mg, 4.52 mmol, 72%) as a colorless 
liquid as a 5:2 mixture of E/Z isomers and in a 21:1 mixture with n-pentane. 
Note: The stated yields were deduced from 1H NMR of respective mixtures with n-pentane. A 
spectroscopically pure sample of oxime 562 was obtained by repeated concentration from 
CDCl3. 
 
Rf (E-562)= 0.32 (i-Hex:EtOAc = 20:1). 
 
Rf (Z-562)= 0.30 (i-Hex:EtOAc = 20:1). 
 
1H NMR (CDCl3, 400 MHz, E-562): δ = 8.06 (s, br, 1H), 7.30 (d, J = 7.0 Hz, 1H), 5.52–5.28 
(m, 2H), 2.39 (sept, J = 6.9 Hz, 1H), 2.06 (m, 2H), 1.59 (m, 3H), 1.56–1.34 (m, 2H), 1.09 (d, 
J = 6.9 Hz, 3H) ppm. 
 
1H NMR (CDCl3, 400 MHz, Z-562): δ = 8.33 (s, br, 1H), 6.53 (d, J = 7.7 Hz, 1H), 5.54–5.26 
(m, 2H), 3.16 (sept, J = 6.9 Hz, 1H), 2.06 (m, 2H), 1.64–1.55 (m, 3H), 1.55–1.32 (m, 2H), 
1.05 (d, J = 6.9 Hz, 3H) ppm. 
 
13C NMR (CDCl3, 100 MHz, E-562): δ = 156.5, 129.8, 124.6, 34.5, 34.2, 24.5, 18.1, 
12.9 ppm. 
 
13C NMR (CDCl3, 100 MHz, Z-562): δ = 157.4, 129.9, 124.5, 34.6, 29.4, 24.8, 17.5, 
12.9 ppm. 
 
EI-MS for C8H15NO+ [M+]: calcd. 141.1154. 
 found 141.1154. 
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IR (ATR): ῦ/cm−1 = 3274, 3012, 2962, 2918, 2854, 1657, 1453, 1404, 1375, 1332, 1308, 
1278, 1122, 1081, 1029, 948, 933, 873, 702. 
 
 = −18.4 (c 0.50, CDCl3). 
 
Synthesis of Isoxazole 541 
   
 
   
To a solution of oxime 562 (580 mg, 4.11 mmol, 1.0 eq.) in CH2Cl2 (22 mL) was slowly 
added aqueous NaOCl (22 mL, 7 wt-% NaOCl, 20.5 mmol, 5.0 eq.). The resulting mixture 
was stirred at room temperature for 12 hours, before being diluted with H2O (20 mL) and 
Et2O (25 mL). The layers were separated and the aqueous phase was extracted with Et2O 
(4 × 10 mL). The combined organic layers were dried over Na2SO4 and carefully concentrated 
under reduced pressure (400 mbar, 30 °C). The crude product was purified by flash column 
chromatography (silica, n-pentane:Et2O = 4:1) to yield isoxazole 541 (543 mg, 4.03 mmol, 
98%) as a colorless liquid as a syn/anti isomeric mixture of 2:3. 
Note: The syn/anti isomeric ratio of compound 541 was determined via GCMS measurements. 
The identity of the isomers was deduced from NOESY and HMBC NMR spectra.  
 
Rf  = 0.44 (i-Hex:EtOAc = 10:1). 
 
1H NMR (CDCl3, 400 MHz, signals not separable): δ = 4.75 (mC, 1H), 3.89–3.74 (m, 1H), 
2.83–2.71 (m, 1H), 2.52 – 2.32 (m, 1H), 1.84–1.54 (m, 3H), 1.25–1.22 (2d, J = 7.1, 6.8 Hz, 
3H), 1.12–1.09 (2d, J = 6.6, 6.6 Hz, 3H) ppm. 
 
13C NMR (CDCl3, 100 MHz, anti-541): δ = 174.3, 78.7, 57.0, 38.9, 29.7, 22.8, 18.8, 
16.5 ppm. 
 
13C NMR (CDCl3, 100 MHz, syn-541): δ = 174.4, 79.2, 57.3, 38.2, 30.1, 20.8, 17.4,  
16.2 ppm. 
[ ]20Dα
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EI-MS for C8H13NO+ [M+]: calcd. 139.0992. 
 found 139.0984. 
 
IR (ATR): ῦ/cm−1 = 2964, 2928, 2870, 1452, 1374, 1334, 1295, 1250, 1177, 1167, 1140, 
1109, 1084, 1046, 1017, 994, 948, 910, 862, 830, 812, 770,730, 660. 
 
 = +8.4 (c 0.50, CDCl3). 
 
Synthesis of Alcohol 582 
   
 
   
To a solution of isoxazole 541 (200 mg, 1.44 mmol, 1.0 eq.) in MeOH (20 mL) and H2O 
(4 mL) was consecutively added B(OMe)3 (490 µL, 4.30 mmol, 3.0 eq.) and Raney® Ni 2400 
(0.1 mL, 50 wt-% suspension in MeOH). The reaction mixture was purged with hydrogen 
(3 times) and stirred under an hydrogen atmosphere (1 atm) for 30 min. After diluting the 
reaction with H2O (20 mL) and Et2O (50 mL), the layers were separated and the aqueous 
phase was extracted with Et2O (4 × 10 mL). The combined organic layers were dried over 
Na2SO4 and then carefully concentrated under reduced pressure (400 mbar, 30 °C). The crude 
product was purified by flash column chromatography (silica, n-pentane:Et2O = 7:3 to 3:2) to 
yield alcohol 582 (150 mg, 1.06 mmol, 73%) as a mixture of all four possible diastereomers.  
Note: Due to the obtained mixture of diastereomers, interpretation of the 1H NMR spectrum 
proved to be extremely complicated. As a consequence, only the 13C shifts for all isomers are 
reported. 
 
Rf  = 0.25–0.30 (i-Hex:EtOAc = 10:1). 
 
13C NMR (CDCl3, 150 MHz): δ = 225.4, 225.2, 223.5, 222.6, 69.1, 67.0, 66.9, 66.5, 55.5, 
55.1, 54.5 (2C), 45.6, 44.8, 43.4, 43.0, 29.8 (2C), 29.3, 28.8, 24.9, 23.9, 22.5, 21.6, 21.5, 21.3, 
21.0, 20.9, 15.3, 14.6, 14.4, 14.2 ppm. 
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EI-MS for C8H14O2+ [M+]: calcd. 142.0994. 
 found 142.0993. 
 
IR (ATR): ῦ/cm−1 =3453, 2964, 2932, 2871, 1727, 1453, 1395, 1373, 1329, 1282, 1250, 1155, 
1128, 1096, 1049, 1017, 986, 949, 917, 887, 852, 835, 742, 600. 
 
 = −69.6 (c 0.33, CDCl3). 
 
Synthesis of Diketone 583 
   
 
   
To a solution of dry DMSO (161 µL, 2.29 mmol, 2.5 eq.) in CH2Cl2 (8.8 mL) was added 
oxalyl chloride (914 µL, 2 M solution in CH2Cl2, 1.83 mmol, 2.0 eq.) dropwise at −78 °C. The 
resulting mixture was stirred for 15 min before a solution of alcohol 582 (130 mg, 0.91 mmol, 
1.0 eq.) in CH2Cl2 (1.5 mL) was added over a period of 10 min. Stirring was continued for 
two hours. Thereafter, Et3N (622 µL, 3.66 mmol, 4.0 eq.) was added slowly. This reaction 
was stirred for an additional two hours at −78 °C, before being warmed gradually to −20 °C 
over one hour. The reaction was quenched by the addition of aqueous phosphate buffer 
(5 mL, 2 M, pH = 6.5) and the layers were separated. The aqueous phase was extracted with 
Et2O (4 × 10 mL) and the combined organic layers were subsequently dried over Na2SO4 and 
carefully concentrated in vacuo (400 mbar, 30 °C). Purification by flash column 
chromatography (silica, n-pentane:Et2O = 19:1 to 9:1) yielded diketone 583 (86 mg, 
6.13 mmol, 67%) as a colorless liquid. 
Note: 1H NMR revealed that diketone 583 exists predominately as the depicted enol tautomer 
and is in equilibrium with both possible diastereomers of the diketo form. 
 
Rf  = 0.85 (i-Hex:EtOAc = 3:1). 
 
1H NMR (CDCl3, 400 MHz, only major tautomer quoted): δ = 13.47 (s, br, 1H), 2.48 (m, 3H), 
2.53–2.42 (m, 2H), 1.98 (s, 3H), 1.46 (dq, J = 12.5, 8.9 Hz, 1H), 1.14 (d, J = 7.0 Hz, 3H) 
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ppm. Characteristic signals for the diketo tautomers: δ = 3.51 (dd, J = 8.6, 4.0 Hz, 1H), 3.38 
(dd, J = 9.9, 8.3 Hz, 1H), 2.34 (s, 3H), 2.32 (s, 3H) ppm. 
 
13C NMR (CDCl3, 100 MHz, only major tautomer quoted): δ = 207.9, 174.9, 109.6, 42.7, 
29.9, 24.1, 20.6, 15.4 ppm. Characteristic signals for the diketo tautomers: δ = 214.5, 214.0, 
202.8, 202.2 ppm. 
 
ESI-MS for C8H11O2− [(M−H)−]: calcd. 139.07645. 
 found 139.07644. 
 
IR (ATR): ῦ/cm−1 =2963, 2931, 2871, 1742, 1709, 1654, 1608, 1453, 1430, 1385, 1357, 1321, 
1283, 1218, 1177, 1144, 1083, 1033, 994, 967, 948, 889, 729, 706. 
 
 = −16.8 (c 0.33, CDCl3). 
 
Synthesis of Triflate 539 
   
 
   
To a stirred suspension of NaH (17 mg, 60 wt-% in mineral oil, 428 µmol, 1.2 eq.) in THF 
(1.4 mL) was added a solution of diketone 583 (50 mg, 357 µmol, 1.0 eq.) in THF (350 µL) 
dropwise at 0 °C and the mixture was stirred for 30 min. Then, a solution of PhNTf2 (159 mg, 
446 µmol, 1.3 eq.) in THF (350 µL) was added and the reaction was stirred for 10 hours at 
0 °C. Subsequently, the reaction was diluted with H2O (10 mL) and extracted with Et2O 
(3 × 15 mL). The combined organic layers were dried over Na2SO4 and concentrated under 
reduced pressure (500 mbar, 30 °C). The crude product was purified by flash column 
chromatography (silica, n-pentane:Et2O = 19:1 to 9:1) to yield the title compound 539 
(5.4 mg, 19.8 µmol, 6%) as a colorless oil. 
 
Rf  = 0.45 (i-Hex:EtOAc = 20:1). 
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1H NMR (CDCl3, 400 MHz): δ = 3.16 (mC, 1H), 2.67–2.62 (m, 2H), 2.36 (s, 3H), 2.24 (mC, 
1H), 1.62–1.53 (m, 2H), 1.22 (d, J = 6.9 Hz, 3H) ppm. 
 
13C NMR (CDCl3, 100 MHz): δ = 194.7, 156.0, 129.7, 118.4 (q, J = 320 Hz), 39.7, 29.9, 27.8, 
18.0 ppm.  
 
EI-MS for C9H11F3O4S+ [M+]: calcd. 272.0330. 
 found 272.0347. 
 
IR (ATR): ῦ/cm−1 = 2970, 2938, 2878, 1698, 1677, 1639, 1457, 1424, 1379, 1362, 1337, 
1289, 1248, 1203, 1168, 1135, 1099, 1082, 1034, 976, 921, 905, 876, 834, 768, 707, 661. 
 
 = +70.8 (c 0.33, CDCl3). 
 
Synthesis of Alkene 587 
   
 
   
KHMDS (35.3 mL, 0.5 M solution in toluene, 17.7 mmol, 1.1 eq.) was added to a solution of 
hydrindanone 361 (3.60 g, 16.1 mmol, 1.0 eq.) in dry THF (144 mL) at room temperature. 
The yellow mixture was stirred for 30 min before being cooled to −78 °C. After the slow 
addition of triethylborane (17.7 mL, 1.0 M freshly prepared solution in THF, 17.7 mmol, 
1.1 eq.) the reaction was stirred for 5 min before Pd(PPh3)4 (927 mg, 0.80 mmol, 5 mol-%) 
and subsequently a solution of allyl bromide (1.53 mL, 17.7 mmol, 1.1 eq.) in dry THF 
(14 mL) were added. The mixture was allowed to warm to room temperature and then stirred 
for another 2.5 hours. The reaction was quenched via addition of saturated aqueous NH4Cl 
(100 mL) and then diluted with diethyl ether (200 mL). The layers were separated and the 
aqueous phase was extracted with diethyl ether (3 × 100 mL). The combined organic layers 
were dried over Na2SO4, concentrated in vacuo and the resulting crude product was purified 
by flash column chromatography (silica, i-Hex:EtOAc = 40:1 to 20:1) to yield alkene 587 
(3.58 g, 13.5 mmol, 84%) as colorless oil and as single diastereomer. 
[ ]20Dα
KHMDS (1.1 eq.)
→ BEt3 (1.1 eq.)
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Pd(PPh3)4 (5 mol-%)
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−78 °C to rt, 3 h
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Rf = 0.75 (i-Hex:EtOAc = 13:1). 
 
1H NMR (CDCl3, 600 MHz): δ = 5.75 (dddd, J = 16.8, 10.1, 7.6, 6.5 Hz, 1H), 5.01–4.96 (m, 
2H), 3.43 (dd, J = 8.9, 7.5 Hz, 1H), 2.54 (mC, 1H), 2.40 (mC, 1H), 2.36–2.27 (m, 2H), 2.05 
(dd, J = 12.8, 6.2 Hz, 1H), 2.00–1.94 (m, 2H), 1.65 (dddd, J = 13.2, 11.9, 7.0, 4.9 Hz,  
1H), 1.60–1.53 (m, 2H), 1.44–1.37 (m, 1H), 1.12 (s, 9H), 1.07 (t, J = 12.6 Hz, 1H), 1.00  
(s, 3H) ppm. 
 
13C NMR (CDCl3, 150 MHz): δ = 212.0, 136.8, 116.3, 79.5, 72.7, 45.8, 45.3, 43.0, 42.7, 42.3, 
34.1, 31.9, 28.8, 25.9, 11.3 ppm. 
 
EI-MS for C17H28O2+ [M+]: calcd. 264.2089 
 found 264.2071. 
 
IR (ATR): ῦ/cm−1 = 2974, 2934, 2875, 2851, 1701, 1642, 1462, 1431, 1386, 1361, 1296, 
1259, 1228, 1190, 1142, 1110, 1026, 998, 967, 916, 899, 849, 774, 754, 723, 693. 
 
 = −32.8 (c 1.00, CH2Cl2). 
 
Synthesis of Alkohol 588 
   
 
   
To a stirred solution of alkene 587 (3.50 g, 13.2 mmol, 1.0 eq.) in dry THF (130 mL) at 
−78 °C was added K-Selectride® (465, 20.5 mL, 1 M solution in THF, 20.5 mmol, 1.6 eq.) 
dropwise over a period of 20 min. After being stirred for further 10 min at this temperature, 
the reaction mixture was allowed to warm to room temperature over the course of two hours. 
Then, the reaction was cooled to 0 °C and excess reagent was quenched with methanol 
(25 mL). Subsequently, aqueous NaOH (3 M, 47 mL) and H2O2 (30 wt-%, 35 mL) were added 
and the biphasic mixture was thoroughly stirred for two hours at room temperature. 
Thereafter, saturated aqueous NH4Cl (50 mL) was added and the mixture was extracted with 
diethyl ether (3 × 150 mL). The combined organic layers were dried over Na2SO4, 
[ ]20Dα
K-Selectride®
(465, 1.6 eq.)
THF 
−78 °C to rt, 3 h
(quant.)
588
C17H30O2
M = 266.43 g/mol
587
Ot-BuMe
HO
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O HH
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concentrated in vacuo and the resulting crude product was purified by flash column 
chromatography (silica, i-Hex:EtOAc = 20:1 to 10:1) to yield alcohol 588 (3.51 g, 13.2 mmol, 
quant.) as colorless oil and as single diastereomer. 
 
Rf = 0.60 (i-Hex:EtOAc = 10:1). 
 
1H NMR (CDCl3, 600 MHz): δ = 5.82 (dddd, J = 16.9, 10.1, 7.6, 6.7 hz, 1H), 5.05 (mC, 1H), 
5.00 (mC, 1H), 3.91 (q, J = 2.8 Hz, 1H), 3.43 (dd, J = 8.9, 7.4 Hz, 1H), 2.18–2.13 (m, 1H), 
2.04–1.99 (m, 1H), 1.93–1.86 (m, 1H), 1.71–1.63 (m, 3H), 1.53–1.40 (m, 5H), 1.31–1.24 (m, 
1H), 1.11 (s, 9H), 1.08 (t, J = 12.7 Hz, 1H), 0.72 (s, 3H) ppm. 
 
13C NMR (CDCl3, 150 MHz): δ = 137.7, 115.8, 80.6, 72.3, 68.9, 43.0, 38.6, 37.6, 37.5, 37.4, 
33.6, 31.3, 28.9, 25.6, 10.9 ppm. 
 
EI-MS for C17H28O+ [(M−H2O)+]: calcd. 248.2140 
 found 248.2136. 
 
IR (ATR): ῦ/cm−1 = 3390, 3076, 2973, 2927, 11462, 1441, 1388, 1361, 1311, 1253, 1195, 
1127, 1110, 1065, 1028, 1004, 976, 948, 906, 863, 753. 
 
 = −45.2 (c 1.00, CH2Cl2). 
 
Synthesis of Lactone 589 
   
 
   
To a stirred solution of alcohol 588 (2.70 g, 10.1 mmol, 1.0 eq.) in 1,4-dioxane (114 mL) and 
water (37 mL) at 0 °C was added 2,6-lutidine (2.35 mL, 20.3 mmol, 2.0 eq.) and then OsO4 
(0.64 mL, 4 wt-% solution in H2O, 0.10 mmol, 1 mol-%). Subsequently, NaIO4 (8.67 g, 
40.5 mmol, 4.0 eq.) was added in one portion and the resulting mixture was allowed to warm 
to room temperature. After being stirred for 16 hours, the reaction was diluted with water 
(200 mL) and extracted with CH2Cl2 (4 × 100 mL). The combined organic layers were dried 
[ ]20Dα
OsO4 (1 mol-%)
2,6-lutidine (2.0 eq.)
NaIO4 (4.0 eq.)
1,4-dioxane, H2O
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641588
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PCC (2.5 eq.)
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CH2Cl2
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over Na2SO4, concentrated in vacuo to yield lactol 641 (Rf = 0.20, i-Hex:EtOAc = 4:1) as 
colorless solid as inconsequential mixture of epimers, requiring no further purification. 
Thus obtained lactol 641 was re-dissolved in dry CH2Cl2 (35 mL) and then slowly added to an 
ice-cold stirred suspension of PCC (5.46 g, 25.3 mmol, 2.5 eq.) in dry CH2Cl2 (148 mL) over 
the course of 15 min. The resulting mixture was allowed to warm to room temperature and 
stirred for further 45 min. After being directly applied to flash column chromatography 
(silica, i-Hex:EtOAc = 3:1), the still crude product was purified via a second flash column 
chromatography (silica, i-Hex:EtOAc = 10:1 to 9:1) step to yield title lactone 589 (2.50 g, 
9.31 mmol, 92%) as a colorless solid. 
 
Rf = 0.55 (i-Hex:EtOAc = 4:1). 
 
Melting point = 120.0–121.3 °C (CH2Cl2). 
 
1H NMR (CDCl3, 600 MHz): δ = 4.56 (td, J = 4.0, 2.0 Hz, 1H), 3.39 (dd, J = 8.9, 7.8 Hz, 1H), 
2.73 (dd, J = 16.8, 7.0 Hz, 1H), 2.51 (mC, 1H), 2.20 (d, J = 16.8 Hz, 1H), 2.11 (dt, J = 14.0, 
2.4 Hz, 1H), 1.95–1.88 (m, 1H), 1.81 (dd, J = 13.1, 6.4 Hz, 1H), 1.62–1.42 (m, 4H), 1.30 (qd, 
J = 11.8, 6.2 Hz, 1H), 1.12 (s, 9H), 0.90 (t, J = 12.6 Hz, 1H), 0.72 (s, 3H) ppm. 
 
13C NMR (CDCl3, 150 MHz): δ = 177.4, 80.2, 80.1, 72.6, 42.1, 39.5, 38.4, 37.0, 33.1, 30.8, 
28.9, 28.5, 25.3, 10.4 ppm. 
 
EI-MS for C16H26O3+ [M+]: calcd. 266.1882 
 found 266.1882. 
 
IR (ATR): ῦ/cm−1 = 2972, 2934, 2869, 1763, 1464, 1426, 1390, 1363, 1334, 1293, 1278, 
1254, 1241, 1214, 1194, 1179, 1156, 1121, 1098, 1062, 1043, 1028, 999, 966, 946, 912, 880, 
858, 818, 738, 693. 
 
 = −13.6 (c 1.00, CH2Cl2). 
 
 
 
 
[ ]20Dα
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Synthesis of Lactone 590 
   
 
    
LiHMDS (15.0 mL, 1 M solution in THF, 15.0 mmol, 1.5 eq.) was added to a stirred solution 
of lactone 589 (2.70 g, 10.0 mmol, 1.0 eq.) in dry THF (150 mL) at −78 °C. The reaction was 
stirred for 30 min at this temperature before freshly distilled methyl iodide (3.12 mL,  
49.8 mmol, 5.0 eq.) was added dropwise over a period of 10 min. After stirring for another 
two hours aqueous HCl (2 M, 34 mL) was added. The mixture was then warmed to room 
temperature and diluted with saturated aqueous NH4Cl (200 mL) and diethyl ether (200 mL). 
The layers were separated and the aqueous phase was extracted with diethyl  
ether (3 × 100 mL). The combined organic layers were dried over Na2SO4, concentrated  
in vacuo and the crude mixture was purified via flash column chromatography (silica, 
i-Hex:EtOAc = 10:1 to 9:1) to yield lactol 590 (2.74 g, 9.80 mmol, 98%) as colorless solid 
and as single diastereomer. 
 
Rf = 0.85 (i-Hex:EtOAc = 4:1). 
 
Melting point = 151.7–152.8 °C (CH2Cl2). 
 
1H NMR (CDCl3, 600 MHz): δ = 4.71 (td, J = 3.9, 2.0 Hz, 1H), 3.37 (t, J = 8.3 Hz, 1H), 2.34 
(q, J = 7.7 Hz, 1H), 2.16–2.10 (m, 2H), 1.91 (mC, 1H), 1.84 (dd, J = 13.1, 6.5 Hz, 1H),  
1.60–1.41 (m, 4H), 1.32–1.26 (m, 1H), 1.31 (d, J = 7.7 Hz, 3H), 1.11 (s, 9H), 0.88 (t, 
J = 12.6 Hz, 1H), 0.70 (s, 3H) ppm. 
 
13C NMR (CDCl3, 150 MHz): δ = 180.5, 80.1, 77.9, 72.5, 45.1, 42.0, 40.0, 37.1, 30.8, 28.9, 
28.5, 25.3, 15.0, 10.4 ppm. 
 
ESI-MS for C17H29O3+ [MH+]: calcd. 281.2111 
 found 281.2119. 
 
589
Ot-BuMe
H
H
O
H
O
LiHMDS (1.5 eq.)
→  MeI (5.0 eq.)
THF
−78 °C, 2 h
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H
H
O
H
O
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IR (ATR): ῦ/cm−1 = 2964, 2937, 2877, 1764, 1458, 1385, 1360, 1311, 1200, 1184, 1128, 
1107, 1084, 1061, 1042, 1024, 976, 945, 905, 882, 808, 716, 674. 
 
 = +4.2 (c 1.00, CH2Cl2). 
 
Synthesis of Diol 591 
    
 
    
A solution of lactone 590 (2.72 g, 9.70 mmol, 1.0 eq.) in dry THF (36 mL) was slowly added 
to a stirred suspension of LiAlH4 (0.74 g, 19.4 mmol, 2.0 eq.) in dry THF (54 mL) at 0 °C 
over the course of 20 min. The resulting mixture was stirred for another 30 min at this 
temperature before being carefully quenched via the addition of half-saturated Rochelle salt 
(80 mL). After being vigorously stirred for another hour, CH2Cl2 (200 mL) was added and the 
layers were separated. The aqueous phase was extracted with CH2Cl2 (3 × 200 mL) and the 
combined organic layers were dried over Na2SO4. Concentration under reduced pressure 
yielded diol 591 (2.75 g, 9.70 mmol, quant.) as colorless solid, which required no further 
purification. 
 
Rf = 0.35 (CH2Cl2:MeOH = 20:1). 
 
Melting point = 130.3–131.8°C (CH2Cl2/MeOH). 
 
1H NMR (CDCl3, 600 MHz): δ = 4.08 (q, J = 2.8 Hz, 1H), 3.65–3.52 (m, 2H), 3.60 (s, br, 
2H), 3.46 (dd, J = 8.9, 7.3 Hz, 1H), 1.89 (mC, 1H), 1.75–1.62 (m, 3H), 1.52–1.39 (m, 5H), 
1.30–1.23 (m, 2H), 1.12 (s, 9H), 0.98 (d, J = 7.1 Hz, 3H), 0.71 (s, 3H) ppm. 
 
13C NMR (CDCl3, 150 MHz): δ = 80.8, 72.4, 66.6, 65.4, 43.0, 42.2, 38.2, 37.6, 37.5, 33.5, 
31.4, 28.9, 25.6, 16.3, 10.9 ppm. 
 
 
[ ]20Dα
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EI-MS for C17H32O3+ [M+]: calcd. 284.2351 
 found 284.2330. 
 
IR (ATR): ῦ/cm−1 = 3149, 2969, 2928, 2909, 2869, 1461, 1437, 1377, 1359, 1342, 1292, 
1278, 1253, 1233, 1191, 1161, 1117, 1090, 1066, 1050, 1033, 1005, 969, 936, 903, 877, 860, 
822, 731. 
 
 = −40.0 (c 1.00, CH2Cl2). 
 
Synthesis of Bis-silyl Ether 473 
    
 
   
To a solution of diol 591 (3.29 g, 11.6 mmol, 1.0 eq.) in dry CH2Cl2 (110 mL) was added 
2,6-lutidine (5.36 mL, 46.3 mmol, 4.0 eq.) and then TESOTf (6.80 mL, 30.7 mmol, 2.6 eq.) 
dropwise at 0 °C. After being stirred for one hour at this temperature, the reaction was 
quenched with saturated aqueous NaHCO3 (66 mL) and the resulting layers were separated. 
The aqueous phase was extracted with CH2Cl2 (3 × 150 mL), the combined organic layers 
were dried over Na2SO4 and concentrated under reduced pressure. Purification via flash 
column chromatography (silica, i-Hex:EtOAc = 100:1 to 75:1) yielded bis-silyl ether 473 
(5.73 g, 11.2 mmol, 97%) as colorless oil. 
 
Rf = 0.95 (i-Hex:EtOAc = 40:1). 
 
1H NMR (CDCl3, 600 MHz): δ = 4.01 (q, J = 2.7 Hz, 1H), 3.52 (dd, J = 9.6, 4.9 Hz, 1H), 
3.53–3.41 (m, 2H), 1.90 (mC, 1H), 1.76–1.67 (m, 2H), 1.56–1.52 (m, 2H), 1.46–1.38 (m, 4H), 
1.25 (qd, J = 12.3, 6.5 Hz, 1H), 1.14 (s, 9H), 0.96 (t, J = 8.0 Hz, 18H), 0.89 (d, J = 6.9 Hz, 
3H), 0.70 (s, 3H), 0.64–0.54 (m, 12H) ppm. 
 
13C NMR (CDCl3, 150 MHz): δ = 81.0, 72.3, 70.5, 66.5, 42.7, 38.7, 37.4, 35.0, 34.7, 31.5, 
29.0, 25.6, 15.1, 11.1, 7.2, 5.5, 4.6 ppm. 
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EI-MS for C29H60O3Si2+ [M+]: calcd. 512.4081 
 found 512.4071. 
 
IR (ATR): ῦ/cm−1 = 2954, 2911, 2876, 1459, 1414, 1388, 1361, 1238, 1195, 1060, 1005, 975, 
944, 902, 861, 796, 723. 
 
 = −23.8 (c 1.00, CH2Cl2). 
 
Synthesis of Aldehyde 592 
   
 
   
To a solution of DMSO (760 µL, 10.7 mmol, 5.0 eq.) in dry CH2Cl2 (21 mL) was added 
oxalyl chloride (2.67 mL, 2 M solution in CH2Cl2, 5.34 mmol, 2.5 eq.) dropwise at −78 °C. 
The resulting mixture was stirred for 15 min before a solution of bis-silyl ether 473 (1.06 g, 
2.14 mmol, 1.0 eq.) in CH2Cl2 (4.2 mL), was added over a period of 30 min. The reaction was 
subsequently warmed to −60 °C and kept at this temperature for 7.5 hours (note: temperature 
control is very significant for this reaction!). Thereafter, Et3N (2.98 mL, 21.4 mmol, 10 eq.) 
was added slowly and the resulting mixture was stirred for one hour at −78 °C, before being 
warmed gradually to −20 °C over the course of another hour. The reaction was quenched by 
the addition of water (20 mL) and the layers were separated. The aqueous phase was extracted 
with CH2Cl2, (4 × 100 mL) and the combined organic layers were subsequently dried over 
Na2SO4 and concentrated in vacuo. Purification by flash column chromatography (silica, 
i-Hex:EtOAc = 60:1 to 40:1) yielded aldehyde 592 (703 mg, 1.77 mmol, 82%) as a colorless 
liquid. 
 
Rf = 0.55 (i-Hex:EtOAc = 40:1). 
 
1H NMR (CDCl3, 600 MHz): δ = 9.74 (d, J = 1.7 Hz, 1H), 4.04 (q, J = 2.7 Hz, 1H), 3.44 (dd, 
J = 9.0, 7.3 Hz, 1H), 2.40 (mC, 1H), 1.95–1.86 (m, 2H), 1.73 (mC, 1H), 1.60 (dt, J = 13.7,  
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3.2 Hz, 1H), 1.58–1.40 (m, 4H), 1.35 (t, J = 12.4 Hz, 1H), 1.31–1.24 (m, 1H), 1.15 (s, 9H), 
1.07 (d, J = 7.2 Hz, 3H), 0.94 (t, J = 8.0 Hz, 9H), 0.74 (s, 3H), 0.58 (q, J = 7.8 Hz, 6H) ppm. 
 
13C NMR (CDCl3, 150 MHz): δ = 205.2, 80.8, 72.4, 68.7, 48.5, 42.9, 40.3, 37.2, 36.2, 33.9, 
31.4, 29.0, 25.5, 12.2, 10.9, 7.2, 5.3 ppm. 
 
ESI-MS for C23H45O3Si+ [MH+]: calcd. 397.3133 
 found 397.3142. 
 
IR (ATR): ῦ/cm−1 = 2955, 2876, 2697, 1721, 1460, 1414, 1389, 1378, 1361, 1237, 1195, 
1126, 1058, 1043, 1004, 972, 944, 918, 902, 860, 822, 795, 724. 
 
 = −65.2 (c 1.00, CH2Cl2). 
 
Synthesis of Alkene 586 
   
 
   
To a suspension of Ph3PMeBr (2.97 g, 8.32 mmol, 3.0 eq.) in THF (40 mL) at −78 °C was 
slowly added n-BuLi (2.05 µL, 2.70 M solution in hexanes, 5.55 mmol, 2.0 eq.). The resulting 
orange solution was allowed to warm to room temperature and stirred for 60 min, before 
being cooled to −78 °C again. Then, a solution of aldehyde 592 (1.10 g, 2.77 mmol, 1.0 eq.) 
in THF (6 mL) was added dropwise. The cold bath was replaced by an ice/water bath and the 
mixture was stirred for additional 60 min at 0 °C prior to quenching the reaction by the 
addition of saturated aqueous NH4Cl (50 mL). The layers were separated and the aqueous 
phase was extracted with diethyl ether (3 × 100 mL). The combined organic layers were dried 
over Na2SO4, concentrated under reduced pressure and the crude product was then purified  
by flash column chromatography (silica, i-Hex:EtOAc = 100:1) to yield alkene 586 (1.06 g, 
2.69 mmol, 97%) as colorless oil . 
 
Rf = 0.85 (i-Hex:EtOAc = 60:1). 
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1H NMR (CDCl3, 600 MHz): δ = 5.77 (ddd, J = 17.1, 10.3, 8.2 Hz, 1H), 4.98 (ddd, J = 17.3, 
2.1, 1.0 Hz, 1H), 4.92 (ddd, J = 10.3, 2.1, 0.7 Hz, 1H), 4.00 (q, J = 2.4 Hz, 1H), 3.43  
(dd, J = 8.9, 7.4 Hz, 1H), 2.22 (mC, 1H), 1.94–1.87 (m, 1H), 1.74 (mC, 1H), 1.58–1.52 (m, 
2H), 1.46–1.36 (m, 3H), 1.29–1.21 (m, 2H), 1.15 (s, 9H), 1.07 (t, J = 12.4 Hz, 1H), 0.97–0.94 
(m, 12H), 0.70 (s, 3H), 0.61–0.56 (m, 6H) ppm. 
 
13C NMR (CDCl3, 150 MHz): δ = 144.9, 112.8, 80.7, 72.1, 69.2, 43.4, 42.6, 38.8, 37.1, 35.4, 
34.2, 31.4, 28.8, 25.3, 18.5, 11.0, 7.1, 5.4 ppm. 
 
EI-MS for C24H46O2Si+ [MH+]: calcd. 394.3267 
 found 394.3254. 
 
IR (ATR): ῦ/cm−1 = 2955, 2909, 2876, 1460, 1415, 1388, 1361, 1237, 1195, 1128, 1101, 
1058, 1044, 1004, 974, 941, 908, 861, 796, 723. 
 
 = −41.4 (c 1.00, CH2Cl2). 
 
Synthesis of Triflate 585 
   
 
   
To a stirred suspension of NaH (228 mg, 60% wt-% in mineral oil, 9.51 mmol, 1.2 eq.) in 
THF (30 mL) was added dropwise a solution of diketone 584 (1.00 g, 7.92 mmol, 1.0 eq.) in 
THF (5 mL) at 0 °C. After 30 min, a solution of PhNTf2 (3.54 g, 9.91 mmol, 1.3 eq.) in THF 
(5 mL) was added and the resulting mixture was stirred for 10 hours at 0 °C. Subsequently, 
the reaction was diluted with H2O (40 mL) and extracted with Et2O (3 × 40 mL). The 
combined organic layers were dried over Na2SO4 and concentrated under reduced pressure 
(500 mbar, 30 °C). The crude product was purified by flash column chromatography (silica, 
n-pentane:Et2O = 9:1) to yield the title compound 585 (1.92 g, 7.41 mmol, 94%) as a 
colorless oil. 
 
Rf = 0.71 (i-Hex:EtOAc = 3:1). 
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1H NMR (C6D6, 400 MHz): δ = 2.25–2.17 (m, 2H), 2.15–2.07 (m, 2H), 1.99 (s, 3H),  
1.20–1.06 (q, J = 7.81 Hz, 2H) ppm. 
 
13C NMR (C6D6, 100 MHz): δ = 192.1, 151.9, 129.7, 118.8 (d, J =320 Hz), 32.5, 29.5, 28.9, 
18.5 ppm.  
 
19F NMR (C6D6, 375 MHz): δ = −74.6 ppm 
 
EI-MS for C8H9F3O4S+ [M+]: calcd. 258.0168. 
 found 258.0164. 
 
IR (ATR): ῦ/cm−1 = 2974, 2920, 2890, 1683, 1650, 1420, 1390, 1370, 1320, 1280, 1250, 
1203, 1138, 1100, 1082, 1011, 920, 901, 875, 830, 767, 710. 
 
Synthesis of Enone 594 
   
 
   
To a solution of alkene 586 (600 mg, 1.52 mmol, 1.0 eq.) in THF (12 mL) was added 9-BBN 
(6.10 mL, 0.5 M solution in THF, 3.04 mmol, 2.0 eq.) and the resulting solution was heated to 
40 °C for 3.5 hours. The mixture was then cooled to 0 °C and degassed aqueous Cs2CO3 (3 M, 
1.78 mL, 5.30 mmol, 3.5 eq.) was added. The reaction was vigorously stirred at room 
temperature for 40 min. Subsequently, a solution of triflate 585 (707 mg, 2.74 mmol, 1.8 eq.) 
and AsPh3 (186 mg, 6.08 mmol, 0.4 eq.) was added. The resulting mixture was degassed and 
Pd(dppf)Cl2⋅CH2Cl2 (124 mg, 1.52 mmol, 10 mol-%) was added in one portion. The mixture 
was stirred for 26 hours and then partitioned between H2O (20 mL) and Et2O (50 mL). The 
aqueous layer was extracted with Et2O (3 × 50 mL) and the combined organic layers were 
dried over Na2SO4. Then, the solvents were removed under reduced pressure and the crude 
product was purified by flash column chromatography (silica, i-Hex:EtOAc = 60:1 to 50:1) to 
yield enone 594 (760 mg, 1.50 mmol, 99%) as a colorless oil. 
586 594
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Rf = 0.68 (i-Hex:EtOAc = 20:1). 
 
1H NMR (CDCl3, 400 MHz): δ = 4.04 (mC, 1H), 3.42 (dd, J = 8.9, 7.3 Hz, 1H), 2.71–2.58 (m, 
3H), 2.56–2.43 (m, 2H), 2.43–2.32 (m, 1H), 2.22 (s, 3H), 1.96–1.67 (m, 4H), 1.65–1.50 (m, 
3H), 1.50–1.34 (m, 4H), 1.34 – 1.17 (m, 3H), 1.14 (s, 9H), 1.14–1.07 (m, 1H), 0.99–0.92 (t, 
J = 7.9 Hz, 9H), 0.90 (d, J = 6.7 Hz, 3H), 0.69 (s, 3H), 0.62–0.52 (m, 6H) ppm. 
 
13C NMR (CDCl3, 100 MHz): δ = 198.5, 159.2, 135.3, 81.0, 72.3, 70.1, 42.7, 42.2, 38.6, 37.4, 
35.3, 34.7 (2C), 34.5, 33.5, 31.6, 30.5, 29.0, 27.9, 25.5, 21.8, 17.2, 11.1, 7.2, 5.5 ppm.  
 
EI-MS for C31H56O3Si+ [M+]: calcd. 504.3993. 
 found 504.3985. 
 
IR (ATR): ῦ/cm−1 = 2953, 2912, 2875, 1712, 1678, 1656, 1608, 1460, 1433, 1417, 1378, 
1359, 1297, 1253, 1236, 1195, 1128, 1106, 1060, 1043, 1005, 976, 943, 925, 902, 860, 796, 
723, 701. 
 
 = −43.2 (c 0.50, CH2Cl2). 
 
Synthesis of Alcohol 603 
   
 
   
To a solution of enone 594 (750 mg, 1.49 mmol, 1.0 eq.) in MeCN (11.5 mL), 3HF⋅NEt3 
(1.21 mL, 5.94 mmol, 5.0 eq.) was added dropwise. The resulting mixture was stirred for  
7 hours. Subsequently, the reaction was quenched by the addition of saturated aqueous 
NaHCO3 (25 mL) and extracted with CH2Cl2 (4 × 50 mL). The combined organic layers were 
dried over Na2SO4 and concentrated in vacuo. Purification by flash column chromatography 
(silica, i-Hex:EtOAc = 23:2 to 22:3) yielded alcohol 603 (575 mg, 1.48 mmol, 99%) as a 
colorless oil. 
 
[ ]20Dα
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Rf = 0.35 (i-Hex:EtOAc = 4:1). 
 
1H NMR (CDCl3, 600 MHz): δ = 4.09 (q, J = 2.8 Hz, 1H), 3.42 (dd, J = 8.9, 7.3 Hz, 1H), 2.64 
(mC, 2H), 2.54–2.43 (m, 4H), 2.19 (s, 3H), 1.92– .85 (m, 1H), 1.83–1.77 (m, 2H), 1.65 (mC, 
4H), 1.52–1.38 (m, 4H), 1.33–1.22 (m, 3H), 1.11 (s, 9H), 1.01 (t, J = 12.9 Hz, 1H), 0.92 (d,  
J = 6.7 Hz, 3H), 0.68 (s, 3H) ppm. 
 
13C NMR (CDCl3, 150 MHz): δ = 198.8, 159.7, 135.2, 80.8, 72.4, 68.0, 42.8, 42.1, 38.7, 37.5, 
36.2, 34.7, 34.6, 34.0, 32.8, 31.4, 30.5, 28.9, 28.3, 25.6, 21.9, 17.7, 11.0 ppm.  
 
ESI-MS for C25H42NaO3+ [MNa+]: calcd. 413.3032. 
 found 413.3023. 
 
IR (ATR): ῦ/cm−1 = 3466, 2971, 2930, 2871, 1707, 1669, 1604, 1462, 1431, 1388, 1360, 
1302, 1256, 1195, 1125, 1061, 1006, 973, 944, 903, 876, 860, 804, 753, 733, 701. 
 
 = −22.8 (c 0.50, CH2Cl2). 
 
Synthesis of Diketone 604 
   
 
   
To a suspension of alcohol 603 (570 mg, 1.46 mmol, 1.0 eq.) and NaHCO3 (245 mg,  
5.80 mmol, 4.0 eq.) in CH2Cl2 (30 mL) was added Dess-Martin periodinane (1.24 g,  
2.92 mmol, 2.0 eq.) in one portion. The mixture was stirred for two hours at room 
temperature, subsequently diluted with a mixture of aqueous saturated Na2S2O3, aqueous 
saturated NaHCO3, as well as H2O (1:1:1, 20 mL) and extracted with CH2Cl2 (4 × 50 mL). 
The combined organic layers were dried over Na2SO4 and concentrated under  
reduced pressure. The crude product was purified by flash column chromatography 
(silica, i-Hex:EtOAc = 23:2 to 22:3) to yield diketone 604 (544 mg, 1.40 mmol, 96%) as a 
colorless oil. 
[ ]20Dα
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Rf = 0.58 (i-Hex:EtOAc = 4:1). 
 
1H NMR (CDCl3, 600 MHz): δ = 3.49–3.44 (dd, J = 8.9, 7.7 Hz, 1H), 2.66 (mC, 2H),  
2.63–2.56 (m, 1H), 2.52–2.42 (m, 3H), 2.40 (mC, 1H), 2.32–2.26 (m, 2H), 2.23–2.28 (m, 1H), 
2.21 (s, 3H), 2.01–1.95 (m, 1H), 1.89 (dd, J = 12.5, 6.3 Hz, 1H), 1.82 (quin, J = 7.6 Hz, 2H), 
1.68–1.52 (m, 3H), 1.45–1.30 (m, 3H), 1.18 (t, J = 12.8 Hz, 1H) 1.15 (m, 9H), 0.99 (s, 3H), 
0.81 (d, J = 6.8 Hz, 3H) ppm. 
 
13C NMR (CDCl3, 150 MHz): δ = 212.5, 198.6, 158.3, 135.6, 78.0, 72.7, 49.3, 44.8, 43.3, 
42.3, 38.4, 35.8, 34.7, 33.0, 31.9, 31.0, 30.5, 28.9, 28.5, 25.9, 21.8, 16.1, 11.2 ppm.  
 
EI-MS for C25H40O3+ [M+]: calcd. 388.2972. 
 found 388.2968. 
 
IR (ATR): ῦ/cm−1 =3347, 2967, 2873, 1703, 1677, 1608, 1461, 1430, 1389, 1350, 1290, 1255, 
1191, 1110, 1060, 1025, 970, 901, 854, 803, 755. 
 
 = −28.0 (c 0.25, CH2Cl2). 
 
Synthesis of Ether 605 
   
 
   
To a vigorously stirred suspension of TiCl3(THF)3 (229 mg, 2.01 mmol, 10 eq.) and Zn–Cu 
couple (106 mg, 1.68 mmol, 33 eq.) in dimethoxyethane (14 mL), a solution of diketone 604 
(20 mg, 51.5 µmol, 1.0 eq.) in dimethoxyethane (5 mL) was added at 80 °C via syringe pump 
over a period of 6 hours. The reaction mixture was stirred for an additional two hours, 
subsequently cooled to room temperature and filtered over Celite© (Et2O washings). The 
crude mixture was washed with saturated aqueous NaHCO3 (20 mL) and the aqueous phase 
was extracted with Et2O (3 × 20 mL). The combined organic layers were dried over Na2SO4 
and concentrated under reduced pressure. Purification by flash column chromatography 
[ ]20Dα
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(silica, n-pentane:Et2O = 200:1) yielded ether 605 (14 mg, 30–50%) as a colorless wax and as 
a single diastereomer. 
Note: The yield of this reaction was approximated from 1H NMR, but could not be determined 
properly due to residual silicon grease that eluted co-polar with ether 605.  
 
Rf = 0.85 (i-Hex:EtOAc = 40:1). 
 
1H NMR (CDCl3, 600 MHz): δ = 3.49–3.35 (m, 2H), 1.91–1.78 (m, 4H), 1.75–1.56 (m, 6H), 
1.53–1.44 (m, 2H), 1.45–1.32 (m, 3H), 1.33–1.15 (m, 2H), 1.12 (d, J = 6.0 Hz, 3H),  
1.16–0.95 (m, 5H), 1.10 (s, 9H), 0.86 (d, J = 6.9 Hz 3H), 0.70 (s, 3H) ppm. 
 
13C NMR (CDCl3, 150 MHz): δ = 85.8, 80.8, 76.1, 72.4, 60.1, 58.9, 42.2, 41.7, 39.8, 39.6, 
36.3, 35.1, 31.7, 30.5, 29.4, 29.3, 29.0, 28.8 (2C), 26.0, 21.6, 20.5, 11.3 ppm.  
 
EI-MS for C25H42O2+ [M+]: calcd. 374.3179. 
 found 374.3174. 
 
IR (ATR): ῦ/cm−1 = 2960, 2927, 2865, 1455, 1386, 1373, 1360, 1259, 1196, 1094, 1062, 
1020, 951, 940, 918, 902, 859, 799, 753, 723, 705, 660. 
 
 = −25.8 (c 1.00, CH2Cl2). 
 
Synthesis of Hemiacetal 606 
   
 
   
To a commercial deep blue solution of SmI2 (14.3 mL, 0.072 M solution in THF, 1.03 mmol, 
10 eq.) was added a solution of diketone 604 (40 mg, 0.10 mmol, 1.0 eq.) in THF (2 mL) 
dropwise at room temperature via syringe pump over a period of one hour. The reaction was 
stirred for further 15 min, upon which it was diluted with Et2O (40 mL). The now colorless 
mixture was washed with saturated aqueous NaHCO3 (20 mL) and the aqueous layer was re-
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extracted with Et2O (3 × 20 mL). The combined organic layers were dried over Na2SO4 and 
concentrated under reduced pressure. Purification by flash column chromatography (silica, 
n-pentane:Et2O = 19:1 to 9:1) yielded hemiacetal 606 (18 mg, 46.1 µmol, 44%) as a colorless 
wax and as a single diastereomer. 
 
Rf = 0.90 (i-Hex:EtOAc = 4:1). 
 
1H NMR (C6D6, 600 MHz): δ = 3.50 (dd, J = 8.9, 7.3 Hz, 1H), 2.25 (dd, J = 12.8, 3.0 Hz, 
1H), 2.20 (dd, J = 9.1, 3.8 Hz, 1H), 2.09–1.92 (m, 6H), 1.80–1.52 (m, 5H), 1.51–1.40 (m, 
3H), 1.38–1.30 (m, 2H), 1.33 (s, 3H), 1.21 (m, 1H), 1.15–1.11 (m, 1H), 1.13 (s, 9H),  
1.10–1.01 (m, 2H), 0.97 (s, 3H), 0.94 (d, J = 6.9 Hz, 3H) ppm. 
 
13C NMR (C6D6, 150 MHz): δ = 103.8, 87.3, 81.5, 72.5, 61.2, 59.5, 42.9, 42.5, 40.7, 39.9, 
36.6, 35.1, 34.2, 32.6, 30.0, 29.7, 29.4, 29.3, 29.1, 27.0, 26.6, 22.0, 12.3 ppm.  
 
EI-MS for C25H42O3+ [M+]: calcd. 390.3129. 
 found 390.3119. 
 
IR (ATR): ῦ/cm−1 =3465, 2969, 2929, 2667, 1460, 1375, 1360, 1253, 1233, 1193, 1122, 1063, 
1026, 1012, 981, 953, 936, 904, 862, 835, 753, 733. 
 
 = −17.3 (c 0.50, CH2Cl2). 
 
Synthesis of Enone 612 
   
 
   
To a solution of alkene 475 (1.1 mg, 2.10 µmol, 1.0 eq.) in THF (300 µL) was added 9-BBN 
(9 µL, 0.5 M solution in THF, 4.20 µmol, 2.0 eq.) and the resulting solution was heated to  
40 °C for 3.5 hours. The mixture was then cooled to 0 °C, degassed aqueous Cs2CO3 (3 M,  
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3 µL, 7.34 µmol, 3.5 eq.) was added and the reaction was stirred vigorously at room 
temperature for 40 min. Subsequently, a solution of triflate 539 (1.1 mg, 4.20 µmol, 2.0 eq.) 
and AsPh3 (0.3 mg, 0.84 µmol, 0.4 eq.) in DMF (500 µL) was added. The resulting mixture 
was degassed and Pd(dppf)Cl2⋅CH2Cl2 (0.2 mg, 0.21 µmol, 10 mol-%) was added in one 
portion. The mixture was stirred for 26 hours and then partitioned between H2O (10 mL) and 
Et2O (20 mL). The aqueous layer was extracted with Et2O (3 × 10 mL) and the combined 
organic layers were dried over Na2SO4. The solvents were removed under reduced  
pressure and the crude product was purified by flash column chromatography (silica, 
i-Hex:EtOAc = 49:1 to 19:1 to 9:1) to yield enone 612 (1.0 mg, 1.57 µmol, 75%) as a 
colorless oil as a diastereomeric mixture of 5:1 together with 613.  
Note: The diastereomeric ratio, which refers to the stereogenic methyl group of the 
cyclopentene subunit, was determined from 1H NMR as HPLC methods did not achieve 
proper separation of the isomers. 
 
Rf  = 0.50 (i-Hex:EtOAc = 25:2). 
 
1H NMR (C6D6, 400 MHz): δ = 4.76 (d, J = 7.0 Hz, 1H), 4.72 (d, J = 7.0 Hz, 1H), 4.39 (td,  
J = 7.6, 4.0 Hz, 1H), 4.32–4.25 (m, 1H), 3.77 (td, J = 9.3, 7.2 Hz, 1H), 3.68 (td, J = 9.3,  
7.2 Hz, 1H), 3.34–3.17 (m, 1H), 2.73–2.63 (m, 2H), 2.42–2.33 (m, 1H), 2.30–2.22 (m, 1H), 
2.20–2.07 (m, 2H), 2.04–1.91 (m, 2H), 1.93 (s, 3H), 1.91–1.76 (m, 2H), 1.74–1.43 (m,  
8H), 1.28–1.20 (m, 1H), 1.15 (d, J = 6.6 Hz, 3H), 1.12–1.00 (m, 8H), 1.06 (s, 9H), 0.98 (d, 
J = 6.9 Hz, 3H), 0.84 (s, 3H), 0.75–0.61 (m, 6H), 0.01 (s, 9H) ppm. 
 
13C NMR (C6D6, 100 MHz): δ = 197.0, 161.7, 134.5, 93.7, 82.0, 70.7, 65.3, 54.9, 48.8, 43.6, 
42.2, 42.1, 41.2, 38.8, 34.5, 33.7, 33.5, 32.8, 31.2, 30.2, 30.1, 24.9, 24.7, 22.2, 20.3, 18.5, 
18.4, 17.6, 7.4, 5.8, −1.3. ppm.  
 
EI-MS for C37H70O4Si2+ [M+]: calcd. 634.4813. 
 found 634.4825. 
 
IR (ATR): ῦ/cm−1 = 2951, 2930, 2873, 1740, 1677, 1655, 1605, 1457, 1416, 1376, 1354, 
1248, 1195, 1159, 1100, 1048, 1029, 947, 921, 859, 834, 793, 740, 834, 691. 
 
 = +36.0 (c 0.05, CDCl3). [ ]20Dα
Experimental Section 
235 
Synthesis of Allyl Alcohol 615 
   
 
   
To a stirred suspension of WCl6 (240 mg, 610 µmol, 50 eq.) in THF (6.5 mL) was added 
n-BuLi (423 µL, 2.86 M solution in hexanes, 1.21 mmol, 100 eq.) dropwise at −78 °C. The 
resulting yellow solution was warmed to room temperature and was stirred for 45 min. After 
cooling to 0 °C, a solution of epoxide 510 (4.9 mg, 12.1 µmol, 1.0 eq.) in THF (2.0 mL) was 
added dropwise over a period of 15 min. The brown reaction mixture was then warmed to 
room temperature and stirred for one hour. Subsequently, half-saturated NaHCO3 solution  
(5 mL) was added at 0 °C and the layers were separated. The aqueous phase was extracted 
with n-pentane (3 × 20 mL). The combined organic layers were washed with saturated aqeous 
NaHCO3 solution (5 mL), dried over Na2SO4 and concentrated under reduced pressure. The 
crude product was purified by flash column chromatography (silica, n-pentane:Et2O = 197:1 
to 193:7) to yield the title compound 615 (4.0 mg, 10.3 µmol, 85%) as a colorless foam. 
Note: 13C NMR analysis was thwarted by signal broadening. Undetected and broad signals 
are attributed to C3 to C9, including C20 (nitidasin numbering). 
 
Rf = 0.83 (i-Hex:EtOAc = 25:1). 
 
1H NMR (C6D6, 400 MHz): δ = 3.85 (s, br, 1H), 3.36 (t, J = 8.2 Hz, 1H), 2.31–2.24 (m, 1H), 
2.21–2.10 (m, 2H), 1.97–1.76 (m, 5H), 1.71–1.59 (m, 2H), 1.60 (s, 3H), 1.54–1.42 (m, 4H), 
1.42–1.22 (m, 4H), 1.12 (s, 9H), 1.04–1.00 (m, 2H), 1.03 (d, J = 7.0 Hz, 3H), 1.01 (d, 
J = 6.8 Hz, 3H), 0.93 (s, 3H), 0.37 (s, br, 1H) ppm. 
 
13C NMR (C6D6, 100 MHz, observable signals quoted): δ = 142.8, 133.1, 81.2, 77.9, 72.2, 
45.4, 44.0 (br), 43.0, 40.3, 39.0 (br), 38.1, 32.3 (br), 31.9, 29.6, 29.0, 26.7 (br), 26.1, 23.9 (br), 
17.9, 15.5, 11.4 ppm. 
 
EI-MS for C26H44O2+ [M+]: calcd. 388.3341. 
 found 388.3321. 
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IR (ATR): ῦ/cm−1 = 3491, 2972, 2931, 2868, 1454, 1388, 1373, 1360, 1330, 1298, 1253, 
1229, 1198, 1133, 1085, 1064, 1038, 1022, 1000, 987, 967, 944, 903, 862, 836, 810, 755, 720. 
 
 = +152.8 (c 1.00, C6D6). 
 
Synthesis of Allyl Alcohol 616 
   
 
   
To a stirred suspension of WCl6 (148 mg, 370 µmol, 25 eq.) in THF (4.1 mL) was added 
n-BuLi (262 µL, 2.86 M solution in hexanes, 740 µmol, 50 eq.) dropwise at −78 °C. The 
resulting yellow solution was warmed to room temperature and was stirred for 45 min. After 
cooling to 0 °C, a solution of epoxide 522 (7.8 mg, 14.9 µmol, 1.0 eq.) in THF (1.5 mL) was 
added dropwise over a period of 15 min. The brown reaction mixture was then warmed to 
room temperature and stirred for one hour. Subsequently, half-saturated NaHCO3 solution  
(10 mL) was added at 0 °C and the layers were separated. The aqueous phase was extracted 
with n-pentane (3 × 40 mL). The combined organic layers were washed with saturated 
aqueous NaHCO3 solution (10 mL), dried over Na2SO4 and concentrated under reduced 
pressure. The crude product was purified by flash column chromatography (silica, 
n-pentane:Et2O = 187:13 to 37:3) to yield the title compound 616 (6.6 mg, 13.1 µmol, 85%) 
as colorless needles. 
Note: 13C NMR analysis was thwarted by signal broadening. Measurement at 50 °C is 
recommended. 
 
Crystals suitable for X-ray analysis were grown from slow evaporation of a solution of allyl 
alcohol 616 in n-pentane/MeOH. 
 
Rf = 0.46 (i-Hex:EtOAc = 40:3). 
 
Melting point = 141.6–143.0 °C (n-pentane/MeOH). 
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1H NMR (C6D6, 400 MHz): δ = 4.78 (d, J = 6.9 Hz, 1H), 4.74 (d, J = 6.9 Hz, 1H), 4.36 (ddd, 
J = 8.3, 6.9, 4.1 Hz, 1H), 3.87–3.77 (m, 2H), 3.70 (td, J = 9.3, 7.3 Hz, 1H), 2.51–2.44 (m, 
1H), 2.32–1.99 (m, 5H), 1.89 (td, J = 10.4, 4.1 Hz, 1H), 1.80 (s, br, 1H), 1.73–1.55 (m,  
3H), 1.62 (s, 3H), 1.50–1.23 (m, 8H), 1.16 (d, J = 6.6 Hz, 3H), 1.08–1.00 (m, 3H), 1.03 (d, 
J = 6.3 Hz, 3H), 1.03 (d, J = 6.8 Hz, 3H), 0.94 (d, J = 7.2 Hz, 3H), 0.74 (s, 3H), 0.30 (s, 1H), 
0.02 (s, 9H) ppm. 
 
13C NMR (C6D6, 100 MHz, 50 °C): δ = 143.1, 133.1, 93.8, 82.4, 78.1, 65.4, 55.3, 48.9, 45.0, 
44.2, 43.7, 42.6, 42.0, 39.0, 38.9, 34.6, 32.4, 30.2, 29.7, 26.8, 24.8, 23.7, 22.3, 20.3, 18.5, 
17.9, 15.5, −1.2 ppm.  
 
EI-MS for C31H54O2Si+ [(M−H2O)+]: calcd. 486.3893. 
 found 486.3896. 
 
IR (ATR): ῦ/cm−1 = 3482, 2952, 2921, 2871, 1462, 1451, 1372, 1302, 1250, 1229, 1204, 
1163, 1146, 1106, 1058, 1031, 990, 858, 834, 758, 741, 710, 692. 
 
 = +82.0 (c 1.00, C6D6). [ ]20Dα
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1. Introduction 
 
1.1 The Physiological Role of Calcium 
 
Calcium ions play a manifold role in the physiology and biochemistry of essentially all higher 
organisms and their intra- and extracellular concentrations are tightly regulated.[370] In 
vertebrates, the bones act as the major mineral storage site for Ca2+ and contain up to 99% of 
its total body content. At this site, it is bound mainly as hydroxylapatite (Ca10(PO4)6(OH)2), 
but also as calcium phosphate, carbonate, citrate, fluoride and sulfate. Calcium is released 
from the bone tissue into the blood stream as free ions or bound to proteins like serum 
albumin in a controlled manner. The major regulation factors are the peptidal hormone 
parathyroid[371] and the activated form of vitamin D3, calcitriol (not shown),[372] which 
promote the resorption of Ca2+ from bone, kidney and the intestines. In contrast, the 
polypeptide calcitonin opposes the effect of parathyroid hormone and reduces the blood levels 
of Ca2+.[373,374] Within the cytoplasm of cells, membrane channels in the plasma membrane 
and in the organelles mediate the inward flow of Ca2+, whereas ATPases, ion exchangers and 
the mitochondrial Ca2+ uptake system[375] are responsible for its removal.[370] 
Calcium plays a pivotal part in a diverse array of cellular processes such as signal 
transduction as second messenger,[376] neurotransmitter release from neurons,[377] secretion of 
bioactive molecules,[376,377] muscle contraction,[378] gene expression[379] and as a co-factor for 
several enzymes.[380] Furthermore, the difference between intra- (~100 nM unbound) and 
extracellular Ca2+ concentrations allows for a precise temporal control of cellular processes 
and is e.g. about 20000-fold in different types of neurons.[376d] In this cell type, voltage-gated 
calcium (CaV) and cation selective ligand-gated ion channels are primarily responsible for the 
spatially confined influx of Ca2+ ions, which is triggered upon membrane depolarization. Thus 
generated micro- and nanodomains of elevated Ca2+ levels are typically of a diameter of 10 to 
1000 nm and are sufficient for the binding to the calcium sensor protein synaptogamin that is 
found in the membranes of the pre-synaptic vesicles.[377b] The following exocytosis of those 
neurotransmitter-loaded vesicles is initiated by the so-called SNARE protein complex and is 
in turn dependent on Ca2+-mediated displacement of complexin by synaptogamin.[381] Release 
of the neurotransmitter may directly open ligand-gated ion channels in the post-synaptic cell 
membrane. Depending on the nature of the receptor and the neurotransmitter, this will cause 
ions to enter or exit the cell, thus changing the local transmembrane potential and propagating 
or inhibiting the action potential.[372] In this context, the small molecules acetylcholine, 
1.1 The Physiological Role of Calcium 
242 
γ-amino-butyric acid (GABA), serotonin, histamine, dopamine and noradrenaline define the 
most significant inter-synaptic signaling systems in human physiology that are known to 
date.[382] However, inhibition of neuronal activity can also occur form the pre-synaptic site 
and is frequently mediated by metabotropic GABA receptors or e.g. the muscarinic 
acetylcholine receptors and adenosine receptors.[383] For this mode of action, overall a 
membrane hyperpolarization is induced by an increased chloride ion conductance that leads to 
a subsequent reduction of Ca2+ entry via CaV channels.[384] 
Another type of process that is associated with the synaptic uptake of calcium ions is the 
regulation of gene expression and dendritic differentiation in those cells. Especially the so-
called L-type calcium channels (LTCCs), which are also voltage-gated and will be discussed 
in more detail in the following chapters, have been subject of numerous investigations on 
their effects on gene transcription.[376e] Historically, in 1986 Greenberg et al. were the first to 
demonstrate that agonists of the nicotinic acetylcholine receptor and similar membrane 
depolarizing agents cause a fast and transient activation of the c-fos proto-oncogene in 
neuronal cell lines via induction of calcium influx through LTCCs.[385] Following studies in 
this field have disclosed that c-fos is only one amongst several hundred genes that are 
controlled by neuronal activity throughout the formation and maturing of synapses.[386] 
Interestingly, many of those genes seem to influence various aspects of synaptic function and 
development, as for instance the synthesis of the neurotropin BDNF (dendritic growth), the 
cytoplasmic protein Arc (glutamate receptor endocytosis) and the formation of synaptic 
protein complexes, which is closely linked to Homer1a.[376e] Considerable efforts were 
undertaken to elucidate the second messenger pathways which propagate the calcium signal to 
the nucleus and it was shown that three distinct mechanisms eventually focus on the 
phosphorylation of the Ser133 residue of the cAMP response element-binding protein 
(CREB). In its active form, this leucine-zipper-type DNA-binding protein constitutes an often 
encountered transcription factor and has amongst others been linked to the circadian 
clock.[387] 
The first of those signaling avenues that lead to CREB phosphorylation was originally 
reported by Deisseroth et al.[388] and proceeds via the binding of up to four calcium ions to 
calmodulin (CaM), which is accommodated closely to the internal face of LTCCs.[376d,389] The 
authors established that CaM translocation is fast enough (1–2 min) to account for the kinetics 
of nuclear CREB activation. In their studies it was proven that even large increases in bulk 
cellular Ca2+ concentration fail to promote the mentioned phosphorylation if not coupled to 
CaM. In addition, it was proposed that CaMKIV would be an intermediary nuclear target of 
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this mechanism, as it is the substrate of CaM-dependent kinases[390] and had been implicated 
in neuronal activity-dependent CREB phosphorylation previously.[391] Several years later, 
another pathway that acts on the same time scale and requires an initial binding of calcium 
ions to apo-CaM was discovered.[392] A further event in this cascade is the activation of 
Ca2+/CaM-dependent protein kinase II (CaMKII), which has been shown to associate for 
instance with CaV1.2 (vide supra).[393] However, the ensuing signaling steps that finally result 
in CREB phosphorylation are still a matter of debate. Independent from this a third and 
comparably slow mechanism (30–60 min) has been shown to transmit the CREB activating 
signal via the Ras-MAP kinase pathway.[394] Therefore, it was suggested that scaffolding 
proteins bound to an LTCC intracellular domain may recruit Ras-MAP kinase activators. This 
would allow CaM, which in this context seems to be basally tethered to the LTCC,[395] to 
switch them on directly or indirectly by a conformational change of the channel.  
As modern biochemistry has made decisive advances toward the understanding of the 
physiological role of calcium, especially its relevance in neuronal activity calls for the 
development of chemical tools that allow a spatial and temporal control of its concentration in 
living tissue. To understand the potential starting points for the design of related small 
molecule-based strategies, the following chapter will provide an introduction on the subtypes 
and structures of CaV channels. 
 
1.2 Voltage-gated Calcium Channels: Structural Composition and Subtypes 
 
Voltage-gated calcium channels are the principal source of depolarization-induced calcium 
influx in neurons and exhibit a great diversity of subtypes that is caused by the existence of 
multiple genes for calcium channel α1 subunits. Furthermore, coassembly with a variety of 
auxiliary calcium channel subunits and alternative gene splicing is observed throughout the 
whole class. This accounts for the high number of specialized roles that they fulfill in several 
distinct neuronal subtypes and particular subcellular loci. Since the discovery of manipulable 
calcium currents in neurons by the seminal investigations of Katz and Miledi,[396] Hagiwara 
and Nakajima,[397] as well as Reuter,[398] several milestone achievements have led to the 
identification of ten sorts of humane CaV channels that show major differences in the 
composition of their α1 subunits.[399] Commonly they are classified either according to those 
α1 domains or to a one letter code that refers to the respective electrophysiological properties 
and first site of characterization. Table 1.1 lists all congeners of this family known to date,  
as well as their primary physiological function and the established specific blocking 
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Table 1.1: Classification and function of known humane CaV channels according to Catterall.[400] 
Ca2+ current 
type 
α1 subunit 
type 
specific 
blockera 
primary physiological 
functions 
    
L CaV1.1  
 
 
DHPs, BTZs, 
PAAs 
(for all L-type) 
excitation-contraction coupling in skeletal muscle, 
transcription regulation 
 CaV1.2 excitation-contraction coupling in cardiac and 
smooth muscle, endocrine secretion, neuronal Ca2+ 
transients in cell bodies and dendrites, enzyme 
activity regulation, transcription regulation 
 CaV1.3 endocrine secretion, cardiac pacemaking, neuronal 
Ca2+ transients in cell bodies and dendrites, auditory 
signal transduction 
 CaV1.4 visual signal transduction 
N CaV2.1 ω-conotoxin 
GVIA[401] 
neurotransmitter release, dendritic Ca2+ transients 
P/Q CaV2.2 ω-agatoxin[402] neurotransmitter release, dendritic Ca2+ transients 
R CaV2.3 SNX-482[403] neurotransmitter release, dendritic Ca
2+ transients 
T CaV3.1 – pacemaking and repetitive firing 
 CaV3.2 – pacemaking and repetitive firing 
 CaV3.3 – pacemaking and repetitive firing 
a) Small molecule based blockers like the dihydropyridines (DHPs) will be discussed in chapter 1.3.1. The remaining agents 
listed are peptide-based toxins. 
agents.[400] Additionally, CaV channels can be distinct whether they are high voltage (about 
−20 mV) or low voltage (about −70 mV) activated. It has been shown that channels of the 
first type are constituted of heteromultimeric protein complexes that are formed by the 
assembly of a pore-forming α1 unit plus auxiliary β and α2δ subunits,[404] whereas the second 
category appears to lack these auxiliary elements.[405] Before discussing the structural features 
of CaV channels more in-depth, a short introduction on the single LTCCs shall be given, as 
they denote the relevant targets of the chemical tools developed within present doctoral thesis. 
The specific properties of N- (‘neuronal’), P- (‘purkinje’), Q- (first recorded in cerebellar 
granule neurons),[406] R- (‘residual’) and T-type (‘transient’) CaV channels have been 
reviewed elsewhere.[399,400,407] 
The four LTCCs encoded by the human genome display slow voltage-dependent gating 
characteristics and therefore are long (L-type) lasting when Ba2+ is the current carrier and 
there is no Ca2+-dependent inactivation.[408] The first member CaV1.1 is mostly expressed in 
skeletal muscle and primarily acts as a voltage sensor, connecting depolarization to release of 
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intracellular calcium by activating the ryanodine receptor in the sarcoplasmic reticulum.[409] 
The coupling of the opening of this channel to membrane depolarization has been shown to be 
rather inefficient and slow.[410] CaV1.2 and CaV1.3 channels exhibit largely similar expression 
behavior in different tissues and are often localized in the same neuronal compartments  
– particularly dendrites – but their subcellular distributions appear distinct.[411] Thus, both 
congeners can be found for example in pancreatic cells, smooth muscle or neurons, whereas 
solely ventricular cardiac muscles harbor CaV1.2 and atrial tissue only CaV1.3 channels, 
respectively.[412] CaV1.2 helps defining the shape of the action potential in cardiac and smooth 
muscle and triggers the signaling cascade that leads to the contraction of those muscles by its 
primary function, the actual Ca2+ influx.[413] In neurons, CaV1.2 has been evidenced to couple 
membrane depolarization to regulation of gene expression (vide supra).[394,414] At this, CaV1.3 
has been demonstrated to induce higher levels of CREB phosphorylation.[415] A common 
feature of both channels is their role in hormone secretion, which is particularly well studied 
in adrenal chromaffin cells, where calcium that enters via this source drives much of the 
release of catecholamine.[416] Their channel kinetics are faster than those of CaV1.1 and they 
will open at membrane potentials of approximately −20 mV and −40 mV, at which CaV1.3 
requires less depolarization.[412] The CaV1.4-encoding gene is expressed almost exclusively in 
the retina and is connected to the rare disorder stationary night blindness.[417] However, RNA 
that is translated to this channel has also been found in dorsal root ganglia.[418] CaV1.4 is 
located at synaptic terminals of retinal bipolar cells and is specifically responsible for Ca2+ 
entry that triggers exocytosis of neurotransmitters.[419] In comparison to other LTCCs, this 
channel undergoes no calcium-dependent inactivation due to an autoinhibitory domain at its 
intracellular C-terminus.[420] 
Although the molecular structure of CaV channels has been investigated intensely, still no 
solid-state structure of their central pore-forming α1 domain has been published in literature 
to date. Knowledge about their structural features and functions thereof is based on sequence 
homology to other channel types (especially KV channels), site-directed mutagenesis and 
analysis of the biochemical properties, glycosylation, and hydrophobicity,[399,400] which all 
became possible after the first cloning and expression of a Ca2+ channel gene by Tanabe and 
co-workers in 1987.[410c,421] Scheme 1.1 illustrates the basic constituents of CaV channels in a 
flat and three-dimensional drawing, of which the latter is based on cryo-electronmicroscopic 
measurements on CaV1.1.[422] 
All ten known α1 subunits share a common topology of four homologue transmembrane 
domains (I-IV), each of which contain six membrane-spanning α-helices (S1-S6). Generally,
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Scheme 1.1: a) Subunit composition and transmembrane topology of CaV subunits. The zigzag line on the α2δ 
portion illustrates the GPI-anchor. The positive charges denote the voltage sensor regions located 
at the S4 helices. b) Side view of native high and low voltage-gated Ca2+ channels and their 
respective subunits. c) Illustration of the CaV1.1 channel based on cryo-electronmicroscopic 
images (reproduced from ref. 400).  
the α1 domain contains about 2000 amino acids and has a mass of roughly 190 kDa.[399,400] 
Like in similar ion channels, a positively charged S4 segment imparts voltage-dependent 
activation and a re-entrant loop motif (P) between S5 and S6 composes the ion-permeating 
pathway. Those P-loop sequences contain highly conserved negatively charged amino acids 
and their amide carbonyl and side chain carboxylic acid functions form a pore that is highly 
selective for permeating cations such as calcium.[423] The greatest sequence variation amongst 
CaV subtypes is given between the major membrane domains I-IV in the cytoplasmic linker 
regions, which mediates important protein-protein interactions with regulatory and second 
messenger elements such as G proteins and protein kinases.[424] 
For the CaVβ subunits, there are currently four encoding genes (β1–β4) and several alternative 
splice transcripts known.[425] This type of protein is located on the cytoplasmic site of CaV 
channels and contains conserved SH3 and GK domains, of which the latter enables the 
association to the loop region between the domain I and II of an α1 unit.[399] As a consequence 
of this interaction, a modification of the gating properties of the pore-forming core[425,426] and 
increased cell surface trafficking is observed. In this regard, it has been proven that the 
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β-subunit leads to an inhibition of ubiquitination and degradation of the channels, as well as to 
a masking of intrinsic endoplasmatic reticulum (ER) retention signals located on the α1 part. 
Currently, four isoforms of the α2δ subunit have been identified (α2δ1–α2δ4), which are all 
transcribed and translated as a single protein, post-translationally cleaved to the α2 and 
δ portion, and then recombined via disulfide linkage.[427] Recent findings oppose the original 
thought that the α2δ complex spans the membrane and indicate that it is attached to the 
extracellular site by a glycophosphatidylinositol (GPI) anchor.[428] Although the overall effect 
of the α2δ part on channel function seems to be relatively small,[429] increased levels of 
expression in neurons have been linked to improved pre-synaptic abundance of CaV channels 
and enhanced synaptic release probability.[430] 
In skeletal muscle the ancillary CaVγ subunit can be found, which is a glycoprotein that 
comprises four transmembrane helices.[431] So far, the genes of seven potential isoforms have 
been identified, including CaVγ2 (‘stargazin’).[432] Besides their evidenced effects of whole-
cell current density,[433] also association with other cellular functions such as AMPA receptor 
trafficking has been described.[434] Furthermore, considerable evidence has been provided that 
all high voltage-gated CaV channels associate with CaM, suggesting that CaM should be 
considered as the fifth calcium channel subunit.[399,435] 
 
1.3 L-Type Calcium Channels: Pharmacological and Functional Aspects 
 
Whilst presented knowledge has contributed much to the understanding of regulation 
mechanisms in CaV channels, drug interactions still have to be calculated using homology 
models with other channel types. The next chapters will provide a short overview of blocking 
agents for LTCCs and will specifically focus on the class of dihydropyridines (DHPs) and 
benzo(thi)azepines (BTZs). To this end, the known structure-activity relationship (SAR) 
studies for the latter compounds will be summarized, as they were of central importance for 
the development of the photoswitchable CaV ligands that were prepared in the course of 
present doctoral thesis. 
 
1.3.1 Channel Gating and Inactivation 
 
In order to understand the mode of action of possible CaV agonists or antagonists, the 
different states which LTCCs undergo while ion gating is initialized or deactivated have to be 
considered.  
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The actual ion filter of the channel pore is composed by the previously mentioned four P-loop 
regions and has recently been investigated by electrophysiological and X-ray crystallographic 
analyses of a mutated NaVAb channel.[423] Introduction of the three aspartate residues of the 
CaV P-loop sequence conferred Ca2+ selectivity to the channel chimera and the authors could 
deduce the structural basis for this finding. Interestingly, it was found that most or all 
interactions of Ca2+ ions with the pore are made through its inner hydration shell. A set of 
three Ca2+ binding sites was identified, cooperating in a knock-off mechanism, at which the 
selectivity filter oscillates between two states with either one hydrated Ca2+ ion bound at a 
central site or two hydrated Ca2+ ions bound at the respective distal sites. 
The primary opened or closed states of the channel are determined by the S4 voltage sensor 
segments of the homologous domains, respectively.[400] Upon membrane depolarization those 
helices move outward and rotate under the influence of the electric field. Thus, a 
conformational change is initiated that opens the pore gate, which is formed by the 
S6 sections and represents an important part of the receptor sites for pore-blocking drugs 
specific for LTCCs (vide supra).[436] 
Besides, two major pathways for CaV inactivation have to be accounted for, which prevent 
Ca2+ overload in response to prolonged membrane depolarization. Understanding of how 
these modes work at a molecular level is particularly important, given that for instance 
clinically used DHP- or benzo(thi)azepine-based drugs show different channel affinities in the 
order inactivated > open > closed state.[437,438] Common to all CaV subtypes is the voltage-
dependent inactivation (VDI), which varies in its extent throughout the channel isoforms and 
is potentially modulated by the β subunit.[439] In their studies, Zamponi and co-workers 
proposed a mechanistic model that involves a structural rearrangement of the S6 segments in 
response to sustained depolarization (scheme 1.2a).[440] This change would presumably lead to 
the exposure of a docking site for the domain I-II linker region, thus giving rise to a hinged-
lid-like gating particle.[439] Notably, in CaV1.3 channels, this docking process has been found 
to be modified by an additional inhibitory element, which was termed the ‘inactivation 
shield’.[441] In contrast, calcium-dependent inactivation (CDI) becomes apparent when CaV 
channel currents are compared in the presence of Ba2+ or Ca2+.[442] For this case it is believed 
that calcium-free CaM preassociates with the C-terminus of the channel in such a way that 
both ends of CaM are bound to specific domains thereon (scheme 1.2b).[443] The rise of 
intracellular Ca2+ levels ultimately promotes molecular repositioning of fully loaded CaM that 
in turn triggers additional interactions with the N-terminus und consequently results in CDI.
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Scheme 1.2: Mechanisms of a) voltage-dependent inactivation (VDI) and b) calcium-dependent inactivation 
(CDI) of CaV channels. CaM can accommodate four calcium ions (purple dots). 
At this, it has been proven that already the formation of calcium nanodomains is sufficient for 
CaV1.2 and CaV1.3 channels to initiate this mechanism.[444] 
From an electrophysiological point of view, a simplified consideration of gating in LTCCs 
has led to two main kinetic models,[445] which suggest multiple closed states and one open 
species. Investigations thereof are mainly linked to the elucidation of the voltage-dependent 
block of DHP antagonists.[446] 
 
1.3.2 Overview on the Known Agonists and Antagonists 
 
In regard of the crucial importance of CaV and especially LTCCs channels for the human 
physiology, the artificial control of their function has become the focus of numerous scientific 
and clinical studies. In 1882, Ringer described for the first time that calcium influences the 
contraction of heart muscle tissue, which was quickly lost when Ca2+ was deprived from 
employed media.[447] The discovery of Ca2+ antagonism for the use in coronary drugs was first 
reported in 1964 by Fleckstein and co-workers, who found that verapamil (642) and 
prenylamine (643), mimic the cardiac effects of simple calcium withdrawal (scheme 1.3).[448] 
In the following years, their laboratories identified a considerable number of similarly acting 
compounds, which were either based on the phenylalkylamine (PAA) structure similar to 
verapamil (642) or congeners of the new class of dihydropyridines (DHPs), like nifedipine 
(644).[449] Diltiazem (645), the archetype of the benzo(thi)azepine (BTZ) family, was  
initially published by a Japanese group of scientists in 1975 for its antagonistic  
effects on Ca2+ currents.[450] Later on, it was proven that most members of the 
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Scheme 1.3: Molecular structures of a) representative selective LTCC antagonists and b) an illustration of 
the location of their binding sites in LTCCs, as well as c) unselective LTCC antagonists. 
above named substance classes would act with high selectivity (90–100%) on Ca2+-type, 
rather than on Na+- or K+-type currents.[449] It was soon established that LTCCs are the 
primary physiological target of those compounds.[446c,451] In the beginning of 1975, nifedipine 
(Adalat®, 644) was approved for treatment of coronary diseases in Germany.[452] Since then, 
several derivatives thereof have been introduced to the market for the reduction of systemic 
vascular resistance and arterial pressure at symptoms like hypertension or for the treatment of 
angina pectoris.[446c,453] Further investigations by means of photoaffinity labeling and antibody 
mapping suggested that all mentioned types of selective LTCC antagonists reside in three 
distinct, but overlapping binding sites near the S6 domain of the channel pore.[454] A plethora 
of studies has been designated to the identification and characterization of those binding sites, 
which mainly referred to mutagenesis experiments.[453,455] The concomitantly generated SAR 
data will be presented in chapter 1.3.4 for the case of BTZ-type CaV channel blockers. 
Notably, only peptide toxins are currently available as selective probes for the  
different members of the non-L-type CaV channel family. Besides this, several rather  
unselective antagonists like mibefradil (646),[456] caroverine (647),[449] fluspirilene  
(648)[457] and flunarizine (649),[458] are known. Furthermore, gabapentin (650) and  
related compounds have been evidenced to disrupt CaV channel trafficking by  
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Scheme 1.4: Molecular structures of prominent LTCC activators and of the α2δ subunit modulator 
gabapentin (650). 
targeting the α2δ subunit (scheme 1.4).[459] Drugs that promote current through LTCCs (CaV 
channel activators) have also been described and prominent examples are the dihydropyridine 
(−)-BAY K 8644 (651),[460] the benzoylpyrrole FPL 64176 (652)[461] and the benzodiazocine 
CGP 48508 (653).[462] 
 
1.3.3 Dihydropyridine-based LTCC Blockers 
 
The class of DHP-based CaV channel ligands is probably the most well investigated and since 
their discovery a considerable number of studies have tried to elucidate their binding site at 
the ion gating enzymes. Thus it was recognized that LTCCs are not all inhibited equally by 
DHP antagonists. Specifically CaV1.3 and CaV1.4 channels are significantly less sensitive 
when compared to CaV1.2.[412,463] One of the most potent congeners developed so far is the 
racemic compound felodipine (654), which exhibits an IC50 value of 14.9 nM (scheme 
1.5).[464] An interesting approach toward probing for the binding pocket of DHPs involved a 
molecular tape measurement, at which a positively charged quaternary ammonium function 
was attached to a DHP core structure via an alkyl linker of varying length.[465] Thus it was 
estimated, that the antagonist resides approximately 11–14 Å away from the channels’ 
extracellular face. Furthermore, a “sidewalk” pathway was found that allows the blockers to 
access the channel interior from the external, but not from the internal side.[466] Today it is 
known that this DHP receptor site lies between the transmembrane helices III-S5, III-S6,  
IV-S6 and the pore loop region III-P.[467] However, due to the lack of crystallographic data on 
CaV α1 domains, the exact interactions between the drugs and the channels remain unknown. 
Modern approaches addressing this problem rely on computational methods and employ 
homology models, as for instance demonstrated by Zhorov et al.[467e] These authors used a 
mixed construct, where the open state was calculated in analogy to KVAP, the closed state 
according to a KcsA template and the selectivity filter was based on a NaV1.4 P-loop domain
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Scheme 1.5: The LTCC blocker felodipine (654), an illustration of a commonly used DHP nomenclature 
and the ineffective azobenzene derivatives (656–659) previously evaluated in the Trauner 
laboratories.  
model. As a consequence, four models of DHP-bound LTCCs have been published to 
date.[468] The major consensus found in these hypotheses is, that the portside group of DHP 
structures (cf. structure 655) is oriented toward the ring of hydrophobic residues in the  
C-terminal halves of S6 helices. Thus, hydrophobic groups at the portside of the DHP-type 
antagonists are proposed to stabilize the closed state of the activation gate, whereas 
hydrophilic groups would act in converse manner.  
With these findings in mind, the Trauner laboratories had set out to design and synthesize 
potential photochromic versions of the mentioned DHP felodipine (654).[469] To this end, the 
compounds Feazo 1–3 (656–658), as well as the FPL 64176 analogue FPL-azo (659) were 
prepared and electrophysiologically evaluated. Although the photochromic DHP derivatives 
remained potent CaV1.3 blockers, no control of Ca2+ currents could be achieved with light. 
The same held true for FPL-azo (659), which additionally induced significantly less activation 
of Ca2+ influx than its respective parent compound.  
 
1.3.4 Benzo(thi)azepine-based LTCC blockers 
 
Benzo(thi)azepines (BTZs) are complex molecules with many different functional groups and 
so is their mode of action as LTCC antagonists, which exhibits several observable 
dependencies. Frequency-dependent block has been demonstrated by increasing the number 
of depolarization stimuli in a given time window. In general this leads to more effective 
inhibition of Ca2+ currents.[470] This ‘use-dependent block’ termed behavior is consistent with 
the hypothesis that the distinct functional states of the channel have different affinities for 
those drugs (vide infra). Furthermore, raising Ca2+ or Ba2+ concentrations counteracts  
the effect of e.g. diltiazem (645), at which the channel block is stronger when calcium is  
used as charge carrier.[471] Thus, the function of BTZs is considered to be potentiated by Ca2+,
   
CO2R
(S)-felodipine (654)
N
H
Cl
COOMeEtOOC
Cl
NH
Me
Me
R'O2C
H
X
starboard
portside
sternbowsprit
655
ortho:
meta:
para:
N
H
Cl
MeOOC
Cl
O
O N N
feazo 1 (656)
feazo 2 (657)
feazo 3 (658)
N N
O
NH
COOMe
FPL-azo (659)
Introduction 
 
253 
 
Scheme 1.6: Molecular structures of SQ 32910 (660) and benziazem (661). The calculated binding mode of 
the latter BTZ was illustrated next to it, with the basic pharmacophore (red) and the 
photolabeling side chain (dark blue). The most significant interactions of BTZs and LTCCs 
known from SAR studies were indicated at the structure of diltiazem (645). 
suggesting that the presence of those ions in the channel is required for high affinity 
binding.[437] A third characteristic of BTZs was revealed when tertiary amine and quaternary 
ammonium containing analogues were either applied from the extra- or intracellular side. 
Interestingly, BTZs did not result in significant block from the cytoplasmic face, leading to 
the conclusion that they enter LTCCs via an extracellular pathway.[472] In contrast to this, 
more recent studies, which employed a quaternary ammonium version of diltiazem (645), 
have disclosed that use-dependent current inhibition is induced by the protonated form of 
diltiazem from the inside.[473] Concomitantly, it was proposed that this derivative accesses the 
same binding pocket as externally applied BTZs via a similar pathway previously found for 
charged PAA antagonists. An early approach to identify this receptor site was conducted by 
Kraus et al. via labeling of LTCCs purified from skeletal muscle by photoincorporation of 
[3H]benziazem (not shown).[474] Accordingly, the ligand could be detected in four tryptic 
fragments of the III-S6 and IV-S6 regions at the α1 domain (cf. chapter 1.2). Further 
elucidation of the BTZ-sensing residues of LTCCs was achieved by different mutational 
studies, which were complicated by the unequal effects on distinct BTZ drugs or the 
characteristics of blocked Ca2+ currents.[475] A common finding was that selectivity filter 
mutations do not alter diltiazem block of closed channels in Ba2+ containing media, but 
disrupt frequency-dependent block and potentiation by calcium ions.[471] Besides, some other 
residues of the P-loops on the SIII and SIV segments seemed to be involved in BTZ-
binding.[475] The determinants for the atomic-level mechanism of block by BTZ-type CaV 
channel antagonists remained largely unclear until Zhorov and Tikhonov published their 
computational analysis, which referred to a homology model of CaV1.2 to KVAP and 
KscA.[437] In their docking experiments, the two ligands SQ 32910 (660)[476] and benziazem 
(661)[477] were used to account for BTZs with small and large substituents at the essential 
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amino function. Scheme 1.6 illustrates the determined interactions of those ligands with the 
channel model on the exemplary structure of diltiazem (645). In the proposed binding mode, 
the carbonyl oxygen of BTZs directly connects with a calcium ion, that in turn is associated to 
two glutamic acid residues in the selectivity filter region of the P-loops of segments III and 
IV. An interpretation of the state-dependent binding of BTZs was given by the calculated 
possibility of the amino group to bind either at the focus of P-helices (channel pore) in the 
presence of Ca2+, or to a selectivity filter glutamate in the absence thereof. In the closed-state 
of the channel, specific hydrophobic interactions to a phenylalanine and isoleucine residue on 
the III-S6 and IV-S6 helices were lost, explaining the experimentally observed lower affinity 
to the ligand (vide supra). A viable entry for BTZs to the receptor site was confirmed and 
would proceed via the III/IV domain interface. Notably, benziazem (661) was found to bind 
in the same mode as smaller BTZs, at which the large substituent on the amino function 
protrudes into the channel pore, being directed toward the cell interior.  
In this context, the previously established SAR data[476,478] on BTZ-type CaV channel ligands 
was reinvestigated. A decisive feature for BTZ potency is administered by the methoxy 
function at the aromatic ring A. Whilst larger substituents, like e.g. an ethyl moiety, were 
proven to result in a pronounced drop in blocking efficiency,[478c] the calculations showed an 
H-bond to a tyrosine residue on the IV-S6 helix that is specific for LTCCs.[437] Both aromatic 
portions exhibit important interactions with hydrophobic residues of the channel interface, 
whereas the substituent at position C-3 of the 7-membered ring system seems to have only a 
moderate effect on the BTZ potency.[478c] However, the absolute and relative configuration of 
the two adjacent stereocenters was demonstrated to be crucial for the efficacy of 
diltiazem (645).[479] The already mentioned amino functionality that constitutes the actual 
pore-blocking moiety can only be substituted by other hydrophilic groups under substantial 
loss of potency.[437,471] However, a multitude of derivatives having large substituents tethered 
to this function were published in the past,[476,478] which is why this position drew our 
attention for the potential installment of an azobenzene side chain.  
 
1.4 Project Outline 
 
As outlined in the preceding chapters, Ca2+ is a major determinant in neurotransmitter release 
and gene regulation via second messenger pathways in neurons. Controlling the influx of Ca2+ 
through CaV channels in a light-dependent manner would allow studying these events in more 
detail. A chemical tool that mediates such a behavior would potentially lead to a deeper 
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understanding of the temporal and spatial correlations of LTCC activity and its downstream 
signaling events. 
    
 
Scheme 1.7: Design of a potential photochromic LTCC antagonist, based on the diltiazem (645) core 
structure and featuring various potential sites for convenient chemical modification. 
The present project aimed at the development of novel, benzo(thi)azepine-based 
photochromic ligands for LTCCs. To this end, it was envisioned to attach an azobenzene 
moiety as molecular switch to an appropriate site of the BTZ pharmacophore. This concept 
has become a leitmotif of the Trauner laboratories and has previously enabled the 
photocontrol of e.g. KV or NaV channels, as well as ionotropic glutamate receptors.[480] Based 
on the known SAR data and homology models (cf. chapter 1.3.4) structure 662 was designed 
as an initial target for a synthetic program (scheme 1.7). Similar to benziazem (661), the large 
aromatic azobenzene core was linked to the pore-blocking amino function. The length of the 
alkyl spacer was considered to be variable and the optimal size would be determined by 
means of electrophysiological evaluation of a compound library. However, it was reasoned 
that shorter distances between the blocking amino function and the azobenzene switch could 
potentially yield higher efficacies of block and unblock, due to a more pronounced effect of 
the change in spatial demand and dipole moment on the position of the amino function. For 
the terminus of this linking chain, an amide function was chosen, which would provide a 
convenient way to attach several azobenzene substructures with desirable substitution patterns 
and photochemical properties. The introduction of more red-shifted and faster relaxing 
diazene switches might be necessary to adjust the ligand to the gating kinetics of the target 
channel. Diltiazem (645) was meant to be the basic pharmacophore, as several laboratory and 
industrial syntheses thereof have been described in literature.[481] In principle those synthetic 
protocols should enable a broader insight in feasible chemical modifications of the bicyclic 
core, once the need to introduce additional structural modifications arises.[482] The second 
stage of the project would involve the electrophysiological evaluation of the synthesized 
compounds and the chemical optimization of a potential lead structure to ultimately combine 
potent LTCC antagonism and efficient light-induced block and unblock. 
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2.  Development of Photochromic Ligands for LTCCs 
 
2.1 An Enantioselective Approach Toward Benzothiazepine-based Photochromic 
LTCC Blockers  
 
Based on the considerations discussed in the project outline, the presented synthetic program 
initially aimed for the synthesis of two prototypic azobenzene analogues of diltiazem (663 
and 664). The retrosynthetic plan for these targets envisioned placing the first disconnection 
at the amide bond to 4-(phenylazo)benzoic acid (665). In order to allow a most convergent 
preparation of several analogues, further cleavage was planned at the alkyl linkage to the 
amide nitrogen of the 7-membered ring system and the C-3 located acetyl group (scheme 2.1). 
Previous syntheses of diltiazem (645) have shown that the first mentioned bond can be 
formed via convenient alkylation procedures,[481b,c] which traces the molecule back to the 
halogenated linker fragments 666 and 667 and the tricyclic core of diltiazem (668). The latter 
was meant to be accessible in an enantiopure fashion via modification of the synthetic 
protocol disclosed by Jacobsen et al.[481g] To this end, the central thiazepine ring system 
would arise from intramolecular lactam formation between the ester moiety of epoxide 
precursor 669 and the aniline nitrogen. The latter function would be present after 
stereospecific addition of o-nitro-thiophenol (670) to this very epoxide (669) and subsequent 
Béchamp reduction thereof.[483] Substance 669 should be synthesized asymmetrically from the
    
 
Scheme 2.1: First-generation retrosynthetic analysis for the enantioselective and convergent synthesis of the 
potential photochromic LTCC antagonists 663 and 664. 
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respective Z-cinnamon ester (not shown) by Jacobsen-Katsuki epoxidation,[484] which is well 
established for those substrates.[481g] To address the required ester, it was intended to employ a 
literature-known sequence[481g] that proceeds via Corey-Fuchs homologation[256] and Lindlar 
reduction[332] of inexpensive para-anisaldehye (671). The respective halogenated side chains 
666 and 667 should be obtained by e.g. Appel reaction[308] of the corresponding alcohols, 
which would stem from an alkylation of the appropriately protected versions of the 
commercially available bromoalkylamines 672 and 673. 
To reduce this plan into practice, the synthesis of thiazepine core 668 was commenced by 
submitting p-anisaldehyde (671) to classical Ramirez conditions[255] and dibromide 676 was 
obtained in good yield (scheme 2.2). This material was then reacted with n-BuLi in a Corey-
Fuchs-type homologation, at which the intermediary generated Li-alkinyl species was 
quenched with excess iso-propyl chloroformate according to the published protocol.[481g] 
Thus, alkyne 677 was accessed on multi-gram scale in a yield being 29% higher than reported 
previously. Subsequent hydrogenation under Lindlar conditions[332] was performed in a 
solvent mixture of n-hexane and 1-hexene and turned out to be highly dependent on the scale 
of the reaction. Due to an increased availability of hydrogen in larger amounts of solvent, the 
reaction sped up from 22 hours (100 mg scale) to one hour (8.39 g scale) and gave rise to 
alkene 678 in complete Z-selectivity without any overreduction. Next, the described Jacobsen 
epoxidation was evaluated, using R,R-salen catalyst 679, picoline N-oxide (680) and common 
bleach solution as terminal oxidant in benzene. Initial experiments provided epoxide 669 only 
in half amounts of the expected yield. Variation of the additive to 4-phenylpyridine N-oxide 
(not shown),[481g] the reaction temperature, the reaction duration, the solvent system to 
1,2-dichloroethane and of the catalyst loading to lower (5 mol-%) and higher (30 mol-%) 
values did not effect any significant change. Notably, an improved diastereomeric ratio of
    
 
Scheme 2.2: Initial 4-step sequence for the asymmetric preparation of glycidate 669, using a protocol that was 
established previously by Jacobsen et al.[481g] 
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Scheme 2. 3: Synthesis of thiazepine core 668 via nucleophilic epoxide opening with freshly prepared 
thiophenol 670, Béchamp reduction and acid catalyzed lactam formation. 
25:2 was observed, which stems from the partial inversion of involved radical 
intermediate.[481g] Due to this isomeric mixture, the enantiomeric excess was not determined 
at this stage. However, measurement of the optical activity indicated that the reaction had 
proceeded in an asymmetric fashion. 
For the envisaged nucleophilic epoxide opening, air sensitive thiophenol 670 was freshly 
prepared from the respective inexpensive disulfide 681 via reduction with NaBH4 
(scheme 2.3). The moderate yield of compound 670 was attributed to partial reoxidation 
during the work-up and purification steps. Reaction of this material with epoxide 669 was 
conducted in ethanol under base catalysis with NaHCO3. Lewis acid catalysis (e.g. with 
MgCl2) or elevated temperatures[485] led to increased amounts of the respective erythro isomer 
(not shown) via a SN1-type mechanism. Although the desired thioether 682 could be obtained 
in 92% and with a threo/erythro ratio of 7:1, the procedure failed at times, presumably when 
the presence of oxygen was not excluded rigorously. Subsequent Béchamp reduction[483] was 
straightforward and furnished the desired aniline (683) in good yield. The undesired isomers 
that originated from the epoxidation and thiol ether formation could be separated at this stage. 
To achieve thiazepine formation, conditions described by Adger et al. were chosen, at which 
substance 683 was directly cyclized employing catalytic amounts of p-TsOH under refluxing 
conditions in m-xylene.[486] Unfortunately, the achieved moderate yield could not be 
optimized by the two-step procedure described by Jacobsen et al. that proceeds by ester 
hydrolysis and separate lactam formation.[481g] Comparison of the optical rotation of 
thiazepine 668 to literature-known values indicated an ee-value of 96%.[487] It has to be 
mentioned that on some occasions the transformation provided only very poor yield and no 
reasonable cause could be identified. 
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Scheme 2.4: A unoptimized sequence toward the β-amino chloride containing azobenzene fragment 693. 
In order to construct the linker fragment between the thiazepine core 668 and an azobenzene 
chromophore, inexpensive ammonium salts 672 and 673 were first protected as their 
respective Boc versions (684 and 685, scheme 2.4). Subsequent nucleophilic substitution with 
2-(methylamino)ethanol (686) under refluxing conditions yielded the amino alcohols 687  
and 688 in moderate and good yield, respectively. Unfortunately, all attempts toward 
converting those substances to their respective chlorides, bromides or iodides via Appel 
reaction[308] or treatment with SOCl2 in CH2Cl2 led to complete decomposition or provided 
very poor yield of bromide 689 (6%). Hence, it was tried to install the planned azobenzene 
moiety directly by first deprotecting the amine function in carbamate 687 with TFA in CH2Cl2 
and ensuing treatment with freshly prepared acid chloride 690. Gratifyingly, only N-acylation 
of amine 691 was observed, although the 2-step procedure suffered from low yields. At this 
point, the search for a more feasible synthesis of intermediate 692 was postponed and a 
potential halogenation of its alcohol function was investigated. This time, reaction with SOCl2 
promoted a clean formation of the desired chloride 693, presumably via a SNi mechanism.[488] 
Apparently, the Boc protecting group present in previous experiments had been to labile and 
undesired side reactions were caused by the in situ freed amino functionality. 
With little amounts of both coupling partners in hand, the desired alkylation of the thiazepine 
core was evaluated. Applying conditions described by Schwartz et al. for their 
enantioselective synthesis of diltiazem (645),[481e] chloride 693 was reacted with lactam 668, 
deprotonating the amide function with K2CO3 in refluxing, wet EtOAc (scheme 2.5). Thus, 
azo-diltiazem 1 (694) was obtained in 84% yield, albeit in low quantities (17.4 mg). When 
this compound was submitted to acetylation protocols using AcCl or Ac2O and DMAP, a 
concomitant participation of the amide function of the azobenzene moiety was triggered. The 
resulting impurity could not be separated by means of chromatography. In the following, a 
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Scheme 2.5: Successful coupling of fragments 668 and 693, yielding the first completed azobenzene 
derivative of diltiazem (694) and acetylation conditions applied thereto. 
shortage of material hampered further investigation of reaction conditions and we chose to 
conserve the remaning azo-diltiazem 1 (694) for biological testing as the substituent on C-3 
has been shown to be of rather small significance for drug potency (cf. chapter 1.3.4). 
Although the presented route had ultimately given rise to a potential photochromic LTCC 
antagonist (694), encountered low yields and unreliable transformations marked this strategy 
as unsuitable to be performed on larger scale, being necessary in order to establish a 
compound library. 
 
2.2 Semisynthesis of Diltiazem-derived Photochromic LTCC Blockers 
 
As (+)-cis-diltiazem hydrochloride (695) itself was commercially available at reasonable 
pricing, we became attracted by a method described by Alexander, which allows for the 
selective mono demethylation of the drug.[489] The generated secondary amine was intended 
to be alkylated or submitted to reductive amination, thus representing a readily available 
precursor for the attachment of several azobenzene-substituted alkyl linker fragments.  
Referring to Olofson’s chemistry,[490] the described demethylation process requires the use of 
stoichiometric amounts of the reagent 1-chloroethyl chloroformate (696) in refluxing DCE 
(scheme 2.6). From a mechanistic point of view, this transformation proceeds via an initial 
acylation of the tertiary amide in diltiazem (645) to yield in an intermediary acyl ammonium 
species (not shown). Under the employed elevated temperatures, the freed chloride ion then 
removes one methyl group by SN2-type nucleophilic substitution.[490] The formed carbamate 
(697) is then no longer reactive enough to undergo a second acylation/demethylation event. 
Accordingly, the respective moisture sensitive carbamate (697) could be obtained after 
simple removal of the volatiles from the reaction vessel. However, when this material was 
subjected to hydrolysis in refluxing methanol, the respective deacetylated and mono dimethyl-
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Scheme 2.6: Optimized two-pot protocol for the gram scale preparation of mono desmethyl diltiazem (698). 
ated compound constituted the major product. Analysis via LCMS methods suggested that 
this ester cleavage had not occurred during the acylation/demethylation step. Furthermore, 
purifying the labile carbamate 697 by means of extraction and chromatography led to a 
significant loss of material. Gratifyingly, conducting the hydrolysis step at 0 °C with 
prolonged reaction times suppressed the undesired deacetylation to 1–5 mol-% and mono 
desmethyl diltiazem (698) could be isolated in 92% over three steps on multi-gram scale. 
Similar reactivity was demonstrated on benzazepine-type LTCC blockers by using 
2,2,2-trichloroethyl chloroformate and subsequent treatment with Zn in acetic acid.[476] Due to 
the thioether function in substrate 645, this reagent combination proved to be not applicable. 
    
 
Scheme 2.7: First-generation approach for the elongation of mono desmethyl diltiazem (698) by alkylation 
and investigated further transformations of obtained carbamates 699 and 700. 
Next, it was planned to install an alkyl handle for the linkage to various photoswitchable 
diazene chromophores and nucleophilic addition to the previously synthesized Ω-bromo 
carbamates 684 and 685 (scheme 2.7) was investigated. In both cases, alkylation in the 
presence of potassium iodide furnished the desired tertiary amines 699 and 700 in good 
yields. The ensuing removal of the respective Boc protecting groups turned out to be 
surprisingly intricate, as standard acidic conditions[266] like TFA in CH2Cl2, HCl in MeOH, 
HCl in dioxane, TMSOTf and 2,6-lutidine in CH2Cl2 and p-TsOH in THF/CH2Cl2 
concomitantly promoted the hydrolysis of the acetyl function. Additionally, silica gel under 
heat and reduced pressure did not effect any reaction until decomposition set in at 200 °C. 
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Interestingly, stirring the compounds in neat formic acid at room temperature, allowed for the 
isolation of desired free amines (701 and 702) in quantitative yields with less than 8% of the 
deacetylated side product. Ensuing attachement of the diazene unit was first tried with the 
preformed acid chloride 690 (cf. scheme 2.4), but resulted in the formation of an inseparable 
bisacylated side product. On the contrary, usage of the coupling reagents DCC and EDCI did 
not trigger any reaction at all.  
Hence, the strategy was changed once again and it was aimed at a possible alkylation of mono 
desmethyl diltiazem (698) by electrophilic reagents that already bear the azobenzene moiety. 
To this end, intially iodide 703 was prepared from commercially available aniline 704 and 
iodoacetic acid (705) by reaction with DCC (scheme 2.8). Although residual amounts of the 
hardly separable urea that is generated in the process contaminated the product at times, this 
method provided a convenient and fast entry to viable coupling partners for the diltiazem core 
698. Reaction of the latter mentioned amine with the activated α-carbonyl iodo compound 
703 in THF furnished azo-diltiazem 2 (706) in excellent yield and the structure of this 
compound could be verified by X-ray crystallographic analysis. The obtained solid-state 
structure of 706 showed a densly packed conformation of the polycyclic molecule. At this, an 
H-bond of 2.3 Å length[491] between the thiazepine carbonyl and the hydrogen atom of the 
newly formed amide functionality mediates additional folding. Notably, mentioned 
connectivity might explain both, the experimentally observed tendency of similar amides to 
undergo two consecutive acylation events (vide supra) and the inherent low solubility of e.g. 
azo-diltiazem 2 (706) in aqeuous media.  
    
 
Scheme 2.8: Alkylation of mono desmethyl diltiazem (698) with acetamide 703 and the solid-state structure 
of synthesized azo-diltiazem 2 (706). The intramolecular H-bond is indicated by a dashed line. 
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Encouraged by these results, we set out to synthesize a small compound library by modifying 
the azobenzene building block, either bearing an elongated alkyl chain, or via substitution 
with an electron donating dimethyl amino portion (table 2.1). At this, the yields for the DCC-
promoted coupling reaction were generally lower, when 3-iodopropanoic acid (707) or 
4-iodobutanoic acid (708) were employed. In the case of butanamide 709 (entry 7) the 
residual starting aniline 704 could not be separated fully by means of flash column 
chromatography. Furthermore, we prepared glycol ether- (710) and morpholino-substituted 
(711) anilines, in order to increase the solubility of the final diltiazem derivatives. Attachment 
of those polar tail functions is an often found concept in medicinal chemistry.[492] The 
synthesis of those anilines is summarized in scheme 2.9 and comprises well established azo 
coupling chemistry (712), an alkylation step (713) and in both cases the reduction of 
respective nitro functions with aqueous sodium sulfide (710 and 711).[480a,493] To the best of 
our knowledge, the latter conditions represent the only known method to achieve 
chemoselective reduction of arylic nitro groups reliably in the presence of a diazene bond. 
   
Table 2.1: Synthesized Ω-iodoalkyl amides for the alkylation of mono desmethyl diltiazem (698). 
 
entrya aniline n R product yield 
      
1 704 1 H 703 75% 
2 717 1 NMe2 718 38% 
3 710 1 OCH2CH2OMe 719 52% 
4 711 1 N-morpholino 720 77% 
5 704 2 H 721 51% 
6 717 2 NMe2 722 49% 
7 704 3 H 709 25–38%b 
8 717 3 NMe2 723 37% 
9 735 3 O(CH2CH2O)3Me 737 28–35%b 
10 736 3 O(CH2CH2O)4Me 738 68–73%b 
a) Reactions were carried out in THF and stirred over night according to the general procedure given at the experimental 
section in chapter 3.2. b) Those compounds were contaminated with inseparable amounts of the respective starting aniline. 
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Scheme 2.9: Preparation of anilines 710 and 711 from nitroaniline 714 via common azo coupling chemistry. 
Coupling of those reagents to mono desmethyl diltiazem (698) showed the expected trend that 
the electronically activated iodoacetamides would react faster and result in better yields 
(table 2.2). The synthesized derivatives that had no – or a dimethyl amino subsitutent – at the 
4’ position of the azobenzene unit (706, 724–728), unfortunately suffered from very low 
solubility in aqueous media, even when their respective hydrochloride salts were formed by 
precipitation from HCl (1 M) in diethyl ether. The preparation of the glycol ether derivate 729 
and the morpholino-substituted compound 730 could not improve this finding either. Notably, 
azo-diltitazem 8 (729) delivered crystals suitable for X-ray crystallographic analysis 
(table 2.2) that revealed a similar molecular arrangement as already described for azo-
diltiazem 2 (706). Meanwhile conducted electrophysiological evaluation (cf. chapter 2.3) 
indicated that photoswitchable currents can be realized with compounds 729 and 727 indeed, 
at which the latter case showed the most promising results. However, only very low 
concentrations could be realized in physiological buffer solutions (HEPES, pH = 7.4), which 
is why small-chain PEGylated versions, having the same alkyl spacer length to the pore-
blocking amino function as azo-diltiazem 4 (727), were synthesized. The required aniline 
building blocks were accessed from phenol 712 via alkylation with tosylates 731 and 732 
(scheme 2.10). In both cases, the high polarity of the generated polyethers (733  
and 734)  complicated their separation from residual alkylating reagents by means of flash
     
 
Scheme 2.10: Syntheses of PEGylated azobenzenes 735 and 736. The preparation of employed tosylates 731 
and 732 is described in the experimental section at chapter 3.2. 
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column chromatography. The remaining minor impurities were lost upon ensuing reduction 
with sodium sulfide. Thus, anilines 735 and 736 were obtained in moderate yields and 
employed for further coupling to 4-iodobutanoic acid (708) as detailed in table 2.1  
(entries 9,10). When the resulting alkylating reagents (737 and 738) were used for the 
synthesis of azo-diltiazem derivatives 739 and 740, moderate to good yields were achieved 
(table 2.2, entries 9,10). Despite their highly polar behavior that was observed at the 
chromatographic purification, the PEGylated compounds only exhibited slightly improved 
solubility in water in form of their respective hydrochloride salts. Transfer to physiological 
buffer solutions (DPBS, HEPES) resulted again in predominant precipitation, due to the 
increased polarity mediated by therein dissolved ions. Hence, those compounds have not been 
evaluated as photochromic LTCC blockers by means of in vivo experiments so far.  
Instead, it was envisaged to raise the solubility in aqueous media by installing a permanent 
charge at the 4’ position of the azobenzene moiety. In this context, it was tried to substitute 
the amide function by an ether linkage, in order to avoid observed conformational folding via 
   
Table 2.2: Synthesis of azo-diltiazem derivatives 706, 724–730, 739 and 740 via an alkylation strategy. 
 
entrya amide n R product yield 
      
1 703 1 H azo-diltiazem 2 (706) 86% 
2 718 1 NMe2 azo-diltiazem 5 (724) 91% 
3 719 1 OCH2CH2OMe azo-diltiazem 8 (729) 95% 
4 720 1 N-morpholino azo-diltiazem 9 (730) 94% 
5 721 2 H azo-diltiazem 3 (725) 51% 
6 722 2 NMe2 azo-diltiazem 6 (726) 32% 
7 709 3 H azo-diltiazem 4 (727) 32% 
8 723 3 NMe2 azo-diltiazem 7 (728) 58% 
9 737 3 O(CH2CH2O)3Me azo-diltiazem 10 (739) 69% 
10 738 3 O(CH2CH2O)4Me azo-diltiazem 11 (740) 61% 
a) Reactions were carried out in THF at room temperature with super-stoichiometrical amounts of the respective Ω-iodoalkyl 
amide. Detailed experimental procedures are given in the experimental section in chapter 3.2.  
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Scheme 2.11: Unsuccessful approach toward a permanently charged azo-diltiazem derivative. 
intramolecular H-bond formation. To this end, alkyl bromide 741 was prepared from  
phenol 712 by reaction with stoichiometric amounts of dibromide 742 (scheme 2.11). 
Subsequent alkylation of mono desmethyl diltiazem (698) provided a higher yield (75%) 
when KI was added for an in situ Finkelstein-type halogen exchange. In the following, 
reaction conditions for a chemoselective reduction of the nitro function of substance 743 to 
the respective aniline were investigated. Whilst treatment with Zn in HOAc induced an 
undesired cleavage of the diazene bond, sodium sulfide-promoted reduction caused a 
simultaneous saponification of the acetyl ester (744). As a consequence, the planned ensuing 
acylation with a betaine-derived acid chloride[480a] did not proceed in a site-selective manner.  
To circumvent the basic reduction conditions, the nitro group was exchanged against an azide 
substituent according to Moses and co-workers,[494] by reacting aniline 745 with t-BuONO 
and quenching with TMSN3 (scheme 2.12). For the mechanism of this reaction, several 
intermediates have been postulated and evidenced. Depending on the reaction temperature, 
either nucleophilic attack of an azide anion at the intermediary generated diazonium salt and a 
subsequent expel of gaseous N2, or a sequential 1,3-diploar cycloaddition and retro-cyclo-
     
 
Scheme 2.12: Synthesis of azide containing derivative 749 and unsuccessful Staudinger reduction thereof. 
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addition takes place.[495] Accordingly, azide 746 could be accessed in 87% on gram scale. The 
following alkylation with dibromide 742 showed a significantly improved yield, when four 
equivalents of the reagent were used instead of one (vide supra). The coupling of the obtained 
bromide 747 to mono desmethyl diltiazem (698) required a threefold prolonged reaction time 
compared to nitro compound 741. In the process, about 30 mol-% of the respective saponified 
congener were isolated as an inseparable mixture with the desired product 748. Gratifyingly, 
complete re-acetylation could be achieved using unbuffered acetyl chloride and catalytic 
amounts of DMAP in CH2Cl2. With this material in hand, PPh3 in wet acetonitrile was applied 
in order to effect a Staudinger-tpye reduction.[496] Interestingly, the transformation stopped at 
the phosphazene intermediate (749), which could be isolated in almost quantitative yield. 
However, this compound could no be hydrolyzed to the desired aniline and remained inert 
even under forcing conditions (H2O:AcOH = 1:1, 100 °C, 12 h).[497] Therefore, the strategy 
was altered and the attachement of alkyne 750 by means of ‘Click’-chemisty[498] (azide-
alkyne Huisgen reaction[499]) was investigated. Optimal reaction conditions involved the use 
of CuSO4·5H2O and sodium ascorbate in a thoroughly degassed mixture of DMSO, CH3CN 
and water at 40 °C under constant sonication (scheme 2.13). Typically, full conversion was 
reached after 2 to 4 hours and the product (751) could then be obtained as the respective 
formiate salt via reversed-phase column chromatography using formic acid (0.1 vol.-%) as an 
additive in the eluent mixture. Additionally bisammonium salt 752 was prepared in a similar 
fashion from alkyne 753. Both compounds showed the desired increased solubility in water, 
as well as in physiological buffer solutions, and concentrations up to 250 µL could be reached
     
 
Scheme 2.13: Synthesis of permanently charged azo-diltiazems 751 and 752 using ‘click’-chemistry. 
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without any difficulty. So far, azo-diltiazem 13 (752) represents the furthermost optimized 
structure for photochromic LTCC antagonists. 
 
2.3 Electrophysiological Evaluation of Diltiazem-derived Photochromic LTCC 
Antagonists 
 
The experimental work required for the electrophysiological evaluation of the synthesized 
azo-diltiazems derivatives was conducted by Dr. T. Fehrentz and was still ongoing as present 
chapter was written. Only preliminary results will be outlined in the following, as it is planned 
to publish the majority of the established data in due course. 
For presented measurements, HEK293T cells were transfected with 1 µg CaV1.3α1, CaVβ3 
and CaVα2δ in a molar ratio of 1:1:1 using the calcium phosphate method. To simplify the 
detection of transfected cells, eGFP (enhanced green fluorescent protein) was co-transfected. 
The employed electrophysiological protocol is described in detail in references 463 and 469. 
As calcium ion conductance in CaV1.3α1 goes along with CDI of the channel current 
(cf. chapter 1.3.1), this effect was dampened by replacing Ca2+ with Ba2+ in the external 
recording solution.[463] Current traces were recorded whilst irradiating the cells with two 
different wavelengths in an alternating mode, in order to switch the diazene bond from trans 
to cis or cis to trans configuration, respectively. Those wavelengths were determined for each 
compound by preceding UV-Vis spectroscopic measurements in water, which addressed the
  
 
Scheme 2.14: Current traces of representative a) azo-diltiazem 4 (727) and b) azo-diltiazem 8 (729) 
photoswitching events on CaV1.3α1 channels expressed in HEK293T cells. The data indicates 
that longer alkyl spacer length to the pore-blocking amino function is desirable. 
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photostationary states with the respective maximum achievable trans- or cis-azobenzene 
content. 
Thus recorded current traces are depicted in scheme 2.14 for azo-diltiazem 4 (727) 
and 8 (729) and the respective irradiation events are indicated at the time scale. The molecular 
concentrations of the antagonists in the external bath solution that were perfused on the cells 
were 40 µM (azo-diltiazem 4) and 40 µM (azo-diltiazem 8). It has to be mentioned that the 
general drop in current strength is attributed to the so-called rundown effect.[500] Despite this, 
a significantly stronger pronounced increase in current was observed for substance 727, when 
470 nm were applied to switch the compound to its trans-state. Accordingly, both compounds 
become more potent LTCC blockers whilst having a cis-configured diazene bond. Notably, 
this was unexpected in regard to the previously calculated orientation of benziazem (661, 
cf. chapter 1.3.4) in LTCCs, which would suggest that a cis-configured azobenzene should 
exert increased steric demand in the channel pore, thus leading to unblock of the channel. 
Scheme 2.15 illustrates similar measurements for the charged and doubly charged derivatives 
azo-diltiazem 12 (751, 25 µM) and 13 (752, 25 µM). Unfortunately, the quality of grown cells 
did not allow recording comparable data sets, yet. Current efforts are directed toward the 
establishment of a more stable gene expression in order to obtain Ca2+/Ba2+ currents of 
improved consistency. Despite this, it can be seen that those water-soluble compounds act at 
least with similar efficacy as photochromic LTCC antagonists as azo-diltiazem 4 (727), but
    
 
Scheme 2.15: Current traces of representative a) azo-diltiazem 12 (751) and b) azo-diltiazem 13 (752) 
photoswitching events on CaV1.3α1 channels expressed in HEK293T cells. For both 
compounds pronounced differences in cell currents were recorded, in respect to the triggered 
photostationary states. 
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can in principal be introduced in higher concentrations. In contrast to cis-blocker 727, the 
permanently charged substances reduced Ca2+ currents preferentially when their diazene 
bonds were trans-configured. As especially azo-diltiazem 13 (752) has a large molecular 
weight (860 Da) and possesses a highly polar tail group, it is speculated that this compound 
might be unable to enter the plasma membrane fully and acts similarly to the ‘molecular 
tapes’ previously developed as DHP-based LTCC antagonists (cf. chapter 1.3.3).[465] Support 
for this hypothesis was found when we measured the distribution of azo-diltiazem 13 (752) 
between water (100 µM) and octan-1-ol, at which the latter is considered as a satisfactory 
surrogate for membrane vesicles.[501] Taking samples of both the aqueous and the organic 
layer and submitting them to LCMS measurements, virtually no ions of the benzothiazepine 
compound (752) could be detected in the octan-1-ol phase and recorded UV-Vis traces 
showed no absorption at the λmax-value (360 nm). To quantify this finding, LTCC antagonists 
having the same chromophore, but shorter or longer alkyl spacer units, are envisaged targets 
for future synthesis. 
    
 
Scheme 2.16: a) Recorded UV-Vis spectra of azo-diltiazem 13 (752) in water at its dark adapted state (black) 
and at the cis (purple) and trans photostationary (blue) states. b) Thermal relaxation after 
preirradiation with 360 nm for 10 minutes. 
Additionally, all synthesized LTCC antagonists were characterized via UV-Vis spectroscopy 
in respect to their photostationary states and thermal relaxations from cis- to trans-
configuration of the diazene units. These results are intended to be subject to publication 
as mentioned before, which is why only representative data is illustrated for azo-
diltiazem 13 (752) in scheme 2.16. Interestingly, the compound exhibits extremely slow 
thermal relaxation in water with a half-life of 2.40 ± 0.01 days. This property is highly 
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desirable for testing, as the antagonist can be preirradiated conveniently and then perfused on 
the cells. Furthermore, largely stable states of channel block and unblock might be achieved 
that allow for a temporal control of Ca2+ currents without constant irradiation.  
  
2.4 Conclusion and Future Aspects 
 
In summary, we have successfully established the first photochromic antagonists for L-type 
voltage-gated calcium channels on basis of the pharmacophore of cis-(+)-diltiazem (645). A 
compound library of 13 azobenzene modified benzothiazepine channel blockers was 
synthesized and a preliminary lead structure (756) was identified by means of 
electrophysiological evaluation on the LTCC subtype CaV1.3 (scheme 2.17). 
Whilst azo-diltiazem 4 (727) and 8 (729) showed more potent channel block in their 
cis-diazene photostationary states, the permanently charged versions 751 and 752 exerted 
more pronounced inhibition of Ca2+ currents, when having their azobenzene moieties 
trans-configured. Furthermore, the latter two derivatives exhibited improved solubility in 
water and physiological buffer solutions. Consequently, azo-diltiazem 13 (752) represents the 
most promising candidate for an efficient photocontrol of Ca2+ currents. This antagonist is 
marked by an unusual long thermal relaxation of its diazene bond and it was proposed that it 
acts as a molecular tape. This means that the charged tail group would reside at the 
extracellular side of the cell membrane and only the pharmacophore could reach to the BTZ 
receptor site (cf. chapter 1.3). To verify this hypothesis, we envisage synthesizing analogues 
of this compound, which vary only in the distance between the pore-blocking amino function 
and the chromophore. Ideally, these experiments should show a maximum in efficacy of 
photocontrol of Ca2+ currents for a specific alkyl spacer length.  
    
 
Scheme 2.17: Developed convergent semisynthesis of photochromic LTCC antagonists. Structure 756 
constitutes the assessed lead motif for further optimization of pharmacological properties. 
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In regard of the conducted synthetic experiments, a scalable and short semisynthetic route was 
successfully developed (cf. chapter 2.2) that allows attaching substituted diazene compounds 
to the parent drug diltiazem (645). To this end, the convergent coupling of mono desmethyl 
diltiazem (698) to a variety of alkylating agents was demonstrated. Crystal structures of the 
compounds azo-diltiazem 2 (706) and 8 (729) were obtained and a plausible explanation for 
their low solubility in aqueous media was deduced. Syntheses of permanently charged 
antagonists were achieved via convenient late-stage coupling of modified alkyne reagents 
using 1,3-dipolar cycloadditions (‘click’ reaction). In contrast, the attempted total synthetic 
route (cf. chapter 2.1) toward this type of antagonists suffered from low yields and not 
consistently reproducible procedures. Future work in this field might rather focus on the 
construction of benzoazepine-derived structures like SQ 32910 (660), which do not bear the 
sensitive thioether and acetyl ester portions (cf. chapter 1.3.4). 
Currently, further physiological experiments are being performed by Dr. T. Fehrentz and 
quantifiable data regarding the efficacy of LTCC photocontrol and general drug potency are 
gathered. We expect that those investigations disclose potential chemical modifications of the 
determined lead structure and allow for the establishment of a useful photopharmacological 
tool for the elucidation of e.g. Ca2+ signaling pathways in neurons. 
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3.  Experimental Section 
 
3.1 General Notes 
 
All reactions were magnetically stirred and carried out under a positive pressure of inert gas 
(N2 or argon) utilizing standard Schlenk-techniques. Glassware was dried in an oven at 
120 °C and repeatedly at 650 °C in vacuo prior to use. Liquid reagents and solvents were 
added by syringes or oven-dried stainless steel cannulas through rubber septa. Solids were 
added under inert gas counter flow or were dissolved in appropriate solvents. Low-
temperature reactions were carried out in a Dewar vessel filled with a cooling agent: 
acetone/dry ice (−78 °C) or H2O/ice (0 °C). Reaction temperatures above room temperature 
were conducted in a heated oil bath. If literature-known procedures were followed, the 
respective reference was added to the experimental details. Yields refer to isolated 
homogenous and spectroscopically pure materials, if not indicated otherwise. 
 
Solvents and Reagents 
 
Tetrahydrofuran (THF) and diethyl ether (Et2O) were distilled under N2 atmosphere from 
Na/benzophenone as drying reagent prior to use. Triethylamine (Et3N) and and Hünig’s base 
(DIPEA) were distilled under N2 atmosphere from CaH2 as drying agent prior to use. Further 
dry solvents such as dichloromethane (CH2Cl2), N,N-dimethylformamide (DMF), acetonitrile 
(MeCN), acetone, dimethyl sulfoxide (DMSO), methanol (MeOH), benzene, m-xylene, and 
toluene were purchased from commercial suppliers and used as received. Solvents for 
extraction, crystallization and flash column chromatography were purchased in technical 
grade and distilled under reduced pressure prior to use. Alkyne 750[502] and quaternary 
ammonium salt 754[503] were prepared according to literature-known procedures. All other 
reagents and solvents were purchased from chemical suppliers (Sigma-Aldrich, Acros 
Organics, Alfa Aesar, TCI Europe, ABCR) and were used as received. 
 
Chromatography 
 
Reactions and chromatography fractions were monitored by qualitative thin-layer 
chromatography (TLC) on silica gel F254 TLC plates from Merck KGaA. Analytes on the 
glass plates were visualized by irradiation with UV-light and/or by immersion of the TLC 
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plate in an appropriate staining solution followed by heating with a hot-air gun (350 °C). The 
following staining solutions were applied: 
• p-anisaldehyde staining solution (3.7 mL p-anisaldehyde (671), 5.0 mL concentrated 
aqueous H2SO4, 1.5 mL glacial AcOH, 135 mL EtOH). 
• Hanessian’s staining solution (CAM, 5.0 g, Ce(SO4)2, 25 g (NH4)6Mo7O24⋅4H2O, 
50 mL concentrated aqueous H2SO4, 450 mL H2O). 
• KMnO4 staining solution, (3.0 g KMnO4, 20 g K2CO3, 5.0 mL aqueous 5% NaOH, 
300 mL H2O). 
Flash column chromatography was performed on Geduran® Si60 (40−63 µm) silica gel from 
Merck KGaA or on C18-reversed-phase silica gel from Waters Corporation. All fractions 
containing a desired substrate were combined and solvents were removed under reduced 
pressure followed by drying in high vacuo (10−2 mbar). 
 
NMR spectroscopy 
 
NMR spectra were measured on a Bruker Avance III HD 400 MHz spectrometer equipped 
with a CryoProbeTM operating at 400 MHz for proton nuclei (100 MHz for carbon nuclei) or 
by the analytic section of the Department of Chemistry of the Ludwig-Maximilians-
Universität München using Bruker AXR300, Varian VXR400 S and Bruker AMX600 
spectrometers operating at 300 MHz, 400 MHz and 600 MHz for proton nuclei (75 MHz, 
100 MHz, 150 MHz for carbon nuclei), respectively. DMF-d7, CD3OD, DMSO-d6, CDCl3 
and C6D6 were purchased from Sigma-Aldrich and Euriso-top. The 1H NMR shifts are 
reported in ppm related to the residual shift of TMS. 1H NMR shifts were calibrated to 
residual solvent resonances: DMF-d7 (8.02 ppm), CD3OD (3.31 ppm), DMSO-d6 (2.50 ppm), 
CDCl3 (7.26 ppm), C6D6 (7.16 ppm). 13C NMR shifts were calibrated to the center of the 
multiplet signal of the residual solvent resonance: DMF-d7 (162.50 ppm), CD3OD 
(49.00 ppm), DMSO-d6 (29.84 ppm), CDCl3 (77.16 ppm), C6D6 (128.06 ppm). 1H NMR 
spectroscopic data are reported as follows: Chemical shift in ppm (multiplicity, coupling 
constants J, integration intensity). The multiplicities are abbreviated with s (singlet), br (broad 
signal), d (doublet), t (triplet), q (quartet), m (multiplet) and mC (centrosymmetric multiplet). 
In case of combined multiplicities, the multiplicity with the larger coupling constant is stated 
first. Except for multiplets, the chemical shift of all signals, as well for centrosymmetric 
multiplets, is reported as the center of the resonance range. Additionally to 1H and 13C NMR 
measurements, 2D NMR techniques as homonuclear correlation spectroscopy (COSY), 
Experimental Section 
275 
heteronuclear single quantum coherence (HSQC) and heteronuclear multiple bond coherence 
(HMBC) were used to assign signals. For further elucidation of 3D structures of the analytes, 
nuclear Overhauser enhancement spectroscopy (NOESY) was conducted. Coupling constants 
J are reported in Hz. All NMR spectra were analyzed using the program MestRe NOVA 8.1 
from Mestrelab Research S. L. 
 
Mass spectrometry 
 
All mass spectra were measured by the analytic section of the Department of Chemistry of the 
Ludwig-Maximilians-Universität München. Mass spectra were recorded on the following 
spectrometers (ionization mode in brackets): MAT 95 (EI) and MAT 90 (ESI) from Thermo 
Finnigan GmbH or JMS-700 (FAB) from Jeol Ltd. Mass spectra were recorded in high-
resolution and the only characteristic molecule fragments or molecule ion peaks are indicated 
for each analyte. The used method is reported at the relevant section of the experimental part. 
Liquid chromatography–mass spectrometry (LCMS) was conducted on a 1260 Infinity LC 
unit that was attached to a 1100 Series LC/MSD mass spectrometer, both being from Agilent 
Technologies Inc. 
 
IR spectroscopy 
 
IR spectra were recorded on a PerkinElmer Spectrum BX II FT-IR system. If required, 
substances were dissolved in CH2Cl2 prior to direct application on the ATR unit. The 
measured wave numbers are reported in cm−1. 
 
Optical rotation 
 
Optical rotation values were recorded on a polarimeter P8000-T from A. Krüss Optronic 
GmbH or on a PerkinElmer 241 polarimeter. The specific rotation is calculated as follows: 
 
! !! =
! ∙ 100
! ∙ !  
 
Thereby, the wavelength λ is reported in nm and the measuring temperature ϑ in °C. 
α resembles the recorded optical rotation at the apparatus, c the concentration of the analyte in 
10 mg/mL and d the length of the cuvette in dm. Thus, the specific rotation is given in 
10−1·deg·cm2·g−1. Usage of the sodium D line (λ = 589 nm) is indicated by D instead of the 
3.1 General Notes 
276 
wavelength in nm. The respective concentration as well as the solvent is denoted in the 
analytical part of the experimental description. Optical rotations of azobenzene containing 
compounds were not recorded, due to the light dependent photostationary states of their 
diazene bonds. 
 
Melting points 
 
Melting points were measured on the apparatus BÜCHI Melting Point B-540 from BÜCHI 
Labortechnik AG or on an EZ-Melt apparatus form Stanford Research Systems and are 
uncorrected. 
 
UV-Vis Spectroscopy 
 
UV-Visible spectra were recorded on a Varian Cary 50 Bio UV-Visible Spectrophotometer 
using Starna 29/B/12 quartz cuvettes with 10 mm section thickness. The evaluation of 
relaxation kinetics was conducted using the software IGOR Pro 6.3 from WaveMetrics Inc. 
 
3.2 Experimental Procedures for Chapter 2: ‘Development of Photochromic Ligands 
for LTCCs’ 
 
Synthesis of Dibromide 676  
   
 
   
Tetrabromomethane (48.7 g, 146 mmol, 2.0 eq.) was dissolved in dry CH2Cl2 (150 mL) and 
cooled to 0 °C. Triphenylphosphine (77.2 g, 293 mmol, 4.0 eq.) was added to the stirred 
solution in portions. The resulting mixture was stirred for 15 min at 0 °C and a solution of 
p-anisaldehyde (671, 8.4 mL, 73 mmol, 1.0 eq.) in dry CH2Cl2 (28 mL) was then added 
dropwise over 20 min. After the mixture was stirred for additional 3 hours at 0 °C, saturated 
aqueous NaHCO3 solution was added until the aqueous phase reached neutrality. The layers 
were separated and the organic layer was washed with portions of saturated aqueous NaCl 
(3 × 250 mL) and dried over Na2SO4. The solvent was removed in vacuo to give a pale yellow 
MeO
O
MeO
Br
Br
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CBr4 (2.0 eq.)
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CH2Cl2
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(88%)
H
676
C9H8Br2O
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solid. Purification by flash column chromatography (silica, i-Hex:EtOAc = 10:0 to 9:1) 
yielded compound 676 (18.9 g, 65 mmol, 88%) as slightly yellow solid. 
 
Rf = 0.81 (i-Hex:EtOAc = 4:1). 
 
Melting point = 34.9–35.3°C (i-Hex:EtOAc). 
 
1H NMR (CDCl3, 300 MHz): δ = 7.54–7.49 (m, 2H), 7.41 (s, 1H), 6.92 (m, 2H), 3.82 (s, 
3H) ppm. 
 
13C NMR (CDCl3, 75 MHz): δ = 159.8, 136.4, 130.0, 128.0, 113.9, 87.4, 55.4 ppm. 
 
EI-MS for C9H8Br2O+ [M+]: calcd. 289.8936 
 found 289.8934. 
 
IR (ATR): ῦ/cm−1 = 3005, 2956, 2928, 2833, 1888, 1711, 1602, 1572, 1507, 1453, 1439, 
1418, 1332, 1306, 1276, 1245, 1176, 1112, 1024, 858, 819, 800. 
 
Synthesis of iso-Propyl Ester 677 
   
 
    
Dibromide 676 (20.0 g, 68.5 mmol, 1.0 eq.) was dissolved in dry THF (800 mL). A solution 
of n-BuLi (77 mL, 2.5 M solution in hexanes, 192 mmol, 2.8 eq.) was added dropwise at  
‒78 °C. After the mixture had been stirred for one hour, a solution of iso-propyl 
chloroformate (308 mL, 1.0 M solution in toluene, 308 mmol, 4.5 eq.) was added dropwise. 
The resulting mixture was stirred for 10 min at −78 °C, allowed to warm up to room 
temperature, and then poured into saturated aqueous NaHCO3 solution (300 mL). The mixture 
was diluted with EtOAc (300 mL) and the phases were separated. The aqueous layer was 
extracted with EtOAc (2 × 250 mL). The combined organic layers were sequentially washed 
with saturated aqueous NaHCO3 (100 mL), saturated aqueous NaCl solutions (100 mL) and 
MeO
676
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−78 °C to rt
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Br
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then dried over Na2SO4. Purification by flash column chromatography (silica, i-Hex:EtOAc = 
10:0 to 9:1) yielded compound 677 (13.2 g, 60.3 mmol, 88%) as a slightly yellow solid.  
 
Rf = 0.50 (i-Hex:EtOAc = 8:1). 
 
Melting point = 59.4–60.3 °C (i-Hex:EtOAc). 
 
1H NMR (CDCl3, 300 MHz): δ = 7.45–7.40 (m, 2H), 6.79–6.74 (m, 2H), 5.04 (sept, 
J = 6.3 Hz, 1H), 3.72 (s, 3H), 1.22 (d, J = 6.3 Hz, 6H) ppm. 
 
13C NMR (CDCl3, 75 MHz): δ = 161.8, 154.3, 135.3, 114.6, 111.9, 86.9, 80.9, 70.2, 55.8, 
22.1 ppm. 
 
EI-MS for C13H14O3+ [M+]: calcd. 218.0943 
 found 218.0936. 
 
IR (ATR): ῦ/cm−1 = 2981, 2838, 2211, 1700, 1603, 1571, 1510, 1459, 1422, 1374, 1286, 
1252, 1196, 1166, 1101, 1028, 961, 897, 828, 745. 
 
Synthesis of E-Alkene 678 
    
 
    
Under an atmosphere of argon, iso-propyl ester 677 (8.99 g, 41.0 mmol, 1.0 eq.) was 
dissolved in a mixture of n-hexane and freshly distilled 1-hexene (411 mL, v/v = 2:1). Then 
freshly distilled quinoline (16 mL, 136 mmol, 3.3 eq.) was added and the mixture was 
degassed (3 × freeze-pump-thaw). Lindlar catalyst,[332] that is Pd/CaCO3 (5 % Pd) poisoned 
with lead (1.40 g, 4.12 mmol, 10 mol-%) was added. The resulting suspension was purged 
with hydrogen for 5 min and the reaction vessel was then connected to a hydrogen filled 
balloon (1 atm) and stirred at room temperature. TLC analysis indicated complete 
consumption of alkyne 677 after one hour. The hydrogen atmosphere was displaced by argon 
and the reaction mixture was then filtered through a Celite® pad. The filtrate was taken up in 
677
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EtOAc (300 mL) and washed with saturated aqueous NaCl solution (3 × 200 mL). The 
combined aqueous layers were re-extracted with ethyl acetate (3 × 200 mL). The combined 
organic layers was dried over Na2SO4 and purified via flash column chromatography (silica, 
i-Hex:EtOAc = 1:0 to 97:3), yielding compound 678 (8.39 g, 38.0 mmol, 92%) as a colourless 
liquid.  
 
Rf = 0.53 (i-Hex:EtOAc = 8:1). 
 
1H NMR (CDCl3, 600 MHz): δ = 7.68–7.63 (m, 2H), 6.87–6.83 (m, 2H), 6.80 (d, J = 12.7 Hz, 
1H), 5.78 (d, J = 12.7 Hz, 1H), 5.05 (sept, J = 6.3 Hz, 1H), 3.81 (s, 3H), 1.24 (d, J = 6.3 Hz, 
6H) ppm. 
 
13C NMR (CDCl3, 150 MHz): δ = 166.2, 160.4, 142.8, 132.2, 127.6, 118.0, 113.5, 67.7, 55.4, 
22.0 ppm. 
 
EI-MS for C13H16O3+ [M+]: calcd. 220.1099 
 found 220.1082. 
 
IR (ATR): ῦ/cm−1 = 2979, 2838, 1709, 1600, 1571, 1510, 1464, 1441, 1385, 1373, 1306, 
1256, 1162, 1103, 958, 847, 785, 741, 698. 
 
Synthesis of Epoxide 669 
   
 
     
To a solution of E-alkene 678 (500 mg, 2.3 mmol, 1.0 eq.) in benzene (5 mL), 4-picoline 
N-oxide (680, 50.0 mg, 0.5 mmol, 0.2 eq.) and R,R–Jacobsen catalyst 679 (216 mg, 0.3 mmol, 
15 mol-%) were added. The resulting mixture was combined with a pre-cooled bleach 
solution (5 mL), and the biphasic mixture was stirred for 23 hours at 4 °C. Then, another 
portion of catalyst (679, 72 mg, 0.1 mmol, 5 mol-%) and precooled bleach solution (1 mL) 
was added, and the mixture was stirred for further 6 hours at 4 °C. Diethyl ether (10 mL) was 
then added to the reaction mixture. The organic layer was separated, filtered through a pad of 
678
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Celite®, washed with water (6 × 10 mL) and then dried over Na2SO4. The solvents were 
removed in vacuo and the residue was purified by flash chromatography (silica, deactivated 
with NEt3, i-Hex:EtOAc = 1:0 to 19:1) to afford epoxide 669 (163 mg, 0.7 mmol, 30%) as a 
colouress liquid as a ratio of syn/anti diastereomers of 25:2.  
Note: The enantiomeric excess of the product mixture was not determined due to its nature as 
mixture of diastereomers. 
 
Rf = 0.40 (i-Hex:EtOAc = 9:1). 
 
1H NMR (CDCl3, 600 MHz): δ = 7.26–7.21 (m, 2H), 6.77–6.72 (m, 2H), 4.77 (sept, 
J = 6.3 Hz 1H), 4.10 (d, J = 4.6 Hz, 1H), 3.69 (s, 3H), 3.65 (d, J = 4.6 Hz, 1H), 0.91 (d, 
J = 6.2 Hz, 3H) ppm. 
 
13C NMR (CDCl3, 150 MHz): δ = 166.5, 159.8, 128.1, 125.1, 113.6, 69.2, 57.3, 56.1, 55.4, 
21.7, 21.6 ppm. 
 
EI-MS for C13H16O4+ [M+]: calcd. 236.1049 
 found 236.1046. 
 
IR (ATR): ῦ/cm−1 = 2981, 2838, 1745, 1722, 1613, 1515, 1466, 1406, 1374, 1294, 1245, 
1205, 1172, 1146, 1030, 971, 923, 866, 836, 806, 784, 722. 
 
 = +15.1 (c 1.00, CH2Cl2). 
 
Synthesis of Thiophenol 670 
    
 
     
Disulfide 681 (5.00 g, 16.2 mmol, 1.0 eq.) was suspended in dry THF (20 mL) and the 
resulting yellow suspension was cooled to 0 °C. NaBH4 (1.22 g, 32.4 mmol, 2.0 eq.) was 
added slowly in three portions. The red reaction mixture was then stirred for 24 hours. The 
reaction mixture was quenched with water (5 mL) and thereafter acidified with aqueous 
[ ]20Dα
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sulfuric acid (15 vol.-%). The mixture was then extracted with diethyl ether (3 × 50 mL). The 
combined organic layers were washed with saturated aqueous NaCl solution (50 mL) and 
dried over Na2SO4. The solvents were evaporated in vacuo and the crude thiol compound  
was purified by flash column chromatography (silica, i-Hex:EtOAc = 10:1 to 5:1). 
2-Nitrothiophenol (670, 1.3 g, 8.5 mmol, 52%) was obtained as yellow solid. 
 
Rf = 0.63 (i-Hex:EtOAc = 4:1). 
 
1H NMR (CDCl3, 300 MHz): δ = 8.19–8.11 (m, 1H), 7.38–7.31 (m, 2H), 7.25–7.12 (m, 1H) 
3.93 (s, 1H) ppm. 
 
13C NMR (CDCl3, 75 MHz): δ = 133.8, 133.8, 132.2, 126.4, 125.9 ppm.  
 
EI-MS for C6H5NO2S+ [M+]: calcd. 155.0041 
 found 155. 0030 
 
IR (ATR): ῦ/cm−1 = 2530, 1589, 1567, 1500, 1453, 1360, 1329, 1306, 1261, 1165, 1112, 
1062, 1039, 979, 852, 783, 731, 678. 
 
Synthesis of Thioether 682 
    
 
     
To a degassed (3 × freeze-pump-thaw) solution of 2-nitrothiophenol (670, 137 mg, 
0.44 mmol, 2.0 eq.) and NaHCO3 (7 mg, 0.09 mmol, 0.2 eq.) in ethanol (0.7 mL),  
epoxide 669 (104 mg, 0.88 mmol, 1.0 eq.) was added. The reaction mixture was stirred at 
room temperature for two days. Concentration under reduced pressure and purification by 
flash chromatography (silica, i-Hex:EtOAc = 9:1 to 4:1) afforded thioether 682 (159 mg, 
0.41 mmol, 92%) as a yellow oil in a mixture of threo and erythro isomers of 7:1. 
669
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Note: The yield of this reaction dropped significantly when the employed solutions were not 
degassed thoroughly. The enantiomeric excess of the product mixture was not determined due 
to its nature as mixture of diastereomers. 
 
Rf = 0.27 (i-Hex:EtOAc = 2:1). 
 
1H NMR (600 MHz, CDCl3): δ = 7.93–7.89 (m, 1H), 7.38–7.35 (m, 2H), 7.28–7.24 (m, 2H), 
7.14–7.09 (m, 1H), 6.77–6.74 (m, 2H), 4.95 (sep, J = 6.3 Hz, 1H), 4.61 (d, J = 3.7 Hz, 1H), 
4.42 (d, J = 3.7 Hz, 1H), 3.68 (s, 3H), 2.84 (br, s, 1H), 1.15 (d, J = 6.2 Hz, 4H), 1.02 (d, 
J = 6.3 Hz, 3H) ppm. 
 
13C NMR (CDCl3, 150 MHz): δ = 171.4, 159.5, 147.9, 134.9, 133.2, 129.8, 129.5, 126.5, 
125.8, 125.6, 114.3, 75.1, 70.8, 55.4, 55.3, 21.8, 21.6 ppm. 
 
EI-MS for C19H21NO6S+ [M+]: calcd. 391.1090 
 found 391.1093. 
 
IR (ATR): ῦ/cm−1 = 3466, 2981, 2935, 2837, 1726, 1609, 1589, 1566, 1508, 1454, 1374, 
1335, 1302, 1248, 1176, 1146, 1099, 1029, 906, 852, 834, 778, 730, 653. 
 
 = +101.3 (c 1.00, CH2Cl2). 
 
Synthesis of Aniline 683 
     
 
    
The diastereomeric mixture of thioether 682 obtained as described above (0.17 g, 0.43 mmol, 
1.0 eq.) was dissolved in a mixture of ethanol and water (3.4 mL, v/v = 1:1) and FeSO4⋅7H2O 
(1.01 g, 3.65 mmol, 8.5 eq.) was added. The resulting solution was heated to 90 °C for 
30 min. Reflux was sustained as concentrated NH4OH (1.2 mL) was added dropwise over 
15 min. After additional 10 min of refluxing, the mixture was allowed to cool to room 
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temperature and was then extracted with EtOAc (3 × 10 mL). The organic layer was washed 
with saturated aqueous NaCl solution (10 mL) and dried over Na2SO4. The solvents were 
removed in vacuo and the crude product was purified by flash chromatography (silica, 
i-Hex:EtOAc = 9:1 to 4:1) to afford substance 683 (113 mg, 0.32 mmol, 73%) as a colorless 
solid as a single diastereomer. 
 
Rf = 0.23 (i-Hex:EtOAc = 2:1). 
 
1H NMR (CDCl3, 600 MHz): δ = 7.22–7.17 (m, 2H), 7.01–6.96 (m, 2H), 6.72–6.67 (m, 2H), 
6.58 (ddd, J = 7.8, 1.3, 0.6 Hz, 1H), 6.48 (td, J = 7.5, 1.3 Hz, 1H), 4.81 (sept, J = 6.2 Hz, 1H), 
4.35 (d, J = 3.5 Hz, 1H), 4.27 (d, J = 3.5 Hz, 1H), 3.69 (s, 3H), 1.13 (d, J = 6.2 Hz, 3H), 
1.00  (d, J = 6.2 Hz, 3H) ppm. 
 
13C NMR (CDCl3, 150 MHz): δ = 172.2, 159.2, 149.1, 137.7, 132.1, 130.6, 129.8, 118.8, 
115.2, 113.8, 74.4, 70.2, 56.3, 55.4, 29.9, 21.9, 21.7 ppm. 
 
ESI-MS for C19H23NNaO4S+ [MNa+]: calcd. 384.1245 
 found 384.1240. 
 
IR (ATR): ῦ/cm−1 = 3452, 3359, 3064, 2979, 2957, 2923, 2852, 1725, 1609, 1587, 1510, 
1479, 1465, 1449, 1423, 1386, 1375, 1303, 1248, 1177, 1146, 1101, 1031, 978, 939, 906, 855, 
834, 817, 749, 680. 
 
 = +89.3 (c 1.00, CH2Cl2). 
 
Synthesis of Thiazepine 668 
     
 
   
Aniline 683 (60 mg, 0.16 mmol, 1.0 eq.) was dissolved in m-xylene (1.4 mL) in a Schlenk 
flask equipped with a Dean-Stark apparatus and a reflux condenser. p-Toluenesulfonic acid 
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(4.0 mg, 0.02 mmol, 10 mol-%) was added and the resulting solution was refluxed at 130 °C 
for 3 days. The reaction mixture was then cooled to room temperature, diluted with EtOAc 
(10 mL) and washed with saturated NaCl solution (10 mL). The aqueous phase was 
re-extracted with EtOAc (3× 20 mL). Subsequently, the combined organic layers were dried 
over Na2SO4 and the solvent was removed in vacuo. The crude product was purified by flash 
column chromatography (silica, i-Hex:EtOAc = 9:1 gradient to 13:7) to afford thiazepine 668 
(17 mg, 0.06 mmol, 41%) as a colorless solid. The enantiomeric excess of thiazepine 668 was 
determined to 96% via comparison of the optical rotation value. 
 
Rf = 0.31 (i-Hex:EtOAc = 1:1). 
 
Melting point = 201.3–203.5 °C (i-Hex:EtOAc). 
 
1H NMR (600 MHz, CDCl3): δ = 8.75 (s, 1H), 7.58 (dd, J = 7.7, 1.4 Hz, 1H), 7.39–7.33 (m, 
2H), 7.29 (td, J = 7.7, 1.4 Hz, 1H), 7.13 (td, J = 7.7, 1.1 Hz, 1H), 7.03 (dd, J = 7.7, 1.1 Hz, 
1H), 6.70–6.64 (m, 2H), 4.99 (d, J = 6.8 Hz, 1H), 4.38 (dd, J = 9.1, 6.8 Hz, 1H), 3.65 (s, 3H), 
2.94 (d, J = 9.1 Hz, 1H) ppm. 
 
13C NMR (150 MHz, CDCl3): δ = 173.7, 160.1, 140.4, 134.9, 131.3, 131.2, 131.2, 131.2, 
130.2, 130.2, 127.5, 127.1, 126.4, 123.2, 113.9, 113.8, 69.4, 57.6, 55.4, 55.4, 55.4 ppm. 
 
ESI-MS for C16H16NNaO3S+ [MNa+]: calcd. 324.0664 
 found 324.0663. 
 
IR (ATR): ῦ/cm−1 = 3334, 3187, 3118, 3074, 3006, 2961, 2906, 2835, 1680, 1640, 1608, 
1584, 1571, 1512, 1474, 1438, 1420, 1359, 1338, 1306, 1253, 1178, 1107, 1034, 952, 922, 
878, 870, 842, 816, 795, 772, 746, 728, 714, 698, 679, 664. 
 
 = +119.3 (c 1.00, EtOH). 
 
 
 
 
 
[ ]20Dα
Experimental Section 
285 
Synthesis of Carbamate 684 
   
 
    
According to the literature,[504] Boc2O (10.7 g, 48.8 mmol, 1.0 eq.) was added to a suspension 
of (2-bromoethyl)amine hydrobromide (672, 10.0 g, 48.8 mmol, 1.0 eq.) in dry CH2Cl2 
(250 mL). The reaction mixture was cooled to 0 °C and NEt3 (6.8 mL, 48.8 mmol, 1.0 eq.) 
was added dropwise over one hour. Stirring was continued and the reaction mixture was 
allowed to warm to room temperature over night. Subsequently the organic phase was washed 
with saturated aqueous NaCl solution (3 × 50 mL). The combined aqueous layers where 
re-extracted with CH2Cl2 (3 × 100 mL). The organic layers where combined and dried over 
Na2SO4. After evaporation of the solvents, the crude product was purified via flash column 
chromatography (silica, CH2Cl2). Thus, carbamate 684 (9.9 g, 44.0 mmol, 90%) was obtained 
as a low melting colourless solid. 
 
Rf = 0.85 (CH2Cl2:MeOH = 10:1). 
 
Melting point = 30–33 °C (CH2Cl2). 
 
1H NMR (CDCl3, 300 MHz): δ = 4.93 (s, br, 1H), 3.48–3.19 (m, 4H), 1.31 (s, 9H) ppm. 
 
13C NMR (CDCl3, 75 MHz): δ = 155.7, 79.8, 42.4, 32.7, 28.4 ppm. 
 
EI-MS for C7H14BrNO2+ [M+]: calcd. 223.0208 
 found 223.0209. 
 
IR (ATR): ῦ/cm−1 = 3239, 2920, 1715, 1610, 1482, 1425, 1322, 1246, 1074, 1018, 961, 921m, 
881, 817, 767, 715. 
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Synthesis of Carbamate 685 
      
 
     
To a suspension of (3-bromopropyl)amine hydrobromide (673, 10.0 g, 45.6 mmol, 1.0 eq.) in 
dry CH2Cl2 (250 mL), Boc2O (10.0 g, 45.6 mmol, 1.0 eq.) was added. The reaction mixture 
was cooled to 0 °C and NEt3 (6.3 mL, 45.6 mmol, 1.0 eq.) was added dropwise over one hour. 
Stirring was continued and the reaction mixture was allowed to warm to room temperature 
over night. Subsequently, the organic phase was washed with saturated aqueous NaCl solution 
(3 × 50 mL) and the combined aqueous layers where re-extracted with CH2Cl2 (3 × 100 mL). 
The organic layers where combined and dried over Na2SO4. After evaporation of the solvent, 
the crude product was purified via flash column chromatography (silica, CH2Cl2). Thus, 
carbamate 685 (10.4 g, 43.5 mmol, 95%) was obtained as colourless solid. 
 
Rf = 0.80 (CH2Cl2:MeOH = 10:1). 
 
Melting point = 38.1–39.2 °C (CH2Cl2). 
 
1H NMR (CDCl3, 300 MHz): δ = 4.58 (s, br, 1H), 3.32 (t, J = 6.5 Hz, 2H), 3.15 (q, J = 6.2 Hz, 
2H), 1.93 (quin, J = 6.5 Hz, 2H), 1.33 (s, 9H) ppm. 
 
13C NMR (75 MHz, CDCl3): δ = 156.0, 79.6, 39.1, 32.9, 30.9, 28.5 ppm. 
 
EI-MS for C8H16BrNO2+ [M+]: calcd. 237.0364 
 found 237.0368. 
 
IR (ATR): ῦ/cm−1 = 3258, 2971, 1675, 1515, 1489, 1449, 1392, 1295, 1246, 1209, 1165, 
1115, 1075, 1044, 949, 909, 817, 764, 682. 
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Synthesis of Aminoalcohol 687 
    
 
   
2-(Methylamino)ethanol (686, 1.4 g, 0.19 mmol, 1.0 eq.) and carbamate 684 (4.7 g, 
0.21 mmol, 1.1 eq.) were dissolved in dry THF (80 mL). The reaction mixture was refluxed 
for 16 hours at 70 °C. The solvent was then removed under reduced pressure and the residue 
was purified by flash column chromatography (silica, CH2Cl2:MeOH = 1:0 to 9:1) to yield 
compound 687 (1.36 g, 6.22 mmol, 33%) as a colorless oil. 
 
Rf = 0.10 (CH2Cl2:MeOH = 9:1). 
 
1H NMR (CD3OD, 400 MHz): δ = 3.69 (t, J = 5.7 Hz, 2H), 3.54 (s, 1H), 3.24 (t, J = 6.4 Hz, 
2H), 2.79–2.63 (m, 4H), 2.46 (s, 3H), 1.44 (s, 9H) ppm. 
 
13C NMR (CD3OD, 100 MHz): δ = 158.6, 80.3, 60.1, 59.2, 58.1, 42.3, 38.4, 28.7 ppm. 
 
ESI-MS for C10H22N2O3+ [MH+]: calcd. 219.1709 
 found 219.1705. 
 
IR (ATR): ῦ/cm−1 = 3318, 2975, 1687, 1513, 1455, 1391, 1365, 1273, 1249, 1165, 1032, 968, 
870, 780. 
 
Synthesis of Aminoalcohol 688 
     
 
     
2-(Methylamino)ethanol (686, 143 mg, 1.91 mmol, 1.0 eq.) and carbamate 685 (500 mg, 
2.09 mmol, 1.1 eq.) were dissolved in THF (15 mL). The reaction mixture was refluxed for 
684
BocHN NBocHN Br OH
HO
H
N
686 (0.9 eq.)
THF
70 °C, 16 h
(33%)
687
C10H22N2O3
M = 218.30 g/mol
685
BocHNBocHN NBr
OH
HO
H
N
686 (0.9 eq.)
THF
70 °C, 16 h
(72%)
688
C11H24N2O3
M = 232.32 g/mol
3.2 Experimental Procedures for Chapter 2:‘Development of Photochromic Ligands for LTCCs’ 
288 
16 hours at 70 °C. The solvent was then removed under reduced pressure, and the residue was 
purified by flash column chromatography (silica, CH2Cl2:MeOH = 1:0 to 9:1) to yield 
compound 688 (353 mg, 1.52 mmol, 72%) as a colourless oil. 
 
Rf = 0.28 (CH2Cl2:MeOH = 10:1). 
 
1H NMR (CDCl3, 300 MHz): δ = 5.43 (s, 1H), 3.97–3.83 (m, 2H), 3.36–3.01 (m, 7H), 2.82 (s, 
3H), 1.99–1.87 (m, 2H), 1.28 (s, 9H) ppm. 
 
13C NMR (CDCl3, 75 MHz): δ = 156.6, 79.7, 57.9, 55.9, 54.6, 41.3, 37.5, 28.5, 24.7 ppm. 
 
EI-MS for C11H24N2O3+ [M+]: calcd. 232.1787 
 found 232.1791. 
 
IR (ATR): ῦ/cm−1 = 3316, 2974, 2705, 1684, 1515, 1455, 1391, 1365, 1274, 1249, 1165, 
1070, 1023, 866, 780. 
 
Synthesis of Bromide 689 
   
 
    
Carbamate 688 (100 mg, 0.46 mmol, 1.0 eq.), and triphenylphosphine (213 mg, 0.81 mmol, 
1.3 eq.) were dissolved in dry THF (2.4 mL). A solution of tetrabromomethane (269 mg, 
0.81 mmol, 1.3 eq.) in acetonitrile (0.9 mL) was added at 0 °C and the mixture was stirred at 
that temperature for 6 hours. The solvent was then removed under reduced pressure and the 
residue was purified via flash column chromatography (silica, CH2Cl2:MeOH = 1:0 to 19:1) 
yielding bromide 689 (8 mg, 0.03 mmol, 6%) as a colourless oil. 
 
Rf = 0.62 (CH2Cl2:MeOH = 9:1). 
 
1H NMR (CD3OD, 400 MHz): δ = 3.50 (t, J = 5.5 Hz, 2H), 3.17 (t, J = 6.7 Hz, 2H), 2.63 (t, 
J = 5.5 Hz, 2H), 2.53 (t, J = 6.8 Hz, 2H), 2.30 (s, 3H), 1.44 (s, 9H) ppm. 
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13C NMR (CD3OD, 100 MHz): δ = 154.8, 71.2, 59.0, 58.0, 57.7, 54.8, 42.8, 28.7 ppm. 
 
EI-MS for C10H21BrN2O2+ [M+]: calcd. 280.0786 
 found 280.0789. 
 
Synthesis of Amide 692 
   
 
    
Carbamate 687 (200 mg, 0.92 mmol, 1.0 eq.) was dissolved in CH2Cl2 (4 mL) and 
trifluoroacetic acid (1 mL) was added. The resulting solution was stirred at room temperature 
for two hours and then concentrated in vacuo. The crude reaction product was dried 
thoroughly in vacuo and used for the next reaction step without further purification. 
4-(Phenyldiazenyl)benzoic acid (207 mg, 0.92 mmol, 1.0 eq.) was dissolved in dry 
acetonitrile (5 mL) and dry DMF (2 drops) was added. Subsequently, oxalyl chloride (504 µL, 
2 M solution in CH2Cl2, 1.01 mmol, 1.1 eq.) was added dropwise. After one hour, when gas 
evolution had stopped, the reaction mixture was concentrated and dried in vacuo for 30 min. 
The resulting solid acid chloride was then re-dissolved in dry DMF (10 mL), cooled to 0 °C 
and DIPEA (0.16 mL, 2.75 mmol, 3.0 eq.) was added thereto. Subsequently, a solution of the 
crude deprotected amino alcohol (691) in dry DMF (10 mL) was added dropwise via cannula. 
The reaction mixture was allowed to warm to room temperature and was then stirred for 
16 hours. Thereafter, EtOAc (30 mL) and saturated aqueous NaHCO3 (30 mL) solution were 
added. The phases where separated and the aqueous layer was extracted with EtOAc 
(3 × 20 mL). The combined organic layers where dried over Na2SO4 and concentrated in 
vacuo. Purification via flash column chromatography (silica, CH2Cl2:MeOH = 1:0 to 9:1) 
yielded amide 692 (70.1 mg, 0.21 mmol, 23%) as an orange solid. 
 
Rf = 0.23 (CH2Cl2:MeOH = 10:1). 
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O
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1H NMR (CDCl3, 600 MHz): δ = 7.87–7.83 (m, 2H), 7.82–7.77 (m, 4H), 7.42–7.35 (m, 3H), 
7.24 (t, J = 4.9 Hz, 1H), 3.56 (t, J = 5.3 Hz, 2H), 3.46 (q, J = 5.5 Hz, 2H), 3.39 (s, 1H), 2.60 (t, 
J = 5.9 Hz, 2H), 2.52 (t, J = 5.3 Hz, 2H), 2.24 (s, 3H) ppm. 
 
13C NMR (CDCl3, 150 MHz): δ = 167.1, 154.2, 152.6, 136.3, 131.6, 129.2, 128.2, 123.1, 
122.9, 59.1, 58.9, 56.4, 42.2, 37.6 ppm. 
 
ESI-MS for C18H23N4O2+ [MH+]: calcd. 327.1816 
 found 327.1812. 
 
IR (ATR): ῦ/cm−1 = 3540, 3267, 2930, 1680, 1645, 1595, 1580, 1523, 1442, 1440, 1423, 
1380, 1331, 1290, 1154, 1140, 1120, 1063, 986, 965, 923, 821, 811, 790, 780, 755, 725. 
 
UV-Vis (DMSO): λmax = 381 nm. 
 
Synthesis of Chloride 693 
     
 
    
Thionyl chloride (0.20 mL, 2.76 mmol, 20.4 eq.) was dissolved in dry CH2Cl2 (0.5 mL) and 
the mixture was then cooled to 0 °C. To this, a solution of amide 692 (40.0 mg, 0.12 mmol, 
1.0 eq.) in dry CH2Cl2 (0.5 mL) was added dropwise via syringe pump over one hour. The 
mixture was stirred for further 3 hours at this temperature and subsequently quenched with 
aqueous sodium hydroxide solution (5 M, 2.2 mL). The phases were separated and the 
aqueous layer was extracted with dichloromethane (3 × 10 mL). The combined organic layers 
were dried over Na2SO4 and concentrated in vacuo. Purification via flash column 
chromatography (silica, CH2Cl2:MeOH = 1:0 to 97:3) yielded chloride 693 (41.9 mg, 
0.12 mmol, quant.) as an orange solid. 
 
Rf = 0.85 (CH2Cl2:MeOH = 10:1). 
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1H NMR (CDCl3, 600 MHz): δ = 7.93–7.79 (m, 6H), 7.47–7.36 (m, 3H), 7.1 (s, br, 1H), 3.55 
(t, J = 5.9 Hz, 2H), 3.49 (q, J = 5.3 Hz, 2H), 2.74 (t, J = 5.8 Hz, 2H), 2.63 (t, J = 5.4 Hz, 2H), 
2.29 (s, 3H) ppm. 
 
13C NMR (CDCl3, 150 MHz): δ = 166.7, 154.3, 152.7, 136.3, 131.6, 129.3, 128.2, 123.2, 
123.0, 58.6, 55.8, 41.7, 37.2 ppm. 
 
ESI-MS for C18H22ClN4O+ [MH+]: calcd. 345.1477 
 found 345.1480. 
 
IR (ATR): ῦ/cm−1 = 2933, 1665, 1640, 1592, 1582, 1553, 1523, 1467, 1442, 1400, 1381, 
1331, 1293, 1120, 1063, 982, 940, 923, 820, 813, 790, 781, 753, 726, 682. 
 
UV-Vis (DMSO): λmax = 380 nm. 
 
Azo-diltiazem 1 (694) 
    
 
   
To a solution of thiazepine 688 (10.1 mg, 33.2 µmol, 1.0 eq.) in EtOAc (0.40 mL) were added 
chloride 693 (18 mg, 66.4 µmol, 2.0 eq.), water (1 drop) and K2CO3 (18.0 mg, 133 µmol, 
4.0 eq.). The resulting suspension was heated to reflux at 82 °C for 22 hours. Subsequently, 
the solvent was removed in vacuo and the crude mixture was purified via flash column 
chromatography (i-Hex:EtOAc = 1:1 to 0:1). Azo-diltiazem 1 (17.4 mg, 28.6 µmol, 86%) was 
obtained as an orange oil of 96% purity, as judged by 1H NMR analysis. Further purification 
was achieved by reversed-phase HPLC (H2O:CH3CN:TFA = 1:0:10−3 to 3:7:10−3). Thus 
obtained pure azo-diltiazem 694 (4.2 mg, 6.8 µmol, 21%) did show broadened signals for 
specific protons in the 1H NMR, due to the basicity of the tertiary amine function. 
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Rf = 0.30 (EtOAc). 
 
1H NMR (CDCl3, 600 MHz): δ = 7.86–7.79 (m, 2H), 7.77–7.67 (m, 4H), 7.59–7.57 (m,  
1H), 7.44–7.33 (m, 8H), 7.25–7.23 (m, 3H), 6.68–6.67 (m, 2H), 4.79 (d, J = 7.2 Hz, 1H),  
4.63–4.59 (m, 1H), 4.19 (d, J = 7.2 Hz, 1H), 3.64 (s, 3H), 3.62–3.54 (m, 2H), 3.53–3.46 (m, 
1H), 2.83 (s, br, 1H), 2.72 (s, br, 1H), 2.53 (s, br, 2H), 2.36 (s, 3H) ppm. 
 
13C NMR (CDCl3, 150 MHz): δ = 172.0, 167.5, 160.1, 154.1, 152.7, 144.5, 135.6, 131.5, 
130.8, 129.2, 128.9, 128.4, 128.0, 126.0, 124.6, 123.2, 122.6, 120.8, 119.9, 113.7, 69.2, 56.8, 
56.6, 56.3, 55.3, 47.2, 42.7, 37.7 ppm. 
 
ESI-MS for C34H36N5O4S+ [MH+]: calcd. 610.2483 
 found 610.2483. 
 
IR (ATR): ῦ/cm−1 = 3337, 3.175, 3101, 3093, 2932, 2902, 1676, 1641, 1609, 1592, 1580, 
1550, 1525, 1512, 1462, 1439, 1400, 1381, 1359, 1338, 1331, 1290, 1145, 1077, 982, 940, 
923, 819, 810, 788, 778, 734, 718, 726, 682, 665. 
 
UV-Vis (DMSO): λmax = 380 nm. 
 
Synthesis of Phenol 712 
   
 
    
According to a literature-known procedure,[493] 4-nitroaniline (714, 5.0 g, 36.0 mmol, 1.0 eq.) 
was suspended in water (36 mL) and concentrated aqueous HCl (9 mL) was added. The 
resulting mixture was heated until the aniline was completely dissolved. This solution was 
then cooled to 0 °C and a mixture of sodium nitrite (2.5 g, 36.2 mmol, 1.0 eq.) in water 
(36 mL) was added slowly. The reaction mixture was stirred for one hour at this temperature 
and subsequently added to a solution of phenol (3.4 g, 36.2 mmol, 1.0 eq.) and NaOH (2.9 g, 
72.5 mmol, 2.0 eq.) in water (36 mL) dropwise via cannula at 0 °C. The resulting suspension 
was stirred for another hour. The formed yellow precipitate was filtered and thoroughly 
 NaNO2 (1.0 eq.), HCl
→ phenol (1.0 eq.), NaOH
 H2O
0 °C to rt, 2 h 
(91%)
714
H2N
NO2
HO
N N
NO2
712
C12H9N3O3
M = 243.22 g/mol
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washed with water. After drying in vacuo, phenol 712 (7.9 g, 32.8 mmol, 91%) was obtained 
as an orange solid, which required no further purification. 
 
Rf = 0.53 (i-Hex:EtOAc = 9:1). 
 
1H NMR (CDCl3, 600 MHz): δ = 8.29–8.24 (m, 2H), 7.90–7.87 (m, 2H), 7.86–7.82 (m, 2H), 
6.91–6.85 (m, 2H), 5.18 (s, br, 1H) ppm. 
 
13C NMR (CDCl3, 150 MHz): δ = 159.6, 156.1, 148.5, 147.3, 126.0, 124.9, 123.3, 116.2 ppm. 
 
ESI-MS for C12H8N3O3− [(M−H)−]: calcd. 242.0571 
 found 242.0567. 
 
IR (ATR): ῦ/cm−1 = 3382, 1603, 1584, 1502, 1457, 1428, 1402, 1379, 1331, 1281, 1179, 
1133, 1108, 1000, 1006, 860, 844, 836, 791, 755, 722, 686, 879. 
 
UV-Vis (DMSO): λmax = 386 nm. 
 
Synthesis of Methyl Ether 713 
    
 
    
Phenol 712 (3.00 g, 12.3 mmol, 1.0 eq.) was dissolved in dry DMF (17 mL). To this solution, 
K2CO3 (1.96 g, 14.2 mmol, 1.2 eq.), KI (0.41 g, 2.5 mmol, 0.2 eq.) and 1-bromo-
2-methoxyethane (715, 1.97 g, 14.2 mmol, 1.2 eq.) were added. The resulting blue suspension 
was stirred at 83 °C for two hours, upon which a colour change to red was observed. 
Subsequent cooling to room temperature led to solidification of the reaction mixture, which 
was then redissolved in EtOAc (200 mL), washed with saturated NaCl solution (2 × 100 mL), 
dried over Na2SO4 and concentrated in vacuo. The product was purified via flash column 
chromatography (silica, i-Hex:EtOAc = 1:0 to 0:1). Thus, methyl ether 713 (3.58 mg, 
11.8 mmol, 97%) was obtained as an orange solid.  
712
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Rf = 0.73 (i-Hex:EtOAc = 3:2). 
 
1H NMR (CDCl3, 600 MHz): δ = 8.29–8.19 (m, 2H), 7.91–7.81 (m, 4H), 7.02–6.92 (m, 2H), 
4.12 (t, J = 4.7 Hz, 2H), 3.69 (t, J = 4.7 Hz, 2H), 3.37 (s, 3H) ppm. 
 
13C NMR (CDCl3, 150 MHz): δ = 162.6, 156.1, 148.4, 147.1, 125.7, 124.8, 123.2, 115.2, 70.9, 
67.9, 59.4 ppm. 
 
EI-MS for C15H15N3O4+ [M+]: calcd. 301.1063 
 found 301.1048. 
 
IR (ATR): ῦ/cm−1 = 3101, 2999, 2925, 2879, 2847, 2810, 1600, 1588, 1580, 1515, 1500, 
1456, 1420, 1400, 1377, 1339, 1318, 1300, 1247, 1198, 1155, 1141, 1113, 1098, 1063, 1032, 
951, 925, 856, 841, 832, 778, 756, 726, 689, 684. 
 
UV-Vis (DMSO): λmax = 376 nm. 
 
Synthesis of Aniline 710 
   
 
    
Nitro compound 713 (3.0 g, 10.0 mmol, 1.0 eq.) was dissolved in 1,4-dioxane (100 mL). To 
this, water (10 mL) and then Na2S (1.6 g, 20.9 mmol, 2.1 eq.) were added. The resulting 
suspension was heated to 95 °C for one hour and the conversion was then judged to be 
complete via TLC analysis. Subsequently, the reaction mixture was poured into saturated 
aqueous NaHCO3 solution (150 mL) and extracted with CH2Cl2 (3 × 200 mL). The combined 
organic layers were dried over Na2SO4 and concentrated in vacuo. Purification via flash 
column chromatography (silica, i-Hex:EtOAc = 1:0 to 0:1) provided aniline 710 (2.0 g, 
7.22 mmol, 72%) as an orange solid. 
 
Rf = 0.36 (i-Hex:EtOAc = 3:2). 
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1H NMR (DMSO-d6, 400 MHz): δ = 7.77–7.67 (m, 2H), 7.66–7.57 (m, 2H), 7.11–7.01 (m, 
2H), 6.72–6.61 (m, 2H), 5.95 (s, 2H), 4.16 (t, J = 4.5 Hz, 2H), 3.66 (t, J = 4.5 Hz, 1H), 3.32 
(s, 3H) ppm. 
 
13C NMR (DMSO-d6, 100 MHz): δ = 159.6, 152.1, 146.6, 142.8, 124.6, 123.3, 114.8, 113.4, 
70.3, 67.2, 58.2 ppm. 
 
ESI-MS for C15H18N3O2+ [MH+]: calcd. 272.1394 
 found 272.1392. 
 
IR (ATR): ῦ/cm−1 = 3460, 3368, 3234, 2978, 2926, 2891, 2820, 1640, 1594, 1578, 1506, 
1499, 1454, 1428, 1405, 1371, 1311, 1296, 1251, 1197, 1190, 1145, 1120, 1107, 1057, 1031, 
1002, 947, 857, 838, 766, 731. 
 
UV-Vis (DMSO): λmax = 403 nm. 
 
Synthesis of Morpholine 711 
   
 
   
4-Nitroaniline (714, 3.00 g, 21.7 mmol, 1.0 eq.) was dissolved in methanol (100 mL) and 
concentrated HCl (10 mL) was added. This solution was cooled to 0 °C and t-BuONO 
(2.35 g, 22.8 mmol, 1.05 eq.) was added slowly. The reaction mixture was stirred for one hour 
at this temperature and subsequently added to a solution of (4-morpholinyl)benzene (716,  
3.56 g, 21.7 mmol, 1.0 eq.) in methanol (100 mL) and concentrated HCl (10 mL) dropwise 
via cannula at 0 °C. The resulting red solution was stirred for 5 hours and allowed to warm to 
room temperature. Subsequently, the reaction mixture was poured into saturated aqueous 
NaHCO3 solution (200 mL) and extracted with EtOAc (3 × 200 mL). The combined organic 
layers were dried over Na2SO4 and concentrated in vacuo. Purification via flash column 
chromatography (silica, CH2Cl2:i-Hex = 1:1 to 1:0) provided nitro compound 758 as an 
714
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orange solid, along with residual (4-morpholinyl)benzene (716, 5 mol-%) as judged by 
1H NMR analysis. 
Thus obtained nitro compound 758 (5.0 g, 16.0 mmol, 1.0 eq.) was dissolved in 1,4-dioxane 
(160 mL). To this, water (16 mL) and then Na2S (2.6 g, 33.6 mmol, 2.1 eq.) were added. The 
resulting suspension was heated to 95 °C for one hour and the reaction was then judged to be 
complete via TLC analysis. Subsequently, the reaction mixture was poured into saturated 
aqueous NaHCO3 solution (200 mL) and extracted with CH2Cl2 (3 × 250 mL). The combined 
organic layers were dried over Na2SO4 and concentrated in vacuo. Purification via flash 
column chromatography (silica, i-Hex:EtOAc = 4:1 to 0:1) provided morpholine 711 (3.7 g, 
13.0 mmol, 62%) as an orange solid. 
 
Rf = 0.76 (i-Hex:EtOAc = 1:1). 
 
1H NMR (CDCl3, 600 MHz): δ = 7.74–7.70 (m, 2H), 7.68–7.63 (m, 2H), 6.88–6.84 (m, 2H), 
6.66–6.62 (m, 2H), 3.86 (s, br, 2H), 3.78 (t, J = 4.8 Hz, 4H), 3.18 (t, J = 4.8 Hz, 4H) ppm. 
 
13C NMR (CDCl3, 150 MHz): δ = 152.5, 148.8, 146.3, 146.0, 124.6, 124.0, 114.9, 114.9, 66.9, 
48.6 ppm. 
 
ESI-MS for C16H19N4O+ [MH+]: calcd. 283.1553 
 found 283.1558. 
 
IR (ATR): ῦ/cm−1 = 3452, 3348, 3214, 3036, 2963, 2898, 2865, 2839, 1628, 1592, 1572, 
1502, 1462, 1445, 1428, 1397, 1381, 1344, 1303, 1296, 1268, 1232, 1180, 1154, 1138, 1115, 
1070, 1050, 1029, 961, 937, 924, 860, 832, 823, 796, 753, 734, 719. 
 
UV-Vis (DMSO): λmax = 453 nm. 
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Synthesis of Mono Desmethyl Diltiazem (698) 
   
 
   
Diltiazem hydrochloride 695 (7.23 g, 16.0 mmol, 1.0 eq.) was dissolved in EtOAc (20 mL) 
and saturated aqueous NaHCO3 solution (100 mL) was added. The resulting solution was 
stirred for 30 min and then diluted with EtOAc (200 mL). Thereafter, the phases were 
separated and the aqueous layer was extracted with EtOAc (3 × 150 mL). The combined 
organic layers were dried over Na2SO4 and concentrated in vacuo to yield diltiazem (645) 
(6.64 g, 16.0 mmol, quant.) as colourless foam. 
Diltiazem (645, 6.64 g, 16.0 mmol, 1.0 eq.) was dissolved in dry DCE (99 mL) and 
1-chloroethyl chloroformiate (696, 2.50 g, 17.5 mmol, 1.1 eq.) was added. The resulting 
solution was heated to 90 °C for one hour and then cooled to room temperature. After 
concentrating in vacuo at 10−2 mbar for one hour, the obtained foamy 1-chloroethyl 
formamide (697, cf. scheme 2.6) was redissolved in dry MeOH (218 mL) at 0 °C and stirred 
for 6 hours until TLC analysis indicated complete conversion. Thereafter, the reaction mixture 
was poured into saturated aqueous NaHCO3 solution (200 mL) and extracted with EtOAc 
(4 × 200 mL). The combined organic layers were dried over Na2SO4 and concentrated in 
vacuo. Purification via flash column chromatography (silica, CH2Cl2:MeOH = 1:0 to 23:2) 
provided mono desmethyl diltiazem 698 (5.84 g, 14.6 mmol, 92%) as foamy colourless solid. 
 
Rf = 0.28 (CH2Cl2:MeOH:H2O:NH4OH = 9.0:1.0:0.1:0.1). 
 
1H NMR (CDCl3, 600 MHz): δ = 7.60 (dd, J = 7.7, 1.5 Hz, 1H), 7.41–7.28 (m, 4H), 7.17 (dt, 
J = 7.7, 1.4 Hz, 2H), 6.80–6.78 (m, 2H), 5.06 (d, J = 7.5 Hz, 1H), 4.92 (d, J = 7.5 Hz, 1H), 
4.49 (dt, J = 13.7, 6.9 Hz, 1H), 3.72 (s, 3H), 3.59 (dt, J = 13.7, 5.8 Hz, 1H), 2.77–2.72 (m, 
2H), 2.31 (s, 3H), 1.80 (s, 3H) ppm. 
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13C NMR (CDCl3, 150 MHz): δ = 170.0, 167.1, 159.9, 145.4, 135.5, 131.3, 130.8, 128.5, 
127.7, 126.6, 124.9, 114.0, 71.2, 55.4, 54.5, 49.4, 49.1, 36.1, 20.6 ppm. 
 
ESI-MS for C21H25N2O4S+ [MH+]: calcd. 401.1530 
 found 401.1529. 
 
IR (ATR): ῦ/cm−1 = 3319, 3063, 2936, 2838, 2797, 2248, 1743, 1675, 1609, 1584, 1512, 
1471, 1444, 1407, 1370, 1304, 1293, 1223, 1179, 1140, 1113, 1852, 1061, 1031, 909s, 836, 
818, 763, 725, 661, 645, 600, 565. 
 
 = +43.6 (c 1.00, CH2Cl2). 
 
Synthesis of Carbamate 699 
    
 
    
Mono desmethyl diltiazem (698, 698 mg, 1.74 mmol, 1.0 eq.) was dissolved in dry THF  
(8 mL). To this, KI (318 mg, 1.92 mmol, 1.1 eq.), K2CO3 (482 mg, 3.49 mmol, 2.0 eq.), and 
substance 684 (469 mg, 2.09 mmol, 1.2 eq.) were added. The reaction mixture was then 
heated to 70 °C for 21 hours, cooled to room temperature and diluted with CH2Cl2 (40 mL). 
The organic phase was washed with saturated aqueous NaCl (20 mL) and the resulting 
aqueous layer was re-extracted with CH2Cl2 (2 × 20 mL). The combined organic layers were 
dried over Na2SO4 and concentrated in vacuo. Purification via flash column chromatography 
(silica, EtOAc) provided carbamate 699 (716 mg, 1.32 mmol, 77%) as a slightly yellow foam. 
 
Rf = 0.26 (EtOAc). 
 
1H NMR (CDCl3, 600 MHz): δ = 7.58 (dd, J = 7.6, 1.4 Hz, 1H), 7.39–7.32 (m, 2H), 7.32–7.27 
(m, 2H), 7.13 (dt, J = 7.6, 1.4 Hz, 1H), 6.78–6.73 (m, 2H), 5.02 (d, J = 7.5 Hz, 1H), 4.90 (s, 
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br, 1H), 4.88 (d, J = 7.5 Hz, 1H), 4.37–4.26 (m, 1H), 3.67 (s, 3H), 3.58 (dt, J = 19.6, 6.5 Hz, 
1H), 3.05–2.97 (m, 2H), 2.63 (dt, J = 12.8, 6.5 Hz, 1H), 2.44 (dt, J = 12.8, 6.5 Hz 1H), 2.38 
(dt, J = 11.7, 5.7 Hz, 1H), 2.34–2.30 (m, 1H), 2.12 (s, 3H), 1.76 (s, 3H), 1.26 (s, 9H) ppm. 
 
13C NMR (CDCl3, 150 MHz): δ = 169.8, 166.9, 159.7, 156.0, 145.5, 135.4, 131.0, 130.8, 
128.5, 127.4, 126.6, 124.5, 113.7, 78.8, 71.1, 56.8, 55.6, 55.2, 54.4, 47.5, 41.6, 37.9, 28.4, 
20.5 ppm. 
 
ESI-MS for C28H38N3O6S+ [MH+]: calcd. 544.2476 
 found 544.2471. 
 
IR (ATR): ῦ/cm−1 = 3374, 2974, 2838, 2802, 1746, 1707, 1678, 1610, 1584, 1512, 1472, 
1445, 1391, 1391, 1365, 1304, 1248, 1169, 1114, 1062, 1033, 960, 922, 836, 764, 734, 661, 
636, 603, 563. 
 
 = +80.4 (c 1.00, CH2Cl2). 
 
Synthesis of Carbamate 700 
   
 
   
Mono desmethyl diltiazem (698, 670 mg, 1.67 mmol, 1.0 eq.) was dissolved in dry THF  
(8.0 mL). To this, KI (305 mg, 1.84 mmol, 1.1 eq.), K2CO3 (462 mg, 3.49 mmol, 2.0 eq.) and 
substance 685 (478 mg, 2.01 mmol, 1.2 eq.) were added. The reaction mixture was then 
heated to 70 °C for 23 hours, cooled to room temperature and diluted with CH2Cl2 (40 mL). 
The organic phase was washed with saturated aqueous NaCl (20 mL) and the resulting 
aqueous layer was re-extracted with CH2Cl2 (2 × 20 mL). The combined organic layers were 
dried over Na2SO4 and concentrated in vacuo. Purification via flash, column chromatography 
(silica, EtOAc) provided carbamate 685 (620 mg, 1.32 mmol, 77%) as a colourless foam. 
[ ]20Dα
698
N
S
O
OAc
OMe
NH
N
S
O
OAc
OMe
N
Br
685 (1.2 eq.)
K2CO3 (2.0 eq.)
 KI (1.1 eq.)
THF, 70 °C
21 h
(67%)
700
C29H39N3O6S
M = 557.71 g/mol
NHBoc
NHBoc
3.2 Experimental Procedures for Chapter 2:‘Development of Photochromic Ligands for LTCCs’ 
300 
Rf = 0.58 (CH2Cl2:MeOH:H2O:NH4OH = 9.0:1.0:0.1:0.1). 
 
1H NMR (CDCl3, 600 MHz): δ = 7.59 (dd, J = 7.7, 1.5 Hz, 1H), 7.44–7.38 (m, 2H), 7.33–7.31 
(m, 2H), 7.18–7.13 (m, 2H), 6.81–6.78 (m, 2H), 5.04 (d, J = 7.5 Hz, 1H), 4.95 (s, br, 1H), 
4.90 (d, J = 7.6 Hz, 1H), 4.20–4.14 (m, 1H), 3.74–3.67 (m, 1H), 3.72 (s, 3H), 3.02–2.99 (m, 
2H), 2.75–2.69 (m, 1H), 2.44–2.40 (m, 1H), 2.36–2.31 (m, 2H), 2.15 (s, 3H), 1.80 (s, 3H), 
1.51–1.46 (m, 2H), 1.31 (s, 9H) ppm. 
 
13C NMR (CDCl3, 150 MHz): δ = 170.1, 167.1, 159.9, 156.2, 145.9, 135.5, 131.2, 130.9, 
128.6, 127.5, 126.8, 124.9, 113.9, 79.0, 71.4, 56.0, 55.4, 55.4, 54.6, 48.4, 42.4, 39.3, 28.6, 
27.5, 20.7 ppm. 
 
ESI-MS for C29H40N3O6S+ [MH+]: calcd. 558.2632 
 found 558.2624. 
 
IR (ATR): ῦ/cm−1 = 3367, 2934, 2837, 2799, 1745, 1676, 1609, 1583, 1511, 1471, 1444, 
1407, 1390, 1364, 1304, 1224, 1166, 1062, 1030, 945, 919, 834, 818, 762, 735, 686, 660. 
 
 = +89.0 (c 1.00, CH2Cl2). 
 
Synthesis of Amine 701 
    
 
    
Carbamate 699 (70 mg, 0.13 mmol) was dissolved in neat formic acid (1.8 mL) at room 
temperature. This solution was stirred for 3 hours until TLC analysis indicated complete 
conversion. Subsequently, saturated aqueous NaHCO3 solution (20 mL) was added slowly 
and the resulting mixture was extracted with CH2Cl2 (3 × 20 mL). The combined organic 
layers were dried over Na2SO4 and concentrated in vacuo, yielding amine 701 (63 mg, 
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0.13 mmol, quant.) as a colourless foam. 1H NMR analysis showed contamination of less than 
5 mol-% of the respective deacetylated amine as an inseparable side product.  
 
Rf = 0.13 (CH2Cl2:MeOH:H2O:NH4OH = 9.0:1.0:0.1:0.1). 
 
1H NMR (CDCl3, 600 MHz): δ = 7.6–7.57 (m, 1H), 7.40–7.36 (m, 2H), 7.32–7.30 (m, 2H), 
7.16–7.13 (m, 1H), 6.80–6.78 (m, 2H), 5.04 (d, J = 7.5 Hz, 1H), 4.90 (d, J = 7.5 Hz, 1H), 4.26 
(ddd, J = 14.0, 7.5, 6.6 Hz, 1H), 3.71 (s, 3H), 3.66–3.61 (m, 1H), 2.69 (ddd, J = 7.5, 6.6 Hz, 
1H), 2.61–2.58 (m, 2H), 2.49–2.46 (m, 1H), 2.36–2.32 (m, 2H), 2.15 (s, 3H), 1.98 (s, br, 2H), 
1.79 (s, 3H) ppm. 
 
13C NMR (CDCl3, 150 MHz): δ = 170.0, 167.1, 159.9, 145.8, 135.5, 131.2, 130.9, 128.6, 
127.5, 126.8, 124.8, 113.9, 71.2, 60.4, 55.7, 55.4, 54.6, 48.1, 42.4, 39.5, 20.6 ppm. 
 
ESI-MS for C23H30N3O4S+ [MH+]: calcd. 444.1952 
 found 444.1950. 
 
IR (ATR): ῦ/cm−1 = 2950, 2838, 2798, 2246, 1743, 1672, 1609, 1584, 1512, 1471, 1444, 
1408, 1370, 1304, 1224, 1179, 1113, 1062, 1031, 909, 834, 763, 725, 662. 
 
 = +39.6 (c 1.00, CH2Cl2). 
 
Synthesis of Amine 702 
    
 
    
Carbamate 700 (300 mg, 0.54 mmol) was dissolved in neat formic acid (3 mL) at room 
temperature. This solution was stirred for 3 hours until TLC analysis indicated complete 
conversion. Subsequently, saturated aqueous NaHCO3 solution (40 mL) was added slowly 
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and the resulting mixture was extracted with CH2Cl2 (3 × 50 mL). The combined organic 
layers were dried over Na2SO4 and concentrated in vacuo, yielding amine 702 (246 mg,  
0.54 mmol, quant.) as a colourless foam. 1H NMR analysis showed contamination with less 
than 8 mol-% of the respective deacetylated amine as an inseparable side product.  
 
Rf = 0.16 (CH2Cl2:MeOH:H2O:NH4OH = 9.0:1.0:0.1:0.1). 
 
1H NMR (CDCl3, 600 MHz): δ = 7.56–7.53 (m, 1H), 7.37–7.30 (m, 4H), 7.29–7.25 (m, 2H), 
7.12–7.09 (m, 1H), 6.75–6.73 (m, 2H), 4.99 (d, J = 7.5 Hz, 1H), 4.86 (d, J = 7.5 Hz, 1H), 4.19 
(ddd, J = 14.0, 7.5, 6.6 Hz, 1H), 3.66 (s, 3H), 3.63–3.59 (m, 1H), 2.66 (ddd, J = 7.5, 6.6 Hz, 
1H), 2.53–2.51 (m, 2H), 2.41–2.34 (m, 1H), 2.30–2.26 (m, 2H), 2.11 (s, 3H), 1.85 (s, br, 2H), 
1.74 (s, 3H) ppm. 
 
13C NMR (CDCl3, 150 MHz): δ = 169.8, 166.8, 159.7, 145.7, 135.3, 131.3, 130.8, 128.5, 
127.3, 126.7, 124.7, 113.7, 71.1, 56.7, 55.7, 55.2, 54.4, 48.0, 42.2, 40.4, 28.4, 20.5 ppm. 
 
ESI-MS for C24H32N3O4S+ [MH+]: calcd. 458.2108 
 found 458.2108. 
 
IR (ATR): ῦ/cm−1 = 3318, 3063, 2936, 2836, 2798, 1744, 1656, 1608, 1582, 1549, 1510, 
1471, 1442, 1409, 1368, 1303, 1250, 1178, 1132, 1110, 1091, 1062, 1031, 911, 834, 818, 753, 
729, 686, 663. 
 
 = +104.8 (c 1.00, CH2Cl2). 
 
General Procedure for the Synthesis of Substituted Ω-Iodoalkyl Amides  
 
The respective Ω-iodoalkanoic acid (1.00 mmol, 1.0 eq.) was dissolved in dry THF (4.9 mL) 
and cooled to 0 °C under an argon gas atmosphere. To this solution the aniline of choice  
(1.00 mmol, 1.0 eq.) was added in portions and the resulting mixture was stirred for 10 min. 
Subsequently, a solution of N,N'-dicyclohexylcarbodiimide (1.10 mmol, 1.1 eq.) in dry THF 
(3.3 mL) was added dropwise via cannula over 15 min. The reaction mixture was stirred for 
one hour and then allowed to warm to room temperature over night. Thereafter, the formed 
precipitate was filtered off and washed thoroughly with Et2O. The filtrate was concentrated 
[ ]20Dα
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and purified via column chromatography to yield the respective Ω-iodoalkyl amide. In some 
cases contamination with 1,3-dicyclohexylurea (not shown) was observed, which did not 
influence reactivity or purification of the following synthetic steps. 
 
Synthesis of Acetamide 703 
   
 
   
Following the general procedure for the synthesis of Ω-iodoalkyl amides, 2-iodoacetic acid 
(705, 1.89 g, 10.1 mmol, 1.0 eq.), aniline 704 (2.00 g, 10.1 mmol, 1.0 eq.) and 
N,N'-dicyclohexylcarbodiimide (2.29 g, 11.1 mmol, 1.1 eq.) were reacted. Purification via 
flash column chromatography (silica, CH2Cl2:i-Hex = 1:1 to 1:0) yielded acetamide 703 
(2.76 g, 7.56 mmol, 75%) as an orange solid.  
 
Rf = 0.21 (CH2Cl2). 
 
1H NMR (CDCl3, 600 MHz): δ = 7.88–7.83 (m, 2H), 7.82–7.78 (m, 2H), 7.75 (s, br, 1H), 7.59 
(d, J = 8.8 Hz, 2H), 7.44–7.39 (m, 2H), 7.39–7.34 (m, 1H), 3.80 (s, 2H) ppm. 
 
13C NMR (CDCl3, 150 MHz): δ = 165.1, 152.8, 149.6, 139.9, 131.1, 129.2, 124.2, 123.0, 
120.0, −0.1 ppm. 
 
ESI-MS for C14H13IN3O+ [MH+]: calcd. 366.0098 
 found 366.0099. 
 
IR (ATR): ῦ/cm−1 = 3283, 2924, 1670, 1634, 1596, 1536, 1498, 1441, 1421, 1325, 1300, 
1274, 1234, 1152, 1084, 1017, 968, 925, 872, 848, 832, 802, 765, 722, 686. 
 
UV-Vis (DMSO): λmax = 361 nm. 
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Synthesis of Propanamide 721 
   
 
    
Following the general procedure for the synthesis of Ω-iodoalkyl amides, 3-iodopropanoic 
acid (707, 2.03 g, 10.1 mmol, 1.0 eq.), aniline 704 (2.00 g, 10.1 mmol, 1.0 eq.) and 
N,N'-dicyclohexylcarbodiimide (2.29 g, 11.1 mmol, 1.1 eq.) were reacted. Purification via 
flash column chromatography (silica, EtOAc:i-Hex = 0:1 to 1:1) yielded propanamide 721 
(1.98 g, 5.22 mmol, 51%) as an orange solid.  
 
Rf = 0.81 (EtOAc:i-Hex = 2:3). 
 
1H NMR (DMSO-d6, 400 MHz): δ = 7.91–7.86 (m, 3H), 7.60–7.54 (m, 3H), 3.45 (t, 
J = 6.7 Hz, 1H), 3.07 (t, J = 6.7 Hz, 1H) ppm. 
 
13C NMR (DMSO-d6, 100 MHz): δ = 169.4, 152.0, 147.6, 142.0, 131.1, 129.4, 123.7, 122.3, 
119.3, 36.6, 0.5 ppm. 
 
ESI-MS for C15H15IN3O+ [MH+]: calcd. 380.0254 
 found 380.0255. 
 
IR (ATR): ῦ/cm−1 = 3280, 3040, 2925, 2850, 1661, 1623, 1593, 1582, 1524, 1483, 1464, 
1448, 1438, 1403, 1373, 1299, 1258, 1247, 1205, 1185, 1166, 1154, 1142, 1126, 1104, 1087, 
1069, 1045, 1018, 1001, 956, 912, 892, 833, 765, 720, 683. 
 
UV-Vis (DMSO): λmax = 361 nm. 
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Synthesis of Butanamide 709 
   
 
   
Following the general procedure for the synthesis of Ω-iodoalkyl amides, 4-iodobutanoic acid 
(708, 500 mg, 2.34 mmol, 1.0 eq.), aniline 704 (461 mg, 2.34 mmol, 1.0 eq.) and 
N,N'-dicyclohexylcarbodiimide (531 mg, 2.57 mmol, 1.1 eq.) were reacted. Purification via 
flash column chromatography (silica, EtOAc:i-Hex = 0:1 to 1:1) yielded butanamide 709  
(350 mg, 0.89 mmol, 25–38%) as an orange solid, along with 20 mol-% of inseparable 
aniline 704, as judged by 1H NMR analysis. 
Note: As a consequence of its impurity, more equivalents of butanamide 709 were employed 
for the alkylation reactions. Analytical data was recorded from the obtained mixture. 
 
Rf = 0.78 (EtOAc:i-Hex = 2:3). 
 
1H NMR (DMSO-d6, 200 MHz, characteristic signals): δ = 7.92–7.54 (m, 9H), 3.34 (t, 
J = 6.8 Hz, 2H), 2.52 (m, 2H), 2.22–1.93 (m, 2H) ppm. 
 
ESI-MS for C16H17IN3O+ [MH+]: calcd. 394.0411 
 found 394.0413. 
 
Synthesis of Acetamide 718 
    
 
   
Following the general procedure for the synthesis of Ω-iodoalkyl amides, 2-iodoacetic acid 
(705, 387 mg, 2.08 mmol, 1.0 eq.), bisaniline 717 (500 mg, 2.08 mmol, 1.0 eq.) and 
N,N'-dicyclohexylcarbodiimide (472 mg, 2.28 mmol, 1.1 eq.) were reacted. Purification via 
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flash column chromatography (silica, CH2Cl2:i-Hex = 1:1 to 1:0) yielded acetamide 718 
(319 mg, 0.78 mmol, 38%) as a brownish solid.  
 
Rf = 0.76 (EtOAc:i-Hex = 1:3). 
 
1H NMR (DMSO-d6, 400 MHz): δ = 10.57 (s, 1H), 7.81–7.71 (m, 6H), 6.83–6.79 (m, 2H), 
3.86 (s, 2H) 3.05 (s, 6H) ppm. 
 
13C NMR (DMSO-d6, 100 MHz): δ = 166.8, 152.3, 148.3, 142.6, 140.2, 124.5, 122.7, 119.3, 
111.6, 39.9, 1.5 ppm. 
 
ESI-MS for C16H18IN4O+ [MH+]: calcd. 409.0520 
 found 409.0519. 
 
IR (ATR): ῦ/cm−1 = 3280, 3184, 3124, 2925, 2852, 1802, 1666, 1644, 1599, 1542, 1491, 
1440, 1417, 1390, 1370, 1330, 1270, 1254, 1233, 1152, 1140, 1103, 1084, 1068, 985, 970, 
944, 892, 870, 840, 824, 806, 766, 730, 738, 664. 
 
UV-Vis (DMSO): λmax = 439 nm. 
 
Synthesis of Propanamide 722 
   
 
   
Following the general procedure for the synthesis of Ω-iodoalkyl amides, 3-iodopropanoic 
acid (707, 1.67 g, 8.33 mmol, 1.0 eq.), aniline 717 (2.00 mg, 8.33 mmol, 1.0 eq.) and 
N,N'-dicyclohexylcarbodiimide (1.89 g, 9.16 mmol, 1.1 eq.) were reacted. Purification via 
flash column chromatography (silica, CH2Cl2:EtOAc = 1:0 then 0:1) yielded 
propanamide 722 (1.72 g, 4.13 mmol, 49%) as a brownish solid.  
 
Rf = 0.50 (EtOAc:i-Hex = 1:1). 
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1H NMR (DMSO-d6, 600 MHz): δ = 7.77–7.76 (m, 6H), 6.84–6.82 (m, 2H), 3.45 (t, 
J = 6.7 Hz, 2H), 3.05 (m, 8H) ppm. 
 
13C NMR (DMSO-d6, 150 MHz): δ = 169.1, 152.2, 148.1, 142.6, 140.3, 124.4, 122.6, 119.3, 
111.6, 39.8, 36.5, 0.6 ppm. 
 
ESI-MS for C17H20IN4O+ [MH+]: calcd. 423.0676 
 found 423.0677. 
 
IR (ATR): ῦ/cm−1 = 3286, 3253, 3191, 3128, 3068, 2924, 2855, 2813, 1660, 1602, 1548, 
1494, 1442, 1419, 1396, 1370, 1312, 1300, 1262, 1234, 1154, 1146, 1117, 1105, 1066, 1009, 
962, 946, 918, 843, 834, 818, 731, 718, 686. 
 
UV-Vis (DMSO): λmax = 431 nm. 
 
Synthesis of Butanamide 723 
    
 
    
Following the general procedure for the synthesis of Ω-iodoalkyl amides, 4-iodobutanoic acid 
(708, 0.89 g, 4.16 mmol, 1.0 eq.), aniline 717 (1.00 mg, 4.16 mmol, 1.0 eq.) and 
N,N'-dicyclohexylcarbodiimide (0.95 g, 4.58 mmol, 1.1 eq.) were reacted. Purification via 
flash column chromatography (silica, i-Hex:EtOAc = 1:0 to 1:1) yielded butanamide 723 
(1.36 g, 3.11 mmol, 37%) as a brownish solid.  
 
Rf = 0.63 (EtOAc:i-Hex = 3:2). 
 
1H NMR (DMSO-d6, 600 MHz): δ = 7.78–7.75 (m, 4H), 7.19 (d, J = 8.8 Hz, 2H), 6.89–6.85 
(m, 2H), 4.25 (t, J = 7.0 Hz, 2H), 3.06 (s, 3H), 2.44–2.40 (m, 2H), 2.18–2.06 (m, 2H) ppm. 
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13C NMR (DMSO-d6, 150 MHz): δ = 177.8, 156.6, 151.9, 142.7, 140.8, 124.5, 123.5, 120.3, 
112.1, 68.3, 40.0, 27.4, 21.7 ppm. 
 
ESI-MS for C18H22IN4O+ [MH+]: calcd. 437.0833 
 found 437.0830. 
 
IR (ATR): ῦ/cm−1 = 3275, 2914, 1650, 1608, 1592, 1558, 1518, 1443, 1420, 1412, 1398, 
1368, 1328, 1312, 1292, 1255, 1217, 1155, 1141, 1120, 1064, 977, 963, 839, 820, 796, 766, 
730. 
 
UV-Vis (DMSO): λmax = 429 nm. 
 
Synthesis of Acetamide 719 
   
 
    
Following the general procedure for the synthesis of Ω-iodoalkyl amides, 2-iodoacetic acid 
(705, 0.69 g, 3.69 mmol, 1.0 eq.), aniline 710 (1.00 mg, 3.69 mmol, 1.0 eq.) and 
N,N'-dicyclohexylcarbodiimide (0.84 g, 4.05 mmol, 1.1 eq.) were reacted. Purification via 
flash column chromatography (silica, i-Hex:EtOAc = 1:0 to 2:3) yielded acetamide 719 
(0.85 g, 1.92 mmol, 52%) as an orange solid.  
 
Rf = 0.85 (EtOAc:i-Hex = 3:1). 
 
1H NMR (DMSO-d6, 400 MHz): δ = 7.86–7.74 (m, 4H), 7.17–7.05 (m, 2H), 4.24–4.14 (m, 
2H), 3.87 (s, 2H), 3.74–3.63 (m, 2H), 3.32 (s, 3H) ppm. 
 
13C NMR (DMSO-d6, 100 MHz): δ = 167.0, 161.0, 147.8, 146.2, 141.2, 124.3, 123.3, 119.3, 
115.0, 70.2, 67.4, 58.2, 1.4 ppm. 
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ESI-MS for C17H19IN3O3+ [MH+]: calcd. 440.0466 
 found 440.0463. 
 
IR (ATR): ῦ/cm−1 = 3236, 3191, 3122, 3450, 2925, 2848, 1652, 1595, 1581, 1532, 1495, 
1450, 1420, 1406, 1371, 1320, 1305, 1297, 1249, 1196, 1153, 1131, 1107, 1096, 1059, 1035, 
1010, 985, 973, 923, 846, 822, 814, 773, 735, 657. 
 
UV-Vis (DMSO): λmax = 371 nm. 
 
Synthesis of Acetamide 720 
    
 
    
Following the general procedure for the synthesis of Ω-iodoalkyl amides, 2-iodoacetic acid 
(705, 0.59 g, 3.19 mmol, 1.0 eq.), aniline 711 (0.90 mg, 3.19 mmol, 1.0 eq.) and 
N,N'-dicyclohexylcarbodiimide (0.72 g, 3.51 mmol, 1.0 eq.) were reacted. Purification via 
flash column chromatography (silica, Et2O:EtOAc = 1:0 then 0:1) yielded acetamide 720 
(1.11 g, 2.47 mmol, 77%) as a brown solid.  
 
Rf = 0.55 (Et2O). 
 
1H NMR (DMF-d7, 400 MHz): δ = 8.07–7.99 (m, 6H, obscured by residual solvent),  
7.33–7.26 (m, 2H), 5.80 (s, br, 1H), 4.17 (s, 2H), 3.97 (d, J = 5.0 Hz, 4H), 3.52 (d, J = 5.0 Hz, 
4H) ppm. 
 
13C NMR (DMF-d7, 100 MHz): δ = 167.5, 153.9, 149.2, 145.2, 141.7, 124.7, 123.5, 119.9, 
114.7, 66.8, 48.2, 0.8 ppm. 
 
ESI-MS for C18H20IN4O2+ [MH+]: calcd. 451.0625 
 found 451.0631. 
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IR (ATR): ῦ/cm−1 = 3283, 3251, 3289, 3123, 3055, 2956, 2924, 2849, 1657, 1596, 1547, 
1507, 1446, 1421, 1400, 1346, 1324, 1307, 1266, 1253, 1234, 1180, 1156, 1120, 1086, 1069, 
1050, 1025, 1008, 969, 927, 891, 843, 817, 759, 731, 715. 
 
UV-Vis (DMSO): λmax = 443 nm. 
 
Synthesis of Azo-diltiazem 2 (706) 
   
 
   
To a solution of mono desmethyl diltiazem (698, 400 mg, 1.00 mmol, 1.0 eq.) in dry THF 
(8 mL), acetamide 703 (365 mg, 1.00 mmol, 1.0 eq.) and K2CO3 (138 mg, 1.00 mmol,  
1.0 eq.) were added. The resulting suspension was stirred at room temperature for two days, 
subsequently filtered and concentrated in vacuo. Purification via flash column 
chromatography (silica, i-Hex:EtOAc = 1:1 to 0:1) yielded diltiazem derivative 706 (546 mg, 
0.86 mmol, 86%) as a red, foamy solid. The analytical sample was further purified by 
recrystallization from CHCl3/n-hexane. 
 
Crystals suitable for X-ray analysis were obtained by slow evaporation of a solution of 706 in 
CH2Cl2. 
 
Rf = 0.70 (EtOAc). 
 
1H NMR (CDCl3, 600 MHz): δ = 9.34 (s, br, 1H), 7.80–7.77 (m, 2H), 7.71–7.65 (m, 2H), 7.63 
(dd, J = 7.7, 1.5 Hz, 1H), 7.53 (d, J = 8.6 Hz, 2H), 7.44–7.34 (m, 7H), 7.19 (td, J = 7.6, 
1.4 Hz, 1H), 6.60 (d, J = 8.5 Hz, 2H), 5.07 (d, J = 7.6 Hz, 1H), 4.96 (d, J = 7.6 Hz, 1H), 4.63 
(ddd, J = 13.5, 8.5, 4.6 Hz, 1H), 3.55 (d, J = 16.0 Hz, 1H), 3.44 (s, 3H), 3.35 (d, J = 15.2 Hz, 
1H), 2.94 (d, J = 15.2 Hz, 1H), 2.73–2.55 (m, 2H), 2.37 (s, 3H), 1.84 (s, 3H) ppm. 
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13C NMR (CDCl3, 150 MHz): δ = 170.0, 169.5, 167.8, 155.9, 152.9, 145.1, 141.1, 135.8, 
131.4, 130.7, 129.5, 129.2, 128.9, 128.0, 126.4, 124.8, 123.8, 122.8, 120.0, 114.1, 71.2, 62.7, 
56.7, 55.2, 54.7, 48.0, 48.0, 44.3, 20.6 ppm. 
 
ESI-MS for C35H36N5O5S+ [MH+]: calcd. 638.2432 
 found 638.2431. 
 
IR (ATR): ῦ/cm−1 = 3265, 2944, 2835, 1744, 1669, 1591, 1583, 1511, 1471, 1461, 1439, 
1406, 1369, 1303, 1251, 1237, 1223, 1180, 1152, 1142, 1111, 1087, 1057, 1034, 1000, 909, 
847, 766, 734, 688, 661. 
 
UV-Vis (DMSO): λmax = 361 nm. 
 
Synthesis of Azo-diltiazem 3 (725) 
    
 
    
To a solution of mono desmethyl diltiazem (698, 500 mg, 1.25 mmol, 1.0 eq.) in dry THF  
(10 mL), propanamide 721 (761 mg, 1.87 mmol, 1.5 eq.) and K2CO3 (259 mg, 1.87 mmol, 
1.5 eq.) were added. The resulting suspension was stirred at room temperature for two days, 
subsequently filtered and concentrated in vacuo. Purification via flash column 
chromatography (silica, i-Hex:EtOAc = 1:1 to 0:1) yielded diltiazem derivative 725 (414 mg, 
0.64 mmol, 51%) as a red, foamy solid. The analytical sample was further purified by 
recrystallization from CHCl3/n-hexane. 
 
Rf = 0.20 (EtOAc). 
 
1H NMR (CDCl3, 600 MHz): δ = 9.95 (s, 1H), 7.81–7.79 (m, 2H), 7.77–7.75 (m, 2H),  
7.57–7.47 (m, 4H), 7.42–7.39 (m, 2H), 7.35–7.28 (m, 4H), 7.08 (td, J = 7.6, 1.3 Hz, 1H), 
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6.81–6.79 (m, 2H), 5.03 (d, J = 7.6 Hz, 1H), 4.93 (d, J = 7.6 Hz, 1H), 4.01–3.93 (m, 2H), 3.70 
(s, 3H), 2.99 (dt, J = 13.1, 7.3 Hz, 1H), 2.86–2.82 (m, 1H), 2.71–2.67 (m, 1H), 2.55 (ddd, 
J = 12.7, 7.6, 4.8 Hz, 1H), 2.42 (ddd, J = 11.9, 7.4, 4.8 Hz, 2H), 2.33 (s, 3 H), 1.84 (s, 
3H) ppm. 
 
13C NMR (CDCl3, 150 MHz): δ = 171.1, 170.5, 167.4, 159.9, 152.8, 148.6, 145.6, 141.5, 
135.4, 131.4, 130.8, 130.7, 129.1, 127.9, 127.6, 126.5, 124.8, 124.0, 122.7, 119.6, 113.9, 71.5, 
55.3, 54.6, 54.3, 53.6, 48.9, 42.5, 34.6, 20.7 ppm. 
 
ESI-MS for C36H38N5O5S+ [MH+]: calcd. 652.2588 
 found 652.2575. 
 
IR (ATR): ῦ/cm−1 = 3316, 1953, 2835, 1745, 1673, 1592, 1532, 1511, 1471, 1440, 1406, 
1369, 1300, 1222, 1178, 1151, 1141, 1060, 1030, 909, 843, 764, 723, 687. 
 
UV-Vis (DMSO): λmax = 360 nm. 
 
Synthesis of Azo-diltiazem 4 (727) 
   
 
    
To a solution of mono desmethyl diltiazem (698, 100 mg, 0.25 mmol, 1.0 eq.) in dry THF 
(2 mL), butanamide 709 (197 mg, 0.50 mmol, 2.0 eq.) and K2CO3 (69 mg, 0.50 mmol, 
2.0 eq.) were added. The resulting suspension was stirred at room temperature for two days, 
subsequently filtered, and concentrated in vacuo. Purification via flash column 
chromatography (silica, i-Hex:EtOAc = 1:1 to 0:1) yielded diltiazem derivative 727 (136 mg, 
0.20 mmol, 32%) as an orange, foamy solid. The analytical sample was further purified by 
recrystallization from CHCl3/n-hexane. 
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Rf = 0.18 (EtOAc). 
 
1H NMR (CDCl3, 600 MHz, 27 °C): δ = 9.18 (s, 1H), 7.79–7.77 (m, 2H), 7.70–7.66 (m, 2H), 
7.61 (dd, J = 7.6, 1.4 Hz, 1H), 7.54–7.50 (m, 2H), 7.41–7.33 (m, 7H), 7.18 (dd, J = 7.4 Hz, 
1H), 6.75–6.73 (m, 2H), 5.06 (d, J = 7.4 Hz, 1H), 4.94 (d, J = 7.4 Hz, 1H), 4.15 (dt, J = 14.4, 
6.8 Hz, 1H), 3.80 (ddd, J = 13.3, 8.0, 4.8 Hz, 1H), 3.59 (s, 3H), 2.76 (dt, J = 14.4, 7.1 Hz, 
1H), 2.48–2.38 (m, 5H), 2.22 (s, 3H), 1.85 (dt, J = 13.7, 6.8 Hz, 2H), 1.76 (s, 3H) ppm.  
 
13C NMR (CDCl3, 150 MHz, 27 °C): δ = 172.7, 170.0, 167.5, 160.0, 152.8, 148.5, 145.5, 
141.7, 135.5, 131.3, 130.9, 130.6, 129.1, 128.4, 127.8, 126.4, 124.7, 123.8, 122.7, 119.5, 
113.8, 71.4, 56.7, 55.2, 54.6, 53.5, 49.2, 43.3, 36.0, 23.9, 20.6 ppm. 
 
ESI-MS for C37H40N5O5S+ [MH+]: calcd. 666.2745 
 found 666.2729. 
 
IR (ATR): ῦ/cm−1 = 3318, 2935, 2797, 1745, 1659, 1593, 1530, 1511, 1471, 1440, 1405, 
1368, 1298, 1250, 1222, 1178, 1152, 1141, 1061, 1031, 920, 845, 763, 735, 723, 688, 662. 
 
UV-Vis (DMSO): λmax = 361 nm. 
 
Synthesis of Azo-diltiazem 5 (724) 
   
 
   
To a solution of mono desmethyl diltiazem (698, 150 mg, 0.38 mmol, 1.0 eq.) in dry THF 
(3 mL), acetamide 718 (229 mg, 0.56 mmol, 1.5 eq.) and K2CO3 (104 mg, 0.56 mmol,  
1.5 eq.) were added. The resulting suspension was stirred at room temperature for two days, 
subsequently filtered, and concentrated in vacuo. Purification via flash column 
chromatography (silica, i-Hex:EtOAc = 1:1 to 0:1) yielded diltiazem derivative 724 (232 mg, 
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0.34 mmol, 91%) as a red, foamy solid. The analytical sample was further purified by 
recrystallization from CHCl3/n-hexane. 
 
Rf = 0.75 (EtOAc). 
 
1H NMR (CDCl3, 600 MHz): δ = 9.21 (s, br, 1H), 7.76–7.74 (m, 2H), 7.63–7.59 (m, 3H), 
7.51–7.47 (m, 2H), 7.40 (ddd, J = 8.0, 7.5, 1.5 Hz, 1H), 7.36–7.32 (m, 3H), 7.19–7.14 (m, 
1H), 6.66–6.61 (m, 4H), 5.06 (d, J = 7.5 Hz, 1H), 4.95 (d, J = 7.5 Hz, 1H), 4.59 (ddd, 
J = 14.2, 8.1, 5.0 Hz, 1H), 3.56 (dt, J = 14.3, 5.1 Hz, 1H), 3.47 (s, 3H), 3.30 (d, J = 15.4 Hz, 
1H), 2.97 (s, 6H), 2.97–2.94 (m, 1H), 2.73–2.68 (m, 1H), 2.63–2.59 (m, 1H), 2.36 (s, 3H), 
1.91 (s, 3H) ppm. 
 
13C NMR (CDCl3, 150 MHz): δ = 170.0, 169.1, 167.7, 159.9, 152.3, 149.4, 145.2, 143.8, 
139.4, 135.7, 131.4, 130.7, 128.7, 127.9, 126.4, 124.8, 124.7, 122.9, 120.0, 114.0, 111.7, 71.2, 
62.6, 56.6, 55.2, 54.7, 47.9, 44.1, 40.4, 20.6 ppm. 
 
ESI-MS for C37H41N6O5S+ [MH+]: calcd. 661.2854 
 found 661.2841. 
 
IR (ATR): ῦ/cm−1 = 3261, 2881, 1744, 1668, 1597, 1511, 1471, 1442, 1400, 1361, 1304, 
1223, 1179, 1152, 1139, 1060, 1029, 944, 844, 821, 763, 728. 
 
UV-Vis (DMSO): λmax = 428 nm. 
 
Synthesis of Azo-diltiazem 6 (726) 
    
 
    
To a solution of mono desmethyl diltiazem (698, 400 mg, 1.00 mmol, 1.0 eq.) in dry THF  
(8 mL), propanamide 722 (632 mg, 1.50 mmol, 1.5 eq.), and K2CO3 (207 mg, 1.50 mmol, 
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1.5 eq.) were added. The resulting suspension was stirred at room temperature for two days, 
subsequently filtered, and concentrated in vacuo. Purification via flash column 
chromatography (silica, i-Hex:EtOAc = 1:1 to 0:1) yielded diltiazem derivative 726 (224 mg, 
0.32 mmol, 32%) as a red, foamy solid. The analytical sample was further purified by 
recrystallization from CHCl3/n-hexane. 
 
Rf = 0.65 (EtOAc). 
 
1H NMR (CDCl3, 600 MHz): δ = 9.83 (s, 1H), 7.77–7.74 (m, 2H), 7.69–7.65 (m, 2H), 7.55 
(dd, J = 7.7, 1.6 Hz, 1H), 7.49–7.46 (m, 3H), 7.34–7.31 (m, 2H), 7.30–7.27 (m, 1H), 7.08 (td, 
J = 7.5, 1.2 Hz, 1H), 6.81–6.79 (m, 2H), 6.67–6.64 (m, 2H), 5.02 (d, J = 7.7 Hz, 1H), 4.93 (d, 
J = 7.6 Hz, 1H), 4.04–3.90 (m, 2H), 3.70 (s, 3H), 3.01–2.96 (m, 1H), 2.97 (s, 6H), 2.84 (m, 
J = 12.9, 8.1, 4.9 Hz, 1H), 2.73–2.66 (m, 1H), 2.55 (ddd, J = 12.7, 7.8, 4.7 Hz, 1H), 2.41 
(ddd, J = 11.9, 7.1, 4.9 Hz, 2H), 2.34 (s, 3H), 1.84 (s, 3H) ppm. 
 
13C NMR (CDCl3, 150 MHz): δ = 170.9, 170.5, 167.5, 156.0, 152.4, 149.3, 145.7, 143.9, 
140.1, 135.5, 131.5, 130.9, 128.0, 127.7, 126.6, 125.0, 124.9, 123.2, 119.8, 114.0, 111.7, 71.6, 
55.4, 54.7, 54.4, 53.8, 48.9, 42.5, 40.5, 34.7, 20.8 ppm. 
 
ESI-MS for C38H43N6O5S+ [MH+]: calcd. 695.3010 
 found 695.3003. 
 
IR (ATR): ῦ/cm−1 = 3316, 2938, 2801, 1742, 1671, 1596, 1511, 1471, 1443, 1422, 1398, 
1361, 1223, 1178, 1151, 1138, 1087, 1060, 1029, 943, 907, 841, 821, 761, 726, 662. 
 
UV-Vis (DMSO): λmax = 429 nm. 
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Synthesis of Azo-diltiazem 7 (728) 
   
 
    
To a solution of mono desmethyl diltiazem (698, 490 mg, 1.22 mmol, 1.0 eq.) in dry THF  
(10 mL), butanamide 723 (800 mg, 1.83 mmol, 1.5 eq.), and K2CO3 (253 mg, 1.83 mmol, 
1.5 eq.) were added. The resulting suspension was stirred at room temperature for two days, 
subsequently filtered, and concentrated in vacuo. Purification via flash column 
chromatography (silica, i-Hex:EtOAc = 1:1 to 0:1) yielded diltiazem derivative 728 (504 mg, 
0.71 mmol, 58%) as a red, foamy solid. The analytical sample was further purified by 
recrystallization from CHCl3/n-hexane. 
 
Rf = 0.15 (EtOAc). 
 
1H NMR (CDCl3, 600 MHz): δ = 9.00 (s, 1H), 7.76–7.73 (m, 2H), 7.63–7.59 (m, 3H), 7.47 (d, 
J = 8.8 Hz, 2H), 7.41–7.34 (m, 4H), 7.20–7.16 (m, 1H), 6.76–6.73 (m, 2H), 6.66–6.64 (m, 
2H), 5.05 (d, J = 7.4 Hz, 1H), 4.93 (d, J = 7.4 Hz, 1H), 4.17 (dt, J = 14.2, 7.2 Hz, 1H),  
3.85–3.80 (m, 1H), 3.61 (s, 3H), 2.97 (s, 6H), 2.82–2.76 (m, 1H), 2.53–2.38 (m, 5H), 2.25 (s, 
3H), 1.89–1.80 (m, 2H), 1.77 (s, 3H) ppm.  
 
13C NMR (CDCl3, 150 MHz): δ = 172.3, 170.2, 167.5, 160.1, 152.3, 149.2, 145.5, 143.8, 
140.2, 135.6, 131.4, 130.9, 128.4, 127.8, 126.4, 124.8, 124.8, 123.1, 119.6, 113.9, 111.7, 71.4, 
56.8, 55.3, 54.7, 53.7, 49.0, 43.2, 40.5, 36.0, 23.7, 20.6 ppm. 
 
ESI-MS for C39H45N6O5S+ [MH+]: calcd. 709.3167 
 found 709.3165. 
 
IR (ATR): ῦ/cm−1 = 3317, 2936, 2797, 1744, 1662, 1597, 1511, 1471, 1443, 1421, 1398, 
1361, 1298, 1224, 1178, 1152, 1139, 1061, 1031, 944, 844, 821, 762, 735, 660. 
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UV-Vis (DMSO): λmax = 427 nm. 
 
Synthesis of Azo-diltiazem 8 (729) 
   
 
   
To a solution of mono desmethyl diltiazem (698, 365 mg, 0.91 mmol, 1.0 eq.) in dry THF 
(7 mL), acetamide 719 (600 mg, 1.37 mmol, 1.5 eq.) and K2CO3 (189 mg, 1.37 mmol,  
1.5 eq.) were added. The resulting suspension was stirred at room temperature for two days, 
subsequently filtered, and concentrated in vacuo. Purification via flash column 
chromatography (silica, i-Hex:EtOAc = 1:1 to 0:1) yielded diltiazem derivative 729 (619 mg, 
0.87 mmol, 95%) as an orange, foamy solid. The analytical sample was further purified by 
recrystallization from CHCl3/n-hexane. 
 
Crystals suitable for X-ray analysis were obtained by slow evaporation of a solution of 729 in 
CH2Cl2. 
 
Rf = 0.57 (EtOAc). 
 
1H NMR (CDCl3, 600 MHz): δ = 9.29 (s, 1H), 7.78 (dd, J = 9.4, 2.7 Hz, 2H), 7.64–7.61 (m, 
3H), 7.52–7.49 (m, 2H), 7.40 (tt, J = 7.7, 1.3 Hz, 1H), 7.36–7.32 (m, 3H), 7.19–7.16 (m, 1H), 
6.94–6.92 (m, 2H), 6.60 (d, J = 8.5 Hz, 2H), 5.06 (d, J = 7.7 Hz, 1H), 4.95 (d, J = 7.7 Hz, 
1H), 4.71–4.66 (m, 1H), 4.11–4.09 (m, 2H), 3.69–3.68 (m, 2H), 3.55 (dt, J = 14.3, 4.8 Hz, 
1H), 3.44 (s, 3H), 3.37 (s, 3H), 3.32 (d, J = 15.3 Hz, 1H), 2.94 (d, J = 15.3 Hz, 1H), 2.69 
(ddd, J = 13.2, 8.2, 4.7 Hz, 1H), 2.59 (ddd, J = 12.9, 4.7, 4.7 Hz, 1H), 2.36 (s, 3H), 1.83 (s, 
3H) ppm.  
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13C NMR (CDCl3, 150 MHz): δ = 167.0, 169.4, 167.8, 161.0, 159.9, 148.8, 147.3, 145.1, 
140.4, 135.8, 131.4, 130.7, 128.8, 128.0, 126.4, 124.8, 124.5, 123.4, 120.0, 114.9, 114.0, 71.2, 
71.0, 67.7, 62.6, 59.4, 56.7, 55.2, 54.7, 47.9, 44.2, 20.6 ppm. 
 
ESI-MS for C38H42N5O7S+ [MH+]: calcd. 712.2799 
 found 712.2797. 
 
IR (ATR): ῦ/cm−1 = 3253, 3058, 2927, 2887, 2839, 1750, 1693, 1662, 1594, 1532, 1511, 
1499, 1472, 1446, 1438, 1413, 1372, 1352, 1301, 1250, 1239, 1225, 1189, 1178, 1151, 1127, 
1120, 1088, 1080, 1063, 1029, 1004, 965, 949, 927, 910, 855, 834, 819, 810, 767, 756, 739, 
733, 689, 663. 
 
UV-Vis (DMSO): λmax = 369 nm. 
 
Synthesis of Azo-diltiazem 9 (730) 
   
 
    
To a solution of mono desmethyl diltiazem (698, 593 mg, 1.48 mmol, 1.0 eq.) in dry THF  
(12 mL), acetamide 720 (1.00 g, 2.22 mmol, 1.5 eq.) and K2CO3 (307 mg, 2.22 mmol, 1.5 eq.) 
were added. The resulting suspension was stirred at room temperature for two days, 
subsequently filtered, and concentrated in vacuo. Purification via flash column 
chromatography (silica, i-Hex:EtOAc = 1:1 to 0:1) yielded diltiazem derivative 730 (1.01 g, 
1.39 mmol, 94%) as a dep red, foamy solid. The analytical sample was further purified by 
recrystallization from CHCl3/n-hexane. 
 
Rf = 0.65 (EtOAc). 
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1H NMR (CDCl3, 600 MHz): δ = 9.25 (s, 1H), 7.77–7.75 (m, 2H), 7.64–7.61 (m, 3H),  
7.52–7.48 (m, 2H), 7.42–7.39 (m, 1H), 7.37–7.32 (m, 3H), 7.18 (td, J = 7.6, 1.4 Hz, 1H), 
6.88–6.86 (m, 2H), 6.63–6.59 (m, 2H), 5.07 (d, J = 7.6 Hz, 1H), 4.95 (d, J = 7.6 Hz, 1H), 4.60 
(ddd, J = 14.2, 8.2, 4.8 Hz, 1H), 3.79–3.77 (m, 4H), 3.55 (dt, J = 14.2, 4.9 Hz, 1H), 3.45 (s, 
3H), 3.31 (d, J = 15.4 Hz, 1H), 3.22–3.19 (m, 4H), 2.94 (d, J = 15.4 Hz, 1H), 2.69 (ddd, 
J = 13.2, 8.2, 4.9 Hz, 1H), 2.59 (dt, J = 13.2, 4.9 Hz, 1H), 2.36 (s, 3H), 1.83 (s, 3H) ppm. 
 
13C NMR (CDCl3, 150 MHz): δ = 170.0, 169.3, 167.7, 159.9, 153.0, 149.1, 146.0, 145.2, 
140.0, 135.8, 131.4, 130.7, 128.8, 128.0, 126.4, 124.8, 124.5, 123.2, 120.0, 114.7, 114.0, 71.2, 
66.8, 62.6, 56.6, 55.2, 54.7, 48.4, 48.0, 44.2, 20.6 ppm. 
 
ESI-MS for C39H43N6O6S+ [MH+]: calcd. 723.2959 
 found 723.2962. 
 
IR (ATR): ῦ/cm−1 = 3262, 3056, 2955, 2834, 1743, 1668, 1596, 1508, 1470, 1445, 1417, 
1402, 1376, 1302, 1226, 1179, 1154, 1120, 1110, 1087, 1049, 1028, 925, 844, 827, 762, 734, 
715, 685, 660. 
 
UV-Vis (DMSO): λmax = 412 nm. 
 
Synthesis of Tosylate 731 
   
 
    
According to the literature,[505] methyl ether 759 (3.00 g, 18.3 mmol, 1.0 eq.) and NEt3 
(3.82 mL, 27.4 mmol, 1.5 eq.) were dissolved in dry CH2Cl2 (50 mL) and cooled to 0 °C. To 
this, a solution of tosylchloride (2.80 mL, 21.9 mmol, 1.2 eq.) in dry CH2Cl2 (10 mL) was 
added slowly over a period of 10 min. The resulting mixture was allowed to warm to room 
temperature and stirred for 16 hours. Thereafter, saturated aqueous NaHCO3 (50 mL) was 
added and the layers were separated. The aqueous phase was extracted with CH2Cl2 
(3 × 30 mL) and the combined organic layers were dried over Na2SO4. After having removed 
the solvent in vacuo, purification of the crude product by flash column chromatography 
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(silica, i-Hex:EtOAc = 1:0 to 1:3) yielded tosylate 731 (5.24 g, 16.5 mmol, 90%) as 
colourless liquid. 
 
Rf = 0.58 (i-Hex:EtOAc = 1:3). 
 
1H NMR (CDCl3, 400 MHz): δ = 7.72–7.67 (m, 2H), 7.24 (d, J = 8.1 Hz, 2H), 4.08–4.03 (m, 
2H), 3.62–3.56 (m, 2H), 3.53–3.47 (m, 6H), 3.43 (dd, J = 5.8, 3.4 Hz, 2H), 3.27 (s, 3H), 2.35 
(s, 3H) ppm. 
 
13C NMR (CDCl3, 100 MHz): δ = 144.9, 133.2, 123.0, 128.1, 72.1, 70.9, 70.7, 70.7, 69.4, 
68.8, 59.2, 21.8 ppm. 
 
EI-MS for C14H22O6S+ [M+]: calcd. 318.1137 
 found 318.1135. 
 
IR (ATR): ῦ/cm−1 = 2877, 1929, 1724, 1598, 1495, 1452, 1399, 1352, 1306, 1291, 1246, 
1189, 1174, 1095, 1011, 916, 847, 815, 773, 705, 689, 661. 
 
Synthesis of Tosylate 732 
   
 
    
According to the literature,[505] methyl ether 760 (3.00 g, 14.4 mmol, 1.0 eq.) and NEt3 
(3.01 mL, 21.6 mmol, 1.5 eq.) were dissolved in dry CH2Cl2 (57 mL) and cooled to 0 °C. To 
this, a solution of tosylchloride (2.21 mL, 17.3 mmol, 1.2 eq.) in dry CH2Cl2 (10 mL) was 
added slowly over a period of 10 min. The resulting mixture was allowed to warm to room 
temperature and stirred for 16 hours. Thereafter, saturated aqueous NaHCO3 (50 mL) was 
added and the layers were separated. The aqueous phase was extracted with CH2Cl2 
(3 × 30 mL) and the combined organic layers were dried over Na2SO4. After having removed 
the solvent in vacuo, purification of the crude product by flash column chromatography 
(silica, i-Hex:EtOAc = 1:0 to 1:2) yielded tosylate 732 (4.20 g, 16.5 mmol, 80%) as 
colourless liquid. 
 
O OH
4 O
OTs
4
TsCl (1.2 eq.)
NEt3 (1.5 eq.)
CH2Cl2
0° to rt, 16 h
(80%)
760 732
C16H26O7S
M = 362.44 g/mol
Experimental Section 
321 
Rf = 0.26 (i-Hex:EtOAc = 1:2). 
 
1H NMR (CDCl3, 400 MHz): δ = 7.73–7.66 (m, 2H), 7.23 (d, J = 8.0 Hz, 2H), 4.07–4.02 (m, 
2H), 3.61–3.55 (m, 2H), 3.55–3.50 (m, 6H), 3.47 (s, 4H), 3.46–3.41 (m, 2H), 3.26 (s, 3H), 
2.34 (s, 3H) ppm. 
 
13C NMR (CDCl3, 100 MHz): δ = 144.9, 133.1, 129.9, 128.1, 72.1, 70.9, 70.7, 70.7, 70.7, 
70.6, 69.4, 68.8, 59.2, 21.8 ppm. 
 
EI-MS for C16H26O7S+ [M+]: calcd. 362.1399 
 found 362.1382. 
 
IR (ATR): ῦ/cm−1 = 2879, 1711, 1598, 1495, 1400, 1330, 1311, 1306, 1291, 1246, 1221, 
1193, 1170, 1105, 1090, 1017, 917, 848, 830, 818, 770, 710, 696, 683, 662. 
 
Synthesis of Polyether 733 
   
 
    
Phenol 712 (2.55 g, 10.4 mmol, 1.0 eq.) was dissolved in dry DMF (38 mL). To this, K2CO3 
(1.88 g, 13.6 mmol, 1.3 eq.) and tosylate 731 (4.00 g, 12.6 mmol, 1.2 eq.) were added and the 
resulting mixture was heated to 70 °C for 3 hours. Subsequently, the suspension was cooled to 
room temperature and diluted with EtOAc (200 mL). The organic layer was washed with half-
saturated aqueous NaCl solution (3 × 50 mL). The respective aqueous phases were 
re-extracted with EtOAc (50 mL) and the combined organic layers were dried over Na2SO4. 
After having removed the solvent in vacuo, purification of the crude product by repeated flash 
column chromatography (silica, i-Hex:EtOAc = 1:1 to 1:2) yielded polyether 733 (4.03 g, 
10.4 mmol, quant.) as an orange solid, which was contaminated with 5 mol-% of tosylate 731, 
as judged by 1H NMR. 
 
Rf = 0.80 (EtOAc). 
N N
OH
O2N
731 (1.2 eq.)
K2CO3 (1.3 eq.)
DMF
70 °C, 3 h
(quant.)
N N
O
O2N
3O
712 733
C19H23N3O6
M = 389.41 g/mol
O OTs
3
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1H NMR (CDCl3, 400 MHz): δ = 8.29–8.22 (m, 2H), 7.86 (mC, 4H), 6.96 (mC, 2H), 4.16–4.11 
(m, 2H), 3.84–3.78 (m, 2H), 3.68–3.63 (m, 2H), 3.62–3.54 (m, 4H), 3.52–3.41 (m, 2H), 3.28 
(s, 3H) ppm. 
 
13C NMR (CDCl3, 100 MHz): δ = 162.7, 156.2, 148.4, 147.1, 125.7, 124.8, 123.3, 115.2, 72.1, 
71.1, 70.8, 70.8, 69.7, 68.0, 59.2 ppm. 
 
ESI-MS for C19H24N3O6+ [MH+]: calcd. 390.1660 
 found 390.1656. 
 
IR (ATR): ῦ/cm−1 = 2928, 2888, 2829, 1601, 1579, 1550, 1516, 1492, 1476, 1450, 1421, 
1399, 1379, 1365, 1294, 1335, 1294, 1246, 1197, 1175, 1135, 1113, 1092, 1068, 1054, 1020, 
998, 957, 917, 850, 822, 778, 755, 723, 683, 663. 
 
UV-Vis (DMSO): λmax = 379 nm 
 
Synthesis of Polyether 734 
   
 
    
Phenol 712 (2.00 g, 8.22 mmol, 1.0 eq.) was dissolved in dry DMF (32 mL). To this, K2CO3 
(1.48 g, 10.7 mmol, 1.3 eq.) and tosylate 732 (3.58 g, 9.87 mmol, 1.2 eq.) were added and the 
resulting mixture was heated to 70 °C for 6 hours. Subsequently, the suspension was cooled to 
room temperature and diluted with EtOAc (150 mL). The organic layer was washed with half-
saturated aqueous NaCl solution (3 × 50 mL). The respective aqueous phases were 
re-extracted with EtOAc (50 mL) and the combined organic layers were dried over Na2SO4. 
After having removed the solvent in vacuo, purification of the crude product by repeated flash 
column chromatography (silica, i-Hex:EtOAc = 1:1 to 1:4) yielded polyether 734 (3.83 g, 
8.84 mmol, 89%) as an orange solid, , which was contaminated with 3 mol-% of tosylate 732, 
as judged by 1H NMR. 
 
N N
OH
O2N
732 (1.2 eq.)
K2CO3 (1.3 eq.)
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70 °C, 6 h
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4
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Rf = 0.15 (i-Hex:EtOAc = 3:2). 
 
1H NMR (CDCl3, 400 MHz): δ = 8.29–8.23 (m, 2H), 7.87 (mC, 4H), 6.96 (mC, 2H), 4.14 (mC, 
2H), 3.84–3.78 (m, 2H), 3.67–3.63 (m, 2H), 3.62–3.50 (m, 8H), 3.47–3.42 (m, 2H), 3.27 (s, 
3H) ppm. 
 
13C NMR (CDCl3, 100 MHz): δ = 162.7, 156.2, 148.4, 147.3, 125.7, 124.9, 123.3, 115.2, 72.1, 
71.1, 70.8, 70.8, 70.8, 70.7, 69.7, 68.0, 59.2 ppm. 
 
ESI-MS for C21H28N3O7+ [MH+]: calcd. 434.1922 
 found 434.1919. 
 
IR (ATR): ῦ/cm−1 = 2898, 1601, 1581, 1517, 1496, 1478, 1455, 1418, 1399, 1379, 1362, 
1337, 1294, 1254, 1193, 1177, 1132, 1095, 1054, 1040, 1023, 1000, 948, 927, 887, 864, 856, 
850, 824, 808, 779, 756, 724, 685, 663. 
 
UV-Vis (DMSO): λmax = 381 nm. 
 
Synthesis of Aniline 735 
   
 
    
Polyether 733 (4.00 g, 10.3 mmol, 1.0 eq.) was dissolved in 1,4-dioxane (100 mL). To this, 
water (10 mL) and Na2S (2.41 g, 30.8 mmol, 3.0 eq.) were added. The resulting suspension 
was heated to 95 °C for one hour and the conversion was then judged to be complete via TLC 
analysis. Subsequently, the reaction mixture was poured into saturated aqueous NaHCO3 
solution (100 mL) and extracted with CH2Cl2 (3 × 150 mL). The combined organic layers 
were dried over Na2SO4 and concentrated in vacuo. Purification via flash column 
chromatography (silica, i-Hex:EtOAc = 1:1 to 1:9) provided aniline 735 (1.81 g, 5.04 mmol, 
49%) as a bright orange solid. 
 
Rf = 0.32 (i-Hex:EtOAc = 1:4). 
N N
O
H2N
3O
735
C19H25N3O4
M = 359.43 g/mol
N N
O
O2N
3O Na2S (3.0 eq.)
 dioxane, H2O
95 °C, 1 h
(49%)733
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1H NMR (CDCl3, 400 MHz): δ = 7.72 (mC, 2H), 7.66 (mC, 2H), 6.90 (mC, 2H), 6.62 (mC, 2H), 
4.12–4.07 (m, 2H), 3.91 (s, br, 2H), 3.81–3.76 (m, 2H), 3.68–3.63 (m, 2H), 3.62–3.54 (m, 
4H), 3.48–3.42 (m, 2H), 3.28 (s, 3H) ppm. 
 
13C NMR (CDCl3, 100 MHz): δ = 160.5, 149.2, 147.4, 145.7, 124.8, 124.1, 114.9, 114.8, 72.1, 
71.0, 70.8, 70.7, 69.8, 67.8, 59.2 ppm. 
 
ESI-MS for C19H26N3O4+ [MH+]: calcd. 360.1918 
 found 360.1915. 
 
IR (ATR): ῦ/cm−1 = 3424, 3345, 3235, 3053, 2993, 2941, 2915, 2875, 2846, 1640, 1597, 
1573, 1536, 1507, 1495, 1469, 1451, 1430, 1408, 1391, 1363, 1348, 1319, 1298, 1283, 1253, 
1192, 1148, 1134, 1125, 1104, 1091, 1060, 1022, 950, 934, 922, 854, 840, 833, 819, 767, 731. 
 
UV-Vis (DMSO): λmax = 405 nm. 
 
Synthesis of Aniline 736 
   
 
    
Polyether 734 (3.50 g, 8.11 mmol, 1.0 eq.) was dissolved in 1,4-dioxane (100 mL). To this, 
water (10 mL) and Na2S (1.89 g, 24.2 mmol, 3.0 eq.) were added. The resulting suspension 
was heated to 95 °C for 90 min and the conversion was then judged to be complete via TLC 
analysis. Subsequently, the reaction mixture was poured into saturated aqueous NaHCO3 
solution (100 mL) and extracted with CH2Cl2 (3 × 150 mL). The combined organic layers 
were dried over Na2SO4 and concentrated in vacuo. Purification via flash column 
chromatography (silica, i-Hex:EtOAc = 1:1 to 0:1) provided aniline 736 (1.89 g, 4.68 mmol, 
58%) as a bright orange solid. 
 
Rf = 0.41 (EtOAc). 
 
N N
O
H2N
4O
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C21H29N3O5
M = 403.48 g/mol
N N
O
O2N
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 dioxane, H2O
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1H NMR (CDCl3, 400 MHz): δ = 7.72 (mC, 2H), 7.66 (mC, 2H), 6.90 (mC, 2H), 6.62 (mC, 2H), 
4.11–4.07 (m, 2H), 3.92 (s, br, 2H), 3.80–3.76 (m, 2H), 3.66–3.62 (m, 2H), 3.62–3.52 (m, 
8H), 3.46–3.41 (m, 2H), 3.27 (s, 3H) ppm. 
 
13C NMR (CDCl3, 100 MHz): δ = 160.5, 149.2, 147.4, 145.7, 124.8, 124.1, 114.9, 114.8, 72.1, 
71.0, 70.8, 70.8, 70.7, 70.7, 69.8, 67.8, 59.2 ppm. 
 
ESI-MS for C21H30N3O5+ [MH+]: calcd. 404.2180 
 found 404.2177. 
 
IR (ATR): ῦ/cm−1 = 3424, 3344, 3236, 3064, 2876, 2813, 1639, 1596, 1574, 1553, 1530, 
1503, 1470, 1453, 1430, 1407, 1358, 1347, 1314, 1299, 1252, 1126, 1099, 1060, 1025, 953, 
923, 843, 811, 766, 732, 672. 
 
UV-Vis (DMSO): λmax = 403 nm. 
 
Synthesis of Butanamide 737 
   
 
   
Following the general procedure for the synthesis of Ω-iodoalkyl amides, 4-iodobutyric acid 
(708, 0.74 g, 3.48 mmol, 1.0 eq.), aniline 735 (1.25 g, 3.48 mmol, 1.0 eq.) and 
N,N'-dicyclohexylcarbodiimide (0.79 g, 3.83 mmol, 1.1 eq.) were reacted. Purification via 
flash column chromatography (silica, EtOAc:i-Hex = 1:0 to 1:0) yielded butanamide 737 
(0.79 g, 7.56 mmol, 28–35%) as brown solid in a 4:1 mixture with inseparable aniline 735, as 
judged by 1H NMR. 
Note: As a consequence of its impurity, more equivalents of butanamide 737 were employed 
for the alkylation reactions. Analytical data was recorded from the obtained mixture. 
 
Rf = 0.36 (i-Hex:EtOAc = 1:4). 
 
735
708 (1.0 eq.)
DCC (1.1 eq.)
THF, 0 °C to rt
16 h
(28–35%) 737C23H30IN3O5
M = 555.41 g/mol
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O
I
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O
H2N
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O
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1H NMR (CDCl3, 400 MHz, characteristic signals): δ = 7.83–7.73 (m, 4H), 7.57 (d, 
J = 8.7 Hz, 2H), 7.28 (s, br, 1H), 6.96–6.87 (m, 2H), 4.17–4.06 (m, 2H), 3.85–3.74 (m, 2H), 
3.70–3.63 (m, 2H), 3.63–3.53 (m, 4H), 3.48–3.44 (m, 2H), 3.28 (s, 3H), 3.23 (t, J = 6.5 Hz, 
2H), 2.46 (t, J = 7.0 Hz, 2H), 2.14 (quin, J = 6.7 Hz, 2H) ppm. 
 
13C NMR (CDCl3, 100 MHz, characteristic signals): δ = 169.6, 161.1, 149.2, 147.1, 139.6, 
124.6, 123.7, 119.7, 114.8, 71.9, 70.9, 70.7, 70.6, 69.7, 67.7, 59.1, 34.0, 28.5, 6.5 ppm. 
 
ESI-MS for C23H31IN3O5+ [MH+]: calcd. 556.1303 
 found 556.1301. 
UV-Vis (DMSO): λmax = 373 nm. 
 
Synthesis of Butanamide 738 
   
 
   
Following the general procedure for the synthesis of Ω-iodoalkyl amides, 4-iodobutyric acid 
(708, 0.66 g, 3.10 mmol, 1.0 eq.), aniline 736 (1.25 g, 3.10 mmol, 1.0 eq.), and 
N,N'-dicyclohexylcarbodiimide (0.70 g, 3.41 mmol, 1.1 eq.) were reacted. Purification via 
flash column chromatography (silica, EtOAc:i-Hex = 4:1 to 1:0) yielded butanamide 738 
(1.37 g, 2.30 mmol, 68–73%) as brown solid in a 6.7:1 mixture with inseparable aniline 736, 
as judged by 1H NMR. 
Note: As a consequence of its impurity, more equivalents of butanamide 738 were employed 
for the alkylation reactions. Analytical data was recorded from the obtained mixture. 
 
Rf = 0.43 (EtOAc). 
 
1H NMR (CDCl3, 400 MHz, characteristic signals): δ = 7.86–7.73 (m, 4H), 7.57 (d,  
J = 8.7 Hz, 2H), 7.25 (s, br, 1H), 7.03–6.86 (m, 2H), 4.14–4.06 (m, 2H), 3.84–3.76 (m, 2H), 
3.69–3.50 (m, 10H), 3.48–3.41 (m, 2H), 3.28–3.22 (m, 2H), 3.27 (s, 53H), 2.46 (t, J = 7.0 Hz, 
2H), 2.14 (quin, J = 6.8 Hz, 2H) ppm. 
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ESI-MS for C25H35IN3O6+ [MH+]: calcd. 600.1565 
 found 600.1563. 
 
UV-Vis (DMSO): λmax = 391 nm. 
 
Synthesis of Azo-diltiazem 10 (739) 
   
 
    
To a solution of mono desmethyl diltiazem (698, 144 mg, 0.36 mmol, 1.0 eq.) in dry THF 
(3 mL), butanamide 737 (600 mg, 1.08 mmol, 3.0 eq.) and K2CO3 (100 mg, 0.72 mmol, 
3.0 eq.) were added. The resulting suspension was stirred at room temperature for two days, 
subsequently filtered, and concentrated in vacuo. Purification via repeated flash column 
chromatography (silica, MeOH:EtOAc = 0:1 to 1:9) yielded diltiazem derivative 739 
(208 mg, 0.25 mmol, 69%) as an orange, foamy solid.  
Note: Early fractions collected at the column chromatographic steps contained little amounts 
of the respective deacetylated compound and were discarded. 
 
Rf = 0.28 (MeOH:EtOAc = 1:19). 
 
1H NMR (CDCl3, 600 MHz): δ = 9.06 (s, br, 1H), 8.11–8.03 (m, 4H), 8.03–7.96 (m, 2H), 
7.62–7.48 (m, 3H), 7.10–6.93 (m, 2H), 6.90–6.76 (m, 5H), 4.99 (d, J = 7.4 Hz, 1H), 4.69 (d, 
J = 7.4 Hz, 1H), 4.00 (dt, J = 14.0, 7.1 Hz, 1H), 3.71 (dd, J = 5.8, 4.1 Hz, 3H), 3.57–3.40 (m, 
8H), 3.34 (dd, J = 5.9, 4.0 Hz, 2H), 3.24 (s, 3H), 3.12 (s, 3H), 2.72–2.49 (m, 2H), 2.37 (mC, 
2H), 2.24 (ddd, J = 12.3, 7.8, 4.7 Hz, 1H), 2.10 (ddd, J = 12.3, 6.6, 4.7 Hz, 1H), 1.95 (s, 3H), 
1.95–1.88 (m, 1H), 1.87–1.73 (m, 1H), 1.47 (s, 3H) ppm 
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13C NMR (C6D6, 150 MHz): δ = 171.9, 169.8, 167.9, 161.5, 160.7, 149.1, 147.9, 146.4, 142.5, 
135.5, 131.5, 131.1, 128.9, 127.4, 127.0, 125.0, 124.9, 124.2, 119.7, 115.1, 114.2, 72.4, 71.7, 
71.2, 71.1, 71.0, 69.8, 67.9, 58.7, 56.8, 55.0, 54.8, 54.0, 49.7, 43.1, 36.1, 24.4, 20.1 ppm. 
 
ESI-MS for C44H54N5O9S+ [MH+]: calcd. 828.3637 
 found 828.3630. 
 
IR (ATR): ῦ/cm−1 = 3320, 3281, 3194, 3120, 3058, 2931, 2874, 2837, 2805, 1745, 1661, 
1594, 1582, 1531, 1511, 1499, 1470, 1446, 1405, 1368, 1299, 1243, 1178, 1148, 1106, 1089, 
1059, 1029, 942, 922, 845, 763, 735, 715, 687, 663. 
 
UV-Vis (DMSO): λmax = 371 nm. 
 
Synthesis of Azo-diltiazem 11 (740) 
   
 
    
To a solution of mono desmethyl diltiazem (698, 356 mg, 0.89 mmol, 1.0 eq.) in dry THF 
(6 mL), butanamide 738 (800 mg, 1.33 mmol, 1.5 eq.) and K2CO3 (184 mg, 1.33 mmol, 
1.5 eq.) were added. The resulting suspension was stirred at room temperature for two days, 
subsequently filtered, and concentrated in vacuo. Purification via repeated flash column 
chromatography (silica, MeOH:EtOAc = 0:1 to 1:9) yielded diltiazem derivative 740 
(478 mg, 0.58 mmol, 61%) as an orange, foamy solid.  
Note: Early fractions collected at the column chromatographic steps contained little amounts 
of the respective deacetylated compound and were discarded. 
 
Rf = 0.25 (MeOH:EtOAc = 1:19). 
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1H NMR (C6D6, 600 MHz): δ = 9.00 (s, br, 1H), 8.04 (d, J = 8.6 Hz, 2H), 8.00 (d, J = 8.7 Hz, 
2H), 7.93 (d, J = 8.5 Hz, 2H), 7.50 (d, J = 8.4 Hz, 2H), 7.47 (d, J = 7.7 Hz, 2H), 7.02–6.92 
(m, 2H), 6.80–6.71 (m, 4H), 4.93 (d, J = 7.4 Hz, 1H), 4.63 (d, J = 7.4 Hz, 1H), 3.94 (dt, 
J = 14.2, 7.2 Hz, 1H), 3.66 (t, J = 5.0 Hz, 3H), 3.46 (t, J = 5.0 Hz, 2H), 3.43–3.36 (m, 10H), 
3.29 (dd, J = 5.8, 4.3 Hz, 2H), 3.18 (s, 3H), 3.06 (s, 3H), 2.58 (dt, J = 13.6, 7.1 Hz, 1H),  
2.54–2.46 (m, 1H), 2.35 (ddd, J = 14.1, 8.6, 6.1 Hz, 1H), 2.28 (ddd, J = 12.8, 7.5, 5.0 Hz, 
1H), 2.18 (ddd, J = 12.4, 7.8, 4.7 Hz, 1H), 2.05 (dt, J = 12.0, 5.6 Hz, 1H), 1.90 (s, 3H),  
1.88–1.82 (m, 1H), 1.79–1.70 (m, 1H), 1.42 (s, 3H) ppm. 
 
13C NMR (C6D6, 150 MHz): δ = 171.5, 169.3, 167.4, 161.1, 160.3, 148.7, 147.4, 145.9, 142.0, 
135.1, 131.0, 130.6, 128.5, 128.1, 127.0, 126.5, 124.6, 124.5, 123.7, 122.8, 119.3, 114.7, 
113.8, 72.0, 71.3, 70.8, 70.7, 70.5, 69.4, 67.4, 58.3, 56.3, 54.6, 54.4, 53.6, 49.3, 42.7, 35.7, 
23.9, 19.7 ppm. 
 
ESI-MS for C46H58N5O10S+ [MH+]: calcd. 872.3900 
 found 872.3888. 
 
IR (ATR): ῦ/cm−1 = 3318, 3194, 3120, 3058, 2936, 2873, 2813, 1744, 1674, 1661, 1594, 
1582, 1532, 1511, 1499, 1470, 1446, 1405, 1368, 1299, 1244, 1178, 1147, 1105, 1089, 1059, 
1029, 943, 922, 845, 763, 735, 715, 686, 662. 
 
UV-Vis (DMSO): λmax = 371 nm. 
 
Synthesis of Bromide 741 
   
 
    
To a solution of phenol 712 (500 mg, 2.06 mmol, 1.0 eq.) in dry DMF (8 mL), K2CO3 
(369 mg, 2.67 mmol, 1.3 eq.) and dibromide 742 (0.30 mL, 2.47 mmol, 1.2 eq.) were added. 
The resulting suspension was heated to 80 °C for 2 hours until the conversion was complete, 
as judged via TLC analysis. Then, the reaction mixture was cooled to room temperature and 
N N
O
O2N
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OH
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diluted with EtOAc (100 mL), as well as half-saturated aqueous NaCl solution (40 mL). The 
layers were separated and the aqueous phase was extracted with EtOAc (3 × 30 mL). 
Subsequently, the combined organic layers were dried over Na2SO4 and concentrated  
in vacuo. The crude product was purified via flash column chromatography (silica, 
i-Hex:EtOAc = 9:1). Thus, bromide 741 (369 mg, 0.98 mmol, 47%) was obtained as an 
orange solid. 
 
Rf = 0.95 (i-Hex:EtOAc = 3:2). 
 
1H NMR (CDCl3, 400 MHz): δ = 8.27 (mC, 2H), 7.93–7.82 (m, 4H), 6.93 (mC, 2H), 4.02 (t, 
J = 6.0 Hz, 2H), 3.41 (t, J = 6.5 Hz, 2H), 2.06–1.96 (m, 2H), 1.96–1.87 (m, 2H) ppm. 
 
13C NMR (CDCl3, 100 MHz): δ = 162.7, 156.2, 148.4, 147.1, 125.8, 124.9, 123.3, 115.0, 67.5, 
33.4, 29.5, 27.9 pmm. 
 
EI-MS for C16H16BrN3O3+ [M+]: calcd. 377.0375 
 found 377.0369. 
 
IR (ATR): ῦ/cm−1 = 3109, 2949, 1601, 1578, 1521, 1499, 1469, 1452, 1417, 1402, 1368, 
1343, 1322, 1292, 1270, 1248, 1203, 1133, 1106, 1060, 1030, 1003, 953, 920, 861, 840, 806, 
771, 754, 734, 723, 684. 
 
UV-Vis (DMSO): λmax = 380 nm. 
 
Synthesis of Diltiazem Derivative 743 
   
 
    
To a stirred solution of mono desmethyl diltiazem (698, 200 mg, 0.50 mmol, 1.0 eq.) in dry 
THF (4 mL), K2CO3 (138 mg, 1.00 mmol, 2.0 eq.), KI (91 mg, 0.55 mmol, 1.1 eq.) and 
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bromide 741 (227 mg, 0.60 mmol, 1.2 eq.) were added. The resulting suspension was heated 
to 70 °C for 3 hours and then cooled to room temperature. Subsequently, water (10 mL) and 
CH2Cl2 (25 mL) were added and the layers were separated. The aqueous phase was extracted 
with CH2Cl2 (2 × 25 mL) and the combined organic layers were dried over Na2SO4. After 
having concentrated the solvents in vacuo, the crude product was purified by flash column 
chromatography (silica, i-Hex:EtOAc = 1:1 to 0:1) to yield diltiazem derivative 743 (260 mg, 
0.37 mmol, 75%) as an orange foam. 
 
Rf = 0.43 (EtOAc). 
 
1H NMR (CDCl3, 600 MHz): δ = 8.26 (mC, 2H), 7.90–7.83 (m, 4H), 7.60–7.59 (m, 1H),  
7.42–7.35 (m, 2H), 7.35–7.30 (m, 2H), 7.18–7.13 (m, 1H), 6.90 (mC, 2H), 6.79 (mC, 2H), 5.06 
(d, J = 7.5 Hz, 1H), 4.91 (d, J = 7.6 Hz, 1H), 4.34–4.27 (m, 1H), 3.94 (t, J = 6.5 Hz, 2H), 3.70 
(s, 3H), 3.69–3.64 (m, 1H), 2.77–2.70 (m, 1H), 2.49 (s, br, 1H), 2.37 (t, J = 7.1 Hz, 2H), 2.18 
(s, 3H), 1.80 (s, 3H), 1.73–1.64 (m, 2H), 1.56–1.49 (t, J = 9.6 Hz, 2H) ppm. 
 
13C NMR (CDCl3, 150 MHz): δ = 170.0, 167.0, 163.0, 159.9, 156.2, 148.3, 146.9, 145.8, 
135.5, 131.5, 131.1, 130.9, 128.7, 127.5, 126.8, 125.7, 124.8, 123.2, 115.1, 113.9, 113.8, 71.3, 
68.4, 57.6, 55.4, 54.6, 48.2, 42.3, 27.1, 24.0, 20.7 ppm. 
 
ESI-MS for C37H40N5O7S+ [MH+]: calcd. 698.2643 
 found 698.2637. 
 
IR (ATR): ῦ/cm−1 = 3278, 3265, 2950, 2934, 2840, 2812, 1732, 1690, 1685, 1623, 1552, 
1500, 1470, 1458, 1443, 1401, 1325, 1270, 1257, 1211, 1186, 1174, 1122, 1100, 1087, 1032, 
1026, 987, 944, 872, 843, 818, 774, 723, 654. 
 
UV-Vis (DMSO): λmax = 378 nm. 
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Synthesis of Diltiazem Derivative 744 
   
 
    
Nitro compound 743 (163 mg, 0.23 mmol, 1.0 eq.) was dissolved in 1,4-dioxane (4.0 mL). To 
this, water (0.4 mL) and Na2S (55.0 mg, 0.70 mmol, 3.0 eq.) were added. The resulting 
suspension was heated to 80 °C for one hour and the conversion was then judged to be 
complete via TLC analysis. Subsequently, the reaction mixture was poured into saturated 
aqueous NaHCO3 solution (20 mL) and extracted with CH2Cl2 (3 × 25 mL). The combined 
organic layers were dried over Na2SO4 and concentrated in vacuo. Purification via flash 
column chromatography (silica, i-Hex:EtOAc = 1:9 to 0:1) provided diltiazem derivative 744 
(127 mg, 0.20 mmol, 87%) as an orange foam. 
 
Rf = 0.40 (EtOAc). 
 
1H NMR (CDCl3, 400 MHz): δ = 7.74 (mC, 2H), 7.68 (mC, 2H), 7.59 (dd, J = 7.7, 1.5 Hz, 
1H), 7.38–7.27 (m, 4H), 7.18–7.11 (m, 1H), 6.88–6.76 (m, 4H), 6.62 (mC, 2H), 4.81 (d, 
J = 7.2 Hz, 1H), 4.37 (ddd, J = 14.1, 8.1, 6.4 Hz, 1H), 4.21 (d, J = 7.2 Hz, 1H), 3.02 (s, br, 
1H), 3.88 (t, J = 6.4 Hz, 4H), 3.69 (s, 3H), 3.67–3.61 (m, 1H), 2.80 (s, br, 1H), 2.72 (dt, 
J = 14.1, 7.0 Hz, 2H), 2.51 (ddd, J = 13.0, 8.0, 5.3 Hz, 1H), 2.34 (t, J = 7.3 Hz, 2H), 2.18 (s, 
3H), 1.64 (quin, J = 6.8 Hz, 2H), 1.55–1.44 (m, 2H) ppm. 
 
13C NMR (CDCl3, 100 MHz): δ = 171.4, 160.7, 159.9, 149.2, 147.1, 145.6, 145.1, 135.4, 
131.4, 130.6, 128.9, 127.5, 126.3, 124.7, 124.5, 124.1, 114.7, 114.7, 113.7, 69.3, 68.1, 57.6, 
56.7, 55.3, 53.5, 47.7, 42.2, 27.0, 23.9 ppm.  
 
ESI-MS for C35H40N5O4S+ [MH+]: calcd. 626.2796 
 found 626.2794. 
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IR (ATR): ῦ/cm−1 = 3464, 3359, 3226, 3039, 2942, 2876, 2833, 2793, 1656, 1623, 1623, 
1596, 1580, 1505, 1470, 1431, 1373, 1296, 1247, 1179, 1146, 1094, 1062, 1030, 965, 919, 
837, 791, 762, 733, 707. 
 
UV-Vis (DMSO): λmax = 405 nm. 
 
Synthesis of Alkyne 753 
   
 
    
Ammonium salt 754 (500 mg, 1.97 mmol, 1.0 eq.) was dissolved in dry CH3CN (4 mL). To 
this, porpagyl bromide (755, 307 mg, 80 wt-% solution in toluene, 2.07 mmol, 1.1 eq.) was 
added and the reaction mixture was stirred at 60 °C for 3 hours. The resulting white 
precipitate was filtered off, thoroughly washed with cold CH3CN and dried in vacuo. Thus, 
alkyne 753 (578 mg, 1.54 mmol, 79%) was obtained as colourless, hygroscopic solid. 
 
1H NMR (DMSO-d6, 400 MHz): δ = 4.73 (d, J = 2.3 Hz, 2H), 4.30 (t, J = 2.2 Hz, 1H), 3.98 
(mC, 12H), 3.35 (s, 3H) ppm. 
 
13C NMR (DMSO-d6, 100 MHz): δ = 85.0, 70.9, 53.2, 52.4, 51.5, 50.5 ppm 
 
ESI-MS for C10H17N2+ [(M−H)+]: calcd. 165.1386 
 found 165.1386. 
 
IR (ATR): ῦ/cm−1 = 3273, 2999, 2983, 2929, 1473, 1426, 1412, 1376, 1324, 1291, 1194, 
1129, 1067, 1053, 1022, 1004, 959, 926, 901, 867, 846, 717, 688, 670. 
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Synthesis of Aniline 745 
   
 
    
Phenol 712 (2.70 g, 1.11 mmol, 1.0 eq.) was dissolved in 1,4-dioxane (100 mL). To this, 
water (10 mL) and Na2S (2.60 g, 33.3 mmol, 3.0 eq.) were added. The resulting suspension 
was heated to reflux at 95 °C for one hour and the conversion was then judged to be complete 
via TLC analysis. Subsequently, the reaction mixture was poured into saturated aqueous 
NaHCO3 solution (100 mL) and extracted with CH2Cl2 (3 × 150 mL). The combined organic 
layers were dried over Na2SO4 and concentrated in vacuo. Purification via flash column 
chromatography (silica, i-Hex:EtOAc = 6:4) provided aniline 745 (1.50 g, 7.03 mmol, 63%) 
as an orange solid. 
 
Rf = 0.66 (i-Hex:EtOAc = 1:1). 
 
1H NMR (DMSO-d6, 400 MHz): δ = 9.94 (s, 1H), 7.66–7.61 (m, 2H), 7.61–7.55 (m, 2H), 
6.93–6.81 (m, 2H), 6.72–6.58 (m, 2H), 5.88 (s, br, 2H) ppm. 
 
13C NMR (DMSO-d6, 100 MHz): δ = 159.1, 151.8, 145.2, 142.8, 124.4, 123.6, 115.7, 
113.4 ppm. 
 
ESI-MS for C12H12N3O+ [MH+]: calcd. 214.0975 
 found 214.0974. 
 
IR (ATR): ῦ/cm−1 = 3359, 3286, 3004, 2672, 1589, 1493, 1470, 1448, 1385, 1238, 1150, 
1143, 1099, 1095, 1088, 1007, 948, 883, 836, 804, 762, 728, 710. 
 
UV-Vis (DMSO): λmax = 403 nm. 
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Synthesis of Azide 746 
   
 
    
A stirred suspension of aniline 745 (1.40 g, 6.57 mmol, 1.0 eq.) in dry CH3CN (28 mL) was 
cooled to 0 °C. Then, t-BuONO (1.02 g, 9.85 mmol, 1.50 eq.) was added slowly and the 
mixture was stirred for 10 min. To the resulting red solution, TMSN3 (1.13 mL, 8.54 mmol, 
1.3 eq.) was added dropwise over a period of 15 min. Subsequently, the reaction was allowed 
to warm to room temperature, stirred for one hour and concentrated under reduced pressure. 
The crude product was purified via flash column chromatography (silica, i-Hex:EtOAc = 17:3 
to 4:1). Thus, azide 746 (1.37 g, 5.72 mmol, 87%) was obtained as a red solid. 
 
Rf = 0.78 (i-Hex:EtOAc = 2:3). 
 
1H NMR (CDCl3, 400 MHz): δ = 7.85–7.73 (m, 4H), 7.09–7.00 (m, 2H), 6.93–6.79 (m, 2H), 
5.04 (s, br, 1H) ppm. 
 
13C NMR (CDCl3, 100 MHz): δ = 158.3, 150.0, 147.3, 142.2, 125.1, 124.4, 119.7, 116.0 ppm. 
 
ESI-MS for C12H8N5O+ [MH+]: calcd. 238.0734 
 found 238.0734. 
 
IR (ATR): ῦ/cm−1 = 3174, 2403, 2252, 2115, 1587, 1579, 1471, 1442, 1413, 1386, 1299, 
1286, 1223, 1152, 1143, 1129, 1107, 1005, 944, 839, 813, 808, 773, 726, 709, 670. 
 
UV-Vis (DMSO): λmax = 371 nm. 
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Synthesis of Bromide 747 
   
 
    
To a solution of azide 746 (800 mg, 3.34 mmol, 1.0 eq.) in dry DMF (15 mL), K2CO3 (1.94 g, 
14.0 mmol, 4.2 eq.) and dibromide 742 (1.60 mL, 13.4 mmol, 4.0 eq.) were added. The 
resulting suspension was heated to 65 °C for 2 hours until the conversion was complete, as 
judged via TLC analysis. Then, the reaction mixture was cooled to room temperature and 
diluted with EtOAc (200 mL) and half-saturated aqueous NaCl solution (50 mL). The layers 
were separated and the aqueous phase was extracted with EtOAc (3 × 50 mL). Subsequently, 
the combined organic layers were dried over Na2SO4 and concentrated in vacuo. The crude 
product was purified via flash column chromatography (silica, i-Hex:EtOAc = 23:2 to 9:1). 
Thus, bromide 747 (1.10 g, 2.82 mmol, 85%) was obtained as an orange solid. 
 
Rf = 0.90 (i-Hex:EtOAc = 3:1). 
 
1H NMR (CDCl3, 400 MHz): δ = 7.83–7.76 (m, 4H), 7.07–7.01 (m, 2H), 6.94–6.86 (m, 2H), 
3.99 (t, J = 6.0 Hz, 2H), 3.41 (t, J = 6.5 Hz, 2H), 2.06–1.95 (m, 2H), 1.93–1.86 (m, 2H) ppm. 
 
13C NMR (CDCl3, 100 MHz): δ = 161.5, 150.0, 147.0, 142.0, 124.9, 124.4, 119.7, 114.8, 67.3, 
33.5, 29.5, 27.9 ppm. 
 
EI-MS for C16H17BrN5O+ [M+]: calcd. 374.0611 
 found 374.0609. 
 
IR (ATR): ῦ/cm−1 = 2944, 2873, 2402, 2116, 1599, 1592, 1582, 1575, 1500, 1491, 1473, 
1462, 1444, 1434, 1422, 1418, 1393, 1348, 1312, 1300, 1287, 1278, 1241, 1209, 1170, 1152, 
1143, 1125, 1106, 1043, 1027, 1009, 966, 944, 844, 824, 830, 810, 779, 744, 737, 731, 679. 
 
UV-Vis (DMSO): λmax = 369 nm. 
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Synthesis of Diltiazem Derivative 748 
   
 
    
To a stirred solution of mono desmethyl diltiazem (698, 412 mg, 1.03 mmol, 1.0 eq.) in dry 
THF (8 mL), K2CO3 (284 mg, 2.06 mmol, 2.0 eq.), KI (171 mg, 1.03 mmol, 1.0 eq.) and 
bromide 742 (500 mg, 1.34 mmol, 1.3 eq.) were added. The resulting suspension was heated 
to 70 °C for 10 hours and then cooled to room temperature. Subsequently, water (15 mL) and 
CH2Cl2 (30 mL) were added and the layers were separated. The aqueous phase was extracted 
with CH2Cl2 (2 × 30 mL) and the combined organic layers were dried over Na2SO4. After 
having concentrated the solvents in vacuo, the crude product was purified by flash column 
chromatography (silica, i-Hex:EtOAc = 1:1 to 1:9) to yield diltiazem derivative 748 (507 mg, 
0.73 mmol, 72%) as an orange foam, being contaminated by 30% of the respective 
deacetylated compound, as judged by 1H NMR. 
Thus obtained partially deacetylated substance 748 was redissolved in dry CH2Cl2 (7 mL) and 
cooled to 0 °C. Under stirring, acetyl chloride (1.04 mL, 8.05 mmol, 20 eq.) and DMAP 
(9.0 mg, 0.07 mmol, 0.1 eq.) were added. The resulting solution was allowed to warm to room 
temperature and stirred for 12 hours, before being quenched by the addition of saturated 
aqueous NaHCO3 (30 mL). Subsequently, the mixture was extracted with EtOAc (3 × 30 mL), 
the combined organic layers were dried over Na2SO4 and the solvents were removed under 
reduced pressure. Purification via flash column chromatography (silica, i-Hex:EtOAc = 1:9 to 
0:1) yielded diltiazem derivative 748 (493 mg, 0.71 mmol, 69%) as an orange foam. 
 
Rf = 0.52 (MeOH:EtOAc = 1:49). 
 
1H NMR (CDCl3, 400 MHz): δ = 8.00 (mC, 2H), 7.92 (mC, 2H), 7.64 (mC, 2H), 7.58 (dd,  
J = 7.7, 1.6 Hz, 1H), 7.27 (dd, J = 8.0, 1.3 Hz, 1H), 7.04 (td, J = 7.7, 1.6 Hz, 1H), 6.89–6.79 
(m, 5H), 6.76–6.70 (m, 2H), 5.15 (d, J = 7.6 Hz, 1H), 4.77 (d, J = 7.6 Hz, 1H), 4.34 (dt,  
J = 13.7, 6.9 Hz, 1H), 3.75 (ddd, J = 13.8, 7.0, 5.4 Hz, 1H), 3.58 (t, J = 6.6 Hz, 2H), 3.24 (s, 
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3H), 2.88 (dt, J = 13.3, 6.8 Hz, 1H), 2.61 (ddd, J = 12.7, 7.2, 5.4 Hz, 1H), 2.23 (t, J = 7.0 Hz, 
2H), 2.08 (s, 3H), 1.60–1.52 (m, 2H), 1.50 (s, 3H), 1.48–1.37 (m, 2H) ppm. 
 
13C NMR (CDCl3, 100 MHz): δ = 169.5, 167.3, 162.3, 160.4, 150.5, 147.5, 147.0, 142.2, 
135.5, 131.6, 130.9, 129.1, 127.6, 126.9, 125.3, 125.0, 124.7, 119.8, 115.2, 114.2, 71.6, 68.3, 
57.8, 56.2, 55.2, 54.7, 48.6, 42.1, 27.2, 24.2, 20.2 ppm. 
 
ESI-MS for C37H40N7O5S+ [MH+]: calcd. 694.2806 
 found 694.2804. 
 
IR (ATR): ῦ/cm−1 = 2942, 2834, 2789, 2112, 1743, 1676, 1595, 1579, 1511, 1497, 1470, 
1443, 1420, 1406, 1369, 1284, 1247, 1179, 1149, 1139, 1105, 1086, 1060, 1031, 943, 840, 
817, 762, 762, 736, 711, 674. 
 
UV-Vis (DMSO): λmax = 369 nm. 
 
Synthesis of Phosphazene 749 
   
 
    
Diltiazem derivative 748 (0.08 g, 0.11 mmol, 1.0 eq.) was dissolved in a mixture of CH3CN 
(3.2 mL) and water (0.3 mL). To this, triphenylphosphine (0.09 g, 3.46 mmol, 3.0 eq.) was 
added and the resulting solution was stirred at room temperature for 3 days. After removing 
the solvents in vacuo, the crude product was purified by flash column chromatography (silica, 
i-Hex:EtOAc = 1:0 to 0:1) to yield phosphazene 749 (103 mg, 0.11 mmol, 96%) as an orange 
foam. 
Note: Phosphazene 749 and azide 748 behaved co-polar at TLC analysis. Due to overlapping 
signals in 2D NMR spectra, it was not possible to resolve the coupling constants of 31P to 13C 
nuclei. Hence, all observed signals are listed instead. 
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Rf = 0.52 (MeOH:EtOAc = 1:49). 
 
1H NMR (C6D6, 400 MHz): δ = 8.21 (mC, 1H), 8.20–8.05 (m, 3H), 7.74 (mC, 5H), 7.69–7.61 
(m, 2H), 7.57 (ddd, J = 7.7, 2.7, 1.6 Hz, 1H), 7.30–7.23 (m, 2H), 7.12–6.93 (m, 9H),  
6.89–6.76 (m, 5H), 6.30–6.23 (m, 1H), 5.14 (d, J = 7.6 Hz, 1H), 4.77 (d, J = 7.6 Hz, 1H), 4.34 
(mC, 1H), 3.82–3.68 (m, 1H), 3.59–3.55 (m, 2H), 3.23 (s, 3H), 2.97 (s, 1H), 2.87 (mC, 1H), 
2.61 (mC, 1H), 2.20 (q, J = 7.0 Hz, 2H), 2.07 (s, 3H), 1.62–1.46 (m, 2H), 1.50 (s, 3H), 1.42 
(ddd, J = 15.1, 12.2, 6.7 Hz, 2H) ppm. 
 
13C NMR (C6D6, 100 MHz): δ = 169.5, 167.3, 161.3, 160.8, 160.4, 149.7, 148.3, 147.9, 147.0, 
146.2, 146.0, 135.5, 134.9, 133.9, 132.9, 132.8, 132.5, 132.4, 131.9, 131.8, 131.8, 131.6, 
131.6, 131.6, 130.9, 129.1, 129.0, 128.9, 128.7, 128.6, 128.5, 126.9, 125.2, 125.1, 124.7, 
124.0, 123.9, 115.1, 115.0, 114.7, 114.1, 71.6, 68.1, 57.8, 56.2, 55.1, 54.7, 48.6, 42.1, 27.2, 
24.3, 20.2 ppm. 
 
ESI-MS for C55H55N5O5PS+ [MH+]: calcd. 928.3656 
 found 928.3651. 
 
IR (ATR): ῦ/cm−1 = 3452, 3346, 3218, 3051, 2941, 2837, 2785, 1743, 1673, 1595, 1583, 
1551, 1510, 1492, 1436, 1404, 1341, 1304, 1237, 1179, 1143, 1105, 1061, 1019, 997, 943, 
919, 837, 755, 718, 693. 
 
UV-Vis (DMSO): λmax = 408 nm. 
 
Synthesis of Azo-diltiazem 12 (751) 
   
 
    
Alkyne 750 (92.0 mg, 0.52 mmol, 4.0 eq.) and diltiazem derivative 748 (90 mg, 0.13 mmol, 
1.0 eq.) were dissolved in DMSO (14 mL) under an argon gas atmosphere and the resulting 
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solution was thoroughly degassed. To this, a degassed solution of CuSO4·5H2O (6.5 mg, 
0.02 mmol, 0.2 eq.) and sodium ascorbate (5.7 mg, 0.3 mmol, 0.3 eq.) in water (5.6 mL) and 
acetonitrile (8.5 mL) was added. This mixture was sonicated at 40 °C for 2 hours until 
analysis via LCMS measurement indicated complete consumption. Subsequently, the solvents 
were removed in vacuo and the crude product was purified by repeated flash column 
chromatography (C-18 reversed-phase silica, H2O:MeOH:HCOOH = 0:1:10−3 to 1:1:10−3) to 
yield the title compound (751, 48.9 mg, 0.06 mmol, 45%) as an orange wax. 
Note: The obtained 1H NMR values varied slightly and exhibited sometimes significant line 
broadening, due to the basicity of the amino function. 
 
Rf = 0.00 (MeOH:EtOAc = 1:49). 
 
1H NMR (CD3OD, 400 MHz): δ = 9.04 (s, 1H), 8.54 (s, br, 1H), 8.11–804 (m, 4H), 7.90 (d, 
J = 8.4 Hz, 2H), 7.74 (d, J = 7.6 Hz, 1H), 7.65–7.59 (m, 2H), 7.45–7.29 (m, 3H), 7.05 (d, 
J = 8.5 Hz, 2H), 6.87 (d, J = 8.2 Hz, 2H), 5.07 (s, 2H), 4.82 (s, br, 2H), 4.47 (mC, 1H), 4.09  
(s, 3H), 3.75 (s, 3H), 3.24 (s, 9H), 3.13–2.94 (m, 4H), 2.69 (s, 3H), 1.86 (s, 3H), 1.84 (s, br,  
4H) ppm. 
 
13C NMR (CD3OD, 100 MHz): δ = 171.3, 169.9, 169.6, 163.5, 161.3, 153.9, 148.1, 146.1, 
138.9, 138.0, 136.6, 132.7, 132.0, 129.6, 129.4, 127.9, 127.6, 126.2, 125.8, 125.0, 122.3, 
116.0, 114.6, 72.5, 68.9, 61.1, 57.5, 55.8, 55.5, 54.5, 53.5, 46.7, 41.6, 27.5, 23.2, 20.3 ppm 
 
ESI-MS for C43H51N8O5S+ [M+]: calcd. 791.3698 
 found 791.3699. 
 
IR (ATR): ῦ/cm−1 = 3402, 3047, 2951, 2781, 1740, 1670, 1653, 1597, 1581, 1559, 1540, 
1508, 1472, 1460, 1444, 1406, 1372, 1303, 1224, 1180, 1140, 1109, 1049, 1021, 985, 897, 
920, 844, 761, 732, 667. 
 
UV-Vis (H2O): λmax = 357 nm. 
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Synthesis of Azo-diltiazem 13 (752) 
   
 
    
Alkyne 753 (47.0 mg, 0.13 mmol, 3.5 eq.) and diltiazem derivative 748 (25 mg, 0.04 mmol, 
1.0 eq.) were dissolved in DMSO (3.5 mL) under an argon gas atmosphere and the resulting 
solution was thoroughly degassed. To this, a degassed solution of CuSO4·5H2O (1.8 mg, 
0.01 mmol, 0.2 eq.) and sodium ascorbate (1.6 mg, 0.1 mmol, 0.3 eq.) in water (1.6 mL) and 
acetonitrile (2.4 mL) was added. This mixture was sonicated at 40 °C for 4 hours until 
analysis via LCMS measurement indicated complete consumption. Subsequently, the solvents 
were removed in vacuo and the crude product was purified by repeated flash column 
chromatography (C-18 reversed-phase silica, H2O:MeOH:HCOOH = 0:1:10−3 to 9:11:10−3) to 
yield the title compound (752, 23.4 mg, 0.02 mmol, 68%) as an orange solid. 
Note: The obtained 1H NMR values varied slightly and exhibited sometimes significant line 
broadening, due to the basicity of the amino function. 
 
Rf = 0.00 (MeOH:EtOAc = 1:49). 
 
1H NMR (CD3OD, 400 MHz): δ = 9.12 (s, br, 2H), 8.07 (t, J = 6.4 Hz, 4H), 7.97–7.85 (m, 
2H), 7.79–7.71 (m, 1H), 7.70–7.54 (m, 2H), 7.47–7.40 (m, 2H), 7.39–7.29 (m, 1H), 7.12–7.00 
(m, 2H), 6.97–6.78 (m, 3H), 5.19–5.04 (m, 4H), 4.43 (ddd, J = 14.2, 8.6, 6.1 Hz, 1H),  
4.31–3.99 (m, 13H), 3.98–3.80 (m, 2H), 3.77 (s, 3H), 3.40 (s, 3H), 2.92 (ddd, J = 13.6, 8.8, 
6.1 Hz, 1H), 2.66 (ddd, J = 13.1, 8.5, 5.3 Hz, 1H), 2.56 (t, J = 7.5 Hz, 2H), 2.34 (s, 3H), 1.87 
(s, 3H), 1.82–1.75 (m, 2H), 1.71–1.63 (m, 2H) ppm. 
 
13C NMR (CD3OD, 100 MHz): δ =171.4, 170.1, 163.6, 161.4, 154.1, 148.2, 146.1, 138.9, 
136.7, 136.2, 132.7, 132.0, 129.7, 129.5, 128.3, 127.9, 126.2, 125.8, 125.1, 122.4, 116.1, 
114.7, 72.5, 68.8, 59.9, 57.5, 55.7, 55.5, 54.7, 54.4, 53.1, 52.5, 46.6, 41.4, 27.4, 23.0, 
20.2 ppm. 
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ESI-MS for C47H57N9O5S2+ [M2+]: calcd. 429.7 
 found 429.7. 
 
FAB-MS for C47H56N9O5S+ [(M−H)+]: calcd. 858.4 
 found 858.3. 
 
IR (ATR): ῦ/cm−1 = 3373, 3029, 2930, 2972, 2698, 1741, 1675, 1580, 1510, 1471, 1445, 
1408, 1373, 1344, 1304, 1248, 1180, 1139, 1128, 1108, 1088, 1058, 1027, 990, 942, 848, 759, 
730, 704, 663. 
 
UV-Vis (H2O): λmax = 360 nm. 
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I. Summary 
 
The first part of present doctoral thesis has detailed the synthetic efforts conducted toward the 
enantioselective construction of the biosynthetically closely related iso-propyl-substituted 
trans-hydrindane sesterterpenoids nitidasin (238), astellatol (213), retigeranic acid B (237) 
and alborosin (252). Developed retrosynthetic approaches relied on the previously established 
unified approach toward this class of natural products, which focused on trans-hydrindane-
based building blocks.[140,156] Owing to an inspiring and fruitful collaboration with Dr. D. T. 
Hog, our combined efforts eventually culminated in the first total synthesis of nitidasin (238). 
  
 
Scheme A.1: Conducted studies toward the construction of retigeranic acid B (237), using model system 361 
and the newly accessed cyclopentane building block 385. 
The experimental research carried out toward a potential total synthesis of retigeranic acid B 
(237) was reported first. To this end, a retrosynthetic proposal was presented, which involved 
a convergent key fragment coupling by means of ketone-ketone aldol addition. The envisaged 
cyclopentane building block 385 was synthesized in a novel 8-step sequence in 20% overall 
yield (cf. chapter 2.4), starting from commercially available chiral (R)-pulegone (176). The 
developed route featured a vinylogous addition to methyl vinyl ketone (300), a regioselective 
dioxolane formation and a substrate-controlled diastereoselective Krapcho decarboxylation 
(scheme A.1) forming intermediate 379. An ensuing Horner-Wadsworth-Emmons olefination 
and a final dioxolane cleavage completed the desired electrophile for the intended aldol 
addition. Unfortunately, all our attempts to affect the envisaged fragment coupling were met 
with failure (cf. chapter 2.5). Besides, it was possible to shed light on the reactivity of utilized 
trans-hydrindanone model system 361 at enolate-based addition reactions. Accordingly, 
it was demonstrated that more electrophilic reagents, like Mander’s reagent (394) and ethyl-
pyruvate (392), readily undergo nucleophilic attack by employed preformed enolate species.
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Scheme A.2: Conducted synthetic route toward enantiopure alcohol 335, according to Hog et al.[140] 
For the total synthesis of nitidasin (238), initially enantiopure alcohol 335 was prepared on 
multi-gram scale. To this end, a previously developed, reliable and high-yielding 10-step 
sequence was followed (scheme A.2). Required trans-hydrindanone 439 was accessed via the 
frequently used and conveniently scalable carboxylation/hydrogenation route, which 
ultimately starts by the preparation of (+)-Hajos-Parrish-Sauer-Eder-Wiechert ketone (138). 
In collaboration with the research group of K. Houk, we are currently working on a 
mechanistic explanation for the experimentally found stereochemical outcome of the cuprate-
mediated formation of alkene 333 and its catalyst-promoted hydrogenative diversification, 
using computational methods.  
   
 
Scheme A.3: Developed 12-step procedure toward trans-hydrindanone 477, achieving the construction of 
stereocenters C-2, C-3 and required functional handles for the envisaged fragment combination.  
Based on earlier experiments,[156] the functional handles for a convergent construction of the 
central 8-membered ring motif of nitidasin (238) were installed (scheme A.3). The major 
portion of those investigations was conducted simultaneously to the reported synthetic studies 
toward astellatol (213), which is why intermediates being en route to both natural products 
took center stage. As a protective group for the C-17 (nitidasin numbering) centered alcohol 
function, a robust SEM ether was installed that proved compatible with all envisaged 
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transformations. Starting from the SEM ether of alcohol 335, the C-2 located stereocenter was 
set via a Pd-catalyzed Tsuji allylation (cf. chapter 3.4). The formation of the stereogenic 
methyl group at C-3 took advantage of the conformational bias of tricyclic system 468. The 
restoration of the terminal alkene function at C-3 involved a reduction of substance 469, a 
TES protection of the resulting alcohol functions, a chemoselective deprotective Swern 
oxidation and a final Wittig olefination. Orthogonal desilylation of 475 and DMP-mediated 
oxidation then gave rise to envisioned trans-hydrindanone 477. Notably, conducted 12-step 
sequence allowed for the scalable preparation of this highly advanced intermediate in 
outstanding 41% yield, starting from alcohol 335. As the majority of those transformations 
had been established on model system 438 previously, this more readily accessible compound 
was utilized for our initial screening phase of ensuing key fragment combination and RCM 
reaction (vide infra).  
  
 
Scheme A.4:  9-step sequence toward building block 410, featuring a zirconocene-mediated enyne cyclization. 
Furthermore, the synthesis of vinyl cyclopentane 410 (scheme A.4) was established (cf. 
chapter 3.3). This compound possesses a literature unprecedented cis-cis-cis relationship in 
respect to its vinyl iodide function and adjacent ring substituents. Starting from inexpensive, 
but scalemic (−)-citronellene (413), building block 410 was prepared in gram quantities by a 
9-step sequence that featured a zirconocene-mediated enyne cyclization. Treatment of 
intermediary generated zirconacycle furnished diiodide 431, which could then be converted to 
alcohol 433 via elimination and subsequent substrate-controlled hydroboration. Mosher ester 
analysis of this compound allowed quantifying its enantiomeric excess to 60%. A final Swern 
oxidation/Wittig olefination protocol gave rise to stable diene 410 as a single diastereomer. 
Model studies toward the completion of nitidasin’s (238) carbocyclic backbone were reported 
in chapter 3.5. In this context, a literature unprecedented and highly diastereoselective 
addition of a tetrasubstituted Li-alkenyl species to a sterically congested trans-hydrindanone 
system (438, scheme A.5) could be demonstrated. A key feature of this remarkable 
transformation was the unexpected kinetic resolution of scalemic vinyl cyclopentane 410, 
which fortunately proceeded in favour of the desired enantiomer. The following elaborate 
studies on RCM-based approaches toward closing of nitidasin’s (238) central 8-membered
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Scheme A.5: Successful construction of the 5-8-6-5 ring system of nitidasin (238) on a model system. Key 
features are the diastereoselective Li-alkenyl addition and the highly efficient RCM reaction. 
ring were hampered due to a predominant side reaction of triene 479. The undesired 
formation of cyclopentene 484, at which participation of the tetrasubstituted double bond is 
presumably induced by adjacent tertiary alcohol, could only be circumvented when planned 
epoxidation step was brought forward. Taking advantage of the system’s stereochemical and 
electronic properties, nitidasin’s (238) epoxide function could be installed in a chemo- and 
diastereoselective manner. Ensuing key RCM reaction furnished nitidasin’s (238) completed 
carbon skeleton (509) in remarkably high yield, being assisted by the beneficial 
conformational preorganization of epoxide 508. 
Thus, the stage was set for the completion of nitidasin (238) (cf. chapter 3.6). The successful 
transfer of developed 3-step protocol allowed for the preparation of tetracycle 515 and the
    
 
Scheme A.6: Completion of the first total synthesis of the natural occurring sesterterpenoid nitidasin (238). 
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proper construction of all stereocenters could be verified by means of X-ray crystallographic 
analysis (scheme A.6). Extended screening provided conditions for the intricate SEM ether 
deprotection and the difficult hydrogenation of the remaining alkene function. Final Ley 
oxidation furnished (−)-nitidasin (238), whose identity was proven by the elucidation of its 
solid-state structure and by comparison of recorded NMR data to the published values of the 
isolated natural product. Furthermore, the absolute configuration of the natural product was 
established via its optical rotation. A total of 16.3 mg of nitidasin (238) were prepared in 
34 steps (longest linear sequence, starting from ketone (+)-138) in 1.8% overall yield. It is our 
intention to subject this material to further biological testing, in order to shed light on 
nitidasin’s (238) yet unknown bioactivity. It was also tried to synthesize alborosin (252) from 
nitidasin (238) biomimetically. These attempts were frustrated by the failure to open the 
epoxide function with the required regioselectivity (cf. chapter 3.7). 
  
 
Scheme A.7: Established 11-step sequence toward the enantioselective construction of triflate 539. 
Regarding a potential total synthesis of the sesterterpenoid astellatol (213), two approaches 
were presented, both of which targeted the biomimetic cationic cascade that would potentially 
construct the natural product’s elaborate carbocyclic backbone. The first strategy involved 
the asymmetric synthesis of vinyl triflate 539, starting from achiral 3-pentynol (540, 
cf. chapter 4.3). In the process, a highly enantioselective Myers alkylation was devised for the 
preparation of intermediate 558 (scheme A.7). The further sequence featured an efficient 
intramolecular nitrile oxide cyclization toward bicycle 541 and a chemoselective 
hydrogenative ring opening that installed the required oxygenation pattern. However, the final 
low yielding triflation step remained as a bottleneck of this 11-step synthetic route. 
In the following (cf. chapter 4.4), a highly optimized fragment combination by means of 
B-alkyl Suzuki coupling was reported, both on a model system (438) and on the actually 
envisaged intermediate (475, scheme A.8). The accessed diketone 604 served as a starting 
point for our investigations on reductive carbonyl-carbonyl coupling. Thereby, an unexpected 
novel cyclization cascade was discovered, which furnished pentacyclic compounds 605 
and 606, using low valent titanium- or SmI2-mediated conditions, respectively. While the 
nature of all four newly formed stereocenters could not be elucidated unambiguously, we 
nevertheless provided a reasonable mechanistic explanation for mentioned cyclization mode. 
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Scheme A.8: B-alkyl Suzuki coupling toward enones 605 and 612, as well as reductive formation of 
pentacyclic products 605 and 606 by a literature unprecedented cyclization cascade. 
Branching off at the nitidasin (238) synthesis at an even later stage, the presented second-
generation approach toward astellatol (213) involved the preparation of allylic alcohol 616 
(cf. chapter 4.5) using a tungsten(IV)-based protocol (scheme A.9). However, our 
experimental efforts to initiate the proposed cationic cascade did not provide the carbon 
skeleton of the natural product under a wide variety of reaction conditions. In parallel 
conducted theoretical investigations revealed that aspired initial [1,2]-hydride shift exhibits an 
energetic barrier (+80.1 kJ/mol), being too high to compete with the experimentally observed 
elimination reactions (cf. chapter 4.6). Moreover, according to these calculations,  
the biomimetic homoallyl-cyclopropylcarbinyl-cyclobutyl rearrangement would proceed 
smoothly, once a homoallylic cation (cf. structure 625, scheme 4.21) can be addressed 
synthetically.  
  
 
Scheme A.9: Second-generation approach toward astellatol (213) and computational rationalization (624) of 
the experimental results of conducted investigations on proposed cationic cascade. 
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Scheme A.10: Illustration of the developed semisynthetic approach toward photochromic benzothiazepine-
based LTCC antagonists, exemplified for the most promising congener azo-diltiazem 13 (752). 
The second part of this doctoral thesis presents the evolution and synthesis of novel, 
benzothiazepine-based photochromic ligands for L-type voltage-gated calcium channels. To 
this end, a short and scalable semisynthetic route was established (cf. chapter 2.2), starting 
from commercially available cis-(+)-diltiazem (645). By means of chemoselective mono 
demethylation, it was possible to access a versatile building block (698) that could be coupled 
to a variety of azobenzene-type chromophores via alkylation reaction methods (scheme A.10). 
Accordingly, a small compound library of 13 azobenzene-modified benzothiazepines 
(azo-diltiazems 1–13) was synthesized and a preliminary lead structure was determined  
by performing electrophysiological experiments xiii  on the channel subtype CaV1.3 
(cf. chapter 2.3). In the process, crystal structures of azo-diltiazem 2 (706) and 8 (729) were 
elucidated and a plausible explanation for their low solubility in aqueous media was deduced 
(scheme A.11). In order to achieve higher drug concentrations in aqueous solutions, two 
permanently charged antagonists were prepared using a late-stage coupling of modified 
alkyne reagents via azide ‘click’ chemistry. Development of a total synthetic route toward this 
class of LTCC antagonists was hampered by low yields and not consistently reproducible 
procedures (cf. chapter 2.1). 
Electrophysiological evaluation proved that azo-diltiazem derivatives 727 and 729 induce a 
    
 
Scheme A.11: Solid-state structures of azo-diltiazem 2 (706) and 8 (729), both revealing folded molecular 
conformations. 
                                                
xiiiElectrophysiological evaluation of synthesized compounds was conducted by Dr. T. Fehrentz. 
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more pronounced channel block in cis configuration of their respective diazene subunits. In 
contrast, charged substances 751 and 752 exert channel block preferentially in their trans 
configurations. Generally, azo-diltiazem 13 (752) is considered to be the most promising 
candidate for an efficient photochromic LTCC antagonist according to currently available 
data. This antagonist features an unusual slow thermal relaxation rate of its diazene bond and 
first evidence was presented that it may act as a molecular tape, at which the charged tail 
group would reside at the extracellular side of the cell membrane and only the pharmacophore 
reaches to the BTZ receptor site. Further chemical modification of the established lead 
structure is aspired and is directed toward the development of a useful small molecule-based 
photopharmacological tool for the temporal and spatial control of Ca2+ currents in living 
tissue. 
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II.  Computational Methods  
 
Conformational searches were conducted with a combination of two programs. An initial 
conformer library was created with the program VEGA ZZ 3.0.3 using the SP4 force-field. 
This was followed by manual search for further conformers via the program Avogadro 1.1.1 
and the MMFF94 force-field method.[358] From the obtained library, species of reasonable low 
energy were selected for further investigations. 
For all quantum mechanical calculations, the program ORCA 3.0.2 was used.[506] Tight 
convergence criteria were selected for structure optimization and SCF convergence. A DFT 
integration grid above the standard accuracy was selected according to the keyword “grid4”. 
Otherwise, the default settings were adopted. The RIJCOSX and RI approximations were 
employed to accelerate the SCF procedure for calculation of vibrational frequencies and for 
the MP2 contribution to the PWPB95 functional.[362] The D3 correction with BJ damping was 
applied in all procedures and the gCP correction was used for calculations with the small 
def2-SVP basis set.[360] The correct nature of all stationary points was verified by conducting 
a frequency analysis. 
Structure optimizations were performed with the B3LYP functional[359] and the def2-SVP 
basis set.[360] Approximate structures for uncharged molecules were obtained from a 
conformational search and for ionic species derived from structures of similar uncharged 
molecules. Starting points for the transition state structures were obtained by relaxed potential 
energy scans along appropriate internal coordinates or constrained optimizations, if related 
structures were known from similar transition states. To identify or confirm the energy 
minima of the transition states, the respective structure was deformed along its reactive mode, 
which was followed by structure optimization in both directions. 
For the located energy minima and transition states, single point energies were calculated with 
the PWPB95 functional and the def2-TZVPP basis set.[360] Furthermore, single point energies 
were calculated with the B3LYP functional and the def2-SVP basis set in the gas phase and in 
THF (ε = 7.25) by modeling the solvent via the COSMO method.[361] Solvation energies can 
be calculated from the difference of the B3LYP/def2-SVP derived energy in the gas phase 
and in solution. 
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III. X-Ray Crystallographic Data 
 
The data collections were performed on an Oxford Diffraction Xcalibur diffractometer or on a 
Bruker D8Quest diffractometer at 173 K using MoKα-radiation (l = 0.71073 Å, graphite 
monochromator). The CrysAlisPro software (version 1.171.33.41)[507] was applied for the 
integration, scaling and multi-scan absorption correction of the data. The structures were 
solved by direct methods with SIR97[508] and refined by least-squares methods against F2 
with SHELXL-97.[509] All non-hydrogen atoms were refined anisotropically. The hydrogen 
atoms were placed in ideal geometry, riding on their parent atoms. Further details are 
summarized in the tables at the respective sections.[510] 
 
Tetraene 504 
 
CCDC 1015223 contains the supplementary crystallographic data for tetraene 504. These data 
can be obtained free of charge from the Cambridge Crystallographic Data Centre via 
www.ccdc.cam.ac.uk/data_request/cif. 
 
Table A.1: Crystallographic data for tetraene 504. 
net formula C33H54O2 
Mr/g mol−1 482.781 
crystal size/mm 0.110 × 0.090 × 0.070 
T/K 100(2) 
radiation MoKα 
diffractometer Bruker D8Venture 
crystal system triclinic 
space group P1 
a/Å 6.5679(8) 
b/Å 8.8671(10) 
c/Å 13.7516(15) 
 a/° 87.171(3) 
b/° 89.358(3) 
g/° 69.215(3) 
V/Å3 747.82(15) 
Z 1 
calc. density/g cm−3 1.0720(2) 
m/mm−1 0.064 
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absorption correction 'multi-scan' 
transmission factor range 0.6687–0.7454 
refls. measured 11635 
Rint 0.0302 
mean σ(I)/I 0.0502 
θ range 2.97–26.40 
observed refls. 4944 
x, y (weighting scheme) 0.0435, 0.0330 
hydrogen refinement mixed 
Flack parameter 0.1(9) 
refls in refinement 5757 
Parameters 327 
Restraints 3 
R(Fobs) 0.0405 
Rw(F2) 0.0885 
S 1.051 
shift/errormax 0.001 
max electron density/e Å−3 0.178 
min electron density/e Å−3 −0.193 
C-bound H: constr, O-bound H: refall. 
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Allyl Alcohol 616 
 
CCDC 1015224 contains the supplementary crystallographic data for allyl alcohol 616. These 
data can be obtained free of charge from the Cambridge Crystallographic Data Centre via 
www.ccdc.cam.ac.uk/data_request/cif. 
 
Table A.2: Crystallographic data for allyl alcohol 616. 
net formula C31H56O3Si 
Mr/g mol−1 504.860 
crystal size/mm 0.20 × 0.15 × 0.12 
T/K 173(2) 
radiation MoKα 
diffractometer Oxford XCalibur 
crystal system orthorhombic 
space group P212121 
a/Å 10.7156(6) 
b/Å 17.0663(12) 
c/Å 17.2385(11) 
 a/° 90 
b/° 90 
g/° 90 
V/Å3 3152.5(3) 
Z 4 
calc. density/g cm−3 1.06373(10) 
m/mm−1 0.101 
absorption correction 'multi-scan' 
transmission factor range 0.97608–1.00000 
refls. measured 16946 
Rint 0.0730 
mean σ(I)/I 0.1060 
θ range 4.20–25.35 
observed refls. 3713 
x, y (weighting scheme) 0.0452, 0 
hydrogen refinement constr 
Flack parameter 0.0(2) 
refls in refinement 5734 
Parameters 327 
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Restraints 0 
R(Fobs) 0.0600 
Rw(F2) 0.1296 
S 1.019 
shift/errormax 0.001 
max electron density/e Å−3 0.236 
min electron density/e Å−3 −0.290 
Two Si-bound methyl groups disordered, split model applied, sof ratio 
0.65/0.35, split atoms refined isotropically. 
 
 
3.3 Alkyne 558 
 
CCDC 1015225 contains the supplementary crystallographic data for alkyne 558. These data 
can be obtained free of charge from the Cambridge Crystallographic Data Centre via 
www.ccdc.cam.ac.uk/data_request/cif. 
   
Table A.3: Crystallographic data for alkyne 558. 
net formula C18H25NO2 
Mr/g mol−1 287.397 
crystal size/mm 0.110 × 0.08 × 0.04 
T/K 173(2) 
radiation MoKα 
diffractometer Bruker D8 Venture 
crystal system orthorhombic 
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space group P212121 
a/Å 8.1742(6) 
b/Å 13.5997(8) 
c/Å 14.6764(9) 
 a/° 90 
b/° 90 
g/° 90 
V/Å3 1631.53(18) 
Z 4 
calc. density/g cm−3 1.17004(13) 
m/mm−1 0.075 
absorption correction 'multi-scan' 
transmission factor range 0.8360–0.9585 
refls. measured 12988 
Rint 0.0324 
mean σ(I)/I 0.0324 
θ range 3.15–26.42 
observed refls. 2773 
x, y (weighting scheme) 0.0380, 0.2338 
hydrogen refinement mixed 
Flack parameter 0.3(12) 
refls in refinement 3323 
Parameters 198 
Restraints 0 
R(Fobs) 0.0361 
Rw(F2) 0.0846 
S 1.051 
shift/errormax 0.001 
max electron density/e Å−3 0.155 
min electron density/e Å−3 −0.164 
C-bound H: constr, O-bound H: refall. 
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Ether 359 
 
CCDC 1028518 contains the supplementary crystallographic data for ether 359. These data 
can be obtained free of charge from the Cambridge Crystallographic Data Centre via 
www.ccdc.cam.ac.uk/data_request/cif. 
   
Table A.4: Crystallographic data for ether 359. 
net formula C14H22O2 
Mr/g mol−1 222.323 
crystal size/mm 0.154 × 0.111 × 0.093 
T/K 100(2) 
radiation MoKα 
diffractometer Bruker D8Venture 
crystal system orthorhombic 
space group P212121 
a/Å 7.6811(6) 
b/Å 11.6826(10) 
c/Å 14.4895(12) 
a/° 90 
b/° 90 
g/° 90 
V/Å3 1300.22(19) 
Z 4 
calc. density/g cm−3 1.13575(17) 
m/mm−1 0.074 
absorption correction 'multi-scan' 
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transmission factor range 0.9385–0.9580 
refls. measured 19361 
Rint 0.0461 
mean σ(I)/I 0.0237 
θ range 3.17–25.41 
observed refls. 2138 
x, y (weighting scheme) 0.0299, 0.2453 
hydrogen refinement constr 
Flack parameter −0.2(11) 
refls in refinement 2362 
Parameters 149 
Restraints 0 
R(Fobs) 0.0306 
Rw(F2) 0.0708 
S 1.057 
shift/errormax 0.001 
max electron density/e Å−3 0.177 
min electron density/e Å−3 −0.126 
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Ketoacid 362 
 
CCDC 1028519 contains the supplementary crystallographic data for ketoacid 362. These 
data can be obtained free of charge from the Cambridge Crystallographic Data Centre via 
www.ccdc.cam.ac.uk/data_request/cif. 
 
Table A.5: Crystallographic data for ketoacid 362. 
net formula C15H22O4 
Mr/g mol−1 266.333 
crystal size/mm 0.150 × 0.097 × 0.034 
T/K 173(2) 
radiation MoKα 
diffractometer Bruker D8Venture 
crystal system orthorhombic 
space group P212121 
a/Å 6.4353(13) 
b/Å 9.217(2) 
c/Å 24.531(5) 
a/° 90 
b/° 90 
g/° 90 
V/Å3 1454.9(5) 
Z 4 
calc. density/g cm−3 1.2159(4) 
m/mm−1 0.087 
absorption correction 'multi-scan' 
transmission factor range 0.9475–0.9585 
refls. measured 22678 
Rint 0.0702 
mean σ(I)/I 0.0498 
θ range 3.27–25.06 
observed refls. 1902 
x, y (weighting scheme) 0.0270, 0.3196 
hydrogen refinement constr 
Flack parameter −1.3(14) 
refls in refinement 2549 
Parameters 177 
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Restraints 0 
R(Fobs) 0.0414 
Rw(F2) 0.0876 
S 1.064 
shift/errormax 0.001 
max electron density/e Å−3 0.152 
min electron density/e Å−3 −0.131 
Flack test meaningless, correct structure derived from synthesis. 
 
 
 
Hydrindanone 361 
 
CCDC 1028520 contains the supplementary crystallographic data for hydrindanone 361. 
These data can be obtained free of charge from the Cambridge Crystallographic Data Centre 
via www.ccdc.cam.ac.uk/data_request/cif. 
    
Table A.6: Crystallographic data for hydrindanone 361. 
net formula C14H24O2 
Mr/g mol−1 224.339 
crystal size/mm 0.3268 × 0.2540 × 0.1079 
T/K 123(2) 
radiation MoKα 
diffractometer Oxford XCalibur 
crystal system monoclinic 
space group P21 
a/Å 12.2555(13) 
b/Å 12.0957(11) 
c/Å 19.4776(18) 
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a/° 90 
b/° 108.240(10) 
g/° 90 
V/Å3 2742.3(5) 
Z 8 
calc. density/g cm−3 1.08676(20) 
m/mm−1 0.070 
absorption correction 'multi-scan' 
transmission factor range 0.97161–1.00000 
refls. measured 9337 
Rint 0.0325 
mean σ(I)/I 0.0809 
θ range 4.33–25.34 
observed refls. 5703 
x, y (weighting scheme) 0.0299, 0 
hydrogen refinement constr 
Flack parameter −2.5(12) 
refls in refinement 7464 
Parameters 594 
Restraints 1 
R(Fobs) 0.0526 
Rw(F2) 0.1036 
S 1.033 
shift/errormax 0.001 
max electron density/e Å−3 0.171 
min electron density/e Å−3 −0.178 
Correct structure derived from synthesis. 
Refined as pseudo-merohedral twin (TWIN −1 0 0 0 −1 0 1 0 1, BASF 0.46). 
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Triene 479 
 
CCDC 987776 contains the supplementary crystallographic data for triene 479. These data 
can be obtained free of charge from the Cambridge Crystallographic Data Centre via 
www.ccdc.cam.ac.uk/data_request/cif. 
    
Table A.7: Crystallographic data for triene 479. 
net formula C28H46O2 
Mr/g mol−1 414.664 
crystal size/mm 0.339 × 0.075 × 0.045 
T/K 173(2) 
radiation MoKα 
diffractometer 'Bruker D8Quest' 
crystal system triclinic 
space group P1 
a/Å 6.4186(17) 
b/Å 11.485(3) 
c/Å 18.983(6) 
a/° 75.300(9) 
b/° 83.856(9) 
g/° 73.935(8) 
V/Å3 1299.8(6) 
Z 2 
calc. density/g cm−3 1.0595(5) 
m/mm−1 0.064 
absorption correction multi-scan 
transmission factor range 0.8645–0.9575 
refls. Measured 16191 
Rint 0.1056 
mean σ(I)/I 0.1262 
θ range 2.56–24.12 
observed refls. 4261 
x, y (weighting scheme) 0.1742, 0.0534 
hydrogen refinement mixed 
Flack parameter −2(3) 
refls in refinement 5541 
Parameters 556 
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Restraints 3 
R(Fobs) 0.1111 
Rw(F2) 0.2567 
S 1.089 
shift/errormax 0.001 
max electron density/e Å−3 0.679 
min electron density/e Å−3 −0.430 
 
 
 
Epoxide 508 
 
CCDC 987777 contains the supplementary crystallographic data for epoxide 508. These data 
can be obtained free of charge from the Cambridge Crystallographic Data Centre via 
www.ccdc.cam.ac.uk/data_request/cif. 
   
Table A.8: Crystallographic data for epoxide 508. 
net formula C28H46O3 
Mr/g mol−1 430.663 
crystal size/mm 0.414 × 0.173 × 0.062 
T/K 173(2) 
radiation MoKα 
diffractometer 'Bruker D8Quest' 
crystal system monoclinic 
space group C2 
a/Å 22.6781(16) 
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b/Å 6.4165(4) 
c/Å 19.4911(13) 
a/° 90 
b/° 109.4868(19) 
g/° 90 
V/Å3 2673.8(3) 
Z 4 
calc. density/g cm−3 1.06985(12) 
m/mm−1 0.067 
absorption correction multi-scan 
transmission factor range 0.9096–0.9590 
refls. Measured 20602 
Rint 0.0454 
mean σ(I)/I 0.0602 
θ range 2.39–27.53 
observed refls. 4457 
x, y (weighting scheme) 0.0487, 0.9170 
hydrogen refinement constr 
Flack parameter −0.6(10) 
refls in refinement 6072 
Parameters 288 
Restraints 1 
R(Fobs) 0.0536 
Rw(F2) 0.1125 
S 1.023 
shift/errormax 0.001 
max electron density/e Å−3 0.180 
min electron density/e Å−3 −0.212 
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Tetracycle 515 
 
CCDC 987778 contains the supplementary crystallographic data for tetracycle 515. These 
data can be obtained free of charge from the Cambridge Crystallographic Data Centre via 
www.ccdc.cam.ac.uk/data_request/cif. 
   
Table A.9: Crystallographic data for tetracycle 515. 
net formula C31H54O4Si 
Mr/g mol−1 518.844 
crystal size/mm 0.357 × 0.116 × 0.078 
T/K 173(2) 
radiation MoKα 
diffractometer 'Bruker D8Quest' 
crystal system orthorhombic 
space group P212121 
a/Å 9.7229(5) 
b/Å 17.7799(10) 
c/Å 18.6273(11) 
a/° 90 
b/° 90 
g/° 90 
V/Å3 3220.1(3) 
Z 4 
calc. density/g cm−3 1.07024(10) 
m/mm−1 0.103 
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absorption correction multi-scan 
transmission factor range 0.9306–0.9705 
refls. Measured 56340 
Rint 0.0823 
mean σ(I)/I 0.0401 
θ range 2.36–25.14 
observed refls. 4594 
x, y (weighting scheme) 0.0471, 0.7328 
hydrogen refinement mixed 
Flack parameter −0.09(19) 
refls in refinement 5731 
Parameters 339 
Restraints 0 
R(Fobs) 0.0461 
Rw(F2) 0.1043 
S 1.074 
shift/errormax 0.001 
max electron density/e Å−3 0.250 
min electron density/e Å−3 −0.331 
C-bound H: constr, O-bound H: refall. Si-bound methyl groups partly 
disordered, split model applied, split atoms refined isotropically.  
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Tetracycle 522 
 
CCDC 988636 contains the supplementary crystallographic data for tetracycle 522. These 
data can be obtained free of charge from the Cambridge Crystallographic Data Centre via 
www.ccdc.cam.ac.uk/data_request/cif. 
    
Table A.10: Crystallographic data for tetracycle 522. 
net formula C31H56O4Si 
Mr/g mol−1 520.859 
crystal size/mm 0.289 × 0.182 × 0.149 
T/K 173(2) 
radiation MoKα 
diffractometer 'Bruker D8Quest' 
crystal system orthorhombic 
space group P212121 
a/Å 9.5112(5) 
b/Å 18.2926(10) 
c/Å 18.4951(11) 
a/° 90 
b/° 90 
g/° 90 
V/Å3 3217.9(3) 
Z 4 
calc. density/g cm−3 1.07514(10) 
m/mm−1 0.103 
absorption correction multi-scan 
transmission factor range 0.9250–0.9580 
refls. Measured 53825 
Rint 0.0532 
mean σ(I)/I 0.0293 
θ range 2.41–25.41 
observed refls. 4905 
x, y (weighting scheme) 0.0625, 1.5206 
hydrogen refinement mixed 
Flack parameter 0.0(2) 
refls in refinement 5910 
Parameters 338 
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Restraints 4 
R(Fobs) 0.0519 
Rw(F2) 0.1315 
S 1.052 
shift/errormax 0.001 
max electron density/e Å−3 0.462 
min electron density/e Å−3 −0.563 
C-bound H: constr, O-bound H: refall. Si-bound methyl partly disordered, 
split model, split atoms refined isotropically. Main part shown in figure.  
 
 
 
(−)-Nitidasin (238) 
 
CCDC 990612 contains the supplementary crystallographic data for (−)-nitidasin (238). These 
data can be obtained free of charge from The Cambridge Crystallographic Data Centre via 
www.ccdc.cam.ac.uk/data_request/cif. The obtained crystallographic parameters were in 
agreement with those reported in the isolation publication.[154] The isolation data can be 
obtained from The Cambridge Crystallographic Data Centre using the CSD code NUWMIB. 
   
Table A.11: Crystallographic data for (−)-nitidasin (238). 
net formula C25H40O3 
Mr/g mol−1 388.592 
crystal size/mm 0.06 × 0.09 × 0.15 
T/K 100(2) 
radiation MoKα 
diffractometer 'Bruker D8Venture' 
crystal system orthorhombic 
space group P212121 
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a/Å 6.4061(4) 
b/Å 13.4536(10) 
c/Å 25.5219(17) 
a/° 90 
b/° 90 
g/° 90 
V/Å3 2199.6(3) 
Z 4 
calc. density/g cm−3 1.17343(16) 
m/mm−1 0.075 
absorption correction multi-scan 
transmission factor range 0.9072–0.9585 
refls. Measured 23884 
Rint 0.0433 
mean σ(I)/I 0.0350 
θ range 3.03–26.41 
observed refls. 3921 
x, y (weighting scheme) 0.0403, 0.4296 
hydrogen refinement mixed 
Flack parameter 0.9(9) 
refls in refinement 4482 
Parameters 263 
Restraints 0 
R(Fobs) 0.0360 
Rw(F2) 0.0830 
S 1.039 
shift/errormax 0.001 
max electron density/e Å−3 0.245 
min electron density/e Å−3 −0.186 
C-bound H: constr, O-bound H: refall. 
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Azo-diltiazem 2 (706) 
 
CCDC 1027093 contains the supplementary crystallographic data for azo-diltiazem 2 (706). 
These data can be obtained free of charge from The Cambridge Crystallographic Data Centre 
via www.ccdc.cam.ac.uk/data_request/cif.  
   
Table A.12: Crystallographic data for azo-diltiazem 2 (706). 
net formula C35H35N5O5S 
Mr/g mol−1 637.749 
crystal size/mm 0.162 × 0.111 × 0.092 
T/K 100(2) 
radiation MoKα 
diffractometer 'Bruker D8Venture' 
crystal system orthorhombic 
space group P212121 
a/Å 8.8467(4) 
b/Å 10.3973(4) 
c/Å 33.9921(12) 
a/° 90 
b/° 90 
g/° 90 
V/Å3 3126.7(2) 
Z 4 
calc. density/g cm−3 1.35481(9) 
m/mm−1 0.156 
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absorption correction multi-scan 
transmission factor range 0.9504–0.9679 
refls. Measured 64458 
Rint 0.0491 
mean σ(I)/I 0.0225 
θ range 3.02–25.51 
observed refls. 5400 
x, y (weighting scheme) 0.0284, 0.8739 
hydrogen refinement mixed 
Flack parameter −0.04(5) 
refls in refinement 5746 
Parameters 422 
Restraints 0 
R(Fobs) 0.0286 
Rw(F2) 0.0643 
S 1.075 
shift/errormax 0.002 
max electron density/e Å−3 0.238 
min electron density/e Å−3 −0.167 
C-bound H: constr, N-bound H: refall. 
 
 
 
III. X-Ray Crystallographic Data 
374 
Azo-diltiazem 8 (729) 
 
CCDC 1027094 contains the supplementary crystallographic data for azo-diltiazem 8 (729). 
These data can be obtained free of charge from The Cambridge Crystallographic Data Centre 
via www.ccdc.cam.ac.uk/data_request/cif.  
   
Table A.13: Crystallographic data for azo-diltiazem 8 (729). 
net formula C38H41N5O7S 
Mr/g mol−1 711.828 
crystal size/mm 0.177 × 0.128 × 0.110 
T/K 123(2) 
radiation MoKα 
diffractometer 'Bruker D8Venture' 
crystal system orthorhombic 
space group P212121 
a/Å 9.6378(5) 
b/Å 16.9354(8) 
c/Å 23.5059(12) 
a/° 90 
b/° 90 
g/° 90 
V/Å3 3836.6(3) 
Z 4 
calc. density/g cm−3 1.23238(10) 
m/mm−1 0.138 
absorption correction multi-scan 
transmission factor range 0.9055–0.9705 
refls. Measured 41701 
Rint 0.0401 
mean σ(I)/I 0.0246 
θ range 2.99–25.02 
observed refls. 6001 
x, y (weighting scheme) 0.0869, 3.4367 
hydrogen refinement mixed 
Flack parameter 0.00(12) 
refls in refinement 6808 
Parameters 468 
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Restraints 0 
R(Fobs) 0.0566 
Rw(F2) 0.1681 
S 1.104 
shift/errormax 0.001 
max electron density/e Å−3 0.795 
min electron density/e Å−3 −0.467 
C-bound H: constr, N-bound H: refall. Split model applied for the disorder of 
the OCH3 group, sof ratio 1:1, split atoms refined isotropically. 
 
 
IV. 1H and 13C NMR Spectra 
376 
IV. 1H and 13C NMR Spectra 
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1H NMR (CDCl3, 600 MHz):  
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1H NMR (CDCl3, 600 MHz):  
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1H NMR (C6D6, 600 MHz):  
 
 
13C NMR (C6D6, 150 MHz): 
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1H NMR (CDCl3, 200 MHz):  
 
 
13C NMR: not recorded due to decomposition of substance 382 in the NMR solvent. 
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1H NMR (C6D6, 600 MHz):  
 
 
13C NMR (C6D6, 150 MHz): 
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1H NMR (CDCl3, 600 MHz):  
 
 
13C NMR (CDCl3, 150 MHz): 
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1H NMR (CDCl3, 600 MHz):  
 
 
13C NMR (CDCl3, 150 MHz): 
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1H NMR (CDCl3, 600 MHz):  
 
 
13C NMR (CDCl3, 150 MHz): 
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1H NMR (CDCl3, 600 MHz):  
 
 
13C NMR (CDCl3, 150 MHz): 
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1H NMR (CDCl3, 400 MHz):  
 
 
13C NMR (CDCl3, 100 MHz): 
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1H NMR (C6D6, 600 MHz):  
 
 
13C NMR (C6D6, 150 MHz): 
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1H NMR (C6D6, 600 MHz):  
 
 
13C NMR (C6D6, 150 MHz): 
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1H NMR (CDCl3, 400 MHz):  
 
 
13C NMR (CDCl3, 100 MHz): 
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1H NMR (CDCl3, 400 MHz):  
 
 
13C NMR (CDCl3, 100 MHz): 
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1H NMR (CDCl3, 400 MHz):  
 
 
13C NMR (CDCl3, 150 MHz): 
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1H NMR (CDCl3, 600 MHz):  
 
 
13C NMR (CDCl3, 150 MHz): 
 
 
444 
OMe
H
O
O
Appendix 
 
395 
1H NMR (CDCl3, 400 MHz):  
 
 
13C NMR (CDCl3, 150 MHz): 
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1H NMR (CDCl3, 400 MHz):  
 
 
13C NMR (CDCl3, 100 MHz): 
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1H NMR (CDCl3, 400 MHz):  
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1H NMR (CDCl3, 400 MHz):  
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1H NMR (CDCl3, 400 MHz):  
 
 
13C NMR (CDCl3, 100 MHz): 
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1H NMR (CDCl3, 400 MHz):  
 
 
13C NMR (CDCl3, 100 MHz): 
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1H NMR (CDCl3, 600 MHz):  
 
 
13C NMR (CDCl3, 150 MHz): 
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1H NMR (CDCl3, 400 MHz):  
 
 
13C NMR (CDCl3, 100 MHz): 
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1H NMR (CDCl3, 400 MHz):  
 
 
13C NMR (CDCl3, 100 MHz): 
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1H NMR (CDCl3, 400 MHz):  
 
 
13C NMR (CDCl3, 100 MHz): 
 
 
469 
Me
H
H
O
H
O OSEM
Me
Appendix 
 
405 
1H NMR (CDCl3, 400 MHz):  
 
 
13C NMR (CDCl3, 100 MHz): 
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1H NMR (CDCl3, 400 MHz):  
 
 
13C NMR (CDCl3, 100 MHz): 
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1H NMR (CDCl3, 400 MHz):  
 
 
13C NMR (CDCl3, 100 MHz): 
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1H NMR (CDCl3, 400 MHz):  
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1H NMR (CDCl3, 400 MHz):  
 
 
13C NMR (CDCl3, 100 MHz): 
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1H NMR (CDCl3, 400 MHz):  
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1H NMR (C6D6, 400 MHz):  
 
 
13C NMR (C6D6, 100 MHz): 
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1H NMR (C6D6, 400 MHz):  
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1H NMR (C6D6, 600 MHz):  
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1H NMR (C6D6, 400 MHz):  
 
 
13C NMR (C6D6, 100 MHz): 
 
 
434 
Me I
HO
Appendix 
 
415 
1H NMR (C6D6, 400 MHz):  
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1H NMR (C6D6, 400 MHz):  
 
 
13C NMR (C6D6, 100 MHz): 
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1H NMR (C6D6, 600 MHz):  
 
 
13C NMR (C6D6, 150 MHz): 
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1H NMR (C6D6, 400 MHz):  
 
 
13C NMR (C6D6, 100 MHz): 
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1H NMR (C6D6, 400 MHz):  
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1H NMR (C6D6, 400 MHz):  
 
 
13C NMR (C6D6, 100 MHz): 
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IV. 1H and 13C NMR Spectra 
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1H NMR (C6D6, 400 MHz):  
 
 
13C NMR (C6D6, 100 MHz): 
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1H NMR (C6D6, 400 MHz):  
 
 
13C NMR (C6D6, 100 MHz): 
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1H NMR (C6D6, 400 MHz):  
 
 
13C NMR (C6D6, 100 MHz): 
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1H NMR (CDCl3, 400 MHz):  
 
 
13C NMR (CDCl3, 100 MHz): 
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1H NMR (C6D6, 400 MHz):  
 
 
13C NMR (C6D6, 100 MHz): 
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1H NMR (CDCl3, 400 MHz):  
 
 
13C NMR (CDCl3, 100 MHz): 
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V. Additional Data 
 
Comparison of NMR Data of Synthetic (−)-Nitidasin with Isolation Data  
 
Note: Synthetic (−)-nitidasin (238) was highly unstable in commercially available CDCl3. In 
order to circumvent decomposition due to traces of acid, molecular sieves (4 Å, activated, 
20 g) was added to CDCl3 (new 100 mL bottle), the bottle was flushed with argon and stored 
over night at 4 °C. Immediately prior to recording the spectra, CDCl3 (2 mL) was filtered over 
basic Al2O3 (4 cm pad in a Pasteur pipette). The first 0.5 mL of CDCl3 were discarded. The 
(−)-nitidasin (238) sample was dissolved in CDCl3 (0.7 mL) and filled into a NMR tube, 
which was flushed with Argon and sealed. In such media, (−)-nitidasin (238) was stable for 
48 hours. CDCl3 was referenced to δ = 7.26 and 77.00 ppm, respectively. 
 
Table A.14: Comparison of 1H NMR data of (−)-nitidasin (238). 
Natural, 1H NMR (CDCl3, 600 MHz)[154] 
δ /ppm 
Synthetic, 1H NMR (CDCl3, 600 MHz) 
δ /ppm 
2.55 (m, 1H) 2.55 (mC, 1H) 
2.46 (m, 1H) 2.46 (mC, 1H) 
2.40 (m, 1H) 2.40 (mC, 1H) 
2.34 (s, 1H, OH) 2.34 (s, 1H) 
2.17 (t, J = 12.5 Hz, 1H) 2.17 (t, J = 13.0 Hz, 1H) 
2.10 (d, J = 17.2 Hz, 1H) 2.11 (d, J = 17.1 Hz, 1H) 
2.06 (m, 1H) 2.09−2.03 (m, 1H) 
1.98 (d, J = 17.2 Hz, 1H) 1.98 (d, J = 17.2 Hz, 1H) 
1.88 (m, 2H) 1.94–1.83 (m, 3H) 
1.87 (m, 1H)  
1.76 (br d, J = 13.5 Hz, 1H) 1.75 (dd, J = 12.6, 2.8 Hz, 1H) 
1.65 (br d, J = 12.5 Hz, 1H) 1.65 (dd, J = 13.1, 2.4 Hz, 1H) 
1.56 (m, 1H) 1.59−1.54 (m, 2H) 
1.55 (m, 1H)  
1.46 (m, 1H) 1.49–1.42 (m, 2H) 
1.44 (m, 1H)  
1.41 (s, 3H) 1.41 (s, 3H) 
1.32 (m, 1H) 1.35–1.21 (m, 4H) 
1.26 (m, 3H)  
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1.12 (m, 1H) 1.12 (mC, 1H) 
1.00 (d, J = 6.2 Hz, 3H) 1.00 (d, J = 6.3 Hz, 3H) 
0.98 (d, J = 6.1 Hz, 3H) 0.99–0.94 (m, 6H) 
0.97 (d, J = 6.1 Hz, 3H)  
0.96 (s, 3H) 0.96 (s, 3H) 
0.89 (d, J = 5.5 Hz, 3H) 0.89 (br d, J = 5.8 Hz, 3H) 
 
Table A.15: Comparison of 13C NMR data of (−)-nitidasin (238). 
Natural, 13C NMR (CDCl3, 150 MHz)[154] 
δ /ppm 
Synthetic, 13C NMR (CDCl3, 100 MHz) 
δ /ppm 
220.50 220.51 
79.17 79.18 
75.06 75.07 
67.29 67.30 
55.83 55.83 
55.77 55.78 
42.35 42.35 
42.18 42.19 
41.84 41.85 
41.70 41.71 
39.11 39.11 
36.00 36.01 
34.83 34.83 
34.20 34.22 
32.22 32.23 
32.13 32.13 
28.35 28.36 
26.56 26.57 
25.32 25.36 
24.67 24.67 
23.08 23.09 
21.16 21.16 
20.11 20.12 
16.34 16.35 
14.89 14.89 
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Gas-phase Energies of Calculated Structures  
 
Tables A.16 and A.17 list the calculated energies for all structures that are depicted in the 
reaction profile in scheme 4.20. Values given in the second row refer to the gas-phase. The 
respective reference points are allyl cation 623 and allylic alcohol 622. Employed 
computational methods are outlined in section I of the appendix. 
    
Table A.16:  Relative energies for transitions states and intermediates given in scheme 4.20. 
Structure 
E [kJ/mol] 
(B3LYP/def-SVP) 
E [kJ/mol] 
(B3LYP/def-SVP, COSMO, THF) 
623 0 0 
[624]‡ +87.6 +80.1 
625 +83.0 +68.6 
[629]‡ +84.7 +73.8 
628 +25.6 +25.3 
[630]‡ +53.9 +45.9 
626 +39.9 +33.1 
622 0 0 
627 + H2O +31.9 +4.6 
 
Table A.17:  Absolute energies for transitions states and intermediates given in scheme 4.20. 
Structure 
E [Hartree] 
(B3LYP/def-SVP) 
E [Hartree] 
(B3LYP/def-SVP, COSMO, THF) 
623 −976.780812 −976.831410 
[624]‡ −976.747450 −976.800896 
625 −976.749199 −976.805292 
[629]‡ −976.748561 −976.803300 
628 −976.771067 −976.821776 
[630]‡ −976.760272 −976.813926 
626 −976.765602 −976.818700 
622 −1052.851393 −1052.209235 
627 + H2O −1052.839256 −1052.207473 
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Cartesian Coordinates of Calculated Structures 
 
Table A.18:  Cartesian coordinates for allylic cation 623. 
C −6.60421657 1.66112306 2.43645479  H −11.3997879  0.03441992 4.71281140 
C −7.83115662  1.20861517 1.60468132  C −6.59767260  1.87114864 −2.39379619 
C −8.69409615  0.25229847 2.49683966  C −9.05128807 2.19614339 −2.04630543 
C −7.58609419  −0.34507743 3.44597372  C −5.22474130  4.46033771 −1.74634733 
C −6.22369624  0.29349965 3.06064492  H −6.28439238  4.67761870 −1.98171520 
C −7.37865831  2.72874108 −0.20352423  H −4.68122825  5.39048327 −1.99347659 
C −6.17168834  3.33160927 0.47917443  C −4.66230645  3.34486709 −2.64124176 
C −7.61267628  2.33721124 −1.55309887  H −3.55763470  3.36115422 −2.59155390 
C −8.45413916  2.39023535 0.79399453  H −4.92887369  3.53052368 −3.69865069 
C −5.04546707  4.17049696 −0.23911593  C −5.11400864  1.91696838 −2.19734174 
H −6.66865041  4.05621321 1.15597904  C −4.57484029  0.74682055 −3.07558395 
C −5.55910005  2.25732256 1.47168976  H −4.81551214  1.78094059 −1.14726674 
H −4.74322975  2.75923707 2.02309438  C −6.89245207  1.15448901 −3.68963898 
H −5.09030894  1.45036987 0.87719655  C −5.52979574  0.75036926 −4.28957441 
H −7.40944111  0.52520801 0.83748907  H −4.76960776  −0.18051142 −2.49619519 
C −6.93942197  2.67178021 3.55819854  C −3.08328546  0.78412139 −3.41896166 
H −7.39936359  3.60695926 3.18790683  H −2.82540150  1.63917081 −4.06950571 
H −6.01699769  2.95401607 4.09741058  H −2.79077476  −0.13325183 −3.96057612 
H −7.63281186  2.25075272 4.30294589  H −2.45654956  0.84385078 −2.50986365 
C −9.93928401  0.78447033 3.26613043  H −5.56832712  −0.22334034 −4.80682673 
H −9.07736347  −0.55012613 1.83558376  H −5.20282609  1.49532847 −5.03907175 
H −9.38487496  2.06820824 0.31839665  H −7.52279846  1.76941041 −4.36124614 
H −8.68081444  3.23779576 1.46282918  H −7.52082166  0.26771168 −3.45492567 
H −5.54072735  0.38197822 3.92442897  H −4.10096131  3.60120933 −0.13264555 
H −5.70406513  −0.32390506 2.30265547  C −4.85335604  5.49057992 0.53919692 
H −9.61904901  1.59130534 3.95520142  H −5.73804320  6.14782847 0.43342183 
C −10.5480361  −0.34774201 4.12195893  H −3.97967215  6.04609212 0.15386202 
C −11.0486719  1.34779954 2.35286603  H −4.68443741  5.31786313 1.61848917 
H −10.8041765  2.32589528 1.90700126  H −9.12292971  2.49461117 −3.10520252 
H −11.9795585  1.49474468 2.92894787  H −9.74609477  2.84283140 −1.49132628 
H −11.2876682  0.64349299 1.53178208  H −9.42432480  1.15627790 −1.97291081 
H −9.82961260  −0.79095893 4.83226972  H −7.54788235  −1.44609440 3.38259394 
H −10.9279436  −1.16456715 3.47774819  H −7.82501130  −0.10615657 4.49672041 
 
Table A.19:  Cartesian coordinates for transition state 624. 
C −6.79172525 1.44521780 2.60385976  H −5.98865451 1.63188054 −2.35482174 
C −7.99038267 1.02381524 1.71135730  C −8.44285960 1.40560191 −2.18967094 
C −9.01273942 0.28818644 2.64367842  C −5.30752952 4.49328636 −1.27221880 
V. Additional Data 
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C −8.05118572 −0.33520150 3.72512783  C −6.40468096 4.60397809 −1.25409153 
C −6.60243063 0.13266222 3.40356078  H −4.90205113 5.51539589 −1.17224862 
C −7.17123997 2.33330709 −0.19643456  H −4.85559387 3.97678028 −2.65291786 
C −6.02276903 2.91397641 0.63933336  C −3.79442659 4.23479798 −2.83385714 
C −7.17201936 1.88468521 −1.48288609  H −5.42510932 4.48733341 −3.45770424 
C −8.39516571 2.10835428 0.68373381  H −5.01121432 2.50554132 −2.90219418 
C −4.82958588 3.61841902 −0.07248249  C −4.13146850 1.76729484 −3.90709598 
H −6.51038589 3.73603238 1.20245126  C −4.84939412 1.83786892 −1.72837513 
C −5.60202147 1.84839573 1.69830853  H −5.81178897 0.24480328 −2.98817171 
H −4.77333525 2.23762619 2.31656728  C −4.39261990 0.27265424 −3.59118433 
H −5.21066140 0.95472896 1.16946055  C −3.07077811 2.03998799 −3.75158476 
H −7.58659801 0.19969003 1.08427591  H −4.53341408 2.18478270 −5.34343860 
C −7.11930840 2.60201407 3.58073244  C −5.59785094 1.97192826 −5.55543072 
H −7.55763019 3.48741861 3.08539261  H −3.92531577 1.61820858 −6.06904181 
H −6.19996464 2.93357017 4.09821656  H −4.34964715 3.25839194 −5.52541024 
H −7.83155775 2.29394869 4.36156309  H −3.65988330 −0.08636729 −2.84386981 
C −10.2152908 1.04750421 3.28124845  H −4.28778765 −0.37233223 −4.47914399 
H −9.46967541 −0.52548124 2.04524207  H −6.58565508 0.13433390 −3.77053905 
H −9.26813233 1.76501446 0.11370877  H −5.98394738 −0.56280872 −2.25628378 
H −8.67920765 3.05064825 1.18523781  H −4.11092397 2.84331141 −0.42888597 
H −5.98870041 0.25889248 4.31397023  H −4.02340215 4.48800551 0.91599410 
H −6.08423475 −0.61230065 2.76863604  C −4.66062197 5.28112580 1.35091322 
H −9.82529746 1.82524067 3.96739744  H −3.18331278 4.98251210 0.39503488 
C −11.0670986 0.06917713 4.12177604  H −3.59644743 3.90365607 1.74788664 
C −11.1374149 1.74371785 2.26076526  H −8.38504728 1.58646440 −3.27873732 
H −10.6776234 2.62655443 1.78882985  H −9.31920365 1.96632296 −1.83102395 
H −12.0597525 2.09759817 2.75656315  H −8.64695974 0.32747393 −2.04190891 
H −11.4474126 1.04566493 1.45830442  H −8.12276243 −1.43639528 3.75025579 
H −10.4771312 −0.47805616 4.87719685  H −8.34340336 0.01062799 4.73216707 
H −11.5549032 −0.68334820 3.47105532  H −5.98865451 1.63188054 −2.35482174 
 
Table A.20:  Cartesian coordinates for homoallylic cation 625. 
C −6.81532270  1.43222755 2.58618718  H −11.9013752  0.82129958 4.69074140 
C −8.04892627  1.11085909 1.69289727  C −5.78634235  1.55406950 −2.15228343 
C −9.10195106  0.41157494 2.61894868  C −8.32337951  1.54970031 −2.27356467 
C −8.16565074  −0.31327357 3.65824625  C −5.22414068  4.48584033 −1.23722436 
C −6.69616639  0.08485089 3.33920709  H −6.30214779  4.70274911 −1.15609385 
C −7.14732944  2.37496028 −0.18073394  H −4.71809193  5.46571173 −1.18662246 
C −5.97959601  2.89885983 0.66305092  C −4.90000862  3.94498473 −2.65983938 
C −7.09542084  1.90377789 −1.44987409  H −3.93262865  4.32665912 −3.03928355 
C −8.39674953  2.23152555 0.67732983  H −5.65671027  4.35789654 −3.37521924 
C −4.76951993  3.60346738 −0.03425519  C −4.98060262  2.50269747 −2.91594328 
Appendix 
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H −6.43675343  3.72053718 1.25064928  C −4.17017401  1.80103217 −3.95156137 
C −5.60072002  1.79309446 1.69123421  H −4.98421706  1.47051788 −1.35177379 
H −4.75221686  2.12109443 2.31960271  C −5.68672480  0.19985651 −2.91529977 
H −5.25721633  0.89088464 1.14307772  C −4.31158052  0.29392693 −3.60205859 
H −7.70153458  0.27696342 1.04635136  H −3.12506499  2.16651290 −3.94226987 
C −7.06512303  2.57377823 3.60360738  C −4.76455102  2.16062968 −5.35841087 
H −7.46168720  3.49595881 3.14131226  H −5.82979449  1.88169678 −5.44439949 
H −6.12261394  2.83853651 4.11813420  H −4.19978943  1.59226334 −6.11633230 
H −7.78242069  2.28021783 4.38533112  H −4.65383285  3.23566597 5−.58073872 
C −10.2421160  1.21815095 3.31007843  H −3.50871953  0.00249037 −2.89891242 
H −9.62060883  −0.34799589 2.00011140  H −4.21354144  −0.34988746 −4.49213749 
H −9.27957048  1.93703592 0.09136122  H −6.50154308  0.12020498 −3.65616038 
H −8.63658317  3.18221047 1.18545740  H −5.78787049  −0.65763035 −2.22958048 
H −6.06930599  0.14434608 4.24761059  H −4.03170018  2.84871500 −0.38049919 
H −6.22494472  −0.66525459 2.67430088  C −4.01281345  4.48701305 0.98112674 
H −9.79287583  1.93539919 4.02559326  H −4.66115824  5.30006817 1.35885997 
C −11.1424916  0.25620689 4.11908844  H −3.12836868  4.95432186 0.51072417 
C −11.1313313  2.02156060 2.34070203  H −3.65812536  3.91034600 1.85169897 
H −10.6115954  2.87702623 1.88079879  H −8.19310022  1.87109725 −3.32571662 
H −12.0056979  2.43418487 2.87681359  H −9.22185818  2.06190709 −1.89709736 
H −11.5213289  1.37779507 1.52770546  H −8.54313804  0.46427031 −2.29415542 
H −10.5774023  −0.35761801 4.84194402  H −8.29945909  1.40874653 −3.63267035 
H −11.6814445  −0.43742072 3.44339509  H −8.42567113  0.00187701 4.68411186 
 
Table A.21:  Cartesian coordinates for transition state 629. 
C −6.81281828  1.48758859 2.67801640  H −12.0859310  0.87397169 4.29896198 
C −7.95638372  1.09700675 1.69956101  C −5.38378304  1.39504373 −1.92864152 
C −9.07798814  0.41984937 2.55768568  C −7.98734619  1.42720189 −2.23776528 
C −8.23653466  −0.20289933 3.73592919  C −4.99991531  4.44067075 −1.11318185 
C −6.74719691  0.18287715 3.51084059  H −6.08073040  4.67432419 −1.08116506 
C −6.93061980  2.33046875 −0.13368806  H −4.48659820  5.41797746 −1.06997311 
C −5.84021119  2.89707272 0.77148438  C −4.65869807  3.85837086 −2.49106394 
C −6.78963382  1.79842932 −1.37973684  H −3.54913462  3.89467654 −2.65249758 
C −8.24157044  2.17438337 0.62038556  H −5.02368326  4.52130346 −3.30646326 
C −4.59764129  3.59196535 0.13221074  C −4.95930528  2.46374777 −2.84996958 
H −6.34936512  3.72829986 1.29838028  C −4.71085435  1.93722291 −4.23048648 
C −5.53492838  1.82515406 1.86610275  H −4.69384307  1.36614554 −1.06996229 
H −4.73893767  2.19146712 2.53978567  C −5.29629804  0.06703228 −2.73736368 
H −5.14155123  0.90699538 1.38291404  C −4.45672448  0.42088445 −3.98828467 
H −7.53697038  0.24750629 1.11939308  H −3.82052255  2.46551864 −4.62851853 
C −7.16489599  2.67112901 3.61177794  C −5.85526522  2.22194275 −5.25207221 
H −7.47818924  3.58272354 3.07164751  H −6.76167943  1.63442364 −5.03464013 
V. Additional Data 
538 
H −6.28740456  2.93824934 4.22903635  H −5.49420131  1.92809997 −6.25223585 
H −7.98073556  2.42007945 4.30700184  H −6.12771190  3.29138219 −5.28514524 
C −10.3083503  1.23138850 3.06366959  H −3.38130966  0.25036382 −3.79594398 
H −9.50443832  −0.39694636 1.94171932  H −4.72950913  −0.18679903 −4.86826662 
H −9.06278260  1.83958333 −0.02792383  H −6.29696569  −0.29014549 −3.02882309 
H −8.54219542  3.13381798 1.07766818  H −4.83858295  −0.73525508 −2.13513073 
H −6.19311852  0.29725410 4.46016389  H −3.84180069  2.83856993 −0.16708793 
H −6.22482877  −0.60042926 2.92748897  C −3.90470429  4.49763888 1.17111048 
H −9.95839310  2.01763266 3.76235258  H −4.57840546  5.30951378 1.50487357 
C −11.2568369  0.29789809 3.84898771  H −3.00199481  4.96780684 0.73998626 
C −11.1150389  1.92365107 1.94644183  H −3.58575694  3.93812287 2.06658917 
H −10.5888928  2.77809928 1.49228966  H −7.75758164  1.47972205 −3.31275488 
H −12.0652444  2.31992000 2.34888155  H −8.83114544  2.11322139 −2.06427266 
H −11.3750854  1.21073490 1.13957336  H −8.34747947  0.39913042 −2.03561729 
H −10.7487561  −0.24116198 4.66717585  H −8.36609966  −1.29705755 3.80165778 
H −11.7041445  −0.46149555 3.17751199  H −8.58720018  0.20221340 4.70143938 
 
Table A.22:  Cartesian coordinates for cyclopropylcarbinyl cation 628. 
C −6.75570137  1.56883164 2.60209442  H −12.1801126  1.28695054 3.84532717 
C −7.86786100  1.27415812 1.55962868  C −5.10869159  1.04143929 −1.62530068 
C −9.09068653  0.66564169 2.32477782  C −7.80617799  1.09651990 −1.99025133 
C −8.36651343  −0.00967427 3.55309302  C −7.80617799  1.09651990 −1.99025133 
C −6.84064443  0.24607206 3.40676295  H −5.61707325  4.86795420 −0.93114480 
C −6.67740159  2.42871737 −0.18533859  H −3.91425340  5.18676631 −1.22535046 
C −5.59671076  2.93897891 0.74318322  C −4.66481342  3.57309319 −2.39737218 
C −6.54708069  1.75458531 −1.42708774  H −3.61994449  3.40607584 −2.73296708 
C −8.00759057  2.42647800 0.50772380  H −5.12348638  4.20829187 −3.17732329 
C −4.29032118  3.54908915 0.17221109  C −5.31086209  2.19736730 −2.48256903 
H −6.07471725  3.78635208 1.26791101  C −5.45271381  1.69186951 −3.94260742 
C −5.42865497  1.82127931 1.84813007  H −4.49233718  1.06835069 −0.72439058 
H −4.63611937  2.15624233 2.54021292  C −5.10539297  −0.25530764 −2.42920240 
H −5.06832317  0.88402329 1.38149321  C −5.47644351  0.13554658 −3.88647016 
H −7.47784646  0.40982340 0.98271927  H −4.47029747  1.98822948 −4.36657731 
C −7.05811502  2.76037392 3.54087737  C −6.51872313  2.34662345 −4.83144374 
H −7.17841914  3.72244855 3.01055417  H −7.54782597  2.11625562 −4.50732032 
H −6.22873873  2.88734683 4.25999363  H −6.41048884  1.98583686 −5.87011037 
H −7.97488808  2.60611359 4.13041273  H −6.40947693  3.44571251 −4.85821394 
C −10.3014619  1.54918607 2.74486468  H −4.75919775  −0.28948868 −4.60857362 
H −9.51530065   −0.12309026 1.67317059  H −6.46029438  −0.26633675 −4.18482778 
H −8.84875401  2.24086214 −0.16793037  H −5.76572041  −1.02864891 −1.99715098 
H −8.84875401  2.24086214 −0.16793037  H −4.07877488  −0.66373280 −2.36699207 
H −6.32502980  0.29290206 4.38231348  H −3.56027713  2.75964049 −0.09180940 
Appendix 
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H −6.36194469  −0.56861269 2.82894445  C −3.62777260  4.44967357 1.23072702 
H −9.95597139  2.31565090 3.46784239  H −4.27729423  5.30872808 1.48560382 
C −11.3490925  0.66848897 3.46117336  H −2.67487407  4.85754784 0.84842548 
C −10.9890696  2.28056903 1.57266224  H −3.40125920  3.90969949 2.16639709 
H −10.3982289  3.11654739 1.16486591  H −7.62771369  0.54447344 −2.91595661 
H −11.9487937  2.71631705 1.90457732  H −8.58347700  1.84778322 −2.21060052 
H −11.2193354  1.58211167 0.74435868  H −8.22816041  0.37437487 −1.26935004 
H −10.9286571  0.11325779 4.31734452  H −8.59296253  −1.08733907 3.62344893 
H −11.7826964 −0.07426971 2.76291357  H −8.73340199  0.44108626 4.49180280 
 
Table A.23:  Cartesian coordinates for transition state 630. 
C −6.69848393 1.77294253 2.62923258  H −5.70916520 1.18164082 −1.20397638 
C −7.60425816 1.06626984 1.59264922  C −8.01684174 2.93143930 −2.38103442 
C −8.73813032 0.34234874 2.39836426  C −4.19771186 4.14622671 −1.25530464 
C −8.02034659 0.07100192 3.77752244  C −5.04146610 4.85003861 −1.41696511 
C −6.58112092 0.64487443 3.68047668  H −3.28421499 4.75435593 −1.38568870 
C −6.55596787 2.32543668 −0.33657241  H −4.19946747 3.06898077 −2.34171611 
C −5.59081313 3.05110615 0.67933454  C −3.31857839 2.40493194 −2.24221546 
C −6.69289447 2.70803774 −1.74117565  H −4.10371459 3.56160680 −3.32799977 
C −7.87898990 1.92808984 0.35512042  H −5.45875211 2.19595375 −2.40046498 
C −4.22587722 3.62148481 0.19200956  C −5.59706055 1.34325147 −3.69337352 
H −6.20161286 3.92672620 0.97574150  C −4.79720096 1.01622918 −0.60859262 
C −5.38534240 2.14926265 1.92245913  H −6.34442336 −0.08765969 −1.79900906 
H −4.70440722 2.65722001 2.62728654  C −6.54762533 0.17846166 −3.31922676 
H −4.85339200 1.22551613 1.61114530  C −4.58018204 0.90876114 −3.79961680 
H −6.98384707 0.22386475 1.21984512  H −5.90993504 2.05685445 −5.01553792 
C −7.33431253 3.02674500 3.28063703  C −6.95026154 2.42377747 −5.07566647 
H −7.69774753 3.77004883 2.54862216  H −5.76326973 1.36177388 −5.86108340 
H −6.59213785 3.53593244 3.92261842  H −5.23692747 2.91567523 −5.18775134 
H −8.19076892 2.77086023 3.92406021  H −6.32986645 −0.72061525 −3.92117400 
C −10.1397398 1.00135513 2.57419000  H −7.59692275 0.44206170 −3.54685859 
H −8.93128571 −0.62451084 1.89136034  H −7.27900832 −0.38490933 −1.29150462 
H −8.51803410 1.37123042 −0.34887962  H −5.63698131 −0.92033720 −1.63933933 
H −8.42866092 2.85097459 0.61498423  H −3.46800530 2.81267579 0.26881528 
H −6.19619354 0.99702673 4.65499356  H −3.78740557 4.76110631 1.14002226 
H −5.87501909 −0.12765434 3.31699391  C −4.46709462 5.62944162 1.04746251 
H −10.0234607 1.94260372 3.14820065  H −2.76981481 5.10782292 0.88743960 
C −11.0502988 0.06005252 3.39285103  H −3.77705217 4.45423068 2.19924607 
C −10.8552733 1.33721110 1.24789561  H −7.91204034 3.31201495 −3.40753524 
H −10.4233310 2.20293552 0.72128877  H −8.59272450 3.64304585 −1.76033764 
H −11.9157786 1.58684921 1.43490492  H −8.62975913 2.01162265 −2.41910745 
H −10.8420638 0.47072194 0.55731044  H −8.01452099 −1.00122935 4.03973557 
V. Additional Data 
540 
H −10.6012408 −0.24556344 4.35358165  H −8.56955680 0.57694910 4.59086992 
H −11.2707166 −0.86364243 2.82207875  H −5.70916520 1.18164082 −1.20397638 
 
Table A.24:  Cartesian coordinates for cyclobutyl cation 626. 
C −6.76248965 1.80538018 2.58705640  H −5.53436598 1.06649210 −1.09670649 
C −7.58787658 0.98975260 1.55995700  C −7.57225783 3.75704466 −2.19303819 
C −8.72204805 0.26658350 2.36502928  C −4.13802206 4.05761672 −1.32417815 
C −8.03193852 0.07966947 3.77218237  C −4.93044469 4.81810390 −1.49562759 
C −6.62966500 0.74548777 3.70677576  H −3.18974106 4.60980482 −1.45301015 
C −6.47467087 2.13399956 −0.40401407  H −4.20556237 2.97730633 −2.41778801 
C −5.59700569 3.04061468 0.63052971  C −3.31625589 2.31918968 −2.38406417 
C −6.58161481 2.80568947 −1.69556345  H −4.20787059 3.47188463 −3.40685328 
C −7.83360709 1.75422084 0.26063360  H −5.45371238 2.05930098 −2.32588977 
C −4.21511280 3.57514581 0.14367239  C −5.77406350 1.21737406 −3.60231731 
H −6.24063449 3.91763938 0.83351888  C −4.59659312 0.87476492 −0.55341312 
C −5.43439271 2.20250473 1.92328618  H −6.16633027 −0.22994705 −1.65573276 
H −4.81520519 2.78059006 2.63264495  C −6.71573130 0.11791397 −3.05918092 
H −4.84978144 1.29160259 1.68628175  C −4.80251591 0.74327613 −3.85591958 
H −6.91616141 0.15338186 1.27359732  H −6.27103159 1.97194221 −4.83842054 
C −7.48248238 3.06116073 3.13812603  C −7.29905132 2.36154843 −4.71595071 
H −7.85048158 3.74293841 2.35033440  H −6.28585358 1.29715358 −5.71262654 
H −6.79162158 3.64222591 3.77657902  H −5.61274407 2.81929757 −5.10347581 
H −8.35059743 2.80084917 3.76369793  H −6.76176685 −0.76115195 −3.72584671 
C −10.1489648 0.88348407 2.48008855  H −7.75217774 0.51372342 −2.99702708 
H −8.87054262 −0.72537693 1.89323098  H −6.93357916 −0.66710672 −0.99267001 
H −8.41791602 1.14646361 −0.45330074  H −5.36926159 −0.98998868 −1.74701532 
H −8.40667202 2.68267557 0.43130411  H −3.47114090 2.76197394 0.26919454 
H −6.31611409 1.17490640 4.67587108  H −3.78953007 4.74997338 1.05536954 
H −5.85876442 0.00266633 3.42283172  C −4.46445504 5.61640602 0.91971192 
H −10.0873723 1.82623369 3.05925366  H −2.76653656 5.08381403 0.80771370 
C −11.0579997 −0.08880945 3.26391824  H −3.79786040 4.48379507 2.12517315 
C −10.8211824 1.20338683 1.12805999  H −7.23034047 4.33041015 −3.06969671 
H −10.3853001 2.07763062 0.61814033  H −7.95373556 4.41444984 −1.39047926 
H −11.8924980 1.43260222 1.27608907  H −8.44770225 3.14628718 −2.52053416 
H −10.7657787 0.33828976 0.43822775  H −7.95932177 −0.98367804 4.05969845 
H −10.6244444 −0.39389346 4.23225820  H −8.64030900 0.56383336 4.55624879 
H −11.2392369 −1.01147930 2.67824294  H −5.53436598 1.06649210 −1.09670649 
 
Table A.25:  Cartesian coordinates for allylic alcohol 622. 
C −0.06567973 0.19680303 0.12116555  H −0.90597146 1.69566124 −1.99024765 
C 0.03240677 −1.21337806 0.81530966  C 0.30048348 1.31255010 −3.70624689 
O −1.46813510 0.51056379 0.03379907  C 1.01237278 2.69202718 −1.72092804 
Appendix 
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C 0.46090753 0.15151417 −1.37261304  H −0.39590060 0.57463075 −4.13760026 
C 0.67204127 1.23793606 1.02002155  H 1.32929046 1.02374894 −4.00062913 
C −0.07803612 −1.09139114 −2.14185588  H 0.07982552 2.28106701 −4.19366618 
H 1.56365655 0.05204657 −1.30303560  C 1.84647650 0.72136645 1.84002909 
C 0.16029188 1.46719565 −2.17529190  H 1.54012346 0.06581202 2.67780102 
C 0.08488460 −2.43141894 −1.40286439  H 2.44117470 1.54036596 2.27285306 
H 0.43992807 −1.15777041 −3.11571416  H 2.53633394 0.12559193 1.21153371 
H −1.15170631 −0.93409220 −2.36489655  C −0.59767969 3.34632619 0.21103844 
C 1.58562071 −2.81107505 −1.32549507  C 0.93766244 3.52987508 2.12746174 
C −0.83077413 −4.61626419 −0.84072867  C 0.20590761 3.80953413 −1.04021434 
C −0.61343408 −2.31283274 −0.02475662  H 1.52022049 3.13350131 −2.60037184 
C −0.83883641 −3.78421710 0.49590545  H 1.83117405 2.36695830 −1.05451963 
H −0.47205862 −1.10984691 1.79515280  C 0.19620087 4.87527612 1.92469107 
H 1.07994095 −1.47503459 1.03286208  C −1.06904301 4.52068675 1.11015745 
H 1.98147253 −2.98624744 −2.34415674  H 0.90127981 4.62872935 −0.76958668 
H 1.76424080 −3.73083031 −0.74422985  H −0.50436127 4.24452186 −1.77155313 
H 2.20627461 −2.02017443 −0.87040633  H 0.82368545 5.58618216 1.35261378 
H −1.63110667 −1.94702152 −0.26063372  H −0.04518531 5.37492054 2.88095326 
H −1.85799363 −3.82906571 0.93140250  H −1.81389953 4.09211094 1.81473798 
C 0.09996709 −4.37743584 1.59264548  C −1.72385116 5.70838802 0.39595399 
H 1.15304238 −4.25293296 1.26377860  H −1.00348989 6.25326668 −0.24292127 
C −0.15260963 −5.89017992 1.78595694  H −2.12810589 6.43561751 1.12502540 
C −0.05333910 −3.69540808 2.96809664  H −2.56208119 5.38167499 −0.24838356 
H 0.02814125 −6.48154970 0.87250017  H −1.77750773 0.70117569 0.93453026 
H −1.19716925 −6.07678883 2.10637958  C −0.71169486 −3.60971308 −2.01035599 
H 0.50909474 −6.29798162 2.57253187  H −1.72260277 −5.26189234 −0.93385015 
H 0.28861171 −2.64906315 2.97816093  H 0.03842049 −5.29793986 −0.86226986 
H 0.53670562 −4.23324551 3.73332416  H −1.71176129 −3.25254075 −2.32518300 
H −1.11021848 −3.71209654 3.30012136  H −0.23161076 −4.05356342 −2.90341805 
C −0.06567973 0.19680303 0.12116555  C 0.32839171 2.54488913 1.11698654 
C 0.03240677 −1.21337806 0.81530966  H −1.45437154 2.75340562 −0.13721106 
 
Table A.26:  Cartesian coordinates for desoxy−astellatol (627). 
H −1.74356382  2.19641481 2.26926296  C −0.18746080  −0.70547138 −0.07443316 
H −1.87386813  3.73782089 3.13744404  C −0.48671324  0.66411847 0.57988348 
H −0.35763751  2.80878208 3.20909924  C −0.28769653  −0.64047285 −1.64670414 
C −0.38480882  −1.85838747 −3.89836349  H −1.35979117  −0.45459960 −1.86453930 
H −1.49153630  −1.85052903 −3.94028851  C 0.10478433  −1.94216015 −2.43557038 
H −0.04216642  −2.73800842 −4.47320000  C 0.54574063  0.55824406 −2.18600624 
H −0.01892025  −0.96350682 −4.43051874  H −1.55610443  0.90676359 0.42986822 
C 1.11742893  −1.47166881 0.37868548  C 0.40970537  1.75828451 0.00143459 
C 1.75220588  −1.16440457 1.75945410  H −0.35202988  0.56290685 1.67015272 
V. Additional Data 
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C 0.23340098  −2.76506834 0.59905007  C 0.20596790  1.91087667 −1.52846367 
C 0.64449691  −3.33142748 1.98241947  H 0.43087459  0.63913967 −3.28237412 
C −0.35613289  −4.24907846 2.69116167  H 1.61939625  0.34075217 −2.00919753 
C 1.03324183  −2.07066204 2.78397463  C −1.21481342  2.36864335 −1.94283072 
H 1.57296820  −3.91750311 1.79963499  C 1.21600102  3.04467211 −1.82517564 
H 1.71548355  −0.09717440 2.04164329  H 1.44270820  1.36130826 0.09393440 
H 2.82483355  −1.43487814 1.72254403  C 0.53416206  3.20498753 0.59533307 
H 1.66584572  −2.30352767 3.66157996  H −1.49605709  3.33407191 −1.48915899 
H 0.11542398  −1.58296930 3.16771778  H −1.25767847  2.50091955 −3.04097994 
H 0.07956116  −4.65644197 3.62305317  H −2.00148060  1.64321857 −1.67254530 
H −0.64302267  −5.11282866 2.06251896  C −0.66983305  3.88540683 1.31160773 
H −1.27672723  −3.70286790 2.96727784  C 1.04503033  4.03311548 −0.64426347 
H 1.89487323  −1.54008108 −0.40099176  H 1.33696249  3.16803049 1.36035475 
C −0.39763331  −3.28788805 −1.85332194  H 1.05131172  3.52875493 −2.80683839 
H 1.21398076  −1.99025727 −2.46479208  H 2.24262919  2.62787798 −1.83320369 
C 0.26193050  −3.77901029 −0.55323557  H 1.98086119  4.57827906 −0.42473725 
C −0.99867645  −1.85511818 0.52003735  H 0.30294602  4.80535567 −0.91728973 
H −0.25581541  −4.70689140 −0.23735108  H −1.50826568  3.98373700 0.59061667 
H 1.31814538  −4.06092384 −0.74578776  C −0.26826645  5.30826565 1.75901355 
H −0.23106023  −4.06642855 −2.62355912  C −1.18854759  3.10719727 2.54025077 
H −1.49530139  −3.23374548 −1.71630530  H 0.05835710  5.94523695 0.91880223 
C −2.27850826  −1.95096664 0.88974806  H 0.56628180  5.26491504 2.48721863 
H −2.69322466  −2.86098643 1.34000679  H −1.11281530  5.82261268 2.25438821 
H −2.97641261  −1.11491252 0.74442609      
 
Table A.27:  Cartesian coordinates for diene (631). 
C −0.18500578 −0.18805095 −0.58867581  C −2.22145674 −2.47941583 −1.63632480 
C 1.08464816 0.65568101 −0.38975266  C −2.49012040 −2.13235970 0.92339418 
C −0.26540524 −1.48777610 −0.20639037  H −3.02736867 −3.23774645 −1.59801265 
C −1.29536865 0.56000389 −1.26018135  H −1.50466687 −2.79705368 −2.41563147 
C 0.94125919 −2.22156574 0.38056864  H −2.67473757 −1.53079099 −1.96404598 
C −1.51732398 −2.37929835 −0.26676747  C −0.98877618 1.02998304 −2.67464502 
C 2.27838683 −1.49073033 0.18689122  H −0.19762836 1.80601783 −2.68742939 
H 0.76113174 −2.41071207 1.46191285  H −1.86806475 1.45617724 −3.18465924 
H 0.99236982 −3.22863823 −0.08319586  H −0.61270909 0.19207668 −3.29285865 
C 2.74624695 −1.66860584 −1.28064441  C −2.83672979 0.46128038 0.78372428 
C 4.37624881 −0.70188564 1.11787445  C −3.62876487 1.62423188 −1.26376728 
C 2.07167392 −0.00247690 0.57631129  C −3.47333443 −0.94988670 0.87380406 
C 3.50766095 0.58510633 0.88139456  H −3.09622287 −3.05288864 1.04988368 
H 1.55957598 0.85828492 −1.37061063  H −1.88005779 −2.05174778 1.84626447 
H 0.75915600 1.64174448 −0.00539194  C −4.64107299 1.83292489 −0.10997156 
H 3.05464874 −2.71690205 −1.45618218  C −3.80925108 1.61960269 1.17453130 
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H 3.60574500 −1.02586298 −1.53701971  H −4.08019568 −1.01384886 1.79669053 
H 1.93832770 −1.44147222 −1.99727895  H −4.19003062 −1.09512107 0.04107064 
H 1.55831066 −0.02905331 1.55977145  H −5.13090425 2.82385844 −0.14247513 
H 3.44128298 1.13361246 1.84293394  H −5.45288646 1.08033400 −0.15798591 
C 4.14225178 1.59282511 −0.12447395  H −3.16425987 2.51521778 1.30511078 
H 4.05486913 1.17269533 −1.14849656  C −4.63199302 1.45247962 2.45631404 
C 5.64500867 1.81437782 0.15951000  H −3.98636347 1.23456056 3.32843120 
C 3.44285032 2.96691735 −0.10474840  H −5.19446911 2.37788995 2.68338613 
H 6.24779460 0.89819654 0.03958273  H −5.37576542 0.63805636 2.37569942 
H 5.80194273 2.18864745 1.19090767  C 3.40238884 −1.89900587 1.16265435 
H 6.06384699 2.57075294 −0.52980090  H 4.99523390 −0.62353524 2.02986545 
H 2.38900037 2.92574084 −0.42185865  H 5.08308497 −0.84732195 0.28123087 
H 3.95710425 3.67751307 −0.77824988  H 3.89085063 −2.85599605 0.89699386 
H 3.47268692 3.40345644 0.91326388  H 2.97762092 −2.02167844 2.17893187 
H −1.13472992 −3.40087715 −0.07443043  C −2.46524986 0.83559001 −0.64804337 
C −0.18500578 −0.18805095 −0.58867581  H −1.94631210 0.47294141 1.44128384 
 
Table A.28:  Cartesian coordinates for diene (632). 
C 0.44176242 −0.19343427 −0.14963278  C −3.07018230 −1.79782060 −0.79275502 
C 0.72994697 1.25340537 −0.55564636  C −0.87144812 −1.96927207 −2.08138206 
C −1.00333393 −0.60674985 0.14597611  H −3.77960029 −1.11591113 −0.29152799 
C 1.45801879 −1.09401551 −0.10840199  H −2.90398417 −2.65063737 −0.10757890 
C −1.84298457 0.48382013 0.91160758  H −3.57401350 −2.19035944 −1.69691426 
C −1.74515967 −1.09177411 −1.15074689  C 2.89878604 −0.67885835 −0.39081679 
C −1.09376594 1.81643960 1.10013527  H 3.33954073 −0.09926203 0.44635640 
H −2.17367954 0.08491001 1.89026432  H 2.97783177 −0.04091333 −1.29092405 
H −2.77032651 0.69642924 0.34659103  H 3.54623759 −1.55708520 −0.55768960 
C −0.05936647 1.67654081 2.24658832  C 0.43937658 −3.43853097 −0.31663510 
C −1.07200180 4.23102167 0.95250022  C 2.01903812 −3.12482834 1.42919028 
C −0.46431016 2.17343698 −0.28141152  C −0.44795498 −3.34871096 −1.53828654 
C −0.34043518 3.75045075 −0.34153779  H 0.02196433 −1.40224664 −2.39653961 
H 1.00782035 1.27299521 −1.62964447  H −1.45114385 −2.14833743 −3.00932855 
H 1.62681477 1.61458090 −0.01932923  C 1.81575442 −4.64525265 1.24945301 
H −0.59564463 1.59674866 3.21183380  C 0.49686419 −4.76938267 0.44114668 
H 0.62875984 2.53764925 2.31579672  H −1.35533937 −3.95841535 −1.35172524 
H 0.56061827 0.76998881 2.14393803  H 0.07299587 −3.89467950 −2.35559826 
H −1.23804810 1.91488234 −1.02979219  H 1.79691226 −5.20350649 2.20360408 
H −0.95720985 4.08472277 −1.20049429  H 2.64915069 −5.05571998 0.64811522 
C 1.06692374 4.35901641 −0.58518767  H 0.54508507 −5.62239000 −0.26797229 
H 1.79251687 3.84975627 0.08300958  C −0.74818596 −4.96667263 1.33455534 
C 1.11425820 5.86580943 −0.25835720  H −0.82613510 −4.16303377 2.09105258 
C 1.51691308 4.15306940 −2.04689003  H −0.71020214 −5.93369207 1.87100254 
V. Additional Data 
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H 0.95922442 6.07461728 0.81446346  H −1.68071688 −4.95305545 0.73988781 
H 0.33834551 6.41915680 −0.82273766  C −1.98060927 3.05513284 1.36129697 
H 2.09339861 6.29622992 −0.54162219  H −1.63063752 5.17219431 0.80062091 
H 1.46888594 3.09888995 −2.36608514  H −0.34203586 4.43463277 1.75840798 
H 2.55450322 4.50465434 −2.20323192  H −2.87405104 3.01917133 0.70594199 
H 0.86824681 4.73196524 −2.73294388  H −2.34490506 3.12804524 2.40376527 
H −2.00067826 −0.18558373 −1.74121017  C 1.26034467 −2.52046423 0.24795578 
C 0.44176242 −0.19343427 −0.14963278  H 3.08738675 −2.83635161 1.44918376 
 
Table A.29:  Cartesian coordinates for diene (633). 
C −0.46770749 0.29918462 −0.88462699  C 1.57790662 −1.81370398 −1.73022479 
C −0.02066305 1.42900117 −0.29388256  H −1.34924576 −2.26847479 −3.66376182 
C −0.24173126 −0.00561494 −2.37053889  H −1.23075508 −2.72269786 −1.94600803 
C −1.32785202 −0.67744974 −0.13586950  H −0.14739195 −3.47863583 −3.14633179 
C 0.55649303 1.10032895 −3.12603922  C −2.81955140 −0.47755206 −0.30989180 
H −1.25292036 −0.04153360 −2.82818584  H −3.12007579 0.53479830 0.02519543 
C 0.40032402 −1.40967325 −2.66695620  H −3.42253804 −1.21323563 0.24644078 
C 0.31662330 2.50769021 −2.55452236  H −3.11069207 −0.55331248 −1.37713121 
H 0.28240763 1.05302650 −4.19958626  C 0.69369154 −1.96066544 0.75861176 
H 1.64050455 0.87614729 −3.06827253  C −1.60011178 −2.73088284 1.37105002 
C −1.16779761 2.89088398 −2.77181321  C 1.31395435 −2.67262805 −0.47076530 
C 1.19868217 4.70020116 −1.93824259  H 2.28648896 −2.39766362 −2.35042886 
C 0.78655819 2.44046217 −1.06848663  H 2.13748751 −0.90342210 −1.43436817 
C 1.06479244 3.91003380 −0.58948086  C −0.53998069 −3.69127238 1.95310161 
H −1.43296474 2.73400152 −3.83517127  C 0.72927644 −2.81979561 2.06594961 
H −1.37772354 3.94646974 −2.53910863  H 0.70678872 −3.55800623 −0.74226370 
H −1.85505819 2.27823157 −2.16507413  H 2.29764043 −3.07914937 −0.16734510 
H 1.80767811 2.00859854 −1.13977406  H −0.35628359 −4.53582702 1.25914673 
H 2.06341031 3.89473561 −0.11082642  H −0.84399222 −4.13736005 2.91844542 
C 0.14610923 4.55354914 0.48787905  H 0.55631915 −2.10607451 2.89979571 
H 0.22021015 3.89595638 1.37961172  C 2.02035860 −3.58741705 2.37208306 
C −1.34684756 4.66213090 0.13111384  H 2.22383816 −4.37913115 1.62769197 
C 0.69433279 5.93615743 0.90397615  H 1.95851894 −4.08275161 3.35969102 
H −1.79022517 3.68218714 −0.11225095  H 2.89740105 −2.91278033 2.39507561 
H −1.52001739 5.33508056 −0.72980015  C 1.22679245 3.64465115 −3.07732116 
H −1.91471372 5.08350470 0.98193315  H 2.09374224 5.34795320 −1.95406458 
H 0.65123040 6.65737714 0.06527374  H 0.33370877 5.37492128 −2.07890646 
H 1.74730864 5.87765301 1.23937052  H 2.25664726 3.26202719 −3.22335079 
H 0.10376699 6.36802515 1.73343487  H 0.89605275 4.06052618 −4.04813504 
H 0.86916555 −1.28085654 −3.66395933  C −0.80094979 −1.68148579 0.59029277 
C −0.63934333 −2.52985505 −2.85657688  H 1.25366082 −1.01872652 0.91011538 
C −0.46770749 0.29918462 −0.88462699  H −2.34463636 −3.25644870 0.74283816 
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Table A.30:  Cartesian coordinates for diene (634). 
C 2.00753906 −1.16074237 −1.00697967  C −0.98822668 −1.71978779 1.14809832 
C 0.69269949 −1.94115219 −0.81705895  H −0.11697471 −1.79337748 1.83444277 
C −0.47279775 −1.08410751 −0.19169304  C −1.07906958 1.34937086 −0.23775754 
C −0.13021623 0.40527469 −0.03081988  C −2.48848782 1.01252720 −0.59007187 
C 1.28082527 0.79315200 0.43033791  C −0.87833736 2.84007848 −0.03389877 
C 2.26197672 −0.38026753 0.31791803  H 0.12127103 3.11416977 0.33969053 
H 0.91185730 −2.79790005 −0.15405332  H −1.06571063 3.38718486 −0.97918405 
H 0.36205635 −2.38278544 −1.77720303  H −1.61803922 3.23269655 0.69150324 
H 1.99799078 −1.08933952 1.12622902  C −1.52046631 −3.15246854 0.91698569 
C 1.91163413 −0.25896786 −2.26500837  H −1.91870908 −3.58351575 1.85530456 
H 2.75487325 0.44899247 −2.35394572  H −2.34108393 −3.16586985 0.17495472 
H 1.91543531 −0.89627415 −3.17040147  H −0.74031061 −3.83854276 0.54556175 
H 0.98191986 0.33434033 −2.28617766  C −3.53583657 0.77382667 0.50236718 
C 3.28430434 −2.02864008 −1.09687684  H −3.43592021 1.53354404 1.30637142 
C 3.82801270 −0.18017512 0.44278029  C −3.03760738 0.91375707 −1.81428727 
H 4.13610464 −0.66830631 1.38984272  C −4.87475496 0.99379939 −0.28066791 
C 4.40770449 −1.04364043 −0.72166520  C −4.52295325 0.62541894 −1.75062258 
C 4.37691988 1.26953104 0.53454216  H −5.04409455 2.08989003 −0.26831727 
H 3.86618490 1.89310693 −0.22873159  H −5.11429760 1.21155282 −2.48103696 
C 5.89171398 1.34243711 0.25096357  H −4.73957746 −0.44350624 −1.97262348 
H 6.14552156 1.07443651 −0.78953288  C −6.13773380 0.32781555 0.27492446 
H 6.27272501 2.36529968 0.43197155  H −7.02251162 0.62500576 −0.31953194 
H 6.45565089 0.66120464 0.91756113  H −6.08107324 −0.77625726 0.25015683 
C 4.10303889 1.87373482 1.92802913  H −6.32777593 0.63121583 1.32214668 
H 4.42780541 2.93043295 1.98162733  C −3.39240744 −0.61480275 1.17574654 
H 3.03726398 1.83499986 2.20854065  C −2.04582507 −0.87356304 1.90288190 
H 4.66689958 1.31744615 2.70228621  H −4.21089265 −0.71766534 1.91318581 
H 4.64934550 −0.40831458 −1.59419122  H −3.57845419 −1.40388669 0.42271732 
H 5.34738612 −1.55258243 −0.44057938  H −2.25693482 −1.41126002 2.84780306 
H 3.23102021 −2.84748071 −0.35110246  H −1.59960230 0.09073113 2.21269862 
H 3.43120623 −2.50052216 −2.08706838  H −1.32416911 −1.13213134 −0.89228712 
C 2.00753906 −1.16074237 −1.00697967  H 1.23240643 1.16272701 1.47414493 
 
Table A.31:  Cartesian coordinates for conformer 635. 
C 0.09374278 −0.16459038 −0.05334760  H −3.25094725 −1.01474055 0.55520799 
C 0.80548482 1.23777566 0.02394943  C −2.11037893 −2.13991143 1.93682235 
O −0.04953665 −0.46896337 −1.44972321  C −2.15029437 −2.36926437 −0.63241648 
C −1.34751700 −0.08482683 0.55541018  H −2.40931390 −1.47409764 2.76859830 
C 0.91868485 −1.23721157 0.69462105  H −1.08980852 −2.50266264 2.14902558 
C −2.16160571 1.09220184 −0.05197012  H −2.78601664 −3.01625872 1.96404102 
H −1.18137261 0.16842486 1.61968183  C 1.60270665 −0.75905540 1.96834471 
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C −2.21275939 −1.39994034 0.58575924  H 2.49057745 −0.13331903 1.75223697 
C −1.44030230 2.45128942 0.06539419  H 1.94741461 −1.58835215 2.60333317 
H −3.13950099 1.14271993 0.46741790  H 0.92517400 −0.14048747 2.58751163 
H −2.37906359 0.87795223 −1.11633909  C 0.34650440 −3.26750252 −0.85702790 
C −1.37212955 2.88466411 1.55249259  C 1.82151855 −3.56614624 1.12650865 
C −0.89086344 4.61526944 −0.91120737  C −1.15871650 −3.55514211 −0.62918406 
C −0.05276801 2.32911229 −0.62384983  H −2.02910867 −1.78670287 −1.56130569 
C 0.45583546 3.79928082 −0.87345414  H −3.15481880 −2.83519707 −0.69866386 
H 1.77616702 1.12891776 −0.49989110  C 1.55508348 −4.92940767 0.46569715 
H 1.04714414 1.50549587 1.06515101  C 1.19998167 −4.57333992 −0.98980224 
H −2.39537994 2.99942613 1.95821578  H −1.28896449 −4.14391147 0.30073323 
H −0.85746036 3.84982497 1.69065876  H −1.48979424 −4.22653891 −1.44413104 
H −0.85082181 2.15300417 2.19284343  H 0.69452265 −5.43446936 0.94835620 
H −0.28890756 1.95057735 −1.63633231  H 2.41305249 −5.62246011 0.54795977 
H 0.90907386 3.82641322 −1.88552105  H 2.14177540 −4.26545909 −1.49381768 
C 1.53323994 4.41787007 0.07172452  C 0.59859153 −5.73555787 −1.78884501 
H 1.19946616 4.29154014 1.12287618  H −0.26920279 −6.18633957 −1.27268662 
C 1.70615640 5.93233824 −0.18467744  H 1.34704255 −6.53880844 −1.92538113 
C 2.91966550 3.75551059 −0.07106603  H 0.26202295 −5.41975403 −2.79501964 
H 0.78486875 6.51202744 −0.00579446  H 0.84311088 −0.53380150 −1.82673008 
H 2.02559310 6.12136075 −1.22910413  C −2.05213731 3.60011371 −0.76903200 
H 2.48634506 6.35200114 0.47717902  H −0.98007762 5.22467466 −1.82851045 
H 2.94125868 2.70764256 0.26601928  H −0.93183876 5.33098008 −0.07087049 
H 3.67259647 4.30092652 0.52775141  H −2.35943377 3.21157548 −1.75951093 
H 3.26068556 3.78172660 −1.12496917  H −2.95096079 4.04990065 −0.30555171 
C 0.09374278 −0.16459038 −0.05334760  C 1.00729390 −2.53703391 0.32613055 
C 0.80548482 1.23777566 0.02394943  H 0.42688517 −2.69074948 −1.79025449 
 
Table A.32:  Cartesian coordinates for water. 
O −3.16767047  −0.72594854 0.01005517      
H −2.19860750  −0.67756464 −0.01280005      
H −3.44037202  0.11642318 −0.38788512      
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VI. List of Abbreviations  
 
ῦ wavenumber 
[1,2]~H [1,2]-hydride shift 
2D two-dimensional 
3D three-dimensional 
9-BBN 9-borabicyclo[3.3.1]nonane 
Ac acetyl 
ADP adenosine diphosphate 
Alk alkyl 
AMPA α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
Ar aryl substituent 
Arc (protein) activity-regulated cytoskeleton-associated (protein) 
atm atmosphere(s) 
ATP adenosine triphosphate 
ATR attenuated total reflection (IR spectroscopy) 
B3LYP Becke, three-parameter, Lee-Yang-Parr 
BDNF brain-derived neurotrophic factor 
BINAP 2,2'-bis(diphenylphosphino)-1,1'-binaphthalene 
BINAPO 2-diphenylphosphino-2′-diphenylphosphinyl-1,1′-binaphthalene 
Boc tert-butyloxycarbonyl 
Bn benzyl 
br broad 
brsm based on recovered starting material 
BTZ benzo(thi)azepine 
Bu butyl 
© copyright 
c cyclo, concentration (optical rotation) 
C2V symmetry point group 
CDI calcium-dependent inactivation 
calcd. calculated 
CaM calmodulin 
cAMP cyclic adenosine monophosphate 
CaMK calmodulin-dependent protein kinase  
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cat. catalyst, catalytic 
CaV (channel) voltage-gated calcium (channel) 
CCDC Camebridge Crystallographic Data Centre 
CMP cytidine monophosphate 
CoA coenzyme A 
COSMO conductor-like screening model 
COSY homonuclear correlation spectroscopy (NMR spectroscopy) 
Cp cyclopentadienyl 
CREB cAMP response element-binding protein 
CSA camphorsulfonic acid 
CTP cytidine triphosphate 
CuTC copper(I)-thiophene-2-carboxylate 
Δ elevated temperature 
δ chemical shift (NMR spectroscopy) 
D sodium D line (optical rotation) 
d doublet (NMR spectroscopy), deutero 
dba dibenzylideneacetone 
DBU 1,8-diazabicyclo[5.4.9]undec-7-ene 
DCC N,N'-dicyclohexylcarbodiimide 
DCE 1,2-dichloroethane 
decomp. decomposition 
DFT density functional theory 
DHP dihydropyridine 
DIBAL diisobutylaluminum hydride 
DIPA diisopropylamine 
DIPEA diisopropylethylamine 
DIPT diisopropyl tartrate 
DMAP 4-(dimethylamino)pyridine 
DMAPP dimethylallyl pyrophosphate 
DME dimethoxyethane 
DMF N,N-dimethylformamide 
DMP Dess-Martin periodinane 
DMPU N,N'-dimethyl-N,N'-trimethyleneurea 
DMSO dimethylsulfoxide 
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DOXP 1-deoxy-D-xylulose 5-phosphate 
DPBS Dulbecco's phosphate-buffered saline 
dppf 1,1’-bis(diphenylphosphino)ferrocene 
dr diastereomeric ratio 
DTMB-SEGPHOS see ref. 511 
E electrophile 
e electron 
E1 unimolecular elimination 
E1cB elimination unimolecular conjugate base 
E2 bimolecular elimination 
EDCI N-(3-dimethylaminopropyl)-N-ethylcarbodiimide hydrochloride 
ee enantiomeric excess 
eGFP enhanced green fluorescent protein 
EI electron impact ionization (mass spectroscopy) 
Enz enzyme 
eq. equivalent(s) 
Et ethyl 
er enantiomeric ratio 
ESI electron spray ionization (mass spectroscopy) 
FAB fast atom bombardment (mass spectroscopy) 
FAD flavin adenine dinucleotide 
FDA Food and Drug Administration 
G2 (phase) growth (phase) 2  
GABA γ-aminobutyric acid 
GCMS gas chromatography–mass spectrometry 
GK guanylate kinase 
GPI glycosylphosphatidylinositol 
GPP geranyl pyrophosphate 
λ wavelength 
H reaction enthalpy 
h Planck constant 
HEK(293T cells) human embryonic kidney (293T cells) 
HEPES 2-(4-(2-hydroxyethyl)-1-piperazinyl)-ethansulfonic acid 
Hex hexane 
VI. List of abbreviations 
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HIV human immunodeficiency virus 
HMG-CoA β-hydroxy-β-methylglutaryl-CoA 
HMPA hexamethylphosphoramide 
HMQC heteronuclear multiple bond coherence (NMR spectroscopy) 
HPLC high-performance liquid chromatography 
HRMS high-resolution mass spectrometry 
HWE Horner-Wadsworth-Emmons 
i iso 
IBX 2-iodoxybenzoic acid 
IL-2 interleukin-2 
im imidazole 
INOC intramolecular nitrile oxide cycloadditon 
Ipc isopinocamphenyl 
IPP isopentenyl pyrophosphate 
IR infrared 
IUPAC International Union of Pure and Applied Chemistry 
J coupling constant (NMR spectroscopy) 
KcsA (channel) potassium crystallographically-sited activation (channel) 
KHMDS potassium hexamethyldisilazide 
K-Selectride® potassium tri-sec-butylborohydride 
KV (channel) voltage-gated potassium (channel) 
L ligand 
LAB lithium amidotrihydroborate 
lat. Latin 
LCMS liquid chromatography–mass spectrometry 
LDA lithium diisopropylamide 
LiHMDS lithium hexamethyldisilazide 
L-Selectride® lithium tri-sec-butylborohydride 
LTCC L-type calcium channels 
M metal, molecule (mass spectrometry) 
M (phase)  mitotic (phase) 
M molecular weight 
M molarity 
m multiplet (NMR spectroscopy) 
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MAP mitogen-activated protein 
max maximum 
mC centrosymmetric multiplet (NMR spectroscopy) 
m-CPBA meta-chloroperbenzoic acid 
Me methyl 
ME-CDP 4-diphosphocytidyl-2-C-methyl-D-erythritol 
MEP methylerythritol phosphate 
Mes mesityl 
MMC methoxymagnesium methyl carboxylate 
MMFF merck molecular force field 
MOM methoxymethyl 
mRNA messenger RNA 
MS mass spectroscopy, molecular sieves 
Ms mesyl 
MVA mevalonic acid 
MVK methyl vinyl ketone 
ν frequency 
NADPH nicotinamide adenine dinucleotide phosphate hydrogen 
NaHMDS sodium hexamethyldisilazide 
Nap naphtyl 
NaV (channel) voltage-gated sodium channel 
NIS N-iodo succinimide 
NMO N-morpholino N-oxide 
NMR nuclear magnetic resonance 
NOE nuclear Overhauser effect 
NOESY 
 
nuclear Overhauser effect correlation spectroscopy (NMR 
spectroscopy) 
n.r. no reaction 
O oxidative step 
p para 
PAA phenylalkylamine 
PAF platelet-activating factor 
PCC pyridinium chlorochromate 
PG undefined protective group 
VI. List of abbreviations 
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Ph phenyl 
PhNTf2 N-phenyl(bistrifuoromethanesulfonate) 
PIFA (bis(trifluoroacetoxy)iodo)benzene 
Pinnick Pinnick oxidation 
Piv pivaloyl 
pKA acid dissociation constant (negative logarithmic value) 
PMB para-methoxybenzyl 
PMP para-methoxyphenyl 
ppm parts per million (NMR spectroscopy) 
PPTS pyridinium para-toluenesulfonate 
Pr propyl 
py pyridine 
p-TsOH para-toluenesulfonic acid 
q quartet (NMR spectroscopy) 
quant. quantitative 
quin quintet (NMR spectroscopy) 
® registered 
R undefined or elsewhere defined substituent 
rac racemic 
Ras rat sarcoma (monomeric G-protein) 
RCM ring-closing metathesis 
ref. reference 
Rf retardation factor 
RRCM relay ring-closing metathesis 
Rt retention time 
rt room temperature 
s singlet (NMR spectroscopy) 
SAR structure activity relationship 
sec secondary 
sept septet (NMR spectroscopy) 
SEM 2-(trimethylsilyl)ethoxymethyl 
Ser serine 
SH3 SRC homology 3  
SN1 nucleophilic chemical substitution of first kinetic order 
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SN2 nucleophilic chemical substitution of second kinetic order 
SNi internal nucleophilic chemical substitution  
SNARE soluble N-ethylmaleimide-sensitive-factor attachment receptor 
T temperature 
T (cells) T(hymus) lymphocytes 
t time, triplet (NMR spectroscopy) 
t (tert) tertiary 
TASF tris(dimethylamino)sulfonium difluorotrimethylsilicate 
TBAF tetrabutylammonium fluoride 
TBDPS tert-butyldiphenylsilyl 
TBS tert-butyldimethylsilyl 
Tebbe Tebbe’s reagent 
TES triethylsilyl 
TFE 2,2,2-trifluoroethanol 
TIPS triisopropylsilyl 
TFA trifluoroacetic acid 
Tf2O trifluoromethanesulfonic anhydride 
Tf triflyl 
THF tetrahydrofurane 
THP tetrahydropyranyl 
TLC thin-layer chromatography 
TM trademark 
TMEDA N,N,N’,N’-tetramethylethylenediamine 
TMS trimethylsilyl, tetramethylsilane (NMR spectroscopy) 
Tol tolyl 
TPAP tetrapropylammonium perruthenate 
TPP tetraphenylporphyrine 
trig trigonal 
Ts tosyl 
u.p. unknown product 
UV-Vis ultraviolet–visible 
VDI voltage-dependent inactivation 
wt-% weight percent 
ψ pseudo 
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